File No. CI 20-01-29284

THE QUEEN'S BENCH
Winnipeg Centre

APPLICATION UNDER: *The Constitutional Questions Act*, C.C.S.M., c. 180

AND UNDER: The Court of Queen's Bench Rules, M.R. 553/88

IN THE MATTER OF: *The Public Health Act*, C.C.S.M. c. P210

BETWEEN:

GATEWAY BIBLE BAPTIST CHURCH, PEMBINA VALLEY BAPTIST CHURCH, REDEEMING GRACE BIBLE CHURCH, THOMAS REMPEL, GRACE COVENANT CHURCH, SLAVIC BAPTIST CHURCH, CHRISTIAN CHURCH OF MORDEN, BIBLE BAPTIST CHURCH, TOBIAS TISSEN, ROSS MACKAY

Applicants,

– and –

HER MAJESTY THE QUEEN IN RIGHT OF THE PROVINCE OF MANITOBA, DR. BRENT ROUSSIN in his capacity as CHIEF PUBLIC HEALTH OFFICER OF MANITOBA, and DR. JAZZ ATWAL in his capacity as ACTING DEPUTY CHIEF OFFICER OF HEALTH MANITOBA

Respondents.

AFFIDAVIT OF DAVID HERSEY
SWORN APRIL 20, 2021

JUSTICE CENTRE FOR CONSTITUTIONAL FREEDOMS
D. Jared Brown / Allison Kindle Pejovic / Jay Cameron
[redacted]

THE QUEEN'S BENCH
Winnipeg Centre

APPLICATION UNDER: *The Constitutional Questions Act*, C.C.S.M., c. 180

AND UNDER: The Court of Queen's Bench Rules, M.R. 553/88

IN THE MATTER OF: *The Public Health Act*, C.C.S.M. c. P210

BETWEEN:

GATEWAY BIBLE BAPTIST CHURCH, PEMBINA VALLEY BAPTIST CHURCH, REDEEMING GRACE BIBLE CHURCH, THOMAS REMPEL, GRACE COVENANT CHURCH, SLAVIC BAPTIST CHURCH, CHRISTIAN CHURCH OF MORDEN, BIBLE BAPTIST CHURCH, TOBIAS TISSEN, ROSS MACKAY

Applicants,

– and –

HER MAJESTY THE QUEEN IN RIGHT OF THE PROVINCE OF MANITOBA, DR. BRENT ROUSSIN in his capacity as CHIEF PUBLIC HEALTH OFFICER OF MANITOBA, and DR. JAZZ ATWAL in his capacity as ACTING DEPUTY CHIEF OFFICER OF HEALTH MANITOBA

Respondents.

AFFIDAVIT OF DAVID HERSEY

I, DAVID HERSEY, of the City of Calgary, in the Province of Alberta,

MAKE OATH AND SAY AS FOLLOWS:

1. I have personal knowledge of the facts and matters hereinafter deposed to by me, except where same are stated to be based upon information and belief, and those I do verily believe to be true.

2. I am a Senior Paralegal at the Justice Centre for Constitutional Freedoms in Calgary, Alberta. I have worked at the Justice Centre since September 2018.

3. I have reviewed the correspondence between the Applicants' and the Respondents' in anticipation of the hearing of this Application.

4. On March 19, 2021, the Applicants sent a letter to the Respondents. A copy of that letter is attached hereto and marked as **Exhibit "A"** to this my affidavit.

5. On March 30, 2021, the Respondents sent a letter to the Applicants by email which contained attachments. Copies of that email, letter, and the attachments to that email are attached hereto and marked as **Exhibit "B"** to this my affidavit.

6. On April 1, 2021, the Applicants sent a letter by email to the Respondents. Copies of that email and letter are attached hereto and marked as **Exhibit "C"** to this my affidavit.

7. On April 6, 2021, the Respondents sent a letter by email to the Applicants. A spreadsheet was attached to that email. Copies of that email, letter, and the spreadsheet are attached hereto and marked as **Exhibit "D"** to this my affidavit.

8. On April 8, 2021, the Respondents emailed the Applicants. A spreadsheet was attached to that email. Copies of that email and the spreadsheet are attached hereto and marked as **Exhibit "E"** to this my affidavit.

9. On April 13, 2021, the Applicants sent a letter to the Respondents. A copy of that letter is attached hereto and marked as **Exhibit "F"** to this my affidavit.

10. On April 14, 2021, the Respondents sent an email to the Applicants which attached one document. Copies of that email and the attached document are attached hereto and marked as **Exhibit "G"** to this my affidavit.

11. I make this affidavit *bona fide*.

SWORN before me in the City of Calgary, in the Province of Alberta, on April 20, 2021	)))	
A Barrister entitled-to-practice in the Province of Alberta John V. Carpay	)))	DAVID HERSEY

EXHIBIT "A"

THIS IS EXH AB658 "
referred to in the Affidavit of
David Hersey
Sworn before me this 20
day of April A.D. 20 21
A Commissioner in and for the Province of Alberta
John Carpay
Barrister and Solicitor

Justice Centre

for Constitutional Freedoms

March 19, 2021

Via-email

Department of Justice
[redacted]

Attention: Heather Leonoff/Michael Conner/Denis Guenette/Sean Boyd

Dear Madam/Sir:

RE: Gateway Bible Baptist Church et al. v. Manitoba and Dr. Roussin – File No. CI 20-01-29284

Upon review of your filed affidavits in this matter, the Applicants request the following information in advance of the hearing which is relevant to both the Respondents' affidavit evidence and the issues in the proceeding:

Specifically, we request that you provide us with the following (subject to further agreement on medium of production and delivery timeline):

1. Affidavit of Carla Loeppky, Exhibit B, page 17
   For all Manitoba Covid deaths listed:
   a. anonymized lab reports with CT threshold used in achieving the Covid-positive test result,
   b. Document(s) identifying whether the deceased was a symptomatic or asymptomatic case,
   c. anonymized death certificates with primary and secondary causes of death

2. Affidavit of Jared Bullard
   Package inserts/manufacturer's instructions from all Covid-19 diagnostic test kits (PCR or otherwise) that Manitoba uses to diagnose Covid-19

[redacted]

3. Affidavit of Jared Bullard, lines 193-199

    a. Document(s) with CT thresholds by percentages of all positive cases between March 2020-March 2021, and specifically, what percentage of cases per month resulted from a positive PCR test with a CT of 36, 37, 38, 39, 40, 40+ (not simply the percentage as a range from 36-40)
    b. for every positive case, the anonymized lab report confirming the CT value used

4. Affidavit of Brent Roussin, para. 70
Documentation on the contact tracing program:
    a. the proportion of traced contacts that became symptomatic during their quarantine period,
    b. the proportion of traced contacts that tested positive for Covid-19 during their quarantine period,
    c. the proportion of symptomatic contacts that were hospitalized, needed ICU, or died,
    d. estimated number and rate of prevented hospitalizations, ICU admissions, or deaths attributable to contact tracing, quarantine and isolation

5. Affidavit of Carla Loeppky, Exhibit B, pp. 16-33
Document(s) or policies used to determine whether a death is "related to Covid-19" or is a death "due to Covid-19", and any document(s) outlining any changes in the usual method of death certification (prior to 2020) with respect to Covid-19's designation in Part 1 or Part 2 of the death certificate.

6. Affidavit of Carla Loeppky, Exhibit D, Affidavit of Lanette Siragusa, para. 10
Document(s) providing the number of total deaths in Manitoba in 2020 due to the following conditions as the primary cause of death:
    a. Malignant neoplasms
    b. Diseases of heart
    c. Cerebrovascular disease
    d. Chronic lower respiratory disease (excluding Covid-19)
    e. Accidents (unintentional injuries)

[redacted]

7. Affidavit of Carla Loeppky, Exhibit F, p. 25
   Document(s) which sets out the 165 parameters in respect of the modelling

8. Affidavit of Carla Loeppky, para. 14
   Document(s) or policies defining a "cluster"

9. Affidavit of Brent Roussin, para. 177
   Document(s) that show:
   a. the total number of ICU beds available in Manitoba for the years 2015-2020
   b. the surge capacity (how many extra beds could be made available for ICU patients) in Manitoba for the years 2015-2020
   c. by month, the highest number of ICU patients in Manitoba for the years 2015-2020 and up to March 2021
   d. how many days per month in the years 2015-2020 and up until March 2021 did ICU patients exceed the number of available ICU beds before and after (if applicable) surge capacity was reached?

10. Documents showing that out of all of the PCR positive cases of Covid-19 in Manitoba, how many of those people were also tested for Influenza within the same time frame as they were tested for Covid-19

11. Please provide Manitoba's Pandemic Response Plan (or similar such emergency plan) for the past 5 years.

We look forward to receiving the foregoing. Please feel free to contact the undersigned should you wish to discuss the method and timeline for delivery. We are content to rely on electronic delivery (i.e. by USB) should that prove more convenient.

Best regards,

A.K Pejovic

Allison Kindle Pejovic
Barrister and Solicitor
Justice Centre for Constitutional Freedoms

cc: Jay Cameron, Litigation Manager, Justice Centre for Constitutional Freedoms, [redacted]

[redacted]

Jared Brown, Lead Counsel, Brown Litigation, [redacted]a

Heather Leonoff, Legal Services Branch, Constitutional Law Section, Manitoba Justice, [redacted]

Denis Guenette, Legal Services Branch, Civil Legal Services, Manitoba Justice, [redacted]

Michael Conner, Legal Services Branch, Constitutional Law Section, Manitoba Justice, [redacted]

Sean Boyd, Legal Services Branch, Civil Legal Services, Manitoba Justice, [redacted]

[redacted]

EXHIBIT "**B**"

AB663

THIS IS EXHIBIT " B *"*
referred to in the Affidavit of
David Hersey
Sworn before me this 20
day of April *A.D. 20* 21

A Commissioner in and for the Province of Alberta
John Carpay
Barrister and Solicitor

From: "Conner, Michael (JUS)" [redacted]
Date: Tuesday, March 30, 2021 at 8:59 AM
To: Allison Pejovic <apejovic@jccf.ca>
Cc: Jared Brown [redacted] Jay Cameron [redacted] "Leonoff, Heather (JUS)" [redacted]>, "Boyd, Sean (JUS)" <[redacted] Guenette, Denis (JUS)" [redacted]
Subject: RE: Gateway Bible Baptist Church v. MB - Letter Requesting Additional Materials

Good morning,

Please see the enclosed letter with attachments in reference to your request for undertakings from our affiants.

Regards,

Michael Conner

Michael Conner
General Counsel
Constitutional Law Section
[redacted]

From: Allison Pejovic <[redacted]>
Sent: March 19, 2021 12:49 PM
To: Leonoff, Heather (JUS) [redacted]; Boyd, Sean (JUS) [redacted] Conner, Michael (JUS) [redacted] Guenette, Denis (JUS) [redacted]
Cc: Jared Brown [redacted]>; Jay Cameron <[redacted]>
Subject: [Caution: Suspicious Email] Gateway Bible Baptist Church v. MB - Letter Requesting Additional Materials

Hello everyone,

Please find enclosed correspondence from the Applicants in respect of the upcoming hearing.

Please be advised that a third counsel has joined the Applicants' team. Jared Brown is Lead Counsel at Brown Litigation in Toronto and he is assisting us on this file. Please copy him on all future correspondence.

Best regards,

Allison Kindle Pejovic, B.A., LL.B., LL.M.
Barrister and Solicitor
Justice Centre for Constitutional Freedoms
[redacted]

[redacted]

"Defending the constitutional freedoms of Canadians"

Manitoba

Justice
Constitutional Law Section, Legal Services Branch
Crown Law Division
[redacted]

In reply, please refer to:

Michael Conner
General Counsel

[redacted]

File No: 230-08-20-114

March 30, 2021

Justice Centre for Constitutional Freedoms
[redacted]

Attention: Allison Kindle Pejovic

Dear Ms Pejovic:

Re: ***Gateway Bible Baptist Church et al. v. Manitoba et al.* – File No. CI 20-01-29284**

This is in response to your letter of March 19, 2021, in which you seek undertakings from the Respondents' affiants for the purpose of cross examination.

As you are aware, there is no entitlement to examinations for discovery in an Application. While undertakings can be requested under Rule 39.03.1, the rules contemplate this would occur during the course of cross examination and not as a means of advance discovery. An undertaking can be refused if it does not relate to an important issue, it would be overly onerous or the information would not significantly assist the court in determining the application.

In our view, many of the items requested are of marginal relevance or significance to the ultimate issue to be decided. Nonetheless, in the interest of being cooperative, we will provide the documents requested if they are readily available. Below, we respond to each item.

<u>Item 1: Affidavit of Carla Loeppky</u>

We decline to give this undertaking.

a) The affiant does not have possession of CT values. Further, the lab has no knowledge of whether a particular individual subsequently died of COVID-19 and therefore does not have a record of the CT values used for persons who later died of COVID-19. It would be unduly onerous to try to reconstruct this information.

b) The affiant does not have access to updated medical files of patients indicating whether the deceased was a symptomatic or asymptomatic case of COVID-19 at the time of death.

c) The affiant does not have possession or control over death certificates. Death certificates are prepared by attending physicians and provided to Vital Statistics in accordance with *The Vital Statistics Act*.

Item 2: Affidavit of Jared Bullard

We have attached manufacturers' inserts for PCR tests used by Cadham Provincial Laboratory.

Item 3: Affidavit of Jared Bullard

We decline to provide this undertaking as requested. The lab reports state whether the case is positive for COVID-19 but do not include CT values. The lab would have to undertake further analysis to provide the information requested.

Item 4: Affidavit of Brent Roussin

We decline this undertaking. Available information about the total number of COVID-19 hospitalizations, ICU admissions and deaths has been provided in the affidavit of Carla Loeppky. Specific information about hospitalization, ICU and deaths of individuals who isolated after contact tracing is not readily available.

Item 5: Affidavit of Carla Loeppky

The information requested is not relevant. The Chief Public Health Officers relies on COVID-19 deaths as reported to Epidemiology and Surveillance by hospitals or health officials in the community. Nonetheless, we can provide the following information.

Public Health has published a document for epidemiology and surveillance purposes entitled "COVID-19 Technical Notes", which is part of its Provincial Respiratory Surveillance Report. For reporting COVID-19 deaths, the document follows the "Word Health Organization Guidelines for Certification and Classification (Coding) of COVID-19 as a Cause of Death". These guidelines are consistent with the Public Health Agency of Canada guidelines entitled "National Case Definition".

The Technical Notes can be found here:
https://www.gov.mb.ca/health/publichealth/surveillance/covid-19/resources/Notes.html

The WHO Guidelines can be found here:
https://www.who.int/classifications/icd/Guidelines_Cause_of_Death_COVID-19.pdf

The Public Health Agency of Canada guidelines can be found here:
https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/health-professionals/national-case-definition.html

The affiant has no role in determining the cause of death. The Government of Manitoba has not issued any changes to how death certificates are prepared with respect to COVID-19. Death

Certificates are prepared in accordance with *The Vital Statistics Act*, which also follows WHO guidelines.

Item 6: Affidavits of Carla Loeppky and Lanette Siragusa

The number of deaths in Manitoba resulting from other non-communicable diseases is irrelevant to this Application. Nonetheless, the 2020 data is published by Statistics Canada.

Table 1: Number of total deaths in Manitoba from December 29, 2019 to November 14, 2020 by primary cause of death

Primary cause of death	Number
Malignant neoplasms	2020
Diseases of heart	1425
Cerebrovascular diseases	385
Chronic lower respiratory diseases	330
Accidents (unintentional injuries)	325

Data source: Statistics Canada. Table 13-10-0810-01 Selected grouped causes of death, by week

Item 7: Affidavit of Carla Loeppky

The list of modelling parameters is attached.

Item 8: Affidavit of Carla Loeppky

The definition of "cluster" is found at Appendix B of the Interim Guidance Public Health Measures. This document is cited at footnote 158 of Dr. Bhattacharya's report. An updated version of this document can be found at:
https://manitoba.ca/asset_library/en/coronavirus/interim_guidance.pdf

Item 9: Affidavit of Brent Roussin

We decline this undertaking. The information requested is not in the possession or control of the affiant. In any event, the historical ICU and surge capacity is not relevant to the Application.

Item 10: How many COVID-19 PCR positive cases were also tested for influenza

The Public Health Agency of Canada's FluWatch Report is attached. At page 2, the report indicates there were 38,500 influenza tests done in Manitoba from August 23, 2020 to March 20, 2021. Only 1 case tested positive for influenza. Since September 1, 2020, all would also have received a test for SARS-CoV-2.

Item 11: Manitoba's Pandemic Response Plan for the past 5 years

A copy of the Manitoba Emergency Plan can be found at:
https://www.gov.mb.ca/emo/pdfs/MEP.pdf

Sincerely,

"Original signed by"

Michael Conner,
General Counsel

c. Jay Cameron and Jared Brown, counsel for the Applicants
Heather Leonoff, Q.C., Denis Guénette and Sean Boyd, counsel for the Respondents

AB670

Rx Only

cobas® SARS-CoV-2

Qualitative assay for use on the cobas® 6800/8800 Systems

For in vitro diagnostic use

cobas® SARS-CoV-2	P/N: 09175431190
cobas® SARS-CoV-2 Control Kit	P/N: 09175440190
cobas® 6800/8800 Buffer Negative Control Kit	P/N: 07002238190

Table of Contents

Intended use

cobas® SARS-CoV-2 for use on the **cobas**® 6800/8800 Systems is a real-time RT-PCR test intended for the qualitative detection of nucleic acids from SARS-CoV-2 in clinician-instructed self-collected nasal swab specimens (collected on site), and clinician-collected nasal, nasopharyngeal and oropharyngeal swab samples from patients with signs and symptoms suggestive of COVID-19 (e.g., fever and/or symptoms of acute respiratory illness).

Results are for the detection of SARS-CoV-2 RNA that are detectable in nasal, nasopharyngeal and oropharyngeal swab samples during infection. Positive results are indicative of SARS-CoV-2 RNA detection, but may not represent the presence of transmissible virus.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.

cobas® SARS-CoV-2 is intended for use by trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures.

Summary and explanation of the test

Explanation of the test

cobas® SARS-CoV-2 is a qualitative test for use on the **cobas**® 6800 System and **cobas**® 8800 System for the detection of the 2019 novel coronavirus (SARS-CoV-2) RNA in nasal, nasopharyngeal and oropharyngeal swab samples collected in Copan Universal Transport Medium System (UTM-RT), BD™ Universal Viral Transport System (UVT), **cobas**® PCR Media, or 0.9% physiological saline. The RNA Internal Control, used to monitor the entire sample preparation and PCR amplification process, is introduced into each specimen during sample processing. In addition, the test utilizes external controls (low titer positive control and a negative control).

Principles of the procedure

cobas® SARS-CoV-2 is based on fully automated sample preparation (nucleic acid extraction and purification) followed by PCR amplification and detection. The **cobas**® 6800/8800 Systems consist of the sample supply module, the transfer module, the processing module, and the analytic module. Automated data management is performed by the **cobas**® 6800/8800 software, which assigns test results for all tests. Results can be reviewed directly on the system screen, and printed as a report.

Nucleic acid from patient samples and added internal control RNA (RNA IC) molecules are simultaneously extracted. Nucleic acid is released by addition of proteinase and lysis reagent to the sample. The released nucleic acid binds to the silica surface of the added magnetic glass particles. Unbound substances and impurities, such as denatured protein, cellular debris and potential PCR inhibitors, are removed with subsequent wash steps and purified nucleic acid is eluted from the magnetic glass particles with elution buffer at elevated temperature. External controls (positive and negative) are processed in the same way with each **cobas**® SARS-CoV-2 run.

Selective amplification of target nucleic acid from the sample is achieved by the use of target-specific forward and reverse primers for ORF1a/b non-structural region that is unique to SARS-CoV-2. Additionally, a conserved region in the structural protein envelope E-gene were chosen for pan-Sarbecovirus detection. The pan-Sarbecovirus detection sets will also detect SARS-CoV-2 virus.

Selective amplification of RNA Internal Control is achieved by the use of non-competitive sequence specific forward and reverse primers which have no homology with the coronavirus genome. A thermostable DNA polymerase enzyme is used for amplification.

The **cobas**® SARS-CoV-2 master mix contains detection probes which are specific for the coronavirus type SARS-CoV-2, members of the Sarbecovirus subgenus, and the RNA Internal Control nucleic acid. The coronavirus and RNA Internal Control detection probes are each labeled with unique fluorescent dyes that act as a reporter. Each probe also has a second dye which acts as a quencher. When not bound to the target sequence, the fluorescent signals of the intact probes are suppressed by the quencher dye. During the PCR amplification step, hybridization of the probes to the specific single-stranded DNA template results in cleavage of the probe by the 5' to 3' exonuclease activity of the DNA polymerase resulting in separation of the reporter and quencher dyes and the generation of a fluorescent signal. With each PCR cycle, increasing amounts of cleaved probes are generated and the cumulative signal of the reporter dye increases concomitantly. Each reporter dye is measured at defined wavelengths, which enables simultaneous detection and discrimination of the amplified coronavirus target and the RNA Internal Control. The master mix includes deoxyuridine triphosphate (dUTP), instead of deoxythimidine triphosphate (dTTP), which is incorporated into the newly synthesized DNA (amplicon). Any contaminating amplicons from previous PCR runs are destroyed by the AmpErase enzyme [uracil-N-glycosylase], which is included in the PCR mix, when heated in the first thermal cycling step. However, newly formed amplicons are not destroyed since the AmpErase enzyme is inactivated once exposed to temperatures above 55°C.

Reagents and materials

The materials provided for **cobas**® SARS-CoV-2 can be found in Table 1. Materials required, but not provided can be found in Table 2, Table 3, Table 4, Table 7, and Table 8.

Refer to the **Reagents and materials** section and **Precautions and handling requirements** section for the hazard information for the product.

cobas® SARS-CoV-2 reagents and controls

All unopened reagents and controls shall be stored as recommended in Table 1 to Table 4.

Table 1 cobas® SARS-CoV-2

cobas® SARS-CoV-2 Store at 2-8°C 192 test cassette (P/N 09175431190)		
Kit components	**Reagent ingredients**	**Quantity per kit 192 tests**
Proteinase Solution (PASE)	Tris buffer, < 0.05% EDTA, calcium chloride, calcium acetate, 8% proteinase EUH210: Safety data sheet available on request. EUH208: Contains Subtilisin. May produce an allergic reaction.	22.3 mL
RNA Internal Control (RNA IC)	Tris buffer, <0.05% EDTA, <0.001% non-Sarbecovirus related armored RNA construct containing primer and probe specific primer sequence regions (non-infectious RNA in MS2 bacteriophage), <0.1% sodium azide	21.2 mL
Elution Buffer (EB)	Tris buffer, 0.2% methyl-4 hydroxybenzoate	21.2 mL
Master Mix Reagent 1 (MMX-R1)	Manganese acetate, potassium hydroxide, < 0.1% sodium azide	7.5 mL
SARS-CoV-2 Master Mix Reagent 2 (SARS-CoV-2 MMX-R2)	Tricine buffer, potassium acetate, < 18% dimethyl sulfoxide, glycerol, < 0.1% Tween 20, EDTA, < 0.12% dATP, dCTP, dGTP, dUTPs, < 0.01% upstream and downstream SARS-CoV-2 and Sarbecovirus primers, < 0.01% Internal Control forward and reverse primers, < 0.01% fluorescent-labeled oligonucleotide probes specific for SARS-CoV-2, Sarbecovirus, and the RNA Internal Control, < 0.01% oligonucleotide aptamer, < 0.1% Z05D DNA polymerase, < 0.10% AmpErase (uracil-N-glycosylase) enzyme (microbial), < 0.1% sodium azide	9.7 mL

Table 2 **cobas**® SARS-CoV-2 Control Kit

cobas® SARS-CoV-2 Control Kit Store at 2–8°C (P/N 09175440190)		
Kit components	**Reagent ingredients**	**Quantity per kit**
SARS-CoV-2 Positive Control **(SARS-CoV-2 (+)C)**	Tris buffer, < 0.05% Sodium azide, < 0.005% EDTA, < 0.003% Poly rA, < 0.01% Non-infectious plasmid DNA (microbial) containing SARS-CoV-2 sequence, < 0.01% Non-infectious plasmid DNA (microbial) containing pan-Sarbecovirus 1 sequence, < 0.01% Non-infectious plasmid DNA (microbial) containing pan-Sarbecovirus sequence	16 mL (16 x 1 mL)

Table 3 **cobas**® Buffer Negative Control Kit

cobas® Buffer Negative Control Kit Store at 2-8°C (P/N 07002238190)		
Kit components	**Reagent ingredients**	**Quantity per kit**
cobas® Buffer Negative Control **(BUF (-) C)**	Tris buffer, < 0.1% sodium azide, EDTA, < 0.002% Poly rA RNA (synthetic)	16 mL (16 x 1 mL)

cobas omni reagents for sample preparation

Table 4 **cobas omni** reagents for sample preparation*

Reagents	Reagent ingredients	Quantity per kit	Safety symbol and warning**
cobas omni MGP Reagent (MGP) Store at 2–8°C (P/N 06997546190)	Magnetic glass particles, Tris buffer, 0.1% methyl-4 hydroxybenzoate, < 0.1% sodium azide	480 tests	Not applicable
cobas omni Specimen Diluent (SPEC DIL) Store at 2–8°C (P/N 06997511190)	Tris buffer, 0.1% methyl-4 hydroxybenzoate, < 0.1% sodium azide	4 x 875 mL	Not applicable
cobas omni Lysis Reagent (LYS) Store at 2–8°C (P/N 06997538190)	43% (w/w) guanidine thiocyanate***, 5% (w/v) polydocanol***, 2% (w/v) dithiothreitol***, dihydro sodium citrate	4 x 875 mL	 **DANGER** H302 + H332: Harmful if swallowed or if inhaled. H314: Causes severe burns and eye damage. H412: Harmful to aquatic life with long lasting effects. EUH032: Contact with acids liberates very toxic gas. P261: Avoid breathing dust/fume/gas/mist/vapours/ spray. P273: Avoid release to the environment. P280: Wear protective gloves/ protective clothing/ eye protection/ face protection. P303 + P361 + P353: IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water. P304 + P340 + P310: IF INHALED: Remove person to fresh air and keep comfortable for breathing. Immediately call a POISON CENTER/doctor. P305 + P351 + P338 + P310: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor. 593-84-0 Guanidinium thiocyanate 9002-92-0 Polidocanol 3483-12-3 (R*,R*)-1,4-dimercaptobutane-2,3-diol
cobas omni Wash Reagent (WASH) Store at 15–30°C (P/N 06997503190)	Sodium citrate dihydrate, 0.1% methyl-4 hydroxybenzoate	4.2 L	Not applicable

* These reagents are not included in the **cobas**® SARS-CoV-2 test kit. See listing of additional materials required (Table 7).

** Product safety labeling primarily follows EU GHS guidance

***Hazardous substance

Reagent storage and handling requirements

Reagents shall be stored and will be handled as specified in Table 5 and Table 6.

When reagents are not loaded on the **cobas**® 6800/8800 Systems, store them at the corresponding temperature specified in Table 5.

Table 5 Reagent storage (when reagent is not on the system)

Reagent	Storage temperature
cobas® SARS-CoV-2 -192	2–8°C
cobas® SARS-CoV-2 Control Kit	2–8°C
cobas® Buffer Negative Control Kit	2–8°C
cobas omni Lysis Reagent	2–8°C
cobas omni MGP Reagent	2–8°C
cobas omni Specimen Diluent	2–8°C
cobas omni Wash Reagent	15–30°C

Reagents loaded onto the **cobas**® 6800/8800 Systems are stored at appropriate temperatures and their expiration is monitored by the system. The **cobas**® 6800/8800 Systems allow reagents to be used only if all of the conditions shown in Table 6 are met. The system automatically prevents use of expired reagents. Table 6 allows the user to understand the reagent handling conditions enforced by the **cobas**® 6800/8800 Systems.

Table 6 Reagent expiry conditions enforced by the **cobas**® 6800/8800 Systems

Reagent	Kit expiration date	Open-kit stability	Number of runs for which this kit can be used	On-board stability (cumulative time on board outside refrigerator)
cobas® SARS-CoV-2 – 192	Date not passed[1]	90 days from first usage[1,2]	Max 40 runs[1]	Max 40 hours[1]
cobas® SARS-CoV-2 Control Kit	Date not passed[1]	Not applicable[3]	Not applicable	Max 8 hours[1]
cobas® Buffer Negative Control Kit	Date not passed	Not applicable[3]	Not applicable	Max 10 hours
cobas omni Lysis Reagent	Date not passed	30 days from loading[2]	Not applicable	Not applicable
cobas omni MGP Reagent	Date not passed	30 days from loading[2]	Not applicable	Not applicable
cobas omni Specimen Diluent	Date not passed	30 days from loading[2]	Not applicable	Not applicable
cobas omni Wash Reagent	Date not passed	30 days from loading[2]	Not applicable	Not applicable

[1] The performance has not been established for suggested use cycles and time, but is based on similar reagents used on the same system.

[2] Time is measured from the first time that reagent is loaded onto the **cobas**® 6800/8800 Systems.

[3] Single use reagents

Additional materials required

Table 7 Materials and consumables for use on **cobas**® 6800/8800 Systems

Material	P/N
cobas omni Processing Plate	05534917001
cobas omni Amplification Plate	05534941001
cobas omni Pipette Tips	05534925001
cobas omni Liquid Waste Container	07094388001
cobas omni Lysis Reagent	06997538190
cobas omni MGP Reagent	06997546190
cobas omni Specimen Diluent	06997511190
cobas omni Wash Reagent	06997503190
Solid Waste Bag	07435967001
Solid Waste Bag and Solid Waste Container or Solid Waste Bag With Insert and Kit Drawer	07435967001 and 07094361001 or 08030073001 and 08387281001
Solid Waste Container	07094361001
cobas omni Secondary Tubes 13x75 (optional)	06438776001

Instrumentation and software required

The **cobas**® 6800/8800 software and **cobas**® SARS-CoV-2 analysis package must be installed on the instrument(s). The Instrument Gateway (IG) server will be provided with the system.

Table 8 Instrumentation

Equipment	P/N
cobas® 6800 System (Moveable Platform)	05524245001 and 06379672001
cobas® 6800 System (Fixed Platform)	05524245001 and 06379664001
cobas® 8800 System	05412722001
Sample Supply Module	06301037001
Instrument Gateway	06349595001

For additional information, please refer to the **cobas**® 6800/8800 Systems – User Assistance and/or User Guide.

Note: Contact your local Roche representative for a detailed order list for sample racks, racks for clotted tips and rack trays accepted on the instruments.

Precautions and handling requirements

Warnings and precautions

As with any test procedure, good laboratory practice is essential to the proper performance of this assay. Due to the high sensitivity of this test, care should be taken to keep reagents and amplification mixtures free of contamination.

- For *in vitro* diagnostic use.
- Positive results are indicative of presence of SARS-CoV-2 RNA.
- All patient samples should be handled as if infectious, using good laboratory procedures as outlined in Biosafety in Microbiological and Biomedical Laboratories and in the CLSI Document M29-A4.[1,2] Only personnel proficient in handling infectious materials and the use of **cobas**® SARS-CoV-2 and **cobas**® 6800/8800 Systems should perform this procedure.
- All human-sourced materials should be considered potentially infectious and should be handled with universal precautions. If spillage occurs, immediately disinfect with a freshly prepared solution of 0.5% sodium hypochlorite in distilled or deionized water (dilute household bleach 1:10) or follow appropriate site procedures.
- The use of sterile disposable pipettes and nuclease-free pipette tips is recommended. Use only supplied or specified required consumables to ensure optimal test performance.
- Safety Data Sheets (SDS) are available on request from your local Roche representative.
- Closely follow procedures and guidelines provided to ensure that the test is performed correctly. Any deviation from the procedures and guidelines may affect optimal test performance.
- False positive results may occur if carryover of samples is not adequately controlled during sample handling and processing.

Reagent handling

- Handle all reagents, controls, and samples according to good laboratory practice in order to prevent carryover of samples or controls.
- Before use, visually inspect each reagent cassette, diluent, lysis reagent, and wash reagent to ensure that there are no signs of leakage. If there is any evidence of leakage, do not use that material for testing.
- **cobas omni** Lysis Reagent contains guanidine thiocyanate, a potentially hazardous chemical. Avoid contact of reagents with the skin, eyes, or mucous membranes. If contact does occur, immediately wash with generous amounts of water; otherwise, burns can occur.
- **cobas**® SARS-CoV-2 test kit, **cobas**® SARS-CoV-2 Control kit, **cobas**® Buffer Negative Control kit, **cobas omni** MGP Reagent, and **cobas omni** Specimen Diluent contain sodium azide as a preservative. Avoid contact of reagents with the skin, eyes, or mucous membranes. If contact does occur, immediately wash with generous amounts of water; otherwise, burns can occur. If these reagents are spilled, dilute with water before wiping dry.
- Do not allow **cobas omni** Lysis Reagent, which contains guanidine thiocyanate, to contact sodium hypochlorite (bleach) solution. This mixture can produce a highly toxic gas.
- Dispose of all materials that have come in contact with samples and reagents in accordance with country, state, and local regulations.

Good laboratory practice

- Do not pipette by mouth.
- Do not eat, drink, or smoke in designated work areas.
- Wear laboratory gloves, laboratory coats, and eye protection when handling samples and reagents. Gloves must be changed between handling samples and **cobas®** SARS-CoV-2 kits, **cobas®** SARS-CoV-2 Control kit, **cobas®** Buffer Negative Control kit and **cobas omni** reagents to prevent contamination. Avoid contaminating gloves when handling samples and controls.
- Wash hands thoroughly after handling samples and kit reagents, and after removing the gloves.
- Thoroughly clean and disinfect all laboratory work surfaces with a freshly prepared solution of 0.5% sodium hypochlorite in distilled or deionized water (dilute household bleach 1:10). Follow by wiping the surface with 70% ethanol.
- If spills occur on the **cobas®** 6800/8800 instrument, follow the instructions in the **cobas®** 6800/8800 Systems – User Assistance and/or User Guide to properly clean and decontaminate the surface of instrument(s).

Sample collection, transport, and storage

Note: Handle all samples and controls as if they are capable of transmitting infectious agents.

Sample collection

- Collect nasal, nasopharyngeal and oropharyngeal specimens according to standard collection technique using flocked or polyester-tipped swabs and immediately place in 3 mL of Copan Universal Transport Medium (UTM-RT) or BD™ Universal Viral Transport (UVT).
- Collect nasal specimens according to standard collection technique using flocked or polyester-tipped swabs and immediately place into **cobas®** PCR Media tube from **cobas®** PCR Media Kit (P/N 06466281190).
- Collect nasal specimens using the **cobas®** PCR Media Uni Swab Sample Kit (P/N 07958030190) or **cobas®** PCR Media Dual Swab Sample Kit (P/N 07958021190) according to instructions below.

Nasal (anterior nares) swab specimen collection - clinician or self-collected on site

WARNING: DO NOT PRE-WET SWAB IN cobas® PCR MEDIA BEFORE COLLECTION!



The **cobas®** PCR Media Uni Swab Sample kit contains:

cobas® PCR Media tube
Woven Swab: A

OR



The **cobas®** PCR Media Dual Swab Sample kit contains:

cobas® PCR Media Tube
Woven Swab: A
Flocked Swab: B



DO NOT PRE-WET SWAB IN cobas® PCR MEDIA BEFORE COLLECTION!

1. **COLLECT:** Hold the woven swab (Swab A) or the flocked swab (Swab B) with the scoreline above your hand. Insert the swab 1-2 cm into one of the anterior nares. Rotate the swab against the nasal mucosa for about 3 seconds and withdraw. Repeat with the other anterior nare using the same swab.

Do not let the swab touch any surface before placing it into the collection tube.



2. **ALIGN:** Remove the cap from the **cobas**® PCR Media Tube and lower the swab specimen into the tube until the visible scoreline on the swab is aligned with the tube rim.

3. **BREAK:** Carefully leverage the swab against the tube rim to break the swab shaft at the scoreline.



4. **CLOSE: Tightly** re-cap the **cobas**® PCR Media Tube. The specimen is now ready for transport. Discard the top portion of the swab.

- Collect nasal specimens according to standard collection technique using flocked or polyester-tipped swabs and immediately place in 3 mL of 0.9% physiological saline.

Transport and storage

Transportation of collected specimens must comply with all applicable regulations for the transport of etiologic agents.

- Transport and store samples collected in **cobas**® PCR Media or 0.9% physiological saline as follows:
  - After collection, specimens in **cobas**® PCR Media or 0.9% physiological saline should be stored at 2-8°C and processed within 48 hours.
- Sample stability when using **cobas**® SARS-CoV-2 has not been established for suggested temperatures and time, but is based on viability data from testing similar viruses in the UTM-RT or UVT Systems as stated in Copan UTM-RT System Instructions For Use and shown below:
  - After collection, the specimen should be stored at 2-25°C and processed within 48 hours.
  - If delivery and processing exceed 48 hours, specimens should be transported in dry ice and once in laboratory frozen at -70°C or colder.

Instructions for use

Procedural notes

- Do not use **cobas**® SARS-CoV-2 reagents, **cobas**® SARS-CoV-2 Control Kit, **cobas**® Buffer Negative Control Kit, or **cobas omni** reagents after their expiry dates.
- Do not reuse consumables. They are for one-time use only.
- Refer to the **cobas**® 6800/8800 Systems – User Assistance and/or User Guide for proper maintenance of instruments.

Running cobas® SARS-CoV-2

cobas® SARS-CoV-2 can be run with a minimum required sample volume of 0.6 mL.

Always use caution when transferring specimens from a primary collection tube to a secondary tube.

Use pipettes with aerosol-barrier or positive-displacement tips to handle specimens.

Always use a new pipette tip for each specimen.

Ensure samples are equilibrated to room temperature prior to transfer into a cobas omni Secondary Tube.

Follow the steps below to transfer patient sample from a primary collection tube into a **cobas omni** Secondary Tube:

- Unscrew the primary sample tube cap.
- Lift the cap and any attached swab to allow a pipette to be inserted into the sample tube.
- Transfer 0.6 mL into the prepared barcoded secondary tube.
- Transfer secondary tube to a rack. Close the primary sample tube cap.

The test procedure is described in detail in the **cobas**® 6800/8800 Systems – User Assistance and/or User Guide. Figure 1 below summarizes the procedure.

Figure 1 **cobas**® SARS-CoV-2 procedure

1 Create order(s)

2 Refill reagents and consumables as prompted by the system:
- Refill wash reagent, lysis reagent and diluent
- Refill processing plates and amplification plates
- Refill magnetic glass particles
- Refill test specific reagents
- Refill control cassettes
- Refill tip racks
- Replace rack for clotted tips

3 Start the run by choosing the Start manually button on the user interface or have it start automatically after 120 minutes or if the batch is full.

4 Review and export results

5 Unload reagents and consumables:
- Unload amplification plates from the analytic module
- Unload empty control cassettes
- Empty solid waste
- Empty liquid waste

Results

The **cobas**® 6800/8800 Systems automatically detect the SARS-CoV-2 , for each individually processed sample and control, displaying individual target results for samples as well as test validity and overall results for controls.

Quality control and validity of results

- One **cobas**® Buffer Negative Control [(-) Ctrl] and one [SARS-CoV-2 (+)C] are processed with each batch.
- In the **cobas**® 6800/8800 software and/or report, check for flags and their associated results to ensure the batch validity.
- All flags are described in the **cobas**® 6800/8800 Systems User Guide.
- The batch is valid if no flags appear for any controls. If the batch is invalid, repeat testing of the entire batch.

Validation of results is performed automatically by the **cobas**® 6800/8800 software based on negative and positive control performance.

Interpretation of results

cobas® SARS-CoV-2 for System Software v1.2

Display examples for **cobas**® SARS-CoV-2 for System Software v1.2 or higher are shown in Figure 2.

Figure 2 Example of **cobas**® SARS-CoV-2 results display for System Software v1.2

Test	Sample ID	Valid*	Flags	Sample type	Overall result*	Target 1	Target 2
SARS-CoV-2 400 µL	Swab_01	Yes		Swab	**Negative**	Negative	Negative
SARS-CoV-2 400 µL	Swab _C1	No	Y40T	Swab	**Invalid**	Invalid	Invalid
SARS-CoV-2 400 µL	Swab _B1	Yes		Swab	**Reactive**	Negative	Positive
SARS-CoV-2 400 µL	Swab _B2	Yes		Swab	**Positive**	Positive	Positive
SARS-CoV-2 400 µL	Swab _D1	Yes		Swab	**Negative**	Negative	Negative
SARS-CoV-2 400 µL	Swab _A6	Yes		Swab	**Reactive**	Positive	Negative
SARS-CoV-2 400 µL	Swab _E1	No	C01H2	Swab	**Invalid**	Positive	Invalid
SARS-CoV-2 400 µL	Swab _A2	No	C01H1	Swab	**Invalid**	Invalid	Positive
SARS-CoV-2	C161420284090428828404	Yes		(-) Ctrl	**Valid**	Valid	Valid
SARS-CoV-2	C161420284093009580264	Yes		SARS-CoV-2 (+) C	**Valid**	Valid	Valid

* The "Valid" and "Overall Result" columns are not applicable to sample results for the **cobas**® SARS-CoV-2. Values reported in these columns are not applicable and do not impact the validity of results reported within individual Target Result columns. Refer to Table 9, **cobas**® SARS-CoV-2 results interpretation, for specific instructions on test results interpretation.

cobas® SARS-CoV-2 for System Software v1.3 or higher

Display examples for **cobas**® SARS-CoV-2 for System Software v1.3 or higher are shown in Figure 3.

Figure 3 Example of **cobas**® SARS-CoV-2 results display for System Software v1.3 or higher

Test	Sample ID	Valid*	Flags	Sample type	Overall result*	Target 1	Target 2
SARS-CoV-2 400 µL	Swab_01	NA		Swab	**NA**	Negative	Negative
SARS-CoV-2 400 µL	Swab _C1	NA	Y40T	Swab	**NA**	Invalid	Invalid
SARS-CoV-2 400 µL	Swab _B1	NA		Swab	**NA**	Negative	Positive
SARS-CoV-2 400 µL	Swab _B2	NA		Swab	**NA**	Positive	Positive
SARS-CoV-2 400 µL	Swab _D1	NA		Swab	**NA**	Negative	Negative
SARS-CoV-2 400 µL	Swab _A6	NA		Swab	**NA**	Positive	Negative
SARS-CoV-2 400 µL	Swab _E1	NA	C01H2	Swab	**NA**	Positive	Invalid
SARS-CoV-2 400 µL	Swab _A2	NA	C01H1	Swab	**NA**	Invalid	Positive
SARS-CoV-2	C161420284090428828404	Yes		(-) Ctrl	**Valid**	Valid	Valid
SARS-CoV-2	C161420284093009580264	Yes		SARS-CoV-2 (+) C	**Valid**	Valid	Valid

* The "Valid" and "Overall Result" columns are not applicable to sample results for the **cobas**® SARS-CoV-2. Values reported in these columns are not applicable and do not impact the validity of results reported within individual Target Result columns. Refer to Table 9, **cobas**® SARS-CoV-2 results interpretation, for specific instructions on test results interpretation.

Interpretation of results

The following result interpretation applies to both **cobas**® 6800/8800 software version 1.2 and **cobas**® 6800/8800 software version 1.3 and higher.

For a valid batch, check each individual sample for flags in the **cobas**® 6800/8800 software and/or report. The result interpretation should be as follows:

- A valid batch may include both valid and invalid sample results.
- **The "Valid" and "Overall Result" columns are not applicable to sample results for the cobas® SARS-CoV-2. Values reported in these columns are not applicable and do not impact the validity of results reported within individual Target Result columns.**
- Invalid results for one or more target combinations are possible and are reported out specifically for each channel.
- Results of this test should only be interpreted in conjunction with information available from clinical evaluation of the patient and patient history.

Results and their corresponding interpretation for detecting SARS-CoV-2 are shown below (Table 9).

Table 9 **cobas**® SARS-CoV-2 results interpretation

Target 1	Target 2	Interpretation
Positive	**Positive**	All Target Results were valid. Result for SARS-CoV-2 RNA is Detected.
Positive	**Negative**	All Target Results were valid. Result for SARS-CoV-2 RNA is Detected. A positive Target 1 result and a negative Target 2 result is suggestive of 1) a sample at concentrations near or below the limit of detection of the test, 2) a mutation in the Target 2, target region, or 3) other factors.
Negative	**Positive**	All Target Results were valid. Result for SARS-CoV-2 RNA is Presumptive Positive. A negative Target 1 result and a positive Target 2 result is suggestive of 1) a sample at concentrations near or below the limit of detection of the test, 2) a mutation in the Target 1 target region in the oligo binding sites, or 3) infection with some other Sarbecovirus (e.g., SARS-CoV or some other Sarbecovirus previously unknown to infect humans), or 4) other factors. Sample should be retested. For samples with a repeated Presumptive Positive result, additional confirmatory testing may be conducted, if it is necessary to differentiate between SARS-CoV-2 and SARS-CoV-1 or other Sarbecovirus currently unknown to infect humans, for epidemiological purposes or clinical management.
Negative	**Negative**	All Target Results were valid. Result for SARS-CoV-2 RNA is Not Detected.
Positive	**Invalid**	Not all Target Results were valid. Result for SARS-CoV-2 RNA is Detected.
Invalid	**Positive**	Not all Target Results were valid. Result for SARS-CoV-2 RNA is Presumptive Positive. Sample should be retested. For samples with a repeated Presumptive Positive result, additional confirmatory testing may be conducted, if it is necessary to differentiate between SARS-CoV-2 and SARS-CoV-1 or other Sarbecovirus currently unknown to infect humans, for epidemiological purposes or clinical management.
Negative	**Invalid**	Not all Target Results were valid. Sample should be retested. If the result is still invalid, a new specimen should be obtained.
Invalid	**Negative**	Not all Target Results were valid. Sample should be retested. If the result is still invalid, a new specimen should be obtained.
Invalid	**Invalid**	All Target Results were invalid. Sample should be retested. If the result is still invalid, a new specimen should be obtained.

Procedural limitations

- **cobas**® SARS-CoV-2 has been evaluated only for use in combination with the **cobas**® SARS-CoV-2 Control Kit, **cobas**® Buffer Negative Control Kit, **cobas omni** MGP Reagent, **cobas omni** Lysis Reagent, **cobas omni** Specimen Diluent, and **cobas omni** Wash Reagent for use on the **cobas**® 6800/8800 Systems.
- Reliable results depend on proper sample collection, storage and handling procedures.
- This test is intended to be used for the detection of SARS-CoV-2 RNA in nasal, nasopharyngeal and oropharyngeal swab samples collected in a Copan UTM-RT System (UTM-RT) or BD™ Universal Viral Transport System (UVT), and nasal swab samples collected in **cobas**® PCR Media and 0.9% physiological saline. Testing of other sample types with **cobas**® SARS-CoV-2 may result in inaccurate results.
- Detection of SARS-CoV-2 RNA may be affected by sample collection methods, patient factors (e.g., presence of symptoms), and/or stage of infection.
- As with any molecular test, mutations within the target regions of **cobas**® SARS-CoV-2 could affect primer and/or probe binding resulting in failure to detect the presence of virus.
- Due to inherent differences between technologies, it is recommended that, prior to switching from one technology to the next, users perform method correlation studies in their laboratory to qualify technology differences. One hundred percent agreement between the results should not be expected due to aforementioned differences between technologies. Users should follow their own specific policies/procedures.
- False negative or invalid results may occur due to interference. The Internal Control is included in **cobas**® SARS-CoV-2 to help identify the specimens containing substances that may interfere with nucleic acid isolation and PCR amplification.
- The addition of AmpErase enzyme into the **cobas**® SARS-CoV-2 Master Mix reagent enables selective amplification of target RNA; however, good laboratory practices and careful adherence to the procedures specified in this Instructions For Use document are necessary to avoid contamination of reagents.

Non-clinical performance evaluation

Key performance characteristics

Analytical sensitivity

Limit of detection (LoD) studies determine the lowest detectable concentration of SARS-CoV-2 at which greater or equal to 95% of all (true positive) replicates test positive.

To determine the LoD, a cultured virus of an isolate from a US patient (USA-WA1/2020, catalog number NR-52281, lot number 70033175, 2.8E+05 $TCID_{50}$/mL[§]) was serially diluted in simulated clinical matrix. A total of 7 concentration levels, with 3-fold serial dilutions between the levels, were tested with a total of 21 replicates per concentration, with an additional 10 replicates of a blank sample (i.e, simulated clinical matrix).

As shown in Table 10, the concentration level with observed hit rates greater than or equal to 95% were 0.009 and 0.003 $TCID_{50}$/mL for SARS-CoV-2 (Target 1) and pan-Sarbecovirus (Target 2), respectively. As shown in Table 11, the Probit predicted 95% hit rates were 0.007 and 0.004 $TCID_{50}$/mL for SARS-CoV-2 (Target 1) and pan-Sarbecovirus (Target 2), respectively.

Table 10 LoD determination using USA-WA1/2020 strain

Strain	Concentration [$TCID_{50}$/mL]	Total valid results	Hit rate [%]^		Mean Ct*	
			Target 1	Target 2	Target 1	Target 2
USA-WA1/2020[§] (stock concentration 2.8E+05 $TCID_{50}$/mL)	0.084	21	100	100	31.0	33.0
	0.028	21	100	100	31.8	34.1
	0.009	21	100	100	32.7	35.2
	0.003	21	38.1	100	33.5	36.4
	0.001	21	0	52.4	n/a	37.9
	0.0003	21	0	14.3	n/a	37.2
	0.0001	21	0	9.5	n/a	38.5
	0 (blank)	10	0	0	n/a	n/a

[§] Reagent was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate USA-WA1/2020, NR-52281

^ All replicates where Target 1 was positive were also positive for Target 2.

* Calculations only include positive results.

Table 11 Probit predicted 95% hit rates using USA-WA1/2020 strain

Strain	Probit Predicted 95% Hit Rate [$TCID_{50}$/mL]	
	Target 1	Target 2
USA-WA1/2020 (stock concentration 2.8E+05 $TCID_{50}$/mL)	0.007 (95% CI: 0.005 – 0.036)	0.004 (95% CI: 0.002 – 0.009)

Cross-reactivity

In silico analysis

The *in silico* analysis for possible cross-reactions with all the organisms listed in Table 12 was conducted by mapping primers in **cobas**® SARS-CoV-2 individually to the sequences downloaded from NCBI and GISAID databases. If any two of the primers were mapped to a sequence on opposite strands with short distance apart, potential amplifications were flagged. No potential unintended cross reactivity is expected based on this *in silico* analysis.

Table 12 In silico analysis for SARS-CoV-2

Strain	***In Silico*** **Analysis for % Identity to Target 1 (nCoV)**	***In Silico*** **Analysis for % Identity to Target 2 (Pan-Sarbecovirus 1)**
CoV 229E	74.47	No alignment was found*
CoV OC43	72.26	No alignment was found*
CoV HKU1	76.52	No alignment was found*
CoV NL63	71.32	No alignment was found*
SARS-CoV	95.04	100
MERS	No alignment was found*	No alignment was found*
AdV	No alignment was found*	No alignment was found*
HMPV	No alignment was found*	No alignment was found*
HPIV1	No alignment was found*	No alignment was found*
HPIV2	No alignment was found*	No alignment was found*
HPIV3	No alignment was found*	No alignment was found*
HPIV4	No alignment was found*	No alignment was found*
Flu A	No alignment was found*	No alignment was found*
Flu B	No alignment was found*	No alignment was found*
EV	No alignment was found*	No alignment was found*
RSV	No alignment was found*	No alignment was found*
RV	No alignment was found*	No alignment was found*
Chlamydia pneumoniae	No alignment was found*	No alignment was found*
Haemophilus influenzae	No alignment was found*	No alignment was found*

Strain	***In Silico* Analysis for % Identity to Target 1 (nCoV)**	***In Silico* Analysis for % Identity to Target 2 (Pan-Sarbecovirus 1)**
Legionella pneumophila	No alignment was found*	No alignment was found*
MTB Mycobacterium bovis subsp. Bovis	No alignment was found*	No alignment was found*
Streptococcus pneumoniae	No alignment was found*	No alignment was found*
Streptococcus pyrogenes	No alignment was found*	No alignment was found*
Bordetella pertussis	No alignment was found*	No alignment was found*
Mycoplasma pneumoniae	No alignment was found*	No alignment was found*
Pneumocystis jirovecii	No alignment was found*	No alignment was found*
Influenza C	No alignment was found*	No alignment was found*
Parechovirus	No alignment was found*	No alignment was found*
Candida albicans	No alignment was found*	No alignment was found*
Corynebacterium diphtheriae	No alignment was found*	No alignment was found*
Legionella non-pneumophila	No alignment was found*	No alignment was found*
Bacillus anthracis (Anthrax)	No alignment was found*	No alignment was found*
Moraxella catarrhalis	No alignment was found*	No alignment was found*
Neisseria elongate and meningitides	No alignment was found*	No alignment was found*
Pseudomonas aeruginosa	No alignment was found*	No alignment was found*
Staphylococcus epidermidis	No alignment was found*	No alignment was found*
Staphylococcus salivarius	No alignment was found*	No alignment was found*
Leptospira	No alignment was found*	No alignment was found*
Chlamydia psittaci	No alignment was found*	No alignment was found*
Coxiella burnetii (Q-Fever)	No alignment was found*	No alignment was found*
Staphylococcus aureus	No alignment was found*	No alignment was found*

Note: * The amplicon sequences were blasted against all the exclusive sequences with very low stringency cutoff (50% and 100bp). No alignment were found passing the cutoff and no concerns for cross-reactivity were observed.

Cross reactivity testing

Cross-reactivity of **cobas**® SARS-CoV-2 was evaluated by testing whole organisms. As listed in Table 13, a panel of multiple unique sub-species of microorganisms were tested. High titer stocks of the potentially cross-reacting microorganisms were spiked into negative simulated clinical matrix to a concentration level of 1.0E+05 units/mL for viruses and 1.0E+06 units/mL for other microorganisms, unless otherwise noted.

None of the organisms tested interfered with **cobas**® SARS-CoV-2 performance by generating false positive results.

Table 13 Cross-reactivity test results

Microorganism	Concentration	Target 1 Result	Target 2 Result
Human coronavirus 229E	1.0E+05 $TCID_{50}$/mL	Negative	Negative
Human coronavirus OC43	1.0E+05 $TCID_{50}$/mL	Negative	Negative
Human coronavirus HKU1	1.0E+05 cp/mL	Negative	Negative
Human coronavirus NL63	1.0E+05 $TCID_{50}$/mL	Negative	Negative
MERS coronavirus	1.0E+05 genomic equivalent/mL	Negative	Negative
SARS coronavirus	1.0E+05 PFU/mL	Negative	Positive
Adenovirus B (Type 34)	1.0E+05 $TCID_{50}$/mL	Negative	Negative
Human Metapneumovirus (hMPV)	1.0E+05 $TCID_{50}$/mL	Negative	Negative
Parainfluenza virus Type 1	1.0E+05 $TCID_{50}$/mL	Negative	Negative
Parainfluenza virus Type 2	1.0E+05 $TCID_{50}$/mL	Negative	Negative
Parainfluenza virus Type 3	1.0E+05 $TCID_{50}$/mL	Negative	Negative
Parainfluenza virus Type 4	1.0E+05 $TCID_{50}$/mL	Negative	Negative
Influenza A (H1N1)	1.0E+05 $TCID_{50}$/mL	Negative	Negative
Influenza B	1.0E+05 $TCID_{50}$/mL	Negative	Negative
Enterovirus E (Type 1)	1.0E+05 $TCID_{50}$/mL	Negative	Negative
Respiratory syncytial virus	1.0E+05 PFU/mL	Negative	Negative
Rhinovirus	1.0E+05 $TCID_{50}$/mL	Negative	Negative
Chlamydia pneumonia	1.0E+06 $TCID_{50}$/mL	Negative	Negative
Haemophilus influenzae	1.0E+06 CFU/mL	Negative	Negative
Legionella pneumophila	1.0E+06 CFU/mL	Negative	Negative
Mycobacterium tuberculosis	1.0E+06 cells/mL	Negative	Negative
Streptococcus pneumonia	1.0E+06 CFU/mL	Negative	Negative
Streptococcus pyrogenes	1.0E+06 CFU/mL	Negative	Negative
Bordetella pertussis	1.0E+06 CFU/mL	Negative	Negative
Mycoplasma pneumoniae	1.0E+06 CFU/mL	Negative	Negative
Pooled human nasal wash	5 - 50%	Negative	Negative

Sample type equivalency

Equivalence between nasopharyngeal swab (NPS) and oropharyngeal swab (OPS) sample types was evaluated using cultured virus (USA-WA1/2020 strain) spiked into paired negative samples (individual samples, not pooled) to prepare contrived low positive (approximately 1.5x Target 1 LoD) and moderate positive (approximately 4x Target 1 LoD) samples for each sample type. A total of 21 low positive paired samples, 11 moderate positive paired samples, and 11 negative paired samples were tested.

As shown in Table 14, all low positive and moderate positive paired samples were positive in both sample matrices. All negative paired samples were negative in both sample types. The observed Ct values for contrived positive samples were comparable in both sample types.

Table 14 Result comparison of nasopharyngeal to oropharyngeal sample types

Sample Type	Sample Concentration	N	Target 1		Target 2	
			% Positive	Mean Ct (95% CI)	% Positive	Mean Ct (95% CI)
NPS	~1.5x LoD (Target 1)	21	100	31.9 (31.7 – 32.0)	100	33.6 (33.5 – 33.7)
OPS			100	32.2 (31.8 – 32.6)	100	33.7 (33.4 – 34.1)
NPS	~4x LoD (Target 1)	11	100	30.9 (30.3 – 31.5)	100	32.2 (31.6 – 32.9)
OPS			100	31.5 (31.2 – 31.9)	100	32.7 (32.4 – 33.0)
NPS	Negative	11	0	n/a	0	n/a
OPS			0	n/a	0	n/a

Matrix equivalency – UTM-RT and cobas® PCR Media

Equivalence between samples collected in UTM-RT and **cobas**® PCR Media (CPM) was evaluated using cultured virus (USA-WA1/2020 strain) spiked into paired negative nasopharyngeal samples from patients with signs and symptoms of an upper respiratory infection (individual samples, not pooled) to prepare contrived low positive (approximately 1.5x LoD) and moderate positive (approximately 4x LoD) samples for each collection media. A total of 21 low positive paired samples, 11 moderate positive paired samples, and 11 negative paired samples were tested.

As shown in Table 15, all low positive and moderate positive paired samples were positive in both sample matrices. All negative paired samples were negative in both sample matrices. The observed Ct values for contrived positive samples were comparable in both sample matrices.

Table 15 Result comparison of UTM-RT to **cobas**® PCR Media

Collection Media	Sample Concentration	N	Target 1		Target 2	
			% Positive	Mean Ct (95% CI)	% Positive	Mean Ct (95% CI)
UTM	~1.5x LoD	21	100	31.8 (31.6 - 32.0)	100	34.0 (33.8 - 34.2)
CPM			100	32.2 (31.9 - 32.4)	100	34.7 (34.4 - 33.8)
UTM	~4x LoD	11	100	30.7 (30.1 - 31.2)	100	32.4 (31.8 - 33.1)
CPM			100	31.6 (31.0 - 32.1)	100	33.7 (33.0 - 34.5)
UTM	Negative	11	0	n/a	0	n/a
CPM			0	n/a	0	n/a

Matrix equivalency –UTM-RT and 0.9% physiological saline

Equivalence between samples collected in UTM-RT and 0.9% physiological saline was evaluated using cultured virus (USA-WA1/2020 strain) spiked into paired negative samples (individual samples, not pooled) to prepare contrived low positive (approximately 1.5x LoD) and moderate positive (approximately 4x LoD) samples for each collection media. Three samples were collected from each of 45 healthy donors using swabs from **cobas**® PCR Media Dual Swab Sample Kit; two nasal sample (NS) collected using dual flocked/woven polyester swabs stored in UTM and one nasal sample (other nostril) collected using a woven polyester swab stored in 0/9% physiological saline. A total of 17 low positive paired samples, 11 moderate positive paired samples, and 45 negative paired samples were tested.

As shown in Table 16, all low positive and moderate positive paired samples were positive in both sample matrices. All negative paired samples were negative in both sample matrices. The observed Ct values for contrived positive samples were comparable in both sample matrices.

Table 16 Result comparison of UTM-RT to 0.9% physiological saline

Collection Device	Sample Concentration	N	Target 1		Target 2	
			% Positive	Mean Ct (95% CI)	% Positive	Mean Ct (95% CI)
Flocked Swab in UTM-RT	~1.5x LoD	17	100	32.2 (32.0 - 32.4)	100	33.6 (33.6 - 33.7)
Woven Swab in UTM-RT		16	100	31.6 (31.1 - 32.1)	100	33.2 (32.7 - 33.8)
Woven Swab in Saline		17	100	31.7 (31.4 - 32.0)	100	33.5 (33.2 - 33.8)
Flocked Swab in UTM-RT	~4x LoD	11	100	31.2 (31.1 - 31.4)	100	32.6 (32.4 - 32.7)
Woven Swab in UTM-RT			100	30.9 (30.4 - 31.4)	100	32.4 (31.9 - 33.0)
Woven Swab in Saline			100	31.0 (30.8 - 31.3)	100	32.6 (32.5 - 32.7)
Flocked Swab in UTM-RT	Negative	45	0	n/a	0	n/a
Woven Swab in UTM-RT			0	n/a	0	n/a
Woven Swab in Saline			0	n/a	0	n/a

Clinical evaluation

The performance of **cobas**® SARS-CoV-2 with prospectively collected nasopharyngeal swab clinical samples was evaluated using 100 individual negative clinical samples and 50 contrived positive clinical samples collected from patients with signs and symptoms of an upper respiratory infection.

Clinical samples were collected by qualified personnel according to the package insert of the collection device. Samples were handled as described in the package insert of the collection device and stored frozen until use. Samples were tested to be negative by a commercially available nucleic acid test for the qualitative detection of microorganisms associated with common upper respiratory tract infections.

Low positive and moderate positive contrived positive clinical samples were prepared by spiking cultured virus (USA-WA1/2020 strain) into individual negative clinical samples to approximately ~1.5x LoD (Target 1) (25 samples) and ~4x LoD (Target 1) (25 samples), respectively.

As shown in Table 17 all low positive and moderate positive samples were positive and all negative samples were negative in the background of individual clinical sample matrix.

Table 17 Clinical evaluation with nasopharyngeal swab samples

Sample Concentration	N	Target 1		Target 2	
		% positive (two-sided 95% CI)	**Mean Ct**	**% positive (two-sided 95% CI)**	**Mean Ct**
~1.5x LoD	25	100 (86.7 – 100)	31.6	100 (86.7 – 100)	33.2
~4x LoD	25	100 (86.7 – 100)	31.1	100 (86.7 – 100)	32.4
Negative	100	0 (n/a)	n/a	0 (n/a)	n/a

Performance against the expected results are:

Positive Percent Agreement	50/50 = 100% (95% CI: 92.9% - 100%)
Negative Percent Agreement	100/100 = 100% (95% CI: 96.3% - 100%)

Additional information

Key test features

Sample type	Nasopharyngeal and oropharyngeal swab samples collected in the Copan UTM-RT System or the BD™ UVT System Nasal swab samples collected in the Copan UTM-RT System, the BD™ UVT System, the **cobas**® PCR Media, and 0.9% physiological saline
Minimum amount of sample required	0.6 mL*
Sample processing volume	0.4 mL
Test duration	Results are available within less than 3.5 hours after loading the sample on the system.

*Dead volume of 0.2 mL is identified for the **cobas omni** Secondary tubes. Other tubes compatible with **cobas**® 6800/8800 Systems (consult User Assistance Guide) may have different dead volume and require more or less minimum volume.

Symbols

The following symbols are used in labeling for Roche PCR diagnostic products.

Table 18 Symbols used in labeling for Roche PCR diagnostics products

Symbol	Meaning	Symbol	Meaning	Symbol	Meaning
SW	Ancillary Software	LLR	Lower Limit of Assigned Range	CONTROL –	Negative Control
EC REP	Authorized representative in the European community	ULR	Upper Limit of Assigned Range	CONTROL +	Positive Control
BARCODE	Barcode Data Sheet		Store in the dark	CONTROL	Control
LOT	Batch code	Σ	Contains sufficient for <*n*> tests	Assigned Range [copies/mL]	Assigned Range (copies/mL)
	Biological risks		Temperature limit	Assigned Range [IU/mL]	Assigned Range (IU/mL)
REF	Catalogue number	TDF	Test Definition File	Procedure Standard	Standard Procedure
	Consult instructions for use		Manufacturer	Procedure UltraSensitive	Ultrasensitive Procedure
Cont.	Contents of kit		Use-by date	QS copies / PCR	QS copies per PCR reaction, use the QS copies per PCR reaction in calculation of the results.
D	Distributed by	GTIN	Global Trade Item Number	QS IU/PCR	QS IU per PCR reaction, use the QS International Units (IU) per PCR reaction in calculation of the results.
	For IVD performance evaluation only	SN	Serial number	CE	This product fulfills the requirements of the European Directive 98/79 EC for *in vitro* diagnostic medical devices.
Rx Only	US Only: Federal law restricts this device to sale by or on the order of a physician.		Date of manufacture		
IVD	*In Vitro* diagnostic medical device		Do not reuse		

US Customer Technical Support 1-800-526-1247

Manufacturer and distributors

Table 19 Manufacturer and distributors

	Roche Molecular Systems, Inc. 1080 US Highway 202 South Branchburg, NJ 08876 USA www.roche.com	
D	Roche Diagnostics GmbH Sandhofer Strasse 116 68305 Mannheim, Germany	Roche Diagnostics 9115 Hague Road Indianapolis, IN 46250-0457 USA (For Technical Assistance call the Roche Response Center toll-free: 1-800-526-1247)

Trademarks and patents

See http://www.roche-diagnostics.us/patents

Copyright

CE

EC REP

Roche Diagnostics GmbH
Sandhofer Str. 116
68305 Mannheim
Germany

IVD

References

1. Center for Disease Control and Prevention. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institutes of Health HHS Publication No. (CDC) 21-1112, revised December 2009.
2. Clinical and Laboratory Standards Institute (CLSI). Protection of laboratory workers from occupationally acquired infections. Approved Guideline-Fourth Edition. CLSI Document M29-A4:Wayne, PA;CLSI, 2014.

Document revision

Document Revision Information	
Doc Rev. 1.0 03/2020	First Publishing.
Doc Rev. 2.0 04/2020	Corrected typographical errors, organism names, and table references. Added nasal swabs (self-collected on site or by the physician), collected in UTM-RT, VTM, **cobas**® PCR Media and 0.9% physiological saline. Addition of the analytical performance data related to the added specimen and media types. Replaced “container” with “collection tube” to improve clarity. Please contact your local Roche Representative if you have any questions.

Aptima™ SARS-CoV-2 Assay (Panther™ System)

For *in vitro* diagnostic use.

For U.S. Export only.

CONTENTS

General Information

Intended Use

The Aptima™ SARS-CoV-2 assay is a nucleic acid amplification *in vitro* diagnostic test intended for the qualitative detection of RNA from SARS-CoV-2 isolated and purified from nasopharyngeal (NP), nasal, mid-turbinate and oropharyngeal (OP) swab specimens, nasopharyngeal wash/aspirate or nasal aspirates obtained from individuals meeting COVID-19 clinical and/or epidemiological criteria.

Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in upper respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA, clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.

The Aptima SARS-CoV-2 assay on the Panther™ and Panther Fusion™ system is intended for use by clinical laboratory personnel specifically instructed and trained in the operation of the Panther and Panther Fusion systems and in vitro diagnostic procedures.

Summary and Explanation of the Test

Coronaviruses are a large family of viruses which may cause illness in animals or humans. In humans, several coronaviruses are known to cause respiratory infections ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The most recently discovered coronavirus, SARS-CoV-2, causes the associated coronavirus disease COVID-19. This new virus and disease were unknown before the outbreak began in Wuhan, China, in December 2019.[1]

The most common symptoms of COVID-19 are fever, tiredness, and dry cough. Some patients may have aches and pains, nasal congestion, runny nose, sore throat, new loss of taste or smell, or diarrhea. These symptoms are usually mild and begin gradually. Some people become infected but don't develop any symptoms and don't feel unwell. The disease can spread through respiratory droplets produced when an infected person coughs or sneezes. These droplets can land in the mouths or noses of people who are nearby or possibly be inhaled into the lungs.[2] These droplets also can land on objects and surfaces around the person. Other people may acquire SARS-CoV-2 by touching these objects or surfaces, then touching their eyes, nose, or mouth.

The virus that causes COVID-19 is infecting people and spreading easily from person to person.[3] On March 11, 2020, the COVID-19 outbreak was characterized as a pandemic by the World Health Organization (WHO).[4,5]

Principles of the Procedure

The Aptima SARS-CoV-2 assay combines the technologies of target capture, Transcription Mediated Amplification (TMA), and Dual Kinetic Assay (DKA).

Specimens are collected and transferred into their respective specimen transport tubes. The transport solutions in these tubes release the RNA target and protect them from degradation during storage. When the Aptima SARS-CoV-2 assay is performed in the laboratory, the target RNA molecules are isolated from specimens by use of capture oligomers via target capture that utilizes magnetic microparticles. The capture oligomers contain sequences complementary to specific regions of the target molecules as well as a string of deoxyadenosine residues. A separate capture oligomer is used for each target. During the hybridization step, the sequence specific regions of the capture oligomers bind to specific regions of the target molecules. The capture oligomer:target complex is then captured out of solution by decreasing the temperature of the reaction to room temperature. This temperature reduction allows hybridization to occur between the deoxyadenosine region on the capture oligomer and the poly-deoxythymidine molecules that are covalently attached to the magnetic particles. The microparticles, including the captured target molecules bound to them, are pulled to the side of the reaction vessel using magnets and the supernatant is aspirated. The particles are washed to remove residual specimen matrix that may contain amplification reaction inhibitors. After the target capture steps are completed, the specimens are ready for amplification.

Target amplification assays are based on the ability of complementary oligonucleotide primers to specifically anneal and allow enzymatic amplification of the target nucleic acid strands. The Aptima SARS-CoV-2 assay replicates specific regions of the RNA from SARS-CoV-2 virus. Detection of the RNA amplification product sequences (amplicon) is achieved using nucleic acid hybridization. Single-stranded chemiluminescent nucleic acid probes, which are unique and complementary to a region of each target amplicon and Internal Control (IC) amplicon, are labeled with different acridinium ester (AE) molecules. The AE labeled probes combine with amplicon to form stable hybrids. The Selection Reagent differentiates hybridized from unhybridized probe, eliminating the generation of signal from unhybridized probe. During the detection step, light emitted from the labeled hybrids is measured as photon signals in a luminometer, and are reported as Relative Light Units (RLU). In DKA, differences in the kinetic profiles of the labeled probes allow for the differentiation of signal; kinetic profiles are derived from measurements of photon output during the detection read time. The chemiluminescent detection reaction for the IC signal has very rapid kinetics and has the “flasher” kinetic type. The chemiluminescent detection reaction for the SARS-CoV-2 signal is relatively slower and has the “glower” kinetic type. Assay results are determined by a cut-off based on the total RLU and the kinetic curve type.

The Aptima SARS-CoV-2 assay amplifies and detects two conserved regions of the ORF1ab gene in the same reaction, using the same “glower” kinetic type. The two regions are not differentiated and amplification of either or both regions leads to RLU signal. The assay results are determined by a cut-off based on the total RLU and the kinetic curve type.

Warnings and Precautions

A. For *in vitro* diagnostic use. Carefully read this entire package insert and the *Panther/Panther Fusion System Operator’s Manual*.

B. Only personnel adequately trained on the use of this assay and in handling potentially infectious materials should perform these procedures. If a spill occurs, immediately disinfect using appropriate site procedures.

C. Handle all specimens as if infectious using safe laboratory procedures. Refer to Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with 2019-nCoV. https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-guidelines.html.

D. Specimens may be infectious. Use Universal Precautions when performing this assay. Proper handling and disposal methods should be established by the laboratory director. Only personnel adequately trained in handling infectious materials should be permitted to perform this diagnostic procedure.[6]

E. If infection with SARS-CoV-2 is suspected based on current clinical screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions.

F. Use only supplied or specified disposable laboratory ware.

G. Use appropriate personal protective equipment when collecting and handling specimens from individuals suspected of being infected with SARS-CoV-2 as outlined in CDC Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with 2019 Novel Coronavirus (2019-nCoV).

H. Wear disposable, powderless gloves, protective eye wear, and laboratory coats when handling specimens and reagents. Wash hands thoroughly after handling specimens and reagents.

I. Dispose of all material that has come into contact with specimens and reagents in accordance with applicable national, international, and regional regulations.

J. Expiration dates listed on the Panther Fusion Specimen Lysis Tubes, Hologic Specimen Lysis Tubes, the Aptima Multitest Collection Kit, the Aptima Swab Unisex Specimen Collection Kit and the Aptima Specimen Transfer Kit pertain to the transfer of sample into the tube and not to testing of the sample. Specimens collected/transferred any time prior to these expiration dates are valid for testing provided they are transported and stored in accordance with the appropriate package insert, even if these expiration dates have passed.

K. Maintain proper storage conditions during specimen shipping to ensure the integrity of the specimen. Specimen stability under shipping conditions other than those recommended has not been evaluated.

L. Avoid cross-contamination during the specimen handling steps. Specimens can contain extremely high levels of virus or other organisms. Ensure that specimen containers do not come in contact with one another, and discard used materials without passing them over any open containers. Change gloves if they come in contact with specimens.

M. Do not use the reagents and controls after the expiration date.

N. Store assay components at the recommended storage condition. See *Reagent Storage and Handling Requirements (*page 5), and *Panther System Test Procedure* (page 12) for more information.

O. Do not combine any assay reagents or fluids. Do not top off reagents or fluids; the Panther system verifies reagent levels.

P. Avoid microbial and ribonuclease contamination of reagents.

Q. Do not use material that may contain Guanidinium thiocyanate or any guanidine-containing materials on the instrument. Highly reactive and/or toxic compounds may form if combined with sodium hypochlorite.

R. A reagent in this kit is labeled with risk and safety symbols.

Note: Hazard Communication reflects the EU Safety Data Sheets (SDS) classification. For hazard communication information specific to your region, refer to the region specific SDS on the Safety Data Sheet Library at www.hologicsds.com.

Selection Reagent
BORIC ACID 1-5%
WARNING
H315 - Causes skin irritation

Reagent Storage and Handling Requirements

A. The following reagents are stable when stored at 2°C to 8°C (refrigerated):

Aptima SARS-CoV-2 Amplification Reagent

Aptima SARS-CoV-2 Enzyme Reagent

Aptima SARS-CoV-2 Probe Reagent

Aptima SARS-CoV-2 Internal Control

Aptima SARS-CoV-2 Positive Control

Aptima SARS-CoV-2 Negative Control

B. The following reagents are stable when stored at 2°C to 30°C:

Aptima SARS-CoV-2 Amplification Reconstitution Solution

Aptima SARS-CoV-2 Enzyme Reconstitution Solution

Aptima SARS-CoV-2 Probe Reconstitution Solution

Aptima SARS-CoV-2 Selection Reagent

C. The following reagents are stable when stored at 15°C to 30°C (room temperature):

Aptima SARS-CoV-2 Target Capture Reagent

Aptima Wash Solution

Aptima Buffer for Deactivation Fluid

Aptima Oil Reagent

D. Working Target Capture Reagent (wTCR) is stable for 30 days when stored at 15°C to 30°C. Do not refrigerate.

E. After reconstitution, the Enzyme Reagent, Amplification Reagent, and Probe Reagent are stable for 30 days when stored at 2°C to 8°C.

F. Discard any unused reconstituted reagents and wTCR after 30 days or after the Master Lot expiration date, whichever comes first.

G. Controls are stable until the date indicated on the vials.

H. Reagents stored on-board the Panther System have 72 hours of on-board stability.

I. The Probe Reagent and Reconstituted Probe Reagent are photosensitive. Store the reagents protected from light. The specified reconstituted stability is based on 12 hours exposure of the Reconstituted Probe Reagent to two 60W fluorescent bulbs, at a distance of 17 inches (43 cm), and temperature less than 30°C. Light exposure of the Reconstituted Probe Reagent should be limited accordingly.

J. Upon warming to room temperature, some control tubes may appear cloudy or contain precipitates. Cloudiness or precipitation associated with controls does not affect control performance. The controls may be used whether they are clear or cloudy/precipitated. If clear controls are desired, solubilization may be expedited by incubating them at the upper end of the room temperature range (15°C to 30°C).

K. Do not freeze the reagents.

Specimen Collection and Storage

Specimens - Clinical material collected from patient placed in an appropriate transport system. For the Aptima SARS-CoV-2 assay, this includes NP, nasal, midturbinate and OP swab specimens, or nasopharyngeal wash/aspirate and nasal aspirate specimen collection in viral transport medium (VTM/UTM), saline, Liquid Amies, or specimen transport medium (STM).

Samples - Represents a more generic term to describe any material for testing on the Panther System including specimens, specimens transferred into a Panther Fusion Specimen Lysis Tube and controls.

Note: *Handle all specimens as if they contain potentially infectious agents. Use Universal Precautions.*

Note: *Take care to avoid cross-contamination during specimen handling steps. For example, discard used material without passing over open tubes.*

Swab Specimen Collection

Collect NP swab, nasal swab, and OP swab specimens according to standard technique using a polyester-, rayon-, or nylon-tipped swab. Immediately place the swab specimen into 3mL of VTM or UTM. Swab specimens may alternatively be added to saline, Liquid Amies or STM. The Aptima Multitest Swab Specimen Collection Kit may be used for the collection of OP and nasal swab samples.

After collection, specimens collected in VTM/UTM can be stored at 2°C to 8°C up to 96 hours before transferring to the Specimen Lysis Tube or transfer tube as described in the specimen processing section below. Remaining specimen volumes can be stored at ≤-70°C.

After collection, specimens in the Aptima Multitest Tube may be stored at 2°C to 30°C up to 6 days.

Note: *It is recommended that specimens transferred to the Aptima Multitest Tube are stored capped and upright in a rack.*

The following types of VTM/UTM can be used.

- Remel MicroTest M4, M4RT, M5 or M6 formulations
- Copan Universal Transport Medium
- BD Universal Viral Transport Medium

Note: *Do not use medium that may contain Guanidium thiocyanate or any guanidine-containing material.*

Nasopharyngeal Wash/aspirate and Nasal Aspirate Specimen Collection

Collect nasopharyngeal wash/aspirate and nasal aspirate specimens according to standard techniques.

Specimen Processing using the Panther Fusion Specimen Lysis Tube

A. Prior to testing on the Panther system, transfer 500 µL of the collected specimen* to a Panther Fusion Specimen Lysis Tube.

***Note:** When testing frozen specimen, allow specimen to reach room temperature prior to processing.*

Note: *When using the Aptima SARS-CoV-2 uncapped tube assay software, prepare the Panther Fusion Specimen Lysis Tube as described below in Specimen* Processing using the Hologic Specimen Lysis Tube with Solid Cap.

Note:

Specimen Processing using the Hologic Specimen Lysis Tube with Solid Cap

A. Uncap the Hologic Specimen Lysis Tube and retain the cap.

B. Prior to testing on the Panther system, transfer 500 uL of the specimen to the Hologic Specimen Lysis Tube

C. It is recommended to recap the tube and gently invert three times to ensure viral inactivation and a homogeneous mixture.

D. To avoid contact with the top of the tube, loosen the cap and place the sample tube into the sample rack.

E. Remove and discard the cap. Inspect the sample tube. If bubbles are present, carefully remove from the sample tube (for example, use the tip of a sterile swab or similar method).

F. Place the rack retainer on the sample rack and load the rack into the instrument.

Note: *Specimen processing using the Hologic Specimen Lysis Tube is for use with the Aptima SARS-CoV-2 uncapped tube assay software.*

Specimen Processing using a Custom Specimen Lysis Tube

A. Using a sterile or non-sterile generic tube made of siliconized glass, polypropylene plastic or similar material that is 12 mm to 13 mm in outer diameter and 75 mm to 100 mm in height, aliquot 0.78 mL ± 0.07 mL of bulk STM into the tube using a pipet or repeat pipettor.

   Note: *If tubes are prepared prior to use, recap the tube and store at* 15°C to 30°C until use in specimen processing.

B. Uncap the custom Specimen Lysis Tube containing STM and retain the cap.

C. Prior to testing on the Panther system, transfer 500 µL of the specimen to the custom Specimen Lysis Tube containing STM.

D. It is recommended to recap the sample tube and gently invert three times to ensure viral inactivation and a homogeneous mixture.

E. To avoid contact with the top of the tube, loosen the cap and place the sample tube into the sample rack.

F. Remove and discard the cap. Inspect the sample tube. If bubbles are present, carefully remove from the tube (for example, use the tip of a sterile swab or similar method).

G. Place the rack retainer on the sample rack and load the rack into the instrument.

Note: *Specimen processing using the custom Specimen Lysis Tube is for use with the Aptima SARS-CoV-2 uncapped tube assay software.*

Specimen Processing using the Aptima Specimen Transfer Tube

A. Prior to testing on the Panther system, transfer 1 mL of the collected specimen* to an Aptima Specimen Transfer Tube**.

   ****Note:*** *When testing frozen specimen, allow specimen to reach room temperature prior to processing.*

   *****Note:*** *Alternatively, an unused Aptima Multitest Tube or Aptima Unisex Tube can be used.*

B. Recap the Aptima Specimen Transfer Tube tightly.

C. Gently invert the tube 2 to 3 times to ensure complete mixture of the specimen.

   Note: *The Aptima Specimen Transfer Tube cannot be tested on a system using the Aptima SARS-CoV-2 uncapped tube assay software.*

Specimen Processing for Specimen Collected with the Aptima Multitest Collection Kit

A. After placing the collected specimen* into the Aptima Multitest Tube using the Aptima Multitest Collection Kit, no further processing is required.

   ****Note:*** *When testing frozen specimen, allow specimen to reach room temperature prior to processing.*

   Note: *On a system using the Aptima SARS-CoV-2 uncapped tube assay software, transfer the collected specimen from the Aptima Multitest Tube to a Hologic Specimen Lysis Tube or custom Specimen Lysis Tube as described in the specimen processing sections above.*

Sample Storage

A. Samples on board the Panther system may be archived for additional testing at a later time.

B. Storing samples before or after testing

1. Samples in the Aptima Multitest Tube, Aptima Specimen Tube, or Specimen Lysis Tube should be stored upright in the rack under the following condition:
   - 2°C to 30°C up to 6 days
2. The samples should be covered with a new, clean plastic film or foil barrier.
3. If assayed samples need to be frozen or shipped, remove the penetrable cap and place a new non-penetrable cap on the specimen tubes. If samples need to be shipped for testing at another facility, recommended temperatures must be maintained. Prior to uncapping, specimen transport tubes must be centrifuged for 5 minutes at 420 Relative Centrifugal Force (RCF) to bring all of the liquid down to the bottom of the tube. Avoid splashing and cross-contamination.

   Note: *The Fisherbrand™ VersaClosure™ tube closure should not be used to cover tubes for freezing or shipping.*

Specimen Transport

Maintain specimen storage conditions as described in the *Specimen Collection and Storage section on* page 6.

Note: *Specimens must be shipped in accordance with applicable national, international, and regional transportation regulations.*

Panther System

Reagents for the Aptima SARS-CoV-2 assay are listed below for the Panther System. Reagent Identification Symbols are also listed next to the reagent name.

Reagents and Materials Provided

Aptima SARS-CoV-2 Assay Kit PRD-06419

250 tests (2 boxes)

Aptima SARS-CoV-2 Refrigerated Box (Box 1 of 2)
(store at 2°C to 8°C upon receipt)

Symbol	Component	Quantity 250 test kit
A	**Aptima SARS-CoV-2 Amplification Reagent** *Non-infectious nucleic acids dried in buffered solution containing < 5% bulking agent.*	1 vial
E	**Aptima SARS-CoV-2 Enzyme Reagent** *Reverse transcriptase and RNA polymerase dried in HEPES buffered solution containing < 10% bulking reagent.*	1 vial
P	**Aptima SARS-CoV-2 Probe Reagent** *Non-infectious chemiluminescent DNA probes dried in succinate buffered solution containing < 5% detergent.*	1 vial
IC	**Aptima SARS-CoV-2 Internal Control**	1 vial

Aptima SARS-CoV-2 Room Temperature Box (Box 2 of 2)
(store at 15°C to 30°C upon receipt)

Symbol	Component	Quantity 250 test kit
AR	**Aptima SARS-CoV-2 Amplification Reconstitution Solution** *Aqueous solution containing preservatives.*	1 x 27.7 mL
ER	**Aptima SARS-CoV-2 Enzyme Reconstitution Solution** *HEPES buffered solution containing a surfactant and glycerol.*	1 x 11.1 mL
PR	**Aptima SARS-CoV-2 Probe Reconstitution Solution** *Succinate buffered solution containing < 5% detergent.*	1 x 35.4 mL
S	**Aptima SARS-CoV-2 Selection Reagent** *600 mM borate buffered solution containing surfactant.*	1 x 108 mL
TCR	**Aptima SARS-CoV-2 Target Capture Reagent** *Buffered salt solution containing solid phase and capture oligomers.*	1 x 54 mL
	Reconstitution Collars	3
	Master Lot Barcode Sheet	1 sheet

AB713

Materials Required and Available Separately

Note: *Materials available from Hologic have catalog numbers listed, unless otherwise specified.*

	Cat. No.
Panther System	303095
Aptima Assay Fluids Kit *(Aptima Wash Solution, Aptima Buffer for Deactivation Fluid, and Aptima Oil Reagent)*	303014 (1000 tests)
Aptima Auto Detect Kit	303013 (1000 tests)
Multi-tube units (MTUs)	104772-02
Panther Waste Bag Kit	902731
Panther Waste Bin Cover	504405
Or Panther Run Kit *contains MTUs, waste bags, waste bin covers, assay fluids, and auto detects*	303096 (5000 tests)
Tips, 1000 µL conductive, liquid sensing	10612513 (Tecan)
Aptima SARS-CoV-2 Controls Kit *PC - Aptima SARS-CoV-2 Positive Control. Non-infectious nucleic acid in a buffered solution containing < 5% detergent. Quantity 5 x 1.7 mL* *NC - Aptima SARS-CoV-2 Negative Control. A buffered solution containing <5% detergent. Quantity 5 x 1.7 mL*	PRD-06420
Aptima Multitest Swab Specimen Collection Kit	PRD-03546
Aptima Specimen Transfer Kit	301154C
Aptima Specimen Transfer Kit - printable	PRD-05110
Aptima Unisex Swab Specimen Collection Kit for Endocervical and Male Urethral Swab Specimens	301041
Panther Fusion Specimen Lysis Tubes, 100 per bag *tube contains 0.71 mL of STM with a penetrable cap*	PRD-04339
Hologic Specimen Lysis Tubes, 100 each *tube contains 0.71 mL of STM with a solid cap*	PRD-06554
Hologic Specimen Lysis Tubes, 1200 each *tube contains 0.71 mL of STM with a solid cap*	PRD-06660
Specimen Transport Medium, 1 bottle, 80 mL	PRD-04423
Specimen Transport Medium, 1 bottle, 120 mL	PRD-06657
Bleach, 5% to 7% (0.7M to 1.0M) sodium hypochlorite solution	—
Disposable gloves	—
Hologic Solid Replacement Caps, 100 per bag	PRD-06720
Fisherbrand VersaClosure Tube Closures*, 1000 per pack **a single-use tube cover for the Hologic Specimen Lysis Tube (PRD-06554 only) after testing*	02-707

	Cat. No.
Replacement Caps for the 250-test kits	—
Amplification and Probe reagent reconstitution solutions CL0041 (100 caps)	
Enzyme Reagent reconstitution solution 501616 (100 caps)	
TCR and Selection reagent CL0040 (100 caps)	

Optional Materials

	Cat. No.
Hologic Bleach Enhancer for Cleaning *for routine cleaning of surfaces and equipment*	302101
Tube rocker	—

Panther System Test Procedure

Note: *Refer to the Panther/Panther System Operator's Manual for additional procedural information.*

A. Work Area Preparation

Clean work surfaces where reagents and samples will be prepared. Wipe down work surfaces with 2.5% to 3.5% (0.35M to 0.5M) sodium hypochlorite solution. Allow the sodium hypochlorite solution to contact surfaces for at least 1 minute and then follow with a water rinse. Do not allow the sodium hypochlorite solution to dry. Cover the bench surface on which the reagents and samples will be prepared with clean, plastic-backed absorbent laboratory bench covers.

B. Reagent Reconstitution/Preparation of a New Kit

Note: *Reagent reconstitution should be performed prior to beginning any work on the Panther System.*

1. To reconstitute Amplification, Enzyme, and Probe Reagents, combine the bottles of lyophilized reagent with the reconstitution solution. If refrigerated, allow the reconstitution solutions to reach room temperature before use.
   a. Pair each reconstitution solution with its lyophilized reagent. Ensure that the reconstitution solution and reagent have matching label colors before attaching the reconstitution collar.
   b. Check the lot numbers on the Master Lot Barcode Sheet to ensure that the appropriate reagents are paired.
   c. Open the lyophilized reagent vial and firmly insert the notched end of the reconstitution collar into the vial opening (Figure 1, Step 1).
   d. Open the matching reconstitution solution, and set the cap on a clean, covered work surface.
   e. While holding the reconstitution solution bottle on the bench, firmly insert the other end of the reconstitution collar into the bottle opening (Figure 1, Step 2).

f. Slowly invert the assembled bottles. Allow the solution to drain from the bottle into the glass vial (Figure 1, Step 3).

g. Thoroughly mix the solution in the glass vial by swirling (Figure 1, Step 4).

h. Wait for the lyophilized reagent to go into solution, then invert the assembled bottles again, tilting at a 45° angle to minimize foaming (Figure 1, Step 5). Allow all of the liquid to drain back into the plastic bottle.

i. Remove the reconstitution collar and glass vial (Figure 1, Step 6).

j. Recap the plastic bottle. Record operator initials and reconstitution date on the label (Figure 1, Step 7).

k. Discard the reconstitution collar and glass vial (Figure 1, Step 8).

Option: Additional mixing of the Amplification, Enzyme, and Probe Reagents using a tube rocker is allowed. The reagents may be mixed by placing the recapped plastic bottle on a tube rocker set to 20 RPM (or equivalent) for a minimum of 5 minutes.

Warning: *Avoid creating foam when reconstituting reagents. Foam compromises the level-sensing in the Panther System.*

Warning: *Adequate mixing of the reagents is necessary to achieve expected assay results.*



Figure 1. Panther System Reconstitution Process

2. Prepare Working Target Capture Reagent (wTCR)
   a. Pair the appropriate bottles of TCR and IC.
   b. Check the reagent lot numbers on the Master Lot Barcode Sheet to make sure that the appropriate reagents in the kit are paired.
   c. Open the bottle of TCR, and set the cap on a clean, covered work surface.
   d. Open the IC bottle and pour the entire contents into the bottle of TCR. Expect a small amount of liquid to remain in the IC bottle.
   e. Cap the bottle of TCR and gently swirl the solution to mix the contents. Avoid creating foam during this step.
   f. Record operator initials and the current date on the label.
   g. Discard the IC bottle and cap.

3. Prepare Selection Reagent
    a. Check the lot number on the reagent bottle to make sure it matches the lot number on the Master Lot Barcode Sheet.
    b. Record operator initials and the current date on the label.

Note: *Thoroughly mix by gently inverting all reagents prior to loading on the system. Avoid creating foam during inversion of reagents.*

C. Reagent Preparation for Previously Reconstituted Reagents

1. Previously reconstituted Amplification, Enzyme, and Probe Reagents must reach room temperature (15°C to 30°C) prior to the start of the assay.

    Option: The reagents may be brought to room temperature by placing the reconstituted Amplification, Enzyme, and Probe Reagents on a tube rocker set to 20 RPM (or equivalent) for a minimum of 25 minutes.

2. If reconstituted Probe Reagent contains precipitate that does not return to solution at room temperature, heat the capped bottle at a temperature that does not exceed 62°C for 1 to 2 minutes. After this heat step, the Probe Reagent may be used even if residual precipitate remains. Mix Probe Reagent by inversion, being careful not to induce foam, prior to loading onto the system.
3. Thoroughly mix each reagent by gently inverting prior to loading on the system. Avoid creating foam during inversion of reagents. This step is not required if reagents are loaded onto the system directly after mixing on the tube rocker.
4. Do not top off reagent bottles. The Panther System will recognize and reject bottles that have been topped off.
5. *Adequate mixing of the reagents is necessary to achieve expected assay results.*

D. Specimen Handling using Panther Fusion Specimen Lysis Tube or Aptima Specimen Transfer Tube

Note: *Prepare specimens per the Specimen Processing instructions in the Specimen Collection and Storage section before loading specimens onto the Panther system.*

1. Inspect sample tubes before loading into the rack. If a sample tube contains bubbles or has a lower volume than is typically observed, gently tap the bottom of the tube to bring contents to the bottom.

Note: *For samples transferred to the Panther Fusion Specimen Lysis Tube or the Aptima Specimen Transfer Tube, to avoid a processing error, ensure adequate specimen volume is added to the tube. When adequate collected specimen is added to the tube, there is sufficient volume to perform 3 nucleic acid extractions.*

E. Specimen Handling using Hologic Specimen Lysis Tube or custom Specimen Lysis Tube

1. Prepare specimens per the specimen processing instructions in the *Specimen Collection and Storage* section.

Note: *For samples transferred to the Hologic Specimen Lysis Tube or a custom Specimen Lysis Tube, to avoid a processing error, ensure adequate specimen volume is added to the tube. When adequate collected specimen is added to the tube, there is sufficient volume to perform 2 nucleic acid extractions.*

***Note:** When using the Aptima SARS-CoV-2 uncapped tube assay software, remove the cap from the Positive and Negative control before loading onto the Panther system.*

F. System Preparation

1. Set up the system according to the instructions in the *Panther/Panther Fusion System Operator's Manual* and *Procedural Notes*. Make sure that the appropriately sized reagent racks and TCR adapters are used.
2. Load samples.

Procedural Notes

A. Controls

1. To work properly with the Aptima Assay software for the Panther system, one pair of controls is required. The Aptima SARS-CoV-2 positive and negative controls can be loaded in any rack position or in any Sample Bay Lane on the Panther system. Patient specimen pipetting will begin when one of the following two conditions has been met:
   a. A pair of controls is currently being processed by the system.
   b. Valid results for the controls are registered on the system.
2. Once the control tubes have been pipetted and are processing for a specific reagent kit, patient specimens can be run with the associated kit up to 24 hours unless:
   a. Controls results are invalid.
   b. The associated assay reagent kit is removed from the system.
   c. The associated assay reagent kit has exceeded stability limits.
3. Each Aptima control tube can be tested once. Attempts to pipette more than once from the tube can lead to processing errors.
4. Patient specimen pipetting begins when one of the following two conditions is met:
   a. Valid results for the controls are registered on the system.
   b. A pair of controls is currently in process on the system.

B. Temperature

Room temperature is defined as 15°C to 30°C.

C. Glove Powder

As in any reagent system, excess powder on some gloves may cause contamination of opened tubes. Powderless gloves are recommended.

D. Lab Contamination Monitoring Protocol for the Panther System

There are many laboratory-specific factors that may contribute to contamination, including testing volume, workflow, disease prevalence and various other laboratory activities. These factors should be taken into consideration when contamination monitoring frequency is being established. Intervals for contamination monitoring should be established based on each laboratory's practices and procedures.

To monitor for laboratory contamination, the following procedure may be performed using the Aptima Unisex Swab Specimen Collection Kit for Endocervical and Male Urethral Swab Specimens:

1. Label swab transport tubes with numbers corresponding to the areas to be tested.
2. Remove the specimen collection swab (blue shaft swab with green printing) from its packaging, wet the swab in the specimen transport medium (STM), and swab the designated area using a circular motion.
3. Immediately insert the swab into transport tube.
4. Carefully break the swab shaft at the score line; use care to avoid splashing of the contents.
5. Recap the swab transport tube tightly.
6. Repeat Steps 2 to 5 for each area to be swabbed.

E. If the results are positive, see *Interpretation of Results*. For additional Panther system-specific contamination monitoring information, contact Hologic Technical Support.

Quality Control

A run or specimen result may be invalidated by the Panther system if problems occur while performing the assay. Specimens with invalid results must be retested.

Negative and Positive Controls

To generate valid results, a set of assay controls must be tested. One replicate of the negative assay control and positive assay control must be tested each time a new kit is loaded on the Panther system or when the current set of valid controls have expired.

The Panther system is configured to require assay controls run at an administrator-specified interval of up to 24 hours. Software on the Panther system alerts the operator when assay controls are required and does not start new tests until the assay controls are loaded and have started processing.

During processing, criteria for acceptance of the assay controls are automatically verified by the Panther system. To generate valid results, the assay controls must pass a series of validity checks performed by the Panther system.

If the assay controls pass all validity checks, they are considered valid for the administrator-specified time interval. When the time interval has passed, the assay controls are expired by the Panther system which requires a new set of assay controls be tested prior to starting any new samples.

If any one of the assay controls fails the validity checks, the Panther system automatically invalidates the affected samples and requires a new set of assay controls be tested prior to starting any new samples.

Internal Control

An internal control is added to each sample with the wTCR. During processing, the internal control acceptance criteria are automatically verified by the Panther system software. Detection of the internal control is not required for samples that are positive for SARS-CoV-2. The internal control must be detected in all samples that are negative for SARS-CoV-2 targets; samples that fail to meet that criteria will be reported as Invalid. Each sample with an Invalid result must be retested.

The Panther system is designed to accurately verify processes when procedures are performed following the instructions provided in this package insert and the *Panther/Panther Fusion System Operator's Manual.*

Interpretation of Results

The Panther system automatically determines the test results for samples and controls. A test result may be negative, positive, or invalid.

Table1 shows the possible results reported in a valid run with result interpretations.

Table 1: Result Interpretation

SARS-CoV-2 Result	IC Result	Interpretation
Neg	Valid	SARS-CoV-2 not detected.
POS	Valid	SARS-CoV-2 detected.
Invalid	Invalid	Invalid. There was an error in the generation of the result; retest sample.

Note: Detection of internal control is not required for samples that are positive for SARS-CoV-2.

Limitations

A. Use of this assay is limited to personnel who are trained in the procedure. Failure to follow these instructions may result in erroneous results.

B. Reliable results are dependent on adequate specimen collection, transport, storage, and processing.

C. Avoid contamination by adhering to good laboratory practices and to the procedures specified in this package insert.

D. A positive result indicates the detection of nucleic acid from the relevant virus. Nucleic acid may persist even after the virus is no longer viable.

E. Nasopharyngeal wash/aspirate or nasal aspirates and self-collected or healthcare provider collected nasal and midturbinate nasal swabs are additional acceptable upper respiratory specimens that can be tested with the Aptima SARS-CoV-2 assay; however, performance with these specimen types have not been determined.

Panther SARS-CoV-2 Assay Performance

Analytical Sensitivity

The analytical sensitivity (limit of detection or LoD) of the Aptima SARS-CoV-2 assay was determined by testing serial dilutions of pooled negative clinical nasopharyngeal swab specimens spiked with inactivated cultured SARS-CoV-2 virus (USA-WA1/2020; BEI Resources; NR-52281). Ten replicates of each serial dilution were evaluated using each of two assay reagent lots across two Panther systems. The LoD was determined to be 0.01 $TCID_{50}$/mL and verified by testing an additional 20 replicates with one assay reagent lot. The LoD was also confirmed using saline, Liquid Amies and specimen transport medium (STM) swab collection media.

The analytical sensitivity of the Aptima SARS-CoV-2 assay was additionally evaluated using reference material from three commercial vendors. Serial dilutions of the reference material were made in STM and 20 or more replicates at each level were tested using each of two assay reagent lots across two Panther systems. The reference materials and the lowest dilution levels resulting in ≥ 95% detection are listed in Table 2.

Table 2: Analytical Sensitivity Evaluation of Commercial Reference Material

Vendor	Name	Reference #	Lot #	Analytical Sensitivity
ZeptoMetrix	SARS-CoV-2 External Run control	NATSARS(COV2)-ERC	324332	83 Copies/mL
SeraCare	AccuPlex SARS-Cov-2 Reference Material	0505-0126	10483977	83 Copies/mL
Exact Diagnostic	SARS-CoV-2 Standard	COV019	20033001	83 Copies/mL

Analytical Sensitivity with the Aptima Specimen Transfer Tube Workflow

The determined 0.01 $TCID_{50}$/mL analytical sensitivity (limit of detection) of the Aptima SARS-CoV-2 assay was confirmed using the Aptima Specimen Transfer tube specimen preparation workflow. Confirmation was performed using inactivated cultured SARS-CoV-2 virus (USA-QA1/2020; BEI Resources; NR-52281) in negative clinical nasopharyngeal (NP) swab, saline, Liquid Amies and specimen transport medium (STM) swab collection media by testing 20 replicates with one reagent lot (Table 3).

Table 3: LoD Confirmation with the Aptima Specimen Transfer Workflow

Target	Matrix	N Valid	N Positive	% Positive	Avg kRLU	StdDev kRLU	%CV
Inactivated SARS-CoV-2 virus	NP Swab	20	20	100%	1063	61	5.8%
	STM	20	20	100%	1064	116	10.9%
	Saline	20	20	100%	1102	60	5.4%
	Liquid Amies	20	20	100%	1101	51	4.7%

Carryover Contamination

The carryover contamination rate of the Aptima SARS-CoV-2 assay for samples tested with the capped tube and uncapped tube workflows was determined. The evaluation consisted of testing high titer SARS-CoV-2 target panels ~5 logs above the assay LoD in a checkerboard pattern with negative panels in four runs on three Panther systems. The capped tube workflow had an observed carryover rate of 0%, whereas the uncapped tube workflow carryover rate was 0.67% with 5 of 744 negative samples evaluated giving a false positive result.

Inclusivity

The inclusivity of the Aptima SARS-CoV-2 assay was evaluated using *in silico* analysis of the assay target capture oligos, amplification primers, and detection probes in relation to 9,896 SARS-CoV-2 sequences available in the NCBI and GISAID gene databases. Any sequence with missing or ambiguous sequence information was removed from the analysis, resulting in 9,879 sequences evaluated for the first target region of the assay and 9,880 for the second target region. The *in silico* analysis showed 100% homology to the assay oligos of both target systems for 9,749 (98.5%) of the evaluated sequences and 100% homology to the assay oligos of at least one target system for all 9,896 sequences. There were no evaluated sequences with identified mismatches predicted to impact binding or performance of both target systems.

Analytical Specificity and Microbial Interference

The analytical specificity of the Aptima SARS-CoV-2 assay was evaluated by testing 30 microorganisms representing common respiratory pathogens or closely related species (Table 4). Bacteria were tested at 10^6 CFU/mL and viruses were tested at 10^5 $TCID_{50}$/mL, except where noted. Microorganisms were tested with and without the presence of SARS-CoV-2 inactivated virus at 3x LoD. Analytical specificity of the Aptima SARS-CoV-2 assay was 100% with no evidence of microbial interference.

In addition to microorganism testing, *in silico* analysis was performed to assess the specificity of the assay in relation to the microorganisms listed in Table 4. The *in silico* analysis showed no probable cross reactivity to any of the 112 GenBank sequences evaluated.

Table 4: Aptima SARS-CoV-2 Analytical Specificity and Microbial Interference Microorganisms

Microorganism	Concentration	Microorganism	Concentration
Human coronavirus 229E	1E+5 $TCID_{50}$/mL	Parainfluenza virus 1	1E+5 $TCID_{50}$/mL
Human coronavirus OC43	1E+5 $TCID_{50}$/mL	Parainfluenza virus 2	1E+5 $TCID_{50}$/mL
Human coronavirus HKU1[1]	1E+6 copies/mL	Parainfluenza virus 3	1E+5 $TCID_{50}$/mL
Human coronavirus NL63	1E+4 $TCID_{50}$/mL	Parainfluenza virus 4	1E+3 $TCID_{50}$/mL
SARS-coronavirus[1]	1E+6 copies/mL	Influenza A	1E+5 $TCID_{50}$/mL
MERS-coronavirus	1E+4 $TCID_{50}$/mL	Influenza B	2E+3 $TCID_{50}$/mL
Adenovirus (e.g. C1 Ad. 71)	1E+5 $TCID_{50}$/mL	Enterovirus (e.g. EV68)	1E+5 $TCID_{50}$/mL
Human Metapneumovirus (hMPV)	1E+6 $TCID_{50}$/mL	Rhinovirus	1E+4 $TCID_{50}$/mL
Respiratory syncytial virus	1E+5 $TCID_{50}$/mL	*Legionella pneumophila*	1E+6 CFU/mL
Chlamydia pneumoniae	1E+6 IFU/mL	*Mycobacterium tuberculosis*	1E+6 $TCID_{50}$/mL
Haemophilus influenzae	1E+6 CFU/mL	*Streptococcus pneumoniae*	1E+6 CFU/mL
Bordetella pertussis	1E+6 CFU/mL	*Streptococcus pyogenes*	1E+6 CFU/mL
Pneumocystis jirovecii (PJP)	1E+6 nuc/mL	*Streptococcus salivarius*	1E+6 CFU/mL
Candida albicans	1E+6 CFU/mL	*Mycoplasma pneumoniae*	1E+6 CFU/mL
Staphylococcus epidermidis	1E+6 CFU/mL	*Pseudomonas aeruginosa*	1E+6 CFU/mL
Pooled human nasal wash[2] - *to represent diverse microbial flora in human respiratory tract*	N/A		

[1] Cultured virus and whole genome purified nucleic acid for Human coronavirus HKU1 and SARS-coronavirus are not readily available. HKU1 and SARS-coronavirus IVTs corresponding to the ORF1ab gene regions targeted by the assay were used to evaluate cross-reactivity and microbial interference.
[2] In place of evaluating pooled human nasal wash, testing of 30 individual negative clinical NP swab specimens was performed to represent diverse microbial flora in the human respiratory tract.

Clinical Performance

The clinical performance of the Aptima SARS-CoV-2 assay was evaluated in comparison to the Panther Fusion SARS-CoV-2 assay (Hologic, Inc.) using a panel of remnant clinical specimens. For the study, remnant clinical nasopharyngeal specimens were collected from US patients with signs and symptoms of respiratory infection.

The Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) was calculated in relation to the Panther Fusion assay as the reference result, as shown in Table 5. The Aptima SARS-CoV-2 assay showed positive and negative agreements of 100% and 98.2%, respectively.

Nasopharyngeal wash/aspirate, nasal aspirates, nasal swabs and midturbinate nasal swabs are acceptable specimens to test for viral respiratory infections. However, performance with these specimen types has not been specifically evaluated with the Aptima SARS-CoV-2 assay.

Table 5: Aptima SARS-CoV-2 Clinical Agreement

		Panther Fusion SARS-CoV-2 Assay	
		Positive	Negative
Aptima SARS-CoV-2 Assay	Positive	50	1
	Negative	0	54

Positive Percent Agreement: (95% CI): 100% (92.9% – 100%)
Negative Percent Agreement: (95% CI): 98.2% (90.4% – 99.7%)
Overall Agreement: (95% CI): 99.0% (94.8% – 99.8%)

Clinical Performance with Contrived Panel

The clinical performance of the Aptima SARS-CoV-2 assay using the Aptima Specimen Transfer tube specimen preparation workflow was evaluated in comparison to a panel of contrived specimens. For the study, a panel of 115 remnant clinical nasopharyngeal specimens was tested using both the Panther Fusion Specimen Lysis Tube (Specimen Lysis Tube) and Aptima Specimen Transfer tube workflows. All specimens were collected from US patients with signs and symptoms of respiratory infection. The panel consisted of 65 SARS-CoV-2 positive and 50 SARS-CoV-2 negative specimens. Of the 65 positive specimens, 40 were at concentrations 0.5-2x LoD and 25 were at concentrations 3-5x LoD using inactivated cultured SARS-CoV-2 virus (USA-QA1/2020; BEI Resources; NR-52281) as the target.

The Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) for both specimen preparation workflows were calculated in relation to the expected result of the contrived specimen panel, as shown in Table 6 for the Aptima Specimen Transfer Tube and Table 7 for the Specimen Lysis Tube. Detection characteristics for the contrived specimens were calculated by target concentration, as shown in Table 8. Both specimen preparation workflows showed 100% agreement for the evaluated panels.

Table 6: Performance of the Aptima Specimen Transfer Tube Workflow Relative to Expected Results

		Expected Result		
		Positive	Negative	Total
Aptima Specimen Transfer Result	Positive	65	0	65
	Negative	0	50	50
	Total	65	50	115

Overall Agreement: 100% (96.8% – 100%)
Positive Agreement: 100% (94.4% – 100%)
Negative Agreement: 100% (92.9% – 100%)

Table 7: Performance of the Specimen Lysis Tube Workflow Relative to Expected Results

		Expected Result		
		Positive	Negative	Total
Specimen Lysis Tube Result	Positive	65	0	65
	Negative	0	50	50
	Total	65	50	115

Overall Agreement: 100% (96.8% – 100%)
Positive Agreement: 100% (94.4% – 100%)
Negative Agreement: 100% (92.9% – 100%)

Table 8: Detection Characteristics for Contrived Nasopharyngeal Swab Specimens

	Aptima Specimen Transfer Sample Workflow						Specimen Lysis Tube Sample Workflow					
Target Conc.	**n Valid**	**n Positive**	**% Positive**	**Average kRLU**	**St Dev kRLU**	**%CV**	**n Valid**	**n Positive**	**% Positive**	**Average kRLU**	**St Dev kRLU**	**%CV**
Neg	50	0	0	299	9.7	3.2	50	0	0	300	9.3	3.1
0.5x LoD	10	10	100	1050	208.5	19.9	10	10	100	1153	113.0	9.8
1.0x LoD	10	10	100	1176	102.1	8.7	10	10	100	1205	24.3	2.0
1.5x LoD	10	10	100	1222	31.6	2.6	10	10	100	1223	21.9	1.8
2.0x LoD	10	10	100	1225	22.6	1.8	10	10	100	1237	26.0	2.1
3.0x LoD	10	10	100	1228	13.6	1.1	10	10	100	1215	25.5	2.1
4.0x LoD	5	5	100	1238	16.7	1.4	5	5	100	1212	12.5	1.0
5.0x LoD	10	10	100	1237	18.2	1.5	10	10	100	1246	28.3	2.3

Clinical Performance with Naturally Infected Positive Specimens

The clinical performance of the Aptima SARS-CoV-2 assay using the Aptima Specimen Transfer tube specimen preparation workflow was evaluated in comparison to the Specimen Lysis Tube workflow tested with both the Aptima and Panther Fusion SARS-CoV-2 assays. For the study, three dilutions of 15 unique SARS-CoV-2 positive nasopharyngeal swab specimens were prepared and processed using both workflows. SARS-CoV-2 samples were previously determined to be positive using a non-Hologic molecular assay.

The positive percent agreement between the Aptima SARS-CoV-2 Assay using the Aptima Specimen Transfer Tube and the Specimen Lysis Tube workflows were 97.5% (87.1% – 99.6%) and 100% (91.0% – 100%), respectively, when compared to the Panther Fusion SARS-CoV-2 assay using the Specimen Lysis Tube workflow as reference. The positive percent agreement of the Aptima Specimen Transfer tube workflow was 95.0% (83.5% – 98.6%) when compared to the Specimen Lysis Tube workflow as reference.

Bibliography

1. **World Health Organization.** Q&A on coronaviruses (COVID-19). March 9, 2020. World Health Organization Web site https://www.who.int/news-room/q-a-detail/q-a-coronaviruses. Accessed March 10, 2020.
2. **Centers for Disease Control and Prevention.** https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/how-covid-spreads.html. Accessed June 17, 2020.
3. **Centers for Disease Control and Prevention.** Coronavirus Disease 2019-(COVID-19) in the U.S. Updated March 10, 2020. Centers for Disease Control and Prevention Web site https://www.cdc.gov/coronavirus/2019-ncov/cases-in-us.html. Accessed March 10, 2020.
4. **Centers for Disease Control and Prevention.** Coronavirus Disease 2019 Information for Travel. Page last reviewed March 8, 2020. Centers for Disease Control and Prevention Web site https://www.cdc.gov/coronavirus/2019-ncov/travelers/index.html. Accessed March 10, 2020.
5. **Centers for Disease Control and Prevention.** Coronavirus Disease 2019-(COVID-19) Situation Summary. Updated March 9, 2020. Centers for Disease Control and Prevention Web site https://www.cdc.gov/coronavirus/2019-ncov/summary.html. Accessed March 10, 2020.
6. **Clinical & Laboratory Standards Institute.** Document M29 Protection of Laboratory Workers from Occupationally Acquired Infections. CLSI Web site https://clsi.org/standards/products/microbiology/documents/m29/. Accessed September 2017.

IVD

Hologic, Inc.
10210 Genetic Center Drive
San Diego, CA 92121 USA

Customer Support: +1 800 442 9892
customersupport@hologic.com

Technical Support: +1 888 484 4747
molecularsupport@hologic.com

For more contact information visit www.hologic.com.

AW-21677-001 Rev. 002
2020-10

AB726

GeneXpert
Powered By CEPHEID INNOVATION

Xpert® Xpress SARS-CoV-2

Instructions for Use

For Use Under an Emergency Use Authorization (EUA) Only

Rx only

REF XPRSARS-COV2-10

For Use with GeneXpert Dx or GeneXpert Infinity Systems

AB727

Trademark, Patents and Copyright Statements

Cepheid®, the Cepheid logo, GeneXpert® and Xpert® are trademarks of Cepheid.

AccuPlex™ is a trademark of SeraCare Life Sciences.

Windows® is a trademark of Microsoft Corporation.

Cepheid
904 Caribbean Drive
Sunnyvale, CA 94089 USA
Phone: +1 408 541 4191
Fax: +1 408 541 4192

Xpert® Xpress SARS-CoV-2

For use under the Emergency Use Authorization (EUA) only.

1 Proprietary Name

Xpert® Xpress SARS-CoV-2

2 Common or Usual Name

Xpert Xpress SARS-CoV-2

3 Intended Use

The Xpert Xpress SARS-CoV-2 test is a rapid, real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in upper respiratory specimens (such as nasopharyngeal, oropharyngeal, nasal, or mid-turbinate swab and/or nasal wash/ aspirate) collected from individuals suspected of COVID-19 by their healthcare provider.

Testing of nasopharyngeal, oropharyngeal, nasal, or mid-turbinate swab and nasal wash/aspirate specimens using the Xpert Xpress SARS-CoV-2 test run on the GeneXpert Dx and GeneXpert Infinity systems is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform high and moderate complexity tests.

Testing of nasopharyngeal, nasal, or mid-turbinate swab specimens using the Xpert Xpress SARS-CoV-2 test run on the GeneXpert Xpress System (Tablet and Hub Configurations) is authorized to be distributed and used in patient care settings outside of the clinical laboratory environment.

Results are for the detection of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in upper respiratory specimens during the acute phase of infection. Positive results are indicative of active infection with SARS-CoV-2; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for treatment or other patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.

Testing with the Xpert Xpress SARS-CoV-2 test is intended for use by trained operators who are proficient in performing tests using either GeneXpert Dx, GeneXpert Infinity and/or GeneXpert Xpress systems. The Xpert Xpress SARS-CoV-2 test is only for use under the Food and Drug Administration's Emergency Use Authorization.

4 Summary and Explanation

An outbreak of respiratory illness of unknown etiology in Wuhan City, Hubei Province, China was initially reported to the World Health Organization (WHO) on December 31, 2019.[1] Chinese authorities identified a novel coronavirus (2019-nCoV), which has resulted in thousands of confirmed human infections in multiple provinces throughout China and exported cases in several Southeast Asian countries and more recently the United States. Cases of severe illness and some deaths have been reported. The International Committee for Taxonomy of Viruses (ICTV) renamed the virus SARS-CoV-2.[2]

The Xpert Xpress SARS-CoV-2 test is a molecular *in vitro* diagnostic test that aids in the detection and diagnosis SARS-CoV-2 and is based on widely used nucleic acid amplification technology. The Xpert Xpress SARS-CoV-2 test contains primers and probes and internal controls used in RT-PCR for the *in vitro* qualitative detection of SARS-CoV-2 RNA in upper respiratory specimens.

The term "qualified laboratories" refers to laboratories in which all users, analysts, and any person reporting results from use of this device are proficient in performing real-time RT-PCR assays.

5 Principle of the Procedure

The Xpert Xpress SARS-CoV-2 test is an automated *in vitro* diagnostic test for qualitative detection of nucleic acid from SARS-CoV-2. The Xpert Xpress SARS-CoV-2 test is performed on GeneXpert Instrument Systems.

The GeneXpert Instrument Systems automate and integrate sample preparation, nucleic acid extraction and amplification, and detection of the target sequences in simple or complex samples using real-time PCR assays. The systems consist of an instrument, computer, and preloaded software for running tests and viewing the results. The systems require the use of single-use disposable cartridges that hold the RT-PCR reagents and host the RT-PCR process. Because the cartridges are self-contained, cross-contamination between samples is minimized. For a full description of the systems, see the *GeneXpert Dx System Operator Manual* or the *GeneXpert Infinity System Operator Manual*.

The Xpert Xpress SARS-CoV-2 test includes reagents for the detection of RNA from SARS-CoV-2 in nasopharyngeal, oropharyngeal, nasal, or mid-turbinate swab and/or nasal wash/aspirate specimens. A Sample Processing Control (SPC) and a Probe Check Control (PCC) are also included in the cartridge utilized by the GeneXpert instrument. The SPC is present to control for adequate processing of the sample and to monitor for the presence of potential inhibitor(s) in the RT-PCR reaction. The SPC also ensures that the RT-PCR reaction conditions (temperature and time) are appropriate for the amplification reaction and that the RT-PCR reagents are functional. The PCC verifies reagent rehydration, PCR tube filling, and confirms that all reaction components are present in the cartridge including monitoring for probe integrity and dye stability.

The nasopharyngeal, oropharyngeal, nasal, or mid-turbinate swab specimen and/or nasal wash/aspirate specimen is collected and placed into a viral transport tube containing 3 mL transport medium or 3 mL of saline. The specimen is briefly mixed by rapidly inverting the collection tube 5 times. Using the supplied transfer pipette, the sample is transferred to the sample chamber of the Xpert Xpress SARS-CoV-2 cartridge. The GeneXpert cartridge is loaded onto the GeneXpert Instrument System platform, which performs hands-off, automated sample processing, and real-time RT-PCR for detection of viral RNA.

6 Reagents and Instruments

6.1 Materials Provided

Σ

The Xpert Xpress SARS-CoV-2 kit contains sufficient reagents to process 10 specimens or quality control samples. The kit contains the following:

Xpert Xpress SARS-CoV-2 Cartridges with Integrated Reaction Tubes	**10**
• Bead 1, Bead 2, and Bead 3 (freeze-dried)	1 of each per cartridge
• Lysis Reagent	1.5 mL per cartridge
• Binding Reagent	1.5 mL per cartridge
• Elution Reagent	3.0 mL per cartridge
Disposable Transfer Pipettes	**12 per kit**
CD	**1 per kit**
• Assay Definition File (ADF)	
• Instructions to import ADF into GeneXpert software	
Flyer	**1 per kit**
• Directions to locate the Product Insert on www.cepheid.com	

Note Safety Data Sheets (SDS) are available at www.cepheidinternational.com under the **SUPPORT** tab.

Note The bovine serum albumin (BSA) in the beads within this product was produced and manufactured exclusively from bovine plasma sourced in the United States. No ruminant protein or other animal protein was fed to the animals; the animals passed ante- and postmortem testing. During processing, there was no mixing of the material with other animal materials.

7 Storage and Handling

+2 +28 °C

- Store the Xpert Xpress SARS-CoV-2 cartridges at 2-28°C.
- Do not open a cartridge lid until you are ready to perform testing.
- Do not use a cartridge that is wet or has leaked.

8 Materials Required but Not Provided

- GeneXpert Dx or GeneXpert Infinity systems (catalog number varies by configuration): GeneXpert instrument, computer, barcode scanner, operator manual.

  For GeneXpert Dx System: GeneXpert Dx software version 4.7b or higher

  For GeneXpert Infinity-80 and Infinity-48s systems: Xpertise software version 6.4b or higher

9 Materials Available but Not Provided

SeraCare AccuPlex™ Reference Material Kit, catalog number 0505-0126 (Order Code CEPHEID)

10 Warnings and Precautions

10.1 General

- For *in vitro* diagnostic use.
- For emergency use only.
- Positive results are indicative of presence of SARS-CoV-2-RNA.
- Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities.
- Performance characteristics of this test have been established with the specimen types listed in the Intended Use Section only. The performance of this assay with other specimen types or samples has not been evaluated.
- Treat all biological specimens, including used cartridges, as if capable of transmitting infectious agents. Because it is often impossible to know which might be infectious, all biological specimens should be handled using standard precautions. Guidelines for specimen handling are available from the U.S. Centers for Disease Control and Prevention[3] and the Clinical and Laboratory Standards Institute.[4]
- Follow safety procedures set by your institution for working with chemicals and handling biological specimens.
- Consult your institution's environmental waste personnel on proper disposal of used cartridges, which may contain amplified material. This material may exhibit characteristics of federal EPA Resource Conservation and Recovery Act (RCRA) hazardous waste requiring specific disposal requirements. Check state and local regulations as they may differ from federal disposal regulations. Institutions should check the hazardous waste disposal requirements within their respective countries.

10.2 Specimens

- Maintain proper storage conditions during specimen transport to ensure the integrity of the specimen (see Section 12, Specimen Collection, Transport, and Storage). Specimen stability under shipping conditions other than those recommended has not been evaluated.

10.3 Assay/Reagent

- Do not open the Xpert Xpress SARS-CoV-2 cartridge lid except when adding specimen.
- Do not use a cartridge that has been dropped after removing it from the packaging.
- Do not shake the cartridge. Shaking or dropping the cartridge after opening the cartridge lid may yield non-determinate results.
- Do not place the sample ID label on the cartridge lid or on the barcode label on the cartridge.
- Do not use a cartridge with a damaged barcode label.
- Do not use a cartridge that has a damaged reaction tube.
- Each single-use Xpert Xpress SARS-CoV-2 cartridge is used to process one test. Do not reuse processed cartridges.
- Each single-use disposable pipette is used to transfer one specimen. Do not reuse disposable pipettes.
- Do not use a cartridge if it appears wet or if the lid seal appears to have been broken.
- Wear clean lab coats and gloves. Change gloves between the handling of each specimen.
- In the event of a spill of specimens or controls, wear gloves and absorb the spill with paper towels. Then, thoroughly clean the contaminated area with a 10% freshly prepared household chlorine bleach. Allow a minimum of two minutes of contact time. Ensure the work area is dry before using 70% denatured ethanol to remove bleach residue. Allow surface to dry completely before proceeding. Or, follow your institution's standard procedures for a contamination or spill event. For equipment, follow the manufacturer's recommendations for decontamination of equipment.

- Biological specimens, transfer devices, and used cartridges should be considered capable of transmitting infectious agents requiring standard precautions. Follow your institution's environmental waste procedures for proper disposal of used cartridges and unused reagents. These materials may exhibit characteristics of chemical hazardous waste requiring specific disposal. If country or regional regulations do not provide clear direction on proper disposal, biological specimens and used cartridges should be disposed per WHO [World Health Organization] medical waste handling and disposal guidelines.

11 Chemical Hazards[5,6]

- Signal Word: WARNING
- **UN GHS Hazard Statements**
  - Harmful if swallowed.
  - May be harmful in contact with skin.
  - Causes eye irritation.
- **UN GHS Precautionary Statements**
  - **Prevention**
    - Wash hands thoroughly after handling.
  - **Response**
    - Call a POISON CENTER or doctor/physician if you feel unwell.
    - If skin irritation occurs: Get medical advice/attention.
    - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
    - If eye irritation persists: Get medical advice/attention.

12 Specimen Collection, Transport, and Storage



Proper specimen collection, storage, and transport are critical to the performance of this test. Inadequate specimen collection, improper specimen handling and/or transport may yield a false result. See Section 12.1 for nasopharyngeal swab collection procedure, Section 12.2 for oropharyngeal swab collection procedure, Section 12.3 for nasal swab collection procedure, Section 12.4 for mid-turbinate swab collection procedure, and Section 12.5 for nasal wash/aspirate procedure. Nasopharyngeal, nasal, and mid-turbinate swabs and nasal wash/aspirate specimens can be stored at room temperature (15-30 °C) for up to 8 hours and refrigerated (2-8 °C) up to seven days until testing is performed on the GeneXpert Instrument Systems. For oropharyngeal swab specimen transport and storage requirements and additional information, refer to the CDC Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons Under Investigation (PUIs) for Coronavirus Disease 2019 (COVID-19) using the link provided below.

https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html

12.1 Nasopharyngeal Swab Collection Procedure

Insert the swab into either nostril, passing it into the posterior nasopharynx (see Figure 1). Rotate swab by firmly brushing against the nasopharynx several times. Remove and place the swab into the tube containing 3 mL of viral transport medium or 3 mL of saline. Break swab at the indicated break line and cap the specimen collection tube tightly.



Figure 1. Nasopharyngeal Swab Collection

12.2 Oropharyngeal Swab Collection Procedure

1. Swab the posterior pharynx, tonsils, and other inflamed areas. Avoid touching the tongue, cheeks, and teeth with the swab when collecting specimens.
2. Remove and place the swab into the tube containing 3 mL of viral transport medium or 3 mL of saline. Break swab at the indicated break line and cap the specimen collection tube tightly.

12.3 Nasal Swab Collection Procedure

1. Insert a nasal swab 1 to 1.5 cm into a nostril. Rotate the swab against the inside of the nostril for 3 seconds while applying pressure with a finger to the outside of the nostril (see Figure 2).



Figure 2. Nasal Swab Collection for First Nostril

2. Repeat on the other nostril with the same swab, using external pressure on the outside of the other nostril (see Figure 3). To avoid specimen contamination, do not touch the swab tip to anything other than the inside of the nostril.

Figure 3. Nasal Swab Collection for Second Nostril

3. Remove and place the swab into the tube containing 3 mL of viral transport medium or 3 mL of saline. Break swab at the indicated break line and cap the specimen collection tube tightly.

12.4 Mid-Turbinate Swab Collection Procedure

1. Insert the mid-turbinate swab into either nostril, passing it into the mid-turbinate area (see Figure 4). Rotate swab by firmly brushing against the mid-turbinate area several times.
2. Remove and place the swab into the tube containing 3 mL of viral transport medium or 3 mL of saline. Break swab at the indicated break line and cap the specimen collection tube tightly.

Figure 4. Mid-turbinate Swab Specimen Collection

12.5 Nasal Wash/Aspirate Procedure

Using a clean transfer pipette, transfer 600 µL of the sample into the tube containing 3 mL of viral transport medium or 3 mL of saline and then cap the tube.

13 Procedure

13.1 Preparing the Cartridge

Important **Start the test within 30 minutes of adding the sample to the cartridge.**

1. Remove a cartridge from the package.
2. Check the specimen transport tube is closed.
3. Mix specimen by rapidly inverting the specimen transport tube 5 times. Open cap on the specimen transport tube.

4. Open the cartridge lid.
5. Remove the transfer pipette from the wrapper.
6. Squeeze the top bulb of the transfer pipette completely and then place the pipette tip in the specimen transport tube (see Figure 5).



Figure 5. Transfer Pipette

7. Release the top bulb of the pipette to fill the pipette before removing from the tube. After filling pipette, excess sample will be seen in the overflow reservoir bulb of the pipette (see Figure 5). Check that the pipette does not contain bubbles.
8. To transfer the sample to the cartridge, squeeze the top bulb of the transfer pipette completely again to empty the contents of the pipette (300 µL) into the large opening (Sample Chamber) in the cartridge shown in Figure 6. Dispose of the used pipette.



Figure 6. Xpert Xpress SARS-CoV-2 Cartridge (Top View)

Note Take care to dispense the entire volume of liquid into the Sample Chamber. False negative results may occur if insufficient sample is added to the cartridge.

9. Close the cartridge lid.

13.2 External Controls

External controls described in Section 9 are available but not provided and may be used in accordance with local, state, and federal accrediting organizations, as applicable.

To run a control using the Xpert Xpress SARS-CoV-2 test, perform the following steps:

1. Mix control by rapidly inverting the external control tube 5 times. Open cap on external control tube.
2. Open the cartridge lid.
3. Using a clean transfer pipette, transfer one draw of the external control sample (300 µL) into the large opening (Sample Chamber) in the cartridge shown in Figure 6.
4. Close cartridge lid.

13.3 Starting the Test

Note

Before you start the test, make sure that the system contains modules with GeneXpert Dx software version 4.7b or higher or Infinity Xpertise software 6.4b or higher, and that the Xpert Xpress SARS-CoV-2 Assay Definition File is imported into the software.

This section lists the default steps to operate the GeneXpert Instrument System. For detailed instructions, see the *GeneXpert Dx System Operator Manual* or the *GeneXpert Infinity System Operator Manual*, depending on the model that is being used.

Note The steps you follow may be different if the system administrator has changed the default workflow of the system.

1. Turn on the GeneXpert Instrument System:
   - **GeneXpert Dx:**
     If using the GeneXpert Dx instrument, first turn on the instrument and then turn on the computer. Log into the Windows operating system. The GeneXpert software may launch automatically or may require double-clicking on the GeneXpert Dx shortcut icon on the Windows® desktop.

     or
   - **GeneXpert Infinity System:**
     If using the GeneXpert Infinity instrument, power up the instrument by turning the power switch clockwise to the **ON** position. On the Windows desktop, double-click the Xpertise Software shortcut icon to launch the software.
2. Log on to the System software. The login screen appears. Type your user name and password.
3. In the GeneXpert System window, click **Create Test** (GeneXpert Dx) or **Orders** followed by **Order Test** (Infinity).
4. Scan or type in the Patient ID (optional). If typing the Patient ID, make sure the Patient ID is typed correctly. The Patient ID is shown on the left side of the View Results window and is associated with the test result.
5. Scan or type in the Sample ID. If typing the Sample ID, make sure the Sample ID is typed correctly. The Sample ID is shown on the left side of the View Results window and is associated with the test result.
6. Scan the barcode on the Xpert Xpress SARS-CoV-2 cartridge. Using the barcode information, the software automatically fills the boxes for the following fields: Reagent Lot ID, Cartridge SN, Expiration Date and Selected Assay.

Note If the barcode on the Xpert Xpress SARS-CoV-2 cartridge does not scan, then repeat the test with a new cartridge.

7. Click **Start Test** (GeneXpert Dx) or **Submit** (Infinity) if Auto-Submit is not enabled. In the dialog box that appears, type your password, if required.

   For the GeneXpert Dx Instrument

   A. Locate the module with the blinking green light, open the instrument module door and load the cartridge.

   B. Close the door. The test starts and the green light stops blinking. When the test is finished, the light turns off and the door will unlock. Remove the cartridge.

   C. Dispose of used cartridges in the appropriate sample waste containers according to your institution's standard practices.

   or

   For the GeneXpert Infinity System

   A. After clicking **Submit**, you will be asked to place the cartridge on the conveyor belt. After placing the cartridge, click **OK** to continue. The cartridge will be automatically loaded, the test will run and the used cartridge will be placed onto the waste shelf for disposal.

   B. When all samples are loaded, click on the **End Order Test** icon.

Note Do not turn off or unplug the instruments while a test is in progress. Turning off or unplugging the GeneXpert instrument or computer will stop the test.

14 Viewing and Printing Results

For detailed instructions on how to view and print the results, see the *GeneXpert Dx System Operator Manual* or the *GeneXpert Infinity System Operator Manual*.

15 Quality Control

15.1 Internal Controls

CONTROL

Each cartridge includes a Sample Processing Control (SPC) and Probe Check Control (PCC).

Sample Processing Control (SPC) - Ensures that the sample was processed correctly. The SPC verifies that sample processing is adequate. Additionally, this control detects sample-associated inhibition of the real-time PCR assay, ensures that the PCR reaction conditions (temperature and time) are appropriate for the amplification reaction, and that the PCR reagents are functional. The SPC should be positive in a negative sample and can be negative or positive in a positive sample. The SPC passes if it meets the validated acceptance criteria.

Probe Check Control (PCC) - Before the start of the PCR reaction, the GeneXpert System measures the fluorescence signal from the probes to monitor bead rehydration, reaction tube filling, probe integrity, and dye stability. The PCC passes if it meets the validated acceptance criteria.

15.2 External Controls

External controls should be used in accordance with local, state, and federal accrediting organizations as applicable.

16 Interpretation of Results

The results are interpreted automatically by the GeneXpert System and are clearly shown in the **View Results** window. The Xpert Xpress SARS-CoV-2 test provides test results based on the detection of two gene targets according to the algorithms shown in Table 1.

Table 1. Xpert Xpress SARS-CoV-2 Possible Results

Result Text	N2	E	SPC
SARS-CoV-2 POSITIVE	+	+/-	+/-
SARS-CoV-2 PRESUMPTIVE POS	-	+	+/-
SARS-CoV-2 NEGATIVE	-	-	+
INVALID	-	-	-

See Table 2 to interpret test result statements for the Xpert Xpress SARS-CoV-2 test.

Table 2. Xpert Xpress SARS-CoV-2 Results and Interpretation

Result	Interpretation
SARS-CoV-2 POSITIVE	The 2019 novel coronavirus (SARS-CoV-2) target nucleic acids are detected. • The SARS-CoV-2 signal for the N2 nucleic acid target or signals for both nucleic acid targets (N2 and E) have a Ct within the valid range and endpoint above the minimum setting • SPC: NA; SPC is ignored because coronavirus target amplification occurred • Probe Check: PASS; all probe check results pass
SARS-CoV-2 PRESUMPTIVE POS	The 2019 novel coronavirus (SARS-CoV-2) nucleic acids may be present. Sample should be retested according to the Retest Procedure in Section 17.2. For samples with a repeated presumptive positive result, additional confirmatory testing may be conducted, if it is necessary to differentiate between SARS-CoV-2 and SARS-CoV-1 or other Sarbecovirus currently unknown to infect humans, for epidemiological purposes or clinical management. • The SARS-CoV-2 signal for only the E nucleic acid target has a Ct within the valid range and endpoint above the minimum setting • SPC: NA; SPC is ignored because a target amplification has occurred. • Probe Check: PASS; all probe check results pass.

Table 2. Xpert Xpress SARS-CoV-2 Results and Interpretation (Continued)

Result	Interpretation
SARS-CoV-2 NEGATIVE	The 2019 novel coronavirus (SARS-CoV-2) target nucleic acids are not detected. • The SARS-CoV-2 signals for two nucleic acid targets (N2 and E) do not have a Ct within the valid range and endpoint above the minimum setting • SPC: PASS; SPC has a Ct within the valid range and endpoint above the minimum setting • Probe Check: PASS; all probe check results pass
INVALID	SPC does not meet acceptance criteria. Presence or absence of the 2019 novel coronavirus (SARS-CoV-2) nucleic acids cannot be determined. Repeat test according to the Retest Procedure in Section 17.2. • SPC: FAIL; SPC and SARS-CoV-2 signals do not have a Ct within valid range and endpoint below minimum setting • Probe Check: PASS; all probe check results pass
ERROR	Presence or absence of the 2019 novel coronavirus (SARS-CoV-2) nucleic acids cannot be determined. Repeat test according to the Retest Procedure in Section 17.2. • SARS-CoV-2: NO RESULT • SPC: NO RESULT • Probe Check: FAIL[1]; all or one of the probe check results fail [1] If the probe check passes, the error is caused by the maximum pressure limit exceeding the acceptable range, no sample added, or by a system component failure.
NO RESULT	Presence or absence of the 2019 novel coronavirus (SARS-CoV-2) nucleic acids cannot be determined. Repeat test according to the Retest Procedure in Section 17.2. A **NO RESULT** indicates that insufficient data were collected. For example, the operator stopped a test that was in progress. • SARS-CoV-2: NO RESULT • SPC: NO RESULT • Probe Check: NA (not applicable)

The Xpert Xpress SARS-CoV-2 test includes an Early Assay Termination (EAT) function which will provide earlier time to results in high titer specimens. When SARS-CoV-2 titers are high enough to initiate the EAT function, the SPC amplification curve may not be seen and its results may not be reported.

17 Retests

17.1 Reasons to Repeat the Assay

If any of the test results mentioned below occur, repeat the test once according to instructions in Section 17.2, Retest Procedure.

- A **PRESUMPTIVE POS** result indicates the 2019 novel coronavirus (SARS-CoV-2) nucleic acids may be present. Only one of the SARS-CoV-2 nucleic acid target was detected (E gene) while the other SARS-CoV-2 nucleic acid target (N2 gene) was not detected.
- An **INVALID** result indicates that the control SPC failed. The sample was not properly processed, PCR is inhibited, or the sample was not properly collected.
- An **ERROR** result could be due to, but not limited to, Probe Check Control failure, system component failure, no sample added, or the maximum pressure limits were exceeded.
- A **NO RESULT** indicates that insufficient data were collected. For example, cartridge failed integrity test, the operator stopped a test that was in progress, or a power failure occurred.

If an External Control fails to perform as expected, repeat external control test and/or contact Cepheid for assistance.

17.2 Retest Procedure

To retest a non-determinate result (**INVALID**, **NO RESULT**, or **ERROR**) or a **PRESUMPTIVE POS** result, use a new cartridge.

Use the leftover sample from the original specimen transport medium tube or new external control tube.

1. Put on a clean pair of gloves. Obtain a new Xpert Xpress SARS-CoV-2 cartridge and a new transfer pipette.
2. Check the specimen transport tube or external control tube is closed.
3. Mix the sample by rapidly invert the specimen transport medium tube or external control tube 5 times. Open the cap on the specimen transport tube or external control tube.
4. Open the cartridge lid.
5. Using a clean transfer pipette (supplied), transfer sample (one draw) to the sample chamber with the large opening in the cartridge.
6. Close the cartridge lid.

18 Limitations

- Performance of the Xpert Xpress SARS-CoV-2 test has only been established in nasopharyngeal swab and nasal wash/aspirate specimens. Use of the Xpert Xpress SARS-CoV-2 test with other specimen types has not been assessed and performance characteristics are unknown.
- Oropharyngeal, nasal swabs and mid-turbinate swabs are considered acceptable specimen types for use with the Xpert Xpress SARS-CoV-2 test but performance with these specimen types has not been established. Testing of nasal and mid-turbinate nasal swabs (self-collected under supervision of or collected by a healthcare provider) is limited to patients with symptoms of COVID-19. Please refer to FDA's FAQs on Diagnostic testing for SARS-CoV-2 for additional information.
- A false negative result may occur if a specimen is improperly collected, transported or handled. False negative results may also occur if inadequate numbers of organisms are present in the specimen.
- As with any molecular test, mutations within the target regions of Xpert Xpress SARS-CoV-2 could affect primer and/or probe binding resulting in failure to detect the presence of virus.
- This test cannot rule out diseases caused by other bacterial or viral pathogens.

19 Conditions of Authorization for Laboratory and Patient Care Settings

The Cepheid Xpert Xpress SARS-CoV-2 Letter of Authorization, along with the authorized Fact Sheet for Healthcare Providers, the authorized Fact Sheet for Patients and authorized labeling are available on the FDA website: https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations#covid19ivd

However, to assist clinical laboratories and/or Patient Care Settings using the Xpert Xpress SARS-CoV-2 (referred to in the Letter of Authorization as "Your Product"), the relevant Conditions of Authorization are listed below.

- Authorized laboratories[1] and patient care settings using your product will include with result reports of the Xpert Xpress SARS-CoV-2 test, all authorized Fact Sheets. Under exigent circumstances, other appropriate methods for disseminating these Fact Sheets may be used, which may include mass media.
- Authorized laboratories using your product will use your product as outlined in the Xpert Xpress SARS-CoV-2 Instructions for Use - For Use with GeneXpert Dx or GeneXpert Infinity systems. Deviations from the authorized procedures, including the authorized instruments, authorized extraction methods, authorized clinical specimen types, authorized control materials, authorized other ancillary reagents and authorized materials required to use the Xpert Xpress SARS-CoV-2 test are not permitted.
- Patient Care Settings using your product will use your product as outlined in the Xpress SARS-CoV-2 Instructions for Use - For Use with GeneXpert Xpress System and associated Quick Reference Instructions for Xpert Xpress SARS-CoV-2 and GeneXpert Xpress System (Hub configuration), and Quick Reference Instructions for Xpert Xpress SARS-CoV-2 and GeneXpert Xpress System (Tablet configuration). Deviations from the authorized procedures, including the authorized instruments, authorized extraction methods, authorized clinical specimen types, authorized control materials, authorized other ancillary reagents and authorized materials required to use your product are not permitted.
- Authorized laboratories and patient care settings will have a process in place for reporting test results to healthcare providers and relevant public health authorities, as appropriate.
- Authorized laboratories and patient care settings that receive your product will notify the relevant public health authorities of their intent to run your product prior to initiating testing.

- Authorized laboratories and patient care settings using the Xpert Xpress SARS-CoV-2 test will collect information on the performance of the test and report to DMD/OHT7-OIR/OPEQ/CDRH (via email: CDRH-EUA Reporting@fda.hhs.gov) and Cepheid (+1 888.838.3222 or techsupport@cepheid.com) any suspected occurrence of false positive or false negative results and significant deviations from the established performance characteristics of the test of which they become aware.
- All operators using your product must be appropriately trained in performing and interpreting the results of your product, use appropriate personal protective equipment when handling this kit, and use your product in accordance with the authorized labeling.
- You, authorized distributors, and authorized laboratories and patient care settings using your product will ensure that any records associated with this EUA are maintained until otherwise notified by FDA. Such records will be made available to FDA for inspection upon request.

[1] The letter of authorization refers to, "Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform moderate or high complexity tests" as "authorized laboratories."

20 Performance Characteristics

20.1 Clinical Evaluation - AccuPlex SARS-CoV-2 Reference Material

The performance of the Xpert Xpress SARS-CoV-2 test was evaluated using contrived clinical NP swab specimens in viral transport medium obtained from U.S. patients with signs and symptoms of respiratory infection. The samples were prepared by spiking each individual negative clinical NP swab sample with AccuPlex SARS-CoV-2 (a quantitated reference material - recombinant Sindbis virus particle containing target sequences from the SARS-CoV-2 genome) at 2x LoD, 3x LoD and 5x LoD levels. The NP swab samples were determined to be negative for SARS-CoV-2 prior to spiking. Individual negative NP swab samples were also tested in the study. All positive and negative samples in the study were tested in a randomized and blinded fashion.

Table 3 shows the number of concordant results out of the total number of samples tested for each target concentration of AccuPlex SARS-CoV-2, the mean Ct values for each of the E and N2 nucleic acid targets as well as the percent agreement with the 95% CI where appropriate. The results show 100% agreement with the expected results in the AccuPlex SARS-CoV-2 spiked samples and 100% agreement with the expected results in the negative samples.

Table 3. Xpert Xpress SARS-CoV-2 Test Agreement with the Expected Results by Target Concentration

Target Concentration	Number Concordant/ Number Tested	E Mean Ct	N2 Mean Ct	% Agreement [95% CI]
2x LoD	20/20	34.8	38.0	100% [83.9% - 100%]
3x LoD	5/5	33.7	37.1	100% [NA*]
5x LoD	5/5	33.7	36.8	100% [NA*]
Negative	35/35	NA	NA	100% [90.1% - 100%]

*95% CI not computed for sample concentrations with sample size of 5 or less.

20.2 Clinical Evaluation – Live SARS-CoV-2 Virus

The performance of the Xpert Xpress SARS-CoV-2 test was evaluated using contrived clinical NP swab specimens in viral transport medium obtained from U.S. patients with signs and symptoms of respiratory infection. The samples were prepared by spiking each individual negative clinical NP swab sample with live SARS-CoV-2 virus (USA_WA1/2020) at 2x LoD, 3x LoD and 5x LoD levels. The NP swab samples were determined to be negative for SARS-CoV-2 prior to spiking. Individual negative NP swab samples were also tested in the study. All positive and negative samples in the study were tested in a randomized and blinded fashion.

Table 4 shows the number of concordant results out of the total number of samples tested for each target concentration of live SARS-CoV-2 virus, the mean Ct values for each of the E and N2 nucleic acid targets as well as the percent agreement with the 95% confidence interval (95% CI), where appropriate. The results show 100% agreement with the expected results in the live SARS-CoV-2 virus spiked samples and 100% agreement with the expected results in the negative samples.

Table 4. Xpert Xpress SARS-CoV-2 Test Agreement with the Expected Results by Target Concentration

Target Concentration	Number Concordant/ Number Tested	E Mean Ct	N2 Mean Ct	% Agreement [95% CI]
2x LoD	20/20	35.4	38.4	100% [83.9% - 100%]
3x LoD	5/5	34.2	37.2	100% [NA*]
5x LoD	5/5	33.9	37.0	100% [NA*]
Negative	30/30	NA	NA	100% [88.7% - 100%]

* 95% CI not computed for sample concentrations with sample size of 5 or less.

21 Analytical Performance

21.1 Analytical Sensitivity (Limit of Detection) - AccuPlex SARS-CoV-2 Reference Material

Studies were performed to determine the analytical limit of detection (LoD) of the Xpert Xpress SARS-CoV-2. The LoD of Xpert Xpress SARS-CoV-2 was established using one lot of reagent and limiting dilutions of AccuPlex SARS-CoV-2 prepared in simulated background matrix and NP swab clinical matrix and probit analysis. Verification of the estimated LoD claim was performed on one reagent lot in replicates of 35 prepared in pooled NP swab clinical matrix. The LoD is the lowest concentration (reported as copies/mL) of AccuPlex SARS-Cov-2 recombinant viral sequence that can be reproducibly distinguished from negative samples ≥ 95% of the time with 95% confidence. The claimed LoD for the assay is 250 copies/mL (Table 5).

Table 5. Limit of Detection of the Xpert Xpress SARS-CoV-2

Material	Claimed LoD (copies/mL)	Positives/ Replicates
SARS-CoV-2 Reference Material	250	35/35

21.2 Analytical Sensitivity (Limit of Detection) – Live SARS-CoV-2 Virus

Studies were performed to determine the analytical limit of detection (LoD) of the Xpert Xpress SARS-CoV-2. The LoD of Xpert Xpress SARS-CoV-2 was established using one lot of reagent and limiting dilutions of live SARS-CoV-2 virus (USA_WA1/2020) prepared in viral transport medium and NP swab clinical matrix and probit analysis. Verification of the estimated LoD claim was performed on one reagent lot in replicates of 22 prepared in pooled NP swab clinical matrix. The LoD is the lowest concentration (reported as PFU/mL) of live SARS-CoV-2 virus samples that can be reproducibly distinguished from negative samples ≥ 95% of the time with 95% confidence. The claimed LoD for the assay is 0.0100 PFU/mL (Table 6).

Table 6. Limit of Detection of the Xpert Xpress SARS-CoV-2

Strain	Claimed LoD (PFU/mL)	E Mean Ct	N2 Mean Ct	Positives/ Replicates
SARS-CoV-2 virus (USA_WA1/2020)	0.0100	35.9	38.9	22/22

21.3 Analytical Reactivity (Inclusivity)

The inclusivity of Xpert Xpress SARS-CoV-2 was evaluated using *in silico* analysis of the assay primers and probes in relation to 324 SARS-CoV-2 sequences available in the GISAID gene database for two targets, E and N2.

For the E target, Xpert Xpress SARS-CoV-2 had 100% match to all sequences with the exception of 4 sequences that had a single mismatch. For the N2 target, Xpert Xpress SARS-CoV-2 had 100% match to all sequences with the exception of 2 sequences that had a single mismatch. None of these mismatches found for both targets are predicted to have a negative impact on the performance of the assay, given the location of the mutations in the primer and probe regions respectively for the two variants. These mutations are not predicted to adversely affect the probe and primer binding to the sequences or reduce assay efficiency.

21.4 Analytical Specificity (Exclusivity)

An *in silico* analysis for possible cross-reactions with all the organisms listed in Table 7 was conducted by mapping primers and probes in the Xpert Xpress SARS-CoV-2 test individually to the sequences downloaded from the GISAID database. E primers and probes are not specific for SARS-CoV-2 and will detect Human and Bat SARS-coronavirus. No potential unintended cross reactivity with other organisms listed in Table 7 is expected based on the *in silico* analysis.

Table 7. Xpert Xpress SARS-CoV-2 Analytical Specificity Microorganisms

Microorganisms from the Same Genetic Family	High Priority Organisms
Human coronavirus 229E	Adenovirus (e.g. C1 Ad. 71)
Human coronavirus OC43	Human Metapneumovirus (hMPV)
Human coronavirus HKU1	Parainfluenza virus 1-4
Human coronavirus NL63	Influenza A
SARS-coronavirus	Influenza B
MERS-coronavirus	Influenza C
Bat coronavirus	Enterovirus (e.g. EV68)
	Respiratory syncytial virus
	Rhinovirus
	Chlamydia pneumoniae
	Haemophilus influenzae
	Legionella pneumophila
	Mycobacterium tuberculosis
	Streptococcus pneumoniae
	Streptococcus pyogenes
	Bordetella pertussis
	Mycoplasma pneumoniae
	Pneumocystis jirovecii (PJP)
	Parechovirus
	Candida albicans
	Corynebacterium diphtheriae
	Legionella non-pneumophila
	Bacillus anthracis (Anthrax)
	Moraxella catarrhalis
	Neisseria elongate and meningitidis
	Pseudomonas aeruginosa
	Staphylococcus epidermidis
	Staphylococcus salivarius
	Leptospira
	Chlamydia psittaci
	Coxiella burnetii (Q-Fever)
	Staphylococcus aureus

22 References

1. Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/index.html. Accessed February 9, 2020.
2. bioRxiv. (https://www.biorxiv.org/content/10.1101/2020.02.07.937862v1). Accessed March 3, 2020.
3. Centers for Disease Control and Prevention. *Biosafety in Microbiological and Biomedical laboratories* (refer to latest edition). http://www.cdc.gov/biosafety/publications/
4. Clinical and Laboratory Standards Institute. *Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline.* Document M29 (refer to latest edition).
5. REGULATION (EC) No 1272/2008 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 December 2008 on the classification labeling and packaging of substances and mixtures amending and repealing, List of Precautionary Statements, Directives 67/548/EEC and 1999/45/EC (amending Regulation (EC) No 1907/2007).
6. Occupational Safety and Health Standards, Hazard Communication, Toxic and Hazard Substances (March 26, 2012) (29 C.F.R., pt. 1910, subpt. Z).

23 Cepheid Headquarters Locations

Corporate Headquarters	European Headquarters
Cepheid 904 Caribbean Drive Sunnyvale, CA 94089 USA	Cepheid Europe SAS Vira Solelh 81470 Maurens-Scopont France
Telephone: +1 408 541 4191	Telephone: +33 563 825 300
Fax: +1 408 541 4192	Fax: +33 563 825 301
www.cepheid.com	www.cepheidinternational.com

24 Technical Assistance

Before contacting Cepheid Technical Support, collect the following information:

- Product name
- Lot number
- Serial number of the instrument
- Error messages (if any)
- Software version and, if applicable, Computer Service Tag number

Region	Telephone	Email
US	+1 888.838.3222	techsupport@cepheid.com
France	+33 563 825 319	support@cepheideurope.com
Australia New Zealand	+1800 130 821 +0800 001 028	techsupportANZ@cepheid.com

Contact information for all Cepheid Technical Support offices is available on our website: www.cepheid.com/en/CustomerSupport.

25 Table of Symbols

Symbol	Meaning
REF	Catalog number
IVD	*In vitro* diagnostic medical device
	Do not re-use
LOT	Batch code
	Consult instructions for use
	Caution
	Manufacturer
	Country of manufacture
	Contains sufficient for <n> tests
CONTROL	Control
	Expiration date
	Temperature limitation
	Biological risks
Rx only	For prescription use only

Cepheid
904 Caribbean Drive
Sunnyvale, CA 94089 USA
Phone: +1 408 541 4191
Fax: +1 408 541 4192

IVD

For use under Emergency Use Authorization (EUA) Only

AB744

GeneXpert
Powered By CEPHEID INNOVATION

Xpert® Xpress SARS-CoV-2/Flu/RSV

Instructions for Use
For Use Under an Emergency Use Authorization (EUA) Only

Rx only

REF **XPCOV2/FLU/RSV-10**

For Use with GeneXpert Xpress System (point of care system)

Cepheid

For use under an Emergency Use Authorization (EUA) Only

IVD

302-4419, Rev. C January 2021

For *In Vitro* Diagnostic use

Trademark, Patents and Copyright Statements

Cepheid®, the Cepheid logo, GeneXpert® and Xpert® are trademarks of Cepheid.
Windows® is a trademark of Microsoft Corporation.

THE PURCHASE OF THIS PRODUCT CONVEYS TO THE BUYER THE NON-TRANSFERABLE RIGHT TO USE IT IN ACCORDANCE WITH THIS INSTRUCTIONS FOR USE. NO OTHER RIGHTS ARE CONVEYED EXPRESSLY, BY IMPLICATION OR BY ESTOPPEL. FURTHERMORE, NO RIGHTS FOR RESALE ARE CONFERRED WITH THE PURCHASE OF THIS PRODUCT.

Cepheid
904 Caribbean Drive
Sunnyvale, CA 94089 USA
Phone: +1 408 541 4191
Fax: +1 408 541 4192

For use under the Emergency Use Authorization (EUA) only.

1 Proprietary Name

Xpert® Xpress SARS-CoV-2/Flu/RSV

2 Common or Usual Name

Xpert Xpress SARS-CoV-2/Flu/RSV

3 Intended Use

The Xpert Xpress SARS-CoV-2/Flu/RSV test is a rapid, multiplexed real-time RT-PCR test intended for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV) viral RNA in either nasopharyngeal swab, nasal swab or nasal wash/ aspirate specimens collected from individuals suspected of respiratory viral infection consistent with COVID-19 by their healthcare provider.[1] Clinical signs and symptoms of respiratory viral infection due to SARS-CoV-2, influenza, and RSV can be similar.

Testing of nasopharyngeal swab, nasal swab, or nasal wash/aspirate specimens using the Xpert Xpress SARS-CoV-2/Flu/RSV test run on the GeneXpert Dx and GeneXpert Infinity systems is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet requirements to perform high or moderate complexity tests.

Testing of nasopharyngeal or nasal swab specimens using the Xpert Xpress SARS-CoV-2/Flu/RSV test run on the GeneXpert Xpress System (Tablet and Hub Configurations) is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

Results are for the simultaneous detection and differentiation of SARS-CoV-2, influenza A virus, influenza B virus and RSV nucleic acids in clinical specimens and is not intended to detect influenza C virus. SARS-CoV-2, influenza A, influenza B and RSV RNA identified by this test are generally detectable in upper respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of the identified virus, but do not rule out bacterial infection or co-infection with other pathogens not detected by the test.

Clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. The agent detected may not be the definite cause of disease. Laboratories within the United States and its territories are required to report all SARS-CoV-2 results to the appropriate public health authorities.

Negative results do not preclude SARS-CoV-2, influenza A virus, influenza B virus and/or RSV infection and should not be used as the sole basis for treatment or other patient management decisions. Negative results must be combined with clinical observations, patient history, and/or epidemiological information.

[1] For this EUA, a healthcare provider includes, but is not limited to, physicians, nurses, pharmacists, technologists, laboratory directors, epidemiologists, or any other practitioners or allied health professionals.

Testing with the Xpert Xpress SARS-CoV-2/Flu/RSV test is intended for use by trained operators who are proficient in performing tests using either GeneXpert Dx, GeneXpert Infinity and/or GeneXpert Xpress systems. The Xpert Xpress SARS-CoV-2/Flu/RSV test is only for use under the Food and Drug Administration's Emergency Use Authorization.

4 Summary and Explanation

An outbreak of respiratory illness of unknown etiology in Wuhan City, Hubei Province, China was initially reported to the World Health Organization (WHO) on December 31, 2019.[1] Chinese authorities identified a novel coronavirus (2019-nCoV), which has since spread globally, resulting in a pandemic of coronavirus disease 2019 (COVID-19). COVID-19 is associated with a variety of clinical outcomes, including asymptomatic infection, mild upper respiratory infection, severe lower respiratory disease including pneumonia and respiratory failure, and in some cases, death. The International Committee on Taxonomy of Viruses (ICTV) renamed the virus SARS-CoV-2.[2]

Influenza, or the flu, is a contagious viral infection of the respiratory tract. Transmission of influenza is primarily airborne (i.e., coughing or sneezing) and the peak of transmission usually occurs in the winter months. Symptoms commonly include fever, chills, headache, malaise, cough and sinus congestion. Gastrointestinal symptoms (i.e., nausea, vomiting or diarrhea) may also occur, primarily in children, but are less common. Symptoms generally appear within two days of exposure to an infected person. Pneumonia may develop as a complication due to influenza infection, causing increased morbidity and mortality in pediatric, elderly, and immunocompromised populations.[3, 4]

Influenza viruses are classified into types A, B, and C, the former two of which cause the most human infections. Influenza A (Flu A) is the most common type of influenza virus in humans and is generally responsible for seasonal flu epidemics and potentially pandemics. Flu A viruses can also infect animals such as birds, pigs, and horses. Infections with influenza B (Flu B) virus are generally restricted to humans and less frequently cause epidemics.[5] Flu A viruses are further divided into subtypes on the basis of two surface proteins: hemagglutinin (H) and neuraminidase (N). Seasonal flu is normally caused by influenza A subtypes H1, H2, H3, N1 and N2.

Respiratory Syncytial Virus (RSV), a member of the *Pneumoviridae* family (formerly *Paramyxoviridae*), consisting of two strains (subgroups A and B) is also the cause of a contagious disease that affects primarily infants, and the elderly who are immunocompromised (e.g. patients with chronic lung disease or undergoing treatment for conditions that reduce the strength of their immune system).[6] The virus can remain infectious for hours on countertops and toys and can cause both upper respiratory infections, such as colds, and lower respiratory infections manifesting as bronchiolitis and pneumonia.[6] By the age of two years, most children have already been infected by RSV and because only weak immunity develops, both children and adults can be re-infected.[6] Symptoms appear four to six days after infection and are usually self-limiting, lasting approximately one to two weeks in infants. In adults, infection lasts about 5 days and presents as symptoms consistent with a cold, such as rhinorrhea, fatigue, headache, and fever. The RSV season mirrors influenza somewhat as infections begin to rise during the fall through early spring.[5, 6]

Active surveillance programs in conjunction with infection prevention precautions are important components for preventing transmission of SARS-CoV-2, influenza and RSV.

The use of assays providing rapid results to identify patients infected with these viruses can be an important factor for effective control, proper choice of treatment, and prevention of widespread outbreaks.

The Xpert Xpress SARS-CoV-2/Flu/RSV test is a molecular *in vitro* diagnostic test that aids in the detection and differentiation of RNA from Flu A, Flu B, RSV and SARS-CoV-2 virus and is based on widely used nucleic acid amplification technology. The Xpert Xpress SARS-CoV-2/Flu/RSV test contains primers and probes and internal controls used in RT-PCR for the *in vitro* qualitative detection and differentiation of RNA from Flu A, Flu B, RSV and SARS-CoV-2 virus in upper respiratory specimens.

5 Principle of the Procedure

The Xpert Xpress SARS-CoV-2/Flu/RSV test is an automated *in vitro* diagnostic test for qualitative detection and differentiation of RNA from Flu A, Flu B, RSV and SARS-CoV-2 virus. The Xpert Xpress SARS-CoV-2/Flu/RSV test is performed on GeneXpert Xpress System.

The GeneXpert Xpress System automate and integrate sample preparation, nucleic acid extraction and amplification, and detection of the target sequences in simple or complex samples using real-time PCR assays. The systems consist of an instrument, computer, and preloaded software for running tests and viewing the results. The systems require the use of single-use disposable cartridges that hold the RT-PCR reagents and host the RT-PCR process. Because the cartridges are self-contained, cross-contamination between samples is minimized. For a full description of the systems, see the GeneXpert Xpress System User's Guide.

The Xpert Xpress SARS-CoV-2/Flu/RSV test includes reagents for the detection of RNA from Flu A, Flu B, RSV and SARS-CoV-2 virus in either nasopharyngeal swab or nasal swab specimens. A Sample Processing Control (SPC) and a Probe Check Control (PCC) are also included in the cartridge utilized by the GeneXpert instrument. The SPC is present to control for adequate processing of the sample and to monitor for the presence of potential inhibitor(s) in the RT-PCR reaction. The SPC also ensures that the RT-PCR reaction conditions (temperature and time) are appropriate for the amplification reaction and that the RT-PCR reagents are functional. The PCC verifies reagent rehydration, PCR tube filling, and confirms that all reaction components are present in the cartridge including monitoring for probe integrity and dye stability.

The nasopharyngeal swab or nasal swab specimen is collected and placed into a transport tube containing 3 mL of viral transport medium or 3mL of saline. The specimen is briefly mixed by rapidly inverting the collection tube 5 times. Using the supplied transfer pipette, the sample is transferred to the sample chamber of the Xpert Xpress SARS-CoV-2/Flu/RSV cartridge. The GeneXpert cartridge is loaded onto the GeneXpert Xpress System platform, which performs hands-off, automated sample processing, and real-time RT-PCR for detection of viral RNA.

6 Reagents and Instruments

6.1 Materials Provided

The Xpert Xpress SARS-CoV-2/Flu/RSV kit contains sufficient reagents to process 10 specimens or quality control samples. The kit contains the following:

Xpert Xpress SARS-CoV-2/Flu/RSV Cartridges with Integrated Reaction Tubes	**10**
• Bead 1, Bead 2, and Bead 3 (freeze-dried)	**1 of each per cartridge**
• Lysis Reagent	**1.0 mL per cartridge**
• Binding Reagent	**1.0 mL per cartridge**
• Elution Reagent	**3.0 mL per cartridge**
• Wash Reagent	**0.4 mL per cartridge**
Disposable Transfer Pipettes	**10-12 per kit**
Flyer	**1 per kit**

- Instructions to locate (and import) the ADF and EUA documentation such as the Product Insert on www.cepheid.com

Quick Reference Instructions (For use with the GeneXpert Xpress Systems – Tablet and Hub Configuration)	**2 per kit**

Note Safety Data Sheets (SDS) are available at www.cepheid.com or www.cepheidinternational.com under the **SUPPORT** tab.

Note The bovine serum albumin (BSA) in the beads within this product was produced and manufactured exclusively from bovine plasma sourced in the United States. No ruminant protein or other animal protein was fed to the animals; the animals passed ante- and post-mortem testing. During processing, there was no mixing of the the material with other animal materials.

7 Storage and Handling

+2 +28 °C

- Store the Xpert Xpress SARS-CoV-2/Flu/RSV cartridges at 2-28°C.
- Do not open a cartridge lid until you are ready to perform testing.
- Do not use a cartridge that is wet or has leaked.

8 Materials Required but Not Provided

- GeneXpert Xpress System (Tablet configuration): GeneXpert Xpress II and IV instruments with proprietary GeneXpert Xpress Software Version 5.0 and 5.1, tablet computer device with touchscreen, barcode scanner, external CD drive, wireless printer, Getting Started Guide, and GeneXpert Xpress System User's Guide.
- GeneXpert Xpress System (Hub configuration): GeneXpert Xpress IV instrument, GeneXpert Hub with proprietary GeneXpert Xpress Software Version 6.1 or higher,

GeneXpert Hub with integrated computer, touchscreen monitor and barcode scanner, external CD drive, Getting Started Guide, and GeneXpert Xpress System User's Guide.

9 Materials Available but Not Provided

External controls in the form of inactivated virus(es) are available from ZeptoMetrix (Buffalo, NY).

- External Positive Control: Catalog # NATFRC-6C (NATtrol Flu/RSV/SARS-CoV-2)
- External Negative Control: Catalog #NATCV9-6C (Coxsackievirus A9)

10 Warnings and Precautions

10.1 General

- For *in vitro* diagnostic use.
- For emergency use only.
- Positive results are indicative of presence of Flu A, Flu B, RSV, or SARS-CoV-2 RNA.
- Laboratories within the United States and its territories are required to report all SARS-CoV-2 results to the appropriate public health authorities.
- Performance characteristics of this test have been established with the specimen types listed in the Intended Use Section only. The performance of this assay with other specimen types or samples has not been evaluated.
- Treat all biological specimens, including used cartridges, as if capable of transmitting infectious agents. Because it is often impossible to know which might be infectious, all biological specimens should be handled using standard precautions. Guidelines for specimen handling are available from the U.S. Centers for Disease Control and Prevention[7] and the Clinical and Laboratory Standards Institute.[8]
- Follow safety procedures set by your institution for working with chemicals and handling biological specimens.
- Consult your institution's environmental waste personnel on proper disposal of used cartridges, which may contain amplified material. This material may exhibit characteristics of federal EPA Resource Conservation and Recovery Act (RCRA) hazardous waste requiring specific disposal requirements. Check state and local regulations as they may differ from federal disposal regulations. Institutions should check the hazardous waste disposal requirements within their respective countries.

10.2 Specimens

- Maintain proper storage conditions during specimen transport to ensure the integrity of the specimen (see Section 12, Specimen Collection, Transport, and Storage). Specimen stability under shipping conditions other than those recommended has not been evaluated.

10.3 Assay/Reagent

- Do not open the Xpert Xpress SARS-CoV-2/Flu/RSV cartridge lid except when adding specimen.
- Do not use a cartridge that has been dropped after removing it from the packaging.
- Do not shake the cartridge. Shaking or dropping the cartridge after opening the cartridge lid may yield non-determinate results.
- Do not place the sample ID label on the cartridge lid or on the barcode label on the cartridge.
- Do not use a cartridge with a damaged barcode label.
- Do not use a cartridge that has a damaged reaction tube.
- Do not use reagents beyond their expiry date.
- Each single-use Xpert Xpress SARS-CoV-2/Flu/RSV cartridge is used to process one test. Do not reuse processed cartridges.
- Each single-use disposable pipette is used to transfer one specimen. Do not reuse disposable pipettes.
- Do not use a cartridge if it appears wet or if the lid seal appears to have been broken.
- Wear clean lab coats and gloves. Change gloves between the handling of each specimen.
- In the event of a spill of specimens or controls, wear gloves and absorb the spill with paper towels. Then, thoroughly clean the contaminated area with a 10% freshly prepared household chlorine bleach. Allow a minimum of two minutes of contact time. Ensure the work area is dry before using 70% denatured ethanol to remove bleach residue. Allow surface to dry completely before proceeding. Or, follow your institution's standard procedures for a contamination or spill event. For equipment, follow the manufacturer's recommendations for decontamination of equipment.
- Biological specimens, transfer devices, and used cartridges should be considered capable of transmitting infectious agents requiring standard precautions. Follow your institution's environmental waste procedures for proper disposal of used cartridges and unused reagents. These materials may exhibit characteristics of chemical hazardous waste requiring specific disposal. If country or regional regulations do not provide clear direction on proper disposal, biological specimens and used cartridges should be disposed per WHO [World Health Organization] medical waste handling and disposal guidelines.

11 Chemical Hazards[9,10]

- **Signal Word: Warning**
- **UN GHS Hazard Statements**
  - Harmful if swallowed
  - May be harmful in contact with skin
  - Causes eye irritation

- **UN GHS Precautionary Statements**
  - **Prevention**
    - Wash hands thoroughly after handling.
  - **Response**
    - Call a POISON CENTER or doctor/physician if you feel unwell.
    - If skin irritation occurs: Get medical advice/attention.
    - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
    - If eye irritation persists: Get medical advice/attention.

12 Specimen Collection, Transport, and Storage





Proper specimen collection, storage, and transport are critical to the performance of this test. Inadequate specimen collection, improper specimen handling and/or transport may yield a false result. See Section 12.1 for nasopharyngeal swab collection procedure and Section 12.2 for nasal swab collection procedure. Nasopharyngeal and nasal swab specimens can be stored at room temperature (15–30 °C) for up to 24 hours in viral transport medium or 48 hours in saline until testing is performed on the GeneXpert Instrument Systems. Alternatively, nasopharyngeal and nasal swab specimens can be stored refrigerated (2–8 °C) up to seven days in viral transport medium or saline until testing is performed on the GeneXpert Xpress System.

Refer to the CDC Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons Under Investigation (PUIs) for Coronavirus Disease 2019 (COVID-19)

https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html.

12.1 Nasopharyngeal Swab Collection Procedure

Insert the swab into either nostril, passing it into the posterior nasopharynx (see Figure 1). Rotate swab by firmly brushing against the nasopharynx several times. Remove and place the swab into the tube containing 3 mL of viral transport medium or 3mL of saline. Break swab at the indicated break line and cap the specimen collection tube tightly.

Figure 1. Nasopharyngeal Swab Collection

12.2 Nasal Swab Collection Procedure

1. Insert a nasal swab 1 to 1.5 cm into a nostril. Rotate the swab against the inside of the nostril for 3 seconds while applying pressure with a finger to the outside of the nostril (see Figure 2).

Figure 2. Nasal Swab Collection for First Nostril

2. Repeat on the other nostril with the same swab, using external pressure on the outside of the other nostril (see Figure 3). To avoid specimen contamination, do not touch the swab tip to anything other than the inside of the nostril.

Figure 3. Nasal Swab Collection for Second Nostril

3. Remove and place the swab into the tube containing 3 mL of viral transport medium or 3mL of saline. Break swab at the indicated break line and cap the specimen collection tube tightly.

13 Starting the System

The recommended environmental operating conditions for Xpert Xpress SARS-CoV-2/Flu/RSV test are 15-30°C (59-86 °F), 20-80% relative humidity, noncondensing.

1. Put on a clean pair of gloves.
2. Determine which system configuration you have (Figure 4).

Tablet Configuration **Hub Configuration**

Figure 4. Tablet and Hub System Configurations

- For the *Tablet* configuration, see Section 13.1, Starting the Tablet Configuration.
- For the *Hub* configuration, see Section 13.2, Starting the Hub Configuration.

13.1 Starting the Tablet Configuration

1. Turn on the GeneXpert Xpress instrument (GeneXpert Xpress II or GeneXpert Xpress IV).
2. Turn on the tablet computer:
   - *Windows 7*: The Windows® 7 account screen appears. Touch the **Cepheid-Admin** icon to continue.
   - *Windows 10*: The Windows Lock screen appears. Swipe up to continue.

   The Windows Password screen appears.
3. Touch **Password** to display the keyboard, then type your password.
4. Touch the arrow button at the right of the password entry area. The GeneXpert Xpress Software starts.

13.2 Starting the Hub Configuration

1. Turn on the GeneXpert Xpress IV instrument (in two or four modules configuration).
2. Turn on the Hub computer. The Windows Lock screen appears.
3. Swipe up to continue. The Windows Password screen appears.
4. Touch **Password** to display the keyboard, then type your Windows password.
5. Touch the arrow button at the right of the password entry area. The GeneXpert Xpress Software starts and a login screen appears.
6. If enabled, you may log in by scanning a barcode on your institutional ID, using the barcode scanner (located behind the right side of the touchscreen). Then proceed to Step 9. Otherwise, follow the steps below to login manually.
7. Enter your User Name and Password (the virtual keyboard appears once you touch the entry fields).
8. Touch the **X** in the upper right of the virtual keyboard. The keyboard disappears and the **LOGIN** button appears at the bottom of the screen. Touch the **LOGIN** button to continue.
9. The Database Maintenance Reminder screen and the Archive Tests Reminder dialog boxes may appear, depending on your system configuration. For more information, see the *GeneXpert Xpress System User's Guide*.

13.3 Determining Your Software Version

When your Xpress opening screen appears, you can determine your software version and the procedure to follow, based on one of the following two screens (see Figure 5).





Software Version 5.0 or Software Version 5.1 **Software Version 6.1 or Higher**

Figure 5. Xpress Opening Screens and Software Versions

- For Software Version 5.0 or Software Version 5.1, see Section 14.
- For Software Version 6.1 or higher, see Section 16.

14 GeneXpert Xpress Software Version 5.0 or Software Version 5.1

1. On the Welcome screen, touch the **TOUCH HERE TO BEGIN** button (see Figure 6).



Figure 6. Welcome Screen

2. The **VIEW PREVIOUS TESTS** button appears. The **RUN NEW TEST** button will appear on the Home screen within 3 minutes.

Note If the Home screen does not display **RUN NEW TEST**, the instrument was not powered up or is no longer powered on. Exit the software using the **EXIT** button. The GeneXpert Xpress instrument must first be turned on then turn on the computer. Click on software icon to launch software and enter password.

14.1 Starting a Test

Note Instructions showing how to prepare the sample and the cartridge are shown on-screen in a video and are also described in the Quick Reference Instructions (QRI).

Important Start the test within 30 minutes of adding the sample to the cartridge.

1. Put on a new pair of gloves if performing a new test. Touch the **RUN NEW TEST** button on the Home screen (see Figure 7) to run a patient specimen or an external control.



Figure 7. RUN NEW TEST button on Home Screen (GeneXpert Xpress IV screen shown)

2. Check that the specimen transport medium tube cap is closed.
3. If there is a Patient/Sample ID barcode, touch the **YES** button, then scan the Patient/Sample ID with the scanner. If there is no Patient/Sample ID barcode, touch the **NO** button, then manually enter the Patient/Sample ID and touch the **OK** button. For external control, type **Positive Control** or **Negative Control**.
4. Confirm the Patient/Sample ID. Touch **YES** if the Patient/Sample ID is correct.

14.2 Preparing the Specimen or External Control and Cartridge

It is recommended that external controls be tested at the frequency noted below.

- Each time a new lot of Xpert Xpress SARS-CoV-2/Flu/RSV kits is received.
- Each time a new shipment of Xpert Xpress SARS-CoV-2/Flu/RSV kits is received even if it is the same lot previously received.
- Each time a new operator is performing the test (i.e., operator who has not performed the test recently).
- When problems (storage, operator, instrument, or other) are suspected or identified.
- If otherwise required by your institution's standard Quality Control (QC) procedures.

1. Remove a cartridge and a transfer pipette from the cartridge kit box.
2. Scan the barcode on the cartridge with the scanner.

Note If the barcode on the Xpert Xpress SARS-CoV-2/Flu/RSV cartridge does not scan or scanning the barcode results in an error message stating the cartridge is expired, then repeat the test with a new cartridge.

If you have scanned the cartridge barcode in the Xpress software and the assay definition file is not available, a screen will appear indicating the assay definition file is not loaded on the system. If this screen appears, contact Cepheid Technical Support.

3. Make the appropriate selection from the Select Assay menu, as shown in Figure 8.
   - SARS-CoV-2, Flu A, Flu B and RSV: Select **Xpert Xpress_SARS-CoV-2_Flu_RSV**
   - SARS-CoV-2 and Flu only: Select **Xpert Xpress_SARS-CoV-2_Flu**
   - SARS-CoV-2 only: Select **Xpert Xpress_SARS-CoV-2**

   Only the test result for the assay selected at this step will be collected once the test is started. SARS-CoV-2, Flu A, Flu B, and RSV results will only be collected if the Xpert Xpress_SARS-CoV-2_Flu_RSV assay is selected.



Figure 8. Confirm Test Screen – Select Assay

4. Confirm the selected test from the Select Assay menu (shown in Figure 9 below) and touch **YES** if the displayed information is correct. Enter your user name and password if prompted.



Figure 9. Confirm Test Screen

In the following steps, keep the cartridges upright when handling or scanning. Do not rotate or tip the cartridge, because damage to the contents or injury to personnel may occur.

5. Watch the video before continuing. The video will repeat. Touch the **SKIP VIDEO AND CONTINUE** button to exit video. The **Load Cartridge** screen appears.
6. Mix sample by rapidly inverting the specimen transport tube or external control tube 5 times. Open cap on the specimen transport tube or external control tube.
7. Open the cartridge lid by lifting the front of the cartridge lid.
8. Remove the transfer pipette from the wrapper

Note Do not place unwrapped pipette on the workbench.

9. Squeeze the top bulb of the transfer pipette **completely until the top bulb is fully flat**. While continuing to hold the bulb fully flat, place the pipette tip in the specimen transport tube. (see Figure 10).



Figure 10. Transfer Pipette

10. Keeping the pipette below the surface of the liquid, release the top bulb of the pipette slowly to fill the pipette with sample before removing from the tube. It is okay if liquid goes into the overflow reservoir (see Figure 10). Check that the pipette does not contain bubbles.

11. To transfer the sample to the cartridge, squeeze the top bulb of the pipette completely again until it is fully flat to empty the contents of the pipette (300 µL) into the large opening (Sample Chamber) in the cartridge shown in Figure 11. Some liquid may remain in the overflow reservoir. Dispose of the used pipette.



Figure 11. Xpert Xpress SARS-CoV-2/Flu/RSV Cartridge (Top View)

Note Take care to dispense the entire volume of liquid into the Sample Chamber. False negative results may occur if insufficient sample is added to the cartridge.

12. Close the cartridge lid.

14.3 Loading the Cartridge

1. Pull open the module door with the flashing green light.
2. Load the cartridge with the barcode facing the operator onto the cartridge bay platform. Do not try to insert the cartridge past the cartridge bay platform.
3. Close the door until it clicks. The green light will stop flashing and the test starts.

The **Test in Progress** screen appears. When the test is completed (green light goes out), the door will automatically unlock and the **Remove Cartridge** screen appears.

4. Follow the on-screen instructions to remove the cartridge and to reset the module for a new test.
5. Touch **CONTINUE** to view the result of the test.
6. To print results, touch the **PRINT RESULT** button.
7. Remove cartridge. Dispose of the used cartridge and gloves according to your institution's standard practices.
8. To log out, touch the **SIGN OUT** button.

Note Do not turn off or unplug the instruments while a test is in progress. Turning off or unplugging the GeneXpert Xpress instrument or computer will stop the test.

Note If the barcode on the Xpert Xpress SARS-CoV-2/Flu/RSV cartridge does not scan or scanning the barcode results in an error message stating that the cartridge is expired, then repeat the test with a new cartridge.

Note If you have scanned the cartridge barcode in the Xpress software and the assay definition file is not available, a screen will appear indicating that the assay definition file is not loaded or that the product code was not found on the system. If this screen appears, contact Cepheid Technical Support.

14.4 Start A New Test While a Test is Running

1. Put on a clean pair of gloves if performing a new test.

2. Touch the **HOME** button to go to the Home Screen.

3. Touch the **SIGN OUT** button to log out the previous user, if applicable.
4. Start a new test following the steps in Section 14.1, Starting a Test.

15 View Status of Tests in Progress, Completed Tests, and View Results of Past Tests

15.1 Tests in Progress

1. Touch the **HOME** button to view the status of tests in progress.
2. To view a test in progress, touch the **Test in progress touch for status** button. The time remaining to complete the testing will appear on the progress bar at the bottom of the **Test in Progress** screen.

15.2 Completed Tests

1. When a test is completed, touch the **Test complete, touch to continue** button. The **Remove Cartridge** screen appears.
2. Follow the on-screen instructions to remove the cartridge. Touch the **CONTINUE** button to view the result of the test. To print results, touch the **PRINT RESULT** button.

15.3 Results of Past Tests

1. Touch the **VIEW PREVIOUS TESTS** button on the Home screen shown in Figure 12.



Figure 12. VIEW PREVIOUS TESTS button on Home Screen

2. Select the test by either touching the test name or using the arrows to select the test.
3. Touch the **SELECT** button shown in Figure 13 to view results.
4. To print results, touch the **PRINT RESULT** button.



Figure 13. SELECT button

16 GeneXpert Xpress Software Version 6.1 or Higher

16.1 Starting a Test

Note Instructions showing how to prepare the sample and the cartridge are shown on-screen in videos and in the following procedure.

Important Start the test within 30 minutes of adding the sample to the cartridge.

1. Put on a new pair of gloves if performing a new test.
2. Touch the **NEW TEST** button on the Home screen (see Figure 14).



Figure 14. Home Screen

3. Check that the specimen transport medium tube cap is closed.

   If Patient Information is configured by an administrator, then the Patient Information screen appears (see Figure 15). If Patient Information is not configured, the Sample ID screen appears.
4. Skip to Section 16.2 if the Sample ID screen appears.

Figure 15. Patient Information Screen

5. Scan patient ID barcode or manually enter the Patient ID.
6. Touch **CONTINUE**. The Confirm Patient Information screen appears.
7. Verify the Patient ID and touch **CONFIRM**. The Sample ID screen appears.

16.2 Preparing the Specimen

1. Remove a cartridge and a transfer pipette from the cartridge kit box.

2. Check that the transport medium tube cap is closed. Scan Sample ID barcode or manually enter the Sample ID for patient specimen.
3. Touch **CONTINUE**. The Confirm Sample ID screen appears.
4. Verify the Sample ID and touch **CONFIRM**. The Scan Cartridge Barcode screen appears (see Figure 16).

In the following steps, keep the cartridges upright when handling or scanning. Do not rotate or tip the cartridge, because damage to the contents or injury to personnel may occur.

Note If the barcode on the Xpert Xpress SARS-CoV-2/Flu/RSV cartridge does not scan or scanning the barcode results in an error message stating that the cartridge is expired, then repeat the test with a new cartridge.

If you have scanned the cartridge barcode in the Xpress software and the assay definition file is not available, a screen will appear indicating the assay definition file is not loaded on the system. If this screen appears, contact Cepheid Technical Support.

Figure 16. Scan Cartridge Barcode Screen

5. Select the appropriate cartridge with the sample and scan the cartridge barcode. After scanning, the Select Test screen appears.
6. Select the test to run (see Figure 17):
   - SARS-CoV-2, Flu A, Flu B and RSV: Select **Xpert Xpress_SARS-CoV-2_Flu_RSV**
   - SARS-CoV-2 and Flu only: Select **Xpert Xpress_SARS-CoV-2_Flu**
   - SARS-CoV-2 only: Select **Xpert Xpress_SARS-CoV-2**

   Only the test result for the assay selected at this step will be collected once the test is started. SARS CoV-2, Flu A, Flu B, and RSV results will only be collected if the Xpert Xpress_SARS-CoV-2_Flu_RSV assay is selected.



Figure 17. Select Test Screen

7. Verify that the correct cartridge has been scanned and that the assay name matches the name of the assay on the cartridge (see Figure 18).



Figure 18. Confirm Test Information Screen

8. Touch **CONFIRM** if the displayed information is correct.
9. Depending on your configuration, the Enter Credentials to Continue screen may appear (see Figure 19). If enabled, you may log in by scanning your institutional ID. Otherwise, manually enter your User Name and Password and touch **LOGIN** to continue.



Figure 19. Enter Credentials to Continue Screen

10. The Cartridge Preparation screen appears (see Figure 20).

Figure 20. Cartridge Preparation Screen

11. Watch the video before continuing. The video will repeat. Touch the **SKIP VIDEO AND CONTINUE** button to exit video.
12. Mix specimen by rapidly inverting the specimen transport tube 5 times. Open the lid on the specimen transport tube.
13. Open the cartridge lid by lifting the front of the cartridge lid.
14. Remove the transfer pipette from the wrapper.

Note Do not place unwrapped pipette on the workbench.

15. Squeeze the top bulb of the transfer pipette **completely until the top bulb is fully flat**. While continuing to hold the bulb fully flat, place the pipette tip in the specimen transport tube (see Figure 21).



Figure 21. Transfer Pipette

16. Keeping the pipette below the surface of the liquid, release the top bulb of the pipette slowly to fill the pipette with sample before removing from the tube. It is okay if liquid goes into the overflow reservoir (see Figure 21). Check that the pipette does not contain bubbles.
17. To transfer the sample to the cartridge, squeeze the top bulb of the pipette **completely** again until it is fully flat to empty the contents of the pipette (300 µL) into the large opening (Sample Chamber) of the cartridge shown in Figure 22. Some liquid may remain in the overflow reservoir. Dispose of the used pipette.

Figure 22. Xpert Xpress SARS-CoV-2/Flu/RSV Cartridge (Top View)

Note Take care to dispense the entire volume of liquid into the Sample Chamber. False negative results may occur if insufficient sample is added to the cartridge.

18. Close the cartridge lid.
19. Go to Section 16.4, Loading the Cartridge.

16.3 Running External Controls

It is recommended that external controls be tested at the frequency noted below.

- Each time a new lot of Xpert Xpress SARS-CoV-2/Flu/RSV kits is received.
- Each time a new shipment of Xpert Xpress SARS-CoV-2/Flu/RSV kits is received even if it is the same lot previously received.
- Each time a new operator is performing the test (i.e., operator who has not performed the test recently)
- When problems (storage, operator, instrument, or other) are suspected or identified
- If otherwise required by your institution's standard Quality Control (QC) procedures

1. Put on a new pair of gloves if performing a new test. Touch the **QC** button on the Home screen (see Figure 23).

Figure 23. Home Screen

2. The Quality Control screen appears. Touch **RUN QC POSITIVE Test**, **RUN QC NEGATIVE TEST** or **RUN PROFICIENCY TEST** option (Figure 24).



Figure 24. Quality Control Screen

3. The Sample ID appears.
4. Enter the Sample ID, by typing **Positive Control** or **Negative Control** or scan the Sample ID barcode.
5. Touch **CONTINUE**. The Confirm Sample ID screen appears.
6. Verify the Sample ID and touch **CONFIRM**. The Scan Cartridge Barcode screen appears (see Figure 25).

In the following steps, keep the cartridges upright when handling or scanning. Do not rotate or tip the cartridge, because damage to the contents or injury to personnel may occur.

Note If the barcode on the Xpert Xpress SARS-CoV-2/Flu/RSV cartridge does not scan or scanning the barcode results in an error message stating that the cartridge is expired, then repeat the test with a new cartridge.

If you have scanned the cartridge barcode in the Xpress software and the assay definition file is not available, a screen will appear indicating the assay definition file is not loaded on the system. If this screen appears, contact Cepheid Technical Support.

Figure 25. Scan Cartridge Barcode Screen

7. Select the appropriate cartridge with the sample and scan the cartridge barcode. After scanning, the Select Test screen appears.
8. Select **Xpert Xpress_SARS-CoV-2_Flu_RSV** from the Select Assay menu.
9. Confirm the test information is correct then touch **CONFIRM** (see Figure 26).



Figure 26. Confirm Test Information

10. Watch the video before continuing. The video will repeat. Touch the **CONTINUE** button to exit video.
11. Mix control by rapidly inverting the external control tube 5 times. Open the lid on the external control tube.
12. Open the cartridge lid by lifting the front of the cartridge lid.
13. Remove the transfer pipette from the wrapper.

Note Do not place unwrapped pipette on the workbench.

14. Squeeze the top bulb of the transfer pipette **completely until the bulb is fully flat.** While continuing to hold the bulb fully flat, place the pipette tip in the specimen transport tube (see Figure 27).



Figure 27. Transfer Pipette

15. Keeping the pipette below the surface of the liquid, release the top bulb of the pipette slowly to fill the pipette before removing from the tube. It is okay if liquid goes into the overflow reservoir (see Figure 27). Check that the pipette does not contain bubbles.
16. To transfer the external control to the cartridge, squeeze the top bulb of the pipette **completely** again until it is fully flat to empty the contents of the pipette into the large opening (Sample Chamber) of the cartridge shown in Figure 28. Dispose of the used pipette.



Figure 28. Xpert Xpress SARS-CoV-2/Flu/RSV Cartridge (Top View)

Note Take care to dispense the entire volume of liquid into the Sample Chamber. False negative results may occur if insufficient sample is added to the cartridge.

17. Close the cartridge lid.
18. Go to Section 16.4, Loading the Cartridge.

16.4 Loading the Cartridge

1. Touch the **CONTINUE** button on the Cartridge Preparation screen. The Load Cartridge into Module screen appears (see Figure 29).
2. Open the module door with the flashing green light.

Figure 29. Load Cartridge into Module Screen

3. Load the cartridge with the barcode facing the operator on the cartridge bay platform. Do not try to insert the cartridge past the cartridge bay platform.
4. Close the door until it clicks. The green light will stop blinking and the test starts.
5. When the cartridge is loaded, the Test Loading screen appears, followed by the Test Running screen showing that the test is running. A circular graphic indicator at the right indicates the progress of the test and the time remaining until a test result is available.

Note While a test is running, you can start another test. See Section 16.5, Start a New Test While a Test is Running.

Note Do not turn off or unplug the instrument while a test is in progress. Turning off or unplugging the GeneXpert Xpress instrument or Hub stops the test. If necessary, touch the **STOP TEST** button to cancel a test while it is loading or running.

6. When the test is done, the green light goes out and the door automatically unlocks. The screen text changes to Test Completed. The Test Completed screen provides the results for the test just completed.

Note If an unexpected result occurs (e.g., Negative Quality Control result is positive or Positive Quality Control result is negative), test a new Quality Control sample using a new cartridge. If an unexpected result occurs upon retest, contact Cepheid Technical Support.

7. Open the module door, remove the used cartridge, and properly dispose of the cartridge according to your institution's policy.
8. Touch **HOME** to go back to the Home screen.
9. To log out, touch the **User Menu** icon, then select Logout.

16.5 Start a New Test While a Test is Running

You can start a new test while another test is in progress.

1. Touch the **HOME** button on the Test Running screen.
2. For a new user log in, touch the **User Menu** icon to log in.
3. Repeat the steps in Section 16.1, Starting a Test, Section 16.2, Preparing the Specimen, and Section 16.4, Loading the Cartridge.
4. After a second test has started, touch the **HOME** button. The status of both tests appears. The Home screen displays the module(s) in use with a circular graphic indicator around each test, and Patient Identification below the module graphic (see Figure 30).



Figure 30. Home Screen showing Two Tests Running

5. After a test has completed, the module icon text changes to Complete (see Figure 31). Touch Complete View Result to view test results.



Figure 31. Home Screen with One of Two Tests Completed

16.6 Viewing Test Results

1. Touch the **RESULTS** button located on the panel at the top of the screen (see Figure 31). The Results screen appears (see Figure 32). Test results are, by default, in order of the date and time that the test was run. Navigate through the test result pages by touching the numbered buttons or arrows at the bottom of the screen.



Figure 32. Results Screen

2. Touch the desired result to open the Test Result screen (see Figure 33).
3. To view test report, touch the **REPORT** button then swipe across the screen from left to right to minimize screen and view report.



Figure 33. Test Result Screen (Example)

Note If an unexpected result occurs (e.g., Negative Quality Control result is positive or Positive Quality Control result is negative), test a new Quality Control sample using a new cartridge. If an unexpected result occurs upon retest, contact Cepheid Technical Support.

17 Quality Control

17.1 Internal Controls

CONTROL

Each cartridge includes a Sample Processing Control (SPC) and Probe Check Control (PCC).

Sample Processing Control (SPC) – Ensures that the sample was processed correctly. The SPC verifies that sample processing is adequate. Additionally, this control detects sample-associated inhibition of the real-time PCR assay, ensures that the PCR reaction conditions (temperature and time) are appropriate for the amplification reaction, and that the PCR reagents are functional. The SPC should be positive in a negative sample and can be negative or positive in a positive sample. The SPC passes if it meets the validated acceptance criteria.

Probe Check Control (PCC) – Before the start of the PCR reaction, the GeneXpert System measures the fluorescence signal from the probes to monitor bead rehydration, reaction tube filling, probe integrity, and dye stability. The PCC passes if it meets the validated acceptance criteria.

17.2 External Controls

External controls should be used in accordance with local, state, and federal accrediting organizations as applicable.

18 Interpretation of Results

The results are interpreted automatically by the GeneXpert Xpress System and are clearly shown in the **View Results** window. The Xpert Xpress SARS-CoV-2/Flu/RSV test provides test results based on the detection of respective gene targets according to the algorithms.

The format of the test results presented will vary depending on the user's choice to run either an Xpert Xpress_SARS-CoV-2_Flu_RSV, Xpert Xpress_SARS-CoV-2_Flu or Xpert Xpress_SARS-CoV-2 test.
Table 1 shows the possible result outcomes when the Xpert Xpress_SARS-CoV-2_Flu_RSV test mode is selected.

Table 1. Xpert Xpress_SARS-CoV-2/Flu/RSV Possible Results and Interpretation

Result	Interpretation
SARS-CoV-2 POSITIVE	The SARS-CoV-2 target RNA is detected. • The SARS-CoV-2 signal has a Ct within the valid range and endpoint above the minimum setting. • SPC: NA (not applicable); SPC is ignored because SARS-CoV-2 target amplification occurred. • Probe Check: PASS; all probe check results pass.
Flu A POSITIVE	• The Flu A signal for either the Flu A1 RNA target or the Flu A2 RNA target or signals for both RNA targets has a Ct within the valid range and endpoint above the threshold setting. • SPC – NA; SPC is ignored because the Flu A target amplification occurred. • Probe Check – PASS; all probe check results pass.
Flu B POSITIVE	• The Flu B signal has a Ct within the valid range and endpoint above the minimum setting. • SPC: NA; SPC is ignored because Flu B target amplification occurred. • Probe Check: PASS; all probe check results pass.
RSV POSITIVE	• The RSV signal has a Ct within the valid range and endpoint above the minimum setting. • SPC: NA; SPC is ignored because RSV target amplification occurred. • Probe Check: PASS; all probe check results pass
SARS-CoV-2 NEGATIVE; Flu A NEGATIVE; Flu B NEGATIVE; RSV NEGATIVE	SARS-CoV-2 target RNA is not detected; Flu A target RNA is not detected; Flu B target RNA is not detected; RSV target RNA is not detected. • SARS-CoV-2, Flu A, Flu B and RSV target RNAs are not detected. • SPC – PASS; SPC has a Ct within the valid range and endpoint above the minimum setting. • Probe Check – PASS; all probe check results pass.
NO RESULT-REPEAT TEST	If result is **NO RESULT - REPEAT TEST**, retest with a new cartridge according to the Retest Procedure in Section 19.2. If retest is **NO RESULT - REPEAT TEST**, obtain a new specimen for testing.

Result	Interpretation
INSTRUMENT ERROR	If result is **INSTRUMENT ERROR**, touch **CLEAR ERROR** and follow the on-screen instructions. When the Home screen appears, repeat the test using a new cartridge according to the Retest Procedure in Section 19.2.
If the SPC is negative and the results for any of the targets are positive, the results for all targets are considered valid.	

If only one viral target is positive but coinfection with multiple targets is suspected, the sample should be re-tested with another FDA cleared, approved, or authorized test, if coinfection would change clinical management.

Table 2 shows the possible result outcomes when the Xpert Xpress_SARS-CoV-2_Flu test mode is selected.

Table 2. Xpert Xpress_SARS-CoV-2_Flu Possible Results and Interpretation

Result	Interpretation
SARS-CoV-2 POSITIVE	The SARS-CoV-2 target RNA is detected. • The SARS-CoV-2 signal has a Ct within the valid range and endpoint above the minimum setting. • SPC: NA (not applicable); SPC is ignored because SARS-CoV-2 target amplification occurred. • Probe Check: PASS; all probe check results pass.
Flu A POSITIVE	• The Flu A signal for either the Flu A1 RNA target or the Flu A2 RNA target or signals for both RNA targets has a Ct within the valid range and endpoint above the threshold setting. • SPC – NA; SPC is ignored because the Flu A target amplification occurred. • Probe Check – PASS; all probe check results pass.
Flu B POSITIVE	• The Flu B signal has a Ct within the valid range and endpoint above the minimum setting. • SPC: NA; SPC is ignored because Flu B target amplification occurred. • Probe Check: PASS; all probe check results pass.
SARS-CoV-2 NEGATIVE; Flu A NEGATIVE; Flu B NEGATIVE	SARS-CoV-2 target RNA is not detected; Flu A target RNA is not detected; Flu B target RNA is not detected. • SARS-CoV-2, Flu A and Flu B target RNAs are not detected. • SPC – PASS; SPC has a Ct within the valid range and endpoint above the minimum setting. • Probe Check – PASS; all probe check results pass.
NO RESULT-REPEAT TEST	If result is **NO RESULT - REPEAT TEST**, retest with a new cartridge according to the Retest Procedure in Section 19.2. If retest is **NO RESULT - REPEAT TEST**, obtain a new specimen for testing.

Result	Interpretation
INSTRUMENT ERROR	If result is **INSTRUMENT ERROR**, touch **CLEAR ERROR** and follow the on-screen instructions. When the Home screen appears, repeat the test using a new cartridge according to the Retest Procedure in Section 19.2.
If the SPC is negative and the results for any of the targets are positive, the results for all targets are considered valid.	

If only one viral target is positive but coinfection with multiple targets is suspected, the sample should be re-tested with another FDA cleared, approved, or authorized test, if coinfection would change clinical management.

Table 3 shows the possible result outcomes when the Xpert Xpress_SARS-CoV-2 test mode is selected.

Table 3. Xpert Xpress_SARS-CoV-2 Possible Results and Interpretation

Result	Interpretation
SARS-CoV-2 POSITIVE	The SARS-CoV-2 target RNA is detected. • The SARS-CoV-2 signal has a Ct within the valid range and endpoint above the minimum setting. • SPC: NA (not applicable); SPC is ignored because SARS-CoV-2 target amplification occurred. • Probe Check: PASS; all probe check results pass.
SARS-CoV-2 NEGATIVE	SARS-CoV-2 target RNA is not detected. • SARS-CoV-2 target RNA is not detected. • SPC – PASS; SPC has a Ct within the valid range and endpoint above the minimum setting. • Probe Check – PASS; all probe check results pass.
NO RESULT-REPEAT TEST	If result is **NO RESULT - REPEAT TEST**, retest with a new cartridge according to the Retest Procedure in Section 19.2. If retest is **NO RESULT - REPEAT TEST**, obtain a new specimen for testing.
INSTRUMENT ERROR	If result is **INSTRUMENT ERROR**, touch **CLEAR ERROR** and follow the on-screen instructions. When the Home screen appears, repeat the test using a new cartridge according to the Retest Procedure in Section 19.2.

The Xpert Xpress SARS-CoV-2/Flu/RSV test can be run to detect SARS-CoV-2, Flu and RSV by selecting Xpert Xpress_SARS-CoV-2_Flu_RSV from the Select Test menu; SARS-CoV-2 and Flu only by selecting Xpert Xpress_SARS-CoV-2_Flu; or SARS-CoV-2 only by selecting Xpert Xpress_SARS-CoV-2. The Xpert Xpress_SARS-CoV-2 test mode includes an Early Assay Termination (EAT) function which will provide earlier time to results in high titer specimens if the signal from the SARS-CoV-2 target reaches a predetermined threshold before the full 45 PCR cycles have been completed. When SARS-CoV-2 titers are high enough to initiate the EAT function, the SPC amplification curve may not be seen and its results may not be reported.

19 Retests

19.1 Reasons to Repeat the Test

If any of the test results mentioned below occur, repeat the test once according to instructions in Section 19.2, Retest Procedure.

- An **INSTRUMENT ERROR** result could be due to, but not limited to, a system component failure, or the maximum pressure limits were exceeded.
- A **NO RESULT- REPEAT TEST** indicates that insufficient data were collected. For example, cartridge failed integrity test, Probe Check Control failure, no sample added, the operator stopped a test that was in progress, or a power failure occurred.

If an External Control fails to perform as expected, repeat external control test and/or contact Cepheid Technical Support for assistance.

19.2 Retest Procedure

To retest a non-determinate result **(NO RESULT-REPEAT TEST, INSTRUMENT ERROR)**, use a new cartridge.

Use the leftover sample from the original specimen transport tube or new external control tube.

1. Put on a clean pair of gloves. Obtain a new Xpert Xpress SARS-CoV-2/Flu/RSV cartridge and a new transfer pipette.
2. Check the specimen transport tube or external control tube is closed.
3. Mix the sample by rapidly invert the specimen transport medium tube or external control tube 5 times. Open the cap on the specimen transport tube or external control tube.
4. Open the cartridge lid by lifting the front of the cartridge lid.
5. Using a clean transfer pipette (supplied), transfer sample (one draw) to the sample chamber with the large opening in the cartridge.
6. Close the cartridge lid.

20 Limitations

- Performance of the Xpert Xpress SARS-CoV-2/Flu/RSV has only been established in nasopharyngeal swab specimens. Use of the Xpert Xpress SARS-CoV-2/Flu/RSV test with other specimen types has not been assessed and performance characteristics are unknown.
- Nasal swabs (self-collected under supervision of, or collected by, a healthcare provider) are considered acceptable specimen types for use with the Xpert Xpress SARS-CoV-2/Flu/RSV test but performance with these specimen types has not been established.
- As with any molecular test, mutations within the target regions of Xpert Xpress SARS-CoV-2/Flu/RSV could affect primer and/or probe binding resulting in failure to detect the presence of virus.
- As with any molecular test, mutations within the target regions of the Xpert Xpress SARS-CoV-2/Flu/RSV test could affect primer and/or probe binding resulting in failure to detect the presence of virus or the virus being detected less predictably.
- This test cannot rule out diseases caused by other bacterial or viral pathogens.
- The performance of this test was validated using the procedures provided in this package insert only. Modifications to these procedures may alter the performance of the test.
- Erroneous test results might occur from improper specimen collection; failure to follow the recommended sample collection, handling, and storage procedures; technical error; or sample mix-up. Careful compliance with the instructions in this insert is necessary to avoid erroneous results.
- False negative results may occur if virus is present at levels below the analytical limit of detection.
- Negative results do not preclude SARS-CoV-2, influenza or RSV infection and should not be used as the sole basis for treatment or other patient management decisions.
- Results from the Xpert Xpress SARS-CoV-2/Flu/RSV test should be correlated with the clinical history, epidemiological data, and other data available to the clinician evaluating the patient.
- Viral nucleic acid may persist *in vivo*, independent of virus viability. Detection of analyte target(s) does not imply that the corresponding virus(es) are infectious or are the causative agents for clinical symptoms.
- This test has been evaluated for use with human specimen material only.
- This test is a qualitative test and does not provide the quantitative value of detected organism present.
- This test has not been evaluated for patients without signs and symptoms of respiratory tract infection.
- This test has not been evaluated for monitoring treatment of infection.
- This test has not been evaluated for screening of blood or blood products for the

presence of SARS-CoV-2, influenza or RSV.

- The effect of interfering substances has only been evaluated for those listed within the labeling. Interference by substances other than those described can lead to erroneous results.
- Results from analytical studies with contrived co-infected samples showed potential for competitive interference when SARS-CoV-2, influenza or RSV was present at 1X LoD levels.
- Cross-reactivity with respiratory tract organisms other than those described herein can lead to erroneous results.
- Recent patient exposure to FluMist® or other live attenuated influenza vaccines may cause inaccurate positive results.
- As the Xpert Xpress SARS-CoV-2/Flu/RSV test does not differentiate between the N2 and E gene targets, the presence of other coronaviruses in the B lineage, *Betacoronavirus* genus, including SARS-CoV-1 may cause a false positive result. None of these other coronaviruses is known to currently circulate in the human population.
- This test is not intended to differentiate RSV subgroups, influenza A subtypes or influenza B lineages. If differentiation of specific RSV or influenza subtypes and strains is needed, additional testing, in consultation with state or local public health departments, is required.
- Specimen transport media that contain guanidine thiocyanate (GTC) may interfere with the test causing false negative results.
- The performance of this device has not been assessed in a population vaccinated against COVID-19.
- This test has not been FDA cleared or approved.
- This test has been authorized by FDA under an EUA for use by authorized laboratories.
- This test has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acids from SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV), and not for any other viruses or pathogens.
- This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

21 Conditions of Authorization for Laboratory and Patient Care Settings

The Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV Letter of Authorization, along with the authorized Fact Sheet for Healthcare Providers, the authorized Fact Sheet for Patients and authorized labeling are available on the FDA website: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas.

However, to assist clinical laboratories and/or Patient Care Settings using the Xpert Xpress SARS-CoV-2/Flu/RSV (referred to in the Letter of Authorization as "Your Product"), the relevant Conditions of Authorization are listed below.

- Authorized laboratories[ii] using your product will include with result reports of the Xpert Xpress SARS-CoV-2/Flu/RSV test, all authorized Fact Sheets. Under exigent circumstances, other appropriate methods for disseminating these Fact Sheets may be used, which may include mass media.
- Authorized laboratories using your product will use your product as outlined in the Xpert Xpress SARS-CoV-2/Flu/RSV Instructions for Use - For Use with GeneXpert Dx or GeneXpert Infinity systems. Deviations from the authorized procedures, including the authorized instruments, authorized extraction methods, authorized clinical specimen types, authorized control materials, authorized other ancillary reagents and authorized materials required to use the Xpert Xpress SARS-CoV-2/Flu/RSV test are not permitted.
- Authorized laboratories operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation using your product will use your product as outlined in the Xpress SARS-CoV-2/Flu/RSV Instructions for Use - For Use with GeneXpert Xpress System and associated Quick Reference Instructions for Xpert Xpress SARS-CoV-2/Flu/RSV and GeneXpert Xpress System (Hub configuration), and Quick Reference Instructions for Xpert Xpress SARS-CoV-2/Flu/RSV and GeneXpert Xpress System (Tablet configuration). Deviations from the authorized procedures, including the authorized instruments, authorized extraction methods, authorized clinical specimen types, authorized control materials, authorized other ancillary reagents and authorized materials required to use your product are not permitted.
- Authorized laboratories that receive your product will notify the relevant public health authorities of their intent to run your product prior to initiating testing.
- Authorized laboratories using the Xpert Xpress SARS-CoV-2/Flu/RSV test will have a process in place for reporting test results to healthcare providers and relevant public health

[ii] The letter of authorization refers to "authorized laboratories as follows: (1) testing of nasopharyngeal swab, nasal swab, or nasal wash/aspirate specimens using the Xpert SARS-CoV-2/Flu/RSV test run on the GeneXpert Dx and GeneXpert Infinity systems is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet requirements to perform high or moderate complexity tests and (2) testing of nasopharyngeal or nasal swab specimens using the Xpert Xpress SARS-CoV-2/Flu/RSV test run on the GeneXpert Xpress System (Tablet and Hub Configurations) is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

authorities, as appropriate.

- Authorized laboratories and will collect information on the performance of the test and report to DMD/OHT7-OIR/OPEQ/CDRH (via email: CDRH-EUA-Reporting@fda.hhs.gov) and Cepheid (+ 1 888 838 3222 or techsupport@cepheid.com) any suspected occurrence of false positive or false negative results and significant deviations from the established performance characteristics of the test of which they become aware.
- All operators using your product must be appropriately trained in performing and interpreting the results of your product, use appropriate personal protective equipment when handling this kit, and use your product in accordance with the authorized labeling.
- Cepheid, authorized distributors, and authorized laboratories and patient care settings using your product will ensure that any records associated with this EUA are maintained until otherwise notified by FDA. Such records will be made available to FDA for inspection upon request.

22 Performance Characteristics

22.1 Clinical Evaluation

The performance of the Xpert Xpress SARS-CoV-2/Flu/RSV test was evaluated using archived clinical nasopharyngeal (NP) swab specimens in viral transport medium. Archived specimens were selected consecutively by date and previously known analyte result. A total of 240 NP swab specimens were tested with Xpert Xpress SARS-CoV-2/Flu/RSV side by side with a SARS-CoV-2 EUA RT-PCR test and the FDA-cleared Xpert Xpress Flu/RSV test in a randomized and blinded fashion.

Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) were determined by comparing the results of the Xpert Xpress SARS-CoV-2/Flu/RSV test relative to the results of a SARS-CoV-2 EUA RT-PCR test for the SARS-CoV-2 target, and Xpert Xpress Flu/RSV for the Flu A, Flu B, and RSV targets, respectively.

Xpert Xpress SARS-CoV-2/Flu/RSV demonstrated a PPA and NPA of 97.9% and 100.0% for SARS-CoV-2, respectively; 100.0% and 100.0% for Flu A, respectively; 100.0% and 99.0% for Flu B, respectively; 100.0% and 100.0% for RSV, respectively (Table 4).

Table 4. Xpert Xpress SARS-CoV-2/Flu/RSV Performance Results

Target	Number of Specimens	TP	FP	TN	FN	PPA (95% CI)	NPA (95% CI)
SARS-CoV-2	240	46	0	193	1	97.9% (88.9% - 99.6%)	100.0% (98.1% - 100.0%)
Flu A	240	48	0	192	0	100.0% (92.6% - 100.0%)	100.0% (98.0% - 100.0%)
Flu B	240	46	2	192	0	100.0% (92.3% - 100.0%)	99.0% (96.3% - 99.7%)
RSV	240	47	0	193	0	100.0% (92.4% - 100.0%)	100.0% (98.1% - 100.0%)

TP: True Positive; FP: False Positive; TN: True Negative; FN: False Negative; CI: Confidence Interval

22.2 Analytical Sensitivity (Limit of Detection)

The analytical sensitivity of the Xpert Xpress SARS-CoV-2/Flu/RSV test was assessed with one lot of reagent and limiting dilutions of the six respiratory viruses (NATtrol SARS-CoV-2, Flu A H1, Flu A H3, Flu B, RSV A and RSV B) into pooled negative clinical NP swab matrix following the guidance in Clinical and Laboratory Standards Institute (CLSI) document EP17-A2. The estimated LoD values as determined by Probit regression analysis were verified using two lots of Xpert Xpress SARS-CoV-2/Flu/RSV reagents. The verified LoD values for the viruses tested are summarized in Table 5.

Table 5. Xpert Xpress SARS-CoV-2/Flu/RSV Limit of Detection

Virus/Strain	LoD Concentration
SARS-CoV-2 (USA-WA1/2020)	131 copies/mL
Influenza A/ California/7/2009	0.004 $TCID_{50}$/mL
Influenza A/Victoria/361/2011	0.087 $TCID_{50}$/mL
Influenza B/Mass/2/2012	0.04 $TCID_{50}$/mL
RSV A/2/Australia/61	0.43 $TCID_{50}$/mL
RSV B/Wash/18537/62	0.22 $TCID_{50}$/mL

22.3 Analytical Reactivity (Inclusivity)

The inclusivity of Xpert Xpress SARS-CoV-2/Flu/RSV was evaluated using *in silico* analysis of the assay amplicons in relation to 48,461 SARS-CoV-2 sequences available in the GISAID gene database for two targets, E and N2.

For analysis of the E target, 113 sequences were excluded due to ambiguous nucleotides, which reduced the total to 48,348 sequences. Of the 48,348 GISAID sequences, 48,108 (99.5%) were an exact match to the SARS-CoV-2 E target amplicon generated in the Xpert Xpress SARS-CoV-2/Flu/RSV test. Single nucleotide mismatches were observed for 223 sequences and two mismatches were observed for 17 sequences. Of the 17 sequences with two mismatches, two sequences contained 2 mismatches in the forward primer region, three sequences have a ‘GA” dinucleotide in the reverse primer, and twelve sequences contained a ‘AA’ dinucleotide that lies between the oligonucleotides used in the assay. None of these mismatches are expected to affect the performance of the assay.

For analysis of the N2 target, 129 sequences were excluded due to ambiguous nucleotides, which reduced the total used in the evaluation to 48,332 sequences. Of the 48,332 GISAID sequences, 47,962 (99.2%) were an exact match to the SARS-CoV-2 N2 target amplicon generated in the Xpert Xpress SARS-CoV-2/Flu/RSV test. Single nucleotide mismatches were observed for 369 sequences and three (3) mismatches were observed for one sequence. For the one sequence with three variant positions, two of the mismatched nucleotides are in the probe region and could have an impact on probe binding. None of the other mismatches are predicted to have a negative impact on the performance of the assay.

The inclusivity of the Xpert Xpress SARS-CoV-2/Flu/RSV for Flu and RSV viruses are as reported for the analytical reactivity evaluation of the Xpert Xpress Flu/RSV test.

Xpert Xpress Flu/RSV test was evaluated against multiple strains of influenza A H1N1 (seasonal pre-2009), influenza A H1N1 (pandemic 2009), influenza A H3N2 (seasonal), avian influenza A (H5N1, H5N2, H6N2, H7N2, H7N3, H2N2, H7N9, and H9N2), influenza B (representing strains from both Victoria and Yamagata lineages), and respiratory syncytial virus subgroups A and B (RSV A and RSV B) at levels near the analytical LoD. A total of 53 strains comprised of 48 influenza viruses (35 influenza A and 13 influenza B) and 5 RSV strains were tested in this study with the Xpert Xpress Flu/RSV test. Three replicates were tested for each strain. All Flu and RSV strains tested positive in all three replicates, except for one Flu A H1N1 strain (A/New Jersey/8/76), which tested positive in 2 of 3 replicates at 0.1 $TCID_{50}$/mL. Results are shown in Table 6. Predicted cross reactivity from *in silico* analyses showed 100% sequence homology for additional pH1N1 strains.

Table 6. Analytical Reactivity (Inclusivity) of the Xpert Xpress Flu/RSV Test

Virus	Strain	Target Concentration	Result		
			Flu A	Flu B	RSV
No Template Control		N/A	NEG	NEG	NEG
Influenza A H1N1 (pre-2009)	A/swine/Iowa/15/30	0.1 $TCID_{50}/mL$	POS	NEG	NEG
	A/WS/33	0.1 $TCID_{50}/mL$	POS	NEG	NEG
	A/PR/8/34	0.1 $TCID_{50}/mL$	POS	NEG	NEG
	A/Mal/302/54	0.1 $TCID_{50}/mL$	POS	NEG	NEG
	A/Denver/1/57	0.1 $TCID_{50}/mL$	POS	NEG	NEG
	A/New Jersey/8/76	0.1 $TCID_{50}/mL$	POS	NEG	NEG
	A/New Caledonia/20/1999	0.1 $TCID_{50}/mL$	POS	NEG	NEG
	A/New York/55/2004	0.1 $TCID_{50}/mL$	POS	NEG	NEG
	A/Solomon Island/3/2006	0.1 $TCID_{50}/mL$	POS	NEG	NEG
	A/Taiwan/42/06	0.1 $TCID_{50}/mL$	POS	NEG	NEG
	A/Brisbane/59/2007	0.1 $TCID_{50}/mL$	POS	NEG	NEG
Influenza A H1N1 (pdm2009)	A/swine/NY/02/2009	0.1 $TCID_{50}/mL$	POS	NEG	NEG
	A/Colorado/14/2012	0.1 $TCID_{50}/mL$	POS	NEG	NEG
	A/Washington/24/2012	0.1 $TCID_{50}/mL$	POS	NEG	NEG
Influenza A H3N2 (Seasonal)	A/Aichi/2/68	2.0 $TCID_{50}/mL$	POS	NEG	NEG
	A/Hong Kong/8/68	2.0 $TCID_{50}/mL$	POS	NEG	NEG
	A/Port Chalmers/1/73	2.0 $TCID_{50}/mL$	POS	NEG	NEG
	A/Hawaii/15/2001	2.0 $TCID_{50}/mL$	POS	NEG	NEG
	A/Wisconsin/67/05	2.0 $TCID_{50}/mL$	POS	NEG	NEG
	A/Brisbane/10/2007	2.0 $TCID_{50}/mL$	POS	NEG	NEG
	A/Minnesota/11/2010 (H3N2)v	2.0 $TCID_{50}/mL$	POS	NEG	NEG
	A/Indiana/08/2011 (H3N2)v	2.0 $TCID_{50}/mL$	POS	NEG	NEG
	A/Texas/50/2012	2.0 $TCID_{50}/mL$	POS	NEG	NEG
Avian influenza A	A/duck/Hunan/795/2002 (H5N1)	$\leq$ 1pg/μL[a]	POS	NEG	NEG
	A/chicken/Hubei/327/2004 (H5N1)	$\leq$ 1pg/μL[a]	POS	NEG	NEG
	A/Anhui/01/2005 (H5N1)	$\leq$ 1pg/μL[a]	POS	NEG	NEG
	A/Japanese white eye/Hong Kong/ 1038/2006 (H5N1)	$\leq$ 1pg/μL[a]	POS	NEG	NEG
	A/mallard/WI/34/75 (H5N2)	$\leq$ 1pg/μL[a]	POS	NEG	NEG
	A/chicken/CA431/00 (H6N2)	$\leq$ 1pg/μL[a]	POS	NEG	NEG
	A/duck/LTC-10-82743/1943 (H7N2)	$\leq$ 1pg/μL[a]	POS	NEG	NEG
	A/chicken/NJ/15086-3/94 (H7N3)	$\leq$ 1pg/μL[a]	POS	NEG	NEG
	A/Anhui/1/2013 (H7N9)	N/A[b]	POS	NEG	NEG
	A/Shanghai/1/2013 (H7N9)	N/A[b]	POS	NEG	NEG
	A/chicken/Korea/38349-p96323/ 1996 (H9N2)	$\leq$ 1pg/μL[a]	POS	NEG	NEG
	A/Mallard/NY/6750/78 (H2N2)	$\leq$ 1pg/μL[a]	POS	NEG	NEG
Influenza B	B/Lee/40	1.0 $TCID_{50}/mL$	NEG	POS	NEG
	B/Allen/45	1.0 $TCID_{50}/mL$	NEG	POS	NEG
	B/GL/1739/54	1.0 $TCID_{50}/mL$	NEG	POS	NEG
	B/Maryland/1/59	1.0 $TCID_{50}/mL$	NEG	POS	NEG
	B/Panama/45/90[c]	1.0 $TCID_{50}/mL$	NEG	POS	NEG
	B/Florida/07/2004[d]	1.0 $TCID_{50}/mL$	NEG	POS	NEG
	B/Florida/02/06[c]	1.0 $TCID_{50}/mL$	NEG	POS	NEG

Virus	Strain	Target Concentration	Result		
			Flu A	Flu B	RSV
	B/Florida/04/06[d]	1.0 $TCID_{50}$/mL	NEG	POS	NEG
	B/Hong Kong/5/72	1.0 $TCID_{50}$/mL	NEG	POS	NEG
	B/Wisconsin/01/2011[d]	1.0 $TCID_{50}$/mL	NEG	POS	NEG
	B/Malaysia/2506/04[c]	1.0 $TCID_{50}$/mL	NEG	POS	NEG
	B/Taiwan/2/62	1.0 $TCID_{50}$/mL	NEG	POS	NEG
	B/Brisbane/60/2008[c]	1.0 $TCID_{50}$/mL	NEG	POS	NEG
RSV A	RSV-A/NY (Clinical unknown)	3.0 $TCID_{50}$/mL	NEG	NEG	POS
	RSV-A/WI/629-8-2/2007	3.0 $TCID_{50}$/mL	NEG	NEG	POS
	RSV-A/WI/629-11-1/2008	3.0 $TCID_{50}$/mL	NEG	NEG	POS
RSV B	RSV-B/WV14617/85	7.0 $TCID_{50}$/mL	NEG	NEG	POS
	RSV-B/CH93(18)-18	7.0 $TCID_{50}$/mL	NEG	NEG	POS

a. Purified viral RNA in simulated background matrix was used for avian influenza A viruses due to biosafety regulations.

b. Inactivated avian influenza A (H7N9) viruses without viral titer was diluted 100,000-fold in simulated background matrix and tested due to biosafety regulations.

c. Known Victoria lineage.

d. Known Yamagata lineage.

22.4 Analytical Specificity (Exclusivity)

An *in silico* analysis for possible cross-reactions with all the organisms listed in Table 7 was conducted by mapping primers and probes in the Xpert Xpress SARS-CoV-2/Flu/RSV test individually to the sequences downloaded from the GISAID database. E primers and probes are not specific for SARS-CoV-2 and will detect Human and Bat SARS-coronavirus. No potential unintended cross reactivity with other organisms listed in Table 7 is expected based on the *in silico* analysis.

Table 7. Xpert Xpress SARS-CoV-2/Flu/RSV Analytical Specificity Microorganisms

Microorganisms from the Same Genetic Family	High Priority Organisms
Human coronavirus 229E	Adenovirus (e.g. C1 Ad. 71)
Human coronavirus OC43	Human metapneumovirus (hMPV)
Human coronavirus HKU1	Parainfluenza viruses 1-4
Human coronavirus NL63	Influenza A
SARS-coronavirus	Influenza B
MERS-coronavirus	Influenza C
Bat coronavirus	Enterovirus (e.g. EV68)
	Respiratory syncytial virus
	Rhinovirus
	Chlamydia pneumoniae
	Haemophilus influenzae
	Legionella pneumophila
	Mycobacterium tuberculosis
	Streptococcus pneumoniae
	Streptococcus pyogenes
	Bordetella pertussis
	Mycoplasma pneumoniae
	Pneumocystis jirovecii (PJP)

Microorganisms from the Same Genetic Family	High Priority Organisms
	Parechovirus
	Candida albicans
	Corynebacterium diphtheriae
	Legionella non-*pneumophila*
	Bacillus anthracis (Anthrax)
	Moraxella catarrhalis
	Neisseria elongata and N. meningitidis
	Pseudomonas aeruginosa
	Staphylococcus epidermidis
	Streptococcus salivarius
	Leptospira
	Chlamydia psittaci
	Coxiella burnetii (Q-Fever)
	Staphylococcus aureus

The analytical specificity of the Xpert Xpress SARS-CoV-2/Flu/RSV for Flu A, Flu B and RSV viruses are as reported for the analytical exclusivity evaluation of the Xpert Xpress Flu/RSV test. The analytical specificity of the Xpert Xpress Flu/RSV test was evaluated by testing a panel of 44 cultures consisting of 16 viral, 26 bacterial, and two yeast strains representing common respiratory pathogens or those potentially encountered in the nasopharynx. Three replicates of each bacterial and yeast strain were tested at concentrations of $\geq 1 \times 10^6$ CFU/mL with the exception of one strain that was tested at 1×10^5 CFU/mL (*Chlamydia pneumoniae*). Three replicates of each virus were tested at concentrations of $\geq 1 \times 10^5$ $TCID_{50}$/mL. The analytical specificity was 100%. Results are shown in Table 8.

Table 8. Analytical Specificity of the Xpert Xpress Flu/RSV Test

Organism	Concentration	Influenza A	Influenza B	RSV
No Template Control	N/A	NEG	NEG	NEG
Adenovirus Type 1	1.12E+06 $TCID_{50}$/mL	NEG	NEG	NEG
Adenovirus Type 7	1.87E+05 $TCID_{50}$/mL	NEG	NEG	NEG
Human coronavirus OC43	2.85E+05 $TCID_{50}$/mL	NEG	NEG	NEG
Human coronavirus 229E	1.00E+05 $TCID_{50}$/mL	NEG	NEG	NEG
Cytomegalovirus	1.00E+05 $TCID_{50}$/mL	NEG	NEG	NEG
Echovirus	3.31E+07 $TCID_{50}$/mL	NEG	NEG	NEG
Enterovirus	3.55E+05 $TCID_{50}$/mL	NEG	NEG	NEG
Epstein Barr Virus	7.16E+07 $TCID_{50}$/mL	NEG	NEG	NEG
Herpes simplex virus	8.90E+05 $TCID_{50}$/mL	NEG	NEG	NEG
Measles	6.31E+05 $TCID_{50}$/mL	NEG	NEG	NEG
Human metapneumovirus	1.00E+05 $TCID_{50}$/mL	NEG	NEG	NEG
Mumps virus	6.31E+06 $TCID_{50}$/mL	NEG	NEG	NEG

Organism	Concentration	Influenza A	Influenza B	RSV
Human parainfluenza virus Type 1	1.15E+06 $TCID_{50}$/mL	NEG	NEG	NEG
Human parainfluenza virus Type 2	6.31E+05 $TCID_{50}$/mL	NEG	NEG	NEG
Human parainfluenza virus Type 3	3.55E+06 $TCID_{50}$/mL	NEG	NEG	NEG
Rhinovirus Type 1A	1.26E+05 $TCID_{50}$/mL	NEG	NEG	NEG
Acinetobacter baumannii	1.00E+06 CFU/mL	NEG	NEG	NEG
Burkholderia cepacia	3.30E+06 CFU/mL	NEG	NEG	NEG
Candida albicans	3.20E+06 CFU/mL	NEG	NEG	NEG
Candida parapsilosis	3.00E+06 CFU/mL	NEG	NEG	NEG
Bordetella pertussis	3.30E+06 CFU/mL	NEG	NEG	NEG
Chlamydia pneumoniae	1.00E+05 CFU/mL	NEG	NEG	NEG
Citrobacter freundii	3.30E+06 CFU/mL	NEG	NEG	NEG
Corynebacterium sp.	3.30E+06 CFU/mL	NEG	NEG	NEG
Escherichia coli	1.00E+07 CFU/mL	NEG	NEG	NEG
Enterococcus faecalis	1.30E+06 CFU/mL	NEG	NEG	NEG
Hemophilus influenzae	1.00E+06 CFU/mL	NEG	NEG	NEG
Lactobacillus reuteri	1.00E+06 CFU/mL	NEG	NEG	NEG
Legionella spp.	1.00E+06 CFU/mL	NEG	NEG	NEG
Moraxella catarrhalis	1.00E+07 CFU/mL	NEG	NEG	NEG
Mycobacterium tuberculosis (avirulent)	1.00E+06 CFU/mL	NEG	NEG	NEG
Mycoplasma pneumoniae	1.00E+06 CFU/mL	NEG	NEG	NEG
Neisseria meningitidis	2.15E+06 CFU/mL	NEG	NEG	NEG
Neisseria mucosa	1.00E+07 CFU/mL	NEG	NEG	NEG
Propionibacterium acnes	2.40E+07 CFU/mL	NEG	NEG	NEG
Pseudomonas aeruginosa	3.70E+06 CFU/mL	NEG	NEG	NEG
Staphylococcus aureus (protein A producer)	2.20E+06 CFU/mL	NEG	NEG	NEG
Staphylococcus epidermidis	3.40E+06 CFU/mL	NEG	NEG	NEG
Staphylococcus haemolyticus	4.00E+06 CFU/mL	NEG	NEG	NEG
Streptococcus agalactiae	3.50E+06 CFU/mL	NEG	NEG	NEG
Streptococcus pneumoniae	1.00E+06 CFU/mL	NEG	NEG	NEG
Streptococcus pyogenes	1.00E+07 CFU/mL	NEG	NEG	NEG
Streptococcus salivarius	1.00E+07 CFU/mL	NEG	NEG	NEG
Streptococcus sanguinis	3.10E+06 CFU/mL	NEG	NEG	NEG

22.5 Competitive Interference

Competitive interference of the Xpert Xpress SARS-CoV-2/Flu/RSV caused by co-infections were evaluated by testing individual SARS-CoV-2, Flu A, Flu B or RSV strains at 1X LoD in the presence of different target strains at a higher concentration in a simulated background matrix. The concentration at LoD was 131 copies/mL for SARS-CoV-2 and ranged from 0.004 $TCID_{50}$/mL to 0.43 $TCID_{50}$/mL for the Flu and RSV strains; the competitive strains were evaluated at 10^4 titer units (copies/mL, $TCID_{50}$/mL, $CEID_{50}$/mL or PFU/mL). The corresponding concentration of RNA (copies/mL) for the Flu and RSV strains was determined by ddPCR.

Analytical competitive interference was assessed using a strain of SARS-CoV-2 (inactivated USA-WA1/2020), Flu A H3 (H3/Victoria/361/2011), Flu B (B/Mass/02/2012), RSV A (RSV-A/2/Australia/61), and RSV B (RSV-B/Wash/18537/62). Replicates of 20 were tested for each target strain and each competitive strain combination. The normal binomial distribution with 20 replicate samples at LoD is between 17 and 20 positive results based on the binomial distribution with N=20, p=0.95 (X~Bin(20,0.95)). Therefore, sets of 20 with 16 or less positives would be rare and an indication of a competitive inhibitory effect due to high levels of a competing analyte. Below is a summary of the results:

Table 9. Summary of Results for Competitive Interference

		Correct Calls (n/20)					
		Test Strain at LoD and Interferent at:					
Test Strain at LoD	**Interferent Strain**	**10^{4}* (2.1e7 cp/mL)**	**10^{3}* (2.1e6 cp/mL)**	**10^{2}* (2.1e5 cp/mL)**	**10* (2.1e4 cp/mL)**	**1* (2.1e3 cp/mL)**	**0.1* (2.1e2 cp/mL)**
Flu B	Flu A	*6/20*	**20/20**				
RSV A	Flu A	*9/20*	**17/20**				
RSV B	Flu A	*11/20*	**18/20**				
SARS-CoV-2	Flu A	*6/20*	**17/20**	**20/20**			
Test Strain at LoD	**Interferent Strain**	**10^{4}* (5.2e7 cp/mL)**	**10^{3}* (5.2e6 cp/mL)**	**10^{2}* (5.2e5 cp/mL)**	**10* (5.2e4 cp/mL)**	**1* (5.2e3 cp/mL)**	**0.1* (5.2e2 cp/mL)**
Flu A	Flu B	*1/20*	*4/20*	*8/20*	*9/19*	*15/20*	**20/20**
RSV A	Flu B	*0/20*	*0/20*	*3/20*	**18/20**		
RSV B	Flu B	*7/20*	*8/20*	*11/20*	**18/20**		
SARS-CoV-2	Flu B	*3/20*	*4/20*	*11/20*	**17/20**	**20/20**	
Test Strain at LoD	**Interferent Strain**	**10^{4}* (3.7e7 cp/mL)**	**10^{3}* (3.7e6 cp/mL)**	**10^{2}* (3.7e5 cp/mL)**	**10* (3.7e4 cp/mL)**	**1* (3.7e3 cp/mL)**	**0.1* (3.7e2 cp/mL)**
Flu A	RSV A	*15/20*	**12/20**	**20/20**			
Flu B	RSV A	*15/20*	**17/20**				
SARS-CoV-2	RSV A	**17/20**	**19/20**				
Test Strain at LoD	**Interferent Strain**	**10^{4}* (1.1e7 cp/mL)**	**10^{3}* (1.1e6 cp/mL)**	**10^{2}* (1.1e5 cp/mL)**	**10* (1.1e4 cp/mL)**	**1* (1.1e3 cp/mL)**	**0.1* (1.1e2 cp/mL)**
Flu A	RSV B	*9/20*	*7/20*	*6/20*	*14/20*	**20/20**	
Flu B	RSV B	*10/20*	*10/20*	*16/20*	**19/20**		
SARS-CoV-2	RSV B	**17/20**	*16/20*	*15/20*	**20/20**		

		Correct Calls (n/20)					
		Test Strain at LoD and Interferent at:					
Test Strain at LoD	Interferent Strain	10^{4}*	10^{3}*	10^{2}*	10*	1*	0.1*
Flu A	SARS-CoV-2	**19/20**					
Flu B	SARS-CoV-2	**18/20**					
RSV A	SARS-CoV-2	**19/20**					
RSV B	SARS-CoV-2	**19/20**					

* Units for the concentration of each organism are as follows: Flu A H3 – $CEID_{50}$/mL; Flu B and RSV B – $TCID_{50}$/mL; RSV A – PFU/mL; SARS-CoV-2 – copies/mL

Italicized font indicates inhibitory effects

Bold font indicates no inhibition (SARS-CoV-2 tested to ≥19/20)

Flu A/Victoria/361/2011 at a concentration of 1 x 10^4 $CEID_{50}$/mL (2.1e7 copies/mL), inhibited Flu B, RSV A, RSV B and SARS-CoV-2 at the LoD.

Flu B/Mass/2/2012 at concentrations shown in Table 9, inhibited SARS-CoV-2, Flu A, RSV A and RSV B at concentrations at the LoD of those targets.

RSV A/2/Australia/61 at a concentration of 1 x 10^4 PFU/mL (3.7e7 copies/mL), inhibited SARS-CoV-2, Flu A and Flu B at the LoD.

RSV-B/Wash/18537/62 at concentrations shown in Table 9, inhibited SARS-CoV-2, Flu A and Flu B at concentrations at the LoD of those targets.

22.6 Potentially Interfering Substances

Potentially interfering substances that could be present in the nasopharynx (or introduced during specimen collection and handling) and interfere with accurate detection of SARS-CoV-2, Flu A, Flu B and RSV were evaluated with select direct testing on the Xpert Xpress SARS-CoV-2/Flu/RSV. Additional substances have also been previously evaluated on the Xpert Xpress Flu/RSV assay.

Potentially interfering substances in the nasal passage and nasopharynx may include, but are not limited to: blood, nasal secretions or mucus, and nasal and throat medications used to relieve congestion, nasal dryness, irritation, or asthma and allergy symptoms, as well as antibiotics and antivirals. Positive and negative samples were prepared in simulated nasal matrix. Negative samples (N = 8) were tested in the presence of each substance to determine the effect on the performance of the sample processing control (SPC). Positive samples (N = 8) were tested per substance with viruses spiked at 3x the analytical LoD determined for each strain. Positive samples tested with the Xpert Xpress SARS-CoV-2/Flu/RSV included one SARS-CoV-2, two influenza A, one influenza B and two RSV (RSV A and RSV B) strains, whereas those tested with the Xpert Xpress Flu/RSV consisted of six influenza (four influenza A and two influenza B) and four RSV (two RSV A and two RSV B). The substances evaluated are listed in Table 10 with active ingredients and final concentrations tested shown. None of the substances caused interference of the assay performance at the concentrations tested in this study. All positive and negative replicates were correctly identified by the Xpert Xpress SARS-CoV-2/Flu/RSV and/or Xpert Xpress Flu/RSV tests.

Table 10. Potentially Interfering Substances in the Xpert Xpress SARS-CoV-2/Flu/RSV Test and/or Xpert Xpress Flu/RSV Test

Substance/Class	Description/Active Ingredient	Concentration Tested
Control	Simulated nasal matrix	100% (v/v)
Beta-adrenergic bronchodilator[a]	Albuterol Sulfate	0.83 mg/mL (equivalent to 1 dose per day)
Blood	Blood (Human)	2% (v/v)
BD Universal Transport System	Transport Media	100% (v/v)
Remel M4®	Transport Media	100% (v/v)
Remel M4RT®	Transport Media	100% (v/v)
Remel M5®	Transport Media	100% (v/v)
Remel M6®	Transport Media	100% (v/v)
Throat lozenges, oral anesthetic and analgesic[a]	Benzocaine, Menthol	1.7 mg/mL
Mucin[a]	Purified Mucin protein (Bovine or porcine submaxillary gland)	0.1% (w/v)[b]
Antibiotic, nasal ointment[a]	Mupirocin	10 mg/mL
Saline Nasal Spray[a]	Sodium Chloride (0.65%)	15% (v/v)
Anefrin Nasal Spray	Oxymetazoline, 0.05%	15% (v/v)
PHNY Nasal Drops	Phenylephrine, 0.5%	15% (v/v)
Tamiflu anti-viral drugs[a]	Zanamivir	7.5 mg/mL
Antibacterial, systemic	Tobramycin	4 µg/mL
Zicam Nasal Gel	Luffa opperculata, Galphimia glauca, Histaminum hydrochloricum Sulfur	15% (w/v)
Nasal corticosteroid	Fluticasone Propionate	5 µg/mL

a. Substances/active ingredients and concentrations specifically evaluated with the Xpert Xpress SARS-CoV-2/Flu/RSV test.

b. No interference to the Xpert Xpress Flu/RSV performance observed at a concentration of 2.5%

22.7 Carry-Over Contamination

Carry-over studies to establish that single-use, self-contained GeneXpert cartridges prevent carry-over contamination have been conducted for previous Xpert tests developed for the GeneXpert systems, including the Xpert Xpress Flu/RSV. The studies demonstrated that a negative sample when preceded by very a high positive sample in the same GeneXpert module resulted in no carry-over.

23 References

1. Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/index.html. Accessed February 9, 2020.
2. bioRxiv. (https://www.biorxiv.org/content/10.1101/2020.02.07.937862v1). Accessed March 3, 2020.
3. Petric M, Comanor L, Petti CA. Role of the laboratory in diagnosis of influenza during seasonal epidemics and potential pandemics. J Infect Dis. 2006;194:S98-110.
4. Schweiger B, Zadow I, Heckler R, et al. Application of a fluorogenic PCR assay for typing and subtyping of influenza viruses in respiratory samples. J Clin Micro. 2000;38:1552-1558.
5. http://www.cdc.gov/flu/about/viruses/types.htm. Accessed on May 19, 2016.
6. http://www.cdc.gov/RSV/index.html. Accessed on March 14, 2013.
7. Centers for Disease Control and Prevention. *Biosafety in Microbiological and Biomedical laboratories* (refer to latest edition). http://www.cdc.gov/biosafety/publications/
8. Clinical and Laboratory Standards Institute. *Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline*. Document M29 (refer to latest edition).
9. REGULATION (EC) No 1272/2008 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 December 2008 on the classification labeling and packaging of substances and mixtures amending and repealing, List of Precautionary Statements, Directives 67/548/EEC and 1999/45/EC (amending Regulation (EC) No 1907/2007).
10. Occupational Safety and Health Standards, Hazard Communication, Toxic and Hazard Substances (March 26, 2012) (29 C.F.R., pt. 1910, subpt. Z).

24 Cepheid Headquarters Locations

Corporate Headquarters	European Headquarters
Cepheid 904 Caribbean Drive Sunnyvale, CA 94089 USA	Cepheid Europe SAS Vira Solelh 81470 Maurens-Scopont France
Telephone: +1 408 541 4191	Telephone: +33 563 825 300
Fax: +1 408 541 4192	Fax: +33 563 825 301
www.cepheid.com	www.cepheidinternational.com

25 Technical Assistance

Before contacting Cepheid Technical Support, collect the following information:

- Product name
- Lot number
- Serial number of the instrument
- Error messages (if any)
- Software version and, if applicable, Computer Service Tag number

Region	Telephone	Email
US	+ 1 888 838 3222	techsupport@cepheid.com
France	+ 33 563 825 319	support@cepheideurope.com
Australia New Zealand	1800 130 821 0800 001 028	techsupportANZ@cepheid.com

Contact information for all Cepheid Technical Support offices is available on our website: www.cepheid.com/en_US/support/contact-us.

26 Table of Symbols

Symbol	Meaning
REF	Catalog number
IVD	*In vitro* diagnostic medical device
	Do not re-use
LOT	Batch code
	Consult instructions for use
	Caution
	Manufacturer
CC	Country of manufacture
Σ	Contains sufficient for <n> tests
CONTROL	Control
	Expiration date
°C	Temperature limitation
	Biological risks
Rx only	For prescription use only

Cepheid
904 Caribbean Drive
Sunnyvale, CA 94089 USA
Phone: +1 408 541 4191
Fax: +1 408 541 4192

IVD

For use under Emergency Use Authorization (EUA) Only

AB798

BioFire® Respiratory Panel 2.1 (RP2.1)

IVD

For Emergency Use Authorization (EUA) only

Rx Only

Instructions for Use	https://www.biofiredx.com/e-labeling/ITI0101
Quick Guide	https://www.biofiredx.com/e-labeling/ITI0072
Safety Data Sheet (SDS)	https://www.biofiredx.com/e-labeling/ITI0060

Customer and Technical Support Information	**U.S. Customers**	Phone: 1-800-735-6544 (toll free) E-mail: support@BioFireDX.com Website: www.biofiredx.com
*For more information on how to contact Customer and Technical Support, refer to Appendix B.	**Outside of the U.S.**	Contact the local bioMérieux sales representative or an authorized distributor.

INTENDED USE

The BioFire Respiratory Panel 2.1 (RP2.1) is a multiplexed nucleic acid test intended for the simultaneous qualitative detection and differentiation of nucleic acids from multiple viral and bacterial respiratory organisms, including nucleic acid from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), in nasopharyngeal swabs (NPS) obtained from individuals suspected of COVID-19 by their healthcare provider. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity or moderate complexity tests.

The BioFire Respiratory Panel 2.1 (RP2.1) is intended for the detection and differentiation of nucleic acid from SARS-CoV-2 and the following organism types and subtypes identified using the BioFire RP2.1.

Viruses	Bacteria
Adenovirus Coronavirus 229E Coronavirus HKU1 Coronavirus NL63 Coronavirus OC43 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Human Metapneumovirus Human Rhinovirus/Enterovirus Influenza A, including subtypes H1, H3 and H1-2009 Influenza B Parainfluenza Virus 1 Parainfluenza Virus 2 Parainfluenza Virus 3 Parainfluenza Virus 4 Respiratory Syncytial Virus	*Bordetella parapertussis* *Bordetella pertussis* *Chlamydia pneumoniae* *Mycoplasma pneumoniae*

SARS-CoV-2 RNA and nucleic acids from the other respiratory viral and bacterial organisms identified by this test are generally detectable in nasopharyngeal swabs (NPS) during the acute phase of infection. The detection and identification of specific viral and bacterial nucleic acids from individuals exhibiting signs and/or symptoms of respiratory infection is indicative of the presence of the identified microorganism and aids in the diagnosis of respiratory infection if used in conjunction with other clinical and epidemiological information. The results of this test should not be used as the sole basis for diagnosis, treatment, or other patient management decisions. Positive results are indicative of the presence of the identified organism, but do not rule out co-infection with other pathogens. The agent(s) detected by the BioFire RP2.1 may not be the definite cause of disease.

Laboratories within the United States and its territories are required to report all SARSCoV-2 positive results to the appropriate public health authorities.

Negative results in the setting of a respiratory illness may be due to infection with pathogens not detected by this test, or lower respiratory tract infection that may not be detected by an NPS specimen. Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for treatment or other patient management decisions. Negative SARSCoV-2 results must be combined with clinical observations, patient history, and epidemiological information. Negative results for other organisms identified by the test may require additional laboratory testing (eg, bacterial and viral culture, immunofluorescence and radiography) when evaluating a patient with possible respiratory tract infection.

The BioFire RP2.1 is intended for use by laboratory personnel who have received specific training on the use of the FilmArray 2.0 and/or the FilmArray Torch Systems. The BioFire RP2.1 is only for use under the Food and Drug Administration's Emergency Use Authorization.

SUMMARY AND EXPLANATION OF THE TEST

The BioFire RP2.1 is a real-time, nested multiplexed polymerase chain reaction test designed to simultaneously identify nucleic acids from 22 different viruses and bacteria associated with respiratory tract infection, including SARS-CoV-2, from a single nasopharyngeal swab (NPS) specimen. Specifically, the SARS-CoV-2 primers contained in the BioFire RP2.1 are designed to detect RNA from the SARS-CoV-2 in nasopharyngeal swabs in transport media from patients who are suspected of COVID-19. Internal controls are used to monitor all stages of the test process.

PRINCIPLE OF THE PROCEDURE

The BioFire® RP2.1 pouch is a closed system disposable that stores all the necessary reagents for sample preparation, reverse transcription, polymerase chain reaction (PCR), and detection in order to isolate, amplify, and detect nucleic acid from multiple respiratory pathogens within a single NPS specimen. After sample collection, the user injects hydration solution and sample combined with Sample Buffer into the pouch, places the pouch into a BioFire® FilmArray® System instrument module, and starts a run. The entire run process takes about 45 minutes. Additional detail can be found in the appropriate BioFire FilmArray System Operator's Manual.

During a run, the FilmArray® system:

- Lyses the sample by agitation (bead beating) in addition to chemical lysis mediated by the Sample Buffer.
- Extracts and purifies all nucleic acids from the sample using magnetic bead technology.
- Performs nested multiplex PCR by:
  - First performing reverse transcription, followed by a multiplexed first stage PCR reaction (PCR1).
  - Then performing multiple simultaneous second-stage PCR reactions (PCR2) in the array to amplify sequences within the PCR1 products.
- Uses endpoint melting curve data to detect target-specific amplicons and analyses the data to generate a result for each analyte on the BioFire RP2.1.



MATERIALS PROVIDED

Each kit contains sufficient reagents to test 30 samples (30-test kit; 423738):

- Individually packaged BioFire RP2.1 pouches
- Single-use (1.0 mL) Sample Buffer ampoules
- Single-use pre-filled (1.5 mL) Hydration Injection Vials (blue)
- Single-use Sample Injection Vials (red)
- Individually packaged Transfer Pipettes

MATERIALS REQUIRED BUT NOT PROVIDED

- BioFire® FilmArray® System including:
  - BioFire® FilmArray® 2.0 or BioFire® FilmArray® Torch Systems, including panel-specific software module, and accompanying system-specific software
  - BioFire® FilmArray® Pouch Loading Station
- 10% bleach solution or a similar disinfectant

WARNINGS AND PRECAUTIONS

General Precautions

1. For *in vitro* diagnostic use under Emergency Use Authorization only.
2. A trained healthcare professional should carefully interpret the results from the BioFire RP2.1 in conjunction with a patient's signs and symptoms, results from other diagnostic tests, and relevant epidemiological information.
3. BioFire RP2.1 pouches are only for use with BioFire FilmArray 2.0 and BioFire FilmArray Torch systems.
4. Always check the expiration date on the pouch. Do not use a pouch after its expiration date.
5. BioFire RP2.1 pouches are stored under vacuum in individually wrapped canisters. To preserve the integrity of the pouch vacuum for proper operation, be sure that a FilmArray instrument/module will be available and operational before unwrapping any pouches for loading.
6. If infection with SARS-CoV-2 is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions.

Safety Precautions

1. Wear appropriate Personal Protective Equipment (PPE), including (but not limited to) disposable clean powder-free gloves and lab coats. Protect skin, eyes, and mucus membranes. Change gloves often when handling reagents or samples.
2. Handle all samples and waste materials as if they were capable of transmitting infectious agents. Observe safety guidelines such as those outlined in:
   - CDC/NIH *Biosafety in Microbiological and Biomedical Laboratories*[1]
   - CLSI Document M29 *Protection of Laboratory Workers from Occupationally Acquired Infections*[2]
   - Refer to Interim Laboratory Safety Guidelines for Handling and Processing Specimens Associated with SARS-CoV-2 www.cdc.gov/coronavirus/2019-nCoV/lab-biosafety-guidelines.html.
3. Follow your institution's safety procedures for handling biological samples.
4. If infection with a novel Influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent influenza viruses and sent to a state or local health department for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens.

5. Dispose of materials used in this assay, including reagents, samples, and used buffer vials, according to federal, state, and local regulations.
6. Sample Buffer is assigned the following classifications:
    - Acute toxicity (Category 4)
    - Serious Eye damage (Category 1)
    - Skin irritation (Category 2).

    Please refer to the BioFire RP2.1 Safety Data Sheet (SDS) for more information.
7. Sample Buffer will form hazardous compounds and fumes when mixed with bleach or other disinfectants.

    WARNING: Never add bleach to Sample Buffer or sample waste.
8. Bleach, a recommended disinfectant, is corrosive and may cause severe irritation or damage to eyes and skin. Vapor or mist may irritate the respiratory tract. Bleach is harmful if swallowed or inhaled.
    - Eye contact: Hold eye open and rinse with water for 15-20 minutes. Remove contact lenses after the first 5 minutes and continue rinsing eye. Seek medical attention.
    - Skin contact: Immediately flush skin with plenty of water for at least 15 minutes. If irritation develops, seek medical attention.
    - Ingestion: Do not induce vomiting. Drink a glassful of water. If irritation develops, seek medical attention.
    - Please refer to the appropriate Safety Data Sheet (SDS) for more information.

Laboratory Precautions

1. **Preventing organism contamination**

    Due to the sensitive nature of the BioFire RP2.1, it is important to guard against contamination of the sample and work area by carefully following the testing process outlined in this instruction document, including these guidelines:

    - Laboratory personnel may carry or shed common respiratory pathogens asymptomatically and can inadvertently contaminate the specimen while it is being processed. Careful adherence to the sample processing steps described in this document is recommended to avoid possible contamination. Samples should be processed in a clean biosafety cabinet if available, or according to local laboratory guidelines. If a biosafety cabinet is not used, a dead air box (e.g., AirClean PCR workstation), a splash shield (e.g., Bel-Art Scienceware Splash Shields), or a face shield can be used when preparing samples instead.
    - Laboratory personnel with active respiratory symptoms (runny nose, cough) should wear a standard surgical mask (or equivalent) and should avoid touching the mask while handling specimens.
    - It is recommended to avoid handling specimens or pouches in an area used to routinely process respiratory pathogen culture, and/or immunofluorescence testing.
    - Prior to processing specimens, thoroughly clean both the work area and the BioFire® Pouch Loading Station using a suitable cleaner such as freshly prepared 10% bleach or a similar disinfectant. To avoid residue build-up and potential damage to the specimen or interference from disinfectants, wipe disinfected surfaces with water.
    - Specimens and pouches should be handled and/or tested one-at-a-time. Always change gloves and clean the work area between each pouch and specimen.

- Use clean gloves when removing Sample Buffer ampoules and Sample/Hydration Injection Vials from bulk packaging bags, and reseal bulk packaging bags when not in use.
- Avoid collecting or handling specimens in areas that are exposed to vaccine material for pathogens detected by the BioFire RP2.1 (*e.g.* influenza and *Bordetella pertussis*). Particular care should be taken during these processes to avoid contamination. Some *B. pertussis* acellular vaccines (i.e. Pentacel®, Daptacel®, and Adacel®) contain PCR-detectable DNA. Contamination of specimens or testing materials with vaccine can cause false-positive *B. pertussis* results (http://www.cdc.gov/pertussis/clinical/diagnostic-testing/diagnosis-pcr-bestpractices.html).

2. **Preventing amplicon contamination**

A common concern with PCR-based assays is false positive results caused by contamination of the work area with PCR amplicon. Because the BioFire RP2.1 pouch is a closed system, the risk of amplicon contamination is low provided that pouches remain intact after the test is completed. Adhere to the following guidelines, in addition to those above, to prevent amplicon contamination:

- Discard used pouches in a biohazard container immediately after the run has completed.
- Avoid excessive handling of pouches after test runs.
- Change gloves after handling a used pouch.
- Avoid exposing pouches to sharp edges or anything that might cause a puncture.

WARNING: If liquid is observed on the exterior of a pouch, the liquid and pouch should be immediately contained and discarded in a biohazard container. The instrument and workspace must be decontaminated as described in the appropriate BioFire FilmArray Operator's Manual.

DO NOT PERFORM ADDITIONAL TESTING UNTIL THE AREA HAS BEEN DECONTAMINATED.

Precautions Related to Public Health Reporting

Local, state, and federal regulations for notification of reportable disease are continually updated and include a number of organisms for surveillance and outbreak investigations.[3,4] Additionally, the Centers for Disease Control and Prevention (CDC) recommends that when pathogens from reportable diseases are detected by a culture independent diagnostic test (CIDT), the laboratory should facilitate obtaining the isolate or clinical materials for submission to the appropriate public health laboratory to aid in outbreak detection and epidemiological investigations. Laboratories are responsible for following their state and/or local regulations and should consult their local and/or state public health laboratories for isolate and/or clinical sample submission guidelines.

Pertussis is a nationally notifiable infectious condition in the U.S. If *Bordetella pertussis* is detected, notify the state and/or local health departments.

Laboratories in the U.S. are required to report all positive SARS-CoV-2 results to the appropriate public health authorities.

REAGENT STORAGE, HANDLING, AND STABILITY

1. Store the test kit, including reagent pouches and buffers, at room temperature (15–25 ºC). **DO NOT REFRIGERATE.**
2. Avoid storage of any materials near heating or cooling vents or in direct sunlight.
3. All kit components should be stored and used together. Do not use components from one kit with those of another kit. Discard any extra components from the kit after all pouches have been consumed.
4. Do not remove pouches from their packaging until a sample is ready to be tested. Once the pouch packaging has been opened, the pouch should be loaded as soon as possible (within approximately 30 minutes).
5. Once a pouch has been loaded, the test run should be started as soon as possible (within approximately 60 minutes). Do not expose a loaded pouch to temperatures above 40°C (104°F) prior to testing.

SAMPLE REQUIREMENTS

The following table describes the requirements for specimen collection, preparation, and handling that will help ensure accurate test results.

Specimen Type	**Nasopharyngeal Swab** (NPS) collected according to standard technique and immediately placed in up to 3 mL of transport media
Minimum Sample Volume	0.3 mL (300 µL)
Transport and Storage	Specimens should be processed and tested with the BioFire RP2.1 as soon as possible. If storage is required, specimens can be held: • At room temperature for up to 4 hours (15-25 °C) • Refrigerated for up to 3 days (2-8 °C) • Frozen (≤-15 °C or ≤-70°C) (for up to 30 days)[a]

[a] Frozen storage for up to 30 days was evaluated for this sample type. However, longer frozen storage may be acceptable. Please follow your institutions rules and protocols regarding sample storage validation.

NOTE: NPS specimens should not be centrifuged before testing.

NOTE: Bleach can damage organisms/nucleic acids within the specimen, potentially causing false negative results. Contact between bleach and specimens during collection, disinfection, and testing procedures should be avoided.

PROCEDURE

Use clean gloves and other Personal Protective Equipment (PPE) when handling pouches and samples. Only prepare one BioFire RP2.1 pouch at a time and change gloves between samples and pouches. Once sample is added to the pouch, promptly transfer to the instrument to start the run. After the run is complete, discard the pouch in a biohazard container.

Step 1: Prepare Pouch

1. Thoroughly clean the work area and the BioFire Pouch Loading Station with freshly prepared 10% bleach (or suitable disinfectant) followed by a water rinse.
2. Remove the pouch from its vacuum-sealed package by tearing or cutting the notched outer packaging and opening the protective canister.

NOTE: The pouch may still be used even if the vacuum seal of the pouch is not intact. Attempt to hydrate the pouch using the steps in the Hydrate Pouch section. If hydration is successful, continue with the run. If hydration fails, discard the pouch and use a new pouch to test the sample.

3. Check the expiration date on the pouch. Do not use expired pouches.
4. Insert the pouch into the Pouch Loading Station, aligning the red and blue labels on the pouch with the red and blue arrows on the Pouch Loading Station.
5. Place a red-capped Sample Injection Vial into the red well of the Pouch Loading Station.
6. Place a blue-capped Hydration Injection Vial into the blue well of the Pouch Loading Station.



Step 2: Hydrate Pouch

1. Unscrew the Hydration Injection Vial from the blue cap.
2. Remove the Hydration Injection Vial, leaving the blue cap in the BioFire Pouch Loading Station.
3. Insert the Hydration Injection Vial's cannula tip into the pouch hydration port located directly below the blue arrow of the Pouch Loading Station.
4. Forcefully push down in a firm and quick motion to puncture seal until a faint "pop" is heard and there is an ease in resistance. Wait as the correct volume of Hydration Solution is pulled into the pouch by vacuum.
   - If the hydration solution is not automatically drawn into the pouch, repeat Step 2 to verify that the seal of the pouch hydration port was broken. If hydration solution is again not drawn into the pouch, discard the current pouch, retrieve a new pouch, and repeat from *Step 1: Prepare Pouch*.



5. Verify that the pouch has been hydrated.
   - Flip the barcode label down and check to see that fluid has entered the reagent wells (located at the base of the rigid plastic part of the pouch). Small air bubbles may be seen.
   - If the pouch fails to hydrate (dry reagents appear as white pellets), repeat Step 2 to verify that the seal of the pouch hydration port was broken. If hydration solution is still not drawn into the pouch, discard the current pouch, retrieve a new pouch, and repeat from *Step 1: Prepare Pouch*.

Step 3: Prepare Sample Mix

1. Add Sample Buffer to the Sample Injection Vial.
    - Hold the Sample Buffer ampoule with the tip facing up.

NOTE: Avoid touching the ampoule tip during handling, as this may introduce contamination.

- Firmly pinch at textured plastic tab on the side of the ampoule until the seal snaps.
- Invert the ampoule over the red-capped Sample Injection Vial and dispense Sample Buffer using a slow, forceful squeeze followed by a second squeeze.

NOTE: Avoid squeezing the ampoule additional times. This will generate foaming, which should be avoided.

WARNING: The Sample Buffer is harmful if swallowed and can cause serious eye damage and skin irritation.



2. Thoroughly mix the NPS specimen by vortex or inversion.
3. Use the transfer pipette provided in the test kit to draw specimen to the third line (approximately 0.3 mL) of the transfer pipette.
4. Add the specimen to the Sample Buffer in the Sample Injection Vial.
5. Tightly close the lid of the Sample Injection Vial and discard the transfer pipette in a biohazard waste container.

    NOTE: DO NOT use the Transfer Pipette to mix the sample once it is loaded into the Sample Injection Vial.

6. Remove the Sample Injection Vial from the Pouch Loading Station and invert the vial at least 3 times to mix.
7. Return the Sample Injection Vial to the red well of the Pouch Loading Station.



Step 4: Load Sample Mix

1. Slowly twist to unscrew the Sample Injection Vial from the red cap and wait for 5 seconds with the vial resting in the cap.

    NOTE: Waiting 5 seconds decreases the risk of dripping and contamination from the sample.



2. Lift the Sample Injection Vial, leaving red cap in the well of the Pouch Loading Station, and insert the Sample Injection Vial cannula tip into the pouch sample port located directly below the red arrow of the Pouch Loading Station.
3. Forcefully push down in a firm and quick motion to puncture seal (a faint "pop" is heard) and sample is pulled into the pouch by vacuum.

4. Verify that the sample has been loaded.
   - Flip the barcode label down and check to see that fluid has entered the reagent well next to the sample loading port.
   - If the pouch fails to pull sample from the Sample Injection Vial, the pouch should be discarded. Retrieve a new pouch and repeat from *Step 1: Prepare Pouch*.
5. Discard the Sample Injection Vial and the Hydration Injection Vial in appropriate biohazard sharps container.
6. Record the Sample ID in the provided area on the pouch label (or affix a barcoded Sample ID) and remove the pouch from the FilmArray Pouch Loading Station.

Step 5: Run Pouch

The FilmArray® Software includes step-by-step, on-screen instructions that guide the operator through performing a run. Brief instructions for FilmArray 2.0 and FilmArray Torch Systems are given below. Refer to the appropriate BioFire FilmArray System Operator's Manual for more detailed instructions.

FilmArray 2.0

1. Ensure that the FilmArray 2.0 system (instrument and computer) is powered on and the software is launched.
2. Follow on-screen instructions and procedures described in the Operator's Manual to place the pouch in a module, enter pouch, sample, and operator information.
3. Pouch identification (Lot Number and Serial Number), Pouch Type and Protocol information will be automatically entered when the barcode is scanned. If it is not possible to scan the barcode, the pouch Lot Number, Serial Number, Pouch Type, and Protocol can be manually entered from the information provided on the pouch label into the appropriate fields. To reduce data entry errors, it is strongly recommended that the pouch information be entered by scanning the barcode.

NOTE: When selecting a Pouch Type manually, ensure that the Pouch Type matches the label on the BioFire RP2.1 pouch.

4. Enter the Sample ID. The Sample ID can be entered manually or scanned in by using the barcode scanner when a barcoded Sample ID is used.
5. If necessary, select and/or confirm the appropriate protocol for your sample type from the Protocol drop down list. The BioFire RP2.1 has a single protocol available in the drop down list.
6. Enter a user name and password in the Name and Password fields.

NOTE: The font color of the username is red until the user name is recognized by the software.

7. Review the entered run information on the screen. If correct, select Start Run.

   Once the run has started, the screen displays a list of the steps being performed by the instrument and the number of minutes remaining in the run.

NOTE: The bead-beater apparatus makes an audible, high-pitched noise during the first minute of operation.

8. When the run is finished, follow the on-screen instructions to remove the pouch, then immediately discard it in a biohazard waste container.

9. The run file is automatically saved in the FilmArray database, and the test report can be viewed, printed, and/or saved as a PDF file.

BioFire FilmArray Torch

1. Ensure that the BioFire FilmArray Torch System is powered on.
2. Select an available module on the touch screen or scan the barcode on the pouch using the barcode scanner.
3. Pouch identification (Lot Number and Serial Number), Pouch Type and Protocol information will be automatically entered when the barcode is scanned. If it is not possible to scan the barcode, the pouch Lot Number, Serial Number, Pouch Type, and Protocol can be manually entered from the information provided on the pouch label into the appropriate fields. To reduce data entry errors, it is strongly recommended that the pouch information be entered by scanning the barcode.

NOTE: When selecting a Pouch Type manually, ensure that the Pouch Type matches the label on the BioFire RP2.1 pouch.

4. Enter the Sample ID. The Sample ID can be entered manually or scanned in by using the barcode scanner when a barcoded Sample ID is used.
5. Insert the pouch into the available module.
    - Ensure that the pouch fitment label is lying flat on top of pouch and not folded over. As the pouch is inserted, the module will grab onto the pouch and pull it into the chamber.
6. If necessary, select and/or confirm the appropriate protocol for your sample type from the Protocol drop down list. The BioFire RP2.1 has a single protocol available in the drop down list.
7. Enter operator user name and password, then select Next.

NOTE: The font color of the username is red until the user name is recognized by the software.

8. Review the entered run information on the screen. If correct, select Start Run.

   Once the run has started, the screen displays a list of the steps being performed by the module and the number of minutes remaining in the run.

NOTE: The bead-beater apparatus can be heard as a high-pitched noise during the first minute of operation.

9. At the end of the run, remove the partially ejected pouch, then immediately discard it in a biohazard waste container.
10. The run file is automatically saved in the FilmArray database, and the test report can be viewed, printed, and/or saved as a PDF file.

QUALITY CONTROL

Process Controls

Two process controls are included in each pouch:

1. **RNA Process Control**

   The RNA Process Control assay targets an RNA transcript from the yeast *Schizosaccharomyces pombe*. The yeast is present in the pouch in a freeze-dried form and becomes rehydrated when sample is loaded. The control material is carried through all stages of the test process, including lysis, nucleic acid purification, reverse transcription, PCR1, dilution, PCR2, and DNA melting. A positive control result indicates that all steps carried out in the BioFire RP2.1 pouch were successful.

2. **PCR2 Control**

   The PCR2 Control assay detects a DNA target that is dried into wells of the array along with the corresponding primers. A positive result indicates that PCR2 was successful.

Both control assays must be positive for the test run to pass. If the controls fail, the sample should be retested using a new pouch.

Monitoring Test System Performance

The FilmArray software will automatically fail the run if the melting temperature (Tm) for either the RNA Process Control or the PCR2 Control is outside of an acceptable range (80.3-84.3°C for the RNA Process Control and 73.8-77.8°C for the PCR2 Control). If required by local, state, or accrediting organization quality control requirements, users can monitor the system by trending Tm values for the control assays and maintaining records according to standard laboratory quality control practices.[5,6] Refer to the appropriate BioFire FilmArray Operator's System Manual for instructions on obtaining control assay Tm values. The PCR2 Control is used in several FilmArray pouch types (e.g., RP, BCID2, BCID, GI, ME, and RP2) and can therefore be used to monitor the system when multiple pouch types are used on the same FilmArray System.

External Controls

Good laboratory practice recommends running external positive and negative controls regularly. Transport media can be used as an external negative control. Previously characterized positive samples or negative samples spiked with well-characterized organisms can be used as external positive controls. Commercial external control materials may be available from other manufacturers; these should be used in accordance with the manufacturers' instructions and appropriate accrediting organization requirements, as applicable.

Due to the COVID-19 pandemic and the resulting shortage of external control material, BioFire recommends that all laboratories perform external QC with each new lot and shipment of reagents, at a minimum, while running the BioFire RP2.1 under Emergency Use Authorization (EUA).

INTERPRETATION OF RESULTS

Assay Interpretation

When PCR2 is complete, the instrument performs a high resolution DNA melting analysis on the PCR products and measures the fluorescence signal generated in each well (for more information see appropriate BioFire FilmArray Operator's System manual). The BioFire FilmArray Software then performs several analyses and assigns a final assay result. The steps in the analyses are described below.

Analysis of melt curves. The BioFire FilmArray Software evaluates the DNA melt curve for each well of the PCR2 array to determine if a PCR product was present in that well. If the melt profile indicates the presence of a PCR product, then the analysis software calculates the melting temperature (Tm) of the curve and compares it against the expected Tm range for the assay. If the software determines that the Tm falls inside the assay-specific Tm range, the melt curve is called positive. If the software determines that the melt curve is not in the appropriate Tm range, the melt curve is called negative.

Analysis of replicates. Once melt curves have been identified, the software evaluates the three replicates for each assay to determine the assay result. For an assay to be called positive, at least two of the three associated melt curves must be called positive, and the Tm for at least two of the three positive melt curves must be similar (within 1°C). Assays that do not meet these criteria are called negative.

Organism Interpretation

For most organisms detected by the BioFire RP2.1, the organism is reported as Detected if a single corresponding assay is positive. For example, Human Metapneumovirus will have a test report result of Human Metapneumovirus Detected if the hMPV assay is positive (at least two of the three hMPV assay wells on the array have similar positive melt peaks with Tm values that are within the assay-specific Tm range). The test results for SARS-CoV-2, Adenovirus, and Influenza A depend on the interpretation of results from more than one assay. Interpretation and actions for these three multi-assay results are provided below.

SARS-CoV-2

The BioFire RP2.1 pouch contains two different assays for the detection of the SARS-CoV-2. The target of each assay is shown in Table 1 below. The BioFire FilmArray software interprets each assay independently and if either one or both of the assays is positive, the test report will show Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) as Detected. If both assays are negative, the test report result will be Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Not Detected.

Table 1. Gene Targets for SARS-CoV-2 Assays on the BioFire RP2.1

Assay Name	Gene Target
SARSCoV2-1	Spike protein (S) gene
SARSCoV2-2	Membrane protein (M) gene

Adenovirus

The BioFire RP2.1 pouch contains five assays (Adeno2, Adeno3, Adeno6, Adeno7.1, and Adeno8) for the detection of Adenovirus. The FilmArray Software interprets each of these assays independently (as described above) and the results are combined as a final test result for the virus. If one assay or any combination of assays is positive, the test report result will be Adenovirus Detected. If all assays are negative, the test report result will be Adenovirus Not Detected.

Influenza A

The assays in the BioFire RP2.1 are designed to both detect Influenza A and to differentiate commonly occurring hemagglutinin subtypes. To accomplish this, the BioFire RP2.1 uses two Influenza A assays, (FluA-pan-1 and FluA-pan-2) and three subtyping assays directed at the hemagglutinin gene (FluA-H1-2, FluA-H1-2009, and FluA-H3). Each of the individual assays is interpreted independently (as described above) and the test result reported for Influenza A is based on the combined results of the five assays as outlined in Table 2. Specimens with an Equivocal result or multiple Influenza A subtypes detected should be retested once.

Table 2. Possible Assay Results for Influenza A and the Corresponding Interpretation

Result \ Assay	FluA-pan Assays (n=2)	FluA-H1-2	FluA-H1-2009	FluA-H3	Action
Influenza A Not Detected	Negative	Negative	Negative	Negative	None
Influenza A H1	**≥1 positive**	**Positive**	Negative	Negative	
Influenza A H3	**≥1 positive**	Negative	Negative	**Positive**	
Influenza A H1-2009	**≥1 positive**	Any result	**Positive**	Negative	
Influenza A H1 **Influenza A H3**	**≥1 positive**	**Positive**	Negative	**Positive**	Multiple infections are possible but rare [a], retest to confirm result [b]
Influenza A H1-2009 **Influenza A H3**	**≥1 positive**	Any result	**Positive**	**Positive**	
Influenza A (no subtype detected)	**2 positive**	Negative	Negative	Negative	Retest (see below)
Influenza A Equivocal	**1 positive**	Negative	Negative	Negative	Retest once (see Result Summary section below for further instruction).
Influenza A H1 Equivocal	Negative	**Positive**	Negative	Negative	
Influenza A H3 Equivocal	Negative	Negative	Negative	**Positive**	
Influenza A H1-2009 Equivocal	Negative	Any result	**Positive**	Negative	

[a] The BioFire RP2.1 can simultaneously detect multiple influenza viruses contained in multivalent vaccines (see Limitations).

[b] Repeated multiple subtype positives should be further confirmed by other FDA cleared Influenza subtyping tests.

Influenza A (no subtype detected)

If both FluA-pan assays are positive, but none of the hemagglutinin subtyping assays are positive, then the interpretation is Influenza A (no subtype detected). This result could occur when the titer of the virus in the specimen is low and not detected by the subtyping assays. This result could also indicate the presence of a novel Influenza A strain. In both cases, the sample in question should be retested. If the retest provides a different result, test the sample a third time to ensure the accuracy of the result. If the retest provides the same result, then the function of the BioFire RP2.1 pouches should be verified by testing with appropriate external control materials (known positive samples for Influenza A H1, Influenza A H3 and Influenza A H1-2009), and a negative control should also be run to test for PCR-product contamination. If the BioFire RP2.1 accurately identifies the external and negative controls, contact the appropriate public health authorities for confirmatory testing.

BioFire RP2.1 Test Report

The BioFire RP2.1 test report is automatically displayed upon completion of a run and can be printed or saved as a PDF file. Each report contains a Run Summary, a Result Summary, and a Run Details section.

BioFire®
Respiratory Panel 2.1

BIOFIRE

www.BioFireDx.com

Run Summary			
Sample ID:	RP2.1example	**Run Date:**	04 April 2020 5:21 PM
Detected:	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)	**Controls:**	Passed
Equivocal:	↔ Influenza A		

Result Summary

Viruses	
Not Detected	Adenovirus
Not Detected	Coronavirus 229E
Not Detected	Coronavirus HKU1
Not Detected	Coronavirus NL63
Not Detected	Coronavirus OC43
✓ Detected	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Not Detected	Human Metapneumovirus
Not Detected	Human Rhinovirus/Enterovirus
↔ Equivocal	Influenza A
Not Detected	Influenza B
Not Detected	Parainfluenza Virus 1
Not Detected	Parainfluenza Virus 2
Not Detected	Parainfluenza Virus 3
Not Detected	Parainfluenza Virus 4
Not Detected	Respiratory Syncytial Virus

Bacteria	
Not Detected	*Bordetella parapertussis* (IS1001)
Not Detected	*Bordetella pertussis* (ptxP)
Not Detected	*Chlamydia pneumoniae*
Not Detected	*Mycoplasma pneumoniae*

Run Details			
Pouch:	RP2.1 v1.0	**Protocol:**	NPS2 v3.2
Run Status:	Completed	**Operator:**	JDoe
Serial No.:	01234567	**Instrument:**	TM8CCF3
Lot No.:	012345		

Run Summary

The Run Summary section of the test report provides the Sample ID, time and date of the run, control results and an overall summary of the test results. Any organism with a Detected result will be listed in the corresponding field of the summary. If all of the organism assays were negative then 'None' will be displayed in the Detected field. Controls are listed as Passed, Failed, or Invalid. Table 3 provides additional information for each of the possible control field results.

Table 3. Interpretation of Controls Field on the BioFire RP2.1 Test Report

Control Result	Explanation	Action
Passed	The run was successfully completed AND Both pouch controls were successful.	None Report the results provided on the test report
Failed	The run was successfully completed BUT At least one of the pouch controls (RNA Process Control and/or PCR2 Control) failed.	Repeat the test using a new pouch. If the error persists, contact Technical Support for further instruction.
Invalid	The controls are invalid because the run did not complete. (Typically this indicates a software or hardware error).	Note any error codes displayed during the run and the Run Status field in the Run Details section of the report. Refer to the appropriate FilmArray operator's manual or contact Technical Support for further instruction. Once the error is resolved, repeat the test or repeat the test using another instrument.

Result Summary

The Result Summary section of the test report lists the result for each target tested by the panel. Possible results for each organism are Detected, Not Detected, or Invalid (Equivocal is also a possible result for Influenza A and its subtypes). Table 4 provides an explanation for each interpretation and any follow-up necessary to obtain a final result.

Table 4. Reporting of Results and Required Actions

Result	Explanation	Action
Detected[a]	The run was successfully completed AND The pouch controls were successful (Passed) AND The assay(s) for the organism were POSITIVE (i.e., met the requirements for a positive result described in the Assay Interpretation section above)	Report results.
Not Detected	The run was successfully completed AND The pouch controls were successful (Passed) AND The assay(s) for the organism were NEGATIVE (i.e., did not meet the requirements for a positive result described in the Assay Interpretation section above)	Report results.
Equivocal	The run was successfully completed AND The pouch controls were successful (Passed) AND The combination of positive and negative assay results for Influenza A were inconclusive (see Table 2)	Retest the original specimen and report the result. If the result of the retest is again 'Equivocal', the final result should be considered 'Detected'.
Invalid	The pouch controls were not successful (Failed) OR The run was not successful (Run Status displayed as: Aborted, Incomplete, Instrument Error or Software Error)	See Table 3 , Interpretation of Control Field on the FilmArray Test Report for instruction.

[a] If four or more organisms are detected in a specimen, retesting is recommended to confirm the polymicrobial result.

Run Details

The **Run Details** section provides additional information about the run including: pouch information (type, lot number, and serial number), Run Status (Completed, Incomplete, Aborted, Instrument Error, or Software Error), the protocol that was used to perform the test, the identity of the operator that performed the test, and the instrument used to perform the test.

Change Summary

It is possible to edit the Sample ID once a run has completed. If this information has been changed, an additional section called **Change Summary** will be added to the test report. This Change Summary section lists the field that was changed, the original entry, the revised entry, the operator that made the change, and the date that the change was made. Sample ID is the only field of the report that can be changed.

Change Summary				
Field	**Changed To**	**Changed From**	**Operator**	**Date**
[1]Sample ID	New Example Id	Old Example Id	Anonymous	06 Apr 2020

LIMITATIONS

1. For prescription use only.
2. The use of this assay as an *in vitro* diagnostic under US FDA Emergency Use Authorization (EUA) is limited to laboratories that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high and moderate complexity tests.
3. BioFire RP2.1 performance has only been established on the BioFire FilmArray 2.0 and BioFire FilmArray Torch systems.
4. The BioFire RP2.1 is a qualitative test and does not provide a quantitative value for the organism(s) in the specimen.
5. Results from this test must be correlated with the clinical history, epidemiological data, and other data available to the clinician evaluating the patient.
6. The performance of the BioFire RP2.1 has been evaluated for use with human specimen material only.
7. The BioFire RP2.1 has not been validated for testing of specimens other than nasopharyngeal swab (NPS) specimens in transport medium.
8. The performance of BioFire RP2.1 has not been established for specimens collected from individuals without signs or symptoms of respiratory infection.
9. The performance of the BioFire RP2.1 has not been specifically evaluated for NPS specimens from immunocompromised individuals.
10. The effect of antibiotic treatment on test performance has not been evaluated.
11. The performance of the BioFire RP2.1 has not been established with potentially interfering medications for the treatment of influenza or cold viruses. The effect of interfering substances has only been evaluated for those listed in the *Interference* section. Interference from substances that were not evaluated could lead to erroneous results.
12. The performance of the BioFire RP2.1 has not been established for monitoring treatment of infection with any of the panel organisms.
13. The performance of BioFire RP2.1 has not been established for screening of blood or blood products.
14. The detection of viral and bacterial nucleic acid is dependent upon proper specimen collection, handling, transportation, storage and preparation. Failure to observe proper procedures in any one of these steps can lead to incorrect results. There is a risk of false positive or false negative values resulting from improperly collected, transported or handled specimens.
15. A negative BioFire RP2.1 result does not exclude the possibility of viral or bacterial infection. Negative test results may occur from the presence of sequence variants (or mutation) in the region targeted by the assay, the presence of inhibitors, technical error, sample mix-up, an infection caused by an organism not detected by the panel, or lower respiratory tract infection that is not detected by a nasopharyngeal swab specimen. Test results may also be affected by concurrent antiviral/antibacterial therapy or levels of organism in the specimen that are below the limit of detection for the test. Negative results should not be used as the sole basis for diagnosis, treatment, or other patient management decisions.
16. If four or more organisms are detected in a specimen, retesting is recommended to confirm the polymicrobial result.

17. Viral and bacterial nucleic acids may persist *in vivo* independent of organism viability. Detection of organism target(s) does not imply that the corresponding organisms are infectious or are the causative agents for clinical symptoms.
18. Positive and negative predictive values are highly dependent on prevalence. False negative test results are more likely during peak activity when prevalence of disease is high. False positive test results are more likely during periods when prevalence is moderate to low.
19. Performance characteristics for Influenza A were established when Influenza A H1-2009, A H1, and A H3 were the predominant Influenza A viruses in circulation. Performance of detecting Influenza A may vary if other Influenza A strains are circulating or a novel Influenza A virus emerges.
20. Due to the small number of positive specimens collected for certain organisms during the prospective clinical study, performance characteristics for *Bordetella parapertussis, Bordetella pertussis, Chlamydia pneumoniae,* Coronavirus 229E, Influenza A H1, Influenza A H3, Influenza B, Parainfluenza Virus 1, and Parainfluenza Virus 4 were established primarily with retrospective clinical specimens. Performance characteristics for Influenza A H1 was established primarily using contrived clinical specimens.
21. The BioFire RP2.1 influenza A subtyping assays target the influenza A hemagglutinin (H) gene only. The BioFire RP2.1 does not detect or differentiate the influenza A neuraminidase (N) subtypes.
22. The BioFire RP2.1 may not be able to distinguish between existing viral strains and new variants as they emerge. For example, the BioFire RP2.1 can detect Influenza A H3N2v (first recognized in August, 2011), but will not be able to distinguish this variant from Influenza A H3N2 seasonal. If variant virus infection is suspected, clinicians should contact their state or local health department to arrange specimen transport and request a timely diagnosis at a state public health laboratory.
23. Recent administration of nasal influenza vaccines (e.g. FluMist) prior to NPS specimen collection could lead to accurate virus detection by the BioFire RP2.1 of the viruses contained in the vaccine, but would not represent infection by those agents
24. Due to the genetic similarity between Human Rhinovirus and Enterovirus, the BioFire RP2.1 cannot reliably differentiate them. A BioFire RP2.1 Rhinovirus/Enterovirus Detected result should be followed-up using an alternate method (e.g. cell culture or sequence analysis) if differentiation between the viruses is required.
25. BioFire RP2.1 detects a single-copy Pertussis Toxin promoter target (*ptxP*, present at one copy per cell) in *B. pertussis*. Other PCR tests for *B. pertussis* target the multi-copy IS*481* insertion sequence (present in both *B. pertussis* and *B. holmesii*) and are therefore capable of detecting lower levels of *B. pertussis* (i.e. more sensitive).
    - BioFire RP2.1 should not be used if *B. pertussis* infection is specifically suspected; a *B. pertussis* molecular test that is FDA-cleared for use on patients suspected of having a respiratory tract infection attributable to *B. pertussis* only should be used instead.
    - Due to lower sensitivity, the BioFire RP2.1 *B. pertussis* assay is less susceptible than IS*481* assays to the detection of very low levels of contaminating *B. pertussis* vaccine material. However, care must always be taken to avoid contamination of specimens with vaccine material as higher levels may still lead to false positive results with the BioFire RP2.1 test (see contamination prevention guidelines).
    - The IS*481* sequence is also present in *B. holmesii* and to a lesser extent in *B. bronchiseptica*, whereas the BioFire RP2.1 assay (*ptxP*) was designed to be specific for *B. pertussis*. However, the BioFire RP2.1 *Bordetella pertussis* (*ptxP*) assay can also amplify pertussis toxin pseudogene sequences when present in *B. bronchiseptica* and *B. parapertussis*. Cross-reactivity was observed only at high concentration (e.g. ≥1.2E+09 CFU/mL).

26. There is a risk of false positive results due to cross-contamination with organisms, nucleic acids or amplified products. Particular attention should be given to the Laboratory Precautions noted under the *Warnings and Precautions* section.
27. Primers for both BioFire RP2.1 SARS-CoV-2 assays share substantial sequence homology with the Bat coronavirus RaTG13 (accession: MN996532) and cross-reactivity with this closely-related viral sequence is predicted. In addition, the SARSCoV2-2 assay may cross-react with Pangolin coronavirus (accession: MT084071) and two other bat SARS-like coronavirus sequences (accession MG772933 and MG772934). It is unlikely that these viruses would be found in a human clinical nasopharyngeal swab; but if present, the cross-reactive product(s) produced by the BioFire RP2.1 will be detected as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
28. There is a risk of false positive results for *Bordetella* species and Human Rhinovirus/Enterovirus due to non-specific amplification and cross-reactivity with organisms that can be found in the respiratory tract. Observed and predicted cross-reactivity for BioFire RP2.1 is described in the *Analytical Specificity* section. Erroneous results due to cross-reactivity with organisms that were not evaluated or new variant sequences that emerge is also possible.
29. Some strains of *B. bronchiseptica* (rarely isolated from humans) do carry IS*1001* insertion sequences identical to those carried by most strains of *B. parapertussis*. These sequences will be amplified by the IS1001 assay and reported by BioFire RP2.1 as *Bordetella parapertussis* (IS*1001*).
30. The BioFire RP2.1 Human Rhinovirus/Enterovirus assay may amplify off-target sequences found in strains of *B. pertussis, B. bronchiseptica* and *B. parapertussis*. Cross-reactivity with *B. pertussis* was observed at a concentration of ≥4.5E+07 CFU/mL.

CONDITIONS OF AUTHORIZATION FOR THE LABORATORY

The BioFire RP2.1 Letter of Authorization, along with the authorized Fact Sheet for Healthcare Providers, the authorized Fact Sheet for Patients, and authorized labeling are available on the FDA website: https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations#covid19ivd.

However, to assist clinical laboratories using the BioFire RP2.1 ("your product" in the conditions below), the relevant Conditions of Authorization are listed below:

- Authorized laboratories* using your product will include with result reports of your product, all authorized Fact Sheets. Under exigent circumstances, other appropriate methods for disseminating these Fact Sheets may be used, which may include mass media.
- Authorized laboratories using your product will use your product as outlined in the Instructions for Use. Deviations from the authorized procedures, including the authorized instruments, authorized extraction methods, authorized clinical specimen types, authorized control materials, authorized other ancillary reagents, and authorized materials required to use your product are not permitted.
- Authorized laboratories that receive your product will notify the relevant public health authorities of their intent to run your product prior to initiating testing.
- Authorized laboratories using your product will have a process in place for reporting test results to healthcare providers and relevant public health authorities, as appropriate.
- Authorized laboratories will collect information on the performance of your product and report to DMD/OHT7-OIR/OPEQ/CDRH (via email: CDRH-EUA-Reporting@fda.hhs.gov) and You (support@BioFireDX.com) any suspected occurrence of false positive or false negative results and

significant deviations from the established performance characteristics of your product of which they become aware.

- All laboratory personnel using your product must be appropriately trained in performing and interpreting the results of your product, use appropriate personal protective equipment when handling this kit, and use your product in accordance with the authorized labeling.
- BioFire Diagnostics, LLC, authorized distributors, and authorized laboratories using your product will ensure that any records associated with this EUA are maintained until otherwise notified by FDA. Such records will be made available to FDA for inspection upon request.

* The letter of authorization refers to, "Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high or moderate complexity tests" as "authorized laboratories."

BIOFIRE RP2 AND RP2.1

The BioFire RP2.1 (Ref #: 423738) was developed by adding the reagents required to detect the SARS-CoV-2 targets into the existing BioFire RP2 (Ref #: RFIT-ASY-0129, RFIT-ASY-0130). Assays for all analytes shared between the two panels and reaction conditions of the test were unchanged from BioFire RP2. Studies were performed to demonstrate the performance of the new SARS-CoV-2 assays and to demonstrate that the performance characteristics of the assays from BioFire RP2 are unaffected by the panel modification. The original studies of the BioFire RP2 remain relevant for the performance of the BioFire RP2.1.

EXPECTED VALUES

In the prospective clinical evaluation of the BioFire RP2, 1612 eligible specimens (NPS), including 918 prospective fresh (Category I) specimens and 694 prospective archived/frozen (Category II) specimens, were collected and tested at three study sites across the United States over approximately six months (January – March and September – November 2016). Expected value (as determined by BioFire RP2) summaries for Category I and II specimens respectively, stratified by specimen collection site are presented in Table 5 and Table 6.

NOTE: Expected values for SARS-CoV-2 have not been determined.

Table 5. Expected Value (As Determined by BioFire RP2) Summary by Collection Site for the BioFire RP2 Prospective Clinical Evaluation (Category I Fresh Prospective Specimens) (September 2016 – November 2016)

	Overall (n=918)		Site 1 (n=331) Salt Lake City, UT		Site 2 (n=284) Chicago, IL		Site 3 (n=303) Columbus, OH	
	No.	Expected Value (%)	No.	Expected Value (%)	No.	Expected Value (%)	No.	Expected Value (%)
Viruses								
Adenovirus	66	7.2%	25	7.6%	7	2.5%	34	11.2%
CoV- 229E	9	1.0%	4	1.2%	5	1.8%	0	0%
CoV-HKU1	1	0.1%	0	0%	1	0.4%	0	0%
CoV-NL63	1	0.1%	0	0%	0	0%	1	0.3%
CoV-OC43	12	1.3%	4	1.2%	1	0.4%	7	2.3%
hMPV	5	0.5%	2	0.6%	2	0.7%	1	0.3%
HRV/EV	378	41.2%	146	44.1%	69	24.3%	163	53.8%
Influenza A	3	0.3%	2	0.6%	0	0%	1	0.3%
Influenza A H1	0	0%	0	0%	0	0%	0	0%
Influenza A 2009-H1	0	0%	0	0%	0	0%	0	0%
Influenza A H3	3	0.3%	2	0.6%	0	0%	1	0.3%
Influenza B	0	0%	0	0%	0	0%	0	0%

Parainfluenza Virus 1	5	0.5%	3	0.9%	2	0.7%	0	0%
Parainfluenza Virus 2	54	5.9%	8	2.4%	13	4.6%	33	10.9%
Parainfluenza Virus 3	49	5.3%	20	6.0%	13	4.6%	16	5.3%
Parainfluenza Virus 4	8	0.9%	3	0.9%	1	0.4%	4	1.3%
RSV	50	5.4%	9	2.7%	5	1.8%	36	11.9%
Bacteria								
Bordetella parapertussis (IS1001)	4	0.4%	0	0%	0	0%	4	1.3%
Bordetella pertussis (ptxP)	3	0.3%	1	0.3%	0	0%	2	0.7%
Chlamydia pneumoniae	3	0.3%	1	0.3%	0	0%	2	0.7%
Mycoplasma pneumoniae	21	2.3%	2	0.6%	7	2.5%	12	4.0%

Table 6. Expected Value (As Determined by BioFire RP2) Summary by Collection Site for the BioFire RP2 Prospective Clinical Evaluation (Category II Archived Prospective Specimens) (January 2016 – March 2016)

	Overall (n=694)		Site 1 (n=250) Salt Lake City, UT		Site 2 (n=243) Chicago, IL		Site 3 (n=201) Columbus, OH	
	No.	Expected Value (%)	No.	Expected Value (%)	No.	Expected Value (%)	No.	Expected Value (%)
Viruses								
Adenovirus	52	7.5%	18	7.2%	20	8.2%	14	7.0%
CoV- 229E	7	1.0%	2	0.8%	3	1.2%	2	1.0%
CoV-HKU1	54	7.8%	28	11.2%	16	6.6%	10	5.0%
CoV-NL63	49	7.1%	24	9.6%	17	7.0%	8	4.0%
CoV-OC43	26	3.7%	8	3.2%	10	4.1%	8	4.0%
hMPV	76	11.0%	26	10.4%	25	10.3%	25	12.4%
HRV/EV	124	17.9%	43	17.2%	44	18.1%	37	18.4%
Influenza A	75	10.8%	9	3.6%	27	11.1%	38	18.9%
Influenza A H1	0	0%	0	0%	0	0%	0	0%
Influenza A 2009-H1	74	10.7%	9	3.6%	27	11.1%	38	18.9%
Influenza A H3	1	0.1%	0	0%	0	0%	1	0.5%
Influenza B	16	2.3%	3	1.2%	7	2.9%	6	3.0%
Parainfluenza Virus 1	5	0.7%	2	0.8%	2	0.8%	1	0.5%
Parainfluenza Virus 2	0	0%	0	0	0	0%	0	0%
Parainfluenza Virus 3	4	0.6%	2	0.8%	0	0%	2	1.0%
Parainfluenza Virus 4	8	1.2%	4	1.6%	2	0.8%	2	1.0%
RSV	149	21.5%	59	23.6%	51	21.0%	39	19.4%
Bacteria								
Bordetella parapertussis (IS*1001*)	2	0.3%	1	0.4%	1	0.4%	0	0%
Bordetella pertussis (*ptxP*)	0	0%	0	0%	0	0%	0	0%
Chlamydia pneumoniae	3	0.4%	0	0%	2	0.8%	1	0.5%
Mycoplasma pneumoniae	7	1.0%	3	1.2%	4	1.6%	0	0%

Expected value (as determined by BioFire RP2) summary by age group for the BioFire RP2 prospective clinical evaluation (Category I and II prospective specimens combined) (January – March and September – November 2016 and) is presented in Table 7.

Table 7. Expected Value (As Determined by BioFire RP2) Summary by Age Group for the BioFire RP2 Prospective Clinical Evaluation (Category I and II Prospective Specimens) (January – March and September – November 2016)

	Overall (N=1612)		≤5 years (N=885)		6-21 years (N=331)		22-49 years (N=128)		50+ years (N=268)	
Viruses										
Adenovirus	118	7.3%	96	10.8%	18	5.4%	2	1.6%	2	0.7%
CoV- 229E	16	1.0%	3	0.3%	7	2.1%	1	0.8%	5	1.9%
CoV-HKU1	55	3.4%	37	4.2%	9	2.7%	2	1.6%	7	2.6%

CoV-NL63	50	3.1%	41	4.6%	6	1.8%	2	1.6%	1	0.4%
CoV-OC43	38	2.4%	28	3.2%	7	2.1%	0	0%	3	1.1%
hMPV	81	5.0%	60	6.8%	12	3.6%	3	2.3%	6	2.2%
HRV/EV	502	31.1%	379	42.8%	88	26.6%	16	12.5%	19	7.1%
Influenza A	78	4.8%	29	3.3%	20	6.0%	13	10.2%	16	6.0%
Influenza A H1	0	0%	0	0%	0	0%	0	0%	0	0%
Influenza A 2009-H1	74	4.6%	26	2.9%	19	5.7%	13	10.2%	16	6.0%
Influenza A H3	4	0.2%	3	0.3%	1	0.3%	0	0%	0	0%
Influenza B	16	1.0%	7	0.8%	7	2.1%	1	0.8%	1	0.4%
Parainfluenza Virus 1	10	0.6%	9	1.0%	0	0%	1	0.8%	0	0%
Parainfluenza Virus 2	54	3.3%	39	4.4%	10	3.0%	1	0.8%	4	1.5%
Parainfluenza Virus 3	53	3.3%	44	5.0%	6	1.8%	2	1.6%	1	0.4%
Parainfluenza Virus 4	16	1.0%	13	1.5%	1	0.3%	0	0%	2	0.7%
RSV	199	12.3%	168	19.0%	10	3.0%	8	6.3%	13	4.9%
Bacteria										
Bordetella parapertussis (IS*1001*)	6	0.4%	4	0.5%	2	0.6%	0	0%	0	0%
Bordetella pertussis (*ptxP*)	3	0.2%	0	0%	3	0.9%	0	0%	0	0%
Chlamydia pneumoniae	6	0.4%	1	0.1%	4	1.2%	1	0.8%	0	0%
Mycoplasma pneumoniae	28	1.7%	10	1.1%	14	4.2%	3	2.3%	1	0.4%

In addition, the most common multiple detections (as determined by BioFire RP2) during the BioFire RP2 prospective clinical evaluation (Category I and II prospective specimens combined) (January – March and September – November 2016 and), stratified by age group, is presented in Table 8. Overall, the BioFire RP2 detected at least one organism in a total of 1020 specimens (63.3% positivity rate; 1020/1612). Two or more organisms were detected by the BioFire RP2 in 24.0% of positive specimens (245/1020; 15.2% of all tested specimens, 245/1612).

Table 8. Expected Value (Multiple Detections with ≥ 5 occurrences as Determined by the BioFire RP2) Summary by Age Group for the Prospective Clinical Evaluation (January – March and September – November 2016)

Multiple Detection Combination	Overall (N=1612)	≤5 years (N=885)	6-21 years (N=331)	22-49 years (N=128)	50+ years (N=268)
Adenovirus + HRV/EV	30 (1.9%)	27 (3.1%)	3 (0.9%)	0 (0%)	0 (0%)
HRV/EV + RSV	22 (1.4%)	22 (2.5%)	0 (0%)	0 (0%)	0 (0%)
CoV-HKU1 + RSV	13 (0.8%)	12 (1.4%)	0 (0%)	0 (0%)	1 (0.4%)
CoV-NL63 + RSV	13 (0.8%)	12 (1.4%)	0 (0%)	0 (0%)	1 (0.4%)
HRV/EV + PIV2	11 (0.7%)	9 (1.0%)	1 (0.3%)	0 (0%)	1 (0.4%)
HRV/EV + PIV3	11 (0.7%)	10 (1.1%)	1 (0.3%)	0 (0%)	0 (0%)
Adenovirus + RSV	10 (0.6%)	8 (0.9%)	2 (0.6%)	0 (0%)	0 (0%)
Adenovirus + HRV/EV + RSV	9 (0.6%)	9 (1.0%)	0 (0%)	0 (0%)	0 (0%)
CoV-NL63 + HRV/EV	8 (0.5%)	7 (0.8%)	1 (0.3%)	0 (0%)	0 (0%)
CoV-HKU1 + HRV/EV	5 (0.3%)	3 (0.3%)	2 (0.6%)	0 (0%)	0 (0%)
CoV-OC43 + HRV/EV	5 (0.3%)	5 (0.6%)	0 (0%)	0 (0%)	0 (0%)
hMPV + HRV/EV	5 (0.3%)	5 (0.6%)	0 (0%)	0 (0%)	0 (0%)

PERFORMANCE CHARACTERISTICS

Clinical Performance of the BioFire RP2.1 SARS-CoV-2 and BioFire RP2 Assays

A three arm clinical evaluation was conducted to evaluate the performance of the new BioFire RP2.1 SARS-CoV-2 assays and to demonstrate equivalent performance of all other assays relative to the BioFire RP2 when testing clinical specimens.

The first arm involved testing of 50 archived NPS specimens that had previously been characterized as positive for SARS-CoV-2. Specimens were obtained from three geographically distinct laboratories in the United States (Table 9).

Table 9. Archived Source and Identification Methods

Site	Location	Positive Samples Tested	Sample ID Method
Site 1	Salt Lake City, Utah	15	Panther Fusion® SARS-CoV-2 (Hologic, Inc.; EUA)
Site 2	Seattle, Washington	15	Laboratory Developed Test (LDT) based on CDC N1 and N2 EUA assays (Washington State EUA)
Site 3	Omaha, Nebraska	20	cobas® SARS-CoV-2 (Roche Molecular Systems; EUA)

Positive specimens were randomized and tested alongside 50 NPS specimens that were collected before December 2019; i.e. expected to be negative for SARS-CoV-2. Positive Percent Agreement (PPA) was determined by comparing the observed test result to the expected test result based on previous laboratory testing, and Negative Percent Agreement (NPA) was determined by comparing the observed test result for SARS-CoV-2 negative specimens to the expected result of Not Detected. In the course of testing, two specimens (one positive and one negative) were excluded due to instrument errors. Results from the remaining 98 evaluable specimens are shown in (Table 10). For SARS-CoV-2 archived specimens the PPA was 98% (48/49) and NPA was 100%.

Table 10. BioFire RP2.1 SARS-CoV-2 Archived NPS Specimen Performance Data Summary

Agreement with known analyte composition						
Comparator Method	**PPA: TP/(TP+FN)**	**%**	**95% CI**	**NPA: TN/(TN+FP)**	**%**	**95% CI**
Panther Fusion® SARS-CoV-2 (Hologic, Inc.)	14/15[1]	93.3	[70.2-98.8%]	N/A	N/A	N/A
LDT based on CDC N1 and N2 EUA assays	15/15	100	[79.6-100%]	N/A	N/A	N/A
cobas® SARS-CoV-2 (Roche Molecular Systems)	20/20	100	[83.9-100%]	N/A	N/A	N/A
Negative Specimens	N/A	NA	N/A	49/49	100	[92.7 – 100%]
Overall Agreement	**48/49[1]**	**98**	**[89.3 – 99.6%]**	**49/49**	**100**	**[92.7 – 100%]**

[1] One FN specimen was positive upon retest

Notably, of the 48 specimens with SARS-CoV-2 Detected results, 10.4% (5/48) had other analytes identified by the BioFire RP2.1 (Table 11).

Table 11. Additional Analytes identified by BioFire RP2.1 in 48 specimens with SARS-CoV-2 Detected Results

Additional Analytes	Number Observed (%)
Adenovirus	1 (2.1%)
HRV/EV	4 (8.3%)

Archived clinical specimens testing was complemented with testing of 50 contrived clinical specimens spiked with inactivated SARS-CoV-2 isolate USA-WA1/2020 at various levels of LoD (25 at 2× LoD, 15 at 3× LoD, and 10 at 5× LoD) and randomized with ten non-spiked specimens. Each specimen was a unique NPS specimen which had been collected before December 2019 and was therefore expected to be negative for SARS-CoV-2. PPA was determined by comparing the observed test results for samples contrived in unique clinical specimens to the expected Detected result. PPA and NPA are shown in Table 12. For SARS-CoV-2 contrived testing, both the PPA and NPA were 100%.

Table 12. Contrived SARS-CoV-2 Testing with the BioFireRP2.1

	Agreement with known analyte composition			
	PPA: TP/(TP+FN)	**%**	**NPA:** TN/(TN+FP)	**%**
Overall Agreement	50/50	100%	10/10	100%
95% CI	**[92.9 – 100%]**		**[72.2-100%]**	

The final arm was a clinical comparison study between the BioFire RP2 and modified BioFire RP2.1 using 220 archived clinical specimens. Archived specimens were chosen solely based on the analyte content. Analyte level, if known, was not used for specimen selection. Specimens were split for testing side-by-side with each test. This comparison of archived specimens demonstrates equivalent performance between the BioFire RP2 and BioFire RP2.1 for shared analytes with 97.6% PPA and 99.8% NPA overall (Table 13).

Table 13. Performance Comparison of the Modified BioFire RP2.1 to the Original BioFire RP2 using Archived Specimens

Analyte	RP2.1+ RP2+	RP2.1- RP2+	PPA	RP2.1- RP2-	RP2.1+ RP2-	NPA
Viruses						
Adenovirus	14	1	93.3%	203	2	99%
Coronavirus 229E	10	1	90.9%	209	0	100%
Coronavirus HKU1	10	0	100%	208	2	99%
Coronavirus NL63	10	0	100%	210	0	100%
Coronavirus OC43	10	0	100%	210	0	100%
Human Metapneumovirus	12	0	100%	208	0	100%
Human Rhinovirus/Enterovirus	19	3	86.4%	195	3	98.5%
Influenza A	30	0	100%	180	0	100%
Influenza A H1	5	0	100%	215	0	100%
Influenza A H1-2009	12	0	100%	208	0	100%
Influenza A H3	13	0	100%	207	0	100%
Influenza B	10	0	100%	210	0	100%
Parainfluenza Virus 1	9	0	100%	211	0	100%
Parainfluenza Virus 2	11	0	100%	209	0	100%
Parainfluenza Virus 3	10	1	90.9%	208	1	99.5%
Parainfluenza Virus 4	11	0	100%	209	0	100%
Respiratory Syncytial Virus	10	0	100%	210	0	100%
Bacteria						
***Bordetella parapertussis* (IS*1001*)**	10	0	100%	210	0	100%
***Bordetella pertussis* (*ptxP*)**	10	0	100%	210	0	100%

Analyte	RP2.1+ RP2+	RP2.1- RP2+	PPA	RP2.1- RP2-	RP2.1+ RP2-	NPA
Chlamydia pneumoniae	10	0	100%	210	0	100%
Mycoplasma pneumoniae	10	0	100%	210	0	100%
Overall	***246***	***6***	***97.6%***	***4350***	***8***	***99.8%***

All 220 specimens tested in the clinical comparison study were collected before December 2019 and were evaluated for SARS-CoV-2 specificity. This data is summarized in Table 14 along with the specificity values from the other studies. Overall NPA (specificity) for all three studies was 279/279 (100%; Table 14).

Table 14. Overall BioFire RP2.1 NPA (Specificity) for SARS-CoV-2

	NPA: TN/(TN+FP)	%	95% CI
Archived Specimens	49/49	100%	[92.7 - 100%]
Contrived Specimens	10/10	100%	[72.2 - 100%]
Comparison Specimens	220/220	100%	[98.3 - 100%]
Overall	**279/279**	**100%**	**[98.6 - 100%]**

Clinical Performance of BioFire RP2

Prospective Clinical Evaluation of BioFire RP2

The clinical performance of the BioFire RP2 was established during a multi-center study conducted at three geographically distinct U.S. study sites during portions of the 2015-2016 and 2016-2017 respiratory illness seasons. A total of 1635 residual NPS specimens in viral transport media (VTM) were acquired for the prospective clinical study. Between January and March 2016, specimens were prospectively collected from all comers meeting the study eligibility criteria and immediately frozen (N=695 specimens) for later testing as prospective archived/frozen (Category II) specimens. Between September and November 2016, specimens were prospectively collected from all comers meeting the study eligibility criteria and tested fresh (N=940 specimens) as prospective fresh (Category I) specimens. Category II specimens were distributed to study sites beginning in September 2016. Study sites also began testing Category I specimens at this time. At each site, Category II specimens were thawed and tested according to the study procedures as time permitted over the remaining duration of the clinical study. A total of 23 prospective specimens (Category I and II specimens) were excluded from the final performance data analysis due to incompliance with the study protocol. The most common reasons for specimen exclusion were that a valid external control was not completed on the day of testing, that specimens were tested outside the 3-day refrigerated storage window, or that the specimen was found to not meet the inclusion criteria after the specimen had been enrolled. The final data set consisted of 1612 prospective specimens. Table 15 provides a summary of demographic information for the 1612 specimens included in the prospective study.

Table 15. Demographic Summary for Prospective BioFire RP2 Clinical Evaluation

		Overall	Site 1	Site 2	Site 3
Sex	Male	867 (54%)	331 (57%)	271 (51%)	265 (53%)
	Female	745 (46%)	250 (43%)	256 (49%)	239 (47%)
Age	≤ 5 years	885 (55%)	379 (65%)	170 (32%)	336 (67%)
	6 - 21 years	331 (21%)	132 (23%)	89 (17%)	110 (22%)
	22 - 49 years	128 (8%)	27 (5%)	79 (15%)	22 (4%)
	50+ years	268 (17%)	43 (7%)	189 (36%)	36 (7%)
Status	Outpatient	329 (20%)	77 (13%)	66 (13%)	186 (37%)
	Hospitalized	640 (40%)	229 (39%)	197 (37%)	214 (42%)
	Emergency	643 (40%)	275 (47%)	264 (50%)	104 (21%)
Total		**1612**	**581**	**527**	**504**

The performance of the BioFire RP2 was evaluated by comparing the BioFire RP2 test results with those from an FDA-cleared multiplexed respiratory pathogen panel (the main comparator method) as well as with results from two analytically-validated PCR assays followed by bi-directional sequencing for *B. parapertussis* (this analyte is not detected by the FDA-cleared multiplexed respiratory pathogen panel). The *B. parapertussis* comparator assays were designed to amplify a different sequence than that amplified by the BioFire RP2. Any specimen that had bi-directional sequencing data meeting pre-defined quality acceptance criteria that matched organism-specific sequences deposited in the NCBI GenBank database (www.ncbi.nlm.nih.gov) with acceptable E-values was considered Positive. Any specimen that tested negative by both of the comparator assays was considered Negative.

Positive Percent Agreement (PPA) for each analyte was calculated as 100% x (TP / (TP + FN)). True positive (TP) indicates that both the BioFire RP2 and the comparator method had a positive result for this specific analyte, and false negative (FN) indicates that the BioFire RP2 result was negative while the comparator result was positive. Negative Percent Agreement (NPA) was calculated as 100% x (TN / (TN + FP)). True negative (TN) indicates that both the BioFire RP2 and the comparator method had negative results, and a false positive (FP) indicates that the BioFire RP2 result was positive but the comparator result was negative. The exact binomial two-sided 95% confidence interval was calculated. Samples for which false positive and/or false negative results (i.e., discrepant results) were obtained when comparing the BioFire RP2 results to the comparator method results were further investigated. The discrepancy investigation was mainly conducted by performing independent molecular methods with primers that are different from that of the BioFire RP2 and/or comparator method retesting. The prospective clinical study results are summarized in Table 16.

Table 16. BioFire RP2 Prospective Clinical Performance Summary

Analyte		Positive Percent Agreement			Negative Percent Agreement		
		TP/(TP + FN)	%	95%CI	TN/(TN + FP)	%	95%CI
Viruses							
Adenovirus[a]	Fresh	36/38	94.7	82.7-98.5	850/880	96.6	95.2-97.6
	Frozen	34/36	94.4	81.9-98.5	640/658	97.3	95.7-98.3
	Overall	***70/74***	***94.6***	***86.9-97.9***	***1490/1538***	***96.9***	***95.9-97.6***
CoV-229E[b]	Fresh	5/5	100	56.6-100	909/913	99.6	98.9-99.8
	Frozen	6/7	85.7	48.7-97.4	686/687	99.9	99.2-100
	Overall	***11/12***	***91.7***	***64.6-98.5***	***1595/1600***	***99.7***	***99.3-99.9***
CoV-HKU1[c]	Fresh	1/1	100	-	917/917	100	99.6-100
	Frozen	42/42	100	91.6-100	640/652	98.2	96.8-98.9
	Overall	***43/43***	***100***	***91.8-100***	***1557/1569***	***99.2***	***98.7-99.6***

Analyte		Positive Percent Agreement			Negative Percent Agreement		
		TP/(TP + FN)	%	95%CI	TN/(TN + FP)	%	95%CI
CoV-NL63[d]	Fresh	0/0	-	-	917/918	99.9	99.4-100
	Frozen	40/40	100	91.2-100	645/654	98.6	97.4-99.3
	Overall	***40/40***	***100***	***91.2-100***	***1562/1572***	***99.4***	***98.8-99.7***
CoV-OC43[e]	Fresh	11/13	84.6	57.8-95.7	904/905	99.9	99.4-100
	Frozen	22/28	78.6	60.5-89.8	662/666	99.4	98.5-99.8
	Overall	***33/41***	***80.5***	***66.0-89.8***	***1566/1571***	***99.7***	***99.3-99.9***
hMPV[f]	Fresh	5/5	100	56.6-100	913/913	100	99.6-100
	Frozen	68/70	97.1	90.2-99.2	616/624	98.7	97.5-99.3
	Overall	***73/75***	***97.3***	***90.8-99.3***	***1529/1537***	***99.5***	***99.0-99.7***
HRV/EV[g]	Fresh	320/328	97.6	95.3-98.8	532/590	90.2	87.5-92.3
	Frozen	105/108	97.2	92.1-99.1	567/586	96.8	95.0-97.9
	Overall	***425/436***	***97.5***	***95.5-98.6***	***1099/1176***	***93.5***	***91.9-94.7***
FluA[h]	Fresh	3/3	100	43.9-100	915/915	100	99.6-100
	Frozen	75/75	100	95.1-100	616/616	100	99.4-100
	Overall	***78/78***	***100***	***95.3-100***	***1531/1531***	***100***	***99.7-100***
FluA H1	Fresh	0/0	-	-	918/918	100	99.6-100
	Frozen	0/0	-	-	691/691	100	99.4-100
	Overall	***0/0***	***-***	***-***	***1609/1609***	***100***	***99.8-100***
FluA H1-2009	Fresh	0/0	-	-	918/918	100	99.6-100
	Frozen	74/74	100	95.1-100	617/617	100	99.4-100
	Overall	***74/74***	***100***	***95.1-100***	***1535/1535***	***100***	***99.8-100***
FluA H3	Fresh	3/3	100	43.9-100	915/915	100	99.6-100
	Frozen	1/1	100	-	690/690	100	99.4-100
	Overall	***4/4***	***100***	***51.0-100***	***1605/1605***	***100***	***99.8-100***
FluB[i]	Fresh	0/0	-	-	918/918	100	99.6-100
	Frozen	14/14	100	78.5-100	678/680	99.7	98.9-99.9
	Overall	***14/14***	***100***	***78.5-100***	***1596/1598***	***99.9***	***99.5-100***
PIV1[j]	Fresh	5/5	100	56.6-100	913/913	100	99.6-100
	Frozen	4/4	100	51.0-100	689/690	99.9	99.2-100
	Overall	***9/9***	***100***	***70.1-100***	***1602/1603***	***99.9***	***99.6-100***
PIV2[k]	Fresh	46/47	97.9	88.9-99.6	863/871	99.1	98.2-99.5
	Frozen	0/0	-	-	694/694	100	99.4-100
	Overall	***46/47***	***97.9***	***88.9-99.6***	***1557/1565***	***99.5***	***99.0-99.7***
PIV3[l]	Fresh	40/42	95.2	84.2-98.7	867/876	99.0	98.1-99.5
	Frozen	3/3	100	43.9-100	690/691	99.9	99.2-100
	Overall	***43/45***	***95.6***	***85.2-98.8***	***1557/1567***	***99.4***	***98.8-99.7***
PIV4[m]	Fresh	6/6	100	61.0-100	910/912	99.8	99.2-99.9
	Frozen	3/3	100	43.9-100	686/691	99.3	98.3-99.7
	Overall	***9/9***	***100***	***70.1-100***	***1596/1603***	***99.6***	***99.1-99.8***
RSV[n]	Fresh	44/45	97.8	88.4-99.6	867/873	99.3	98.5-99.7
	Frozen	131/131	100	97.2-100	545/563	96.8	95.0-98.0
	Overall	***175/176***	***99.4***	***96.9-99.9***	***1412/1436***	***98.3***	***97.5-98.9***
Bacteria							
***B. parapertussis* (IS*1001*)**[o]	Fresh	4/5	80.0	37.6-96.4	913/913	100	99.6-100
	Frozen	2/2	100	34.2-100	692/692	100	99.4-100

Analyte		Positive Percent Agreement			Negative Percent Agreement		
		TP/(TP + FN)	%	95%CI	TN/(TN + FP)	%	95%CI
	Overall	***6/7***	***85.7***	***48.7-97.4***	***1605/1605***	***100***	***99.8-100***
***B. pertussis* (*ptxP*)[p]**	Fresh	2/2	100	34.2-100	915/916	99.9	99.4-100
	Frozen	0/1	0.0	-	693/693	100	99.4-100
	Overall	***2/3***	***66.7***	***20.8-93.9***	***1608/1609***	***99.9***	***99.6-100***
***C. pneumoniae*[q]**	Fresh	2/2	100	34.2-100	915/916	99.9	99.4-100
	Frozen	3/3	100	43.9-100	691/691	100	99.4-100
	Overall	***5/5***	***100***	***56.6-100***	***1606/1607***	***99.9***	***99.6-100***
***M. pneumoniae*[r]**	Fresh	17/17	100	81.6-100	897/901	99.6	98.9-99.8
	Frozen	6/7	85.7	48.7-97.4	686/687	99.9	99.2-100
	Overall	***23/24***	***95.8***	***79.8-99.3***	***1583/1588***	***99.7***	***99.3-99.9***

[a] Adenovirus was detected in 3/4 FN specimens using an independent molecular method. Adenovirus was detected in 38/48 FP specimens using an independent molecular method; an additional two FP specimens were indicated to have been collected from subjects with an acute history of adenovirus infection.

[b] The single FN specimen was negative for CoV-229E when tested using an independent molecular method. All five FP specimens were negative for CoV-229E when tested using an independent molecular method.

[c] CoV-HKU1 was detected in 3/12 FP specimens upon comparator method retest.

[d] CoV-NL63 was detected in 3/10 FP specimens during discrepancy investigation; two were detected using an independent molecular method and one was detected upon comparator method retest.

[e] Of the eight FN specimens, six were TP for CoV-HKU1. They were confirmed to be due to a known cross-reactivity with CoV-HKU1 by the comparator method; All six specimens were negative for CoV-OC43 when tested with two independent PCR assays; the remaining two FN specimens were negative for CoV-OC43 when tested using an independent molecular method. CoV-OC43 was detected in 2/5 FP specimens upon comparator method retest.

[f] Both FN specimens were negative for hMPV when tested using an independent molecular method. hMPV was detected in 6/8 FP specimens during discrepancy investigation; one was detected using an independent molecular method and five were detected upon comparator method retest.

[g] HRV/EV was detected in 5/11 FN specimens during discrepancy investigation; one was detected using an independent molecular method and four were detected upon BioFire RP2 retest. HRV/EV was detected in 33/77 FP specimens during discrepancy investigation; four were detected using an independent molecular method and 29 were detected upon comparator method retest.

[h] Three specimens were excluded from influenza A analysis: one with a comparator method result of Influenza A (No Subtype Detected) and two BioFire RP2 Influenza A (Equivocal) detections.

[i] FluB was detected in both FP specimens during discrepancy investigation; one was detected using an independent molecular method and one was detected upon comparator method retest.

[j] The single FP specimen was negative for PIV1 when tested using an independent molecular method.

[k] The single FN specimen was negative for PIV2 when tested using an independent molecular method. PIV2 was detected in 5/8 FP specimens during discrepancy investigation; one was detected using an independent molecular method and four were detected upon comparator method retest.

[l] PIV3 was detected in both FN specimens during discrepancy investigation; one was detected using an independent molecular method and one was detected upon BioFire RP2 retest. PIV3 was detected in 4/10 FP specimens during discrepancy investigation; two were detected using an independent molecular method and two were detected upon comparator method retest.

[m] PIV4 was detected in 1/7 FP specimens using an independent molecular method.

[n] The single FN specimen was negative for RSV when tested using an independent molecular method. RSV was detected in 8/24 FP specimens during discrepancy investigation; three were detected using an independent molecular method and five were detected upon comparator method retest.

[o] *B. parapertussis* was detected in the single FN specimen upon BioFire RP2 retest.

[p] *B. pertussis* was detected in the both the FN and FP specimens using an independent molecular method.

[q] *C. pneumoniae* was detected in the single FP specimen using an independent molecular method.

[r] *M. pneumoniae* was detected in the single FN specimen upon BioFire RP2 retest. *M. pneumoniae* was detected in all five FP specimens during discrepancy investigation; three were detected using an independent molecular method and two were detected upon comparator method retest.

BioFire RP2 reported a total of 245 specimens with discernible multiple organism detections (15.2% of all specimens, 245/1612; and 24.0% of positive specimens, 245/1020; Table 17). The majority of multiple detections (190/245; 77.6%) contained two organisms, while 20.0% (49/245) contained three organisms, 1.6% (4/245) contained four organisms, 0.4% (1/245) contained five organisms, and 0.4% (1/245) contained six organisms. Out of the 245 specimens with multiple detections, 124 specimens (50.6%; 124/245) were concordant with the comparator methods. One hundred twenty-one (121) specimens (49.4%; 121/245) contained one or more organisms that had not been detected by the comparator methods (i.e. false positive results).

The three organisms that were most prevalent in multiple detections were also the three most prevalent organisms in the study as a whole (i.e. HRV/EV, RSV, and adenovirus). The most prevalent multiple detections (≥5 instances) are shown in Table 18.

Table 17. Prevalence of Analytes in Multiple Detections as determined by the BioFire RP2

Analyte	Prevalence in Multiple Detections (N=245)	
Viruses		
Adenovirus	85	34.7%
CoV-229E	6	2.4%
CoV-HKU1	41	16.7%
CoV-NL63	31	12.7%
CoV-OC43	19	7.8%
hMPV	33	13.5%
HRV/EV	150	61.2%
FluA H1	0	0%
FluA H1-2009	9	3.7%
FluA H3	2	0.8%
FluB	6	2.4%
PIV1	5	2.0%
PIV2	15	6.1%
PIV3	21	8.6%
PIV4	12	4.9%
RSV	105	42.9%
Bacteria		
B. parapertussis (IS*1001*)	6	2.4%
B. pertussis (*ptxP*)	0	0%
C. pneumoniae	1	0.4%
M. pneumoniae	7	2.9%

The most prevalent multiple detection was adenovirus with HRV/EV (1.9% of all specimens; 30/1612) followed by HRV/EV with RSV (1.4% of all specimens; 22/1612); as previously stated these were also the most prevalent organisms detected in the study.

Table 18. Multiple Detection Combinations (≥5 instances) as Determined by the BioFire RP2

Distinct Multiple Detection Combinations			Total Multiple Detections	Number of Specimens with False Positive Detections	False Positive Analyte(s)[a]
Analyte 1	Analyte 2	Analyte 3			
Adenovirus	HRV/EV		30	15	Adenovirus (15), HRV/EV (1)
HRV/EV	RSV		22	7	HRV/EV (3), RSV (4)
CoV-HKU1	RSV		13	7	CoV-HKU1 (4), RSV (3)
CoV-NL63	RSV		13	3	CoV-NL63 (2), RSV (1)
HRV/EV	PIV2		11	7	HRV/EV (6), PIV2 (2)
HRV/EV	PIV3		11	6	HRV/EV (3), PIV3 (4)
Adenovirus	RSV		10	5	Adenovirus (4), RSV (1)
Adenovirus	HRV/EV	RSV	9	5	Adenovirus (2), HRV/EV (3), RSV (1)
CoV-NL63	HRV/EV		8	2	CoV-NL63 (2)

Distinct Multiple Detection Combinations			Total Multiple Detections	Number of Specimens with False Positive Detections	False Positive Analyte(s)[a]
Analyte 1	Analyte 2	Analyte 3			
CoV-HKU1	HRV/EV		5	2	CoV-HKU1 (1), HRV/EV (1)
CoV-OC43	HRV/EV		5	3	HRV/EV (3)
hMPV	HRV/EV		5	1	HRV/EV

[a] Of the 67 discrepant analytes (out of 293 total analytes), 32 (47.8%) were observed as being present in the specimen during discrepancy investigation; 22/67 (32.8%) were observed using an independent molecular method and 13/67 (19.4%) were observed upon comparator method retest.

The overall success rate for initial specimen tests in the prospective study was 99.3% (1611/1623) (95% CI: 98.7% - 99.6%); 12 tests were unsuccessful (one due to an incomplete test, one due to an instrument error, and ten due to control failures). Two tests (2/1623; 0.1%) did not complete on the initial run, resulting in an instrument success rate of 99.9% (1621/1623) (95% CI: 99.6% - 100%) for initial specimen tests. Both specimens were able to be retested and valid results were produced after a single retest. Ten tests (10/1621; 0.6%) did not produce valid pouch controls, resulting in a pouch control success rate of 99.4% (1611/1621) (95% CI: 98.9% - 99.7%) for completed runs in the initial specimen tests. Nine of the 10 invalid specimens were able to be retested and produced valid control results after a single retest; one was not able to be retested due to insufficient specimen volume.

Testing of Preselected Archived Specimens with BioFire RP2

Some of the analytes on the BioFire RP2 were of low prevalence and were not encountered in large enough numbers during the prospective study to adequately demonstrate system performance. To supplement the results of the prospective clinical study, an evaluation of preselected archived retrospective specimens was performed at BioFire. These specimens were archived NPS in VTM specimens that were selected because they had previously tested positive for one of the following analytes: coronavirus 229E, influenza A H1, influenza A H3, influenza B, parainfluenza virus 1, parainfluenza virus 4, *Bordetella parapertussis*, *B. pertussis*, and *Chlamydia pneumoniae*. Parainfluenza virus 2, parainfluenza virus 3, and *Mycoplasma pneumoniae* were also expected to be low prevalence based on BioFire data collected during the 2015-2016 respiratory season, therefore archived testing was performed for these analytes as well and included in the study data (although ultimately they were observed in larger numbers during the prospective clinical study).

A total of 217 preselected archived retrospective clinical specimens were initially received for testing in this retrospective study. Prior to testing with the BioFire RP2, the composition/integrity of the specimens was first confirmed with confirmatory molecular methods (PCR followed by bi-directional sequencing for *B. parapertussis* or an FDA-cleared multiplexed respiratory pathogens panel.

The specimens were divided into two different groups for testing based on the method of confirmation testing performed: all specimens containing analytes on the FDA-cleared multiplexed respiratory pathogens panel comparator method were tested in Group 1 and specimens containing *B. parapertussis* were tested in Group 2. Negative NPS specimens were also included in each group for testing.

The FDA-cleared multiplexed respiratory pathogen panel comparator method was performed on 197 of the 217 preselected archived retrospective clinical specimens only (Group 1). One of the 197 specimens was excluded from performance analysis because of an invalid BioFire RP2 run with insufficient volume to retest. Additionally, two of the 197 specimens were also excluded from performance analysis because a valid FDA-cleared multiplexed respiratory pathogens panel comparator method confirmation result was not obtained and there was insufficient specimen volume for retesting: one comparator run was incomplete and the other comparator run had a control failure. Valid comparator method and BioFire RP2 results were obtained for 194 of these 197 archived specimens (Group 1).

The *B. parapertussis* PCR followed by bi-directional sequencing comparator assays were performed on 20 of the 217 preselected archived retrospective clinical specimens only (Group 2). The FDA-cleared multiplexed respiratory pathogens panel comparator method was not performed on Group 2 specimens. Valid comparator method and BioFire RP2 results were obtained for 20 of these 20 archived specimens.

A summary of the available demographic information of these 214 valid archived specimens is provided in Table 19.

Table 19. Available Demographic Summary for All Valid Archived Specimens

Total Specimens		214
Sex	Female (%)	75 (35%)
	Male (%)	81 (38%)
	Unknown	58 (27%)
Age Range	≤ 5 years	78 (36%)
	6 - 21 years	46 (21%)
	22 - 49 years	13 (6%)
	50+ years	19 (9%)
	Unknown	58 (27%)

All Group 1 and Group 2 positive archived specimens (as determined at the source laboratory) that were not confirmed by the respective comparator method were further excluded from the performance calculation for each of the respective analytes.

The BioFire RP2 retrospective specimens testing performance data against the comparator methods are provided in Table 20 by analyte.

Table 20. BioFire RP2 Archived Specimen Performance Data Summary

Analyte	Positive Percent Agreement			Negative Percent Agreement		
	TP/(TP + FN)	%	95% CI	TN/(TN + FP)	%	95% CI
Viruses						
Adenovirus	0/0	0	N/A	189/194	97.4	94.1-98.9
CoV- 229E [a]	15/15	100	79.6-100	175/175	100	97.9-100
CoV-HKU1	0/0	0	N/A	194/194	100	98.1-100
CoV-NL63	2/2	100	34.2-100	192/192	100	98.0-100
CoV-OC43	0/0	0	N/A	194/194	100	98.1-100
hMPV	1/1	100	20.7-100	192/193	99.5	97.1-99.9
HRV/EV	18/19	94.7	75.4-99.1	168/175	96.0	92.0-98.0
Influenza A	22/22	100	85.1-100	172/172	100	97.8-100
Influenza A H1	3/3	100	43.9-100	191/191	100	98.0-100
Influenza A 2009-H1	1/1	100	20.7-100	193/193	100	98.0-100
Influenza A H3	18/18	100	82.4-100	176/176	100	97.9-100
Influenza B [b]	16/16	100	80.6-100	177/177	100	97.9-100
Parainfluenza Virus 1	16/16	100	80.6-100	178/178	100	97.9-100
Parainfluenza Virus 2 [c]	16/16	100	80.6-100	177/177	100	97.9-100
Parainfluenza Virus 3	17/17	100	81.6-100	175/177	98.9	96.0-99.7
Parainfluenza Virus 4	17/17	100	81.6-100	174/177	98.3	95.1-99.4

Analyte	Positive Percent Agreement			Negative Percent Agreement		
	TP/(TP + FN)	%	95% CI	TN/(TN + FP)	%	95% CI
RSV	2/2	100	34.2-100	191/192	99.5	97.1-99.9
Bacteria						
Bordetella parapertussis (IS*1001*) [d]	16/16	100	80.6-100	4/4	100	51.0-100
Bordetella pertussis (*ptx*P) [e]	25/26	96.2	81.1-99.3	160/162	98.8	95.6-99.7
Chlamydia pneumoniae [f]	17/17	100	81.6-100	176/176	100	97.9-100
Mycoplasma pneumoniae [g]	16/16	100	80.6-100	171/173	98.8	95.9-99.7

[a] Four of 19 CoV-229E positive archived specimens by the source laboratory were not confirmed by the comparator method and therefore were excluded from the performance calculation for CoV-229E .

[b] One of the 17 Influenza B positive archived specimens by the source laboratory was not confirmed by the comparator method and therefore was excluded from the performance calculation for Influenza B.

[c] One of the 17 Parainfluenza Virus 2 positive archived specimens the source laboratory was not confirmed by the comparator method and therefore was excluded from the performance calculation for Parainfluenza Virus 2 .

[d] The comparator *B. parapertussis* PCR followed by sequencing assays were performed on 20 archived specimens only (Group 2). The comparator method for the other analytes was not performed on these 20 specimens.

[e] Six of the 31 *B. pertussis* positive archived specimens by the source laboratory were not confirmed by the comparator method and therefore were excluded from the performance calculation for *B. pertussis*.

[f] One of the 17 *C. pneumoniae* positive archived specimens by the source laboratory was not confirmed by the comparator method and therefore was excluded from the performance calculation for *C. pneumoniae*.

[g] Five of the 21 *M. pneumoniae* positive archived specimens by the source laboratory were not confirmed by the comparator method and therefore were excluded from the performance calculation for *M. pneumoniae*.

Testing of Contrived Specimens with BioFire RP2

Influenza A H1 is of such rarity that that both prospective and retrospective archived testing efforts were insufficient to demonstrate system performance. To supplement the prospective and retrospective data, an evaluation of contrived specimens was performed at one of the three clinical testing sites participating in the prospective evaluation. Contrived clinical specimens were prepared using individual unique residual NPS specimens that had previously tested negative by the FDA-cleared multiplexed respiratory pathogens panel (i.e., the same test as the comparator method employed in the prospective and retrospective clinical evaluations) at the source laboratory. Spiking was performed using multiple quantified isolates of Influenza A H1. The spiking scheme was such that at least 25 of the contrived positive specimens had analyte concentrations at 2 × the limit of detection (LoD), while the remaining 25 contrived positive specimens were at additional concentrations that spanned the clinically relevant range which was based on BioFire RP2 Cp observations of influenza A (A H1, A H-2009, and H3) from the prospective and archived specimen studies. Contrived positive specimens were prepared and randomized along with 50 un-spiked influenza A H1 negative specimens such that the analyte status of each contrived specimen was unknown to the users performing the testing. The results of the BioFire RP2 testing contrived specimens are presented in Table 21.

Table 21. BioFire RP2 Performance Using Contrived Specimens

Analyte	Positive Percent Agreement				Negative Percent Agreement		
	× LoD	TP/(TP + FN)	%	95% CI	TN/(TN + FP)	%	95% CI
Influenza A H1	2	22/23 [a]	95.7%	79.0-99.2	50/50	100	92.9-100
	10	10/10	100%	72.3-100			
	50	5/5	100%	56.6-100			
	200	5/5	100%	56.6-100			
	1000	5/5	100%	56.6-100			
	Combined	47/48 [a]	97.9%	89.1-99.6			

[a] The FN specimen was spiked with influenza A/Weiss/43; this strain was detected at all other concentrations. Two specimens (also spiked with strain A/Weiss/43) had a result of Influenza A Equivocal or Influenza A H1 Equivocal and were excluded from Influenza A H1 performance calculation.

Limit of Detection

LoD for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

The BioFire RP2.1 limit of detection (LoD) for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was estimated by testing serial dilutions of contrived samples containing known concentrations of inactivated or infectious virus culture (concentration of viral RNA in the cultures determined by digital droplet (dd) PCR or quantitative real-time PCR, respectively). The estimated LoD was the lowest concentration tested with detection in all replicates. Confirmation of the LoD concentration for the inactivated virus (in transport medium) and infectious virus (in pooled clinical NPS) was achieved when the virus was detected in at least 19 of 20 replicates (≥95%) tested on FilmArray 2.0 and FilmArray Torch systems (Table 22).

Table 22. Limit of Detection (LoD) for SARS-CoV-2

BioFire RP2.1 Analyte	Isolate		LoD Concentration	#Detected/Total
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)	USA-WA1/2020	Heat-inactivated virus ATCC VR-1986HK	**5.0E+02 copies/mL[a]** 6.9E-02 $TCID_{50}$/mL	**20/20** 100%
		Infectious virus[b]	**1.6E+02 copies/mL[c]** 1.1E-02 $TCID_{50}$/mL	**20/20** 100%

[a] Concentration of viral RNA determined by ddPCR, as indicated on the Certificate of Analysis from ATCC.

[b] Obtained for culturing in a biosafety level 3 laboratory from the World Reference Center for Emerging Viruses and Arboviruses (WRCEVA), contributed by the U.S. Centers for Disease Control (CDC).

[c] Concentration of viral RNA determined by quantitative real-time PCR using primers and probe as described on the World Health Organization (WHO) website: https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf

SARS-CoV-2 Comparison Testing Near LoD

Detection of SARS-CoV-2 by the BioFire RP2.1 was compared to detection of SARS-CoV-2 by two other tests that have received Emergency Use Authorization from the U.S. Food and Drug Administration (BioFire® COVID-19 Test from BioFire Defense, LLC and the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel from the U.S. Centers for Disease Control).

For comparison to the BioFire COVID-19 Test, contrived samples were prepared by spiking inactivated SARS-CoV-2 (USA-WA1/2020; ATCC VR-1986HK) into transport medium and serially diluting, with an intermediate dilution near the LoD of the BioFire COVID-19 Test. Five replicates of each sample were tested with the BioFire RP2.1 and BioFire COVID-19 Test according to the manufacturer's instructions for use. SARS-CoV-2 was detected equivalently at concentrations ≥3.0E+02 copies/mL (Table 23).

Table 23. Inactivated SARS-CoV-2 Detection Comparison Between BioFire RP2.1 and the BioFire COVID-19 Test

D = Detected, ND = Not Detected

	5.0E+04 copies/mL		5.0E+03 copies/mL		5.0E+02 copies/mL		3.0E+02 copies/mL		5.0E+01 copies/mL	
Replicate	**RP2.1**	**COVID-19**	**RP2.1**	**COVID-19**	**RP2.1**	**COVID-19**	**RP2.1**	**COVID-19**	**RP2.1**	**COVID-19**
1	D	D	D	D	D	D	D	D	D	ND
2	D	D	D	D	D	D	D	D	ND	Equivocal
3	D	D	D	D	D	D	ND	D	D	ND
4	D	D	D	D	D	D	D	ND	D	ND
5	D	D	D	D	D	D	D	D	ND	ND
#Detected /Total	**5/5**	**5/5**	**5/5**	**5/5**	**5/5**	**5/5**	**4/5**	**4/5**	**3/5**	**0/5**

For comparison to the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel, contrived samples were prepared by spiking infectious SARS-CoV-2 (USA-WA1/2020; WRCEVA) into pooled clinical NPS and serially diluting the sample. Six replicates of each sample were tested with the BioFire RP2.1 and CDC 2019-nCoV Real-Time RT-PCR Diagnostic

Panel according to the manufacturer's instructions for use. The CDC 2019-nCOV Diagnostic Panel testing included all extraction and PCR controls, with three extraction events (QIAGEN QIAmp Viral RNA Mini Kit) and duplicate PCR reactions for each extract. Results from the N1 and N2 (and RP) assays were interpreted as Positive, Inconclusive or Negative. SARS-CoV-2 was detected by both panels equivalently at each concentration.

Table 24. Infectious SARS-CoV-2 Detection Comparison Between BioFire RP2.1 and CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel

D = Detected, ND = Not Detected

	1.6E+05 copies/mL		1.6E+04 copies/mL		1.6E+03 copies/mL		1.6E+02 copies/mL		1.6E+01 copies/mL	
Replicate	BioFire RP2.1	CDC 2019-nCoV	BioFire RP2.1	CDC 2019-nCoV	BioFire RP2.1	CDC 2019-nCoV	BioFire RP2.1	CDC 2019-nCoV	BioFire RP2.1	CDC 2019-nCoV
1	D	Positive	D	Positive	D	Positive	D	Positive	D	Positive
2	D	Positive	D	Positive	D	Positive	D	Positive	ND	Inconclusive
3	D	Positive	D	Positive	D	Positive	D	Positive	ND	Positive
4	D	Positive	D	Positive	D	Positive	D	Positive	D	Positive
5	D	Positive	D	Positive	D	Positive	D	Positive	D	Inconclusive
6	D	Positive	D	Positive	D	Positive	D	Positive	ND	Inconclusive
#Detected /Total	6/6	6/6	6/6	6/6	6/6	6/6	6/6	6/6	3/6	3/6

LoD for Other BioFire RP2.1 Analytes (non-SARS-CoV-2)

BioFire RP2.1 LoD confirmation testing for all other analytes was performed with contrived samples containing analytes spiked at the BioFire RP2 LoD concentration in transport medium. Confirmation of the LoD was achieved when detection was observed in at least 19 of 20 replicates (≥95%) tested on FilmArray 2.0 and FilmArray Torch systems. BioFire RP2.1 LoD concentration is provided in viable or infectious units (e.g. CFU/mL, CCU/mL or $TCID_{50}$/mL) and/or nucleic acid copies/mL based on a quantitative real-time PCR (Table 25). The confirmed LoD for all analytes is equivalent (within 2-fold) between BioFire RP2.1 and the BioFire RP2.

Table 25. Summary of Limit of Detection (LoD) for BioFire RP2.1 Analytes (non-SARS-CoV-2)

BioFire RP2.1 Analyte	Isolate	LoD Concentration	#Detected/Total
Viruses			
Adenovirus	Species C Serotype 2 WHO International Standard NIBSC 16/324	3.0E+03 IU/mL[a] (3.0E+03 copies/mL)	**20/20** 100%
Coronavirus 229E	ATCC VR-740	4.0E-01 $TCID_{50}$/mL 6.5E+01 copies/mL	**20/20** 100%
Coronavirus HKU1	Clinical specimen	2.0E+03 copies/mL	**19/20**[b] 95.0%
Coronavirus NL63	BEI NR-470	2.5 E-01 $TCID_{50}$/mL 5.4E+01 copies/mL	**20/20** 100%
Coronavirus OC43	ATCC VR-759	3.0E+01 $TCID_{50}$/mL 5.6E+02 copies/mL	**20/20** 100%
Human Metapneumovirus	16, Type A1 IA10-2003 Zeptometrix 0810161CF	1.0E+01 $TCID_{50}$/mL[b] 1.2E+03 copies/mL[b]	**20/20** 100%
Human Rhinovirus/ Enterovirus[d]	Human Rhinovirus Type 1A Zeptometrix 0810012CFN	8.6E-02 $TCID_{50}$/mL[c] 3.8E+01 copies/mL[c]	**19/20** 95.0%
	Enterovirus D68 ATCC VR-1823	3.0E+02 $TCID_{50}$/mL 2.6E+01 copies/mL	**20/20** 100%
Influenza A H1	Influenza A H1N1 A/New Caledonia/20/99 Zeptometrix 0810036CF	1.0E+03 $TCID_{50}$/mL 1.4E+02 copies/mL	**20/20** 100%
Influenza A H1-2009	Influenza A H1N1pdm09 A/Swine/NY/03/2009 Zeptometrix 0810249CF	5.0E-01 $TCID_{50}$/mL 3.3E+02 copies/mL	**20/20** 100%
Influenza A H3			**20/20**

BioFire RP2.1 Analyte	Isolate	LoD Concentration	#Detected/Total
	Influenza H3N2 A/Port Chalmers/1/73 ATCC VR-810	1.0E-01 $TCID_{50}$/mL 2.1E+01 copies/mL	100%
Influenza B	B/FL/04/06 Zeptometrix 0810255CF	5.0E+00 $TCID_{50}$/mL 3.4E+01 copies/mL	**20/20** 100%
Parainfluenza Virus 1	Type 1 Zeptometrix 0810014CF	5.0E+00 $TCID_{50}$/mL 1.0E+03 copies/mL	**20/20** 100%
Parainfluenza Virus 2	Type 2 Zeptometrix 0810015CF	5.0E-01 $TCID_{50}$/mL 3.0E+01 copies/mL	**19/20** 95.0%
Parainfluenza Virus 3	Type 3 Zeptometrix 0810016CF	2.5E+00 $TCID_{50}$/mL 3.8E+01 copies/mL	**20/20** 100%
Parainfluenza Virus 4	Type 4a Zeptometrix 0810060CF	5.0E+01 $TCID_{50}$/mL 1.6E+03 copies/mL	**19/20** 95.0%
Respiratory Syncytial Virus	Type A Zeptometrix 0810040ACF	2.0E-02 $TCID_{50}$/mL 9.0E+00 copies/mL	**20/20** 100%
Bacteria			
***Bordetella parapertussis* (IS*1001*)**	A747 Zeptometrix 0801461	6.0E+01 IS*1001* copies/mL[d] 4.1E+01 CFU/mL	**20/20** 100%
***Bordetella pertussis* (*ptxP*)**	A639 Zeptometrix 0801459	1.0E+03 CFU/mL	**19/20** 95.0%
Chlamydia pneumoniae	TW183 ATCC VR-2282	2.0E-01 $TCID_{50}$/mL 1.3E+02 copies/mL[e]	**20/20** 100%
Mycoplasma pneumoniae	M129 Zeptometrix 0801579	6.3E+00 CCU/mL[f] 4.6E+02 copies/mL[f]	**20/20** 100%

[a] IU = International Units. Adenovirus LoD in IU/mL was first established through estimate and confirmation testing on the BioFire RP2 and the BioFire RP2.1 LoD was confirmed at the same concentration. BioFire Diagnostics quantified the WHO International Standard by quantitative real-time PCR to demonstrate that 3.0E+03 IU/mL=3.0E+03 copies/mL.

[b] The LoD sample for Human Metapneumovirus was prepared based on $TCID_{50}$/mL. The copies/mL LoD for Human Metapneumovirus is extrapolated from the LoD established when testing a different culture of the same isolate at the same $TCID_{50}$/mL concentration on the BioFire RP2. A copies/mL value for the culture tested on BioFire RP2.1 has not been determined.

[c] The BioFire RP2.1 copies/mL LoD concentration for Human Rhinovirus is the same as the LoD concentration in copies/mL on the BioFire RP2. The $TCID_{50}$/mL LoD concentration varies between the two panels because a different culture of the same isolate was tested on BioFire RP2.1 and the ratios of copies:$TCID_{50}$ differs between the culture events.

[d] IS*1001* sequences can be present in more than one copy per cell, so the relationship between CFU/mL and copies/mL may vary from strain to strain and culture to culture. LoD was determined based on the copy number of IS*1001* measured by an independent quantitative real-time PCR assay.

[e] The copies/mL LoD concentration for *Chlamydia pneumoniae* on BioFire RP2.1 is 2-fold higher than the LoD concentration on the BioFire RP2.

[f] The BioFire RP2.1 copies/mL LoD concentration for *Mycoplasma pneumoniae* is the same as the LoD concentration in copies/mL on the BioFire RP2. The LoD concentration in viable/infectious units varies between the two panels because a different culture of the same isolate was tested on BioFire RP2.1 and a different unit of measurement (CCU/mL vs. $TCID_{50}$/mL) was used between the culture events.

NOTE: LoD concentrations of the cultured viruses and the obligate intracellular bacterium M. pneumoniae are provided in units of TCID50 (50% Tissue Culture Infectious Dose) or CCU/mL (color changing units). $TCID_{50}$ and CCU are not a direct virus or cell count, but an indirect measure of viral or bacterial concentration based on infectivity and cytotoxicity and will therefore vary considerably depending on technique and methodology (including cell type, culture media and conditions, cytotoxicity of the virus, etc.). It is not appropriate to make determinations on relative sensitivity of different molecular assays for detection of viruses and bacteria based on LoD values measured in $TCID_{50}$/mL or CCU/mL. Concentrations are also presented in estimated copies/mL based upon independent quantitative PCR assays (qPCR). Note that the accuracy of qPCR assays may also be affected by assay conditions and sequence variance between strains.

AB833

Analytical Reactivity (Inclusivity)

Reactivity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Assays

Evaluation of analytical reactivity for the BioFire RP2.1 SARS-CoV-2 assays (SARSCoV2-1 and SARSCoV2-2) was based on *in silico* sequence analysis of all available sequences in the NCBI and GISAID databases as of April 6, 2020. In total, 4281 sequences from around the globe were aligned to the assay primers and less than 0.07% (3/4281) were found to have a mismatched base within the 3' half of one or more primer(s) that could have an impact on amplification by one of the assays. All three sequences with a 3' mismatched base in one assay are 100% identical to all primers of the other assay.

This analysis determined that all database sequences evaluated will be amplified by one or both SARS-CoV-2 assays and all sequences (4281/4281; 100%) are predicted to be detected by the BioFire RP2.1 (Table 26).

Table 26. ***In silico*** **Prediction of SARS-CoV-2 Detection by BioFire RP2.1 Assays**

+/+ indicates detected by both assays with no impairment, +/- indicates detection by one assay with no impairment and potential for impaired detection by the other assay, -/- indicates potential for impaired detection by both assays

Predicted Assay Result / # sequences		SARSCoV2-1		# (%) sequences predicted to be detected (one or both assays positive)
		+	-	
SARSCoV2-2	+	4278	2	4281/4281 (100%)
	-	1	0	

NOTE: At this time, only one isolate of known sequence (USA-WA1/2020) has been tested analytically with the BioFire RP2.1 and it was detected at a concentration as low as 1.6E+02 copies/mL (see Limit of Detection section above).

Reactivity of the BioFire RP2 Assays (non-SARS-CoV-2)

Analytical reactivity (inclusivity) of the non-SARS-CoV-2 assays was evaluated by *in silico* analysis and testing on the BioFire RP2 with a collection of 177 isolates that represent temporal and geographic diversity of the analytes, including relevant species, strains, serotypes, or genotypes. All isolates were tested at a concentration near LoD and all isolates were detected by the BioFire RP2 at concentrations within 10× LoD. In addition, *in silico* analysis of sequence data was used to make predictions of assay reactivity for less common strains or serotypes that were not tested but that may be detected by the BioFire RP2 (and BioFire RP2.1).

Because the BioFire RP2 assays and reaction conditions are the same in the modified BioFire RP2.1 and testing has demonstrated the LoD for these analytes is equivalent between panels (see *Limit of Detection* section); the analytical reactivity data from the BioFire RP2 has been applied to BioFire RP2.1 (Table 27 –Table 38) in all cases except *C. pneumoniae*, which was tested on BioFire RP2.1 based on the BioFire RP2.1 LoD for this analyte (Table 37).

NOTE: BioFire RP2.1 influenza A assays will react variably with non-human influenza A viruses and rarely encountered human influenza A viruses that are not H1, H1-2009 or H3; generally producing Influenza A Equivocal or Influenza A (no subtype detected) results.

NOTE: BioFire RP2.1 Influenza A (subtype) and Influenza B assays are predicted to react with attenuated viruses used in vaccines.

Table 27. Adenovirus Isolates Tested and Detected by BioFire RP2

Species	Serotype[a]	Isolate ID/Source	[Strain/Location/Year]	xLoD[b] Detected	Result
A	12	ATCC VR-863	[Huie/Massachusetts]	3x	Adenovirus Detected
	18	ATCC VR-19	[Washington DC/1954]	1x	
	31	Zeptometrix 0810073CF	-	3x	
B	3	Zeptometrix 0810062CF	-	3x	
	7A	Zeptometrix 0810021CF	-	1x	
	7d/d2	Univ of Iowa Research Foundation	[Iowa/2001]	3x	
	7h	Univ of Iowa Research Foundation	[Iowa/1999]	3x	
	11	Univ of Iowa Research Foundation	[Wisconsin/2005]	3x	
	14	Univ of Iowa Research Foundation	[Missouri/2005]	3x	
	16	ATCC VR-17	[CH.79/Saudia Arabia/1955]	3x	
	21	Univ of Iowa Research Foundation	[Missouri/2005]	3x	
	34	ATCC VR-716	[Compton/1972]	3x	
	35	ATCC VR-718	[Holden]	3x	
	50	ATCC VR-1602	[Wan/Amsterdam/1988]	3x	
C	1	Zeptometrix 0810050CF	-	3x	
	2	ATCC VR-846	[Adenoid 6]	1x	
	5	Zeptometrix 0810020CF	-	3x	
	6	ATCC VR-6	[Tonsil 99/Washington DC]	3x	
D	8	Zeptometrix 0810069CF	-	3x	
	20	Zeptometrix 0810115CF	-	3x	
	37	Zeptometrix 0810119CF	-	1x	
E	4a	Univ of Iowa Research Foundation	[S Carolina/2004]	1x	
	4	Zeptometrix 0810070CF	-	3x	
F	40	Zeptometrix 0810084CF	-	3x	
		NCPV 0101141v	-	3x	
	41	ATCC VR-930	[Tak/73-3544/Netherlands/1973]	1x	
		Zeptometrix 0810085CF	-	3x	

[a] *In silico* analysis of available sequences predicts that the BioFire RP2/RP2.1 will also react with Adenovirus B55, C57, species D serotypes, and G52.

[b] xLoD refers to the multiple of the BioFire RP2 LoD concentration for each adenovirus species that was tested and detected on BioFire RP2 pouches. These concentrations are equal to or less than the equivalent BioFire RP2.1 xLoD based on the LoD established in IU/mL and copies/mL with the Adenovirus WHO International Standard.

Table 28. Coronavirus (non-SARS-CoV-2) Isolates/Specimens Tested and Detected by BioFire RP2

Coronavirus Type	Isolate ID/Source	[Location/Year]	xLoD Detected	Result
229E	ATCC VR-740	-	1x	Coronavirus 229E
	Zeptometrix 0810229CF	-	3x	
HKU1	Clinical Specimen	[Utah/2015]	1x	Coronavirus HKU1
	Clinical Specimen	[Utah/2015]	3x	
	Clinical Specimen	[Utah/2015]	3x	
	Clinical Specimen	[S. Carolina/2010]	3x	
	Clinical Specimen	[Detroit/2010]	3x	
NL63	BEI NR-470[a]	[Amsterdam/2003]	1x	Coronavirus NL63
	Zeptometrix 0810228CF	-	3x	
OC43	ATCC VR-759[b]	-	1x	Coronavirus OC43
	Zeptometrix 0810024CF	-	3x	

[a] Organism obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Human Coronavirus NL63, NR-470.

[b] Discontinued part number; see ATCC VR-1558.

Table 29. Human Metapneumovirus Isolates Tested and Detected by BioFire RP2

Genotype	Serotype	Isolate ID/Source	[Location/Year]	xLoD Detected	Result
A1	16	Zeptometrix 0810161CF	[Iowa10/2003]	1x	Human Metapneumovirus
	9	Zeptometrix 0810160CF	[Iowa3/2002]	3x	
A2	20	Zeptometrix 0810163CF	[Iowa14/2003]	3x	
	27	Zeptometrix 0810164CF	[Iowa27/2004]	3x	
B1	3	Zeptometrix 0810156CF	[Peru2/2002]	3x	
	5	Zeptometrix 0810158CF	[Peru3/2003]	3x	
	13	Univ of Iowa Research Foundation	[Iowa7/2003]	3x	
B2	4	Zeptometrix 0810157CF	[Peru1/2002]	3x	
	8	Zeptometrix 0810159CF	[Peru6/2003]	3x	

AB835

Genotype	Serotype	Isolate ID/Source	[Location/Year]	xLoD Detected	Result
	18	Zeptometrix 0810162CF	[Iowa18/2003]	3x	
	22	Univ of Iowa Research Foundation	[Iowa16/2003]	3x	

Table 30. Human Rhinovirus and Enterovirus Isolates Tested and Detected by BioFire RP2

Species	Serotype	Isolate ID/Source	[Strain/Location/Year]	xLoD Detected	Result
Human Rhinovirus					
A	1	Zeptometrix 0810012CFN	[1A]	1x	Human Rhinovirus/ Enterovirus
	2	ATCC VR-482	[HGP]	3x	
	7	ATCC VR-1601	[68-CV11]	3x	
	16	ATCC VR-283	[11757/Washington DC/1960]	3x	
	34	ATCC VR-507[a]	[137-3]	3x	
	57	ATCC VR-1600	[Ch47]	3x	
	77	ATCC VR-1187	[130-63]	3x	
	85	ATCC VR-1195	[50-525-CV54]	3x	
B	3	ATCC VR-483	[FEB]	3x	
	14	ATCC VR-284	[1059/S Carolina/1959]	3x	
	17	ATCC VR-1663	[33342/N Carolina/1959]	3x	
	27	ATCC VR-1137	[5870]	3x	
	42	ATCC VR-338	[56822]	3x	
	83	ATCC VR-1193	[Baylor 7]	3x	
Enterovirus					
A	Coxsackievirus 10	ATCC VR-168	[NY/1950]	3x	Human Rhinovirus/ Enterovirus
	Enterovirus 71	ATCC VR-1432	[H]	3x	
B	Coxsackievirus A9	Zeptometrix 0810017CF	-	3x	
	Coxsackievirus B3	Zeptometrix 0810074CF	-	3x	
	Coxsackievirus B4	Zeptometrix 0810075CF	-	3x	
	Echovirus 6	Zeptometrix 0810076CF	-	3x	
	Echovirus 9	Zeptometrix 0810077CF	-	3x	
	Echovirus 11	Zeptometrix 0810023CF	-	3x	
C	Coxsackievirus A21	ATCC VR-850	[Kuykendall/California/1952]	3x	
	Coxsackievirus A24	ATCC VR-583	[DN-19/Texas/1963]	3x	
D	68	ATCC VR-1823	[US/MO/2014-18947]	1x	

[a] Discontinued part number; see ATCC VR-1365.

Table 31. Influenza A Isolates Tested and Detected by BioFire RP2

Type		Isolate ID/Source	[Strain/Location/Year]	xLoD Detected	Result
H1N1	Human	Zeptometrix 0810036CF	[New Caledonia/20/1999]	1x	Influenza A H1
		ATCC VR-219	[NWS/1933]	3x	
		ATCC VR-95	[PR/8/1934]	10x[a]	
		ATCC VR-96	[Weiss/1943]	3x	
		ATCC VR-97	[FM/1/1947]	3x	
		ATCC VR-98	[Mal/302/1954]	3x	
		ATCC VR-546	[Denver/1/1957]	3x	
		Zeptometrix 0810036CFN	[Solomon Isl/03/2006]	3x	
		Zeptometrix 0810244CF	[Brisbane/59/2007]	3x	
	Swine	ATCC VR-333	[A/Swine/Iowa/15/1930]	3x	
		ATCC VR-99	[A/Swine/1976/1931]	3x	
		ATCC VR-897	[A/New Jersey/8/76 (Hsw1N1)]	10x[a]	
H1N2	Recombinant	BEI NR-9677[b]	[Kilbourne F63, A/NWS/1934 (HA) x A/Rockefeller Institute/5/1957 (NA)]	3x	
H1N1 pdm09	Human	Zeptometrix 0810249CFN	[SwineNY/03/2009]	1x	Influenza A H1-2009
		Zeptometrix 0810248CFN	[SwineNY/01/2009]	3x	
		Zeptometrix 0810109CFN	[SwineNY/02/2009]	3x	
		Zeptometrix 0810109CFJ	[Canada/6294/2009]	3x	
		Zeptometrix 0810165CF	[California/07/2009]	3x	
		Zeptometrix 0810166CF	[Mexico/4108/2009]	3x	
		BEI NR-19823[c]	[Netherlands/2629/2009]	3x	
		BEI NR-44345[d]	[Hong Kong/H090-761-V1(0)/2009]	10x[e]	
		BEI NR-42938[f]	[Georgia/F32551/2012]	3x	
H3N2	Human	ATCC VR-810	[Port Chalmers/1/1973]	1x	Influenza A H3
		ATCC VR-776	[Alice (live attenuated vaccine)]	3x	
		Zeptometrix 0810238CF	[Texas/50/2012]	3x	

Type	Isolate ID/Source		[Strain/Location/Year]	xLoD Detected	Result
		ATCC VR-547	[Aichi/2/1968]	3x	
		ATCC VR-544	[Hong Kong/8/1968]	3x	
		ATCC VR-822	[Victoria/3/1975]	3x	
		Zeptometrix 0810252CF	[Wisconsin/67/2005]	3x	
		Zeptometrix 0810138CF	[Brisbane/10/2007]	3x	
	Recombinant	ATCC VR-777	[MCR2(A/England/42/72xA/PR8/34)]	3x	
H3N2v[g]	Human	Clinical Specimen	[Ohio/2012]	3x	
H2N2	Human	BEI NR-2775[h]	[Japan/305/1957]	10x[e]	Influenza A (no subtype detected)
	Recombinant	BEI NR-9679[i]	[Korea/426/1968xPuerto Rico/8/1934]	10x[e]	
H2N3	Avian	MRI Global[j]	Mallard/Alberta/79/2003	3x	Influenza A Equivocal
H5N1		MRI Global[j]	A/Chicken/Yunnan/1251/2003	3x	Influenza A (no subtype detected)
H5N2		MRI Global[j]	[A/Northern pintail/Washington/40964/2014]	3x	
H5N3		BEI NR-9682[k]	A/Duck/Singapore/645/1997	3x	
H5N8		MRI Global[j]	[AGyrfalcon/Washington/41088-6/2014]	3x	
H7N7		MRI Global[j]	A/Netherlands/219/2003	3x	
H7N9		MRI Global[j]	A/Anhui/01/2013	3x	
H10N7		BEI NR-2765[l]	Chicken/Germany/N/49	3x	Influenza A Equivocal

[a] Reported as Influenza A (no subtype detected) at 3× LoD.

[b] Genomic RNA obtained through BEI Resources NAID, NIH: Kilbourne F63: A/NWS/1934 (HA) x A/Rockefeller Institute/5/1957 (NA) (H1N2), Reassortant NWS-F, NR-9677.

[c] Virus obtained through BEI Resources, NIAID, NIH: Influenza A Virus, A/Netherlands/2629/2009 (H1N1)pdm09, NR-19823.

[d] Virus obtained through BEI Resources, NIAID, NIH: Influenza A Virus, A/Hong Kong/H090-761-V1(0)/2009 (H1N1)pdm09, NR-44345.

[e] Reported as Influenza A Equivocal or Influenza A (no subtype detected) at 3× LoD.

[f] Virus obtained through BEI Resources, NIAID, NIH: Influenza A Virus, A/Georgia/F32551/2012 (H1N1)pdm09, NR-42938.

[g] Human isolate of recent swine variant H3N2 virus.

[h] Genomic RNA obtained through BEI Resources, NIAID, NIH: Genomic RNA from Influenza A Virus, A/Japan/305/1957 (H2N2), NR-2775.

[i] Genomic RNA obtained through BEI Resources, NIAID, NIH: Genomic RNA from Kilbourne F38: A/Korea/426/1968 (HA, NA) x A/Puerto Rico/8/1934 (H2N2), NR-9679.

[j] Isolate provided and tested by MRI Global, Kansas City, MO.

[k] Genomic RNA obtained through BEI Resources, NIAID, NIH: Genomic RNA from Kilbourne F181: A/duck/Singapore/645/1997 (H5N3), Wild Type, NR-9682.

[l] Genomic RNA obtained through BEI Resources, NIAID, NIH: Genomic RNA from Influenza A Virus, A/chicken/Germany/N/1949 (H10N7), NR-2765.

Table 32. Influenza B Isolates Tested and Detected by BioFire RP2

Lineage	Isolate ID/Source	[Strain/Location/Year]	xLoD Detected	Result
N/A	ATCC VR-101	[Lee/1940]	3x	Influenza B
	ATCC VR-102	[Allen/1945]	3x	
	ATCC VR-103	[GL/1739/1954]	3x	
	ATCC VR-296	[1/Maryland/1959]	3x	
	ATCC VR-295	[2/Taiwan/1962]	3x	
	ATCC VR-786	[Brigit/Russia/1969]	3x	
Victoria	ATCC VR-823	[5/Hong Kong/1972]	3x	
	Zeptometrix 0810258CF	[2506/Malaysia/2004]	3x	
	CDC 2005743348	[1/Ohio/2005]	3x	
Yamagata	Zeptometrix 0810256CF	[07/Florida/2004]	3x	
	Zeptometrix 0810255CF	[04/Florida/2006]	1x	
	Zeptometrix 0810241CF	[1/Wisconsin/2010]	3x	
	Zeptometrix 0810239CF	[2/Massachusetts/2012]	3x	

Table 33. Parainfluenza Virus Isolates Tested and Detected by BioFire RP2

Type	Subtype	Isolate ID/Source	[Strain/Location/Year]	xLoD Detected	Result
1		Zeptometrix 0810014CF	-	1x	Parainfluenza Virus 1
		ATCC VR-94	[C-35/Washington DC/1957]	3x	
		BEI NR-3226[a]	[C39]	3x	
		BEI NR-48680[b]	[FRA/29221106/2009]	3x	
2		Zeptometrix 0810015CF	-	1x	Parainfluenza Virus 2
		ATCC VR-92	[Greer/Ohio/1955]	3x	
3		Zeptometrix 0810016CF	-	1x	Parainfluenza Virus 3
		ATCC VR-93	[C-243/Washington DC/1957]	3x	

Type	Subtype	Isolate ID/Source	[Strain/Location/Year]	xLoD Detected	Result
		BEI NR-3233[c]	[NIH 47885, Wash/47885/57]	3x	
4	A	Zeptometrix 0810060CF	-	1x	Parainfluenza Virus 4
		ATCC VR-1378	[M-25/1958]	3x	
	B	Zeptometrix 0810060BCF	-	3x	
		ATCC VR-1377	[CH-19503/Washington DC/1962]	3x	

[a] Discontinued part number.

[b] Virus obtained through BEI Resources, NIAID, NIH: Human Parainfluenza Virus 1, HPIV1/FRA/29221106/2009, NR-48680.

[c] Virus obtained through BEI Resources, NIAID, NIH: Human Parainfluenza Virus 3, NIH 47885, NR-3233.

Table 34. Respiratory Syncytial Virus Isolates Tested and Detected by BioFire RP2

Type	Source	[Strain/Location/Year]	xLoD Detected	Result
A	Zeptometrix 0810040ACF	[2006]	1x	Respiratory Syncytial Virus
	ATCC VR-26	[Long/Maryland/1956]	3x	
	ATCC VR-1540	[A2/Melbourne/1961]	3x	
B	Zeptometrix 0810040CF	[Ch-93 (18)-18]	3x	
	ATCC VR-1400	[WV/14617/1985]	3x	
	ATCC VR-955	[9320/Massachusetts/1977]	3x	
	ATCC VR-1580	[18537/Washington DC/1962]	10x	

Table 35. *Bordetella parapertussis* (and *Bordetella bronchiseptica*) Isolates Tested and Detected by BioFire RP2

Species	Source	[Strain/Location/Year]	xLoD Detected	Result
Bordetella parapertussis	Zeptometrix 0801461	[A747]	1x	*Bordetella parapertussis* (IS*1001*)
	Zeptometrix 0801462	[E595]	3x	
	ATCC 15237	[NCTC 10853]	3x	
	ATCC 15311	[NCTC 5952]	3x	
	ATCC BAA-587	[12822/Germany/1993]	3x	
Bordetella bronchiseptica (containing IS*1001*)	NRRL B-59909	[MBORD849/ Pig/Netherlands]	3x	

[a] Reactivity with IS*1001* sequences in *B. bronchiseptica* represents the intended reactivity of the assay, however the analyte will be inaccurately reported as *B. parapertussis*. The assay does not react with IS*1001*-like sequences in *B. holmesii* (see *Analytical Reactivity*).

Table 36. *Bordetella pertussis* Isolates Tested and Detected by BioFire RP2

Isolate ID/Source	[Strain]	xLoD Detected	Result
Zeptometrix 0801459	[A639]	1x	*Bordetella pertussis* (*ptxP*)
Zeptometrix 0801460	[E431]	3x	
ATCC 8467	[F]	3x	
ATCC 9340	[5,17921]	3x	
ATCC 9797	[18323/NCTC 10739]	3x	
ATCC 10380	[10-536]	3x	
ATCC 51445	[CNCTC Hp 12/63,623]	3x	
ATCC BAA-589	[Tohama]	3x	
ATCC BAA-1335	[MN2531]	3x	

Table 37. *Chlamydia pneumoniae* Isolates Tested and Detected by BioFire RP2.1[a]

Isolate ID/Source	[Strain/Location/Year]	xLoD Detected[a]	Result
ATCC VR-2282	[TW-183/Taiwan/1965]	1x	*Chlamydia pneumoniae*
ATCC VR-1310	[CWL-029]	3x	
ATCC VR-1360	[CM-1/Georgia]	3x	
ATCC 53592	[AR-39/Seattle/1983]	3x	

[a] xLoD refers to the multiple of the BioFire RP2.1 LoD concentration (1.3E+02 copies/mL) tested and detected on BioFire RP2.1 pouches.

Table 38. *Mycoplasma pneumoniae* Isolates Tested and Detected by BioFire RP2

Type	Isolate ID/Source	[Strain]	xLoD Detected	Result
1	Zeptometrix 0801579	[M129]	1x	*Mycoplasma pneumoniae*
	ATCC 29342	[M129-B7]	3x	
	ATCC 29085	[PI 1428]	3x	
2	ATCC 15531	[FH strain of Eaton Agent [NCTC 10119]	3x	
	ATCC 15492	[Mac]	3x	
unknown	ATCC 15293	[M52]	3x	

Type	Isolate ID/Source	[Strain]	xLoD Detected	Result
	ATCC 15377	[Bru]	3x	
	ATCC 39505	[Mutant 22]	3x	
	ATCC 49894	[UTMB-10P]	3x	

Analytical Specificity (Cross-Reactivity)

All known or predicted risks of cross-reactivity for the BioFire RP2.1 assays (including SARS-CoV-2) are summarized in Table 39 with the *in silico* and laboratory evaluations of analytical specificity described below.

Table 39. Predicted and Observed Cross-Reactivity of the BioFire RP2.1

Cross-reactive Organism(s)/Sequence(s)	BioFire RP2.1 Result	Description
Bat coronavirus_RTG13[7] (accession# MN996532) **Pangolin coronavirus**[8] (accession# MT08407) **Bat SARS-like coronavirus** (accession# MG772933 and MG772934)	**Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)**	The SARS-CoV-2 assays can amplify a small selection of sequences from closely-related Sarbecoviruses isolated from bats and pangolin. The SARSCoV2-2 assay is predicted to cross-react with all four sequences, while the SARSCoV2-1 assay will likely only cross-react with the bat coronavirus_RTG13.
Non-pertussis *Bordetella* species *(e.g., Bordetella parapertussis, Bordetella bronchiseptica*[a])	***Bordetella pertussis* (*ptxP*)** [b,c]	The *Bordetella pertussis* (*ptxP*) assay can amplify pertussis toxin pseudogene sequences in *B. bronchiseptica* and *B. parapertussis* primarily when present at high concentration (≥1.2E+09 CFU/mL).
Bordetella bronchiseptica[a] (with IS*1001* sequences)	***Bordetella parapertussis* (IS*1001*)**	Some strains of *B. bronchiseptica* carry IS*1001* insertion sequences identical to those carried by *B. parapertussis*. These sequences will be efficiently amplified by the IS1001 assay and reported by BioFire RP2.1 as *Bordetella parapertussis* (IS*1001*).
Bordetella pertussis ***Bordetella parapertussis*** ***Bordetella bronchiseptica***	**Human Rhinovirus/Enterovirus**[d,e]	The Human Rhinovirus/Enterovirus assay may amplify off-target sequences found in strains of *B. pertussis*, *B. bronchiseptica*, and *B. parapertussis* when present at high concentration. Cross-reactivity with *B. pertussis* was observed at a concentration of 4.5E+07 CFU/mL or higher.
Influenza A H1N1 (swine origin)	**Influenza A H1-2009**[f]	The Influenza A H1-2009 assay may react with H1 hemagglutinin gene sequences from viruses of swine origin. BioFire RP2.1 will report either Influenza A H1 or Influenza A H1-2009, depending on the strain and concentration in the sample.

[a] *B. bronchiseptica* infection is rare in humans and more common in domesticated animals ('kennel cough').

[b] Cross-reactivity between the *Bordetella pertussis* (ptxP) assay and *B. parapertussis* will be reported as a co-detection (*Bordetella parapertussis* (IS1001) Detected and *Bordetella pertussis* (*ptxP*) Detected); while cross-reactivity with most strains of *B. bronchiseptica* (that do not carry IS1001) will be reported only as *Bordetella pertussis* (*ptxP*) Detected.

[d] Cross-reactivity with *B. parapertussis* and *B. bronchiseptica* is predicted based on *in silico* analysis but was not observed when tested at a concentration of 1.2E+09 CFU/mL.

[e] Cross-reactivity between the Human Rhinovirus/Enterovirus assays and *B. pertussis* or *B. parapertussis* will be reported as a co-detection (*Bordetella pertussis* (*ptxP*) Detected and Human Rhinovirus/Enterovirus Detected or *Bordetella parapertussis* (IS1001) Detected and Human Rhinovirus/Enterovirus Detected); while cross-reactivity with most strains of *B. bronchiseptica* (that do not carry IS1001) will be reported (falsely) only as Human Rhinovirus/Enterovirus Detected.

[f] Swine origin Hsw1N1 (A/New Jersey/8/1976 ; ATCC VR-897) was detected as either Influenza A H1 or Influenza A H1-2009 at a concentration of 8.9E+06 $CEID_{50}$/mL.

AB839

In Silico Analysis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Assays

Cross-reactivity of the BioFire RP2.1 SARS-CoV-2 assays was evaluated using both *in silico* analysis and by testing whole organisms or purified nucleic acid from other organisms. *In silico* analysis included primer BLAST search of database sequences, and only sequences from SARS coronavirus and others in the Sarbecovirus subgenus of betacoronaviruses were returned. Based on this analysis, both assays are predicted to cross-react with a single Bat coronavirus sequence (accession number MN996532; isolated from bat species *Rhinolophus affinisin* in Yunan province, China[7]). A risk of possible cross-reactivity was also identified for two other bat SARS-like coronaviruses (accession numbers MG772933 and MG772934) and a pangolin coronavirus (accession number MT08407[8]). It is unlikely that these viruses would be found in a human clinical nasopharyngeal swab; but, if present, the cross-reactive product(s) produced by the BioFire RP2.1 assay(s) will be detected as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

No other cross-reactivities with the BioFire RP2.1 SARS-CoV-2 assays were predicted by sequence analysis nor observed in high level on-panel and off-panel organism testing (including SARS-CoV, MERS-CoV, CoV-299E, CoV-HKU1, CoV-NL63, CoV-OC43 and two recombinant bat SARS-like coronaviruses; see Table 40 and Table 41).

Cross-Reactivity Testing for the BioFire RP2.1 Assays

The potential for non-specific amplification by assays for detection of SARS-CoV-2 and other analytes was evaluated by testing high concentrations of organisms or nucleic acids with the BioFire RP2.1. On-panel organisms were tested to assess the potential for intra-panel cross-reactivity, and off-panel organisms were tested to evaluate panel specificity. Off-panel organisms included normal respiratory flora and pathogens that may be present in NPS specimens as well as near-neighbors or species genetically related to the organisms detected by the BioFire RP2.1. The concentration of organism tested (in triplicate) was at least 1.0E+06 units/mL for bacteria and fungi and at least 1.0E+05 unit/mL for viruses. For the few organisms of interest that were not available for laboratory testing, results of *in silico* analysis of the organism whole genome sequences are indicated.

The on-panel and off-panel organisms and concentrations tested are shown in Table 40 and Table 41.

Table 40. On-Panel Organisms Tested for Evaluation of BioFire RP2.1 Analytical Specificity

Organism		Isolate ID	Concentration Tested	Cross-Reactivity Detected
Bacteria				
Bordetella parapertussis		Zeptometrix 0801462	6.43E+09 CFU/mL	***Bordetella pertussis* (ptxp)[a]**
Bordetella pertussis		ATCC 9797	5.50E+09 CFU/mL	**Human Rhinovirus/Enterovirus[b]**
Chlamydia pneumoniae		ATCC 53592	1.93E+07 IFU/mL	None
Mycoplasma pneumoniae		Zeptometrix 0801579	2.65E+07 CCU/mL	None
Viruses				
Adenovirus	7A (species B)	Zeptometrix 0810021CF	1.02E+07 $TCID_{50}$/mL	None
	1 (species C)	Zeptometrix 0810050CF	2.26E+07 $TCID_{50}$/mL	None
	4 (species E)	ATCC VR-1572	1.58E+06 $TCID_{50}$/mL	None
Coronavirus 229E		Zeptometrix 0810229CF	1.13E+05 $TCID_{50}$/mL	None
Coronavirus HKU1		Clinical specimen	8.94E+06 RNA copies/mL	None
Coronavirus NL63		Zeptometrix 0810228CF	2.34E+05 $TCID_{50}$/mL	None
Coronavirus OC43		Zeptometrix 0810024CF	6.37E+06 $TCID_{50}$/mL	None
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)		USA-WA1/2020	2.4E+09 copies/mL	None
Human Metapneumovirus		Zeptometrix 0810159CF	1.05E+06 $TCID_{50}$/mL	None
Human Rhinovirus (Type 1A)		Zeptometrix 0810012CFN	8.40E+05 $TCID_{50}$/mL	None
Enterovirus (D68)		ATCC VR-1823	1.58E+07 $TCID_{50}$/mL	None
Influenza A H1N1 (A1/FM/1/47)		ATCC VR-97	1.58E+08 $CEID_{50}$/mL	None
Influenza A Hsw N1 (A/NewJersey/8/76)		ATCC VR-897	8.89E+06 $CEID_{50}$/mL	**Influenza A H1-2009[c]**
Influenza A (H1N1) pdm09		Zeptometrix 0810538CF	9.40E+04 $TCID_{50}$/mL	None

Organism	Isolate ID	Concentration Tested	Cross-Reactivity Detected
(Michigan/45/15)			
Influenza A H3N2 (A/Alice)	ATCC VR-776	3.33E+08 $CEID_{50}$/mL	None
Influenza B (Massachusetts/2/12)	Zeptometrix 0810239CF	9.55E+05 $TCID_{50}$/mL	None
Parainfluenza Virus 1	Zeptometrix 0810014CF	6.80E+07 $TCID_{50}$/mL	None
Parainfluenza Virus 2	Zeptometrix 0810357CF	4.57E+06 $TCID_{50}$/mL	None
Parainfluenza Virus 3	ATCC VR-93	6.80E+07 $TCID_{50}$/mL	None
Parainfluenza Virus 4	ATCC VR-1377	4.17E+04 $TCID_{50}$/mL	None
Respiratory Syncytial Virus	Zeptometrix 0810040ACF	7.00E+05 $TCID_{50}$/mL	None

[a] *Bordetella pertussis* (*ptxP*) assay may amplify pertussis toxin pseudogene sequences from some strains of *B. parapertussis* at high concentration (>1.2E+09 CFU/mL).

[b] Human Rhinovirus/Enterovirus assay may amplify non-target sequences from *Bordetella* species (*B. pertussis*, *B. parapertussis*, and *B. bronchiseptica*) at a concentration ≥4.5E+07 CFU/mL.

[c] The H1 hemagglutinin (HA) gene of Influenza A H1N1 strains of swine origin (prior to 2009) will be amplified by the H1 assay (Influenza A H1 Detected). However, some strains/sequences of swine origin may also be amplified by the H1-2009 assay (Influenza A H1-2009 Detected) at higher concentrations. Testing of this strain at 8.89E+06 $CEID_{50}$/mL generated an Influenza A H1 Detected result in 1/3 replicates and an Influenza A H1-2009 Detected in 2/3 replicates.

Table 41. Off-Panel Organisms Tested for Evaluation of BioFire RP2.1 Analytical Specificity

Organism	Isolate ID	Concentration Tested	Cross-Reactivity Detected/Predicted
Bacteria			
Acinetobacter calcoaceticus	ATCC 23055	5.15E+09 CFU/mL	None
Arcanobacterium haemolyticum	ATCC 9345	5.70E+09 CFU/mL	None
Bacillus anthracis	Evaluated *in silico*		None
Bordetella avium	ATCC 35086	1.88E+09 cells/mL	None
Bordetella bronchiseptica	ATCC 10580	2.09E+09 cells/mL	***Bordetella pertussis* (*ptxp*)[a]**
Bordetella hinzii	ATCC 51783	4.30E+06 CFU/mL	None
Bordetella holmesii	ATCC 700052	3.15E+07 CFU/mL	None
Burkholderia cepacia	ATCC 17762	5.04E+09 CFU/mL	None
Chlamydia trachomatis	Zeptometrix 0801775	1.67E+08 IFU/mL	None
Chlaymdia psittaci	Evaluated *in silico*		None
Corynebacterium diphtheriae	Zeptometrix 0801882	7.47E+08 CFU/mL	None
Corynebacterium striatum	ATCC BAA-1293	5.20E+09 CFU/mL	None
Coxiella burnetii	Evaluated *in silico*		None
Escherichia coli	AR Bank #0538	5.53E+09 CFU/mL	None
Fusobacterium necrophorum	ATCC 27852	1.33E+08 cells/mL	None
Haemophilus influenzae	ATCC 33391	5.85E+09 CFU/mL	None
Klebsiella (Enterobacter) aerogenes	AR Bank #0074	6.83E+09 CFU/mL	None
Klebsiella oxytoca	JMI 7818	5.60E+09 CFU/mL	None
Klebsiella pneumoniae	NCTC 13465	1.75E+08 CFU/mL	None
Lactobacillus acidophilus	Zeptometrix 0801540	1.60E+08 CFU/mL	None
Lactobacillus plantarum	Zeptometrix 0801507	1.20E+09 CFU/mL	None
Legionella (Fluoribacter) bozemanae	ATCC 33217	3.24E+09 cells/mL	None
Legionella (Fluoribacter) dumoffii	ATCC 33279	2.65E+09 cells/mL	None
Legionella feeleii	ATCC 35849	1.49E+09 cells/mL	None
Legionella longbeachae	Zeptometrix 0801577	1.93E+08 CFU/mL	None
Legionella (Tatlockia) micdadei	Zeptometrix 0801576	1.80E+09 CFU/mL	None
Legionella pneumophila	Zeptometrix 0801530	1.75E+09 CFU/mL	None
Leptospira interrogans	ATCC BAA-1198D-5 (genomic DNA)	7.89E+08 GE/mL	None
Moraxella catarrhalis	ATCC 8176	5.73E+09 CFU/mL	None
Mycobacterium tuberculosis	Zeptometrix 0801660 (avirulent strain)	9.07E+06 CFU/mL	None
Mycoplasma genitalium	ATCC 33530D (genomic DNA)	8.40E+07 GE/mL	None
Mycoplasma hominis	Zeptometrix 0804011	2.11E+09 CCU/mL	None
Mycoplasma orale	ATCC 19524	1.00E+07 CCU/mL	None
Neisseria elongata	Zeptometrix 0801510	1.99E+08 CFU/mL	None
Neisseria gonorrhoeae	ATCC 19424	2.31E+09 CFU/mL	None
Neisseria meningitidis	ATCC 13090	1.99E+09 CFU/mL	None
Proteus mirabilis	ATCC 12453	5.60E+09 CFU/mL	None
Pseudomonas aeruginosa	ATCC 27853	4.33E+09 CFU/mL	None
Serratia marcescens	JMI 697	4.75E+09 CFU/mL	None
Staphylococcus aureus (MRSA)	ATCC 10832	1.88E+08 CFU/mL	None
Staphylococcus epidermidis	ATCC 29887	4.95E+09 CFU/mL	None

Organism	Isolate ID	Concentration Tested	Cross-Reactivity Detected/Predicted
Stenotrophomonas maltophilia	ATCC 700475	4.93E+09 CFU/mL	None
Streptococcus agalactiae	ATCC 13813	5.45E+09 CFU/mL	None
Streptococcus dysgalactiae	ATCC 43078	5.70E+09 CFU/mL	None
Streptococcus pneumoniae	ATCC BAA-341	5.20E+09 CFU/mL	None
Streptococcus pyogenes	ATCC 19615	5.46E+07 CFU/mL	None
Streptococcus salivarius	ATCC 13419	4.92E+09 CFU/mL	None
Ureaplasma urealyticum	ATCC 27618	1.00E+08 CCU/mL	None
Fungi			
Aspergillus flavus	Zeptometrix 0801598	1.15E+08 CFU/mL	None
Aspergillus fumigatus	Zeptometrix 0801716	5.47E+07 CFU/mL	None
Blastomyces dermatitidis	ATCC 26199D-2 (genomic DNA)	7.05E+07 GE/mL	None
Candida albicans	ATCC 10231	1.19E+06 CFU/mL	None
Cryptococcus neoformans	ATCC MYA-4564	6.00E+07 CFU/mL	None
Histoplasma capsulatum	Evaluated *in silico*		None
Pneumocystis jirovecii (carinii)	ATCC PRA-159	6.67E+07 nuclei/mL	None
Viruses (SARS-CoV-2 Related Coronaviruses)			
Bat SARS-like Coronavirus (recombinantt)	BEI NR-44009	Unknown[b] (undiluted culture)	None
Bat SARS-like Coronavirus HKU5 (recombinant)	BEI NR-48814	Unknown[b] (undiluted culture)	None
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)	BEI NR-44260 EMC/2012	2.7E+09 copies/mL	None
Severe Acute Respiratory Syndrome Coronavirus (SARS)	BEI NR-18925 Urbani strain	5.3E+09 copies/mL	None
Viruses			
Bocavirus	Clinical specimen	1.40E+08 copies/mL	None
Cytomegalovirus (CMV)	Zeptometrix 0810003CF	7.67E+06 $TCID_{50}$/mL	None
Epstein-Barr Virus (EBV)	Zeptometrix 0810008CF	3.65E+07 copies/mL	None
Herpes Simplex Virus 1 (HSV1)	ATCC VR-1778	3.30E+08 copies/mL	None
Herpes Simplex Virus 2 (HSV2)	Zeptometrix 0810217CF	1.30E+07 $TCID_{50}$/mL	None
Human Herpes Virus 6 (HHV6)	Zeptometrix 0810072CF	4.11E+08 copies/mL	None
Human Parechovirus (HPeV)	Zeptometrix 0810147CF	2.26E+07 $TCID_{50}$/mL	None
Influenza C	Evaluated *in silico*		None
Measles Virus	Zeptometrix 0810025CF	1.63E+05 $TCID_{50}$/mL	None
Mumps	Zeptometrix 0810079CF	4.83E+05 units/mL	None

[a] *Bordetella pertussis* (*ptxP*) assay may amplify pertussis toxin pseudogene sequences from some strains of *B. bronchiseptica* at high concentration (≥1.2E+09 CFU/mL).

[b] Each coronavirus was cultured in a contracted biosafety level 3 laboratory and tested as undiluted culture. No quantification of the Bat SARS-like coronaviruses was available at the time of testing.

Reproducibility

The reproducibility of SARS-CoV-2 detection by the BioFire RP2.1 has not been specifically evaluated for the Emergency Use Authorization of the panel. Reproducibility results for the BioFire RP2 (presented below) are applicable to the BioFire RP2.1, as the panel tests the same sample type, by the same methods, on the same systems.

Reproducibility testing of contrived samples was performed with the BioFire RP2 at three test sites on a combination of FilmArray 2.0 and FilmArray Torch systems. The study incorporated a range of potential variation introduced by site, day, operator (at least two per site), system, instrument or Torch module (at least three per site/sample), and pouch lot (at least three). The samples contained various combinations of twelve different BioFire RP2 analytes, each at three different concentrations (Negative, Low Positive (1×LoD), and Moderate Positive (3×LoD)). Frozen samples were repeatedly tested on five different days for 120 data points per sample (60 per system) from 480 total valid runs.

A summary of results (percent (%) agreement with the expected Detected or Not Detected result) for each analyte (by site and system) is provided in Table 42.

Table 42. Reproducibility of BioFire RP2 Results on FilmArray Torch and FilmArray 2.0 Systems

Analyte	Concentration Tested	Expected Result	Agreement with Expected Result						
			FilmArray Torch			FilmArray 2.0			All Sites/Systems (95% CI)
			Site A	Site C	System Sub-Total	Site B	Site C	System Sub-Total	
Viruses									
Adenovirus C2 ATCC VR-846	**Moderate Positive 3× LoD** 6.0E+00 $TCID_{50}$/mL (1.1E+02 copies/mL)	Detected	30/30 100%	29/30 96.7%	59/60 98.3%	29/30 96.7%	30/30 100%	59/60 98.3%	118/120 98.3% (94.1%-99.8%)
	Low Positive 1× LoD 2.1E+00 $TCID_{50}$/mL (3.7E+01 copies/mL)	Detected	30/30 100%	30/30 100%	60/60 100%	30/30 100%	29/30 96.7%	59/60 98.3%	119/120 99.2% (95.4%-100%)
	None (no analyte)	Not Detected	60/60 100%	60/60 100%	120/120 100%	60/60 100%	60/60 100%	120/120 100%	240/240 100% (98.5%-100%)
Coronavirus 229E	**None** (no analyte)	Not Detected	120/120 100%	120/120 100%	240/240 100%	120/120 100%	120/120 100%	240/240 100%	480/480 100% (99.2%-100%)
Coronavirus HKU1	**None** (no analyte)	Not Detected	120/120 100%	120/120 100%	240/240 100%	120/120 100%	120/120 100%	240/240 100%	480/480 100% (99.2%-100%)
Coronavirus OC43 ATCC VR-759	**Moderate Positive 3× LoD** 9.0E+01 $TCID_{50}$/mL (1.7E+03 copies/mL)	Detected	29/30 96.7%	29/30 96.7%	58/60 96.7%	29/30 96.7%	30/30 100%	59/60 98.3%	117/120 97.5% (92.9%-99.5%)
	Low Positive 1× LoD 3.0E+01 $TCID_{50}$/mL (5.6E+02 copies/mL)	Detected	30/30 100%	30/30 100%	60/60 100%	30/30 100%	27/30 90.0%	57/60 95.0%	117/120 97.5% (92.9%-99.5%)
	None (no analyte)	Not Detected	60/60 100%	60/60 100%	120/120 100%	60/60 100%	60/60 100%	120/120 100%	240/240 100% (98.5%-100%)
Coronavirus NL63	**None** (no analyte)	Not Detected	120/120 100%	120/120 100%	240/240 100%	120/120 100%	120/120 100%	240/240 100%	480/480 100% (99.2%-100%)
Human Metapneumovirus Type 16, A1 IA10-2003 Zeptometrix 0810161CF	**Moderate Positive 3× LoD** 3.0E+01 $TCID_{50}$/mL (3.6E+03 copies/mL)	Detected	30/30 100%	30/30 100%	60/60 100%	30/30 100%	30/30 100%	60/60 100%	120/120 100% (97.0%-100%)
	Low Positive 1× LoD 1.0E+01 $TCID_{50}$/mL (1.2E+03 copies/mL)	Detected	30/30 100%	30/30 100%	60/60 100%	28/30 93.3%	30/30 100%	58/60 96.7%	118/120 98.3% (94.1%-99.8%)
	None (no analyte)	Not Detected	60/60 100%	60/60 100%	120/120 100%	60/60 100%	60/60 100%	120/120 100%	240/240 100% (98.5%-100%)
Human Rhinovirus/ Enterovirus Rhinovirus 1A Zeptometrix 0810012CFN	**Moderate Positive 3× LoD** 3.0E-01 $TCID_{50}$/mL (1.1E+02 copies/mL)	Detected	30/30 100%	30/30 100%	60/60 100%	28/30 93.3%	30/30 100%	58/60 96.7%	118/120 98.3% (94.1%-99.8%)
	Low Positive 1× LoD 1.0E-01 $TCID_{50}$/mL (3.8E+01 copies/mL)	Detected	30/30 100%	30/30 100%	60/60 100%	30/30 100%	30/30 100%	60/60 100%	120/120 100% (97.0%-100%)
	None (no analyte)	Not Detected	60/60 100%	60/60 100%	120/120 100%	60/60 100%	60/60 100%	120/120 100%	240/240 100% (98.5%-100%)
Influenza A H3 Influenza A H3N2 A/Port	**Moderate Positive 3× LoD** 3.0E-01 $TCID_{50}$/mL (6.3E+01 copies/mL)	Detected	30/30 100%	30/30 100%	60/60 100%	29/30 96.7%	30/30 100%	59/60 98.3%	119/120 99.2% (95.4%-100%)

AB843

Analyte	Concentration Tested	Expected Result	Agreement with Expected Result						
			FilmArray Torch			FilmArray 2.0			All Sites/Systems (95% CI)
			Site A	Site C	System Sub-Total	Site B	Site C	System Sub-Total	
Chalmers/1/73 ATCC VR-810	**Low Positive** **1× LoD** 1.0E-01 $TCID_{50}$/mL (2.1E+01 copies/mL)	**Detected**	**30/30** 100%	**30/30** 100%	**60/60** 100%	**30/30** 100%	**30/30** 100%	**60/60** 100%	**120/120** **100%** (97.0%-100%)
	None (no analyte)	**Not Detected**	**60/60** 100%	**60/60** 100%	**120/120** 100%	**60/60** 100%	**60/60** 100%	**120/120** 100%	**240/240** **100%** (98.5%-100%)
Influenza A H1-2009	**None** (no analyte)	**Not Detected**	**120/120** 100%	**120/120** 100%	**240/240** 100%	**120/120** 100%	**120/120** 100%	**240/240** 100%	**480/480** **100%** (99.2%-100%)
Influenza A H1	**None** (no analyte)	**Not Detected**	**120/120** 100%	**120/120** 100%	**240/240** 100%	**120/120** 100%	**120/120** 100%	**240/240** 100%	**480/480** **100%** (99.2%-100%)
Influenza B B/FL/04/06 Zeptometrix 0810255CF	**Moderate Positive** **3× LoD** 1.5E+01 $TCID_{50}$/mL (1.0E+02 copies/mL)	**Detected**	**30/30** 100%	**30/30** 100%	**60/60** 100%	**30/30** 100%	**30/30** 100%	**60/60** 100%	**120/120** **100%** (97.0%-100%)
	Low Positive **1× LoD** 5.0E+00 $TCID_{50}$/mL (3.4E+01 copies/mL)	**Detected**	**30/30** 100%	**30/30** 100%	**60/60** 100%	**30/30** 100%	**30/30** 100%	**60/60** 100%	**120/120** **100%** (97.0%-100%)
	None (no analyte)	**Not Detected**	**60/60** 100%	**60/60** 100%	**120/120** 100%	**60/60** 100%	**60/60** 100%	**120/120** 100%	**240/240** **100%** (98.5%-100%)
Parainfluenza Virus 1	**None** (no analyte)	**Not Detected**	**120/120** 100%	**120/120** 100%	**240/240** 100%	**120/120** 100%	**120/120** 100%	**240/240** 100%	**480/480** **100%** (99.2%-100%)
Parainfluenza Virus 2 Type 2 Zeptometrix 0810015CF	**Moderate Positive** **3× LoD** 1.5E+00 $TCID_{50}$/mL (9.0E+01 copies/mL)	**Detected**	**30/30** 100%	**29/30** 96.7%	**59/60** 98.3%	**29/30** 96.7%	**30/30** 100%	**59/60** 98.3%	**118/120** **98.3%** (94.1%-99.8%)
	Low Positive **1× LoD** 5.0E-01 $TCID_{50}$/mL (3.0E+01 copies/mL)	**Detected**	**30/30** 100%	**29/30** 96.7%	**59/60** 98.3%	**30/30** 100%	**27/30** 90.0%	**57/60** 95.0%	**116/120** **96.7%** (91.7%-99.1%)
	None (no analyte)	**Not Detected**	**60/60** 100%	**60/60** 100%	**120/120** 100%	**60/60** 100%	**60/60** 100%	**120/120** 100%	**240/240** **100%** (98.5%-100%)
Parainfluenza Virus 3	**None** (no analyte)	**Not Detected**	**120/120** 100%	**120/120** 100%	**240/240** 100%	**120/120** 100%	**120/120** 100%	**240/240** 100%	**480/480** **100%** (99.2%-100%)
Parainfluenza Virus 4 Type 4a Zeptometrix 0810060CF	**Moderate Positive** **3× LoD** 1.5E+02 $TCID_{50}$/mL (4.8E+03 copies/mL)	**Detected**	**30/30** 100%	**30/30** 100%	**60/60** 100%	**30/30** 100%	**30/30** 100%	**60/60** 100%	**120/120** **100%** (97.0%-100%)
	Low Positive **1× LoD** 5.0E+01 $TCID_{50}$/mL (1.6E+03 copies/mL)	**Detected**	**30/30** 100%	**29/30** 96.7%	**59/60** 98.3%	**29/30** 96.7%	**30/30** 100%	**59/60** 98.3%	**118/120** **98.3%** (94.1%-99.8%)
	None (no analyte)	**Not Detected**	**60/60** 100%	**60/60** 100%	**120/120** 100%	**60/60** 100%	**60/60** 100%	**120/120** 100%	**240/240** **100%** (98.5%-100%)
Respiratory Syncytial Virus Type A	**Moderate Positive** **3× LoD** 6.0E-02 $TCID_{50}$/mL (2.7E+01 copies/mL)	**Detected**	**30/30** 100%	**30/30** 100%	**60/60** 100%	**30/30** 100%	**30/30** 100%	**60/60** 100%	**120/120** **100%** (97.0%-100%)

AB844

Analyte	Concentration Tested	Expected Result	Agreement with Expected Result: FilmArray Torch Site A	FilmArray Torch Site C	FilmArray Torch System Sub-Total	FilmArray 2.0 Site B	FilmArray 2.0 Site C	FilmArray 2.0 System Sub-Total	All Sites/Systems (95% CI)
Zeptometrix 0810040ACF	**Low Positive** **1× LoD** 2.0E-02 $TCID_{50}$/mL (9.0E+00 copies/mL)	**Detected**	**29/30** 96.7%	**30/30** 100%	**59/60** 98.3%	**30/30** 100%	**29/30** 96.7%	**59/60** 98.3%	**118/120** **98.3%** (94.1%-99.8%)
	None (no analyte)	**Not Detected**	**60/60** 100%	**60/60** 100%	**120/120** 100%	**60/60** 100%	**60/60** 100%	**120/120** 100%	**240/240** **100%** (98.5%-100%)
Bacteria									
Bordetella parapertussis (IS*1001*) A747 Zeptometrix 0801461	**Moderate Positive** **3× LoD** 1.8E+02 IS*1001* copies/mL (1.2E+02 CFU/mL)	**Detected**	**30/30** 100%	**30/30** 100%	**60/60** 100%	**29/30** 96.7%	**30/30** 100%	**59/60** 98.3%	**119/120** **99.2%** (95.4%-100%)
	Low Positive **1× LoD** 6.0E+01 IS*1001* copies/mL (4.1E+01 CFU/mL)	**Detected**	**24/30**[a] 80.0%	**29/30** 96.7%	**53/60**[a] 88.3%	**29/30** 96.7%	**30/30** 100%	**59/60** 98.3%	**112/120** **93.3%** (87.3%-97.1%)
	None (no analyte)	**Not Detected**	**60/60** 100%	**60/60** 100%	**120/120** 100%	**60/60** 100%	**60/60** 100%	**120/120** 100%	**240/240** **100%** (98.5%-100%)
Bordetella pertussis (ptxP) A639 Zeptometrix 0801459	**Moderate Positive** **3× LoD** 3.0E+03 CFU/mL	**Detected**	**30/30** 100%	**30/30** 100%	**60/60** 100%	**30/30** 100%	**30/30** 100%	**60/60** 100%	**120/120** **100%** (97.0%-100%)
	Low Positive **1× LoD** 1.0E+03 CFU/mL	**Detected**	**28/30** 93.3%	**30/30** 100%	**58/60** 96.7%	**30/30** 100%	**30/30** 100%	**60/60** 100%	**118/120** **98.3%** (94.1%-99.8%)
	None (no analyte)	**Not Detected**	**60/60** 100%	**60/60** 100%	**120/120** 100%	**60/60** 100%	**60/60** 100%	**120/120** 100%	**240/240** **100%** (98.5%-100%)
Chlamydia (Chlamydophila) pneumoniae TW183 ATCC VR-2282	**Moderate Positive** **3× LoD** 3.0E-01 $TCID_{50}$/mL (2.0E+02 copies/mL)	**Detected**	**30/30** 100%	**30/30** 100%	**60/60** 100%	**30/30** 100%	**30/30** 100%	**60/60** 100%	**120/120** **100%** (97.0%-100%)
	Low Positive **1× LoD** 1.0E-01 $TCID_{50}$/mL (6.6E+01 copies/ml)	**Detected**	**28/30** 93.3%	**30/30** 100%	**58/60** 96.7%	**29/30** 96.7%	**30/30** 100%	**59/60** 98.3%	**117/120** **97.5%** (92.9%-99.5%)
	None (no analyte)	**Not Detected**	**60/60** 100%	**60/60** 100%	**120/120** 100%	**60/60** 100%	**60/60** 100%	**120/120** 100%	**240/240** **100%** (98.5%-100%)
Mycoplasma pneumoniae	**None** (no analyte)	**Not Detected**	**120/120** 100%	**120/120** 100%	**240/240** 100%	**120/120** 100%	**120/120** 100%	**240/240** 100%	**480/480** **100%** (99.2%-100%)
Overall Agreement with the Expected Result **All Analytes and All Test Levels** **(95% Confidence Interval)**			**9,562/9,600** **99.6%** **(99.5% – 99.7%)**						

[a] Data from Site A were further reviewed by the unique site-specific variables including test day, Torch module, and operator. No correlation could be found between the Not Detected results and any one or more of these variables. The Not Detected results at Site A were found to be statistically non-significant (p>0.05 by Fisher's exact test) and therefore do not indicate a site- or system-dependent variance in precision of the BioFire RP2 *Bordetella parapertussis* (IS*1001*) results.

Interference

The ability of endogenous or exogenous substances that could be present in NPS specimens (or introduced during specimen collection and handling) to interfere with accurate detection of SARS-CoV-2 and other analytes was evaluated with select direct testing on the BioFire RP2.1 and extrapolated from the interference evaluation of the BioFire RP2. Results from testing using the BioFire RP2 are applicable to the BioFire RP2.1, because the panel tests the same sample type, by the same methods, on the same systems, with no change to primers or reaction chemistry and conditions.

Potentially interfering substances were evaluated using contrived samples spiked with substance. Results from samples containing a substance were compared to results from control samples without substance. The substances tested included endogenous substances that may be found in specimens at normal or elevated levels (e.g. blood, mucus/mucin, human genomic DNA), various commensal or infectious microorganisms, medications, washes or topical applications for the nasal passage, various swabs and transport media for specimen collection, and substances used to clean, decontaminate, or disinfect work areas. Each substance was added to contrived samples containing representative organisms at concentrations near (2-3×) LoD. The concentration of substance added to the samples was equal to or greater than the highest level expected to be in NPS specimens and each sample was tested in triplicate.

None of the substances were shown to interfere with the BioFire RP2 or BioFire RP2.1 function. However, it was observed that exposure of samples to bleach prior to testing could damage the organisms/nucleic acids in the sample, leading to inaccurate BioFire RP2/RP2.1 test results (lack of analyte detection). The effect of bleach was dependent on the concentration and/or length of time the bleach was allowed to interact with the sample.

Table 43. Evaluation of Potentially Interfering Substances for NPS Specimens on the BioFire RP2 and BioFire RP2.1

Substances in **bold** font were tested with the BioFire RP2.1 on samples containing SARS-CoV-2 and other organisms at 3× LoD. All other substances were tested with the BioFire RP2.

Substance Tested	Concentration Tested	Result
Endogenous Substances		
Human Whole Blood	**10% v/v**	**No Interference**
Human Mucus (Sputum)	1 swab/mL sample	No Interference
Human Genomic DNA	**20 ng/µL**	**No Interference**
Human Peripheral Blood Mononuclear Cells (PBMCs)	**1.0E+03 cell/µL**	**No Interference**
Competitive Microorganisms		
Coronavirus 229E	1.7E+04 $TCID_{50}$/mL	No Interference
Coronavirus OC43	**9.6E+05 $TCID_{50}$/mL**	**No Interference**
Adenovirus A12	8.9E+05 $TCID_{50}$/mL	No Interference
Parainfluenza Virus 3	6.6E+05 $TCID_{50}$/mL	No Interference
Bordetella pertussis	5.8E+08 CFU/mL	No Interference
Enterovirus D68	1.6E+07 $TCID_{50}$/mL	No Interference
Echovirus 6	1.0E+07 $TCID_{50}$/mL	No Interference
Respiratory Syncytial Virus	4.2E+04 $TCID_{50}$/mL	No Interference
Staphylococcus aureus	2.5E+07 CFU/mL	No Interference
Streptococcus pneumoniae	1.7E+07 CFU/mL	No Interference
Streptococcus salivarius	**2.5E+09 CFU/mL**	**No Interference**
Haemophilus influenzae	6.2E+07 CFU/mL	No Interference
Candida albicans	1.0E+06 CFU/mL	No Interference
Herpes Simplex Virus 1	1.6E+06 $TCID_{50}$/mL	No Interference
Cytomegalovirus	1.2E+06 $TCID_{50}$/mL	No Interference
Exogenous Substances[a]		
Tobramycin (systemic antibiotic)	0.6 mg/mL	No Interference
Mupirocin (active ingredient in anti-bacterial ointment)	2% w/v	No Interference
Saline Nasal Spray with Preservatives (0.65% NaCl, Phenylcarbinol, Benzalkonium chloride)	1% v/v	No Interference
Nasal Decongestant Spray (Oxymetazoline HCl 0.05%, Benzalkonium chloride, phosphate)	1% v/v	No Interference
Analgesic ointment (Vicks®VapoRub®)	1% w/v	No Interference
Petroleum Jelly (Vaseline®)	1% w/v	No Interference
Snuff (Tobacco)	1% w/v	No Interference
Disinfecting/Cleaning Substances		

AB846

Substance Tested	Concentration Tested	Result
Bleach	1% and 2% v/v [up to 1024 ppm chlorine]	Interference[b]
Disinfecting wipes (ammonium chloride)	½ in^2	No Interference
Ethanol	7% v/v	No Interference
DNA*Zap* (Ambion™ AM9891G & AM9892G)	1% v/v	No Interference
RNase*Zap* (Ambion™ AM9782)	1% v/v	No Interference
Specimen Collection Materials		
Rayon Swabs (Copan 168C)	N/A	No Interference
Nylon Flocked Swabs (Copan 553C)	N/A	No Interference
Polyester Swabs (Copan 175KS01)	N/A	No Interference
Calcium Alginate Swabs (Puritan 25-801 A 50)	N/A	No Interference
M4® Transport Medium (Remel)	100%	No Interference
M4-RT® Transport Medium (Remel)	100%	No Interference
M5® Transport Medium (Remel)	100%	No Interference
M6™ Transport Medium (Remel)	100%	No Interference
Universal Viral Transport vial (BD)	100%	No Interference
PrimeStore® Molecular Transport Medium (MTM)	**70% v/v**	**No Interference**
Sigma-Virocult™ Viral Collection and Transport System (Swab and Transport Medium)	100%	No Interference
Copan ESwab™ Sample Collection and Delivery System (Swab and Liquid Amies Medium)	100%	No Interference

[a] Nasal influenza vaccines (e.g. FluMist) were not evaluated, but are predicted to be reactive with the BioFire RP2.1 Influenza A (subtype) and Influenza B assays.

[b] Not Detected results were reported for several analytes after incubation of the sample with 2% bleach for 10 minutes or overnight. It was concluded that interference resulted primarily from damage to the organisms/nucleic acids in the sample, rather than inhibition or interference with pouch function(s).

NOTE: Compatibility of the BioFire RP2.1 with NPS in PrimeStore® MTM has not been evaluated in the intended use setting. PrimeStore® MTM and BioFire FilmArray Sample Buffer contain guanidine salts that will react with bleach to form a toxic gas. Use caution if using bleach for disinfection purposes when collecting or testing NPS specimens.

AB847

APPENDIX A

Symbols Glossary

ISO 15223-1:2012 **Medical devices - Symbols to be used with medical devices labels, labeling and information to be supplied**					
5.1.1	Manufacturer	5.1.2 EC REP	Authorized representative in the European Community	5.1.4	Use-By date (YYYY-MM-DD)
5.1.5 LOT	Batch Code (Lot Number)	5.1.6 REF	Catalog Number	5.1.7 SN	Serial Number
5.2.8	Do Not Use if Package Is Damaged	5.3.2	Keep Away from Sunlight	5.3.7	Temperature Limit
5.4.2	Do Not Reuse	5.4.3	Consult Instructions for Use	5.5.1 IVD	In vitro Diagnostic Medical Device
5.5.5 Σ n	Contains Sufficient For <n> Tests				
Use of Symbols in Labeling – 81 FR 38911, Docket No. (FDA-2013-N-0125)					
Rx Only	Prescription Use Only				
United Nations Globally Harmonized System of Classification and Labeling of chemicals (GHS) (ST/SG/AC.10/30)					
	Serious eye damage, cat. 1		Acute toxicity, cat. 4 & Skin irritation, cat. 2		Acute aquatic hazard, cat.1 & Long-term aquatic hazard, cat.1
European Union Directive 98/79/EC of the European Parliament and of the Council on in vitro Diagnostic Medical Device					
CE	European Union Conformity				
Manufacturer Symbols (BioFire Diagnostics, LLC)					
	The NOTE symbols explains how to perform the BioFire RP2.1 test more efficiently.				
+ SARS-CoV-2	A BioFire RP2.1 Panel				

AB848

APPENDIX B

Contact and Legal Information

Customer and Technical Support for U.S. Customers	
Reach Us on the Web http://www.BioFireDX.com **Reach Us by E-mail** support@BioFireDX.com **Reach Us by Mail** 515 Colorow Drive Salt Lake City, UT 84108 USA	**Reach Us by Phone** 1-800-735-6544 – Toll Free (801) 736-6354 – Utah **Reach Us by Fax** (801) 588-0507
Customer and Technical Support outside of the U.S.	
Contact the local bioMérieux sales representative or an authorized distributor for technical support.	

BioFire Diagnostics, LLC
515 Colorow Drive
Salt Lake City, UT 84108
USA

The purchase of this product includes a limited, nontransferable license under specific claims of one or more U.S. patents as listed on BioFire Diagnostics' Web site (http://www.biofiredx.com/legal-notices/) and owned by BioFire and the University of Utah Research Foundation.

Warranty Information

Product warranty information is available online at:

http://www.biofiredx.com/support/documents/

For warranty information for customers outside the United States, contact the local bioMérieux sales representative or an authorized distributor.

APPENDIX C

References

1. Biosafety in Microbiological and Biomedical Laboratories. (2009).

2. Protection of Laboratory Workers From Occupationally Acquired Infections; Approved Guideline M29.

3. Adams, D. A. *et al.* Summary of Notifiable Diseases - United States, 2011. *MMWR Morb. Mortal. Wkly. Rep.* **60**, 1–117 (2013).

4. *CIFOR Analysis of State Legal Authorities*. http://www.cifor.us/.

5. Statistical Quality Control for Quantitative Measurement Procedures: Principles and Definitions; NCCLS Approved Guideline. (2006).

6. User Protocol for Evaluation of Qualitative Test Performance; NCCLS Approved Guideline. (2008).

7. Zhou, P. *et al.* A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **579**, 270–273 (2020).

8. Cagliani, R., Forni, D., Clerici, M. & Sironi, M. Computational inference of selection underlying the evolution of the novel coronavirus, SARS-CoV-2. *J. Virol.* (2020) doi:10.1128/JVI.00411-20.

REVISION HISTORY

Version	Revision Date	Description of Revision(s)
01	May 2020	Initial release

INDEX

BioFire® FilmArray® Respiratory Panels (RP2.1, RP2.1*plus* and RP2.1-EZ) SARS-CoV-2 Reactivity

Introduction

The BioFire RP2.1, RP2.1*plus* and RP2.1-EZ are multiplexed nucleic acid tests intended for use with BioFire® FilmArray® Systems for the simultaneous qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs (NPS) obtained from individuals suspected of respiratory tract infections. This includes the detection of SARS-CoV-2 which is identified with two independent assays: SARSCoV2-1 which targets the S (Spike) gene and SARSCoV2-2 which targets the M (Membrane) gene. A positive result from either assay will result in a SARS-CoV-2 Detected result.

Note: BioFire tests do not report cycle threshold (Ct) values and the BioFire RP2.1 SARS-CoV-2 assays are not intended to monitor for novel mutations.

Emerging UK SARS-CoV-2 Variants

Several SARS-CoV-2 variants of concern have recently been observed in the United Kingdom. These variants were described in a COVID-19 Genomics UK Consortium report (COG-UK update on SARS-CoV-2 Spike mutations of special interest – Report 1 Dec 20, 2020) and are purported to enhance infectivity and/or transmissibility of the virus.

BioFire has conducted a comprehensive analysis of the predicted assay reactivity for the variants described in the Dec 20, 2020 COG-UK report can be found in Table 1. Briefly, none of the identified mutations are expected to affect performance of either BioFire SARS-CoV-2 assay

Table 1. List of mutations identified in Dec 20, 2020 COG-UK report and BioFire RP2.1 assay reactivity summary

Mutation		BioFire RP2.1 SARS-CoV-2 Assay		BioFire RP2.1 SARS-CoV-2 Overall Result Expected
Nucleotide	Amino Acid	SARSCoV2-2 Assay: M-gene (Membrane)	SARSCoV2-1 Assay: S-gene (Spike)	
		ORF1ab		
ACT3263ATT	T1001I	Not targeted	Not targeted	Detection Unaffected
GCT5384GAT	A1708D	Not targeted	Not targeted	Detection Unaffected
ATA6950ACA	I2230T	Not targeted	Not targeted	Detection Unaffected
TCTGGTTTT11284	Δ3675-7 SGF	Not targeted	Not targeted	Detection Unaffected
		Spike		

Mutation		BioFire RP2.1 SARS-CoV-2 Assay		BioFire RP2.1 SARS-CoV-2 Overall Result Expected
Nucleotide	**Amino Acid**	**SARSCoV2-2 Assay: M-gene (Membrane)**	**SARSCoV2-1 Assay: S-gene (Spike)**	
ACATGT21763	Δ69-70	Not targeted	Primers unaffected (Assay located in a different area of the gene)	Detection Unaffected
TTA21991	Δ145	Not targeted	Primers unaffected (Assay located in a different area of the gene)	Detection Unaffected
AAT23063TAT	N501Y	Not targeted	Primers unaffected (Assay located in a different area of the gene)	Detection Unaffected
GCT23269GAT	A570D	Not targeted	Primers unaffected (Assay located in a different area of the gene)	Detection Unaffected
CCT23602CAT	P681H	Not targeted	Primers unaffected (Assay located in a different area of the gene)	Detection Unaffected
ACA23707ATA	T716I	Not targeted	Primers unaffected (Assay located in a different area of the gene)	Detection Unaffected
TCA24505GCA	S982A	Not targeted	Primers unaffected (Assay located in a different area of the gene)	Detection Unaffected
GAC24913CAC	D1118H	Not targeted	Located in 5' end of one primer; no effect on performance expected.	Detection Unaffected
		ORF8		
CAA27969TAA	Q27 stop	Not targeted	Not targeted	Detection Unaffected
AGA28044ATA	R52I	Not targeted	Not targeted	Detection Unaffected
TAC28107TGC	Y73C	Not targeted	Not targeted	Detection Unaffected
		N		
GAT28277CTA	D3L	Not targeted	Not targeted	Detection Unaffected
TCT28973TTT	S235F	Not targeted	Not targeted	Detection Unaffected

Additionally, BioFire has performed an updated in silico analysis and assay reactivity prediction for sequences from SARS-CoV-2 variants of lineages B.1.1, B.1.1.7, and B.1.258 (discussed in the COG-UK report) that contain Δ69-70 and N501Y mutations in the spike gene, including sequence that appears to correspond to VUI-202012/01 (named the first 'Variant Under Investigation' by Public Health England in December 2020). In total, 1,920 sequences of UK lineage strains were retrieved and analyzed (GISAID sequences, all complete high-coverage sequences available until Dec 22, 2020).

Overall, 100% of the 1,920 UK SARS-CoV-2 sequences evaluated from lineages B.1.1, B.1.1.7 and B.1.258 that contain modifications to the Spike gene are predicted to be detected by one or both assays with no limitations (Table 2).

Table 2. *In silico* Prediction of SARS-CoV-2 Detection by BioFire SARSCoV2-1 and SARSCoV2-2 Assays (Lineages B.1.1, B.1.1.7, & B.1.258 with Δ69-70 and N501Y mutations from the UK, Dec 22, 2020)
+/+ indicates detected by both assays with no impairment, +/- indicates detection by one assay with no impairment and potential for impaired detection by the other assay, -/- indicates potential for impaired detection by both assays

Predicted Assay Result / # sequences		SARSCoV2-1 (S-gene) +	SARSCoV2-1 (S-gene) -	# (%) sequences predicted to be detected with no limitations (one or both assays positive)
SARSCoV2-2 (M-gene)	+	1910	3	1920/1920 (100.0%)
	-	7	0	

This analysis indicates that the BioFire RP2.1 family of tests will be able to amplify and detect 100% of sequences retrieved on Dec 22, 2020, representing lineages B.1.1, B.1.1.7, & B.1.258 with Δ69-70 and N501Y mutations circulating in the UK.

Global in silico SARS-CoV-2 Variant Analysis

Table 27 in the BioFire® RP2.1 and RP2.1*plus* Instructions for Use (IFU) and Table 28 in the RP2.1-EZ IFU summarizes an evaluation of analytical reactivity for the BioFire RP2.1 SARS-CoV-2 assays (SARSCoV2-1 and SARSCoV2-2) based on in silico sequence analysis of all available sequences in the NCBI and GISAID databases at the time of EUA submission (April or September 2020, respectively). BioFire has performed periodic updates of this in silico analysis with the most recent performed on December 20, 2020 as shown in Table 3 below.

Table 3. *In silico* Prediction of SARS-CoV-2 Detection by BioFire SARSCoV2-1 and SARSCoV2-2 Assays (December 20, 2020)
+/+ indicates detected by both assays with no impairment, +/- indicates detection by one assay with no impairment and potential for impaired detection by the other assay, -/- indicates potential for impaired detection by both assays

Predicted Assay Result / # sequences		SARSCoV2-1 (S-gene) +	SARSCoV2-1 (S-gene) -	# (%) sequences predicted to be detected with no limitations (one or both assays positive)
SARSCoV2-2 (M-gene)	+	219,197	1643	221,275/221,279 (99.99%)*
	-	435	4*	

*Four sequences have mismatches in the 3' half of primer(s) for both the SARSCoV2-1 and SARSCoV2-2 assays. The mismatches are predicted to impair detection at low analyte concentration.

An experiment was performed using synthetic nucleic acid template to estimate the impact of the mismatches observed in the four sequences indicated in Table 3 on amplification and detection by both assays. Testing verified that the identified mismatch under the SARSCoV2-1 assay primers had a significant (10,000-fold) impact on amplification and detection relative to the control sequence while the mismatch under the SARSCoV2-2 primer had only a minor (2-4-fold) impact on amplification and detection relative to the control sequence. The BioFire® RP2.1, RP2.1*plus* and RP2.1-EZ SARS-CoV-2 test only requires one assay to be positive in order to report "SARS-CoV-2 detected" therefore these four rare variants are expected to be detected by the BioFire RP2.1 family of tests but could demonstrate a mild reduction in analytical sensitivity near the limit of detection.

This analysis supports the conclusion that all 221,279 sequences evaluated as of December 20, 2020 can be amplified and detected by the BioFire RP2.1 family of tests, though a limitation or impairment on detection is predicted at low concentrations (≤10x the limit of detection) for 0.0018% of the sequences (4/221,279).

Conclusions

1. The BioFire® Respiratory 2.1 Panels (RP2.1, RP2.1*plus* and RP2.1-EZ) SARS-CoV-2 assays are not affected by the circulating UK variants reported in the Genomics UK Consortium report (COG-UK update on SARS-CoV-2 Spike mutations of special interest – Report 1 Dec 20, 2020).
2. Global in silico analysis (as of December 20, 2020) predicts that the BioFire® Respiratory Panels (RP2.1, RP2.1*plus* and RP2.1-EZ) SARS-CoV-2 assays will detect all 221,279 sequences evaluated.
3. BioFire tests do not report cycle threshold (Ct) values and the BioFire RP2.1 SARS-CoV-2 assays are not intended to monitor for novel mutations.

Bioinformatics for the SARS-CoV-2 virus is expanding at a rapid rate since the emergence of the virus in human infection in late 2019. Thousands of viral whole genome sequences are being evaluated and submitted to public and private databases on a monthly basis. As the pandemic persists and viral genomes evolve, monitoring of assay reactivity with new sequences is important for understanding the state-of-the-art for performance of the SARS-CoV-2 assays in the BioFire RP2.1 family of products (RP2.1, RP2.1*plus* and RP2.1-EZ).

BioFire continues to monitor these new sequences and is performing regular revised in silico analyses of the RP2.1 family SARS-CoV-2 assays.

Technical Support Contact Information

BioFire is dedicated to providing the best customer support available. If you have any questions or concerns about this process, please contact the BioFire Technical Support team for assistance.

BioFire Technical Support
Email: support@biofiredx.com
Phone: +1-801-736-6354, select Option 5

AB858

parameter_descirption
Max number of days to be simulated
Number of days to allocate in sim_summary vectors
Real population size
pop_scale
Population Parameters / Social Compartments Parameters
Population size
Household size: 1 agent (cumulative "probability")
Household size: 2 agents
Household size: 3 agents
Household size: 4 agents
Household size: 5 agents
Household size: 'num_of_agents_in_care_home' agents (care homes)
Total num of agents in PCH
max_num_agents_in_PCH (scaled for pop_size)
Num. agents per care home
Num. agents in other social compartment
Num. agents in other social compartment if healthcare worker (must be smaller than 'other' group size)
Total num. of healthcare workers (**make it divisible by 'num_of_agents_per_healthcare_team'**)
Num. of agents per healthcare team
Healthcare Capacity
Total number of clinical beds available
Max. num. of clinical beds available (scaled for pop_size)
Total number of ICU beds available
Max. num. of ICU beds available (scaled for pop_size)
Transmission Dynamics Paramters / Beahaviour Parameters
basic reproduction number
Transmission rate number of contacts correction factor (determined by simulating SC1 pure scenario)
Transmission probability reduction factor for asymptomatic infections - lower limit
Transmission probability reduction factor for asymptomatic infections - mode
Transmission probability reduction factor for asymptomatic infections - upper limit
Number of interactions on a day - min (PERT distribution)
Number of interactions on a day - mode (PERT distribution)
Number of interactions on a day - min (PERT distribution)
Number of random interactions on a day - min (PERT distribution)
Number of random interactions on a day - mode (PERT distribution)
Number of random interactions on a day - max (PERT distribution)
Probability of a random contact happening outside social compartments (3/7 = 3 times per week)
Daily probability of participating in a large event
Number of random interactions on a large event - min (PERT distribution)
Number of random interactions on a large event - mode (PERT distribution)
Number of random interactions on a large event - max (PERT distribution)
Probability of HCW to have one contact with co-workers during work days (5/7 = 5 workdays, week of 7 days)
Probability of HCW to have one contact with a PCH resident during work days (3/7 = assuming part-time 3 days/w
Probability of interaction of a HCW with a hospitalized agents (infectious)
Daily num. of agents to import due to unecessary travel - min (PERT distribution)

AB859

Daily num. of agents to import due to unecessary travel - mode (PERT distribution)
Daily num. of agents to import due to unecessary travel - max (PERT distribution)

State Duration / Length of Stay

Exposed duration meanLog (\mu lognormal distribution)
Exposed duration sdLog (\sigma lognormal distribution)
Exposed duration maximum (truncate lognormal at this value)
Infectious pre-symptomatic minumum duration (uniform distribution)
Infectious pre-symptomatic maximum duration (uniform distribution)
Infectious asymptomatic duration minimun (min PERT distribution)
Infectious asymptomatic duration mode (mode PERT distribution)
Infectious asymptomatic duration maximum (max PERT distribution)
Infectious symptomatic duration minimun (min PERT distribution)
Infectious symptomatic duration mode (mode PERT distribution)
Infectious symptomatic duration maximum (max PERT distribution)
Number of days **presenting symptoms** prior to being **hospitalized** - lower limit
Number of days **presenting symptoms** prior to being **hospitalized** - mode
Number of days **presenting symptoms** prior to being **hospitalized** - upper limit
Number of days in **hospital** if recovering (not from ICU) meanLog (\mu lognormal distribution)
Number of days in **hospital** if recovering (not from ICU) sdLog (\sigma lognormal distribution)
Number of days in **hospital** if recovering (not from ICU) max (truncate lognormal distribution)
Number of days in **hospital** before going to ICU - meanLog (\mu lognormal distribution)
Number of days in **hospital** before going to ICU - sdLog (\sigma lognormal distribution)
Number of days in **hospital** before going to ICU - max (truncate lognormal distribution)
Average number of days in **hospital** after stepping down from **ICU** mean - (normal distribution)
Average number of days in **hospital** after stepping down from **ICU** sd - (normal distribution)
Average number of days in **hospital** after stepping down from **ICU** max - (truncate normal distribution)
Average number of days in **ICU** if **recovering** mean - (normal distribution)
Average number of days in **ICU** if **recovering** sd - (normal distribution)
Average number of days in **ICU** if **recovering** max - (truncate normal distribution)
Average number of days in **ICU** if **dying** mean - (normaldistribution)
Average number of days in **ICU** if **dying** sd - (normal distribution)
Average number of days in **ICU** if **dying** max - (truncate normal distribution)

State Transition

Prob. of **staying asymptomatic** throughout the infection - lower limit
Prob. of **staying asymptomatic** throughout the infection - mode
Prob. of **staying asymptomatic** throughout the infection - upper limit
Probability of being **hospitalized** once **symptomatic** - lower limit
Probability of being **hospitalized** once **symptomatic** - mode
Probability of being **hospitalized** once **symptomatic** - upper limit
Probability of requiring **ICU** after being **hospitalized** - lower limit
Probability of requiring **ICU** after being **hospitalized** - mode
Probability of requiring **ICU** after being **hospitalized** - upper limit
Probability of **dying** when in **ICU** - lower limite

Probability of **dying** when in **ICU** - mode
Probability of **dying** when in **ICU** - upper limite
Probability of **dying** if there are no more **clinical beds** available - lower limit
Probability of **dying** if there are no more **clinical beds** available - mode
Probability of **dying** if there are no more **clinical beds** available - upper limit
Probability of **dying** if there are no more **ICU beds** available (hard-coded at 100%)

Public Health Measures and Interventions

Sim. day to close borders to unecessary travel
Close care-home visitation
Daily prob. of an infectious household member visiting a family member in a care home (1/7 days)
Max. daily probability of an Infectious symptomatic agent being diagnosed
Number of lab tests per day for the real population - (\mu lognormal distribution)
Number of lab tests per day for the real population - (\sigma lognormal distribution)
Number of lab tests per day for the real population - (truncate lognormal distribution at this value)
Number of lab tests per day for the real population - (truncate lognormal distribution at this value)
Number of lab tests per day for the real population - (truncate lognormal distribution at this value)
Percentage of lab tests reserved for contact tracng testing (automatic)
Test positivity rate (percent)
Test positivity rate (percent)
Test positivity rate (percent)
Prob. of being tested if Infectious Asymptomatic/Pre-symptomatic
Testing delay (num of days between becoming I and performing contact tracing when diagnosed)
Contact tracing efficiency
Start **quarantining** agents on a specific simulation day
Stop **quarantining** agents on a specific simulation day
Quarantine agents upond being diagnosed (**decrease num. of contacts to Hospital levels**)
Healthcare worker, self-isolation compliance when symptomatic and diagnosed
Healthcare worker, self-isolation prob of an interaction to happen when symptomatic and diagnosed
Healthcare worker, physical distancing compliance when symptomatic and diagnosed
Healthcare worker, self-isolation prob of an interaction to happen when symptomatic and diagnosed
Healthcare worker, self-isolation compliance when symptomatic and non-diagnosed
Healthcare worker, self-isolation prob of an interaction to happen when symptomatic and non-diagnosed
Healthcare worker, physical distancing compliance when symptomatic and non-diagnosed
Healthcare worker, self-isolation prob of an interaction to happen when symptomatic and non-diagnosed
Healthcare worker, self-isolation compliance when asymptomatic and diagnosed
Healthcare worker, self-isolation prob of an interaction to happen when asymptomatic and diagnosed
Healthcare worker, physical distancing compliance when asymptomatic and diagnosed
Healthcare worker, self-isolation prob of an interaction to happen when asymptomatic and diagnosed
Healthcare worker, self-isolation compliance when asymptomatic and non-diagnosed
Healthcare worker, self-isolation prob of an interaction to happen when asymptomatic and non-diagnosed
Healthcare worker, physical distancing compliance when asymptomatic and non-diagnosed
Healthcare worker, self-isolation prob of an interaction to happen when asymptomatic and non-diagnosed
Personal Care Home resident, self-isolation compliance when symptomatic and diagnosed
Personal Care Home resident, self-isolation prob of an interaction to happen when symptomatic and diag

Personal Care Home resident, physical distancing compliance when symptomatic and diagnosed
Personal Care Home resident, self-isolation prob of an interaction to happen when symptomatic and diag
Personal Care Home resident, self-isolation compliance when symptomatic and non-diagnosed
Personal Care Home resident, self-isolation prob of an interaction to happen when symptomatic and non-
Personal Care Home resident, physical distancing compliance when symptomatic and non-diagnosed
Personal Care Home resident, self-isolation prob of an interaction to happen when symptomatic and non-
Personal Care Home resident, self-isolation compliance when asymptomatic and diagnosed
Personal Care Home resident, self-isolation prob of an interaction to happen asymptomatic and diagnose
Personal Care Home resident, physical distancing compliance when asymptomatic and diagnosed
Personal Care Home resident, self-isolation prob of an interaction to happen when asymptomatic and dia
Personal Care Home resident, self-isolation compliance when asymptomatic and non-diagnosed
Personal Care Home resident, self-isolation prob of an interaction to happen when asymptomatic and nor
Personal Care Home resident, physical distancing compliance when asymptomatic and non-diagnosed
Personal Care Home resident, self-isolation prob of an interaction to happen when asymptomatic and nor
Regular agent, self-isolation compliance when symptomatic and diagnosed
Regular agent, self-isolation prob of an interaction to happen when symptomatic and diagnosed
Regular agent, physical distancing compliance when symptomatic and diagnosed
Regular agent, self-isolation prob of an interaction to happen when symptomatic and diagnosed
Regular agent, self-isolation compliance when symptomatic and non-diagnosed
Regular agent, self-isolation prob of an interaction to happen when symptomatic and non-diagnosed
Regular agent, physical distancing compliance when symptomatic and non-diagnosed
Regular agent, self-isolation prob of an interaction to happen when symptomatic and non-diagnosed
Regular agent, self-isolation compliance when asymptomatic and diagnosed
Regular agent, self-isolation prob of an interaction to happen when asymptomatic and diagnosed
Regular agent, physical distancing compliance when asymptomatic and diagnosed
Regular agent, self-isolation prob of an interaction to happen when asymptomatic and diagnosed
Regular agent, self-isolation compliance when asymptomatic and non-diagnosed
Regular agent, self-isolation prob of an interaction to happen when asymptomatic and non-diagnosed
Regular agent, physical distancing compliance when asymptomatic and non-diagnosed
Regular agent, self-isolation prob of an interaction to happen when asymptomatic and non-diagnosed

AB864

AB865

ı-diagnosed

ı-diagnosed

Respiratory Virus Report, Week 11 - ending March 20, 2021

The Respiratory Virus Detection Surveillance System collects data from select laboratories across Canada on the number of tests performed and the number of tests positive for influenza and other respiratory viruses. Data are reported on a weekly basis year-round to the Centre for Immunization and Respiratory Infectious Diseases (CIRID), Public Health Agency of Canada. These data are also summarized in the weekly FluWatch report.

In this Respiratory Virus Report, the number of detections of coronavirus reflects only seasonal human coronaviruses, not the novel pandemic coronavirus (SARS-CoV2) that causes COVID-19. For information on COVID-19, see the Coronavirus disease (COVID-19): Outbreak

Table 1: Respiratory Virus Detections/Isolations for the week ending March 20, 2021 (Reporting Week 202111)

Reporting Laboratory	Flu Tested	A(H1N1)pdm09 Positive	A(H3) Positive	A(UnS) Positive	Total Flu A Positive	Total Flu B Positive	RSV Tested	RSV Positive	PIV Tested	PIV 1 Positive	PIV 2 Positive	PIV 3 Positive	PIV 4 Positive	Other PIV Positive	Adeno Tested	Adeno Positive	hMPV Tested	hMPV Positive	Entero/Rhino Tested	Entero/Rhino Positive	Coron Tested	Coron Positive
Newfoundland	380	0	0	0	0	0	380	0	380	0	0	0	0	0	384	1	380	0	380	8	N.A.	N.A.
Prince Edward Island	138	0	0	0	0	0	138	0	138	0	0	0	0	0	138	0	138	0	138	6	138	0
Nova Scotia	400	0	0	0	0	0	400	0	39	0	0	0	0	0	39	0	39	0	39	2	39	0
New Brunswick	581	0	0	0	0	0	334	0	128	0	0	0	0	0	128	0	128	0	128	0	128	0
Atlantic	**1499**	**0**	**0**	**0**	**0**	**0**	**1252**	**0**	**685**	**0**	**0**	**0**	**0**	**0**	**689**	**1**	**685**	**0**	**685**	**16**	**305**	**0**
Région Nord-Est	272	0	0	0	0	0	20	0	0	0	0	0	0	0	0	0	0	0	N.A.	N.A.	0	0
Québec-Chaudière-Appalaches	12	0	0	0	0	0	14	0	10	0	0	0	0	0	10	0	10	0	N.A.	N.A.	10	0
Centre-du-Québec	30	0	0	0	0	0	30	0	11	0	0	0	0	0	11	0	11	0	N.A.	N.A.	11	1
Montréal-Laval	250	0	0	0	0	0	249	6	109	0	0	0	0	0	109	5	108	0	N.A.	N.A.	108	4
Ouest du Québec	112	0	0	0	0	0	112	0	0	0	0	0	0	0	0	0	0	0	N.A.	N.A.	0	0
Montérégie	83	0	0	0	0	0	83	0	0	0	0	0	0	0	0	0	0	0	N.A.	N.A.	0	0
Province of Québec	**759**	**0**	**0**	**0**	**0**	**0**	**508**	**6**	**130**	**0**	**0**	**0**	**0**	**0**	**130**	**5**	**129**	**0**	**N.A.**	**N.A.**	**129**	**5**
P.H.O.L. - Ottawa	19	0	0	0	0	0	19	0	15	0	0	0	0	0	15	0	15	0	15	0	15	0
CHEO - Ottawa	104	0	0	0	0	0	104	1	14	0	0	0	0	0	14	0	14	0	14	2	14	0
P.H.O.L. - Kingston	13	0	0	0	0	0	13	0	10	0	0	0	0	0	10	0	10	0	10	0	10	0
UHN / Mount Sinai Hospital	487	0	0	0	0	0	487	0	444	0	0	0	0	0	444	0	444	0	444	4	444	1
P.H.O.L. - Toronto	131	0	0	0	0	0	131	0	85	0	0	0	0	0	85	1	85	0	85	0	85	0
Sick Kids Hospital - Toronto	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
Sunnybrook & Women's College HSC	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
P.H.O.L. - Sault Ste. Marie	3	0	0	0	0	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
P.H.O.L. - Timmins	3	0	0	0	0	0	3	0	2	0	0	0	0	0	2	0	2	0	2	0	2	0
St. Joseph's - London	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
P.H.O.L. - London	26	0	0	0	0	0	26	0	14	0	0	0	0	0	14	0	14	0	14	1	14	0
P.H.O.L. - Orillia	5	0	0	0	0	0	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
P.H.O.L. - Thunder Bay	9	0	0	0	0	0	9	0	9	0	0	0	0	0	9	0	9	0	9	0	9	0
P.H.O.L. - Sudbury	7	0	0	0	0	0	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
P.H.O.L. - Hamilton	17	0	0	0	0	0	17	0	13	0	0	0	0	0	13	0	13	0	13	0	13	0
P.H.O.L. - Peterborough	5	0	0	0	0	0	5	0	5	0	0	0	0	0	5	0	5	0	5	0	5	0
St. Joseph's - Hamilton	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
Province of Ontario	**829**	**0**	**0**	**0**	**0**	**0**	**829**	**1**	**611**	**0**	**0**	**0**	**0**	**0**	**611**	**1**	**611**	**0**	**611**	**7**	**611**	**1**
Province of Manitoba	1418	0	0	0	0	0	1418	0	61	0	0	0	0	0	61	0	112	0	61	4	112	0
Province of Saskatchewan	11976	0	0	0	0	0	2161	0	32	0	0	0	0	0	32	0	32	4	32	3	32	5
Province of Alberta	2249	0	0	0	0	0	533	0	533	0	0	0	0	0	533	1	533	0	533	58	533	0
Prairies	**15643**	**0**	**0**	**0**	**0**	**0**	**4112**	**0**	**626**	**0**	**0**	**0**	**0**	**0**	**626**	**1**	**677**	**4**	**626**	**65**	**677**	**5**
British Columbia	**2879**	**0**	**0**	**0**	**0**	**0**	**2800**	**0**	**442**	**0**	**0**	**0**	**0**	**0**	**442**	**2**	**442**	**0**	**436**	**19**	**422**	**1**
Yukon	41	0	0	0	0	0	41	0	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
Northwest Territories	12	0	0	0	0	0	8	0	8	0	0	0	0	0	8	0	8	0	8	1	8	0
Nunavut	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Territories	**54**	**0**	**0**	**0**	**0**	**0**	**49**	**0**	**8**	**0**	**0**	**0**	**0**	**0**	**8**	**0**	**8**	**0**	**8**	**1**	**8**	**0**
CANADA	**21663**	**0**	**0**	**0**	**0**	**0**	**9550**	**7**	**2502**	**0**	**0**	**0**	**0**	**0**	**2506**	**10**	**2552**	**4**	**2366**	**108**	**2152**	**12**

The data in the RVDSS report represent surveillance data available at the time of writing. Missing data are denoted by N.A.

Specimens from Yukon (YT), Northwest Territories (NT) and Nunavit (NU) are sent to reference laboratories in other provinces and reported results reflect specimens identified as originating from YT, NT or NU.

Results from British Columbia comprise of specimens from the following sites: BC Children's and Women's Hospital, Children's and Women's Hospital Laboratory, Fraser Health Medical Microbiology Laboratory, Island Health, Providence Health Care, Powell River Hospital , St. Paul's Hospital , Vancouver General Hospital, Victoria General Hospital, BCCDC Public Health Laboratory, Interior Health Authority sites and Northern Health Authority sites.

Delays in the reporting of data may cause data to change retrospectively.

Influenza co-detections may cause the sum of A(H1N1)pdm09, A(H3), and A(UnS) positive results to exceed the sum of Total Flu A Positive results.

AB866

Table 2: Respiratory Virus Detections/Isolations for the period August 23, 2020 - March 20, 2021 (Reporting Weeks 202035-202111)

Reporting Laboratory	Flu Tested	A(H1N1)pdm09 Positive	A(H3) Positive	A(UnS) Positive	Total Flu A Positive	Total Flu B Positive	RSV Tested	RSV Positive	PIV Tested	PIV 1 Positive	PIV 2 Positive	PIV 3 Positive	PIV 4 Positive	Other PIV Positive	Adeno Tested	Adeno Positive	hMPV Tested	hMPV Positive	Entero/Rhino Tested	Entero/Rhino Positive	Coron Tested	Coron Positive
Newfoundland	9242	0	0	0	0	0	9242	10	9242	1	0	1	0	0	9259	43	8655	2	9242	1948	N.A.	N.A.
Prince Edward Island	2574	0	0	0	0	0	2574	3	2570	2	0	0	0	0	2570	29	2570	0	2570	275	2570	0
Nova Scotia	3226	0	0	0	0	0	3229	0	461	0	0	0	0	0	461	7	461	0	461	62	461	0
New Brunswick	49907	0	0	0	0	1	17348	0	695	0	0	0	0	0	686	8	686	0	686	48	641	0
Atlantic	**64949**	**0**	**0**	**0**	**0**	**1**	**32393**	**13**	**12968**	**3**	**0**	**1**	**0**	**0**	**12976**	**87**	**12372**	**2**	**12959**	**2333**	**3672**	**0**
Région Nord-Est	3089	0	0	0	0	0	860	1	0	0	0	0	0	0	0	0	0	0	N.A.	N.A.	0	0
Québec-Chaudière-Appalaches	662	0	0	1	1	0	733	0	445	0	0	0	0	0	447	24	442	0	N.A.	N.A.	425	7
Centre-du-Québec	728	0	0	0	0	0	737	1	240	0	0	0	0	0	238	17	240	0	N.A.	N.A.	237	1
Montréal-Laval	5745	0	0	0	0	0	4788	13	3166	0	0	1	0	0	3220	115	3150	1	N.A.	N.A.	3150	25
Ouest du Québec	1275	0	0	0	0	0	1219	0	0	0	0	0	0	0	0	0	0	0	N.A.	N.A.	0	0
Montérégie	331	0	0	0	0	0	331	0	0	0	0	0	0	0	0	0	0	0	N.A.	N.A.	0	0
Province of Québec	**11830**	**0**	**0**	**1**	**1**	**0**	**8668**	**15**	**3851**	**0**	**0**	**1**	**0**	**0**	**3905**	**156**	**3832**	**1**	**N.A.**	**N.A.**	**3812**	**33**
P.H.O.L. - Ottawa	454	0	0	0	0	0	454	1	384	0	0	0	0	0	384	0	383	0	384	22	383	1
CHEO - Ottawa	4126	0	0	1	1	1	3723	5	625	0	0	0	0	0	625	12	625	1	625	71	625	0
P.H.O.L. - Kingston	737	0	0	1	1	0	737	0	493	0	0	0	0	0	493	3	487	0	493	102	487	0
UHN / Mount Sinai Hospital	9545	2	0	2	4	1	9476	6	9024	3	2	3	8	0	7398	9	8984	8	8781	91	6820	6
P.H.O.L. - Toronto	4997	0	0	0	0	0	4994	2	4379	0	0	0	0	2	4380	12	4378	0	4379	144	4378	4
Sick Kids Hospital - Toronto	854	0	0	0	0	0	0	0	854	0	0	0	0	0	854	12	854	0	854	88	854	0
Sunnybrook & Women's College HSC	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
P.H.O.L. - Sault Ste. Marie	127	0	0	2	2	0	125	0	87	0	0	0	0	0	87	0	87	0	87	6	87	0
P.H.O.L. - Timmins	596	0	0	0	0	0	596	0	152	0	0	0	0	0	152	0	151	0	152	30	151	0
St. Joseph's - London	218	0	0	0	0	0	218	0	55	0	0	0	0	0	55	0	55	0	91	8	36	0
P.H.O.L. - London	1714	1	0	5	6	2	1704	0	1222	0	0	0	0	2	1222	2	1217	0	1222	125	1217	3
P.H.O.L. - Orillia	349	0	0	1	1	0	347	0	189	0	0	0	0	0	189	1	189	0	189	12	189	0
P.H.O.L. - Thunder Bay	378	0	0	0	0	0	378	0	366	0	0	0	0	0	367	2	366	0	366	135	366	0
P.H.O.L. - Sudbury	424	0	0	0	0	0	422	0	320	0	0	0	0	0	320	2	320	0	320	28	320	0
P.H.O.L. - Hamilton	1375	0	0	0	0	0	1324	1	1120	0	0	0	0	0	1120	2	1120	0	1120	95	1120	0
P.H.O.L. - Peterborough	413	0	0	1	1	0	367	0	280	0	0	0	0	0	280	0	280	0	280	20	280	0
St. Joseph's - Hamilton	7629	0	0	0	0	0	7629	1	7629	0	0	0	0	0	7629	18	7629	0	7629	403	0	0
Province of Ontario	**33936**	**3**	**0**	**13**	**16**	**4**	**32494**	**16**	**27179**	**3**	**2**	**3**	**8**	**4**	**25555**	**75**	**27125**	**9**	**26972**	**1380**	**17313**	**14**
Manitoba	38500	0	0	0	0	1	38490	68	2652	0	1	1	0	0	2652	17	2748	1	2652	135	2748	3
Province of Saskatchewan	71810	0	0	0	0	0	11653	3	1537	0	0	1	1	0	1537	10	1537	4	1537	158	1537	7
Province of Alberta	104631	4	0	6	10	0	71887	0	71887	2	18	3	5	0	71887	128	71887	11	71887	6010	71887	21
Prairies	**214941**	**4**	**0**	**6**	**10**	**1**	**122030**	**71**	**76076**	**2**	**19**	**5**	**6**	**0**	**76076**	**155**	**76172**	**16**	**76076**	**6303**	**76172**	**31**
British Columbia	**66553**	**3**	**8**	**1**	**10**	**8**	**66204**	**5**	**14018**	**1**	**4**	**0**	**7**	**5**	**14562**	**77**	**14412**	**56**	**14233**	**1222**	**10256**	**19**
Yukon	4434	0	0	8	8	7	4372	4	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
Northwest Territories	1103	0	0	0	0	0	1070	0	1070	0	0	0	1	0	1070	9	1070	1	1070	315	1070	1
Nunavut	1099	0	0	0	0	0	1086	0	1086	3	1	0	0	0	1086	25	1086	5	1086	280	183	0
Territories	**6636**	**0**	**0**	**8**	**8**	**7**	**6528**	**4**	**2156**	**3**	**1**	**0**	**1**	**0**	**2156**	**34**	**2156**	**6**	**2156**	**595**	**1253**	**1**
CANADA	**398845**	**10**	**8**	**29**	**45**	**21**	**268317**	**124**	**136248**	**12**	**26**	**10**	**22**	**9**	**135230**	**584**	**136069**	**90**	**132396**	**11833**	**112478**	**98**

The data in the RVDSS report represent surveillance data available at the time of writing. Missing data are denoted by N.A.

Specimens from YT, NT and NU are sent to reference laboratories in other provinces and reported results reflect specimens identified as originating from YT, NT or NU.

Results from British Columbia comprise of specimens from the following sites: BC Children's and Women's Hospital, Children's and Women's Hospital Laboratory, Fraser Health Medical Microbiology Laboratory, Island Health, Providence Health Care, Powell River Hospital , St. Paul's Hospital , Vancouver General Hospital, Victoria General Hospital, BCCDC Public Health Laboratory, Interior Health Authority sites and Northern Health Authority sites.

Delays in the reporting of data may cause data to change retrospectively.

Due to reporting delays, the sum of weekly report totals do not add up to cumulative totals.

Influenza co-detections may cause the sum of A(H1N1)pdm09, A(H3), and A(UnS) positive results to exceed the sum of Total Flu A Positive results.

AB867

AB868

Figure 1: Number positive laboratory tests for other respiratory viruses by report week, Canada, 2020-21



AB869

Figure 2 : Positive Influenza Tests (%) in Canada by Region by Week of Report



AB870

Figure 3: Positive Respiratory syncytial virus (RSV) Tests (%) in Canada by Region by Week of Report



AB871

Figure 4: Positive Parainfluenza (PIV) Tests (%) in Canada by Region by Week of Report



AB872

Figure 5: Positive Adenovirus (adeno) Tests (%) in Canada by Region by Week of Report



AB873

Figure 6: Positive human metapneumovirus (hMPV) Tests (%) in Canada by Region by Week of Report



AB874

Figure 7: Positive Enterovirus/Rhinovirus (entero/rhino) Tests (%) in Canada by Region by Week of Report



AB875

Figure 8: Positive Coronavirus (coron) Tests (%) in Canada by Region by Week of Report



Abbreviations:

A(H1N1)pdm09: Influenza A(H1N1)pdm09

A(H3): Influenza A(H3N2)

A (UnS): Influenza A (Unsubtyped)

Adeno: Adenovirus

CHEO: Children's Hospital of Eastern Ontario

Coron: Coronavirus

Entero: Enterovirus

hMPV: human metapneumovirus

HSC: Health Sciences Centre

N.A.: Not Applicable

P.H.L.: Public Health Laboratory

P.H.O.L.: Public Health Ontario Laboratory

PIV: Parainfluenza

Rhino: Rhinovirus

RSV: Respiratory syncytial virus

UHN: University Health Network

Notes:

The data in the RVDSS report represent surveillance data available at the time of writing. Missing data are denoted by N.A.

Specimens from Yukon (YT), Northwest Territories (NT) and Nunavut (NU) are sent to reference laboratories in other provinces. Results reported for the Territories reflect the number of specimens that are identified as originating from YT, NT or NU.

Delays in the reporting of data may cause data to change retrospectively.

Due to reporting delays, the sum of weekly report totals do not add up to cumulative totals.

AB877

EXHIBIT "C"

THIS IS EXHIBIT " C "
referred to in the Affidavit of
David Hersey
Sworn before me this 20
day of April A.D. 20 21

A Commissioner in and for the Province of Alberta
John Carpay
Barrister and Solicitor

From: Allison Pejovic [redacted]
Date: Thursday, April 1, 2021 at 10:57 PM
To: "Leonoff, Heather (JUS)" [redacted] "Conner, Michael (JUS)" [redacted], "Guenette, Denis (JUS)" [redacted] "Boyd, Sean (JUS)" [redacted]
Cc: Jared Brown [redacted], Jay Cameron < [redacted]
Subject: Gateway Bible Baptist Church et al. v. MB et al. - Letter Further Requesting Production of Documents

Good evening,

Please see the attached correspondence.

Best regards,

Allison Kindle Pejovic, B.A., LL.B., LL.M.
Barrister and Solicitor
Justice Centre for Constitutional Freedoms

AB879

[redacted]

"Defending the constitutional freedoms of Canadians"

Justice Centre
for Constitutional Freedoms

April 1, 2021

Via-email

Department of Justice
[redacted]

Attention: Heather Leonoff/Michael Conner/Denis Guenette/Sean Boyd

Dear Madam/Sir:

RE: Gateway Bible Baptist Church et al. v. Manitoba and Dr. Roussin – File No. CI 20-01-29284

We are in receipt of your letter dated March 30, 2021 in response to our March 19, 2021 request for further documentation. Thank you for the information that you provided to us.

In respect of the information that you declined to provide, we reiterate our request for production of the following information in advance of the hearing which the Applicants maintain is relevant and material to the Respondents' affidavit evidence and the issues in the proceeding:

1. Affidavit of Jared Bullard, lines 193-199

    a. Document(s) with CT thresholds by percentages of all positive cases between March 2020-March 2021, and specifically, what percentage of cases per month resulted from a positive PCR test with a CT of 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 (not simply the percentage as a range from 36-40)

[redacted]

2. Affidavit of Brent Roussin, para. 177, Affidavit of Lanette Siragusa, paras. 15-23, Affidavit of Carla Loeppky, paras. 17-18

   Document(s) that show:
   a. the total number of ICU beds available in Manitoba for the years 2015-2020 and up to March 2021
   b. the surge capacity (how many extra beds could be made available for ICU patients) in Manitoba for the years 2015-2020
   c. by month, the highest number of ICU patients in Manitoba for the years 2015-2020 and up to March 2021
   d. how many days per month in the years 2015-2020 and up until March 2021 did ICU patients exceed the number of available ICU beds before and after (if applicable) surge capacity was reached?

We have, at the court's instruction, filed the motion to compel production of documents and it is our position that the court, with the inherent authority over its own processes, can and should order production of documentation which is relevant and material and is accessible by the Respondents.

We note that the court's inherent jurisdiction to do justice between the parties and secure a fair trial between them has been considered and affirmed by the Supreme Court of Canada:

> "…the inherent jurisdiction of the court may be defined as being the reserve or fund of powers, a residual source of powers, which the court may draw upon as necessary whenever it is just or equitable to do so, and in particular to ensure the observance of the due process of law, to prevent improper vexation or oppression, to do justice between the parties and to secure a fair trial between them."
>
> *Ontario v. Criminal Lawyers' Association of Ontario*, 2013 SCC 43 (CanLII), [2013] 3 SCR 3, at para. 20

> "Inherent jurisdiction was described by this Court in *R. v. Caron*, 2011 SCC 5, [2011] 1 S.C.R. 78, at para. 24:
>
> The inherent jurisdiction of the provincial superior courts, is broadly defined as "a residual source of powers, which the court may draw upon as necessary whenever it is just or equitable to do so": I. H. Jacob, "The Inherent Jurisdiction of the Court" (1970), 23 *Curr. Legal Probs.* 23, at p. 51. These powers are derived "not from any statute or rule of law, but from the very nature of the court as a superior court of law" (Jacob, at p. 27) to enable "the

[redacted]

judiciary to uphold, to protect and to fulfil the judicial function of administering justice according to law in a regular, orderly and effective manner" (p. 28).""

Conseil scolaire francophone de la Colombie-Britannique v. British Columbia, 2013 SCC 42 (CanLII), [2013] 2 SCR 774, at para. 72

We look forward to receiving the foregoing.

Best regards,

A.K. Pejovic

Allison Kindle Pejovic
Barrister and Solicitor
Justice Centre for Constitutional Freedoms

Encl. (2) – Applicants' March 19, 2021 letter to the Respondents; Respondents' March 30, 2021 letter to the Applicants

cc: Jay Cameron, Justice Centre for Constitutional Freedoms, [redacted]

Jared Brown, Lead Counsel, Brown Litigation, [redacted]

[redacted]

EXHIBIT "D"

THIS IS EXHIBIT " D "
referred to in the Affidavit of
David Hersey
Sworn before me this 20
day of April A.D. 20 21
A Commissioner in and for the Province of Alberta
John Carpay
Barrister and Solicitor

From: "Conner, Michael (JUS)" [redacted]
Date: Tuesday, April 6, 2021 at 4:50 PM
To: Allison Pejovic [redacted]
Cc: Jay Cameron <[redacted] Jared Brown [redacted] "Guenette, Denis (JUS)" [redacted] "Leonoff, Heather (JUS)" [redacted] "Boyd, Sean (JUS)" [redacted]
Subject: RE: Gateway Bible Baptist Church et al. v. MB et al - request for further documents

Further to your letter dated April 1, 2021 requesting further documents, please see the attached letter and enclosed spreadsheet of Ct values for positive PCR tests from March 2020 to March 2021.

We hope to be able to provide you with available information on ICU shortly.

Michael Conner
General Counsel
Constitutional Law Section
[redacted]

From: Allison Pejovic [redacted]>
Sent: April 6, 2021 3:47 PM
To: Conner, Michael (JUS) [redacted]>; Guenette, Denis (JUS) <[redacted]>; Leonoff, Heather (JUS) [redacted] Boyd, Sean (JUS) [redacted]>
Cc: Jay Cameron [redacted]; Jared Brown [redacted]
Subject: [Caution: Suspicious Email] Gateway Bible Baptist Church et al. v. MB et al - April 6, 2021 Letter to Chief Justice Joyal

Please find enclosed a copy of correspondence which was filed with the court this afternoon.

Allison Kindle Pejovic, B.A., LL.B., LL.M.
Barrister and Solicitor
Justice Centre for Constitutional Freedoms
[redacted]

www.jccf.ca

"Defending the constitutional freedoms of Canadians"

Manitoba

Justice
Constitutional Law Section, Legal Services Branch
[redacted]

In reply, please refer to:

Michael Conner
General Counsel

[redacted]

April 6, 2021

Justice Centre for Constitutional Freedoms
[redacted]

Attention: Allison Kindle Pejovic

Dear Ms Pejovic:

Re: ***Gateway Bible Baptist Church et al. v. Manitoba et al.*** **– File No. CI 20-01-29284**

This is in response to the Applicants motion to compel production of two categories of documents for the purpose of cross-examining affiants.

1. Documents providing CT thresholds for all positive PCR test from March 2020 to March 2021, broken down by monthly percentages of each CT value of 36 and higher

Cadham Provincial Laboratory (CPL) does not have documents setting out the percentages of positive PCR tests for each month that resulted from a CT threshold of 36, 37, 38, 39 or 40. PCR tests with a CT threshold above 40 would be considered a negative test.

CPL is able to provide a list of all positive PCR tests that the lab conducted from March 2020 to March 2021, with the corresponding CT values. We have attached the list. Note that any test results conducted on the Panther instrument uses a different method that does not rely on CT values.

2. ICU capacity for 2015 to March 2021, including "surge capacity"

We can provide the Applicants with information showing the daily number of available ICU beds and daily number of ICU patients, going back to April 1, 2016. We do not have data available prior to that date. We hope to provide this shortly.

Manitoba does not have documents indicating a "surge capacity". Hospital and ICU resources are managed every day of the year and appropriate actions are taken.

Sincerely,

Michael Conner,
General Counsel

c. Jay Cameron and Jared Brown, counsel for the Applicants
Heather Leonoff, Q.C., Denis Guénette and Sean Boyd, counsel for the Respondents

AB888

Year_Received	Month_Received	Day_Received	Analysis	Result_Name	Result_Entry
2020	3	11	PCR_COV_N2019	E Gene CT	25.5
2020	3	11	PCR_COV_N2019	E Gene CT	27.43
2020	3	12	PCR_COV_N2019	E Gene CT	26.07
2020	3	13	PCR_COV_N2019	E Gene CT	20.27
2020	3	13	PCR_COV_N2019	E Gene CT	14.29
2020	3	13	PCR_COV_N2019	E Gene CT	22.73
2020	3	14	PCR_COV_N2019	E Gene CT	13.13
2020	3	14	PCR_COV_N2019	E Gene CT	33.01
2020	3	14	PCR_COV_N2019	E Gene CT	36.09
2020	3	14	PCR_COV_N2019	E Gene CT	33.74
2020	3	14	PCR_COV_N2019	E Gene CT	15.65
2020	3	14	PCR_COV_N2019	E Gene CT	36.74
2020	3	16	PCR_COV_N2019	E Gene CT	37.71
2020	3	16	PCR_COV_N2019	E Gene CT	19.33
2020	3	16	PCR_COV_N2019	E Gene CT	20.66
2020	3	16	PCR_COV_N2019	E Gene CT	36.09
2020	3	16	PCR_COV_N2019	E Gene CT	16.38
2020	3	17	PCR_COV_N2019	E Gene CT	24.32
2020	3	17	PCR_COV_N2019	E Gene CT	24.16
2020	3	17	PCR_COV_N2019	E Gene CT	17.46
2020	3	17	PCR_COV_N2019	E Gene CT	21.27
2020	3	20	PCR_COV_N2019	E Gene CT	15.11
2020	3	23	PCR_COV_N2019	E Gene CT	33.58
2020	3	23	PCR_COV_N2019	E Gene CT	27.62
2020	3	23	PCR_COV_N2019	E Gene CT	17.81
2020	3	23	PCR_COV_N2019	E Gene CT	17.02
2020	3	23	PCR_COV_N2019	E Gene CT	28.37
2020	3	23	PCR_COV_N2019	E Gene CT	17
2020	3	23	PCR_COV_N2019	E Gene CT	18.15
2020	3	23	PCR_COV_N2019	E Gene CT	20.03
2020	3	23	PCR_COV_N2019	E Gene CT	22.25
2020	3	24	PCR_COV_N2019	E Gene CT	16.27
2020	3	24	PCR_COV_N2019	E Gene CT	23.33
2020	3	24	PCR_COV_N2019	E Gene CT	26.72
2020	3	24	PCR_COV_N2019	E Gene CT	27.1
2020	3	24	PCR_COV_N2019	E Gene CT	33.81
2020	3	24	PCR_COV_N2019	E Gene CT	20.79
2020	3	26	PCR_COV_N2019	E Gene CT	15.47
2020	3	26	PCR_COV_N2019	E Gene CT	33.62
2020	3	26	PCR_COV_N2019	E Gene CT	17.61
2020	3	26	PCR_COV_N2019	E Gene CT	14.96
2020	3	26	PCR_COV_N2019	E Gene CT	17.61
2020	3	26	PCR_COV_N2019	E Gene CT	25.66
2020	3	26	PCR_COV_N2019	E Gene CT	24.51
2020	3	26	PCR_COV_N2019	E Gene CT	23.55
2020	3	26	PCR_COV_N2019	E Gene CT	19.32

AB889

2020	3	26	PCR_COV_N2019	E Gene CT	17.44
2020	3	26	PCR_COV_N2019	E Gene CT	27.07
2020	3	26	PCR_COV_N2019	E Gene CT	15.01
2020	3	26	PCR_COV_N2019	E Gene CT	27.64
2020	3	26	PCR_COV_N2019	E Gene CT	30.67
2020	3	26	PCR_COV_N2019	E Gene CT	20.55
2020	3	27	PCR_COV_N2019	E Gene CT	17.32
2020	3	27	PCR_COV_N2019	E Gene CT	31.3
2020	3	27	PCR_COV_N2019	E Gene CT	17.03
2020	3	27	PCR_COV_N2019	E Gene CT	23.12
2020	3	27	PCR_COV_N2019	E Gene CT	19.97
2020	3	27	PCR_COV_N2019	E Gene CT	29.93
2020	3	27	PCR_COV_N2019	E Gene CT	16.53
2020	3	27	PCR_COV_N2019	E Gene CT	27.21
2020	3	27	PCR_COV_N2019	E Gene CT	22.12
2020	3	27	PCR_COV_N2019	E Gene CT	20.19
2020	3	27	PCR_COV_N2019	E Gene CT	29.49
2020	3	27	PCR_COV_N2019	E Gene CT	17.36
2020	3	27	PCR_COV_N2019	E Gene CT	16.08
2020	3	27	PCR_COV_N2019	E Gene CT	20.14
2020	3	27	PCR_COV_N2019	E Gene CT	18.82
2020	3	27	PCR_COV_N2019	E Gene CT	33.23
2020	3	27	PCR_COV_N2019	E Gene CT	20.19
2020	3	27	PCR_COV_N2019	E Gene CT	24.12
2020	3	27	PCR_COV_N2019	E Gene CT	20.2
2020	3	27	PCR_COV_N2019	E Gene CT	19.37
2020	3	27	PCR_COV_N2019	E Gene CT	27.01
2020	3	27	PCR_COV_N2019	E Gene CT	19.13
2020	3	27	PCR_COV_N2019	E Gene CT	19.41
2020	3	27	PCR_COV_N2019	E Gene CT	30.49
2020	3	27	PCR_COV_N2019	E Gene CT	30.62
2020	3	27	PCR_COV_N2019	E Gene CT	25.55
2020	3	27	PCR_COV_N2019	E Gene CT	33.34
2020	3	27	PCR_COV_N2019	E Gene CT	24.65
2020	3	27	PCR_COV_N2019	E Gene CT	23.58
2020	3	27	PCR_COV_N2019	E Gene CT	19.01
2020	3	27	PCR_COV_N2019	E Gene CT	26.69
2020	3	27	PCR_COV_N2019	E Gene CT	19.58
2020	3	27	PCR_COV_N2019	E Gene CT	24.42
2020	3	27	PCR_COV_N2019	E Gene CT	20.96
2020	3	27	PCR_COV_N2019	E Gene CT	17.87
2020	3	27	PCR_COV_N2019	E Gene CT	33.03
2020	3	27	PCR_COV_N2019	E Gene CT	30.66
2020	3	27	PCR_COV_N2019	E Gene CT	16.77
2020	3	27	PCR_COV_N2019	E Gene CT	27.08
2020	3	28	PCR_COV_N2019	E Gene CT	31.93
2020	3	28	PCR_COV_N2019	E Gene CT	37.43

AB890

2020	3	28	PCR_COV_N2019	E Gene CT	33.63
2020	3	28	PCR_COV_N2019	E Gene CT	25.06
2020	3	28	PCR_COV_N2019	E Gene CT	30.66
2020	3	28	PCR_COV_N2019	E Gene CT	24.45
2020	3	28	PCR_COV_N2019	E Gene CT	33.26
2020	3	28	PCR_COV_N2019	E Gene CT	28.1
2020	3	28	PCR_COV_N2019	E Gene CT	17.77
2020	3	28	PCR_COV_N2019	E Gene CT	29.14
2020	3	28	PCR_COV_N2019	E Gene CT	25.29
2020	3	28	PCR_COV_N2019	E Gene CT	21.43
2020	3	28	PCR_COV_N2019	E Gene CT	25.98
2020	3	28	PCR_COV_N2019	E Gene CT	20.12
2020	3	28	PCR_COV_N2019	E Gene CT	28.71
2020	3	28	PCR_COV_N2019	E Gene CT	18.36
2020	3	28	PCR_COV_N2019	E Gene CT	26.53
2020	3	29	PCR_COV_N2019	E Gene CT	23.25
2020	3	29	PCR_COV_N2019	E Gene CT	24.1
2020	3	29	PCR_COV_N2019	E Gene CT	15.27
2020	3	29	PCR_COV_N2019	E Gene CT	22.16
2020	3	29	PCR_COV_N2019	E Gene CT	16.28
2020	3	29	PCR_COV_N2019	E Gene CT	28.61
2020	3	29	PCR_COV_N2019	E Gene CT	22.17
2020	3	29	PCR_COV_N2019	E Gene CT	32.64
2020	3	29	PCR_COV_N2019	E Gene CT	24.81
2020	3	29	PCR_COV_N2019	E Gene CT	26.01
2020	3	29	PCR_COV_N2019	E Gene CT	27.09
2020	3	29	PCR_COV_N2019	E Gene CT	19.39
2020	3	29	PCR_COV_N2019	E Gene CT	31.62
2020	3	29	PCR_COV_N2019	E Gene CT	31.23
2020	3	29	PCR_COV_N2019	E Gene CT	26.39
2020	3	29	PCR_COV_N2019	E Gene CT	24.55
2020	3	29	PCR_COV_N2019	E Gene CT	24.56
2020	3	29	PCR_COV_N2019	E Gene CT	29.36
2020	3	29	PCR_COV_N2019	E Gene CT	27.05
2020	3	29	PCR_COV_N2019	E Gene CT	18.23
2020	3	29	PCR_COV_N2019	E Gene CT	18.88
2020	3	29	PCR_COV_N2019	E Gene CT	15.62
2020	3	29	PCR_COV_N2019	E Gene CT	18.51
2020	3	29	PCR_COV_N2019	E Gene CT	37.16
2020	3	29	PCR_COV_N2019	E Gene CT	27.65
2020	3	29	PCR_COV_N2019	E Gene CT	21.99
2020	3	30	PCR_COV_N2019	E Gene CT	15.61
2020	3	30	PCR_COV_N2019	E Gene CT	14.31
2020	3	30	PCR_COV_N2019	E Gene CT	20.03
2020	3	30	PCR_COV_N2019	E Gene CT	16.72
2020	3	30	PCR_COV_N2019	E Gene CT	36.32
2020	3	30	PCR_COV_N2019	E Gene CT	19.21

AB891

2020	3	30	PCR_COV_N2019	E Gene CT	17.59
2020	3	30	PCR_COV_N2019	E Gene CT	19.6
2020	3	30	PCR_COV_N2019	E Gene CT	32.02
2020	3	30	PCR_COV_N2019	E Gene CT	29.73
2020	3	30	PCR_COV_N2019	E Gene CT	20.53
2020	3	30	PCR_COV_N2019	E Gene CT	22.61
2020	3	30	PCR_COV_N2019	E Gene CT	38.1
2020	3	30	PCR_COV_N2019	E Gene CT	15.78
2020	3	30	PCR_COV_N2019	E Gene CT	34.56
2020	3	30	PCR_COV_N2019	E Gene CT	37.2
2020	3	30	PCR_COV_N2019	E Gene CT	39.6
2020	3	30	PCR_COV_N2019	E Gene CT	24.4
2020	3	30	PCR_COV_N2019	E Gene CT	32.1
2020	3	30	PCR_COV_N2019	E Gene CT	29.29
2020	3	30	PCR_COV_N2019	E Gene CT	20.4
2020	3	31	PCR_COV_N2019	E Gene CT	35.61
2020	3	31	PCR_COV_N2019	E Gene CT	18.18
2020	3	31	PCR_COV_N2019	E Gene CT	19.68
2020	3	31	PCR_COV_N2019	E Gene CT	25.18
2020	3	31	PCR_COV_N2019	E Gene CT	18.53
2020	3	31	PCR_COV_N2019	E Gene CT	14.15
2020	3	31	PCR_COV_N2019	E Gene CT	15.89
2020	3	31	PCR_COV_N2019	E Gene CT	16.69
2020	3	31	PCR_COV_N2019	E Gene CT	18.5
2020	3	31	PCR_COV_N2019	E Gene CT	16.12
2020	3	31	PCR_COV_N2019	E Gene CT	14.81
2020	3	31	PCR_COV_N2019	E Gene CT	17.22
2020	3	31	PCR_COV_N2019	E Gene CT	15.07
2020	3	31	PCR_COV_N2019	E Gene CT	32
2020	3	31	PCR_COV_N2019	E Gene CT	30.6
2020	3	31	PCR_COV_N2019	E Gene CT	28.8
2020	3	31	PCR_COV_N2019	E Gene CT	31.8
2020	3	31	PCR_COV_N2019	E Gene CT	29.4
2020	3	31	PCR_COV_N2019	E Gene CT	15.28
2020	3	31	PCR_COV_N2019	E Gene CT	30.63
2020	3	31	PCR_COV_N2019	E Gene CT	27.9
2020	3	31	PCR_COV_N2019	E Gene CT	19.31
2020	3	31	PCR_COV_N2019	E Gene CT	16.61
2020	3	31	PCR_COV_N2019	E Gene CT	24.5
2020	3	31	PCR_COV_N2019	E Gene CT	23.51
2020	3	31	PCR_COV_N2019	E Gene CT	20.49
2020	3	31	PCR_COV_N2019	E Gene CT	22.59
2020	3	31	PCR_COV_N2019	E Gene CT	23.08
2020	4	1	PCR_COV_N2019	E Gene CT	20.2
2020	4	1	PCR_COV_N2019	E Gene CT	19.47
2020	4	1	PCR_COV_N2019	E Gene CT	23.53
2020	4	1	PCR_COV_N2019	E Gene CT	23.97

AB892

2020	4	1	PCR_COV_N2019	E Gene CT	22.84
2020	4	1	PCR_COV_N2019	E Gene CT	31.87
2020	4	1	PCR_COV_N2019	E Gene CT	20.6
2020	4	1	PCR_COV_N2019	E Gene CT	17.6
2020	4	1	PCR_COV_N2019	E Gene CT	19.38
2020	4	1	PCR_COV_N2019	E Gene CT	20.17
2020	4	2	PCR_COV_N2019	E Gene CT	36.13
2020	4	2	PCR_COV_N2019	E Gene CT	25.01
2020	4	2	PCR_COV_N2019	E Gene CT	29.08
2020	4	3	PCR_COV_N2019	E Gene CT	15.91
2020	4	3	PCR_COV_N2019	E Gene CT	15.3
2020	4	3	PCR_COV_N2019	E Gene CT	24.01
2020	4	3	PCR_COV_N2019	E Gene CT	26.73
2020	4	4	PCR_COV_N2019	E Gene CT	35.84
2020	4	4	PCR_COV_N2019	E Gene CT	23.19
2020	4	4	PCR_COV_N2019	E Gene CT	24.46
2020	4	4	PCR_COV_N2019	E Gene CT	26.11
2020	4	4	PCR_COV_N2019	E Gene CT	33.43
2020	4	4	PCR_COV_N2019	E Gene CT	22.73
2020	4	4	PCR_COV_N2019	E Gene CT	33.65
2020	4	4	PCR_COV_N2019	E Gene CT	34.02
2020	4	4	PCR_COV_N2019	E Gene CT	38.15
2020	4	4	PCR_COV_N2019	E Gene CT	22.02
2020	4	5	PCR_COV_N2019	E Gene CT	26.76
2020	4	5	PCR_COV_N2019	E Gene CT	18.38
2020	4	5	PCR_COV_N2019	E Gene CT	36.15
2020	4	5	PCR_COV_N2019	E Gene CT	19.19
2020	4	5	PCR_COV_N2019	E Gene CT	27.2
2020	4	5	PCR_COV_N2019	E Gene CT	20.24
2020	4	5	PCR_COV_N2019	E Gene CT	21.24
2020	4	5	PCR_COV_N2019	E Gene CT	16.19
2020	4	5	PCR_COV_N2019	E Gene CT	32.8
2020	4	5	PCR_COV_N2019	E Gene CT	24.44
2020	4	5	PCR_COV_N2019	E Gene CT	20.29
2020	4	6	PCR_COV_N2019	E Gene CT	33.42
2020	4	7	PCR_COV_N2019	E Gene CT	33.89
2020	4	7	PCR_COV_N2019	E Gene CT	36.39
2020	4	8	PCR_COV_N2019	E Gene CT	22.03
2020	4	8	PCR_COV_N2019	E Gene CT	20.51
2020	4	8	PCR_COV_N2019	E Gene CT	32.69
2020	4	9	PCR_COV_N2019	E Gene CT	15.42
2020	4	9	PCR_COV_N2019	E Gene CT	22.54
2020	4	9	PCR_COV_N2019	E Gene CT	32.47
2020	4	10	PCR_COV_N2019	E Gene CT	30.8
2020	4	10	PCR_COV_N2019	E Gene CT	18.31
2020	4	10	PCR_COV_N2019	E Gene CT	23.77
2020	4	10	PCR_COV_N2019	E Gene CT	32.32

2020	4	11	PCR_COV_N2019	E Gene CT	16.37
2020	4	12	PCR_COV_N2019	E Gene CT	25.43
2020	4	13	PCR_COV_N2019	E Gene CT	22.42
2020	4	13	PCR_COV_N2019	E Gene CT	35.53
2020	4	14	PCR_COV_N2019	E Gene CT	28.61
2020	4	16	PCR_COV_N2019	E Gene CT	20.18
2020	4	16	PCR_COV_N2019	E Gene CT	22.08
2020	4	16	PCR_COV_N2019	E Gene CT	37.18
2020	4	16	PCR_COV_N2019	E Gene CT	31.42
2020	4	16	PCR_COV_N2019	E Gene CT	16.1
2020	4	16	PCR_COV_N2019	E Gene CT	31.34
2020	4	20	PCR_COV_N2019	E Gene CT	17.91
2020	4	20	PCR_COV_N2019	E Gene CT	27.73
2020	4	20	PCR_FUSION_COV19_E	E Gene CT	34.1
2020	4	20	PCR_COV_N2019	E Gene CT	31.75
2020	4	20	PCR_COV_N2019	E Gene CT	31.23
2020	4	21	PCR_FUSION_COV19_E	E Gene CT	39.1
2020	4	21	PCR_FUSION_COV19_E	E Gene CT	21.5
2020	4	22	PCR_FUSION_COV19_E	E Gene CT	38.9
2020	4	22	PCR_COV_N2019	E Gene CT	34.36
2020	4	23	PCR_COV_N2019	E Gene CT	21.04
2020	4	23	PCR_COV_N2019	E Gene CT	18.1
2020	4	24	PCR_COV_N2019	E Gene CT	23.39
2020	4	24	PCR_COV_N2019	E Gene CT	33.99
2020	4	27	PCR_FUSION_COV19_E	E Gene CT	39.1
2020	4	28	PCR_COV_N2019	E Gene CT	36.75
2020	4	28	PCR_COV_N2019	E Gene CT	25.26
2020	4	28	PCR_COV_N2019	E Gene CT	31.28
2020	4	29	PCR_COV_N2019	E Gene CT	20.49
2020	5	1	PCR_COV_N2019	E Gene CT	24.12
2020	5	1	PCR_COV_N2019	E Gene CT	31.05
2020	5	3	PCR_COV_N2019	E Gene CT	29.38
2020	5	4	PCR_COV_N2019	E Gene CT	29.45
2020	5	4	PCR_COV_N2019	E Gene CT	21.4
2020	5	8	PCR_COV_N2019	E Gene CT	20.75
2020	5	8	PCR_COV_N2019	E Gene CT	34.52
2020	5	9	PCR_FUSION_COV19_E	E Gene CT	19.4
2020	5	9	PCR_COV_N2019	E Gene CT	18.02
2020	5	14	PCR_COV_N2019	E Gene CT	32.11
2020	5	23	PCR_COV_N2019	E Gene CT	27.78
2020	5	23	PCR_COV_N2019	E Gene CT	27.37
2020	5	28	PCR_COV_N2019	E Gene CT	32.1
2020	5	28	PCR_COV_N2019	E Gene CT	34.72
2020	5	31	PCR_COV_N2019	E Gene CT	26.34
2020	5	31	PCR_COV_N2019	E Gene CT	26.79
2020	6	2	PCR_COV_N2019	E Gene CT	32.1
2020	6	2	PCR_COV_N2019	E Gene CT	19.08

AB894

2020	6	3	PCR_COV_N2019	E Gene CT	14.8
2020	6	9	PCR_FUSION_COV19_E	E Gene CT	36.4
2020	6	10	PCR_COV_N2019	E Gene CT	18.52
2020	6	12	PCR_COV_N2019	E Gene CT	21.29
2020	6	17	PCR_COV_N2019	E Gene CT	18.97
2020	6	17	PCR_COV_N2019	E Gene CT	20.24
2020	6	17	PCR_COV_N2019	E Gene CT	23.69
2020	6	17	PCR_FUSION_COV19_E	E Gene CT	37.4
2020	6	18	PCR_COV_N2019	E Gene CT	20.83
2020	6	26	PCR_COV_N2019	E Gene CT	19.2
2020	6	26	PCR_COV_N2019	E Gene CT	24.11
2020	6	26	PCR_COV_N2019	E Gene CT	32.88
2020	6	27	PCR_COV_N2019	E Gene CT	25.59
2020	7	7	PCR_COV_N2019	E Gene CT	33.35
2020	7	11	PCR_COV_N2019	E Gene CT	16.5
2020	7	11	PCR_COV_N2019	E Gene CT	20.36
2020	7	11	PCR_COV_N2019	E Gene CT	13.07
2020	7	11	PCR_FUSION_COV19_E	E Gene CT	29.7
2020	7	15	PCR_COV_N2019	E Gene CT	25.19
2020	7	15	PCR_COV_N2019	E Gene CT	33.83
2020	7	15	PCR_COV_N2019	E Gene CT	15.81
2020	7	15	PCR_COV_N2019	E Gene CT	22.82
2020	7	16	PCR_COV_N2019	E Gene CT	14.19
2020	7	16	PCR_COV_N2019	E Gene CT	24.34
2020	7	16	PCR_COV_N2019	E Gene CT	29.93
2020	7	17	PCR_COV_N2019	E Gene CT	17.9
2020	7	18	PCR_COV_N2019	E Gene CT	33.48
2020	7	18	PCR_COV_N2019	E Gene CT	23.88
2020	7	18	PCR_COV_N2019	E Gene CT	16.62
2020	7	18	PCR_COV_N2019	E Gene CT	27.13
2020	7	18	PCR_COV_N2019	E Gene CT	17.55
2020	7	18	PCR_COV_N2019	E Gene CT	17.02
2020	7	18	PCR_COV_N2019	E Gene CT	14.91
2020	7	18	PCR_COV_N2019	E Gene CT	16.33
2020	7	18	PCR_COV_N2019	E Gene CT	13.83
2020	7	18	PCR_COV_N2019	E Gene CT	15.68
2020	7	18	PCR_COV_N2019	E Gene CT	13.95
2020	7	18	PCR_COV_N2019	E Gene CT	12.56
2020	7	18	PCR_COV_N2019	E Gene CT	14.34
2020	7	18	PCR_COV_N2019	E Gene CT	13.63
2020	7	18	PCR_COV_N2019	E Gene CT	20.04
2020	7	18	PCR_COV_N2019	E Gene CT	16.21
2020	7	18	PCR_COBAS_COV19	CT 2	18.22
2020	7	19	PCR_COV_N2019	E Gene CT	23
2020	7	19	PCR_FUSION_COV19_E	E Gene CT	37.2
2020	7	19	PCR_FUSION_COV19_E	E Gene CT	33.5
2020	7	19	PCR_COV_N2019	E Gene CT	18.89

AB895

2020	7	19	PCR_COV_N2019	E Gene CT	21.87
2020	7	20	PCR_COV_N2019	E Gene CT	27.35
2020	7	20	PCR_COV_N2019	E Gene CT	16.15
2020	7	20	PCR_COV_N2019	E Gene CT	29.99
2020	7	20	PCR_COV_N2019	E Gene CT	24.1
2020	7	20	PCR_COV_N2019	E Gene CT	17.88
2020	7	20	PCR_COV_N2019	E Gene CT	14.56
2020	7	20	PCR_COV_N2019	E Gene CT	13.03
2020	7	20	PCR_COV_N2019	E Gene CT	16.09
2020	7	20	PCR_COV_N2019	E Gene CT	14.88
2020	7	20	PCR_FUSION_COV19_E	E Gene CT	34.4
2020	7	21	PCR_COV_N2019	E Gene CT	31.59
2020	7	21	PCR_COV_N2019	E Gene CT	23.27
2020	7	21	PCR_COV_N2019	E Gene CT	21.6
2020	7	21	PCR_COV_N2019	E Gene CT	19.36
2020	7	21	PCR_COV_N2019	E Gene CT	18.99
2020	7	22	PCR_COV_N2019	E Gene CT	16.74
2020	7	22	PCR_COV_N2019	E Gene CT	20.78
2020	7	22	PCR_COV_N2019	E Gene CT	25.82
2020	7	22	PCR_COV_N2019	E Gene CT	16.34
2020	7	22	PCR_COV_N2019	E Gene CT	18.2
2020	7	22	PCR_COV_N2019	E Gene CT	13.36
2020	7	23	PCR_COV_N2019	E Gene CT	15.52
2020	7	23	PCR_COV_N2019	E Gene CT	20.05
2020	7	23	PCR_COV_N2019	E Gene CT	15.86
2020	7	23	PCR_COV_N2019	E Gene CT	21.34
2020	7	24	PCR_COV_N2019	E Gene CT	17.31
2020	7	24	PCR_COV_N2019	E Gene CT	15.04
2020	7	24	PCR_COV_N2019	E Gene CT	27.14
2020	7	24	PCR_COV_N2019	E Gene CT	31.2
2020	7	24	PCR_COV_N2019	E Gene CT	19.77
2020	7	24	PCR_COV_N2019	E Gene CT	18.43
2020	7	25	PCR_COV_N2019	E Gene CT	22.5
2020	7	25	PCR_FUSION_COV19_E	E Gene CT	37
2020	7	25	PCR_COV_N2019	E Gene CT	28.99
2020	7	25	PCR_COV_N2019	E Gene CT	29.1
2020	7	25	PCR_COV_N2019	E Gene CT	15.17
2020	7	26	PCR_COV_N2019	E Gene CT	14.25
2020	7	26	PCR_COV_N2019	E Gene CT	28.77
2020	7	26	PCR_COV_N2019	E Gene CT	19.65
2020	7	27	PCR_COV_N2019	E Gene CT	31.55
2020	7	27	PCR_COV_N2019	E Gene CT	15.7
2020	7	28	PCR_FUSION_COV19_E	E Gene CT	19.7
2020	7	28	PCR_FUSION_COV19_E	E Gene CT	24.1
2020	7	29	PCR_COV_N2019	E Gene CT	20.19
2020	7	29	PCR_COV_N2019	E Gene CT	15.04
2020	7	29	PCR_COV_N2019	E Gene CT	32.63

AB896

2020	7	29	PCR_COV_N2019	E Gene CT	28.11
2020	7	29	PCR_COV_N2019	E Gene CT	32.42
2020	7	30	PCR_COV_N2019	E Gene CT	16.28
2020	7	30	PCR_COV_N2019	E Gene CT	29.22
2020	7	30	PCR_COV_N2019	E Gene CT	27.91
2020	7	30	PCR_COV_N2019	E Gene CT	25.64
2020	7	31	PCR_COV_N2019	E Gene CT	17.68
2020	7	31	PCR_COV_N2019	E Gene CT	20.83
2020	7	31	PCR_COV_N2019	E Gene CT	18.87
2020	7	31	PCR_COV_N2019	E Gene CT	26.68
2020	7	31	PCR_COV_N2019	E Gene CT	13.72
2020	7	31	PCR_COV_N2019	E Gene CT	19.52
2020	7	31	PCR_COV_N2019	E Gene CT	15.53
2020	7	31	PCR_COV_N2019	E Gene CT	18.64
2020	8	1	PCR_COV_N2019	E Gene CT	19.92
2020	8	1	PCR_COV_N2019	E Gene CT	14.02
2020	8	1	PCR_COV_N2019	E Gene CT	15.22
2020	8	1	PCR_COV_N2019	E Gene CT	17.87
2020	8	1	PCR_COV_N2019	E Gene CT	33.76
2020	8	1	PCR_COV_N2019	E Gene CT	18.04
2020	8	1	PCR_COV_N2019	E Gene CT	30.61
2020	8	1	PCR_COV_N2019	E Gene CT	26.77
2020	8	2	PCR_COV_N2019	E Gene CT	27.4
2020	8	2	PCR_COV_N2019	E Gene CT	22.1
2020	8	2	PCR_COV_N2019	E Gene CT	12.53
2020	8	4	PCR_COV_N2019	E Gene CT	17.32
2020	8	4	PCR_COV_N2019	E Gene CT	15.44
2020	8	4	PCR_COV_N2019	E Gene CT	17.47
2020	8	4	PCR_COV_N2019	E Gene CT	36.6
2020	8	4	PCR_COV_N2019	E Gene CT	35.51
2020	8	4	PCR_COV_N2019	E Gene CT	31.88
2020	8	4	PCR_COV_N2019	E Gene CT	17.56
2020	8	4	PCR_COV_N2019	E Gene CT	14.52
2020	8	4	PCR_COV_N2019	E Gene CT	14.18
2020	8	4	PCR_COV_N2019	E Gene CT	24.51
2020	8	4	PCR_COV_N2019	E Gene CT	15.86
2020	8	4	PCR_COV_N2019	E Gene CT	27.29
2020	8	4	PCR_COV_N2019	E Gene CT	17.33
2020	8	4	PCR_COV_N2019	E Gene CT	18.34
2020	8	4	PCR_COV_N2019	E Gene CT	28.43
2020	8	4	PCR_COV_N2019	E Gene CT	24.69
2020	8	4	PCR_COV_N2019	E Gene CT	19.17
2020	8	4	PCR_COV_N2019	E Gene CT	25.02
2020	8	4	PCR_COV_N2019	E Gene CT	18.24
2020	8	4	PCR_COV_N2019	E Gene CT	23.14
2020	8	4	PCR_COV_N2019	E Gene CT	20.69
2020	8	4	PCR_COV_N2019	E Gene CT	13.39

AB897

2020	8	4	PCR_COV_N2019	E Gene CT	13.14
2020	8	4	PCR_COV_N2019	E Gene CT	30.65
2020	8	4	PCR_COV_N2019	E Gene CT	29.43
2020	8	4	PCR_COV_N2019	E Gene CT	14.12
2020	8	4	PCR_FUSION_COV19_E	E Gene CT	22.5
2020	8	5	PCR_COV_N2019	E Gene CT	20.38
2020	8	5	PCR_COV_N2019	E Gene CT	34.18
2020	8	5	PCR_COV_N2019	E Gene CT	17.17
2020	8	5	PCR_COV_N2019	E Gene CT	16.38
2020	8	5	PCR_COV_N2019	E Gene CT	22.32
2020	8	5	PCR_COV_N2019	E Gene CT	31.95
2020	8	5	PCR_COV_N2019	E Gene CT	30.38
2020	8	5	PCR_COV_N2019	E Gene CT	33.41
2020	8	5	PCR_COV_N2019	E Gene CT	16.49
2020	8	5	PCR_COV_N2019	E Gene CT	33.84
2020	8	5	PCR_COV_N2019	E Gene CT	27.2
2020	8	5	PCR_COV_N2019	E Gene CT	23.6
2020	8	5	PCR_COV_N2019	E Gene CT	28.12
2020	8	5	PCR_COV_N2019	E Gene CT	21.63
2020	8	5	PCR_COV_N2019	E Gene CT	19.19
2020	8	6	PCR_COV_N2019	E Gene CT	19.49
2020	8	6	PCR_COV_N2019	E Gene CT	18.15
2020	8	6	PCR_COV_N2019	E Gene CT	30.05
2020	8	6	PCR_COV_N2019	E Gene CT	30.79
2020	8	6	PCR_COV_N2019	E Gene CT	20.58
2020	8	6	PCR_COV_N2019	E Gene CT	34.03
2020	8	6	PCR_COV_N2019	E Gene CT	16.37
2020	8	6	PCR_COV_N2019	E Gene CT	28.98
2020	8	6	PCR_COV_N2019	E Gene CT	19.7
2020	8	6	PCR_COV_N2019	E Gene CT	24.3
2020	8	7	PCR_COV_N2019	E Gene CT	31.41
2020	8	7	PCR_COV_N2019	E Gene CT	19.06
2020	8	7	PCR_COV_N2019	E Gene CT	19.15
2020	8	7	PCR_COV_N2019	E Gene CT	32.01
2020	8	7	PCR_COV_N2019	E Gene CT	32.33
2020	8	7	PCR_COV_N2019	E Gene CT	24.49
2020	8	7	PCR_COV_N2019	E Gene CT	22.27
2020	8	7	PCR_COV_N2019	E Gene CT	20.62
2020	8	7	PCR_COV_N2019	E Gene CT	21.55
2020	8	7	PCR_COV_N2019	E Gene CT	25.36
2020	8	7	PCR_COV_N2019	E Gene CT	17.06
2020	8	7	PCR_COV_N2019	E Gene CT	16.84
2020	8	7	PCR_COV_N2019	E Gene CT	29.58
2020	8	7	PCR_COV_N2019	E Gene CT	22.68
2020	8	7	PCR_COV_N2019	E Gene CT	25.04
2020	8	7	PCR_COV_N2019	E Gene CT	18.85
2020	8	7	PCR_COV_N2019	E Gene CT	25.95

AB898

2020	8	7	PCR_COV_N2019	E Gene CT	16.09
2020	8	7	PCR_COV_N2019	E Gene CT	20.87
2020	8	7	PCR_COV_N2019	E Gene CT	21.54
2020	8	7	PCR_COV_N2019	E Gene CT	19.39
2020	8	7	PCR_COV_N2019	E Gene CT	34.01
2020	8	7	PCR_COV_N2019	E Gene CT	30.38
2020	8	7	PCR_COV_N2019	E Gene CT	24.7
2020	8	7	PCR_COV_N2019	E Gene CT	26.11
2020	8	7	PCR_COV_N2019	E Gene CT	20.45
2020	8	7	PCR_COV_N2019	E Gene CT	16.24
2020	8	8	PCR_COV_N2019	E Gene CT	12.6
2020	8	8	PCR_FUSION_COV19_E	E Gene CT	29.1
2020	8	8	PCR_FUSION_COV19_E	E Gene CT	23.9
2020	8	8	PCR_FUSION_COV19_E	E Gene CT	18.7
2020	8	8	PCR_FUSION_COV19_E	E Gene CT	23.6
2020	8	8	PCR_COV_N2019	E Gene CT	21.17
2020	8	8	PCR_FUSION_COV19_E	E Gene CT	21.5
2020	8	8	PCR_FUSION_COV19_E	E Gene CT	18.6
2020	8	8	PCR_COV_N2019	E Gene CT	13.25
2020	8	8	PCR_COV_N2019	E Gene CT	27.73
2020	8	8	PCR_COV_N2019	E Gene CT	16.35
2020	8	8	PCR_COV_N2019	E Gene CT	17.86
2020	8	8	PCR_COV_N2019	E Gene CT	12.81
2020	8	8	PCR_COV_N2019	E Gene CT	31.71
2020	8	8	PCR_COV_N2019	E Gene CT	18.13
2020	8	8	PCR_COV_N2019	E Gene CT	29.73
2020	8	8	PCR_COV_N2019	E Gene CT	14.92
2020	8	9	PCR_FUSION_COV19_E	E Gene CT	34.7
2020	8	9	PCR_FUSION_COV19_E	E Gene CT	23.2
2020	8	9	PCR_FUSION_COV19_E	E Gene CT	20.9
2020	8	9	PCR_FUSION_COV19_E	E Gene CT	22.6
2020	8	9	PCR_FUSION_COV19_E	E Gene CT	18.6
2020	8	9	PCR_COV_N2019	E Gene CT	17.24
2020	8	9	PCR_COV_N2019	E Gene CT	16.85
2020	8	10	PCR_FUSION_COV19_E	E Gene CT	28.4
2020	8	10	PCR_COV_N2019	E Gene CT	32.47
2020	8	10	PCR_COV_N2019	E Gene CT	27.27
2020	8	10	PCR_COV_N2019	E Gene CT	25.02
2020	8	10	PCR_COV_N2019	E Gene CT	18.36
2020	8	11	PCR_COV_N2019	E Gene CT	29.67
2020	8	11	PCR_COV_N2019	E Gene CT	23.48
2020	8	11	PCR_FUSION_COV19_E	E Gene CT	35.4
2020	8	11	PCR_FUSION_COV19_E	E Gene CT	20.9
2020	8	11	PCR_FUSION_COV19_E	E Gene CT	25.2
2020	8	11	PCR_FUSION_COV19_E	E Gene CT	28.5
2020	8	11	PCR_FUSION_COV19_E	E Gene CT	18.4
2020	8	11	PCR_FUSION_COV19_E	E Gene CT	20.6

AB899

2020	8	11	PCR_FUSION_COV19_E	E Gene CT	33.1
2020	8	11	PCR_FUSION_COV19_E	E Gene CT	35.3
2020	8	11	PCR_FUSION_COV19_E	E Gene CT	30.2
2020	8	11	PCR_COV_N2019	E Gene CT	26.29
2020	8	11	PCR_COV_N2019	E Gene CT	16.15
2020	8	11	PCR_COV_N2019	E Gene CT	33.35
2020	8	11	PCR_COV_N2019	E Gene CT	10.19
2020	8	11	PCR_COV_N2019	E Gene CT	26.97
2020	8	11	PCR_COV_N2019	E Gene CT	15.34
2020	8	11	PCR_COV_N2019	E Gene CT	14.33
2020	8	11	PCR_COV_N2019	E Gene CT	23.63
2020	8	11	PCR_COV_N2019	E Gene CT	17.19
2020	8	11	PCR_COV_N2019	E Gene CT	17.88
2020	8	11	PCR_FUSION_COV19_E	E Gene CT	19.2
2020	8	11	PCR_FUSION_COV19_E	E Gene CT	21.3
2020	8	11	PCR_COV_N2019	E Gene CT	18.64
2020	8	11	PCR_COV_N2019	E Gene CT	19.28
2020	8	11	PCR_COV_N2019	E Gene CT	23.53
2020	8	11	PCR_COV_N2019	E Gene CT	14.65
2020	8	11	PCR_COV_N2019	E Gene CT	22.22
2020	8	12	PCR_COV_N2019	E Gene CT	16.66
2020	8	12	PCR_COV_N2019	E Gene CT	32.63
2020	8	12	PCR_FUSION_COV19_E	E Gene CT	21
2020	8	12	PCR_FUSION_COV19_E	E Gene CT	27.7
2020	8	12	PCR_FUSION_COV19_E	E Gene CT	24.5
2020	8	12	PCR_FUSION_COV19_E	E Gene CT	19.4
2020	8	12	PCR_FUSION_COV19_E	E Gene CT	24.5
2020	8	12	PCR_FUSION_COV19_E	E Gene CT	18.9
2020	8	12	PCR_COV_N2019	E Gene CT	22.34
2020	8	12	PCR_COV_N2019	E Gene CT	31.84
2020	8	12	PCR_COV_N2019	E Gene CT	23.23
2020	8	12	PCR_COV_N2019	E Gene CT	23.24
2020	8	12	PCR_COV_N2019	E Gene CT	20.15
2020	8	12	PCR_COV_N2019	E Gene CT	24.09
2020	8	12	PCR_COV_N2019	E Gene CT	14.62
2020	8	12	PCR_COV_N2019	E Gene CT	22.95
2020	8	12	PCR_COV_N2019	E Gene CT	23.95
2020	8	12	PCR_COV_N2019	E Gene CT	15.72
2020	8	12	PCR_COV_N2019	E Gene CT	15.05
2020	8	12	PCR_COV_N2019	E Gene CT	18.36
2020	8	12	PCR_COV_N2019	E Gene CT	23.32
2020	8	12	PCR_FUSION_COV19_E	E Gene CT	18.8
2020	8	13	PCR_COV_N2019	E Gene CT	19.22
2020	8	13	PCR_COV_N2019	E Gene CT	16.47
2020	8	13	PCR_FUSION_COV19_E	E Gene CT	30
2020	8	13	PCR_COV_N2019	E Gene CT	28.73
2020	8	13	PCR_COV_N2019	E Gene CT	32.28

AB900

2020	8	13	PCR_COV_N2019	E Gene CT	21.13
2020	8	13	PCR_COV_N2019	E Gene CT	28.57
2020	8	13	PCR_COV_N2019	E Gene CT	17.12
2020	8	13	PCR_COV_N2019	E Gene CT	16.01
2020	8	13	PCR_COV_N2019	E Gene CT	25.59
2020	8	13	PCR_COV_N2019	E Gene CT	15.9
2020	8	13	PCR_COV_N2019	E Gene CT	25.73
2020	8	13	PCR_COV_N2019	E Gene CT	19.16
2020	8	13	PCR_COV_N2019	E Gene CT	18.17
2020	8	13	PCR_COV_N2019	E Gene CT	15.08
2020	8	13	PCR_COV_N2019	E Gene CT	14.9
2020	8	13	PCR_COV_N2019	E Gene CT	30.1
2020	8	13	PCR_COV_N2019	E Gene CT	29.53
2020	8	13	PCR_COV_N2019	E Gene CT	12.2
2020	8	13	PCR_COV_N2019	E Gene CT	24.65
2020	8	13	PCR_COV_N2019	E Gene CT	28.85
2020	8	13	PCR_COV_N2019	E Gene CT	18.74
2020	8	13	PCR_COV_N2019	E Gene CT	22.52
2020	8	13	PCR_COV_N2019	E Gene CT	22.3
2020	8	13	PCR_COV_N2019	E Gene CT	21.13
2020	8	13	PCR_COV_N2019	E Gene CT	27.43
2020	8	14	PCR_COV_N2019	E Gene CT	29.04
2020	8	14	PCR_COV_N2019	E Gene CT	15.76
2020	8	14	PCR_COV_N2019	E Gene CT	15.04
2020	8	14	PCR_COV_N2019	E Gene CT	37.88
2020	8	14	PCR_COV_N2019	E Gene CT	13.11
2020	8	14	PCR_COV_N2019	E Gene CT	15.31
2020	8	14	PCR_COV_N2019	E Gene CT	39.07
2020	8	14	PCR_COBAS_COV19	CT 2	35.27
2020	8	14	PCR_FUSION_COV19_E	E Gene CT	25.4
2020	8	14	PCR_COV_N2019	E Gene CT	22.2
2020	8	14	PCR_COV_N2019	E Gene CT	24.31
2020	8	14	PCR_FUSION_COV19_E	E Gene CT	20.2
2020	8	14	PCR_FUSION_COV19_E	E Gene CT	30.8
2020	8	14	PCR_FUSION_COV19_E	E Gene CT	34.2
2020	8	14	PCR_FUSION_COV19_E	E Gene CT	19.1
2020	8	14	PCR_FUSION_COV19_E	E Gene CT	27.3
2020	8	14	PCR_FUSION_COV19_E	E Gene CT	37.1
2020	8	14	PCR_COV_N2019	E Gene CT	14.24
2020	8	14	PCR_COV_N2019	E Gene CT	25.81
2020	8	14	PCR_FUSION_COV19_E	E Gene CT	25.1
2020	8	14	PCR_FUSION_COV19_E	E Gene CT	36.3
2020	8	14	PCR_COV_N2019	E Gene CT	18.93
2020	8	14	PCR_FUSION_COV19_E	E Gene CT	22.2
2020	8	14	PCR_COV_N2019	E Gene CT	16.73
2020	8	15	PCR_COV_N2019	E Gene CT	32.62
2020	8	15	PCR_COV_N2019	E Gene CT	18.99

AB901

2020	8	15	PCR_COV_N2019	E Gene CT	27.15
2020	8	15	PCR_COV_N2019	E Gene CT	13.51
2020	8	15	PCR_FUSION_COV19_E	E Gene CT	35.4
2020	8	15	PCR_FUSION_COV19_E	E Gene CT	33.2
2020	8	15	PCR_FUSION_COV19_E	E Gene CT	36.2
2020	8	15	PCR_COV_N2019	E Gene CT	30.63
2020	8	15	PCR_FUSION_COV19_E	E Gene CT	34.1
2020	8	15	PCR_FUSION_COV19_E	E Gene CT	32.5
2020	8	15	PCR_FUSION_COV19_E	E Gene CT	29.4
2020	8	15	PCR_FUSION_COV19_E	E Gene CT	22.3
2020	8	15	PCR_FUSION_COV19_E	E Gene CT	20.4
2020	8	15	PCR_FUSION_COV19_E	E Gene CT	19.6
2020	8	15	PCR_FUSION_COV19_E	E Gene CT	29.1
2020	8	15	PCR_FUSION_COV19_E	E Gene CT	27.5
2020	8	15	PCR_FUSION_COV19_E	E Gene CT	27.5
2020	8	15	PCR_FUSION_COV19_E	E Gene CT	36.9
2020	8	15	PCR_FUSION_COV19_E	E Gene CT	33.4
2020	8	15	PCR_COV_N2019	E Gene CT	15.52
2020	8	15	PCR_COV_N2019	E Gene CT	31.77
2020	8	15	PCR_COV_N2019	E Gene CT	27.18
2020	8	15	PCR_COV_N2019	E Gene CT	27.77
2020	8	16	PCR_COV_N2019	E Gene CT	22.37
2020	8	16	PCR_COV_N2019	E Gene CT	24.59
2020	8	16	PCR_COV_N2019	E Gene CT	26.85
2020	8	16	PCR_COV_N2019	E Gene CT	24.2
2020	8	16	PCR_COV_N2019	E Gene CT	19.06
2020	8	16	PCR_FUSION_COV19_E	E Gene CT	20.5
2020	8	16	PCR_FUSION_COV19_E	E Gene CT	21.8
2020	8	16	PCR_COV_N2019	E Gene CT	35.05
2020	8	16	PCR_FUSION_COV19_E	E Gene CT	25.1
2020	8	16	PCR_FUSION_COV19_E	E Gene CT	27.1
2020	8	16	PCR_FUSION_COV19_E	E Gene CT	16.7
2020	8	16	PCR_FUSION_COV19_E	E Gene CT	20.2
2020	8	16	PCR_FUSION_COV19_E	E Gene CT	25.1
2020	8	16	PCR_FUSION_COV19_E	E Gene CT	22.8
2020	8	16	PCR_COV_N2019	E Gene CT	28.72
2020	8	16	PCR_FUSION_COV19_E	E Gene CT	26.6
2020	8	16	PCR_FUSION_COV19_E	E Gene CT	22.5
2020	8	16	PCR_FUSION_COV19_E	E Gene CT	25
2020	8	16	PCR_COV_N2019	E Gene CT	19.88
2020	8	16	PCR_COV_N2019	E Gene CT	20.63
2020	8	16	PCR_COV_N2019	E Gene CT	31.11
2020	8	17	PCR_COV_N2019	E Gene CT	23.44
2020	8	17	PCR_COV_N2019	E Gene CT	32.21
2020	8	17	PCR_FUSION_COV19_E	E Gene CT	17.7
2020	8	17	PCR_FUSION_COV19_E	E Gene CT	26.5
2020	8	17	PCR_COV_N2019	E Gene CT	26.35

AB902

2020	8	18	PCR_COV_N2019	E Gene CT	16.27
2020	8	18	PCR_COV_N2019	E Gene CT	12.84
2020	8	18	PCR_COV_N2019	E Gene CT	15.85
2020	8	18	PCR_FUSION_COV19_E	E Gene CT	36.8
2020	8	18	PCR_FUSION_COV19_E	E Gene CT	36.6
2020	8	18	PCR_FUSION_COV19_E	E Gene CT	19.9
2020	8	18	PCR_FUSION_COV19_E	E Gene CT	20.8
2020	8	18	PCR_FUSION_COV19_E	E Gene CT	28.8
2020	8	18	PCR_FUSION_COV19_E	E Gene CT	23.7
2020	8	18	PCR_FUSION_COV19_E	E Gene CT	36.4
2020	8	18	PCR_FUSION_COV19_E	E Gene CT	27.6
2020	8	18	PCR_FUSION_COV19_E	E Gene CT	35.6
2020	8	18	PCR_COV_N2019	E Gene CT	18.37
2020	8	18	PCR_FUSION_COV19_E	E Gene CT	21.2
2020	8	18	PCR_FUSION_COV19_E	E Gene CT	25.1
2020	8	18	PCR_FUSION_COV19_E	E Gene CT	17.4
2020	8	18	PCR_FUSION_COV19_E	E Gene CT	33.4
2020	8	18	PCR_FUSION_COV19_E	E Gene CT	20.6
2020	8	18	PCR_FUSION_COV19_E	E Gene CT	19
2020	8	18	PCR_FUSION_COV19_E	E Gene CT	27.7
2020	8	18	PCR_COV_N2019	E Gene CT	16.45
2020	8	18	PCR_COV_N2019	E Gene CT	13.41
2020	8	18	PCR_COV_N2019	E Gene CT	25.96
2020	8	18	PCR_COV_N2019	E Gene CT	27.86
2020	8	18	PCR_COV_N2019	E Gene CT	13.14
2020	8	18	PCR_COV_N2019	E Gene CT	17.32
2020	8	18	PCR_COV_N2019	E Gene CT	14.5
2020	8	18	PCR_COV_N2019	E Gene CT	18.3
2020	8	18	PCR_COV_N2019	E Gene CT	18.49
2020	8	18	PCR_COV_N2019	E Gene CT	19.98
2020	8	18	PCR_COV_N2019	E Gene CT	16.12
2020	8	18	PCR_COV_N2019	E Gene CT	25.23
2020	8	18	PCR_COV_N2019	E Gene CT	12.11
2020	8	18	PCR_COV_N2019	E Gene CT	11.47
2020	8	18	PCR_COV_N2019	E Gene CT	25.07
2020	8	18	PCR_COV_N2019	E Gene CT	19.79
2020	8	18	PCR_FUSION_COV19_E	E Gene CT	33.8
2020	8	18	PCR_FUSION_COV19_E	E Gene CT	18.3
2020	8	18	PCR_FUSION_COV19_E	E Gene CT	37
2020	8	19	PCR_COV_N2019	E Gene CT	20.31
2020	8	19	PCR_COV_N2019	E Gene CT	16.6
2020	8	19	PCR_COV_N2019	E Gene CT	23.32
2020	8	19	PCR_COV_N2019	E Gene CT	16.26
2020	8	19	PCR_COV_N2019	E Gene CT	33.62
2020	8	19	PCR_COV_N2019	E Gene CT	32.84
2020	8	19	PCR_COV_N2019	E Gene CT	15.56
2020	8	19	PCR_COV_N2019	E Gene CT	12.06

2020	8	19	PCR_COV_N2019	E Gene CT	27.02
2020	8	19	PCR_FUSION_COV19_E	E Gene CT	18.8
2020	8	19	PCR_FUSION_COV19_E	E Gene CT	36.2
2020	8	19	PCR_FUSION_COV19_E	E Gene CT	21.2
2020	8	19	PCR_FUSION_COV19_E	E Gene CT	18.3
2020	8	19	PCR_COV_N2019	E Gene CT	17.83
2020	8	19	PCR_COV_N2019	E Gene CT	16.49
2020	8	19	PCR_COV_N2019	E Gene CT	24.11
2020	8	19	PCR_COV_N2019	E Gene CT	29.24
2020	8	19	PCR_COV_N2019	E Gene CT	31.05
2020	8	19	PCR_COV_N2019	E Gene CT	16.35
2020	8	19	PCR_COV_N2019	E Gene CT	28.06
2020	8	19	PCR_COV_N2019	E Gene CT	22.08
2020	8	19	PCR_COV_N2019	E Gene CT	21.16
2020	8	19	PCR_COV_N2019	E Gene CT	21.06
2020	8	19	PCR_COV_N2019	E Gene CT	31.45
2020	8	19	PCR_COV_N2019	E Gene CT	13.19
2020	8	19	PCR_COV_N2019	E Gene CT	16.66
2020	8	19	PCR_FUSION_COV19_E	E Gene CT	26
2020	8	19	PCR_FUSION_COV19_E	E Gene CT	24.3
2020	8	19	PCR_FUSION_COV19_E	E Gene CT	37.2
2020	8	19	PCR_FUSION_COV19_E	E Gene CT	37
2020	8	19	PCR_FUSION_COV19_E	E Gene CT	26.5
2020	8	19	PCR_FUSION_COV19_E	E Gene CT	19.8
2020	8	19	PCR_COV_N2019	E Gene CT	29.16
2020	8	19	PCR_COV_N2019	E Gene CT	27.02
2020	8	19	PCR_COV_N2019	E Gene CT	23.46
2020	8	20	PCR_COV_N2019	E Gene CT	22.46
2020	8	20	PCR_COBAS_COV19	CT 2	38.12
2020	8	20	PCR_COV_N2019	E Gene CT	25.05
2020	8	20	PCR_FUSION_COV19_E	E Gene CT	18.1
2020	8	20	PCR_FUSION_COV19_E	E Gene CT	37.5
2020	8	20	PCR_FUSION_COV19_E	E Gene CT	22.8
2020	8	20	PCR_FUSION_COV19_E	E Gene CT	24.2
2020	8	20	PCR_FUSION_COV19_E	E Gene CT	23
2020	8	20	PCR_FUSION_COV19_E	E Gene CT	32.1
2020	8	20	PCR_FUSION_COV19_E	E Gene CT	20.1
2020	8	20	PCR_COV_N2019	E Gene CT	29.05
2020	8	20	PCR_COV_N2019	E Gene CT	31.11
2020	8	20	PCR_COV_N2019	E Gene CT	21.59
2020	8	20	PCR_COV_N2019	E Gene CT	16.01
2020	8	20	PCR_COV_N2019	E Gene CT	26.82
2020	8	20	PCR_COV_N2019	E Gene CT	18.32
2020	8	20	PCR_COV_N2019	E Gene CT	25.48
2020	8	20	PCR_COV_N2019	E Gene CT	17.69
2020	8	20	PCR_COV_N2019	E Gene CT	15.03
2020	8	20	PCR_COV_N2019	E Gene CT	13.24

AB904

2020	8	20	PCR_COV_N2019	E Gene CT	34.45
2020	8	20	PCR_COV_N2019	E Gene CT	32.25
2020	8	20	PCR_FUSION_COV19_E	E Gene CT	30.1
2020	8	20	PCR_COV_N2019	E Gene CT	34.18
2020	8	20	PCR_COV_N2019	E Gene CT	20.07
2020	8	20	PCR_COV_N2019	E Gene CT	16.83
2020	8	20	PCR_COV_N2019	E Gene CT	31.68
2020	8	20	PCR_COV_N2019	E Gene CT	20.84
2020	8	20	PCR_FUSION_COV19_E	E Gene CT	17.2
2020	8	20	PCR_COV_N2019	E Gene CT	14.64
2020	8	20	PCR_COV_N2019	E Gene CT	21.22
2020	8	20	PCR_COV_N2019	E Gene CT	22
2020	8	20	PCR_COV_N2019	E Gene CT	18.89
2020	8	21	PCR_COV_N2019	E Gene CT	17.5
2020	8	21	PCR_COV_N2019	E Gene CT	33.96
2020	8	21	PCR_FUSION_COV19_E	E Gene CT	17
2020	8	21	PCR_FUSION_COV19_E	E Gene CT	15.7
2020	8	21	PCR_FUSION_COV19_E	E Gene CT	22.1
2020	8	21	PCR_FUSION_COV19_E	E Gene CT	30.3
2020	8	21	PCR_COV_N2019	E Gene CT	18.32
2020	8	21	PCR_FUSION_COV19_E	E Gene CT	27
2020	8	21	PCR_FUSION_COV19_E	E Gene CT	25.5
2020	8	21	PCR_FUSION_COV19_E	E Gene CT	28.2
2020	8	21	PCR_COV_N2019	E Gene CT	17.62
2020	8	21	PCR_COV_N2019	E Gene CT	17.3
2020	8	21	PCR_COV_N2019	E Gene CT	13.14
2020	8	21	PCR_COV_N2019	E Gene CT	32.32
2020	8	21	PCR_COV_N2019	E Gene CT	34.71
2020	8	21	PCR_FUSION_COV19_E	E Gene CT	23.6
2020	8	21	PCR_FUSION_COV19_E	E Gene CT	37.1
2020	8	21	PCR_COV_N2019	E Gene CT	15.37
2020	8	21	PCR_COV_N2019	E Gene CT	19.05
2020	8	21	PCR_COV_N2019	E Gene CT	33.28
2020	8	21	PCR_COBAS_COV19	CT 2	22.5
2020	8	21	PCR_COBAS_COV19	CT 2	23.86
2020	8	21	PCR_COBAS_COV19	CT 2	22.36
2020	8	21	PCR_COBAS_COV19	CT 2	31.63
2020	8	21	PCR_COBAS_COV19	CT 2	25.06
2020	8	21	PCR_COBAS_COV19	CT 2	23.21
2020	8	21	PCR_COBAS_COV19	CT 2	21.94
2020	8	21	PCR_COBAS_COV19	CT 2	33.56
2020	8	21	PCR_COBAS_COV19	CT 2	20.18
2020	8	21	PCR_COBAS_COV19	CT 2	21.28
2020	8	21	PCR_COBAS_COV19	CT 2	23.55
2020	8	21	PCR_COBAS_COV19	CT 2	20.73
2020	8	21	PCR_COBAS_COV19	CT 2	21.94
2020	8	21	PCR_COBAS_COV19	CT 2	18.09

AB905

2020	8	21	PCR_COBAS_COV19	CT 2	24.34
2020	8	21	PCR_COBAS_COV19	CT 2	22.3
2020	8	21	PCR_COBAS_COV19	CT 2	30.81
2020	8	21	PCR_COBAS_COV19	CT 2	22.96
2020	8	21	PCR_COBAS_COV19	CT 2	21.81
2020	8	21	PCR_COBAS_COV19	CT 2	18.24
2020	8	21	PCR_COBAS_COV19	CT 2	19.02
2020	8	21	PCR_COBAS_COV19	CT 2	23.91
2020	8	21	PCR_COBAS_COV19	CT 2	27.61
2020	8	21	PCR_COV_N2019	E Gene CT	21.02
2020	8	21	PCR_COV_N2019	E Gene CT	18.54
2020	8	21	PCR_COV_N2019	E Gene CT	19.53
2020	8	21	PCR_COV_N2019	E Gene CT	19.17
2020	8	21	PCR_COV_N2019	E Gene CT	20.42
2020	8	21	PCR_COV_N2019	E Gene CT	26.04
2020	8	21	PCR_COV_N2019	E Gene CT	15.22
2020	8	21	PCR_COV_N2019	E Gene CT	14.8
2020	8	21	PCR_COV_N2019	E Gene CT	18.22
2020	8	21	PCR_COV_N2019	E Gene CT	18.96
2020	8	21	PCR_COV_N2019	E Gene CT	13.86
2020	8	21	PCR_COV_N2019	E Gene CT	32.54
2020	8	21	PCR_COV_N2019	E Gene CT	16.62
2020	8	21	PCR_COV_N2019	E Gene CT	12.37
2020	8	21	PCR_COV_N2019	E Gene CT	20.7
2020	8	21	PCR_COV_N2019	E Gene CT	18.08
2020	8	21	PCR_COV_N2019	E Gene CT	23.73
2020	8	21	PCR_COV_N2019	E Gene CT	16.45
2020	8	21	PCR_COV_N2019	E Gene CT	15.09
2020	8	21	PCR_COV_N2019	E Gene CT	20.26
2020	8	21	PCR_COV_N2019	E Gene CT	14.87
2020	8	21	PCR_COV_N2019	E Gene CT	17.84
2020	8	21	PCR_COV_N2019	E Gene CT	16.93
2020	8	21	PCR_COV_N2019	E Gene CT	24.18
2020	8	21	PCR_COV_N2019	E Gene CT	26.59
2020	8	21	PCR_FUSION_COV19_E	E Gene CT	24.7
2020	8	21	PCR_FUSION_COV19_E	E Gene CT	21.2
2020	8	22	PCR_COV_N2019	E Gene CT	15.05
2020	8	22	PCR_COV_N2019	E Gene CT	15.29
2020	8	22	PCR_COV_N2019	E Gene CT	28.99
2020	8	22	PCR_COV_N2019	E Gene CT	11.14
2020	8	22	PCR_COV_N2019	E Gene CT	13.62
2020	8	22	PCR_COV_N2019	E Gene CT	24.91
2020	8	22	PCR_COV_N2019	E Gene CT	15.57
2020	8	22	PCR_COV_N2019	E Gene CT	33.18
2020	8	22	PCR_FUSION_COV19_E	E Gene CT	20.1
2020	8	22	PCR_FUSION_COV19_E	E Gene CT	26.5
2020	8	22	PCR_FUSION_COV19_E	E Gene CT	21.7

AB906

2020	8	22	PCR_FUSION_COV19_E	E Gene CT	35
2020	8	22	PCR_FUSION_COV19_E	E Gene CT	20.4
2020	8	22	PCR_FUSION_COV19_E	E Gene CT	20.6
2020	8	22	PCR_FUSION_COV19_E	E Gene CT	23.7
2020	8	22	PCR_FUSION_COV19_E	E Gene CT	31.9
2020	8	22	PCR_FUSION_COV19_E	E Gene CT	25.2
2020	8	22	PCR_FUSION_COV19_E	E Gene CT	23.6
2020	8	23	PCR_COV_N2019	E Gene CT	32.73
2020	8	23	PCR_COV_N2019	E Gene CT	13.77
2020	8	23	PCR_COV_N2019	E Gene CT	27.64
2020	8	23	PCR_COV_N2019	E Gene CT	19.03
2020	8	23	PCR_COV_N2019	E Gene CT	26.59
2020	8	23	PCR_COV_N2019	E Gene CT	15.39
2020	8	23	PCR_COV_N2019	E Gene CT	18.83
2020	8	23	PCR_COV_N2019	E Gene CT	18.34
2020	8	23	PCR_COV_N2019	E Gene CT	15.48
2020	8	23	PCR_COV_N2019	E Gene CT	23.37
2020	8	23	PCR_COV_N2019	E Gene CT	26.49
2020	8	23	PCR_COV_N2019	E Gene CT	33.5
2020	8	23	PCR_FUSION_COV19_E	E Gene CT	22.8
2020	8	23	PCR_FUSION_COV19_E	E Gene CT	37.2
2020	8	23	PCR_FUSION_COV19_E	E Gene CT	31.4
2020	8	23	PCR_FUSION_COV19_E	E Gene CT	37.2
2020	8	23	PCR_FUSION_COV19_E	E Gene CT	28.5
2020	8	23	PCR_FUSION_COV19_E	E Gene CT	18.8
2020	8	23	PCR_COV_N2019	E Gene CT	32.23
2020	8	23	PCR_COV_N2019	E Gene CT	14.5
2020	8	23	PCR_COV_N2019	E Gene CT	25.38
2020	8	23	PCR_COV_N2019	E Gene CT	19.47
2020	8	23	PCR_COV_N2019	E Gene CT	17.09
2020	8	23	PCR_COV_N2019	E Gene CT	16.73
2020	8	23	PCR_COV_N2019	E Gene CT	16.16
2020	8	23	PCR_COV_N2019	E Gene CT	12.45
2020	8	23	PCR_COV_N2019	E Gene CT	16.8
2020	8	23	PCR_COV_N2019	E Gene CT	17.49
2020	8	23	PCR_COV_N2019	E Gene CT	22.09
2020	8	23	PCR_COV_N2019	E Gene CT	25.05
2020	8	23	PCR_COV_N2019	E Gene CT	23.06
2020	8	24	PCR_COV_N2019	E Gene CT	17.46
2020	8	24	PCR_COV_N2019	E Gene CT	22.3
2020	8	24	PCR_COV_N2019	E Gene CT	15.84
2020	8	24	PCR_COV_N2019	E Gene CT	14.86
2020	8	24	PCR_COV_N2019	E Gene CT	18.88
2020	8	24	PCR_COV_N2019	E Gene CT	27.94
2020	8	24	PCR_COV_N2019	E Gene CT	29.05
2020	8	24	PCR_COV_N2019	E Gene CT	16.14
2020	8	24	PCR_COV_N2019	E Gene CT	32.8

AB907

2020	8	24	PCR_COV_N2019	E Gene CT	21.33
2020	8	24	PCR_FUSION_COV19_E	E Gene CT	26.1
2020	8	24	PCR_FUSION_COV19_E	E Gene CT	32
2020	8	24	PCR_FUSION_COV19_E	E Gene CT	17.3
2020	8	24	PCR_FUSION_COV19_E	E Gene CT	18.3
2020	8	24	PCR_FUSION_COV19_E	E Gene CT	33
2020	8	24	PCR_FUSION_COV19_E	E Gene CT	20.6
2020	8	24	PCR_FUSION_COV19_E	E Gene CT	25.9
2020	8	24	PCR_FUSION_COV19_E	E Gene CT	19
2020	8	25	PCR_COV_N2019	E Gene CT	14.66
2020	8	25	PCR_COV_N2019	E Gene CT	21.16
2020	8	25	PCR_COV_N2019	E Gene CT	18.33
2020	8	25	PCR_COV_N2019	E Gene CT	20.66
2020	8	25	PCR_COV_N2019	E Gene CT	18.97
2020	8	25	PCR_COV_N2019	E Gene CT	14.91
2020	8	25	PCR_FUSION_COV19_E	E Gene CT	33
2020	8	25	PCR_FUSION_COV19_E	E Gene CT	20.1
2020	8	25	PCR_FUSION_COV19_E	E Gene CT	38
2020	8	25	PCR_FUSION_COV19_E	E Gene CT	21.3
2020	8	25	PCR_COV_N2019	E Gene CT	11.84
2020	8	25	PCR_FUSION_COV19_E	E Gene CT	34.3
2020	8	25	PCR_FUSION_COV19_E	E Gene CT	20
2020	8	25	PCR_COV_N2019	E Gene CT	19.22
2020	8	25	PCR_FUSION_COV19_E	E Gene CT	34.1
2020	8	26	PCR_COV_N2019	E Gene CT	15.44
2020	8	26	PCR_COV_N2019	E Gene CT	24.86
2020	8	26	PCR_COV_N2019	E Gene CT	17.22
2020	8	26	PCR_COV_N2019	E Gene CT	35.76
2020	8	26	PCR_FUSION_COV19_E	E Gene CT	37.7
2020	8	26	PCR_FUSION_COV19_E	E Gene CT	18.2
2020	8	26	PCR_COV_N2019	E Gene CT	34.01
2020	8	26	PCR_FUSION_COV19_E	E Gene CT	17.1
2020	8	26	PCR_FUSION_COV19_E	E Gene CT	34.7
2020	8	26	PCR_FUSION_COV19_E	E Gene CT	18.3
2020	8	26	PCR_FUSION_COV19_E	E Gene CT	26.1
2020	8	26	PCR_FUSION_COV19_E	E Gene CT	26.1
2020	8	26	PCR_FUSION_COV19_E	E Gene CT	29.2
2020	8	26	PCR_FUSION_COV19_E	E Gene CT	38
2020	8	26	PCR_FUSION_COV19_E	E Gene CT	18.8
2020	8	26	PCR_FUSION_COV19_E	E Gene CT	37.1
2020	8	26	PCR_FUSION_COV19_E	E Gene CT	23.4
2020	8	26	PCR_FUSION_COV19_E	E Gene CT	32.7
2020	8	26	PCR_FUSION_COV19_E	E Gene CT	33
2020	8	26	PCR_FUSION_COV19_E	E Gene CT	24.5
2020	8	26	PCR_COV_N2019	E Gene CT	27.24
2020	8	26	PCR_COV_N2019	E Gene CT	17.68
2020	8	26	PCR_COV_N2019	E Gene CT	22.83

AB908

2020	8	26	PCR_COV_N2019	E Gene CT	32.51
2020	8	26	PCR_COV_N2019	E Gene CT	30.42
2020	8	26	PCR_COV_N2019	E Gene CT	18.37
2020	8	26	PCR_COV_N2019	E Gene CT	33.16
2020	8	26	PCR_COV_N2019	E Gene CT	16.31
2020	8	26	PCR_COV_N2019	E Gene CT	20.99
2020	8	26	PCR_COV_N2019	E Gene CT	28.63
2020	8	26	PCR_COV_N2019	E Gene CT	28.63
2020	8	26	PCR_COV_N2019	E Gene CT	29.5
2020	8	26	PCR_COV_N2019	E Gene CT	26.09
2020	8	26	PCR_COV_N2019	E Gene CT	30.24
2020	8	26	PCR_COV_N2019	E Gene CT	25.81
2020	8	26	PCR_COV_N2019	E Gene CT	23.03
2020	8	26	PCR_COV_N2019	E Gene CT	32.53
2020	8	26	PCR_COV_N2019	E Gene CT	17.76
2020	8	26	PCR_FUSION_COV19_E	E Gene CT	37.1
2020	8	26	PCR_FUSION_COV19_E	E Gene CT	20.9
2020	8	27	PCR_COV_N2019	E Gene CT	27.51
2020	8	27	PCR_COV_N2019	E Gene CT	30.4
2020	8	27	PCR_COV_N2019	E Gene CT	29.7
2020	8	27	PCR_COV_N2019	E Gene CT	21.65
2020	8	27	PCR_COV_N2019	E Gene CT	12.14
2020	8	27	PCR_COV_N2019	E Gene CT	32.24
2020	8	27	PCR_COV_N2019	E Gene CT	14.72
2020	8	27	PCR_COV_N2019	E Gene CT	34.15
2020	8	27	PCR_COV_N2019	E Gene CT	23.94
2020	8	27	PCR_FUSION_COV19_E	E Gene CT	28.7
2020	8	27	PCR_FUSION_COV19_E	E Gene CT	18.2
2020	8	27	PCR_FUSION_COV19_E	E Gene CT	26.2
2020	8	27	PCR_FUSION_COV19_E	E Gene CT	31
2020	8	27	PCR_FUSION_COV19_E	E Gene CT	37.2
2020	8	27	PCR_FUSION_COV19_E	E Gene CT	19.1
2020	8	27	PCR_FUSION_COV19_E	E Gene CT	29.1
2020	8	27	PCR_FUSION_COV19_E	E Gene CT	19.5
2020	8	27	PCR_FUSION_COV19_E	E Gene CT	21.1
2020	8	27	PCR_COV_N2019	E Gene CT	16.01
2020	8	28	PCR_COV_N2019	E Gene CT	34.67
2020	8	28	PCR_COV_N2019	E Gene CT	37.49
2020	8	28	PCR_COV_N2019	E Gene CT	30.95
2020	8	28	PCR_FUSION_COV19_E	E Gene CT	19
2020	8	28	PCR_FUSION_COV19_E	E Gene CT	19.7
2020	8	28	PCR_FUSION_COV19_E	E Gene CT	19.6
2020	8	28	PCR_FUSION_COV19_E	E Gene CT	20.4
2020	8	28	PCR_FUSION_COV19_E	E Gene CT	20.2
2020	8	28	PCR_FUSION_COV19_E	E Gene CT	17
2020	8	28	PCR_FUSION_COV19_E	E Gene CT	29.3
2020	8	28	PCR_FUSION_COV19_E	E Gene CT	26.2

AB909

2020	8	29	PCR_COV_N2019	E Gene CT	22.37
2020	8	29	PCR_COV_N2019	E Gene CT	33.15
2020	8	29	PCR_COV_N2019	E Gene CT	24.34
2020	8	29	PCR_FUSION_COV19_E	E Gene CT	27.9
2020	8	29	PCR_FUSION_COV19_E	E Gene CT	37.9
2020	8	29	PCR_FUSION_COV19_E	E Gene CT	28.4
2020	8	29	PCR_FUSION_COV19_E	E Gene CT	26.2
2020	8	29	PCR_FUSION_COV19_E	E Gene CT	20.9
2020	8	29	PCR_FUSION_COV19_E	E Gene CT	24.5
2020	8	29	PCR_FUSION_COV19_E	E Gene CT	17.5
2020	8	29	PCR_FUSION_COV19_E	E Gene CT	21.8
2020	8	29	PCR_FUSION_COV19_E	E Gene CT	34.8
2020	8	29	PCR_FUSION_COV19_E	E Gene CT	28
2020	8	29	PCR_FUSION_COV19_E	E Gene CT	24.3
2020	8	29	PCR_COV_N2019	E Gene CT	27.49
2020	8	29	PCR_FUSION_COV19_E	E Gene CT	19.9
2020	8	29	PCR_COV_N2019	E Gene CT	24.38
2020	8	29	PCR_COV_N2019	E Gene CT	18.28
2020	8	30	PCR_COV_N2019	E Gene CT	14.6
2020	8	30	PCR_COV_N2019	E Gene CT	32.38
2020	8	30	PCR_COV_N2019	E Gene CT	18.88
2020	8	30	PCR_COV_N2019	E Gene CT	16.44
2020	8	30	PCR_COV_N2019	E Gene CT	32.12
2020	8	30	PCR_COV_N2019	E Gene CT	27.66
2020	8	30	PCR_COV_N2019	E Gene CT	34.41
2020	8	30	PCR_FUSION_COV19_E	E Gene CT	18.2
2020	8	30	PCR_FUSION_COV19_E	E Gene CT	26.7
2020	8	30	PCR_FUSION_COV19_E	E Gene CT	38
2020	8	30	PCR_COV_N2019	E Gene CT	32.88
2020	8	30	PCR_FUSION_COV19_E	E Gene CT	20.1
2020	8	30	PCR_FUSION_COV19_E	E Gene CT	30.9
2020	8	30	PCR_FUSION_COV19_E	E Gene CT	37.6
2020	8	30	PCR_FUSION_COV19_E	E Gene CT	37.5
2020	8	31	PCR_FUSION_COV19_E	E Gene CT	18.4
2020	8	31	PCR_FUSION_COV19_E	E Gene CT	20.4
2020	8	31	PCR_COV_N2019	E Gene CT	31.57
2020	8	31	PCR_COV_N2019	E Gene CT	30
2020	9	1	PCR_COV_N2019	E Gene CT	18.14
2020	9	1	PCR_COV_N2019	E Gene CT	30.26
2020	9	1	PCR_FUSION_COV19_E	E Gene CT	32.3
2020	9	1	PCR_FUSION_COV19_E	E Gene CT	26.4
2020	9	1	PCR_FUSION_COV19_E	E Gene CT	17.4
2020	9	1	PCR_FUSION_COV19_E	E Gene CT	22.3
2020	9	1	PCR_COBAS_COV19	CT 2	36
2020	9	2	PCR_COV_N2019	E Gene CT	23.97
2020	9	2	PCR_COV_N2019	E Gene CT	22.54
2020	9	3	PCR_COV_N2019	E Gene CT	21

AB910

2020	9	3	PCR_COV_N2019	E Gene CT	25.25
2020	9	3	PCR_FUSION_COV19_E	E Gene CT	35.9
2020	9	3	PCR_FUSION_COV19_E	E Gene CT	30.9
2020	9	3	PCR_FUSION_COV19_E	E Gene CT	21.1
2020	9	3	PCR_FUSION_COV19_E	E Gene CT	31.7
2020	9	3	PCR_FUSION_COV19_E	E Gene CT	29.4
2020	9	3	PCR_FUSION_COV19_E	E Gene CT	24.8
2020	9	3	PCR_FUSION_COV19_E	E Gene CT	18.5
2020	9	3	PCR_FUSION_COV19_E	E Gene CT	37.6
2020	9	3	PCR_COV_N2019	E Gene CT	13.48
2020	9	3	PCR_COV_N2019	E Gene CT	17.18
2020	9	3	PCR_FUSION_COV19_E	E Gene CT	37.6
2020	9	4	PCR_COV_N2019	E Gene CT	30.7
2020	9	4	PCR_COV_N2019	E Gene CT	17.16
2020	9	4	PCR_COV_N2019	E Gene CT	34.08
2020	9	4	PCR_COV_N2019	E Gene CT	32.15
2020	9	4	PCR_COV_N2019	E Gene CT	29.8
2020	9	4	PCR_COV_N2019	E Gene CT	28.04
2020	9	4	PCR_COV_N2019	E Gene CT	32.1
2020	9	4	PCR_COV_N2019	E Gene CT	33.33
2020	9	4	PCR_COV_N2019	E Gene CT	25.53
2020	9	4	PCR_COV_N2019	E Gene CT	18.41
2020	9	4	PCR_FUSION_COV19_E	E Gene CT	20.2
2020	9	4	PCR_FUSION_COV19_E	E Gene CT	26.7
2020	9	4	PCR_COV_N2019	E Gene CT	13.88
2020	9	4	PCR_COBAS_COV19	CT 2	23.11
2020	9	4	PCR_COV_N2019	E Gene CT	29.34
2020	9	4	PCR_COV_N2019	E Gene CT	23.41
2020	9	5	PCR_COV_N2019	E Gene CT	27.66
2020	9	5	PCR_FUSION_COV19_E	E Gene CT	31.7
2020	9	5	PCR_FUSION_COV19_E	E Gene CT	27.1
2020	9	5	PCR_FUSION_COV19_E	E Gene CT	19
2020	9	5	PCR_FUSION_COV19_E	E Gene CT	26
2020	9	5	PCR_COBAS_COV19	CT 2	22.04
2020	9	5	PCR_COV_N2019	E Gene CT	20.3
2020	9	6	PCR_COV_N2019	E Gene CT	33.66
2020	9	6	PCR_FUSION_COV19_E	E Gene CT	24
2020	9	7	PCR_COV_N2019	E Gene CT	31.55
2020	9	7	PCR_COV_N2019	E Gene CT	20.54
2020	9	8	PCR_COV_N2019	E Gene CT	30.04
2020	9	8	PCR_COV_N2019	E Gene CT	15.61
2020	9	8	PCR_COBAS_COV19	CT 2	21.27
2020	9	8	PCR_COV_N2019	E Gene CT	34.79
2020	9	8	PCR_FUSION_COV19_E	E Gene CT	22.8
2020	9	8	PCR_FUSION_COV19_E	E Gene CT	22.8
2020	9	8	PCR_COV_N2019	E Gene CT	29.8
2020	9	8	PCR_FUSION_COV19_E	E Gene CT	31.8

AB911

2020	9	9	PCR_COV_N2019	E Gene CT	14.51
2020	9	9	PCR_COV_N2019	E Gene CT	32.43
2020	9	9	PCR_FUSION_COV19_E	E Gene CT	35.3
2020	9	9	PCR_FUSION_COV19_E	E Gene CT	28.2
2020	9	9	PCR_FUSION_COV19_E	E Gene CT	37.8
2020	9	10	PCR_COV_N2019	E Gene CT	26.43
2020	9	10	PCR_COV_N2019	E Gene CT	16.38
2020	9	10	PCR_COV_N2019	E Gene CT	20.57
2020	9	10	PCR_FUSION_COV19_E	E Gene CT	18
2020	9	10	PCR_COV_N2019	E Gene CT	34.28
2020	9	10	PCR_FUSION_COV19_E	E Gene CT	28.8
2020	9	10	PCR_FUSION_COV19_E	E Gene CT	18.9
2020	9	10	PCR_FUSION_COV19_E	E Gene CT	20.5
2020	9	10	PCR_COV_N2019	E Gene CT	29.07
2020	9	10	PCR_FUSION_COV19_E	E Gene CT	19.4
2020	9	11	PCR_COV_N2019	E Gene CT	28.37
2020	9	11	PCR_COV_N2019	E Gene CT	27.84
2020	9	11	PCR_FUSION_COV19_E	E Gene CT	30.8
2020	9	11	PCR_FUSION_COV19_E	E Gene CT	36.7
2020	9	11	PCR_FUSION_COV19_E	E Gene CT	28.6
2020	9	12	PCR_COV_N2019	E Gene CT	15.27
2020	9	12	PCR_FUSION_COV19_E	E Gene CT	32.2
2020	9	12	PCR_FUSION_COV19_E	E Gene CT	29.5
2020	9	12	PCR_FUSION_COV19_E	E Gene CT	24.7
2020	9	13	PCR_FUSION_COV19_E	E Gene CT	32.6
2020	9	14	PCR_COV_N2019	E Gene CT	19.06
2020	9	14	PCR_COV_N2019	E Gene CT	15.3
2020	9	14	PCR_COV_N2019	E Gene CT	14
2020	9	14	PCR_COV_N2019	E Gene CT	19.17
2020	9	14	PCR_COV_N2019	E Gene CT	30.1
2020	9	14	PCR_COV_N2019	E Gene CT	15.29
2020	9	14	PCR_COV_N2019	E Gene CT	21.16
2020	9	14	PCR_COV_N2019	E Gene CT	12.79
2020	9	14	PCR_COV_N2019	E Gene CT	32.96
2020	9	14	PCR_FUSION_COV19_E	E Gene CT	19.1
2020	9	15	PCR_COV_N2019	E Gene CT	31.49
2020	9	15	PCR_COV_N2019	E Gene CT	21.19
2020	9	15	PCR_FUSION_COV19_E	E Gene CT	20.1
2020	9	15	PCR_COV_N2019	E Gene CT	30.57
2020	9	16	PCR_COV_N2019	E Gene CT	32.32
2020	9	16	PCR_COV_N2019	E Gene CT	33.37
2020	9	16	PCR_COV_N2019	E Gene CT	28.25
2020	9	16	PCR_COV_N2019	E Gene CT	13.37
2020	9	16	PCR_FUSION_COV19_E	E Gene CT	33.3
2020	9	16	PCR_FUSION_COV19_E	E Gene CT	22.8
2020	9	16	PCR_COV_N2019	E Gene CT	25.33
2020	9	16	PCR_COV_N2019	E Gene CT	24.9

AB912

2020	9	16	PCR_FUSION_COV19_E	E Gene CT	27.6
2020	9	16	PCR_COV_N2019	E Gene CT	22.46
2020	9	16	PCR_COV_N2019	E Gene CT	13.09
2020	9	16	PCR_COV_N2019	E Gene CT	11.61
2020	9	16	PCR_COV_N2019	E Gene CT	17.75
2020	9	17	PCR_COV_N2019	E Gene CT	19.03
2020	9	17	PCR_COV_N2019	E Gene CT	16.4
2020	9	17	PCR_COV_N2019	E Gene CT	23.32
2020	9	17	PCR_COV_N2019	E Gene CT	33.62
2020	9	17	PCR_COBAS_COV19	CT 2	37.76
2020	9	17	PCR_COBAS_COV19	CT 2	25.11
2020	9	18	PCR_COV_N2019	E Gene CT	17.72
2020	9	18	PCR_COV_N2019	E Gene CT	31.44
2020	9	18	PCR_COV_N2019	E Gene CT	23.3
2020	9	18	PCR_COV_N2019	E Gene CT	17.2
2020	9	18	PCR_COV_N2019	E Gene CT	21.18
2020	9	19	PCR_COV_N2019	E Gene CT	17.19
2020	9	19	PCR_COV_N2019	E Gene CT	13.79
2020	9	19	PCR_COV_N2019	E Gene CT	30.42
2020	9	19	PCR_COV_N2019	E Gene CT	18.06
2020	9	19	PCR_COV_N2019	E Gene CT	22.6
2020	9	19	PCR_COV_N2019	E Gene CT	21.82
2020	9	19	PCR_COV_N2019	E Gene CT	22.04
2020	9	19	PCR_COBAS_COV19	CT 2	33.98
2020	9	20	PCR_COV_N2019	E Gene CT	33.07
2020	9	20	PCR_COV_N2019	E Gene CT	30.91
2020	9	20	PCR_COV_N2019	E Gene CT	18.07
2020	9	20	PCR_COV_N2019	E Gene CT	29.7
2020	9	20	PCR_COV_N2019	E Gene CT	21.39
2020	9	20	PCR_COV_N2019	E Gene CT	33.12
2020	9	20	PCR_COV_N2019	E Gene CT	15.66
2020	9	20	PCR_COV_N2019	E Gene CT	29.17
2020	9	20	PCR_COV_N2019	E Gene CT	13.18
2020	9	20	PCR_COV_N2019	E Gene CT	35.99
2020	9	20	PCR_COV_N2019	E Gene CT	17.87
2020	9	20	PCR_COV_N2019	E Gene CT	32.59
2020	9	21	PCR_COV_N2019	E Gene CT	11.79
2020	9	21	PCR_COV_N2019	E Gene CT	17.71
2020	9	21	PCR_COV_N2019	E Gene CT	14.84
2020	9	21	PCR_COV_N2019	E Gene CT	17.36
2020	9	21	PCR_COV_N2019	E Gene CT	14.72
2020	9	21	PCR_COBAS_COV19	CT 2	34.05
2020	9	21	PCR_COV_N2019	E Gene CT	12.2
2020	9	21	PCR_COV_N2019	E Gene CT	24.59
2020	9	22	PCR_COV_N2019	E Gene CT	24.18
2020	9	22	PCR_COV_N2019	E Gene CT	20.42
2020	9	22	PCR_COV_N2019	E Gene CT	29.3

AB913

2020	9	22	PCR_COV_N2019	E Gene CT	16.35
2020	9	22	PCR_COV_N2019	E Gene CT	19.73
2020	9	22	PCR_COV_N2019	E Gene CT	19.16
2020	9	22	PCR_COV_N2019	E Gene CT	13.79
2020	9	22	PCR_COV_N2019	E Gene CT	22.01
2020	9	22	PCR_COV_N2019	E Gene CT	18.27
2020	9	22	PCR_COV_N2019	E Gene CT	23.29
2020	9	22	PCR_COBAS_COV19	CT 2	29.02
2020	9	22	PCR_COBAS_COV19	CT 2	16.74
2020	9	22	PCR_COBAS_COV19	CT 2	33.17
2020	9	22	PCR_COV_N2019	E Gene CT	15.05
2020	9	23	PCR_COV_N2019	E Gene CT	17.26
2020	9	23	PCR_COV_N2019	E Gene CT	16.12
2020	9	23	PCR_COBAS_COV19	CT 2	24.6
2020	9	23	PCR_COV_N2019	E Gene CT	17.36
2020	9	23	PCR_COV_N2019	E Gene CT	11.29
2020	9	23	PCR_COV_N2019	E Gene CT	20.15
2020	9	23	PCR_COV_N2019	E Gene CT	14.72
2020	9	23	PCR_COV_N2019	E Gene CT	23.83
2020	9	24	PCR_COV_N2019	E Gene CT	24.21
2020	9	24	PCR_COV_N2019	E Gene CT	29.09
2020	9	24	PCR_COV_N2019	E Gene CT	24.44
2020	9	24	PCR_COV_N2019	E Gene CT	14.07
2020	9	24	PCR_FUSION_COV19_E	E Gene CT	29.7
2020	9	24	PCR_COV_N2019	E Gene CT	38.81
2020	9	24	PCR_COBAS_COV19	CT 2	31.48
2020	9	24	PCR_COBAS_COV19	CT 2	28.92
2020	9	24	PCR_COBAS_COV19	CT 2	23.12
2020	9	24	PCR_COV_N2019	E Gene CT	14.97
2020	9	25	PCR_COV_N2019	E Gene CT	17.26
2020	9	25	PCR_COV_N2019	E Gene CT	23.02
2020	9	25	PCR_COV_N2019	E Gene CT	33.06
2020	9	25	PCR_COBAS_COV19	CT 2	27.96
2020	9	25	PCR_COV_N2019	E Gene CT	10.55
2020	9	25	PCR_COV_N2019	E Gene CT	29.4
2020	9	26	PCR_COV_N2019	E Gene CT	23.38
2020	9	26	PCR_COV_N2019	E Gene CT	29.87
2020	9	26	PCR_COV_N2019	E Gene CT	32.18
2020	9	26	PCR_COV_N2019	E Gene CT	20.65
2020	9	26	PCR_COV_N2019	E Gene CT	18.26
2020	9	26	PCR_COV_N2019	E Gene CT	17.15
2020	9	26	PCR_COV_N2019	E Gene CT	18.18
2020	9	26	PCR_COV_N2019	E Gene CT	16.17
2020	9	26	PCR_COV_N2019	E Gene CT	13.43
2020	9	26	PCR_COV_N2019	E Gene CT	15.41
2020	9	26	PCR_COV_N2019	E Gene CT	33.21
2020	9	26	PCR_COV_N2019	E Gene CT	18.54

AB914

2020	9	26	PCR_COV_N2019	E Gene CT	16.78
2020	9	27	PCR_COV_N2019	E Gene CT	29.42
2020	9	27	PCR_COV_N2019	E Gene CT	28.49
2020	9	27	PCR_COV_N2019	E Gene CT	15.61
2020	9	27	PCR_COV_N2019	E Gene CT	29.27
2020	9	27	PCR_COV_N2019	E Gene CT	13.37
2020	9	27	PCR_COV_N2019	E Gene CT	28.73
2020	9	27	PCR_COV_N2019	E Gene CT	25.65
2020	9	27	PCR_COV_N2019	E Gene CT	17.76
2020	9	27	PCR_COV_N2019	E Gene CT	35.05
2020	9	27	PCR_COV_N2019	E Gene CT	24.66
2020	9	28	PCR_COV_N2019	E Gene CT	23.98
2020	9	28	PCR_COV_N2019	E Gene CT	20.51
2020	9	28	PCR_COV_N2019	E Gene CT	14.18
2020	9	28	PCR_COV_N2019	E Gene CT	16.37
2020	9	28	PCR_COV_N2019	E Gene CT	16.71
2020	9	28	PCR_COV_N2019	E Gene CT	15.32
2020	9	28	PCR_COV_N2019	E Gene CT	22.14
2020	9	28	PCR_COV_N2019	E Gene CT	28.41
2020	9	28	PCR_COV_N2019	E Gene CT	15.58
2020	9	28	PCR_COV_N2019	E Gene CT	21.75
2020	9	28	PCR_COV_N2019	E Gene CT	14.23
2020	9	28	PCR_COV_N2019	E Gene CT	20.64
2020	9	28	PCR_COV_N2019	E Gene CT	28.5
2020	9	28	PCR_COV_N2019	E Gene CT	26.28
2020	9	29	PCR_COV_N2019	E Gene CT	17.18
2020	9	29	PCR_COV_N2019	E Gene CT	16.97
2020	9	29	PCR_COV_N2019	E Gene CT	16.7
2020	9	29	PCR_COV_N2019	E Gene CT	26.02
2020	9	29	PCR_COV_N2019	E Gene CT	26.26
2020	9	29	PCR_COV_N2019	E Gene CT	12.2
2020	9	29	PCR_COV_N2019	E Gene CT	17.67
2020	9	29	PCR_COV_N2019	E Gene CT	19.07
2020	9	29	PCR_COV_N2019	E Gene CT	31.91
2020	9	29	PCR_COV_N2019	E Gene CT	16.47
2020	9	29	PCR_COV_N2019	E Gene CT	26.31
2020	9	29	PCR_COV_N2019	E Gene CT	16.26
2020	9	29	PCR_COV_N2019	E Gene CT	15.33
2020	9	29	PCR_COV_N2019	E Gene CT	34.47
2020	9	29	PCR_COV_N2019	E Gene CT	18.99
2020	9	29	PCR_COV_N2019	E Gene CT	20.54
2020	9	30	PCR_COV_N2019	E Gene CT	13.29
2020	9	30	PCR_COV_N2019	E Gene CT	32.1
2020	9	30	PCR_COV_N2019	E Gene CT	25.55
2020	9	30	PCR_COV_N2019	E Gene CT	19.09
2020	9	30	PCR_COV_N2019	E Gene CT	19.58
2020	9	30	PCR_COV_N2019	E Gene CT	11.08

AB915

2020	9	30	PCR_COV_N2019	E Gene CT	16.37
2020	9	30	PCR_COV_N2019	E Gene CT	17.22
2020	10	1	PCR_COV_N2019	E Gene CT	16.04
2020	10	1	PCR_COV_N2019	E Gene CT	17.07
2020	10	1	PCR_COV_N2019	E Gene CT	15.35
2020	10	1	PCR_COV_N2019	E Gene CT	19.68
2020	10	1	PCR_COV_N2019	E Gene CT	16.89
2020	10	1	PCR_COV_N2019	E Gene CT	28.57
2020	10	1	PCR_COV_N2019	E Gene CT	15.26
2020	10	1	PCR_COV_N2019	E Gene CT	31.7
2020	10	1	PCR_COV_N2019	E Gene CT	16.38
2020	10	1	PCR_COV_N2019	E Gene CT	15.42
2020	10	1	PCR_COV_N2019	E Gene CT	17.6
2020	10	1	PCR_COV_N2019	E Gene CT	20.49
2020	10	1	PCR_COV_N2019	E Gene CT	20.65
2020	10	1	PCR_COV_N2019	E Gene CT	24.37
2020	10	1	PCR_COV_N2019	E Gene CT	23.82
2020	10	1	PCR_COV_N2019	E Gene CT	14.1
2020	10	1	PCR_COV_N2019	E Gene CT	19.06
2020	10	1	PCR_COV_N2019	E Gene CT	20.53
2020	10	1	PCR_COV_N2019	E Gene CT	31.26
2020	10	1	PCR_COV_N2019	E Gene CT	13.2
2020	10	1	PCR_COV_N2019	E Gene CT	22.66
2020	10	1	PCR_COV_N2019	E Gene CT	31.12
2020	10	1	PCR_COV_N2019	E Gene CT	16.26
2020	10	1	PCR_COV_N2019	E Gene CT	29.05
2020	10	1	PCR_COV_N2019	E Gene CT	16.49
2020	10	2	PCR_COV_N2019	E Gene CT	36.32
2020	10	2	PCR_COV_N2019	E Gene CT	25.89497887
2020	10	2	PCR_FUSION_COV19_E	E Gene CT	37.9
2020	10	2	PCR_COV_N2019	E Gene CT	22.11986131
2020	10	2	PCR_COV_N2019	E Gene CT	14.48882053
2020	10	2	PCR_COV_N2019	E Gene CT	15.00376614
2020	10	3	PCR_COV_N2019	E Gene CT	26.29491787
2020	10	3	PCR_COV_N2019	E Gene CT	20.66487535
2020	10	3	PCR_COV_N2019	E Gene CT	11.1787077
2020	10	3	PCR_COV_N2019	E Gene CT	21.27085256
2020	10	3	PCR_FUSION_COV19_E	E Gene CT	22.6
2020	10	3	PCR_FUSION_COV19_E	E Gene CT	31.2
2020	10	3	PCR_COV_N2019	E Gene CT	18.53429933
2020	10	3	PCR_COV_N2019	E Gene CT	32.24554426
2020	10	3	PCR_COBAS_COV19	CT 2	36.13
2020	10	3	PCR_COBAS_COV19	CT 2	17.52
2020	10	3	PCR_COBAS_COV19	CT 2	35.15
2020	10	3	PCR_COBAS_COV19	CT 2	34.66
2020	10	3	PCR_COBAS_COV19	CT 2	16.05
2020	10	4	PCR_COV_N2019	E Gene CT	30.92064251

AB916

2020	10	4	PCR_COV_N2019	E Gene CT	29.68394571
2020	10	4	PCR_COV_N2019	E Gene CT	32.88
2020	10	4	PCR_COV_N2019	E Gene CT	31.46
2020	10	4	PCR_COV_N2019	E Gene CT	18.84
2020	10	4	PCR_COV_N2019	E Gene CT	18.21
2020	10	4	PCR_COV_N2019	E Gene CT	25.87
2020	10	4	PCR_COV_N2019	E Gene CT	33.22
2020	10	4	PCR_COV_N2019	E Gene CT	14.21
2020	10	4	PCR_COV_N2019	E Gene CT	25.9
2020	10	4	PCR_COV_N2019	E Gene CT	30.31
2020	10	5	PCR_COV_N2019	E Gene CT	25.38
2020	10	5	PCR_COV_N2019	E Gene CT	26.06
2020	10	5	PCR_COV_N2019	E Gene CT	15.41
2020	10	5	PCR_COV_N2019	E Gene CT	23.38
2020	10	5	PCR_COV_N2019	E Gene CT	12.11
2020	10	5	PCR_COV_N2019	E Gene CT	21.64
2020	10	5	PCR_COV_N2019	E Gene CT	15.82
2020	10	5	PCR_COV_N2019	E Gene CT	28.6
2020	10	5	PCR_COV_N2019	E Gene CT	24.79
2020	10	5	PCR_COBAS_COV19	CT 2	17.12
2020	10	5	PCR_COV_N2019	E Gene CT	14.44
2020	10	5	PCR_COV_N2019	E Gene CT	26.39
2020	10	5	PCR_COV_N2019	E Gene CT	26.27
2020	10	5	PCR_FUSION_COV19_E	E Gene CT	25
2020	10	5	PCR_COV_N2019	E Gene CT	13.75
2020	10	5	PCR_FUSION_COV19_E	E Gene CT	17.4
2020	10	5	PCR_FUSION_COV19_E	E Gene CT	36.6
2020	10	5	PCR_FUSION_COV19_E	E Gene CT	28
2020	10	5	PCR_FUSION_COV19_E	E Gene CT	16.7
2020	10	5	PCR_FUSION_COV19_E	E Gene CT	16.3
2020	10	5	PCR_FUSION_COV19_E	E Gene CT	26.6
2020	10	5	PCR_FUSION_COV19_E	E Gene CT	20.6
2020	10	5	PCR_FUSION_COV19_E	E Gene CT	16.1
2020	10	5	PCR_FUSION_COV19_E	E Gene CT	28.6
2020	10	6	PCR_COV_N2019	E Gene CT	19.34
2020	10	6	PCR_COV_N2019	E Gene CT	16.6
2020	10	6	PCR_COV_N2019	E Gene CT	30.58
2020	10	6	PCR_COV_N2019	E Gene CT	18.39
2020	10	6	PCR_COV_N2019	E Gene CT	16.05
2020	10	6	PCR_COV_N2019	E Gene CT	19.05
2020	10	6	PCR_COV_N2019	E Gene CT	16.41
2020	10	6	PCR_COV_N2019	E Gene CT	22.09
2020	10	6	PCR_COV_N2019	E Gene CT	17.79
2020	10	6	PCR_COV_N2019	E Gene CT	29.41
2020	10	6	PCR_COV_N2019	E Gene CT	17.76
2020	10	6	PCR_COV_N2019	E Gene CT	13.54
2020	10	6	PCR_COV_N2019	E Gene CT	14.03

2020	10	6	PCR_COV_N2019	E Gene CT	20.62
2020	10	6	PCR_COV_N2019	E Gene CT	18.23
2020	10	6	PCR_COV_N2019	E Gene CT	27.71
2020	10	6	PCR_FUSION_COV19_E	E Gene CT	31.7
2020	10	6	PCR_COV_N2019	E Gene CT	19.78
2020	10	7	PCR_COBAS_COV19	CT 2	24.34
2020	10	7	PCR_COV_N2019	E Gene CT	20.73
2020	10	7	PCR_COV_N2019	E Gene CT	9.45
2020	10	7	PCR_COV_N2019	E Gene CT	22.23
2020	10	7	PCR_COV_N2019	E Gene CT	27.77
2020	10	7	PCR_COV_N2019	E Gene CT	18.05
2020	10	7	PCR_COV_N2019	E Gene CT	16.16
2020	10	7	PCR_COV_N2019	E Gene CT	14.75
2020	10	7	PCR_COV_N2019	E Gene CT	16.82
2020	10	7	PCR_COV_N2019	E Gene CT	13.65
2020	10	7	PCR_COV_N2019	E Gene CT	26.26
2020	10	7	PCR_COV_N2019	E Gene CT	22.65
2020	10	7	PCR_COV_N2019	E Gene CT	31.11
2020	10	7	PCR_COV_N2019	E Gene CT	16.07
2020	10	7	PCR_COV_N2019	E Gene CT	17.38
2020	10	7	PCR_COV_N2019	E Gene CT	30.71
2020	10	7	PCR_COV_N2019	E Gene CT	25.25
2020	10	7	PCR_COV_N2019	E Gene CT	28.2
2020	10	7	PCR_FUSION_COV19_E	E Gene CT	22.2
2020	10	7	PCR_FUSION_COV19_E	E Gene CT	29.9
2020	10	7	PCR_FUSION_COV19_E	E Gene CT	25.7
2020	10	7	PCR_COV_N2019	E Gene CT	12.48
2020	10	7	PCR_FUSION_COV19_E	E Gene CT	24
2020	10	7	PCR_COV_N2019	E Gene CT	16.35
2020	10	7	PCR_COV_N2019	E Gene CT	17.07
2020	10	7	PCR_COV_N2019	E Gene CT	19.5
2020	10	7	PCR_COV_N2019	E Gene CT	20.27
2020	10	7	PCR_COV_N2019	E Gene CT	26.13
2020	10	7	PCR_COV_N2019	E Gene CT	23.33
2020	10	7	PCR_COV_N2019	E Gene CT	21.25
2020	10	7	PCR_COV_N2019	E Gene CT	14.04
2020	10	7	PCR_COV_N2019	E Gene CT	31.21
2020	10	8	PCR_COV_N2019	E Gene CT	14.43
2020	10	8	PCR_COV_N2019	E Gene CT	24.27
2020	10	8	PCR_COV_N2019	E Gene CT	20.87
2020	10	8	PCR_COV_N2019	E Gene CT	16.44
2020	10	8	PCR_COV_N2019	E Gene CT	18.65
2020	10	8	PCR_COV_N2019	E Gene CT	18.35
2020	10	8	PCR_COV_N2019	E Gene CT	22.79
2020	10	8	PCR_COV_N2019	E Gene CT	21.05
2020	10	8	PCR_COV_N2019	E Gene CT	13.17
2020	10	8	PCR_COV_N2019	E Gene CT	23.7

AB918

2020	10	8	PCR_COV_N2019	E Gene CT	19.05
2020	10	8	PCR_COV_N2019	E Gene CT	21.53
2020	10	8	PCR_COV_N2019	E Gene CT	22.1
2020	10	8	PCR_COV_N2019	E Gene CT	22.38
2020	10	8	PCR_COV_N2019	E Gene CT	17.39
2020	10	8	PCR_COV_N2019	E Gene CT	23.62
2020	10	8	PCR_COV_N2019	E Gene CT	33.72
2020	10	8	PCR_COV_N2019	E Gene CT	24.34
2020	10	8	PCR_COV_N2019	E Gene CT	20.47
2020	10	8	PCR_COV_N2019	E Gene CT	12.11
2020	10	8	PCR_COV_N2019	E Gene CT	12.51
2020	10	8	PCR_COV_N2019	E Gene CT	18.75
2020	10	8	PCR_COV_N2019	E Gene CT	15.38
2020	10	8	PCR_COV_N2019	E Gene CT	21.83
2020	10	8	PCR_COV_N2019	E Gene CT	18.82
2020	10	8	PCR_COV_N2019	E Gene CT	24.84
2020	10	8	PCR_COV_N2019	E Gene CT	19.51
2020	10	9	PCR_COV_N2019	E Gene CT	12.45
2020	10	9	PCR_COV_N2019	E Gene CT	27.31
2020	10	9	PCR_COV_N2019	E Gene CT	33.19
2020	10	9	PCR_COV_N2019	E Gene CT	25.59
2020	10	9	PCR_COV_N2019	E Gene CT	24.24
2020	10	9	PCR_COV_N2019	E Gene CT	17.55
2020	10	9	PCR_COV_N2019	E Gene CT	32.5
2020	10	9	PCR_COV_N2019	E Gene CT	17.65
2020	10	9	PCR_COV_N2019	E Gene CT	16.17
2020	10	9	PCR_FUSION_COV19_E	E Gene CT	20.3
2020	10	9	PCR_COV_N2019	E Gene CT	10.93
2020	10	9	PCR_COV_N2019	E Gene CT	19.94
2020	10	9	PCR_COV_N2019	E Gene CT	32.31
2020	10	9	PCR_FUSION_COV19_E	E Gene CT	24.5
2020	10	9	PCR_COV_N2019	E Gene CT	27.17
2020	10	9	PCR_COV_N2019	E Gene CT	23.91
2020	10	9	PCR_COV_N2019	E Gene CT	28.09
2020	10	9	PCR_COV_N2019	E Gene CT	22.36
2020	10	9	PCR_COV_N2019	E Gene CT	13.87
2020	10	9	PCR_COV_N2019	E Gene CT	24.37
2020	10	9	PCR_COV_N2019	E Gene CT	25.36
2020	10	9	PCR_FUSION_COV19_E	E Gene CT	23
2020	10	9	PCR_FUSION_COV19_E	E Gene CT	24
2020	10	9	PCR_FUSION_COV19_E	E Gene CT	28.9
2020	10	9	PCR_COV_N2019	E Gene CT	35.3
2020	10	10	PCR_COV_N2019	E Gene CT	21.07
2020	10	10	PCR_COV_N2019	E Gene CT	17.11
2020	10	10	PCR_COV_N2019	E Gene CT	22.26
2020	10	10	PCR_COV_N2019	E Gene CT	23
2020	10	10	PCR_COV_N2019	E Gene CT	12.22

AB919

2020	10	10	PCR_COV_N2019	E Gene CT	17.23
2020	10	10	PCR_COV_N2019	E Gene CT	12.24
2020	10	10	PCR_COV_N2019	E Gene CT	16.05
2020	10	10	PCR_COV_N2019	E Gene CT	14.23
2020	10	10	PCR_COV_N2019	E Gene CT	25.12
2020	10	10	PCR_COV_N2019	E Gene CT	14.73
2020	10	10	PCR_COV_N2019	E Gene CT	24.83
2020	10	10	PCR_COV_N2019	E Gene CT	25.69
2020	10	10	PCR_COV_N2019	E Gene CT	19.3
2020	10	10	PCR_COV_N2019	E Gene CT	14.8
2020	10	10	PCR_COV_N2019	E Gene CT	32.03
2020	10	10	PCR_COV_N2019	E Gene CT	17.56
2020	10	10	PCR_COV_N2019	E Gene CT	15.17
2020	10	10	PCR_COV_N2019	E Gene CT	22.06
2020	10	10	PCR_COV_N2019	E Gene CT	27.12
2020	10	10	PCR_COV_N2019	E Gene CT	25.34
2020	10	10	PCR_COV_N2019	E Gene CT	23.7
2020	10	10	PCR_FUSION_COV19_E	E Gene CT	17.9
2020	10	10	PCR_FUSION_COV19_E	E Gene CT	17.9
2020	10	10	PCR_FUSION_COV19_E	E Gene CT	24.8
2020	10	10	PCR_FUSION_COV19_E	E Gene CT	27.4
2020	10	10	PCR_FUSION_COV19_E	E Gene CT	19.1
2020	10	10	PCR_COV_N2019	E Gene CT	17.23
2020	10	10	PCR_FUSION_COV19_E	E Gene CT	30.1
2020	10	10	PCR_COV_N2019	E Gene CT	24.7
2020	10	11	PCR_COV_N2019	E Gene CT	15.2
2020	10	11	PCR_COV_N2019	E Gene CT	26.04
2020	10	11	PCR_COV_N2019	E Gene CT	15.38
2020	10	11	PCR_COV_N2019	E Gene CT	29.04
2020	10	11	PCR_COV_N2019	E Gene CT	16.78
2020	10	11	PCR_COV_N2019	E Gene CT	14.7
2020	10	11	PCR_COV_N2019	E Gene CT	16.03
2020	10	11	PCR_COV_N2019	E Gene CT	31.46
2020	10	11	PCR_COV_N2019	E Gene CT	34.37
2020	10	11	PCR_FUSION_COV19_E	E Gene CT	35.9
2020	10	11	PCR_FUSION_COV19_E	E Gene CT	24.1
2020	10	11	PCR_COV_N2019	E Gene CT	30.28
2020	10	11	PCR_COV_N2019	E Gene CT	21.5
2020	10	11	PCR_COV_N2019	E Gene CT	33.16
2020	10	11	PCR_COV_N2019	E Gene CT	28.52
2020	10	11	PCR_COV_N2019	E Gene CT	30.65
2020	10	11	PCR_COV_N2019	E Gene CT	24.95
2020	10	11	PCR_COV_N2019	E Gene CT	14.18
2020	10	11	PCR_FUSION_COV19_E	E Gene CT	22.5
2020	10	11	PCR_COV_N2019	E Gene CT	20.12
2020	10	11	PCR_COV_N2019	E Gene CT	20.54
2020	10	11	PCR_COV_N2019	E Gene CT	23.2

AB920

2020	10	12	PCR_COV_N2019	E Gene CT	28.42
2020	10	12	PCR_COV_N2019	E Gene CT	30.71
2020	10	12	PCR_COV_N2019	E Gene CT	24.32
2020	10	12	PCR_COV_N2019	E Gene CT	21.99
2020	10	12	PCR_COV_N2019	E Gene CT	14.41
2020	10	12	PCR_COV_N2019	E Gene CT	22.59
2020	10	12	PCR_COV_N2019	E Gene CT	27.82
2020	10	12	PCR_COV_N2019	E Gene CT	24.89
2020	10	12	PCR_COV_N2019	E Gene CT	16.7
2020	10	12	PCR_COV_N2019	E Gene CT	18.03
2020	10	12	PCR_COV_N2019	E Gene CT	25.22
2020	10	12	PCR_COV_N2019	E Gene CT	20.23
2020	10	12	PCR_COV_N2019	E Gene CT	31.13
2020	10	12	PCR_FUSION_COV19_E	E Gene CT	20.4
2020	10	12	PCR_FUSION_COV19_E	E Gene CT	20.9
2020	10	12	PCR_FUSION_COV19_E	E Gene CT	27.3
2020	10	12	PCR_COV_N2019	E Gene CT	34.57
2020	10	12	PCR_COV_N2019	E Gene CT	16.68
2020	10	12	PCR_COV_N2019	E Gene CT	18.17
2020	10	12	PCR_COV_N2019	E Gene CT	13.67
2020	10	12	PCR_COV_N2019	E Gene CT	14.75
2020	10	12	PCR_COV_N2019	E Gene CT	33.17
2020	10	12	PCR_COV_N2019	E Gene CT	23.73
2020	10	12	PCR_COV_N2019	E Gene CT	33.19
2020	10	12	PCR_COV_N2019	E Gene CT	18.03
2020	10	12	PCR_COV_N2019	E Gene CT	25.56
2020	10	12	PCR_COV_N2019	E Gene CT	14.55
2020	10	12	PCR_COV_N2019	E Gene CT	18.54
2020	10	12	PCR_COV_N2019	E Gene CT	24.77
2020	10	13	PCR_COV_N2019	E Gene CT	28.39
2020	10	13	PCR_COV_N2019	E Gene CT	35.4
2020	10	13	PCR_COV_N2019	E Gene CT	23.85
2020	10	13	PCR_COV_N2019	E Gene CT	16.84
2020	10	13	PCR_COV_N2019	E Gene CT	18.32
2020	10	13	PCR_COV_N2019	E Gene CT	20.6
2020	10	13	PCR_COV_N2019	E Gene CT	23.9
2020	10	13	PCR_COV_N2019	E Gene CT	18.52
2020	10	13	PCR_COV_N2019	E Gene CT	22.74
2020	10	13	PCR_COV_N2019	E Gene CT	21.63
2020	10	13	PCR_COV_N2019	E Gene CT	18.02
2020	10	13	PCR_COV_N2019	E Gene CT	21.19
2020	10	13	PCR_COV_N2019	E Gene CT	17.67
2020	10	13	PCR_COV_N2019	E Gene CT	24.22
2020	10	13	PCR_COV_N2019	E Gene CT	19.12
2020	10	13	PCR_COV_N2019	E Gene CT	15.22
2020	10	13	PCR_COV_N2019	E Gene CT	16.03
2020	10	13	PCR_COV_N2019	E Gene CT	16.42

AB921

2020	10	13	PCR_COV_N2019	E Gene CT	32.44
2020	10	13	PCR_COV_N2019	E Gene CT	14.03
2020	10	13	PCR_COV_N2019	E Gene CT	22.07
2020	10	13	PCR_COV_N2019	E Gene CT	17.39
2020	10	13	PCR_COV_N2019	E Gene CT	27.04
2020	10	13	PCR_COV_N2019	E Gene CT	21.88
2020	10	13	PCR_COV_N2019	E Gene CT	31.5
2020	10	13	PCR_COV_N2019	E Gene CT	19.61
2020	10	13	PCR_COV_N2019	E Gene CT	27.73
2020	10	13	PCR_COV_N2019	E Gene CT	33.18
2020	10	13	PCR_COV_N2019	E Gene CT	16.16
2020	10	13	PCR_COV_N2019	E Gene CT	20.12
2020	10	13	PCR_COV_N2019	E Gene CT	16.24
2020	10	13	PCR_COV_N2019	E Gene CT	14.71
2020	10	13	PCR_COV_N2019	E Gene CT	18.34
2020	10	13	PCR_COV_N2019	E Gene CT	13.58
2020	10	13	PCR_COV_N2019	E Gene CT	10.83
2020	10	13	PCR_COV_N2019	E Gene CT	32.39
2020	10	13	PCR_COV_N2019	E Gene CT	29.26
2020	10	13	PCR_COV_N2019	E Gene CT	11.24
2020	10	13	PCR_COV_N2019	E Gene CT	18.67
2020	10	13	PCR_COV_N2019	E Gene CT	16.27
2020	10	13	PCR_COV_N2019	E Gene CT	13.16
2020	10	13	PCR_COV_N2019	E Gene CT	24.35
2020	10	13	PCR_COV_N2019	E Gene CT	22.5
2020	10	13	PCR_COV_N2019	E Gene CT	32.83
2020	10	13	PCR_COV_N2019	E Gene CT	36.15
2020	10	13	PCR_COV_N2019	E Gene CT	30.86
2020	10	13	PCR_FUSION_COV19_E	E Gene CT	34.9
2020	10	13	PCR_FUSION_COV19_E	E Gene CT	31.1
2020	10	13	PCR_FUSION_COV19_E	E Gene CT	26.7
2020	10	13	PCR_FUSION_COV19_E	E Gene CT	19.1
2020	10	13	PCR_COV_N2019	E Gene CT	18.75
2020	10	13	PCR_FUSION_COV19_E	E Gene CT	30.8
2020	10	13	PCR_FUSION_COV19_E	E Gene CT	27.5
2020	10	13	PCR_COV_N2019	E Gene CT	23.55925703
2020	10	13	PCR_COV_N2019	E Gene CT	19.44473945
2020	10	13	PCR_COV_N2019	E Gene CT	18.52007102
2020	10	13	PCR_COV_N2019	E Gene CT	23.46176236
2020	10	13	PCR_COV_N2019	E Gene CT	29.0402093
2020	10	13	PCR_COV_N2019	E Gene CT	27.96657965
2020	10	13	PCR_FUSION_COV19_E	E Gene CT	21.9
2020	10	13	PCR_FUSION_COV19_E	E Gene CT	19.1
2020	10	14	PCR_FUSION_COV19_E	E Gene CT	26.3
2020	10	14	PCR_FUSION_COV19_E	E Gene CT	21.9
2020	10	14	PCR_FUSION_COV19_E	E Gene CT	34.1
2020	10	14	PCR_COV_N2019	E Gene CT	20.51

AB922

2020	10	14	PCR_COV_N2019	E Gene CT	24.97
2020	10	14	PCR_COV_N2019	E Gene CT	20.44
2020	10	14	PCR_COV_N2019	E Gene CT	18.32
2020	10	14	PCR_COV_N2019	E Gene CT	27.58
2020	10	14	PCR_COV_N2019	E Gene CT	28.9
2020	10	14	PCR_COV_N2019	E Gene CT	27.58
2020	10	14	PCR_FUSION_COV19_E	E Gene CT	21.2
2020	10	14	PCR_COV_N2019	E Gene CT	25.37
2020	10	14	PCR_COV_N2019	E Gene CT	11.92
2020	10	14	PCR_COV_N2019	E Gene CT	23.75
2020	10	14	PCR_COV_N2019	E Gene CT	19.45
2020	10	14	PCR_COV_N2019	E Gene CT	20.84
2020	10	14	PCR_COV_N2019	E Gene CT	32.49
2020	10	14	PCR_COV_N2019	E Gene CT	17.62
2020	10	14	PCR_COV_N2019	E Gene CT	33.74576579
2020	10	15	PCR_COV_N2019	E Gene CT	14.14
2020	10	15	PCR_COV_N2019	E Gene CT	20.09
2020	10	15	PCR_COV_N2019	E Gene CT	13.36
2020	10	15	PCR_COV_N2019	E Gene CT	18.56
2020	10	15	PCR_COV_N2019	E Gene CT	29.44
2020	10	15	PCR_COV_N2019	E Gene CT	31.95
2020	10	15	PCR_COV_N2019	E Gene CT	21.96
2020	10	15	PCR_COV_N2019	E Gene CT	37.88
2020	10	15	PCR_FUSION_COV19_E	E Gene CT	19.5
2020	10	15	PCR_FUSION_COV19_E	E Gene CT	37.9
2020	10	15	PCR_FUSION_COV19_E	E Gene CT	22.3
2020	10	15	PCR_FUSION_COV19_E	E Gene CT	28.4
2020	10	15	PCR_COV_N2019	E Gene CT	25.75875942
2020	10	15	PCR_COV_N2019	E Gene CT	26.51895665
2020	10	15	PCR_FUSION_COV19_E	E Gene CT	24.5
2020	10	16	PCR_COV_N2019	E Gene CT	16.4938587
2020	10	16	PCR_COV_N2019	E Gene CT	19.75027845
2020	10	16	PCR_COV_N2019	E Gene CT	28.91231529
2020	10	16	PCR_COV_N2019	E Gene CT	30.00393048
2020	10	16	PCR_COV_N2019	E Gene CT	14.20688355
2020	10	16	PCR_COV_N2019	E Gene CT	20.85483404
2020	10	16	PCR_COV_N2019	E Gene CT	15.66915654
2020	10	16	PCR_COV_N2019	E Gene CT	20.71428257
2020	10	16	PCR_COV_N2019	E Gene CT	12.81805593
2020	10	16	PCR_COV_N2019	E Gene CT	18.954636
2020	10	16	PCR_COV_N2019	E Gene CT	15.02801473
2020	10	16	PCR_COV_N2019	E Gene CT	21.4588247
2020	10	16	PCR_COV_N2019	E Gene CT	24.82605692
2020	10	16	PCR_COV_N2019	E Gene CT	25.50669185
2020	10	16	PCR_COV_N2019	E Gene CT	22.639366
2020	10	16	PCR_COV_N2019	E Gene CT	13.45689724
2020	10	16	PCR_COV_N2019	E Gene CT	19.4147236

AB923

2020	10	16	PCR_COV_N2019	E Gene CT	18.86
2020	10	16	PCR_COV_N2019	E Gene CT	13.44
2020	10	16	PCR_COV_N2019	E Gene CT	24.83
2020	10	16	PCR_COV_N2019	E Gene CT	33.67
2020	10	16	PCR_FUSION_COV19_E	E Gene CT	28
2020	10	16	PCR_FUSION_COV19_E	E Gene CT	19.1
2020	10	16	PCR_COV_N2019	E Gene CT	13.13
2020	10	16	PCR_COV_N2019	E Gene CT	34.3
2020	10	16	PCR_COV_N2019	E Gene CT	28.26
2020	10	16	PCR_COV_N2019	E Gene CT	29.92
2020	10	16	PCR_COV_N2019	E Gene CT	12.85
2020	10	16	PCR_COV_N2019	E Gene CT	23.54
2020	10	17	PCR_COV_N2019	E Gene CT	17.09
2020	10	17	PCR_COV_N2019	E Gene CT	14.35
2020	10	17	PCR_COV_N2019	E Gene CT	16.11
2020	10	17	PCR_COV_N2019	E Gene CT	14.94
2020	10	17	PCR_COV_N2019	E Gene CT	35.39
2020	10	17	PCR_COV_N2019	E Gene CT	20.97
2020	10	17	PCR_COV_N2019	E Gene CT	15.86
2020	10	17	PCR_COV_N2019	E Gene CT	31.4
2020	10	17	PCR_COV_N2019	E Gene CT	19.94
2020	10	17	PCR_COV_N2019	E Gene CT	17.94
2020	10	17	PCR_COV_N2019	E Gene CT	23.61
2020	10	17	PCR_COV_N2019	E Gene CT	25.16
2020	10	17	PCR_COV_N2019	E Gene CT	23.24
2020	10	17	PCR_COV_N2019	E Gene CT	33.43
2020	10	17	PCR_COV_N2019	E Gene CT	15.89
2020	10	17	PCR_COV_N2019	E Gene CT	18.49
2020	10	17	PCR_COV_N2019	E Gene CT	32.34
2020	10	17	PCR_COV_N2019	E Gene CT	30.55
2020	10	17	PCR_COV_N2019	E Gene CT	12.15
2020	10	17	PCR_COV_N2019	E Gene CT	26.76
2020	10	17	PCR_COV_N2019	E Gene CT	15.42
2020	10	17	PCR_COV_N2019	E Gene CT	15.11
2020	10	17	PCR_COV_N2019	E Gene CT	39.67
2020	10	17	PCR_COV_N2019	E Gene CT	26.92
2020	10	17	PCR_COV_N2019	E Gene CT	15.62
2020	10	17	PCR_COV_N2019	E Gene CT	32.5
2020	10	17	PCR_COV_N2019	E Gene CT	16.72
2020	10	17	PCR_COV_N2019	E Gene CT	32.83
2020	10	17	PCR_FUSION_COV19_E	E Gene CT	31.5
2020	10	17	PCR_COV_N2019	E Gene CT	17.21
2020	10	17	PCR_COV_N2019	E Gene CT	35.07
2020	10	17	PCR_COV_N2019	E Gene CT	22.72
2020	10	17	PCR_COV_N2019	E Gene CT	21.22
2020	10	17	PCR_COV_N2019	E Gene CT	27.15
2020	10	17	PCR_COV_N2019	E Gene CT	32.19

2020	10	17	PCR_COV_N2019	E Gene CT	28.89
2020	10	17	PCR_FUSION_COV19_E	E Gene CT	27.8
2020	10	17	PCR_COV_N2019	E Gene CT	16.48
2020	10	17	PCR_COV_N2019	E Gene CT	24.27
2020	10	18	PCR_COV_N2019	E Gene CT	34.93
2020	10	18	PCR_FUSION_COV19_E	E Gene CT	21.3
2020	10	18	PCR_COV_N2019	E Gene CT	37.55
2020	10	18	PCR_FUSION_COV19_E	E Gene CT	20.2
2020	10	18	PCR_COBAS_COV19	CT 2	19.11
2020	10	18	PCR_FUSION_COV19_E	E Gene CT	31.6
2020	10	18	PCR_FUSION_COV19_E	E Gene CT	25.5
2020	10	18	PCR_FUSION_COV19_E	E Gene CT	29.2
2020	10	18	PCR_FUSION_COV19_E	E Gene CT	36.2
2020	10	18	PCR_COV_N2019	E Gene CT	30.07
2020	10	18	PCR_COV_N2019	E Gene CT	28.21
2020	10	18	PCR_COV_N2019	E Gene CT	27.35
2020	10	18	PCR_COV_N2019	E Gene CT	28.1
2020	10	18	PCR_COV_N2019	E Gene CT	26.94
2020	10	18	PCR_COV_N2019	E Gene CT	34.14
2020	10	18	PCR_FUSION_COV19_E	E Gene CT	24.1
2020	10	18	PCR_FUSION_COV19_E	E Gene CT	37.8
2020	10	18	PCR_COBAS_COV19	CT 2	17.51
2020	10	18	PCR_COBAS_COV19	CT 2	17.75
2020	10	18	PCR_COBAS_COV19	CT 2	20.67
2020	10	19	PCR_COV_N2019	E Gene CT	21.39
2020	10	19	PCR_COV_N2019	E Gene CT	22.48
2020	10	19	PCR_COV_N2019	E Gene CT	15.25
2020	10	19	PCR_COV_N2019	E Gene CT	11.68
2020	10	19	PCR_COV_N2019	E Gene CT	26.75
2020	10	19	PCR_COV_N2019	E Gene CT	18.2
2020	10	19	PCR_COV_N2019	E Gene CT	37.96
2020	10	19	PCR_COV_N2019	E Gene CT	21.31
2020	10	19	PCR_COV_N2019	E Gene CT	29.11
2020	10	19	PCR_COV_N2019	E Gene CT	17.47
2020	10	19	PCR_COV_N2019	E Gene CT	31.78
2020	10	19	PCR_COV_N2019	E Gene CT	28.23
2020	10	19	PCR_COV_N2019	E Gene CT	19.92
2020	10	19	PCR_COV_N2019	E Gene CT	28.85
2020	10	19	PCR_COV_N2019	E Gene CT	26.26
2020	10	19	PCR_COV_N2019	E Gene CT	18.13
2020	10	19	PCR_COV_N2019	E Gene CT	18.56
2020	10	19	PCR_FUSION_COV19_E	E Gene CT	32.8
2020	10	19	PCR_FUSION_COV19_E	E Gene CT	26.6
2020	10	19	PCR_FUSION_COV19_E	E Gene CT	19.7
2020	10	19	PCR_FUSION_COV19_E	E Gene CT	17.7
2020	10	19	PCR_FUSION_COV19_E	E Gene CT	14.2
2020	10	19	PCR_FUSION_COV19_E	E Gene CT	23.8

AB925

2020	10	19	PCR_COV_N2019	E Gene CT	28.69
2020	10	19	PCR_FUSION_COV19_E	E Gene CT	37.8
2020	10	19	PCR_FUSION_COV19_E	E Gene CT	26.8
2020	10	19	PCR_COV_N2019	E Gene CT	27.75
2020	10	19	PCR_COV_N2019	E Gene CT	28.12
2020	10	19	PCR_FUSION_COV19_E	E Gene CT	20.2
2020	10	19	PCR_FUSION_COV19_E	E Gene CT	23.7
2020	10	19	PCR_COV_N2019	E Gene CT	17.25
2020	10	19	PCR_COV_N2019	E Gene CT	27.04
2020	10	19	PCR_COV_N2019	E Gene CT	17.3
2020	10	19	PCR_COV_N2019	E Gene CT	26.11
2020	10	19	PCR_COV_N2019	E Gene CT	27.02
2020	10	19	PCR_COV_N2019	E Gene CT	16.55
2020	10	19	PCR_COV_N2019	E Gene CT	19.76
2020	10	19	PCR_COV_N2019	E Gene CT	22.14
2020	10	19	PCR_COV_N2019	E Gene CT	31.82
2020	10	19	PCR_COV_N2019	E Gene CT	13.28
2020	10	19	PCR_COV_N2019	E Gene CT	25.42
2020	10	19	PCR_COV_N2019	E Gene CT	14.28
2020	10	19	PCR_COV_N2019	E Gene CT	15.47
2020	10	19	PCR_COV_N2019	E Gene CT	34.18
2020	10	19	PCR_FUSION_COV19_E	E Gene CT	24.5
2020	10	19	PCR_FUSION_COV19_E	E Gene CT	25.5
2020	10	19	PCR_FUSION_COV19_E	E Gene CT	18
2020	10	19	PCR_FUSION_COV19_E	E Gene CT	19.1
2020	10	19	PCR_COV_N2019	E Gene CT	17.31
2020	10	19	PCR_COV_N2019	E Gene CT	19.57
2020	10	19	PCR_COV_N2019	E Gene CT	19.69
2020	10	19	PCR_COV_N2019	E Gene CT	15.41
2020	10	19	PCR_COV_N2019	E Gene CT	30.27
2020	10	20	PCR_COV_N2019	E Gene CT	14.82
2020	10	20	PCR_COV_N2019	E Gene CT	25.27
2020	10	20	PCR_COV_N2019	E Gene CT	13.23
2020	10	20	PCR_COV_N2019	E Gene CT	16.07
2020	10	20	PCR_COV_N2019	E Gene CT	22.36
2020	10	20	PCR_COV_N2019	E Gene CT	33.873
2020	10	20	PCR_COV_N2019	E Gene CT	26.09
2020	10	20	PCR_COV_N2019	E Gene CT	25.13
2020	10	20	PCR_COV_N2019	E Gene CT	30.52
2020	10	20	PCR_COV_N2019	E Gene CT	22.18
2020	10	20	PCR_COV_N2019	E Gene CT	32.54
2020	10	20	PCR_COV_N2019	E Gene CT	17.27
2020	10	20	PCR_COV_N2019	E Gene CT	24.74
2020	10	20	PCR_COV_N2019	E Gene CT	32.31
2020	10	20	PCR_FUSION_COV19_E	E Gene CT	20.6
2020	10	20	PCR_COV_N2019	E Gene CT	16.86
2020	10	20	PCR_COV_N2019	E Gene CT	27.2

AB926

2020	10	20	PCR_COV_N2019	E Gene CT	21.48
2020	10	20	PCR_COV_N2019	E Gene CT	13.1
2020	10	20	PCR_COV_N2019	E Gene CT	11.41
2020	10	20	PCR_COV_N2019	E Gene CT	25.35
2020	10	20	PCR_COV_N2019	E Gene CT	18.11
2020	10	20	PCR_COV_N2019	E Gene CT	14.1
2020	10	20	PCR_COV_N2019	E Gene CT	31.12
2020	10	20	PCR_COV_N2019	E Gene CT	30.08
2020	10	20	PCR_COV_N2019	E Gene CT	13.07
2020	10	21	PCR_COV_N2019	E Gene CT	15.3
2020	10	21	PCR_COV_N2019	E Gene CT	21.88
2020	10	21	PCR_COV_N2019	E Gene CT	20.52
2020	10	21	PCR_COV_N2019	E Gene CT	17.52
2020	10	21	PCR_COV_N2019	E Gene CT	20.24
2020	10	21	PCR_COV_N2019	E Gene CT	25.39
2020	10	21	PCR_COV_N2019	E Gene CT	22.81
2020	10	21	PCR_COV_N2019	E Gene CT	29.53
2020	10	21	PCR_COV_N2019	E Gene CT	18.75
2020	10	21	PCR_COV_N2019	E Gene CT	36.62
2020	10	21	PCR_COV_N2019	E Gene CT	23.4
2020	10	21	PCR_COV_N2019	E Gene CT	15.8
2020	10	21	PCR_COV_N2019	E Gene CT	14.79
2020	10	21	PCR_COV_N2019	E Gene CT	12.15
2020	10	21	PCR_COV_N2019	E Gene CT	18.62
2020	10	21	PCR_COV_N2019	E Gene CT	29.25
2020	10	21	PCR_COV_N2019	E Gene CT	21.79
2020	10	21	PCR_COV_N2019	E Gene CT	32.07
2020	10	21	PCR_COV_N2019	E Gene CT	21.65
2020	10	21	PCR_COV_N2019	E Gene CT	21.64
2020	10	21	PCR_FUSION_COV19_E	E Gene CT	16.7
2020	10	21	PCR_FUSION_COV19_E	E Gene CT	37.1
2020	10	21	PCR_FUSION_COV19_E	E Gene CT	24.5
2020	10	21	PCR_COV_N2019	E Gene CT	18.66
2020	10	21	PCR_COV_N2019	E Gene CT	21.37
2020	10	21	PCR_COV_N2019	E Gene CT	14.28
2020	10	21	PCR_COV_N2019	E Gene CT	11.18
2020	10	21	PCR_COV_N2019	E Gene CT	20.61
2020	10	21	PCR_COV_N2019	E Gene CT	18.15
2020	10	21	PCR_COV_N2019	E Gene CT	15.39
2020	10	21	PCR_COV_N2019	E Gene CT	12.42
2020	10	21	PCR_COV_N2019	E Gene CT	12.91
2020	10	21	PCR_COV_N2019	E Gene CT	16.94
2020	10	21	PCR_COV_N2019	E Gene CT	16.14
2020	10	21	PCR_COV_N2019	E Gene CT	30.81
2020	10	21	PCR_COV_N2019	E Gene CT	11.09
2020	10	21	PCR_COV_N2019	E Gene CT	15.25
2020	10	21	PCR_COV_N2019	E Gene CT	31.55

AB927

2020	10	21	PCR_COV_N2019	E Gene CT	12.2
2020	10	21	PCR_COV_N2019	E Gene CT	11.34
2020	10	21	PCR_COV_N2019	E Gene CT	25.88
2020	10	21	PCR_COV_N2019	E Gene CT	17.42
2020	10	21	PCR_FUSION_COV19_E	E Gene CT	24.1
2020	10	21	PCR_COV_N2019	E Gene CT	32.02
2020	10	21	PCR_COV_N2019	E Gene CT	26.31
2020	10	21	PCR_COV_N2019	E Gene CT	26.19
2020	10	21	PCR_FUSION_COV19_E	E Gene CT	22.8
2020	10	21	PCR_COV_N2019	E Gene CT	32.44
2020	10	21	PCR_FUSION_COV19_E	E Gene CT	26.1
2020	10	21	PCR_FUSION_COV19_E	E Gene CT	32
2020	10	21	PCR_COV_N2019	E Gene CT	32.13
2020	10	21	PCR_COV_N2019	E Gene CT	28.58
2020	10	21	PCR_COV_N2019	E Gene CT	28.39
2020	10	21	PCR_COV_N2019	E Gene CT	31.28
2020	10	21	PCR_COV_N2019	E Gene CT	22.91
2020	10	21	PCR_COV_N2019	E Gene CT	25.24
2020	10	21	PCR_FUSION_COV19_E	E Gene CT	25
2020	10	21	PCR_FUSION_COV19_E	E Gene CT	26.8
2020	10	21	PCR_COV_N2019	E Gene CT	17.52
2020	10	21	PCR_FUSION_COV19_E	E Gene CT	17.8
2020	10	22	PCR_COV_N2019	E Gene CT	19.65
2020	10	22	PCR_COV_N2019	E Gene CT	22.69
2020	10	22	PCR_COV_N2019	E Gene CT	27.15
2020	10	22	PCR_COV_N2019	E Gene CT	16.13
2020	10	22	PCR_COV_N2019	E Gene CT	15.11
2020	10	22	PCR_COV_N2019	E Gene CT	28.06
2020	10	22	PCR_COV_N2019	E Gene CT	32.84
2020	10	22	PCR_COV_N2019	E Gene CT	14.7
2020	10	22	PCR_COV_N2019	E Gene CT	13.34
2020	10	22	PCR_COV_N2019	E Gene CT	15.64
2020	10	22	PCR_COV_N2019	E Gene CT	16.11
2020	10	22	PCR_COV_N2019	E Gene CT	22.26
2020	10	22	PCR_COV_N2019	E Gene CT	17.66
2020	10	22	PCR_COV_N2019	E Gene CT	19.24
2020	10	22	PCR_COV_N2019	E Gene CT	15.81
2020	10	22	PCR_COV_N2019	E Gene CT	20.1
2020	10	22	PCR_COV_N2019	E Gene CT	20.06
2020	10	22	PCR_COV_N2019	E Gene CT	17.06
2020	10	22	PCR_COV_N2019	E Gene CT	24.76
2020	10	22	PCR_COV_N2019	E Gene CT	15.09
2020	10	22	PCR_COV_N2019	E Gene CT	30.51
2020	10	22	PCR_COV_N2019	E Gene CT	17.08
2020	10	22	PCR_COV_N2019	E Gene CT	14.43
2020	10	22	PCR_COV_N2019	E Gene CT	20.65
2020	10	22	PCR_COV_N2019	E Gene CT	15.05

2020	10	22	PCR_COV_N2019	E Gene CT	24.75
2020	10	22	PCR_FUSION_COV19_E	E Gene CT	18.2
2020	10	22	PCR_FUSION_COV19_E	E Gene CT	20
2020	10	22	PCR_FUSION_COV19_E	E Gene CT	18.8
2020	10	22	PCR_FUSION_COV19_E	E Gene CT	31
2020	10	22	PCR_COV_N2019	E Gene CT	27.91
2020	10	22	PCR_COV_N2019	E Gene CT	18.02
2020	10	22	PCR_COV_N2019	E Gene CT	20.66
2020	10	22	PCR_COV_N2019	E Gene CT	34.40312025
2020	10	22	PCR_COV_N2019	E Gene CT	13.95905337
2020	10	22	PCR_COV_N2019	E Gene CT	17.18865411
2020	10	22	PCR_COV_N2019	E Gene CT	33.19
2020	10	22	PCR_COV_N2019	E Gene CT	30.33766721
2020	10	22	PCR_COV_N2019	E Gene CT	31.07212628
2020	10	22	PCR_COV_N2019	E Gene CT	21.45638328
2020	10	22	PCR_FUSION_COV19_E	E Gene CT	36.3
2020	10	22	PCR_COV_N2019	E Gene CT	18.19646984
2020	10	22	PCR_FUSION_COV19_E	E Gene CT	29.2
2020	10	22	PCR_FUSION_COV19_E	E Gene CT	29.9
2020	10	22	PCR_FUSION_COV19_E	E Gene CT	34.4
2020	10	22	PCR_FUSION_COV19_E	E Gene CT	24.9
2020	10	22	PCR_FUSION_COV19_E	E Gene CT	31.8
2020	10	22	PCR_FUSION_COV19_E	E Gene CT	22.5
2020	10	22	PCR_FUSION_COV19_E	E Gene CT	35.5
2020	10	22	PCR_FUSION_COV19_E	E Gene CT	20.9
2020	10	22	PCR_FUSION_COV19_E	E Gene CT	17.3
2020	10	22	PCR_FUSION_COV19_E	E Gene CT	23.6
2020	10	22	PCR_COV_N2019	E Gene CT	27.05119926
2020	10	22	PCR_FUSION_COV19_E	E Gene CT	32.6
2020	10	22	PCR_FUSION_COV19_E	E Gene CT	33.2
2020	10	23	PCR_COV_N2019	E Gene CT	32.4286744
2020	10	23	PCR_COV_N2019	E Gene CT	30.41412432
2020	10	23	PCR_COV_N2019	E Gene CT	31.82542112
2020	10	23	PCR_FUSION_COV19_E	E Gene CT	21.5
2020	10	23	PCR_FUSION_COV19_E	E Gene CT	25.9
2020	10	23	PCR_COV_N2019	E Gene CT	30.39448602
2020	10	23	PCR_COV_N2019	E Gene CT	28.983043
2020	10	23	PCR_FUSION_COV19_E	E Gene CT	17
2020	10	23	PCR_FUSION_COV19_E	E Gene CT	19.5
2020	10	23	PCR_FUSION_COV19_E	E Gene CT	22
2020	10	23	PCR_FUSION_COV19_E	E Gene CT	34.4
2020	10	23	PCR_COV_N2019	E Gene CT	21.4627986
2020	10	23	PCR_COV_N2019	E Gene CT	21.14601839
2020	10	23	PCR_COV_N2019	E Gene CT	25.93079139
2020	10	23	PCR_COV_N2019	E Gene CT	15.29176801
2020	10	23	PCR_COV_N2019	E Gene CT	21.39143324
2020	10	23	PCR_COV_N2019	E Gene CT	15.05705302

AB929

2020	10	23	PCR_COV_N2019	E Gene CT	29.94021603
2020	10	23	PCR_COV_N2019	E Gene CT	32.54087179
2020	10	23	PCR_COV_N2019	E Gene CT	16.32354429
2020	10	23	PCR_COV_N2019	E Gene CT	20.9633329
2020	10	23	PCR_FUSION_COV19_E	E Gene CT	27.1
2020	10	23	PCR_FUSION_COV19_E	E Gene CT	19
2020	10	23	PCR_FUSION_COV19_E	E Gene CT	21.3
2020	10	23	PCR_COV_N2019	E Gene CT	21.42508575
2020	10	23	PCR_COV_N2019	E Gene CT	27.72291191
2020	10	23	PCR_COV_N2019	E Gene CT	32.82954188
2020	10	23	PCR_COV_N2019	E Gene CT	28.33187109
2020	10	23	PCR_FUSION_COV19_E	E Gene CT	37.4
2020	10	23	PCR_COV_N2019	E Gene CT	26.38057815
2020	10	23	PCR_COV_N2019	E Gene CT	31.23344551
2020	10	23	PCR_COV_N2019	E Gene CT	23.10081813
2020	10	23	PCR_COV_N2019	E Gene CT	13.36039762
2020	10	23	PCR_COV_N2019	E Gene CT	12.25834643
2020	10	23	PCR_COV_N2019	E Gene CT	28.38415729
2020	10	23	PCR_FUSION_COV19_E	E Gene CT	19.4
2020	10	23	PCR_FUSION_COV19_E	E Gene CT	21.6
2020	10	23	PCR_FUSION_COV19_E	E Gene CT	24
2020	10	23	PCR_FUSION_COV19_E	E Gene CT	27.7
2020	10	23	PCR_FUSION_COV19_E	E Gene CT	20.3
2020	10	23	PCR_COV_N2019	E Gene CT	21.16360619
2020	10	23	PCR_COV_N2019	E Gene CT	32.52129039
2020	10	23	PCR_COV_N2019	E Gene CT	13.34405384
2020	10	23	PCR_COV_N2019	E Gene CT	16.24414971
2020	10	23	PCR_COV_N2019	E Gene CT	31.18628482
2020	10	23	PCR_COV_N2019	E Gene CT	20.4536654
2020	10	23	PCR_COV_N2019	E Gene CT	17.52791492
2020	10	23	PCR_COV_N2019	E Gene CT	23.04068989
2020	10	23	PCR_FUSION_COV19_E	E Gene CT	24.3
2020	10	23	PCR_COV_N2019	E Gene CT	24.01885473
2020	10	23	PCR_COV_N2019	E Gene CT	26.80604548
2020	10	23	PCR_COV_N2019	E Gene CT	24.47462405
2020	10	23	PCR_COV_N2019	E Gene CT	18.22664117
2020	10	23	PCR_FUSION_COV19_E	E Gene CT	29.1
2020	10	23	PCR_FUSION_COV19_E	E Gene CT	27.3
2020	10	23	PCR_FUSION_COV19_E	E Gene CT	37.3
2020	10	23	PCR_COV_N2019	E Gene CT	24.05471729
2020	10	23	PCR_COV_N2019	E Gene CT	30.4978776
2020	10	24	PCR_COV_N2019	E Gene CT	25.60064736
2020	10	24	PCR_FUSION_COV19_E	E Gene CT	25
2020	10	24	PCR_FUSION_COV19_E	E Gene CT	19.7
2020	10	24	PCR_COV_N2019	E Gene CT	25.53469254
2020	10	24	PCR_COV_N2019	E Gene CT	31.85286487
2020	10	24	PCR_COV_N2019	E Gene CT	32.39259182

AB930

2020	10	24	PCR_COV_N2019	E Gene CT	27.36815975
2020	10	24	PCR_FUSION_COV19_E	E Gene CT	22
2020	10	24	PCR_FUSION_COV19_E	E Gene CT	18
2020	10	24	PCR_FUSION_COV19_E	E Gene CT	18
2020	10	24	PCR_FUSION_COV19_E	E Gene CT	28.8
2020	10	24	PCR_FUSION_COV19_E	E Gene CT	21
2020	10	24	PCR_FUSION_COV19_E	E Gene CT	18.5
2020	10	24	PCR_FUSION_COV19_E	E Gene CT	24.8
2020	10	24	PCR_FUSION_COV19_E	E Gene CT	23.2
2020	10	24	PCR_FUSION_COV19_E	E Gene CT	23.2
2020	10	24	PCR_COV_N2019	E Gene CT	27.22428987
2020	10	24	PCR_COV_N2019	E Gene CT	27.63124057
2020	10	24	PCR_COV_N2019	E Gene CT	16.32622427
2020	10	24	PCR_COV_N2019	E Gene CT	21.60673988
2020	10	24	PCR_COV_N2019	E Gene CT	28.41954003
2020	10	24	PCR_COV_N2019	E Gene CT	27.22751565
2020	10	24	PCR_COV_N2019	E Gene CT	21.29584544
2020	10	24	PCR_COV_N2019	E Gene CT	21.35028035
2020	10	24	PCR_COV_N2019	E Gene CT	31.67700539
2020	10	24	PCR_COV_N2019	E Gene CT	31.17208133
2020	10	24	PCR_COV_N2019	E Gene CT	31.31988644
2020	10	24	PCR_COV_N2019	E Gene CT	15.10644731
2020	10	24	PCR_COV_N2019	E Gene CT	16.15356554
2020	10	24	PCR_COV_N2019	E Gene CT	19.08078058
2020	10	24	PCR_COV_N2019	E Gene CT	15.13638273
2020	10	24	PCR_COV_N2019	E Gene CT	14.36096081
2020	10	24	PCR_COV_N2019	E Gene CT	14.83413095
2020	10	24	PCR_COV_N2019	E Gene CT	30.00745028
2020	10	24	PCR_COV_N2019	E Gene CT	14.04959794
2020	10	24	PCR_COV_N2019	E Gene CT	24.09379058
2020	10	24	PCR_FUSION_COV19_E	E Gene CT	33.5
2020	10	24	PCR_COV_N2019	E Gene CT	25.03238623
2020	10	24	PCR_COV_N2019	E Gene CT	15.59923438
2020	10	24	PCR_COV_N2019	E Gene CT	11.24430704
2020	10	24	PCR_COV_N2019	E Gene CT	22.77911112
2020	10	24	PCR_COBAS_COV19	CT 2	27.51
2020	10	24	PCR_COBAS_COV19	CT 2	31.95
2020	10	24	PCR_COBAS_COV19	CT 2	20.01
2020	10	24	PCR_COBAS_COV19	CT 2	14.14
2020	10	24	PCR_COBAS_COV19	CT 2	18.99
2020	10	24	PCR_COBAS_COV19	CT 2	18.85
2020	10	24	PCR_COBAS_COV19	CT 2	27.87
2020	10	24	PCR_COBAS_COV19	CT 2	24.85
2020	10	24	PCR_COBAS_COV19	CT 2	37.08
2020	10	24	PCR_FUSION_COV19_E	E Gene CT	18.6
2020	10	24	PCR_COV_N2019	E Gene CT	14.40534508
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	26.5

AB931

2020	10	25	PCR_FUSION_COV19_E	E Gene CT	21.9
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	29.6
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	24.8
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	26.5
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	24.2
2020	10	25	PCR_COV_N2019	E Gene CT	22.75514537
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	21
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	16.5
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	18.9
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	18.3
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	16.3
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	26.1
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	20.3
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	23.1
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	31.1
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	19.6
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	18.2
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	25.6
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	17.2
2020	10	25	PCR_COBAS_COV19	CT 2	27.32
2020	10	25	PCR_COV_N2019	E Gene CT	18.55093935
2020	10	25	PCR_COV_N2019	E Gene CT	16.33660697
2020	10	25	PCR_COV_N2019	E Gene CT	29.19678624
2020	10	25	PCR_COV_N2019	E Gene CT	14.95178285
2020	10	25	PCR_COV_N2019	E Gene CT	18.74793808
2020	10	25	PCR_COV_N2019	E Gene CT	20.77535377
2020	10	25	PCR_COV_N2019	E Gene CT	33.53138753
2020	10	25	PCR_COV_N2019	E Gene CT	14.02977753
2020	10	25	PCR_COV_N2019	E Gene CT	20.73604141
2020	10	25	PCR_COV_N2019	E Gene CT	27.99465733
2020	10	25	PCR_COV_N2019	E Gene CT	25.57197324
2020	10	25	PCR_COV_N2019	E Gene CT	14.69132705
2020	10	25	PCR_COV_N2019	E Gene CT	13.35132941
2020	10	25	PCR_COV_N2019	E Gene CT	13.40861393
2020	10	25	PCR_COV_N2019	E Gene CT	21.6257872
2020	10	25	PCR_COV_N2019	E Gene CT	23.25883366
2020	10	25	PCR_COV_N2019	E Gene CT	25.97539678
2020	10	25	PCR_COV_N2019	E Gene CT	34.82827119
2020	10	25	PCR_COV_N2019	E Gene CT	14.66947005
2020	10	25	PCR_COV_N2019	E Gene CT	14.47667463
2020	10	25	PCR_COV_N2019	E Gene CT	30.70690282
2020	10	25	PCR_COV_N2019	E Gene CT	28.64246071
2020	10	25	PCR_COV_N2019	E Gene CT	15.35938685
2020	10	25	PCR_COV_N2019	E Gene CT	29.11711739
2020	10	25	PCR_COV_N2019	E Gene CT	23.59441939
2020	10	25	PCR_COV_N2019	E Gene CT	29.64361831
2020	10	25	PCR_COV_N2019	E Gene CT	21.87483982

AB932

2020	10	25	PCR_COV_N2019	E Gene CT	12.30714819
2020	10	25	PCR_COV_N2019	E Gene CT	11.74454752
2020	10	25	PCR_COV_N2019	E Gene CT	17.74909801
2020	10	25	PCR_COV_N2019	E Gene CT	18.15594021
2020	10	25	PCR_COV_N2019	E Gene CT	14.16184306
2020	10	25	PCR_COV_N2019	E Gene CT	29.45839697
2020	10	25	PCR_COV_N2019	E Gene CT	19.90500914
2020	10	25	PCR_COV_N2019	E Gene CT	17.18943113
2020	10	25	PCR_COV_N2019	E Gene CT	22.62523055
2020	10	25	PCR_COV_N2019	E Gene CT	16.58274506
2020	10	25	PCR_COV_N2019	E Gene CT	19.11549951
2020	10	25	PCR_COV_N2019	E Gene CT	17.50489628
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	28.7
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	24.2
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	26
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	23.8
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	32.7
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	31.2
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	22
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	20.1
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	18.2
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	18
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	18
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	20.9
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	18.7
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	18.7
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	20.4
2020	10	25	PCR_COV_N2019	E Gene CT	17.85766443
2020	10	25	PCR_COV_N2019	E Gene CT	23.34323728
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	15.9
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	16.2
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	29.3
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	24.5
2020	10	25	PCR_FUSION_COV19_E	E Gene CT	29.4
2020	10	25	PCR_COV_N2019	E Gene CT	18.57864773
2020	10	25	PCR_COBAS_COV19	CT 2	24.35
2020	10	25	PCR_COBAS_COV19	CT 2	16.81
2020	10	25	PCR_COBAS_COV19	CT 2	25.74
2020	10	25	PCR_COV_N2019	E Gene CT	16.00820661
2020	10	26	PCR_COV_N2019	E Gene CT	27.47166057
2020	10	26	PCR_COV_N2019	E Gene CT	18.84395717
2020	10	26	PCR_COV_N2019	E Gene CT	23.75727811
2020	10	26	PCR_COV_N2019	E Gene CT	13.83958134
2020	10	26	PCR_COV_N2019	E Gene CT	13.36553896
2020	10	26	PCR_COV_N2019	E Gene CT	27.99100712
2020	10	26	PCR_FUSION_COV19_E	E Gene CT	22.9
2020	10	26	PCR_FUSION_COV19_E	E Gene CT	18.8

AB933

2020	10	26	PCR_FUSION_COV19_E	E Gene CT	37.9
2020	10	26	PCR_FUSION_COV19_E	E Gene CT	30
2020	10	26	PCR_FUSION_COV19_E	E Gene CT	18
2020	10	26	PCR_FUSION_COV19_E	E Gene CT	28.6
2020	10	26	PCR_COV_N2019	E Gene CT	17.9102983
2020	10	26	PCR_COV_N2019	E Gene CT	24.90719293
2020	10	26	PCR_COV_N2019	E Gene CT	12.15109487
2020	10	26	PCR_COV_N2019	E Gene CT	14.43489394
2020	10	26	PCR_COV_N2019	E Gene CT	24.65779122
2020	10	26	PCR_COV_N2019	E Gene CT	22.28500428
2020	10	26	PCR_COV_N2019	E Gene CT	32.24518026
2020	10	26	PCR_COV_N2019	E Gene CT	25.09093102
2020	10	26	PCR_COV_N2019	E Gene CT	23.26035802
2020	10	26	PCR_COV_N2019	E Gene CT	26.09388006
2020	10	26	PCR_COV_N2019	E Gene CT	15.66432245
2020	10	26	PCR_COV_N2019	E Gene CT	24.20558838
2020	10	26	PCR_COV_N2019	E Gene CT	28.19732384
2020	10	26	PCR_COV_N2019	E Gene CT	13.11354666
2020	10	26	PCR_COV_N2019	E Gene CT	18.95178486
2020	10	26	PCR_COV_N2019	E Gene CT	26.72939887
2020	10	26	PCR_COV_N2019	E Gene CT	17.25136337
2020	10	26	PCR_COV_N2019	E Gene CT	24.6394941
2020	10	26	PCR_COV_N2019	E Gene CT	18.36747836
2020	10	26	PCR_COV_N2019	E Gene CT	16.70328839
2020	10	26	PCR_COV_N2019	E Gene CT	27.05035225
2020	10	26	PCR_COV_N2019	E Gene CT	36.05931209
2020	10	27	PCR_COV_N2019	E Gene CT	33.75
2020	10	27	PCR_COV_N2019	E Gene CT	30.04
2020	10	27	PCR_COV_N2019	E Gene CT	34.7
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	19.6
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	19
2020	10	27	PCR_COV_N2019	E Gene CT	35.76
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	18.8
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	19.4
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	22.8
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	18.1
2020	10	27	PCR_COV_N2019	E Gene CT	28.81
2020	10	27	PCR_COV_N2019	E Gene CT	27.3836106
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	17.2
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	17.1
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	21.4
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	19.3
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	28.5
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	24.7
2020	10	27	PCR_COV_N2019	E Gene CT	17.2641104
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	24.7
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	18.7

AB934

2020	10	27	PCR_COV_N2019	E Gene CT	35.27865354
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	18.2
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	20.8
2020	10	27	PCR_COV_N2019	E Gene CT	28.17167566
2020	10	27	PCR_COV_N2019	E Gene CT	34.36101126
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	21.9
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	18.6
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	17.5
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	20.2
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	18.1
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	22.1
2020	10	27	PCR_COV_N2019	E Gene CT	30.56918282
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	22.7
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	21.8
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	24.2
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	20
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	22.5
2020	10	27	PCR_COV_N2019	E Gene CT	22.95905378
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	23.6
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	24.1
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	27.8
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	25.8
2020	10	27	PCR_COV_N2019	E Gene CT	25.7956484
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	17.6
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	18.1
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	18.2
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	20.5
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	19.9
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	18
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	24.1
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	20.3
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	28.4
2020	10	27	PCR_COV_N2019	E Gene CT	36.87483043
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	18.1
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	30.3
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	29.9
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	27.7
2020	10	27	PCR_COV_N2019	E Gene CT	19.67
2020	10	27	PCR_COV_N2019	E Gene CT	33.78
2020	10	27	PCR_COV_N2019	E Gene CT	35.3
2020	10	27	PCR_COV_N2019	E Gene CT	18.24
2020	10	27	PCR_COV_N2019	E Gene CT	26.5
2020	10	27	PCR_COV_N2019	E Gene CT	17.25
2020	10	27	PCR_COV_N2019	E Gene CT	19.07
2020	10	27	PCR_COV_N2019	E Gene CT	35.45369197
2020	10	27	PCR_COV_N2019	E Gene CT	34.82804191
2020	10	27	PCR_COV_N2019	E Gene CT	12.32683743

AB935

2020	10	27	PCR_COV_N2019	E Gene CT	15.6254912
2020	10	27	PCR_COV_N2019	E Gene CT	16.64110301
2020	10	27	PCR_COV_N2019	E Gene CT	13.42120343
2020	10	27	PCR_COV_N2019	E Gene CT	12.30493086
2020	10	27	PCR_COV_N2019	E Gene CT	34.3348722
2020	10	27	PCR_COV_N2019	E Gene CT	30.25142388
2020	10	27	PCR_COV_N2019	E Gene CT	15.46929053
2020	10	27	PCR_COV_N2019	E Gene CT	17.2829691
2020	10	27	PCR_COV_N2019	E Gene CT	13.09696383
2020	10	27	PCR_COV_N2019	E Gene CT	21.25093717
2020	10	27	PCR_COV_N2019	E Gene CT	13.72194572
2020	10	27	PCR_COV_N2019	E Gene CT	25.31450668
2020	10	27	PCR_COV_N2019	E Gene CT	15.48582916
2020	10	27	PCR_COV_N2019	E Gene CT	27.95073937
2020	10	27	PCR_COV_N2019	E Gene CT	14.55431847
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	30.6
2020	10	27	PCR_COV_N2019	E Gene CT	24.7043456
2020	10	27	PCR_COV_N2019	E Gene CT	32.03635793
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	32.6
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	37.8
2020	10	27	PCR_COV_N2019	E Gene CT	25.45224925
2020	10	27	PCR_COV_N2019	E Gene CT	10.21945644
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	26.8
2020	10	27	PCR_COV_N2019	E Gene CT	26.4481577
2020	10	27	PCR_COV_N2019	E Gene CT	14.39271395
2020	10	27	PCR_COV_N2019	E Gene CT	15.06829505
2020	10	27	PCR_COV_N2019	E Gene CT	30.64799719
2020	10	27	PCR_COV_N2019	E Gene CT	23.9995683
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	33.2
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	36.5
2020	10	27	PCR_COV_N2019	E Gene CT	29.43324439
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	22.8
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	24.4
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	32.2
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	35.2
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	31.7
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	29.5
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	28.6
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	36.4
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	34.3
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	26.9
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	34
2020	10	27	PCR_COV_N2019	E Gene CT	33.10760724
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	22.8
2020	10	27	PCR_COV_N2019	E Gene CT	29.03310852
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	21.8
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	28.2

AB936

2020	10	27	PCR_FUSION_COV19_E	E Gene CT	29.6
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	33.7
2020	10	27	PCR_COV_N2019	E Gene CT	34.67059328
2020	10	27	PCR_COV_N2019	E Gene CT	15.76581429
2020	10	27	PCR_COV_N2019	E Gene CT	23.61882674
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	28.1
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	34.1
2020	10	27	PCR_COV_N2019	E Gene CT	31.28985123
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	35.9
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	23.9
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	26.5
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	33.2
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	34.5
2020	10	27	PCR_COV_N2019	E Gene CT	30.74909958
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	37.2
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	33.3
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	31.9
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	25.2
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	31.2
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	21.4
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	24.2
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	34.2
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	25
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	20.5
2020	10	27	PCR_FUSION_COV19_E	E Gene CT	29.7
2020	10	27	PCR_COV_N2019	E Gene CT	14.01498171
2020	10	27	PCR_COV_N2019	E Gene CT	15.06760268
2020	10	27	PCR_COV_N2019	E Gene CT	15.77559186
2020	10	27	PCR_COV_N2019	E Gene CT	32.88167564
2020	10	27	PCR_COV_N2019	E Gene CT	38.25471511
2020	10	27	PCR_COV_N2019	E Gene CT	15.46670829
2020	10	27	PCR_COV_N2019	E Gene CT	32.4788372
2020	10	27	PCR_COV_N2019	E Gene CT	15.60092944
2020	10	27	PCR_COV_N2019	E Gene CT	20.09239835
2020	10	27	PCR_COV_N2019	E Gene CT	30.60232622
2020	10	27	PCR_COV_N2019	E Gene CT	16.50863677
2020	10	27	PCR_COV_N2019	E Gene CT	16.2823657
2020	10	27	PCR_COV_N2019	E Gene CT	33.03561162
2020	10	27	PCR_COV_N2019	E Gene CT	29.50292808
2020	10	28	PCR_COV_N2019	E Gene CT	14.06709389
2020	10	28	PCR_FUSION_COV19_E	E Gene CT	18.4
2020	10	28	PCR_FUSION_COV19_E	E Gene CT	23.4
2020	10	28	PCR_FUSION_COV19_E	E Gene CT	21.4
2020	10	28	PCR_FUSION_COV19_E	E Gene CT	18
2020	10	28	PCR_FUSION_COV19_E	E Gene CT	27.7
2020	10	28	PCR_FUSION_COV19_E	E Gene CT	24.4
2020	10	28	PCR_FUSION_COV19_E	E Gene CT	24.4

AB937

2020	10	28	PCR_COV_N2019	E Gene CT	21.22549066
2020	10	28	PCR_COV_N2019	E Gene CT	15.58768726
2020	10	28	PCR_COV_N2019	E Gene CT	27.48636692
2020	10	28	PCR_COV_N2019	E Gene CT	24.85264518
2020	10	28	PCR_COV_N2019	E Gene CT	21.00066473
2020	10	28	PCR_COV_N2019	E Gene CT	14.08813457
2020	10	28	PCR_COV_N2019	E Gene CT	13.53904453
2020	10	28	PCR_FUSION_COV19_E	E Gene CT	22.5
2020	10	28	PCR_COV_N2019	E Gene CT	17.10930507
2020	10	28	PCR_COV_N2019	E Gene CT	13.98091091
2020	10	28	PCR_COV_N2019	E Gene CT	12.98379925
2020	10	28	PCR_COV_N2019	E Gene CT	26.55972768
2020	10	28	PCR_COV_N2019	E Gene CT	20.13615702
2020	10	28	PCR_COV_N2019	E Gene CT	15.4913206
2020	10	28	PCR_COV_N2019	E Gene CT	18.43531677
2020	10	28	PCR_COV_N2019	E Gene CT	20.26114111
2020	10	28	PCR_COV_N2019	E Gene CT	24.4897534
2020	10	28	PCR_COV_N2019	E Gene CT	16.76936126
2020	10	28	PCR_COV_N2019	E Gene CT	18.00252669
2020	10	28	PCR_COV_N2019	E Gene CT	35.8268812
2020	10	28	PCR_COV_N2019	E Gene CT	17.33794817
2020	10	28	PCR_COV_N2019	E Gene CT	13.48238226
2020	10	28	PCR_COV_N2019	E Gene CT	14.63443263
2020	10	28	PCR_COV_N2019	E Gene CT	23.48640684
2020	10	28	PCR_COV_N2019	E Gene CT	28.4804683
2020	10	28	PCR_COV_N2019	E Gene CT	33.54794897
2020	10	28	PCR_COV_N2019	E Gene CT	14.52371331
2020	10	28	PCR_COV_N2019	E Gene CT	36.19113199
2020	10	28	PCR_COV_N2019	E Gene CT	14.68049123
2020	10	28	PCR_COV_N2019	E Gene CT	21.13235934
2020	10	28	PCR_COV_N2019	E Gene CT	14.09468763
2020	10	28	PCR_COV_N2019	E Gene CT	26.67848437
2020	10	28	PCR_COV_N2019	E Gene CT	14.40671372
2020	10	28	PCR_COV_N2019	E Gene CT	14.043548
2020	10	28	PCR_COV_N2019	E Gene CT	26.0704046
2020	10	28	PCR_COV_N2019	E Gene CT	20.23777151
2020	10	28	PCR_COV_N2019	E Gene CT	24.20359018
2020	10	28	PCR_COV_N2019	E Gene CT	22.68859256
2020	10	28	PCR_COV_N2019	E Gene CT	18.65353156
2020	10	28	PCR_COV_N2019	E Gene CT	17.66520895
2020	10	28	PCR_COV_N2019	E Gene CT	20.79495776
2020	10	28	PCR_COV_N2019	E Gene CT	12.5028136
2020	10	28	PCR_COBAS_COV19	CT 2	33.03
2020	10	28	PCR_COBAS_COV19	CT 2	28.4
2020	10	29	PCR_COV_N2019	E Gene CT	28.79143618
2020	10	29	PCR_COV_N2019	E Gene CT	14.44751265
2020	10	29	PCR_COV_N2019	E Gene CT	20.83523779

AB938

2020	10	29	PCR_COV_N2019	E Gene CT	16.34104537
2020	10	29	PCR_COV_N2019	E Gene CT	34.63326177
2020	10	29	PCR_COV_N2019	E Gene CT	26.40869919
2020	10	29	PCR_COV_N2019	E Gene CT	17.0847913
2020	10	29	PCR_COV_N2019	E Gene CT	20.16154511
2020	10	29	PCR_COV_N2019	E Gene CT	34.27328252
2020	10	29	PCR_COV_N2019	E Gene CT	11.07570482
2020	10	29	PCR_COV_N2019	E Gene CT	16.32443578
2020	10	29	PCR_COV_N2019	E Gene CT	16.09423076
2020	10	29	PCR_COV_N2019	E Gene CT	22.87611697
2020	10	29	PCR_COV_N2019	E Gene CT	20.71763292
2020	10	29	PCR_COV_N2019	E Gene CT	23.33267952
2020	10	29	PCR_COV_N2019	E Gene CT	30.13123922
2020	10	29	PCR_COV_N2019	E Gene CT	18.17002789
2020	10	29	PCR_COV_N2019	E Gene CT	14.30189075
2020	10	29	PCR_COV_N2019	E Gene CT	20.14062651
2020	10	29	PCR_COV_N2019	E Gene CT	16.52550122
2020	10	29	PCR_COV_N2019	E Gene CT	12.76466411
2020	10	29	PCR_COV_N2019	E Gene CT	31.46100383
2020	10	29	PCR_COV_N2019	E Gene CT	24.61692537
2020	10	29	PCR_COV_N2019	E Gene CT	22.88334125
2020	10	29	PCR_COV_N2019	E Gene CT	17.07209179
2020	10	29	PCR_COV_N2019	E Gene CT	28.49980342
2020	10	29	PCR_COV_N2019	E Gene CT	20.59796693
2020	10	29	PCR_COV_N2019	E Gene CT	11.69599095
2020	10	29	PCR_COV_N2019	E Gene CT	34.1294524
2020	10	29	PCR_COV_N2019	E Gene CT	15.07221586
2020	10	29	PCR_COV_N2019	E Gene CT	14.13023925
2020	10	29	PCR_COV_N2019	E Gene CT	29.9497867
2020	10	29	PCR_COV_N2019	E Gene CT	15.57272422
2020	10	29	PCR_COV_N2019	E Gene CT	14.25810517
2020	10	29	PCR_COV_N2019	E Gene CT	13.06914723
2020	10	29	PCR_COV_N2019	E Gene CT	20.56994903
2020	10	29	PCR_COV_N2019	E Gene CT	22.31191247
2020	10	29	PCR_COV_N2019	E Gene CT	17.70724789
2020	10	29	PCR_COV_N2019	E Gene CT	14.69506872
2020	10	29	PCR_COV_N2019	E Gene CT	11.08880196
2020	10	29	PCR_COV_N2019	E Gene CT	14.51746879
2020	10	29	PCR_COV_N2019	E Gene CT	24.90961559
2020	10	29	PCR_COV_N2019	E Gene CT	15.59560996
2020	10	29	PCR_COV_N2019	E Gene CT	17.09182161
2020	10	29	PCR_COV_N2019	E Gene CT	30.8756353
2020	10	29	PCR_COV_N2019	E Gene CT	23.24786837
2020	10	29	PCR_COV_N2019	E Gene CT	31.95434048
2020	10	29	PCR_COV_N2019	E Gene CT	20.23520158
2020	10	29	PCR_COV_N2019	E Gene CT	19.05460586
2020	10	29	PCR_COV_N2019	E Gene CT	33.68667144

2020	10	29	PCR_FUSION_COV19_E	E Gene CT	37.8
2020	10	29	PCR_COV_N2019	E Gene CT	22.19298808
2020	10	29	PCR_FUSION_COV19_E	E Gene CT	23
2020	10	29	PCR_FUSION_COV19_E	E Gene CT	37.8
2020	10	29	PCR_COV_N2019	E Gene CT	28.28304786
2020	10	29	PCR_FUSION_COV19_E	E Gene CT	20.1
2020	10	29	PCR_COV_N2019	E Gene CT	14.33246699
2020	10	29	PCR_COV_N2019	E Gene CT	28.10324344
2020	10	29	PCR_COV_N2019	E Gene CT	14.74379691
2020	10	29	PCR_FUSION_COV19_E	E Gene CT	23
2020	10	29	PCR_COV_N2019	E Gene CT	31.00191675
2020	10	29	PCR_COV_N2019	E Gene CT	29.57862462
2020	10	29	PCR_COV_N2019	E Gene CT	21.45114993
2020	10	29	PCR_COV_N2019	E Gene CT	19.7834662
2020	10	29	PCR_COV_N2019	E Gene CT	18.47566358
2020	10	29	PCR_COV_N2019	E Gene CT	14.42324735
2020	10	29	PCR_COV_N2019	E Gene CT	12.24977641
2020	10	29	PCR_COV_N2019	E Gene CT	20.70112614
2020	10	29	PCR_COV_N2019	E Gene CT	17.98415061
2020	10	29	PCR_COV_N2019	E Gene CT	24.48035467
2020	10	29	PCR_COV_N2019	E Gene CT	26.0996798
2020	10	29	PCR_COV_N2019	E Gene CT	20.16785204
2020	10	29	PCR_COV_N2019	E Gene CT	28.2791269
2020	10	29	PCR_COV_N2019	E Gene CT	19.29412801
2020	10	29	PCR_COV_N2019	E Gene CT	27.14136275
2020	10	29	PCR_COV_N2019	E Gene CT	16.25024454
2020	10	29	PCR_COV_N2019	E Gene CT	17.63045721
2020	10	29	PCR_COV_N2019	E Gene CT	29.02211123
2020	10	29	PCR_COV_N2019	E Gene CT	14.25402897
2020	10	29	PCR_COV_N2019	E Gene CT	20.33911031
2020	10	29	PCR_COV_N2019	E Gene CT	19.25254293
2020	10	29	PCR_COV_N2019	E Gene CT	22.93962893
2020	10	29	PCR_COV_N2019	E Gene CT	32.13607268
2020	10	29	PCR_COV_N2019	E Gene CT	18.61824354
2020	10	29	PCR_COV_N2019	E Gene CT	14.34441071
2020	10	29	PCR_COV_N2019	E Gene CT	12.3818429
2020	10	29	PCR_COV_N2019	E Gene CT	12.5354728
2020	10	29	PCR_FUSION_COV19_E	E Gene CT	20.1
2020	10	29	PCR_FUSION_COV19_E	E Gene CT	34.7
2020	10	29	PCR_FUSION_COV19_E	E Gene CT	26.8
2020	10	29	PCR_COV_N2019	E Gene CT	30.02707559
2020	10	29	PCR_COV_N2019	E Gene CT	30.15255995
2020	10	29	PCR_COV_N2019	E Gene CT	17.66388409
2020	10	29	PCR_COV_N2019	E Gene CT	21.54452163
2020	10	29	PCR_COV_N2019	E Gene CT	25.59947109
2020	10	29	PCR_FUSION_COV19_E	E Gene CT	19.6
2020	10	29	PCR_FUSION_COV19_E	E Gene CT	23.3

AB940

2020	10	30	PCR_COV_N2019	E Gene CT	13.05041497
2020	10	30	PCR_COV_N2019	E Gene CT	18.41329385
2020	10	30	PCR_COV_N2019	E Gene CT	30.61154576
2020	10	30	PCR_COV_N2019	E Gene CT	25.78933369
2020	10	30	PCR_COV_N2019	E Gene CT	14.03529083
2020	10	30	PCR_COV_N2019	E Gene CT	14.06220505
2020	10	30	PCR_COV_N2019	E Gene CT	13.83654445
2020	10	30	PCR_COV_N2019	E Gene CT	20.88590808
2020	10	30	PCR_COV_N2019	E Gene CT	20.1634269
2020	10	30	PCR_COV_N2019	E Gene CT	23.31973948
2020	10	30	PCR_COV_N2019	E Gene CT	22.84330482
2020	10	30	PCR_COV_N2019	E Gene CT	12.02558105
2020	10	30	PCR_COV_N2019	E Gene CT	17.62735929
2020	10	30	PCR_COV_N2019	E Gene CT	16.34396179
2020	10	30	PCR_COV_N2019	E Gene CT	14.48499012
2020	10	30	PCR_COV_N2019	E Gene CT	21.85318537
2020	10	30	PCR_COV_N2019	E Gene CT	21.11284534
2020	10	30	PCR_COV_N2019	E Gene CT	14.04715879
2020	10	30	PCR_COV_N2019	E Gene CT	19.36650847
2020	10	30	PCR_COV_N2019	E Gene CT	16.87912813
2020	10	30	PCR_COV_N2019	E Gene CT	15.86508967
2020	10	30	PCR_COV_N2019	E Gene CT	19.94645382
2020	10	30	PCR_COV_N2019	E Gene CT	16.25768919
2020	10	30	PCR_COV_N2019	E Gene CT	20.8740366
2020	10	30	PCR_COV_N2019	E Gene CT	19.53644914
2020	10	30	PCR_COV_N2019	E Gene CT	29.547527
2020	10	30	PCR_COV_N2019	E Gene CT	18.95
2020	10	30	PCR_COV_N2019	E Gene CT	23.44326593
2020	10	30	PCR_COV_N2019	E Gene CT	14.5282056
2020	10	30	PCR_COV_N2019	E Gene CT	19.65602928
2020	10	30	PCR_FUSION_COV19_E	E Gene CT	34.7
2020	10	30	PCR_FUSION_COV19_E	E Gene CT	24.6
2020	10	30	PCR_FUSION_COV19_E	E Gene CT	31.6
2020	10	30	PCR_FUSION_COV19_E	E Gene CT	19.3
2020	10	30	PCR_FUSION_COV19_E	E Gene CT	27.5
2020	10	30	PCR_FUSION_COV19_E	E Gene CT	23.7
2020	10	30	PCR_FUSION_COV19_E	E Gene CT	18.3
2020	10	30	PCR_FUSION_COV19_E	E Gene CT	23.1
2020	10	30	PCR_FUSION_COV19_E	E Gene CT	27.4
2020	10	30	PCR_COV_N2019	E Gene CT	24.84964414
2020	10	30	PCR_COV_N2019	E Gene CT	17.63116841
2020	10	30	PCR_COV_N2019	E Gene CT	19.32920692
2020	10	30	PCR_COV_N2019	E Gene CT	17.08428574
2020	10	30	PCR_COV_N2019	E Gene CT	13.45944459
2020	10	30	PCR_FUSION_COV19_E	E Gene CT	18.5
2020	10	30	PCR_FUSION_COV19_E	E Gene CT	15.7
2020	10	30	PCR_FUSION_COV19_E	E Gene CT	17.7

AB941

2020	10	30	PCR_FUSION_COV19_E	E Gene CT	30.5
2020	10	30	PCR_FUSION_COV19_E	E Gene CT	33
2020	10	30	PCR_FUSION_COV19_E	E Gene CT	19.3
2020	10	30	PCR_FUSION_COV19_E	E Gene CT	37.3
2020	10	30	PCR_FUSION_COV19_E	E Gene CT	18
2020	10	30	PCR_FUSION_COV19_E	E Gene CT	23.9
2020	10	30	PCR_FUSION_COV19_E	E Gene CT	21.3
2020	10	30	PCR_FUSION_COV19_E	E Gene CT	18.4
2020	10	30	PCR_FUSION_COV19_E	E Gene CT	37.2
2020	10	30	PCR_FUSION_COV19_E	E Gene CT	18.8
2020	10	30	PCR_FUSION_COV19_E	E Gene CT	36
2020	10	30	PCR_COV_N2019	E Gene CT	19.33583545
2020	10	30	PCR_COV_N2019	E Gene CT	22.33614801
2020	10	30	PCR_COV_N2019	E Gene CT	19.03022918
2020	10	30	PCR_COV_N2019	E Gene CT	23.34140696
2020	10	30	PCR_COV_N2019	E Gene CT	16.74433647
2020	10	30	PCR_COV_N2019	E Gene CT	27.22254967
2020	10	30	PCR_COV_N2019	E Gene CT	23.37537698
2020	10	30	PCR_COV_N2019	E Gene CT	17.06093158
2020	10	30	PCR_COV_N2019	E Gene CT	15.90157421
2020	10	30	PCR_COV_N2019	E Gene CT	11.25761641
2020	10	30	PCR_COV_N2019	E Gene CT	16.30870157
2020	10	30	PCR_COV_N2019	E Gene CT	16.49235817
2020	10	30	PCR_COV_N2019	E Gene CT	26.06348416
2020	10	30	PCR_COV_N2019	E Gene CT	29.73465399
2020	10	30	PCR_COV_N2019	E Gene CT	17.68481595
2020	10	30	PCR_COV_N2019	E Gene CT	26.68525029
2020	10	30	PCR_COV_N2019	E Gene CT	31.47469284
2020	10	30	PCR_COV_N2019	E Gene CT	12.79273306
2020	10	30	PCR_COV_N2019	E Gene CT	27.60756819
2020	10	30	PCR_COV_N2019	E Gene CT	18.63101725
2020	10	30	PCR_FUSION_COV19_E	E Gene CT	22.6
2020	10	30	PCR_COV_N2019	E Gene CT	26.04492504
2020	10	30	PCR_COV_N2019	E Gene CT	14.02790769
2020	10	30	PCR_COV_N2019	E Gene CT	14.18512955
2020	10	31	PCR_COV_N2019	E Gene CT	30.11051435
2020	10	31	PCR_COV_N2019	E Gene CT	13.13920252
2020	10	31	PCR_COV_N2019	E Gene CT	16.96547762
2020	10	31	PCR_COV_N2019	E Gene CT	21.21463401
2020	10	31	PCR_COV_N2019	E Gene CT	30.89877094
2020	10	31	PCR_COV_N2019	E Gene CT	17.86902153
2020	10	31	PCR_COV_N2019	E Gene CT	16.27044006
2020	10	31	PCR_COV_N2019	E Gene CT	14.13964485
2020	10	31	PCR_COV_N2019	E Gene CT	14.21758548
2020	10	31	PCR_COV_N2019	E Gene CT	16.09846977
2020	10	31	PCR_COV_N2019	E Gene CT	26.46642067
2020	10	31	PCR_COV_N2019	E Gene CT	25.69881646

AB942

2020	10	31	PCR_COV_N2019	E Gene CT	22.27187503
2020	10	31	PCR_COV_N2019	E Gene CT	14.64310039
2020	10	31	PCR_COV_N2019	E Gene CT	18.85600785
2020	10	31	PCR_COV_N2019	E Gene CT	29.15215368
2020	10	31	PCR_COV_N2019	E Gene CT	17.42189049
2020	10	31	PCR_COV_N2019	E Gene CT	16.8491841
2020	10	31	PCR_COV_N2019	E Gene CT	20.51104714
2020	10	31	PCR_COV_N2019	E Gene CT	14.92851842
2020	10	31	PCR_COV_N2019	E Gene CT	19.6677923
2020	10	31	PCR_COV_N2019	E Gene CT	17.10257805
2020	10	31	PCR_COV_N2019	E Gene CT	32.01383219
2020	10	31	PCR_COV_N2019	E Gene CT	17.45103744
2020	10	31	PCR_COV_N2019	E Gene CT	17.83116781
2020	10	31	PCR_COV_N2019	E Gene CT	22.67153472
2020	10	31	PCR_COV_N2019	E Gene CT	31.56103055
2020	10	31	PCR_COV_N2019	E Gene CT	29.28560013
2020	10	31	PCR_COV_N2019	E Gene CT	15.7972534
2020	10	31	PCR_COV_N2019	E Gene CT	20.14493142
2020	10	31	PCR_COV_N2019	E Gene CT	22.29435714
2020	10	31	PCR_COV_N2019	E Gene CT	23.14220028
2020	10	31	PCR_COV_N2019	E Gene CT	22.31878698
2020	10	31	PCR_COV_N2019	E Gene CT	13.29754102
2020	10	31	PCR_COV_N2019	E Gene CT	13.11219399
2020	10	31	PCR_COV_N2019	E Gene CT	17.6349254
2020	10	31	PCR_COV_N2019	E Gene CT	32.70740555
2020	10	31	PCR_COV_N2019	E Gene CT	22.25330271
2020	10	31	PCR_COV_N2019	E Gene CT	20.29435187
2020	10	31	PCR_COV_N2019	E Gene CT	19.09115039
2020	10	31	PCR_COV_N2019	E Gene CT	14.97393324
2020	10	31	PCR_COV_N2019	E Gene CT	35.59943175
2020	10	31	PCR_COV_N2019	E Gene CT	15.35752634
2020	10	31	PCR_COV_N2019	E Gene CT	15.50125107
2020	10	31	PCR_COV_N2019	E Gene CT	13.92827866
2020	10	31	PCR_FUSION_COV19_E	E Gene CT	22.8
2020	10	31	PCR_FUSION_COV19_E	E Gene CT	18.6
2020	10	31	PCR_COV_N2019	E Gene CT	29.9162108
2020	10	31	PCR_COV_N2019	E Gene CT	13.01344271
2020	10	31	PCR_COV_N2019	E Gene CT	20.26770315
2020	10	31	PCR_COV_N2019	E Gene CT	12.78254551
2020	10	31	PCR_FUSION_COV19_E	E Gene CT	25.3
2020	10	31	PCR_COV_N2019	E Gene CT	24.31139726
2020	10	31	PCR_COV_N2019	E Gene CT	16.30483755
2020	10	31	PCR_COV_N2019	E Gene CT	16.20413474
2020	10	31	PCR_FUSION_COV19_E	E Gene CT	24.2
2020	10	31	PCR_COV_N2019	E Gene CT	15.77098359
2020	10	31	PCR_COV_N2019	E Gene CT	19.37304127
2020	11	1	PCR_COV_N2019	E Gene CT	23.32911747

AB943

2020	11	1	PCR_COV_N2019	E Gene CT	29.16177678
2020	11	1	PCR_COV_N2019	E Gene CT	28.61014644
2020	11	1	PCR_COV_N2019	E Gene CT	30.94246967
2020	11	1	PCR_COV_N2019	E Gene CT	30.8109355
2020	11	1	PCR_COV_N2019	E Gene CT	23.56079195
2020	11	1	PCR_COV_N2019	E Gene CT	17.54199917
2020	11	1	PCR_COV_N2019	E Gene CT	15.62403214
2020	11	1	PCR_COV_N2019	E Gene CT	18.22666625
2020	11	1	PCR_COV_N2019	E Gene CT	17.825912
2020	11	1	PCR_COV_N2019	E Gene CT	14.5152354
2020	11	1	PCR_COV_N2019	E Gene CT	14.43078055
2020	11	1	PCR_COV_N2019	E Gene CT	19.20911392
2020	11	1	PCR_COV_N2019	E Gene CT	19.03375536
2020	11	1	PCR_COV_N2019	E Gene CT	20.02791589
2020	11	1	PCR_COV_N2019	E Gene CT	25.05160345
2020	11	1	PCR_COV_N2019	E Gene CT	30.24553377
2020	11	1	PCR_COV_N2019	E Gene CT	30.35135868
2020	11	1	PCR_COV_N2019	E Gene CT	30.95442561
2020	11	1	PCR_COV_N2019	E Gene CT	27.89565902
2020	11	1	PCR_COV_N2019	E Gene CT	18.78654548
2020	11	1	PCR_COV_N2019	E Gene CT	29.00071432
2020	11	1	PCR_COV_N2019	E Gene CT	31.35111647
2020	11	1	PCR_COV_N2019	E Gene CT	15.11016791
2020	11	1	PCR_COV_N2019	E Gene CT	24.65934614
2020	11	1	PCR_COV_N2019	E Gene CT	26.67749163
2020	11	1	PCR_COV_N2019	E Gene CT	20.90921985
2020	11	1	PCR_COV_N2019	E Gene CT	20.47977598
2020	11	1	PCR_COV_N2019	E Gene CT	18.24820402
2020	11	1	PCR_COV_N2019	E Gene CT	19.15237444
2020	11	1	PCR_COV_N2019	E Gene CT	20.0347517
2020	11	1	PCR_COV_N2019	E Gene CT	28.12635496
2020	11	1	PCR_COV_N2019	E Gene CT	28.80117253
2020	11	1	PCR_COV_N2019	E Gene CT	19.39552041
2020	11	1	PCR_COV_N2019	E Gene CT	21.08687558
2020	11	1	PCR_COV_N2019	E Gene CT	18.47901978
2020	11	1	PCR_COV_N2019	E Gene CT	21.34621751
2020	11	1	PCR_COV_N2019	E Gene CT	20.42259345
2020	11	1	PCR_COV_N2019	E Gene CT	14.52507884
2020	11	1	PCR_COV_N2019	E Gene CT	15.62203933
2020	11	1	PCR_FUSION_COV19_E	E Gene CT	15.5
2020	11	1	PCR_FUSION_COV19_E	E Gene CT	22
2020	11	1	PCR_FUSION_COV19_E	E Gene CT	26.1
2020	11	1	PCR_FUSION_COV19_E	E Gene CT	23.3
2020	11	1	PCR_FUSION_COV19_E	E Gene CT	23.4
2020	11	1	PCR_FUSION_COV19_E	E Gene CT	21
2020	11	1	PCR_COV_N2019	E Gene CT	25.5722066
2020	11	1	PCR_COV_N2019	E Gene CT	29.73866573

AB944

2020	11	1	PCR_COV_N2019	E Gene CT	25.92445706
2020	11	1	PCR_COV_N2019	E Gene CT	17.68228668
2020	11	1	PCR_FUSION_COV19_E	E Gene CT	20.6
2020	11	1	PCR_FUSION_COV19_E	E Gene CT	18.8
2020	11	1	PCR_COV_N2019	E Gene CT	20.77178105
2020	11	1	PCR_COV_N2019	E Gene CT	18.74733148
2020	11	1	PCR_COV_N2019	E Gene CT	14.8485721
2020	11	1	PCR_COV_N2019	E Gene CT	17.42316422
2020	11	1	PCR_FUSION_COV19_E	E Gene CT	23
2020	11	1	PCR_FUSION_COV19_E	E Gene CT	31.3
2020	11	1	PCR_COBAS_COV19	CT 2	16.94
2020	11	2	PCR_COV_N2019	E Gene CT	22.01022627
2020	11	2	PCR_COV_N2019	E Gene CT	37.54223394
2020	11	2	PCR_COV_N2019	E Gene CT	17.89029969
2020	11	2	PCR_COV_N2019	E Gene CT	23.87397321
2020	11	2	PCR_COV_N2019	E Gene CT	21.55324168
2020	11	2	PCR_COV_N2019	E Gene CT	16.62
2020	11	2	PCR_COV_N2019	E Gene CT	22.16247318
2020	11	2	PCR_COV_N2019	E Gene CT	18.52575272
2020	11	2	PCR_COV_N2019	E Gene CT	18.67129408
2020	11	2	PCR_COV_N2019	E Gene CT	18.2587272
2020	11	2	PCR_COV_N2019	E Gene CT	21.06993448
2020	11	2	PCR_COV_N2019	E Gene CT	21.22542609
2020	11	2	PCR_COV_N2019	E Gene CT	31.54067864
2020	11	2	PCR_COV_N2019	E Gene CT	16.87819592
2020	11	2	PCR_COV_N2019	E Gene CT	32.04340282
2020	11	2	PCR_COV_N2019	E Gene CT	16.86636233
2020	11	2	PCR_COV_N2019	E Gene CT	17.99272791
2020	11	2	PCR_COV_N2019	E Gene CT	15.61723748
2020	11	2	PCR_COV_N2019	E Gene CT	13.34788646
2020	11	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.47337947
2020	11	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.38081633
2020	11	2	PCR_FUSION_COV19_E	E Gene CT	24.1
2020	11	2	PCR_FUSION_COV19_E	E Gene CT	29.6
2020	11	2	PCR_FUSION_COV19_E	E Gene CT	37.7
2020	11	2	PCR_COV_N2019	E Gene CT	23.6599789
2020	11	2	PCR_COV_N2019	E Gene CT	27.38935878
2020	11	2	PCR_COV_N2019	E Gene CT	23.46628342
2020	11	2	PCR_COV_N2019	E Gene CT	17.16973954
2020	11	2	PCR_COV_N2019	E Gene CT	17.07755439
2020	11	2	PCR_COV_N2019	E Gene CT	15.54580327
2020	11	2	PCR_FUSION_COV19_E	E Gene CT	29.5
2020	11	2	PCR_COV_N2019	E Gene CT	21.64391457
2020	11	2	PCR_COV_N2019	E Gene CT	18.75917482
2020	11	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.27455309
2020	11	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.56015801
2020	11	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.29299281

2020	11	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.35294857
2020	11	2	PCR_COV_N2019	E Gene CT	18.12540801
2020	11	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.72415859
2020	11	2	PCR_COV_N2019	E Gene CT	28.69051727
2020	11	2	PCR_COV_N2019	E Gene CT	19.30868102
2020	11	2	PCR_COV_N2019	E Gene CT	23.16467751
2020	11	2	PCR_COV_N2019	E Gene CT	27.92907276
2020	11	2	PCR_FUSION_COV19_E	E Gene CT	19.4
2020	11	2	PCR_FUSION_COV19_E	E Gene CT	37.6
2020	11	2	PCR_FUSION_COV19_E	E Gene CT	22
2020	11	2	PCR_FUSION_COV19_E	E Gene CT	20.7
2020	11	2	PCR_FUSION_COV19_E	E Gene CT	17.2
2020	11	3	PCR_COV_N2019	E Gene CT	18.93141835
2020	11	3	PCR_COV_N2019	E Gene CT	23.43027937
2020	11	3	PCR_COV_N2019	E Gene CT	15.64982655
2020	11	3	PCR_COV_N2019	E Gene CT	19.86684269
2020	11	3	PCR_COV_N2019	E Gene CT	19.53398406
2020	11	3	PCR_COV_N2019	E Gene CT	21.8114997
2020	11	3	PCR_COBAS_COV19	CT 2	17.41
2020	11	3	PCR_COV_N2019	E Gene CT	16.28301874
2020	11	3	PCR_COV_N2019	E Gene CT	17.7273129
2020	11	3	PCR_COV_N2019	E Gene CT	16.00132344
2020	11	3	PCR_COV_N2019	E Gene CT	19.8907377
2020	11	3	PCR_COV_N2019	E Gene CT	11.72590728
2020	11	3	PCR_COV_N2019	E Gene CT	31.72861861
2020	11	3	PCR_COV_N2019	E Gene CT	33.33882098
2020	11	3	PCR_COV_N2019	E Gene CT	30.15736
2020	11	3	PCR_COV_N2019	E Gene CT	23.26029522
2020	11	3	PCR_COV_N2019	E Gene CT	15.95959508
2020	11	3	PCR_COV_N2019	E Gene CT	16.0266747
2020	11	3	PCR_COV_N2019	E Gene CT	15.29178198
2020	11	3	PCR_COV_N2019	E Gene CT	18.03939801
2020	11	3	PCR_COV_N2019	E Gene CT	18.11608081
2020	11	3	PCR_COV_N2019	E Gene CT	16.03150635
2020	11	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.05806435
2020	11	3	PCR_FUSION_COV19_E	E Gene CT	35.9
2020	11	3	PCR_FUSION_COV19_E	E Gene CT	37.3
2020	11	3	PCR_FUSION_COV19_E	E Gene CT	17.3
2020	11	3	PCR_FUSION_COV19_E	E Gene CT	24.1
2020	11	3	PCR_COV_N2019	E Gene CT	29.49970234
2020	11	3	PCR_COV_N2019	E Gene CT	36.32090298
2020	11	3	PCR_COV_N2019	E Gene CT	13.06069951
2020	11	3	PCR_COV_N2019	E Gene CT	27.73920413
2020	11	3	PCR_COV_N2019	E Gene CT	29.7894651
2020	11	3	PCR_COV_N2019	E Gene CT	26.47685136
2020	11	3	PCR_COV_N2019	E Gene CT	17.33029776
2020	11	3	PCR_FUSION_COV19_E	E Gene CT	16.4

AB946

2020	11	3	PCR_FUSION_COV19_E	E Gene CT	28.1
2020	11	3	PCR_FUSION_COV19_E	E Gene CT	25.6
2020	11	3	PCR_COV_N2019	E Gene CT	21.3573086
2020	11	3	PCR_COV_N2019	E Gene CT	19.86575681
2020	11	3	PCR_COV_N2019	E Gene CT	30.99392056
2020	11	3	PCR_COV_N2019	E Gene CT	19.38084915
2020	11	3	PCR_COV_N2019	E Gene CT	30.55357585
2020	11	3	PCR_COV_N2019	E Gene CT	18.36958412
2020	11	3	PCR_FUSION_COV19_E	E Gene CT	27.2
2020	11	3	PCR_FUSION_COV19_E	E Gene CT	34.2
2020	11	3	PCR_FUSION_COV19_E	E Gene CT	21
2020	11	3	PCR_FUSION_COV19_E	E Gene CT	20.6
2020	11	3	PCR_FUSION_COV19_E	E Gene CT	16.9
2020	11	3	PCR_COV_N2019	E Gene CT	30.54659789
2020	11	3	PCR_COV_N2019	E Gene CT	32.71584394
2020	11	3	PCR_COV_N2019	E Gene CT	14.66524615
2020	11	3	PCR_COV_N2019	E Gene CT	21.09527342
2020	11	3	PCR_COV_N2019	E Gene CT	29.21351323
2020	11	3	PCR_COV_N2019	E Gene CT	37.91357351
2020	11	3	PCR_FUSION_COV19_E	E Gene CT	28.3
2020	11	3	PCR_FUSION_COV19_E	E Gene CT	17.8
2020	11	3	PCR_FUSION_COV19_E	E Gene CT	24.3
2020	11	3	PCR_FUSION_COV19_E	E Gene CT	18.5
2020	11	3	PCR_FUSION_COV19_E	E Gene CT	23.5
2020	11	3	PCR_FUSION_COV19_E	E Gene CT	24.5
2020	11	3	PCR_COV_N2019	E Gene CT	15.29337861
2020	11	3	PCR_COV_N2019	E Gene CT	20.57746151
2020	11	3	PCR_COV_N2019	E Gene CT	20.62696617
2020	11	3	PCR_COV_N2019	E Gene CT	14.38336492
2020	11	3	PCR_COV_N2019	E Gene CT	12.85603244
2020	11	3	PCR_FUSION_COV19_E	E Gene CT	31.3
2020	11	3	PCR_COV_N2019	E Gene CT	20.38793178
2020	11	3	PCR_FUSION_COV19_E	E Gene CT	17.2
2020	11	3	PCR_COV_N2019	E Gene CT	15.70010678
2020	11	3	PCR_COV_N2019	E Gene CT	14.75893241
2020	11	3	PCR_COV_N2019	E Gene CT	29.87584574
2020	11	3	PCR_COV_N2019	E Gene CT	18.62250002
2020	11	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.83741288
2020	11	4	PCR_COV_N2019	E Gene CT	13.86008662
2020	11	4	PCR_COV_N2019	E Gene CT	17.96176722
2020	11	4	PCR_COV_N2019	E Gene CT	35.67362851
2020	11	4	PCR_COV_N2019	E Gene CT	22.54061346
2020	11	4	PCR_COV_N2019	E Gene CT	28.27762238
2020	11	4	PCR_COV_N2019	E Gene CT	15.73259427
2020	11	4	PCR_COV_N2019	E Gene CT	31.00404742
2020	11	4	PCR_COV_N2019	E Gene CT	29.71459171
2020	11	4	PCR_COV_N2019	E Gene CT	12.03282097

AB947

2020	11	4	PCR_COV_N2019	E Gene CT	27.97733039
2020	11	4	PCR_COV_N2019	E Gene CT	12.57437762
2020	11	4	PCR_COV_N2019	E Gene CT	17.06442429
2020	11	4	PCR_COV_N2019	E Gene CT	19.16389006
2020	11	4	PCR_COV_N2019	E Gene CT	15.1025444
2020	11	4	PCR_COV_N2019	E Gene CT	13.68545754
2020	11	4	PCR_COV_N2019	E Gene CT	29.87892248
2020	11	4	PCR_COV_N2019	E Gene CT	14.25740599
2020	11	4	PCR_COV_N2019	E Gene CT	19.08864785
2020	11	4	PCR_COV_N2019	E Gene CT	15.59168166
2020	11	4	PCR_COV_N2019	E Gene CT	24.3703345
2020	11	4	PCR_COV_N2019	E Gene CT	26.45368201
2020	11	4	PCR_COV_N2019	E Gene CT	18.42971796
2020	11	4	PCR_COV_N2019	E Gene CT	31.22352622
2020	11	4	PCR_COV_N2019	E Gene CT	27.90992255
2020	11	4	PCR_COV_N2019	E Gene CT	23.45244496
2020	11	4	PCR_COV_N2019	E Gene CT	37.74364253
2020	11	4	PCR_COV_N2019	E Gene CT	16.32436779
2020	11	4	PCR_COV_N2019	E Gene CT	28.60849192
2020	11	4	PCR_COV_N2019	E Gene CT	13.54944406
2020	11	4	PCR_COV_N2019	E Gene CT	17.54176329
2020	11	4	PCR_COV_N2019	E Gene CT	35.63510841
2020	11	4	PCR_COV_N2019	E Gene CT	27.05083939
2020	11	4	PCR_COV_N2019	E Gene CT	16.79396133
2020	11	4	PCR_FUSION_COV19_E	E Gene CT	30.2
2020	11	4	PCR_FUSION_COV19_E	E Gene CT	28.3
2020	11	4	PCR_FUSION_COV19_E	E Gene CT	32.1
2020	11	4	PCR_FUSION_COV19_E	E Gene CT	26.2
2020	11	4	PCR_FUSION_COV19_E	E Gene CT	18
2020	11	4	PCR_FUSION_COV19_E	E Gene CT	30.7
2020	11	4	PCR_FUSION_COV19_E	E Gene CT	24.7
2020	11	4	PCR_FUSION_COV19_E	E Gene CT	25.5
2020	11	4	PCR_FUSION_COV19_E	E Gene CT	27.1
2020	11	4	PCR_FUSION_COV19_E	E Gene CT	30.3
2020	11	4	PCR_FUSION_COV19_E	E Gene CT	27.3
2020	11	4	PCR_FUSION_COV19_E	E Gene CT	26.6
2020	11	4	PCR_COV_N2019	E Gene CT	33.77833689
2020	11	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.54
2020	11	4	PCR_COV_N2019	E Gene CT	11.24467423
2020	11	4	PCR_COV_N2019	E Gene CT	13.26009538
2020	11	4	PCR_COV_N2019	E Gene CT	25.50338261
2020	11	4	PCR_COV_N2019	E Gene CT	10.5009039
2020	11	4	PCR_COV_N2019	E Gene CT	11.50655892
2020	11	4	PCR_COV_N2019	E Gene CT	17.02752015
2020	11	4	PCR_COV_N2019	E Gene CT	11.852873
2020	11	4	PCR_COV_N2019	E Gene CT	13.04452668
2020	11	4	PCR_COV_N2019	E Gene CT	13.01560419

AB948

2020	11	4	PCR_COV_N2019	E Gene CT	23.17443335
2020	11	4	PCR_COV_N2019	E Gene CT	25.5803207
2020	11	4	PCR_COV_N2019	E Gene CT	14.00291591
2020	11	4	PCR_COV_N2019	E Gene CT	33.16674753
2020	11	4	PCR_COV_N2019	E Gene CT	17.1970805
2020	11	4	PCR_COV_N2019	E Gene CT	22.10179428
2020	11	4	PCR_COV_N2019	E Gene CT	16.22888315
2020	11	4	PCR_COV_N2019	E Gene CT	32.5141105
2020	11	4	PCR_COV_N2019	E Gene CT	11.35691353
2020	11	4	PCR_COV_N2019	E Gene CT	13.28650976
2020	11	4	PCR_COV_N2019	E Gene CT	27.78137113
2020	11	4	PCR_COV_N2019	E Gene CT	34.33367753
2020	11	4	PCR_COV_N2019	E Gene CT	16.80615708
2020	11	4	PCR_COV_N2019	E Gene CT	20.9803782
2020	11	4	PCR_COV_N2019	E Gene CT	12.48897873
2020	11	4	PCR_COV_N2019	E Gene CT	16.21528037
2020	11	4	PCR_COV_N2019	E Gene CT	29.00220159
2020	11	4	PCR_COV_N2019	E Gene CT	29.02854926
2020	11	4	PCR_COV_N2019	E Gene CT	16.32374568
2020	11	4	PCR_COV_N2019	E Gene CT	25.07290002
2020	11	4	PCR_COV_N2019	E Gene CT	16.65081726
2020	11	4	PCR_COV_N2019	E Gene CT	17.52777896
2020	11	4	PCR_COV_N2019	E Gene CT	26.09232619
2020	11	4	PCR_COV_N2019	E Gene CT	12.07374517
2020	11	4	PCR_COV_N2019	E Gene CT	12.456725
2020	11	4	PCR_COV_N2019	E Gene CT	20.15349904
2020	11	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.9693794
2020	11	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.60123791
2020	11	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.97210811
2020	11	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.18038129
2020	11	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.37965951
2020	11	4	PCR_FUSION_COV19_E	E Gene CT	30.4
2020	11	4	PCR_FUSION_COV19_E	E Gene CT	17.8
2020	11	4	PCR_FUSION_COV19_E	E Gene CT	28.2
2020	11	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.54514011
2020	11	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.51298338
2020	11	4	PCR_COBAS_COV19	CT 2	24.06
2020	11	5	PCR_COV_N2019	E Gene CT	31.37150768
2020	11	5	PCR_COV_N2019	E Gene CT	12.15744761
2020	11	5	PCR_COV_N2019	E Gene CT	25.13030637
2020	11	5	PCR_COV_N2019	E Gene CT	22.23016986
2020	11	5	PCR_COV_N2019	E Gene CT	27.1736387
2020	11	5	PCR_COV_N2019	E Gene CT	22.22028804
2020	11	5	PCR_COV_N2019	E Gene CT	19.81495463
2020	11	5	PCR_COV_N2019	E Gene CT	21.58815745
2020	11	5	PCR_COV_N2019	E Gene CT	22.05492543
2020	11	5	PCR_COV_N2019	E Gene CT	22.06600712

AB949

2020	11	5	PCR_COV_N2019	E Gene CT	22.24561682
2020	11	5	PCR_COV_N2019	E Gene CT	31.20125979
2020	11	5	PCR_COV_N2019	E Gene CT	29.48313026
2020	11	5	PCR_COV_N2019	E Gene CT	21.51425037
2020	11	5	PCR_COV_N2019	E Gene CT	17.94011321
2020	11	5	PCR_COV_N2019	E Gene CT	28.64012986
2020	11	5	PCR_COV_N2019	E Gene CT	26.93067478
2020	11	5	PCR_COV_N2019	E Gene CT	18.10729091
2020	11	5	PCR_COV_N2019	E Gene CT	29.94570011
2020	11	5	PCR_COV_N2019	E Gene CT	29.74076207
2020	11	5	PCR_COV_N2019	E Gene CT	14.94831471
2020	11	5	PCR_COV_N2019	E Gene CT	24.13585271
2020	11	5	PCR_COV_N2019	E Gene CT	30.55382075
2020	11	5	PCR_COV_N2019	E Gene CT	13.41595149
2020	11	5	PCR_COV_N2019	E Gene CT	13.5
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	17.7
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	21.3
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	17.4
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	18.1
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	20.2
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	17
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	16.8
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	29.3
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	22.5
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	29.1
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	29.9
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	17.5
2020	11	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.67730275
2020	11	5	PCR_COV_N2019	E Gene CT	15.15987797
2020	11	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.15245913
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	23.9
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	28.1
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	22.5
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	33.2
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	28.4
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	29.4
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	27.5
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	29.8
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	23
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	36.4
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	19.3
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	27
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	26.7
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	27.2
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	35.5
2020	11	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.26799293
2020	11	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.20890977

2020	11	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.91414835
2020	11	5	PCR_COV_N2019	E Gene CT	15.48630036
2020	11	5	PCR_COV_N2019	E Gene CT	34.4778532
2020	11	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.36362697
2020	11	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.31485973
2020	11	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.80649975
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	28
2020	11	5	PCR_FUSION_COV19_E	E Gene CT	33.4
2020	11	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.25590864
2020	11	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.10024321
2020	11	5	PCR_COV_N2019	E Gene CT	14.90086886
2020	11	5	PCR_COV_N2019	E Gene CT	32.1399284
2020	11	5	PCR_COV_N2019	E Gene CT	20.52150161
2020	11	5	PCR_COV_N2019	E Gene CT	15.16967912
2020	11	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.67437394
2020	11	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.69241465
2020	11	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.36916911
2020	11	6	PCR_COV_N2019	E Gene CT	13.93191936
2020	11	6	PCR_COBAS_COV19	CT 2	16.52
2020	11	6	PCR_COBAS_COV19	CT 2	18.5
2020	11	6	PCR_COBAS_COV19	CT 2	15.12
2020	11	6	PCR_COBAS_COV19	CT 2	24.15
2020	11	6	PCR_COBAS_COV19	CT 2	34.32
2020	11	6	PCR_COBAS_COV19	CT 2	22.34
2020	11	6	PCR_COBAS_COV19	CT 2	23.12
2020	11	6	PCR_COBAS_COV19	CT 2	32.58
2020	11	6	PCR_COBAS_COV19	CT 2	30.85
2020	11	6	PCR_COBAS_COV19	CT 2	16.46
2020	11	6	PCR_COBAS_COV19	CT 2	16.67
2020	11	6	PCR_COBAS_COV19	CT 2	22.16
2020	11	6	PCR_COBAS_COV19	CT 2	26.37
2020	11	6	PCR_COBAS_COV19	CT 2	23.59
2020	11	6	PCR_COBAS_COV19	CT 2	17.41
2020	11	6	PCR_COBAS_COV19	CT 2	32.5
2020	11	6	PCR_COBAS_COV19	CT 2	33.96
2020	11	6	PCR_COBAS_COV19	CT 2	16.11
2020	11	6	PCR_COBAS_COV19	CT 2	19.53
2020	11	6	PCR_COBAS_COV19	CT 2	19.59
2020	11	6	PCR_COBAS_COV19	CT 2	23.79
2020	11	6	PCR_COBAS_COV19	CT 2	34.44
2020	11	6	PCR_COBAS_COV19	CT 2	27.61
2020	11	6	PCR_COBAS_COV19	CT 2	15.99
2020	11	6	PCR_COBAS_COV19	CT 2	32.46
2020	11	6	PCR_COBAS_COV19	CT 2	22.66
2020	11	6	PCR_COBAS_COV19	CT 2	19.68
2020	11	6	PCR_COBAS_COV19	CT 2	17.1
2020	11	6	PCR_COBAS_COV19	CT 2	23.2

AB951

2020	11	6	PCR_COBAS_COV19	CT 2	20.58
2020	11	6	PCR_COBAS_COV19	CT 2	17.22
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.66108758
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.30291953
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.27660752
2020	11	6	PCR_FUSION_COV19_E	E Gene CT	16.3
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.2566077
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.35646459
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.22172338
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.15478599
2020	11	6	PCR_COV_N2019	E Gene CT	34.09187389
2020	11	6	PCR_FUSION_COV19_E	E Gene CT	22.7
2020	11	6	PCR_COV_N2019	E Gene CT	9.769696975
2020	11	6	PCR_COV_N2019	E Gene CT	21.88105246
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.44390082
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.05645035
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.93928363
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.53823921
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.24830713
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.86145306
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.27300237
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.08874297
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.59700142
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.28693403
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.5294939
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.29895858
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.83611806
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.33862444
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.5995776
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.67146811
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.21014439
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.22209652
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.05495952
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.60875702
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.96389901
2020	11	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.19330519
2020	11	7	PCR_PANTH_COV19	RLU	1175
2020	11	7	PCR_COBAS_COV19	CT 2	18
2020	11	7	PCR_COBAS_COV19	CT 2	22.58
2020	11	7	PCR_COBAS_COV19	CT 2	34.38
2020	11	7	PCR_COBAS_COV19	CT 2	17.29
2020	11	7	PCR_COBAS_COV19	CT 2	17.92
2020	11	7	PCR_COBAS_COV19	CT 2	18.74
2020	11	7	PCR_COBAS_COV19	CT 2	20.59
2020	11	7	PCR_COBAS_COV19	CT 2	14.79
2020	11	7	PCR_COBAS_COV19	CT 2	19.68
2020	11	7	PCR_COBAS_COV19	CT 2	20.03

AB952

2020	11	7	PCR_COBAS_COV19	CT 2	28.2
2020	11	7	PCR_COBAS_COV19	CT 2	33.73
2020	11	7	PCR_COBAS_COV19	CT 2	22.96
2020	11	7	PCR_COBAS_COV19	CT 2	18.25
2020	11	7	PCR_COBAS_COV19	CT 2	31.71
2020	11	7	PCR_COBAS_COV19	CT 2	20.25
2020	11	7	PCR_COBAS_COV19	CT 2	18.09
2020	11	7	PCR_COBAS_COV19	CT 2	17.3
2020	11	7	PCR_COBAS_COV19	CT 2	30.8
2020	11	7	PCR_COBAS_COV19	CT 2	15.66
2020	11	7	PCR_COBAS_COV19	CT 2	34.88
2020	11	7	PCR_COBAS_COV19	CT 2	18.48
2020	11	7	PCR_COBAS_COV19	CT 2	33.2
2020	11	7	PCR_COBAS_COV19	CT 2	19.14
2020	11	7	PCR_COBAS_COV19	CT 2	31.89
2020	11	7	PCR_COBAS_COV19	CT 2	33.23
2020	11	7	PCR_COBAS_COV19	CT 2	20.93
2020	11	7	PCR_COBAS_COV19	CT 2	27.54
2020	11	7	PCR_COBAS_COV19	CT 2	16.01
2020	11	7	PCR_COBAS_COV19	CT 2	19.09
2020	11	7	PCR_COBAS_COV19	CT 2	31.6
2020	11	7	PCR_COBAS_COV19	CT 2	25.77
2020	11	7	PCR_COBAS_COV19	CT 2	33.25
2020	11	7	PCR_COBAS_COV19	CT 2	34.18
2020	11	7	PCR_COBAS_COV19	CT 2	20.42
2020	11	7	PCR_COBAS_COV19	CT 2	35.3
2020	11	7	PCR_COBAS_COV19	CT 2	28.96
2020	11	7	PCR_COBAS_COV19	CT 2	33.11
2020	11	7	PCR_COBAS_COV19	CT 2	22.87
2020	11	7	PCR_COBAS_COV19	CT 2	21.01
2020	11	7	PCR_COBAS_COV19	CT 2	17.74
2020	11	7	PCR_COBAS_COV19	CT 2	17.39
2020	11	7	PCR_COBAS_COV19	CT 2	19.4
2020	11	7	PCR_COBAS_COV19	CT 2	22.54
2020	11	7	PCR_COBAS_COV19	CT 2	26.55
2020	11	7	PCR_COBAS_COV19	CT 2	33.63
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.25690139
2020	11	7	PCR_COBAS_COV19	CT 2	37.58
2020	11	7	PCR_COBAS_COV19	CT 2	19.21
2020	11	7	PCR_FUSION_COV19_E	E Gene CT	26.1
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.12524629
2020	11	7	PCR_COBAS_COV19	CT 2	30.5
2020	11	7	PCR_COBAS_COV19	CT 2	38.47
2020	11	7	PCR_COBAS_COV19	CT 2	25.92
2020	11	7	PCR_COBAS_COV19	CT 2	17.38
2020	11	7	PCR_COBAS_COV19	CT 2	23.18
2020	11	7	PCR_COBAS_COV19	CT 2	34.73

AB953

2020	11	7	PCR_COBAS_COV19	CT 2	20.78
2020	11	7	PCR_COBAS_COV19	CT 2	18.68
2020	11	7	PCR_FUSION_COV19_E	E Gene CT	31.2
2020	11	7	PCR_FUSION_COV19_E	E Gene CT	25.4
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.95782708
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.76812828
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.89035055
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.55782423
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.88541616
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.79397153
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.94357684
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.28297552
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.89042546
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.67866662
2020	11	7	PCR_FUSION_COV19_E	E Gene CT	19.9
2020	11	7	PCR_FUSION_COV19_E	E Gene CT	32.1
2020	11	7	PCR_FUSION_COV19_E	E Gene CT	34.6
2020	11	7	PCR_FUSION_COV19_E	E Gene CT	30.6
2020	11	7	PCR_FUSION_COV19_E	E Gene CT	27.1
2020	11	7	PCR_FUSION_COV19_E	E Gene CT	27.1
2020	11	7	PCR_FUSION_COV19_E	E Gene CT	36.8
2020	11	7	PCR_FUSION_COV19_E	E Gene CT	33.1
2020	11	7	PCR_FUSION_COV19_E	E Gene CT	26.2
2020	11	7	PCR_FUSION_COV19_E	E Gene CT	18.2
2020	11	7	PCR_FUSION_COV19_E	E Gene CT	32.5
2020	11	7	PCR_FUSION_COV19_E	E Gene CT	20.9
2020	11	7	PCR_FUSION_COV19_E	E Gene CT	32.9
2020	11	7	PCR_FUSION_COV19_E	E Gene CT	36.7
2020	11	7	PCR_FUSION_COV19_E	E Gene CT	24.8
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.16163228
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.8599272
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.69533791
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.63301612
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.88412209
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.1895263
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.27719714
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.04997864
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.69463407
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.79474884
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.99481613
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.97689972
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.4013955
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.06122582
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.62743121
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.91491939
2020	11	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.0071075
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.7718319

AB954

2020	11	8	PCR_COBAS_COV19	CT 2	25.01
2020	11	8	PCR_COBAS_COV19	CT 2	21.63
2020	11	8	PCR_COBAS_COV19	CT 2	19.09
2020	11	8	PCR_COBAS_COV19	CT 2	24.5
2020	11	8	PCR_COBAS_COV19	CT 2	16.55
2020	11	8	PCR_COBAS_COV19	CT 2	32.79
2020	11	8	PCR_COBAS_COV19	CT 2	24.92
2020	11	8	PCR_COBAS_COV19	CT 2	23.56
2020	11	8	PCR_COBAS_COV19	CT 2	17.7
2020	11	8	PCR_COBAS_COV19	CT 2	20.67
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.86737531
2020	11	8	PCR_COBAS_COV19	CT 2	16.9
2020	11	8	PCR_COBAS_COV19	CT 2	14.69
2020	11	8	PCR_COBAS_COV19	CT 2	20.74
2020	11	8	PCR_COBAS_COV19	CT 2	34.76
2020	11	8	PCR_COBAS_COV19	CT 2	24.24
2020	11	8	PCR_COBAS_COV19	CT 2	29.25
2020	11	8	PCR_COBAS_COV19	CT 2	24.45
2020	11	8	PCR_COBAS_COV19	CT 2	34.55
2020	11	8	PCR_COBAS_COV19	CT 2	35.85
2020	11	8	PCR_COBAS_COV19	CT 2	32.13
2020	11	8	PCR_COBAS_COV19	CT 2	34.03
2020	11	8	PCR_COBAS_COV19	CT 2	35.16
2020	11	8	PCR_COBAS_COV19	CT 2	30.89
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.14611384
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.04100551
2020	11	8	PCR_FUSION_COV19_E	E Gene CT	23.5
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.62082601
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.94974676
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.84541481
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.07149759
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.55500326
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.59756513
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.44778327
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.1910975
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.39600977
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.18290666
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.12996607
2020	11	8	PCR_FUSION_COV19_E	E Gene CT	18.2
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.69280451
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.1908134
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.03403352
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.51122677
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.25419113
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.78856845
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.53357623
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.02468676

AB955

2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.25825183
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.70835354
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.7319231
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.72962896
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.68249739
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.3185878
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.17982796
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.45646702
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.18237681
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.26090699
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.40933908
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.9572764
2020	11	8	PCR_COV_N2019	E Gene CT	24.47986022
2020	11	8	PCR_COV_N2019	E Gene CT	26.63170669
2020	11	8	PCR_COV_N2019	E Gene CT	22.78947037
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.90369074
2020	11	8	PCR_COV_N2019	E Gene CT	26.39410366
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.26728348
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.02068901
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.39853801
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.90208778
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.05123939
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.38810357
2020	11	8	PCR_COV_N2019	E Gene CT	34.66842263
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.12971582
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.29650413
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.12772334
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.11628427
2020	11	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.99569627
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.77744138
2020	11	9	PCR_COBAS_COV19	CT 2	35.89
2020	11	9	PCR_COBAS_COV19	CT 2	22.82
2020	11	9	PCR_COBAS_COV19	CT 2	27.68
2020	11	9	PCR_COBAS_COV19	CT 2	18.17
2020	11	9	PCR_COBAS_COV19	CT 2	21.11
2020	11	9	PCR_COBAS_COV19	CT 2	20.99
2020	11	9	PCR_COBAS_COV19	CT 2	19.8
2020	11	9	PCR_COBAS_COV19	CT 2	27.01
2020	11	9	PCR_COBAS_COV19	CT 2	29.85
2020	11	9	PCR_COBAS_COV19	CT 2	18.72
2020	11	9	PCR_COBAS_COV19	CT 2	20.9
2020	11	9	PCR_COBAS_COV19	CT 2	33.48
2020	11	9	PCR_COBAS_COV19	CT 2	27.64
2020	11	9	PCR_COBAS_COV19	CT 2	34.08
2020	11	9	PCR_COBAS_COV19	CT 2	23.85
2020	11	9	PCR_COBAS_COV19	CT 2	13.69
2020	11	9	PCR_COBAS_COV19	CT 2	28.5

AB956

2020	11	9	PCR_COBAS_COV19	CT 2	19.47
2020	11	9	PCR_COBAS_COV19	CT 2	31.47
2020	11	9	PCR_COBAS_COV19	CT 2	23.2
2020	11	9	PCR_COBAS_COV19	CT 2	36.24
2020	11	9	PCR_COBAS_COV19	CT 2	33.62
2020	11	9	PCR_COBAS_COV19	CT 2	18.62
2020	11	9	PCR_COBAS_COV19	CT 2	21.77
2020	11	9	PCR_COBAS_COV19	CT 2	30.99
2020	11	9	PCR_COBAS_COV19	CT 2	16.38
2020	11	9	PCR_COBAS_COV19	CT 2	18.03
2020	11	9	PCR_COBAS_COV19	CT 2	27.89
2020	11	9	PCR_COBAS_COV19	CT 2	17.59
2020	11	9	PCR_COBAS_COV19	CT 2	14.92
2020	11	9	PCR_COBAS_COV19	CT 2	20.2
2020	11	9	PCR_COBAS_COV19	CT 2	36.71
2020	11	9	PCR_COBAS_COV19	CT 2	37.1
2020	11	9	PCR_COBAS_COV19	CT 2	19.19
2020	11	9	PCR_COBAS_COV19	CT 2	17.63
2020	11	9	PCR_COBAS_COV19	CT 2	27.28
2020	11	9	PCR_COBAS_COV19	CT 2	21.95
2020	11	9	PCR_COBAS_COV19	CT 2	35.23
2020	11	9	PCR_COBAS_COV19	CT 2	27.17
2020	11	9	PCR_COBAS_COV19	CT 2	29.76
2020	11	9	PCR_COBAS_COV19	CT 2	22.15
2020	11	9	PCR_COBAS_COV19	CT 2	23.44
2020	11	9	PCR_FUSION_COV19_E	E Gene CT	35.4
2020	11	9	PCR_FUSION_COV19_E	E Gene CT	32
2020	11	9	PCR_FUSION_COV19_E	E Gene CT	28.9
2020	11	9	PCR_FUSION_COV19_E	E Gene CT	32.5
2020	11	9	PCR_FUSION_COV19_E	E Gene CT	15.3
2020	11	9	PCR_FUSION_COV19_E	E Gene CT	22.1
2020	11	9	PCR_FUSION_COV19_E	E Gene CT	18.6
2020	11	9	PCR_FUSION_COV19_E	E Gene CT	19.3
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.42682375
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.73548084
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.67474473
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.27982798
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.35176686
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.0673128
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.99421618
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.58045948
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.8466974
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.37246201
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.24146627
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.22219844
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.43498077
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.98503737

AB957

2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.71539703
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.86267965
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.57955622
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.91418601
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.05320565
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.75285303
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.15294445
2020	11	9	PCR_COV_N2019	E Gene CT	11.73473808
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.66774059
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.62373362
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.08280644
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.71764967
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.70050788
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.59858851
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.82662563
2020	11	9	PCR_FUSION_COV19_E	E Gene CT	29.3
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.13447637
2020	11	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.71581136
2020	11	10	PCR_COV_N2019	E Gene CT	33.95857413
2020	11	10	PCR_COV_N2019	E Gene CT	36.70146163
2020	11	10	PCR_COV_N2019	E Gene CT	32.61910206
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.05758543
2020	11	10	PCR_COBAS_COV19	CT 2	20.54
2020	11	10	PCR_COBAS_COV19	CT 2	16.78
2020	11	10	PCR_COBAS_COV19	CT 2	17.85
2020	11	10	PCR_COBAS_COV19	CT 2	16.67
2020	11	10	PCR_COBAS_COV19	CT 2	32.34
2020	11	10	PCR_COBAS_COV19	CT 2	21.58
2020	11	10	PCR_COBAS_COV19	CT 2	32.88
2020	11	10	PCR_COBAS_COV19	CT 2	17.94
2020	11	10	PCR_COBAS_COV19	CT 2	32.48
2020	11	10	PCR_COBAS_COV19	CT 2	24.34
2020	11	10	PCR_COBAS_COV19	CT 2	20.23
2020	11	10	PCR_COBAS_COV19	CT 2	36.5
2020	11	10	PCR_COBAS_COV19	CT 2	16.42
2020	11	10	PCR_COBAS_COV19	CT 2	17.55
2020	11	10	PCR_COBAS_COV19	CT 2	16.33
2020	11	10	PCR_COBAS_COV19	CT 2	17.99
2020	11	10	PCR_COBAS_COV19	CT 2	22.38
2020	11	10	PCR_COBAS_COV19	CT 2	24.82
2020	11	10	PCR_COBAS_COV19	CT 2	24.81
2020	11	10	PCR_COBAS_COV19	CT 2	32.2
2020	11	10	PCR_COBAS_COV19	CT 2	22.31
2020	11	10	PCR_COBAS_COV19	CT 2	24.46
2020	11	10	PCR_COBAS_COV19	CT 2	15.31
2020	11	10	PCR_COBAS_COV19	CT 2	34.6
2020	11	10	PCR_COBAS_COV19	CT 2	20.9

AB958

2020	11	10	PCR_COBAS_COV19	CT 2	21.01
2020	11	10	PCR_COBAS_COV19	CT 2	30.83
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.637603
2020	11	10	PCR_COBAS_COV19	CT 2	34.99
2020	11	10	PCR_COBAS_COV19	CT 2	23.86
2020	11	10	PCR_COBAS_COV19	CT 2	23.4
2020	11	10	PCR_COBAS_COV19	CT 2	35.26
2020	11	10	PCR_COBAS_COV19	CT 2	18.64
2020	11	10	PCR_COBAS_COV19	CT 2	36.21
2020	11	10	PCR_COBAS_COV19	CT 2	36.69
2020	11	10	PCR_COBAS_COV19	CT 2	15.49
2020	11	10	PCR_COBAS_COV19	CT 2	16.17
2020	11	10	PCR_COBAS_COV19	CT 2	15.73
2020	11	10	PCR_COBAS_COV19	CT 2	26.88
2020	11	10	PCR_COBAS_COV19	CT 2	26.75
2020	11	10	PCR_COBAS_COV19	CT 2	29.42
2020	11	10	PCR_FUSION_COV19_E	E Gene CT	23.2
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.28846099
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.94259571
2020	11	10	PCR_FUSION_COV19_E	E Gene CT	32.6
2020	11	10	PCR_FUSION_COV19_E	E Gene CT	27.4
2020	11	10	PCR_FUSION_COV19_E	E Gene CT	27.1
2020	11	10	PCR_FUSION_COV19_E	E Gene CT	36.1
2020	11	10	PCR_FUSION_COV19_E	E Gene CT	25
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.28455912
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.99265221
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.05456565
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.94710847
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.35616497
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.40580755
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.60455868
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.53398429
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.94776347
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.26088942
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.95559203
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.54238963
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.03737437
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	39.84436121
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.20387202
2020	11	10	PCR_FUSION_COV19_E	E Gene CT	24.7
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.49832689
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.55095284
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.6380869
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.06831582
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.24049532
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.42182922
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.38530047

2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.73935145
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.26082154
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.73936484
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.99982842
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.8761401
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.46551045
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.88052883
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.85276117
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.98326123
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.28535739
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.29002594
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.46819479
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.72311879
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.97475206
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.30637871
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.25451041
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.99540439
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.3570199
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.47048939
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.75605345
2020	11	10	PCR_FUSION_COV19_E	E Gene CT	17.8
2020	11	10	PCR_FUSION_COV19_E	E Gene CT	28.1
2020	11	10	PCR_FUSION_COV19_E	E Gene CT	37.9
2020	11	10	PCR_FUSION_COV19_E	E Gene CT	34.3
2020	11	10	PCR_FUSION_COV19_E	E Gene CT	36.3
2020	11	10	PCR_FUSION_COV19_E	E Gene CT	37.2
2020	11	10	PCR_FUSION_COV19_E	E Gene CT	30.4
2020	11	10	PCR_FUSION_COV19_E	E Gene CT	33.6
2020	11	10	PCR_FUSION_COV19_E	E Gene CT	33.3
2020	11	10	PCR_FUSION_COV19_E	E Gene CT	36.4
2020	11	10	PCR_FUSION_COV19_E	E Gene CT	33.1
2020	11	10	PCR_FUSION_COV19_E	E Gene CT	31.8
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.12160512
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.07708335
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.63199845
2020	11	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.22890651
2020	11	11	PCR_COBAS_COV19	CT 2	19.48
2020	11	11	PCR_COBAS_COV19	CT 2	28.9
2020	11	11	PCR_COBAS_COV19	CT 2	15.54
2020	11	11	PCR_COBAS_COV19	CT 2	32.61
2020	11	11	PCR_COBAS_COV19	CT 2	18.44
2020	11	11	PCR_COBAS_COV19	CT 2	22.31
2020	11	11	PCR_COBAS_COV19	CT 2	25.8
2020	11	11	PCR_COBAS_COV19	CT 2	32.8
2020	11	11	PCR_COBAS_COV19	CT 2	22.95
2020	11	11	PCR_COBAS_COV19	CT 2	22.76
2020	11	11	PCR_COBAS_COV19	CT 2	17.95

AB960

2020	11	11	PCR_COBAS_COV19	CT 2	33.99
2020	11	11	PCR_COBAS_COV19	CT 2	17.93
2020	11	11	PCR_COBAS_COV19	CT 2	17.31
2020	11	11	PCR_COBAS_COV19	CT 2	18.87
2020	11	11	PCR_COBAS_COV19	CT 2	21.33
2020	11	11	PCR_COBAS_COV19	CT 2	35.92
2020	11	11	PCR_COBAS_COV19	CT 2	34.99
2020	11	11	PCR_COBAS_COV19	CT 2	14.88
2020	11	11	PCR_COBAS_COV19	CT 2	18.99
2020	11	11	PCR_COBAS_COV19	CT 2	24.8
2020	11	11	PCR_COBAS_COV19	CT 2	21.73
2020	11	11	PCR_COBAS_COV19	CT 2	32.88
2020	11	11	PCR_COBAS_COV19	CT 2	15.9
2020	11	11	PCR_COBAS_COV19	CT 2	18.33
2020	11	11	PCR_COBAS_COV19	CT 2	21.64
2020	11	11	PCR_COBAS_COV19	CT 2	22.22
2020	11	11	PCR_COBAS_COV19	CT 2	27.27
2020	11	11	PCR_COBAS_COV19	CT 2	14.97
2020	11	11	PCR_COBAS_COV19	CT 2	17.15
2020	11	11	PCR_COBAS_COV19	CT 2	18.61
2020	11	11	PCR_COBAS_COV19	CT 2	24.15
2020	11	11	PCR_COBAS_COV19	CT 2	23.91
2020	11	11	PCR_COBAS_COV19	CT 2	25.38
2020	11	11	PCR_COBAS_COV19	CT 2	22.03
2020	11	11	PCR_COBAS_COV19	CT 2	29.59
2020	11	11	PCR_COBAS_COV19	CT 2	22.71
2020	11	11	PCR_COBAS_COV19	CT 2	28.45
2020	11	11	PCR_COBAS_COV19	CT 2	19.28
2020	11	11	PCR_COBAS_COV19	CT 2	29.93
2020	11	11	PCR_COBAS_COV19	CT 2	24.49
2020	11	11	PCR_COBAS_COV19	CT 2	17.53
2020	11	11	PCR_COBAS_COV19	CT 2	23.07
2020	11	11	PCR_COV_N2019	E Gene CT	28.99233737
2020	11	11	PCR_COV_N2019	E Gene CT	23.37510643
2020	11	11	PCR_COV_N2019	E Gene CT	21.67194772
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	9.378413086
2020	11	11	PCR_COV_N2019	E Gene CT	33.40446119
2020	11	11	PCR_FUSION_COV19_E	E Gene CT	26
2020	11	11	PCR_FUSION_COV19_E	E Gene CT	24.3
2020	11	11	PCR_FUSION_COV19_E	E Gene CT	37.9
2020	11	11	PCR_FUSION_COV19_E	E Gene CT	36.8
2020	11	11	PCR_FUSION_COV19_E	E Gene CT	33.1
2020	11	11	PCR_FUSION_COV19_E	E Gene CT	36.8
2020	11	11	PCR_COV_N2019	E Gene CT	34.00164674
2020	11	11	PCR_FUSION_COV19_E	E Gene CT	38
2020	11	11	PCR_FUSION_COV19_E	E Gene CT	35.9
2020	11	11	PCR_FUSION_COV19_E	E Gene CT	36

AB961

2020	11	11	PCR_COV_N2019	E Gene CT	31.16578869
2020	11	11	PCR_FUSION_COV19_E	E Gene CT	36.1
2020	11	11	PCR_COV_N2019	E Gene CT	30.96577229
2020	11	11	PCR_COV_N2019	E Gene CT	32.61596136
2020	11	11	PCR_FUSION_COV19_E	E Gene CT	29.6
2020	11	11	PCR_COV_N2019	E Gene CT	34.40766698
2020	11	11	PCR_FUSION_COV19_E	E Gene CT	34.3
2020	11	11	PCR_FUSION_COV19_E	E Gene CT	38
2020	11	11	PCR_FUSION_COV19_E	E Gene CT	35.1
2020	11	11	PCR_COV_N2019	E Gene CT	29.85649122
2020	11	11	PCR_FUSION_COV19_E	E Gene CT	37.1
2020	11	11	PCR_FUSION_COV19_E	E Gene CT	36.1
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.99813566
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.53707208
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.09896658
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.32828514
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.11895703
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.74895518
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.55215652
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.52495417
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.19554238
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.81379723
2020	11	11	PCR_FUSION_COV19_E	E Gene CT	32.1
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.04027117
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.63730513
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.93078652
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.85422009
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.68491021
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.02382941
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.94837297
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.24816055
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.95828411
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.51695264
2020	11	11	PCR_FUSION_COV19_E	E Gene CT	32.9
2020	11	11	PCR_FUSION_COV19_E	E Gene CT	18.6
2020	11	11	PCR_COV_N2019	E Gene CT	36.67909611
2020	11	11	PCR_FUSION_COV19_E	E Gene CT	24.6
2020	11	11	PCR_FUSION_COV19_E	E Gene CT	33.6
2020	11	11	PCR_FUSION_COV19_E	E Gene CT	24.6
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.02170219
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.10632993
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.49717338
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.35096527
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.59575355
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.53708876
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.84879179
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.34644829

AB962

2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.84043225
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.15715035
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.81444784
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.51853125
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.58352431
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.34726726
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.27796815
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.11451695
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.16465699
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.72455348
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.17550869
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.57908717
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.80715847
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.48597959
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.68903818
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.35502357
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.5157719
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.34604164
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.06617814
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.21045618
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.20337444
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.31173107
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.13833938
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.89075237
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.37743458
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.04533943
2020	11	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.92127368
2020	11	12	PCR_COBAS_COV19	CT 2	34.57
2020	11	12	PCR_COV_N2019	E Gene CT	26.03844701
2020	11	12	PCR_COBAS_COV19	CT 2	23.31
2020	11	12	PCR_COBAS_COV19	CT 2	15.3
2020	11	12	PCR_COBAS_COV19	CT 2	25.71
2020	11	12	PCR_COBAS_COV19	CT 2	17.12
2020	11	12	PCR_COBAS_COV19	CT 2	22
2020	11	12	PCR_COBAS_COV19	CT 2	37.82
2020	11	12	PCR_COBAS_COV19	CT 2	30.81
2020	11	12	PCR_COBAS_COV19	CT 2	16.95
2020	11	12	PCR_COBAS_COV19	CT 2	34.98
2020	11	12	PCR_COBAS_COV19	CT 2	35.41
2020	11	12	PCR_COBAS_COV19	CT 2	17.62
2020	11	12	PCR_COBAS_COV19	CT 2	33.78
2020	11	12	PCR_COBAS_COV19	CT 2	36.74
2020	11	12	PCR_COBAS_COV19	CT 2	19.13
2020	11	12	PCR_COBAS_COV19	CT 2	29.91
2020	11	12	PCR_COBAS_COV19	CT 2	25.65
2020	11	12	PCR_COBAS_COV19	CT 2	19.69
2020	11	12	PCR_COBAS_COV19	CT 2	36.25

AB963

2020	11	12	PCR_COBAS_COV19	CT 2	31.25
2020	11	12	PCR_COBAS_COV19	CT 2	21.48
2020	11	12	PCR_COBAS_COV19	CT 2	17.33
2020	11	12	PCR_COBAS_COV19	CT 2	18.23
2020	11	12	PCR_COBAS_COV19	CT 2	34.64
2020	11	12	PCR_COBAS_COV19	CT 2	20.9
2020	11	12	PCR_COBAS_COV19	CT 2	22.18
2020	11	12	PCR_COBAS_COV19	CT 2	23.96
2020	11	12	PCR_COBAS_COV19	CT 2	31.58
2020	11	12	PCR_COBAS_COV19	CT 2	28.29
2020	11	12	PCR_COBAS_COV19	CT 2	22.81
2020	11	12	PCR_COV_N2019	E Gene CT	22.12142661
2020	11	12	PCR_COBAS_COV19	CT 2	15.65
2020	11	12	PCR_COBAS_COV19	CT 2	34.38
2020	11	12	PCR_COBAS_COV19	CT 2	26.5
2020	11	12	PCR_COBAS_COV19	CT 2	30.46
2020	11	12	PCR_COBAS_COV19	CT 2	25.42
2020	11	12	PCR_COBAS_COV19	CT 2	17.75
2020	11	12	PCR_COBAS_COV19	CT 2	25.7
2020	11	12	PCR_COBAS_COV19	CT 2	19.21
2020	11	12	PCR_COBAS_COV19	CT 2	23.09
2020	11	12	PCR_COBAS_COV19	CT 2	30.47
2020	11	12	PCR_COBAS_COV19	CT 2	17.86
2020	11	12	PCR_COBAS_COV19	CT 2	16.44
2020	11	12	PCR_COBAS_COV19	CT 2	18.49
2020	11	12	PCR_COBAS_COV19	CT 2	18.13
2020	11	12	PCR_COBAS_COV19	CT 2	20.77
2020	11	12	PCR_COBAS_COV19	CT 2	17.73
2020	11	12	PCR_COBAS_COV19	CT 2	17.86
2020	11	12	PCR_COBAS_COV19	CT 2	23.88
2020	11	12	PCR_COBAS_COV19	CT 2	28.39
2020	11	12	PCR_COBAS_COV19	CT 2	21.87
2020	11	12	PCR_COBAS_COV19	CT 2	26.83
2020	11	12	PCR_COBAS_COV19	CT 2	21.32
2020	11	12	PCR_COBAS_COV19	CT 2	15.73
2020	11	12	PCR_COBAS_COV19	CT 2	33.84
2020	11	12	PCR_COBAS_COV19	CT 2	26.35
2020	11	12	PCR_COBAS_COV19	CT 2	34.06
2020	11	12	PCR_COBAS_COV19	CT 2	19.38
2020	11	12	PCR_COBAS_COV19	CT 2	19.85
2020	11	12	PCR_COBAS_COV19	CT 2	26.92
2020	11	12	PCR_COBAS_COV19	CT 2	17.23
2020	11	12	PCR_COBAS_COV19	CT 2	25.11
2020	11	12	PCR_COBAS_COV19	CT 2	19.26
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.07395328
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.1759984
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.60894177

AB964

2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.84063915
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.32690619
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.95440237
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.44399953
2020	11	12	PCR_FUSION_COV19_E	E Gene CT	27.9
2020	11	12	PCR_FUSION_COV19_E	E Gene CT	24.9
2020	11	12	PCR_FUSION_COV19_E	E Gene CT	29.9
2020	11	12	PCR_FUSION_COV19_E	E Gene CT	18.9
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.25734314
2020	11	12	PCR_FUSION_COV19_E	E Gene CT	16.8
2020	11	12	PCR_FUSION_COV19_E	E Gene CT	33.6
2020	11	12	PCR_COV_N2019	E Gene CT	33.76505169
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.08051878
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.84480535
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.38735098
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.74856728
2020	11	12	PCR_FUSION_COV19_E	E Gene CT	25.3
2020	11	12	PCR_FUSION_COV19_E	E Gene CT	22
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.27895998
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.03556922
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.23840296
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.14488088
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.69090381
2020	11	12	PCR_FUSION_COV19_E	E Gene CT	37.2
2020	11	12	PCR_FUSION_COV19_E	E Gene CT	22.7
2020	11	12	PCR_FUSION_COV19_E	E Gene CT	35.2
2020	11	12	PCR_FUSION_COV19_E	E Gene CT	37.7
2020	11	12	PCR_FUSION_COV19_E	E Gene CT	24.4
2020	11	12	PCR_FUSION_COV19_E	E Gene CT	18.6
2020	11	12	PCR_FUSION_COV19_E	E Gene CT	37
2020	11	12	PCR_FUSION_COV19_E	E Gene CT	22.5
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.54775435
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.93849814
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.86068166
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.67901292
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.91245943
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.92511194
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.82757842
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.62590453
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.524668
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.16708506
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.23076345
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.00042596
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.0353891
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.4819519
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.32794811
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.2499753

AB965

2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.67161683
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.364859
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.2564292
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.85275729
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.34654059
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.83235219
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.55802142
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.56828032
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.91389413
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.00233538
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.96170275
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.60077992
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.34980167
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.52621374
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.39186431
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.85145354
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.00273742
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.65897748
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.96437637
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.90576243
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.32569765
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.11570828
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.91475736
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.59562238
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.36453221
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.13155119
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.99218821
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.07647448
2020	11	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.0222143
2020	11	12	PCR_COBAS_COV19	CT 2	22.03
2020	11	13	PCR_COBAS_COV19	CT 2	18.99
2020	11	13	PCR_COBAS_COV19	CT 2	18.28
2020	11	13	PCR_COBAS_COV19	CT 2	29.18
2020	11	13	PCR_COBAS_COV19	CT 2	33.65
2020	11	13	PCR_COBAS_COV19	CT 2	31.63
2020	11	13	PCR_COBAS_COV19	CT 2	23.28
2020	11	13	PCR_COBAS_COV19	CT 2	17.55
2020	11	13	PCR_COBAS_COV19	CT 2	25.44
2020	11	13	PCR_COBAS_COV19	CT 2	15.99
2020	11	13	PCR_COBAS_COV19	CT 2	25.62
2020	11	13	PCR_COBAS_COV19	CT 2	19.8
2020	11	13	PCR_COBAS_COV19	CT 2	23.81
2020	11	13	PCR_COBAS_COV19	CT 2	20.35
2020	11	13	PCR_COBAS_COV19	CT 2	20.74
2020	11	13	PCR_COBAS_COV19	CT 2	23.55
2020	11	13	PCR_COBAS_COV19	CT 2	34.25
2020	11	13	PCR_COBAS_COV19	CT 2	22.87

AB966

2020	11	13	PCR_COBAS_COV19	CT 2	32.72
2020	11	13	PCR_COBAS_COV19	CT 2	32.71
2020	11	13	PCR_COBAS_COV19	CT 2	30.48
2020	11	13	PCR_COBAS_COV19	CT 2	33.38
2020	11	13	PCR_COBAS_COV19	CT 2	28.75
2020	11	13	PCR_COBAS_COV19	CT 2	37.49
2020	11	13	PCR_COBAS_COV19	CT 2	27.6
2020	11	13	PCR_COBAS_COV19	CT 2	28.99
2020	11	13	PCR_COBAS_COV19	CT 2	32.96
2020	11	13	PCR_COBAS_COV19	CT 2	33.71
2020	11	13	PCR_COBAS_COV19	CT 2	21.73
2020	11	13	PCR_COBAS_COV19	CT 2	22.7
2020	11	13	PCR_COBAS_COV19	CT 2	20.92
2020	11	13	PCR_COBAS_COV19	CT 2	31.55
2020	11	13	PCR_COBAS_COV19	CT 2	32.26
2020	11	13	PCR_COBAS_COV19	CT 2	29.54
2020	11	13	PCR_COBAS_COV19	CT 2	17.35
2020	11	13	PCR_COBAS_COV19	CT 2	16.51
2020	11	13	PCR_COBAS_COV19	CT 2	17.19
2020	11	13	PCR_COBAS_COV19	CT 2	24.93
2020	11	13	PCR_COBAS_COV19	CT 2	30.56
2020	11	13	PCR_COBAS_COV19	CT 2	23.07
2020	11	13	PCR_COBAS_COV19	CT 2	17.63
2020	11	13	PCR_COBAS_COV19	CT 2	36.98
2020	11	13	PCR_COBAS_COV19	CT 2	18.15
2020	11	13	PCR_COBAS_COV19	CT 2	22.16
2020	11	13	PCR_COBAS_COV19	CT 2	16.08
2020	11	13	PCR_COBAS_COV19	CT 2	29.22
2020	11	13	PCR_COBAS_COV19	CT 2	18.25
2020	11	13	PCR_COBAS_COV19	CT 2	24.03
2020	11	13	PCR_COBAS_COV19	CT 2	23.78
2020	11	13	PCR_COBAS_COV19	CT 2	35.25
2020	11	13	PCR_COBAS_COV19	CT 2	21.7
2020	11	13	PCR_COBAS_COV19	CT 2	25.55
2020	11	13	PCR_COBAS_COV19	CT 2	27.9
2020	11	13	PCR_COBAS_COV19	CT 2	24.04
2020	11	13	PCR_COBAS_COV19	CT 2	29.1
2020	11	13	PCR_COBAS_COV19	CT 2	28.66
2020	11	13	PCR_COBAS_COV19	CT 2	23.41
2020	11	13	PCR_COBAS_COV19	CT 2	32.08
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.20189874
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.71389061
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.91139541
2020	11	13	PCR_FUSION_COV19_E	E Gene CT	18.2
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.37732142
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.21171081
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.51032654

AB967

2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.3755888
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.07965592
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.38395619
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.03071569
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.12616602
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.39803133
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.28543413
2020	11	13	PCR_FUSION_COV19_E	E Gene CT	17.7
2020	11	13	PCR_FUSION_COV19_E	E Gene CT	28.6
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.44995652
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.13455292
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.41488986
2020	11	13	PCR_FUSION_COV19_E	E Gene CT	27.8
2020	11	13	PCR_FUSION_COV19_E	E Gene CT	29.2
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.49657571
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.07982692
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.53581276
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.76434663
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.99326603
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.28866508
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.13183579
2020	11	13	PCR_FUSION_COV19_E	E Gene CT	23
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.42348584
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.80553712
2020	11	13	PCR_FUSION_COV19_E	E Gene CT	30.4
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.35109087
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.05101149
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.4584077
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.12658119
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.23114292
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.17001499
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.09085779
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.66396273
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.76109226
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.84924953
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.48325222
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.56625109
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.80749667
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.56630753
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.12130364
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.28304242
2020	11	13	PCR_FUSION_COV19_E	E Gene CT	21.5
2020	11	13	PCR_FUSION_COV19_E	E Gene CT	31.5
2020	11	13	PCR_FUSION_COV19_E	E Gene CT	19.8
2020	11	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.08063937
2020	11	13	PCR_COBAS_COV19	CT 2	23.24
2020	11	13	PCR_COBAS_COV19	CT 2	30.42

AB968

2020	11	14	PCR_COBAS_COV19	CT 2	36.21
2020	11	14	PCR_COBAS_COV19	CT 2	31.02
2020	11	14	PCR_COBAS_COV19	CT 2	18.9
2020	11	14	PCR_COBAS_COV19	CT 2	21.81
2020	11	14	PCR_COBAS_COV19	CT 2	27.91
2020	11	14	PCR_COBAS_COV19	CT 2	23.9
2020	11	14	PCR_COBAS_COV19	CT 2	26.75
2020	11	14	PCR_COBAS_COV19	CT 2	21.45
2020	11	14	PCR_COBAS_COV19	CT 2	24.78
2020	11	14	PCR_COBAS_COV19	CT 2	27.9
2020	11	14	PCR_COBAS_COV19	CT 2	36.54
2020	11	14	PCR_COBAS_COV19	CT 2	29.83
2020	11	14	PCR_COBAS_COV19	CT 2	22.4
2020	11	14	PCR_COBAS_COV19	CT 2	27.42
2020	11	14	PCR_COBAS_COV19	CT 2	15.55
2020	11	14	PCR_COBAS_COV19	CT 2	30.04
2020	11	14	PCR_COBAS_COV19	CT 2	17.54
2020	11	14	PCR_COBAS_COV19	CT 2	21.55
2020	11	14	PCR_COBAS_COV19	CT 2	36.15
2020	11	14	PCR_COBAS_COV19	CT 2	16.39
2020	11	14	PCR_COBAS_COV19	CT 2	25.17
2020	11	14	PCR_COBAS_COV19	CT 2	24.57
2020	11	14	PCR_COBAS_COV19	CT 2	14.92
2020	11	14	PCR_COBAS_COV19	CT 2	18.87
2020	11	14	PCR_COBAS_COV19	CT 2	37.14
2020	11	14	PCR_COBAS_COV19	CT 2	24.26
2020	11	14	PCR_COBAS_COV19	CT 2	36.95
2020	11	14	PCR_COBAS_COV19	CT 2	18.13
2020	11	14	PCR_COBAS_COV19	CT 2	26.36
2020	11	14	PCR_COBAS_COV19	CT 2	19
2020	11	14	PCR_COBAS_COV19	CT 2	19.15
2020	11	14	PCR_COBAS_COV19	CT 2	31.86
2020	11	14	PCR_COBAS_COV19	CT 2	24.03
2020	11	14	PCR_COBAS_COV19	CT 2	35.09
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.72550235
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.78949834
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.64565657
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.4822718
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.29070279
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.25399149
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.19819304
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.32947514
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.97874164
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.07430757
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.00055863
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.61004705
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.06726405

AB969

2020	11	14	PCR_FUSION_COV19_E	E Gene CT	35.8
2020	11	14	PCR_FUSION_COV19_E	E Gene CT	24.3
2020	11	14	PCR_FUSION_COV19_E	E Gene CT	31.8
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.81526624
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.9612033
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.35200074
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.38575294
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.05544431
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.18009045
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.14349081
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.44153847
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.79171371
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.88625418
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.77758831
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.43325506
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.39946654
2020	11	14	PCR_FUSION_COV19_E	E Gene CT	21.4
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.99052957
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.73180385
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.12216768
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.18234858
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.98129867
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.3539063
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.48916834
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.60994892
2020	11	14	PCR_FUSION_COV19_E	E Gene CT	28.2
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.22727675
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.40556924
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.4186142
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.28301725
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.11201504
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.59620392
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.00461271
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.50995867
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.91669495
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.12646516
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.54134289
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.10981251
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.7742387
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.11151645
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.61924786
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.25460202
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.15448345
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.59896984
2020	11	14	PCR_FUSION_COV19_E	E Gene CT	30
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.34460716
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.09895673

AB970

2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.06765109
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.62036683
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.25612572
2020	11	14	PCR_FUSION_COV19_E	E Gene CT	19
2020	11	14	PCR_FUSION_COV19_E	E Gene CT	24.6
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.02694211
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.84973163
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.12223557
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.36944796
2020	11	14	PCR_FUSION_COV19_E	E Gene CT	30
2020	11	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.20375891
2020	11	15	PCR_COBAS_COV19	CT 2	34.43
2020	11	15	PCR_COBAS_COV19	CT 2	25.53
2020	11	15	PCR_COBAS_COV19	CT 2	36.04
2020	11	15	PCR_COBAS_COV19	CT 2	29.97
2020	11	15	PCR_COBAS_COV19	CT 2	26.68
2020	11	15	PCR_COBAS_COV19	CT 2	19.99
2020	11	15	PCR_COBAS_COV19	CT 2	18.05
2020	11	15	PCR_COBAS_COV19	CT 2	21.91
2020	11	15	PCR_COBAS_COV19	CT 2	24.74
2020	11	15	PCR_COBAS_COV19	CT 2	24.97
2020	11	15	PCR_COBAS_COV19	CT 2	20.11
2020	11	15	PCR_COBAS_COV19	CT 2	17.51
2020	11	15	PCR_COBAS_COV19	CT 2	20.57
2020	11	15	PCR_COBAS_COV19	CT 2	18.39
2020	11	15	PCR_COBAS_COV19	CT 2	27.98
2020	11	15	PCR_COBAS_COV19	CT 2	35.86
2020	11	15	PCR_COBAS_COV19	CT 2	33.67
2020	11	15	PCR_COBAS_COV19	CT 2	23.46
2020	11	15	PCR_COBAS_COV19	CT 2	17.17
2020	11	15	PCR_COBAS_COV19	CT 2	30.05
2020	11	15	PCR_COBAS_COV19	CT 2	24.5
2020	11	15	PCR_COBAS_COV19	CT 2	27.78
2020	11	15	PCR_COBAS_COV19	CT 2	21.57
2020	11	15	PCR_COBAS_COV19	CT 2	17.24
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.08719774
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.58005237
2020	11	15	PCR_FUSION_COV19_E	E Gene CT	31.3
2020	11	15	PCR_FUSION_COV19_E	E Gene CT	34.2
2020	11	15	PCR_FUSION_COV19_E	E Gene CT	20.3
2020	11	15	PCR_FUSION_COV19_E	E Gene CT	26.6
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.89020909
2020	11	15	PCR_FUSION_COV19_E	E Gene CT	37.6
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.77401627
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.11731249
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.63024652
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.19750667

AB971

2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.23685336
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.12566465
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.76177131
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.8543761
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.21343084
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.79452379
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.87379276
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.02181049
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.1801752
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.47447948
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.81420177
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.12950021
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.55574357
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.51374921
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.23818573
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.52194707
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.07182703
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.15573535
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.91379219
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	9.631063351
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.63504431
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.75108062
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.77189122
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.07179052
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.36420525
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.40789212
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.5828336
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.9101358
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.29432848
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.17827038
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.08048737
2020	11	15	PCR_COBAS_COV19	CT 2	33.45
2020	11	15	PCR_COBAS_COV19	CT 2	18.27
2020	11	15	PCR_COBAS_COV19	CT 2	27.28
2020	11	15	PCR_COBAS_COV19	CT 2	36.59
2020	11	15	PCR_COBAS_COV19	CT 2	14.03
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.36542794
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.83745376
2020	11	15	PCR_COV_N2019	E Gene CT	13.45512614
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.91228776
2020	11	15	PCR_FUSION_COV19_E	E Gene CT	21.6
2020	11	15	PCR_FUSION_COV19_E	E Gene CT	18.7
2020	11	15	PCR_FUSION_COV19_E	E Gene CT	20.4
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.70217871
2020	11	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.19707475
2020	11	16	PCR_COBAS_COV19	CT 2	16.13
2020	11	16	PCR_COBAS_COV19	CT 2	24.22

AB972

2020	11	16	PCR_COBAS_COV19	CT 2	17.52
2020	11	16	PCR_COBAS_COV19	CT 2	17.27
2020	11	16	PCR_COBAS_COV19	CT 2	22.14
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.83026816
2020	11	16	PCR_COBAS_COV19	CT 2	33.16
2020	11	16	PCR_COBAS_COV19	CT 2	19.28
2020	11	16	PCR_COBAS_COV19	CT 2	36.46
2020	11	16	PCR_COBAS_COV19	CT 2	23.87
2020	11	16	PCR_COBAS_COV19	CT 2	28.62
2020	11	16	PCR_COBAS_COV19	CT 2	29.76
2020	11	16	PCR_COBAS_COV19	CT 2	32.07
2020	11	16	PCR_COBAS_COV19	CT 2	18.71
2020	11	16	PCR_COBAS_COV19	CT 2	16.87
2020	11	16	PCR_COBAS_COV19	CT 2	13.79
2020	11	16	PCR_COBAS_COV19	CT 2	19.16
2020	11	16	PCR_COBAS_COV19	CT 2	34.87
2020	11	16	PCR_COBAS_COV19	CT 2	21.66
2020	11	16	PCR_COBAS_COV19	CT 2	15.44
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.01483278
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.78094154
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.6960976
2020	11	16	PCR_COV_N2019	E Gene CT	28.34798932
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.65891234
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.39805005
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.74941363
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.09051035
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.31307907
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.41415214
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.96970738
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.35257391
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.12812951
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.99524378
2020	11	16	PCR_FUSION_COV19_E	E Gene CT	21.6
2020	11	16	PCR_FUSION_COV19_E	E Gene CT	26.4
2020	11	16	PCR_FUSION_COV19_E	E Gene CT	21.9
2020	11	16	PCR_FUSION_COV19_E	E Gene CT	28.9
2020	11	16	PCR_FUSION_COV19_E	E Gene CT	27.6
2020	11	16	PCR_FUSION_COV19_E	E Gene CT	30.2
2020	11	16	PCR_COV_N2019	E Gene CT	33.33286411
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.84428911
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.8596211
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.03822372
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.47405721
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.55141363
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.8660325
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.15389627
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.57054557

AB973

2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.64800194
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.69880996
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.02017361
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.84376163
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.24772363
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.3495228
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.82897281
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.30152391
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.29064067
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.6419142
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.96839973
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.2785763
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.08106478
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.96574419
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.61627293
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.14513516
2020	11	16	PCR_FUSION_COV19_E	E Gene CT	15.9
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.62420602
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.14955233
2020	11	16	PCR_FUSION_COV19_E	E Gene CT	36.8
2020	11	16	PCR_FUSION_COV19_E	E Gene CT	15.7
2020	11	16	PCR_FUSION_COV19_E	E Gene CT	22.5
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.93489738
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.01413035
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.13041397
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.0259435
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.86251128
2020	11	16	PCR_COV_N2019	E Gene CT	28.71478026
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.4102848
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.46018893
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.25082711
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.08225092
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.97986619
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.78497305
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.01120442
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.27926958
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.33965888
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.3773737
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.15899686
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.67644174
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.54058574
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.69579656
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.02277089
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.12783183
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.87413299
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.74340193
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.950883

AB974

2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.33230844
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.00119083
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.6116453
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.96011569
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.44716383
2020	11	16	PCR_COV_N2019	E Gene CT	15.02614571
2020	11	16	PCR_COV_N2019	E Gene CT	16.42432019
2020	11	16	PCR_COV_N2019	E Gene CT	34.72910367
2020	11	16	PCR_FUSION_COV19_E	E Gene CT	33.3
2020	11	16	PCR_FUSION_COV19_E	E Gene CT	23.8
2020	11	16	PCR_FUSION_COV19_E	E Gene CT	21.4
2020	11	16	PCR_FUSION_COV19_E	E Gene CT	18.7
2020	11	16	PCR_COV_N2019	E Gene CT	30.97929556
2020	11	16	PCR_COV_N2019	E Gene CT	22.22101473
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.13120349
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.08125294
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.03638205
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.72155438
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.52806814
2020	11	16	PCR_COBAS_COV19	CT 2	29.23
2020	11	16	PCR_COV_N2019	E Gene CT	16.18085981
2020	11	16	PCR_COV_N2019	E Gene CT	18.92895532
2020	11	16	PCR_COV_N2019	E Gene CT	34.95982565
2020	11	16	PCR_COBAS_COV19	CT 2	30.63
2020	11	16	PCR_COBAS_COV19	CT 2	35.71
2020	11	16	PCR_COBAS_COV19	CT 2	30.1
2020	11	16	PCR_COBAS_COV19	CT 2	23.65
2020	11	16	PCR_COBAS_COV19	CT 2	33.64
2020	11	16	PCR_COV_N2019	E Gene CT	12.7211582
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.23435386
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.19376564
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.31916158
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.10960779
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.64740282
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.35958797
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.86739762
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.88804223
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.43724894
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.61261516
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.95276469
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.03058819
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.53009876
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.39150655
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.72662969
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.07636648
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.89206296
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.97644745

AB975

2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.60535598
2020	11	16	PCR_FUSION_COV19_E	E Gene CT	36.9
2020	11	16	PCR_FUSION_COV19_E	E Gene CT	16.4
2020	11	16	PCR_FUSION_COV19_E	E Gene CT	30.2
2020	11	16	PCR_FUSION_COV19_E	E Gene CT	26.2
2020	11	16	PCR_FUSION_COV19_E	E Gene CT	18.5
2020	11	16	PCR_FUSION_COV19_E	E Gene CT	31.4
2020	11	16	PCR_FUSION_COV19_E	E Gene CT	35.1
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.01982663
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.71944071
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.58990527
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.16120916
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.8749402
2020	11	16	PCR_FUSION_COV19_E	E Gene CT	33.5
2020	11	16	PCR_FUSION_COV19_E	E Gene CT	36.8
2020	11	16	PCR_FUSION_COV19_E	E Gene CT	25.6
2020	11	16	PCR_FUSION_COV19_E	E Gene CT	36.3
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.59047861
2020	11	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.88264464
2020	11	16	PCR_COV_N2019	E Gene CT	23.20606814
2020	11	17	PCR_COBAS_COV19	CT 2	22.51
2020	11	17	PCR_COBAS_COV19	CT 2	28.36
2020	11	17	PCR_COBAS_COV19	CT 2	19.31
2020	11	17	PCR_COBAS_COV19	CT 2	34.21
2020	11	17	PCR_COBAS_COV19	CT 2	20.74
2020	11	17	PCR_COBAS_COV19	CT 2	27.17
2020	11	17	PCR_COBAS_COV19	CT 2	29.22
2020	11	17	PCR_COBAS_COV19	CT 2	19.78
2020	11	17	PCR_COBAS_COV19	CT 2	22.63
2020	11	17	PCR_COBAS_COV19	CT 2	34.39
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.82678037
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	18
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	37.1
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	30
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	31.4
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	19.4
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	32
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	25.1
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	28.3
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	19.5
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.23143098
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.9319047
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.74889373
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.31232553
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.09646048
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.18568771
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.23179464

AB976

2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.43505771
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.87227638
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.40262765
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.44944266
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.3618536
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.66672406
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.81266105
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.40198837
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.62279706
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.14281206
2020	11	17	PCR_COBAS_COV19	CT 2	22.85
2020	11	17	PCR_COBAS_COV19	CT 2	34.66
2020	11	17	PCR_COBAS_COV19	CT 2	20.52
2020	11	17	PCR_COBAS_COV19	CT 2	27.55
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	27.9
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.11671897
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.11988532
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.14459446
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.06208403
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.54659964
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.30479791
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.22238133
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.01523529
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.63635291
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.35976289
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.07450592
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.4470882
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.66197716
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.93414155
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.14404567
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.54624373
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.0518547
2020	11	17	PCR_COV_N2019	E Gene CT	15.87662288
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.86044638
2020	11	17	PCR_COV_N2019	E Gene CT	17.63254183
2020	11	17	PCR_COV_N2019	E Gene CT	23.35656232
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	31.4
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	26.6
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	29.7
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	20.3
2020	11	17	PCR_COV_N2019	E Gene CT	31.99657848
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	23.7
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	17.3
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	17
2020	11	17	PCR_COBAS_COV19	CT 2	18.7
2020	11	17	PCR_COBAS_COV19	CT 2	22.76
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	31.2

AB977

2020	11	17	PCR_FUSION_COV19_E	E Gene CT	28.1
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	26
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	22.7
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	21.3
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	21.6
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	37.3
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	19.7
2020	11	17	PCR_COV_N2019	E Gene CT	35.08931302
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	22.9
2020	11	17	PCR_COBAS_COV19	CT 2	28.07
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	33.9
2020	11	17	PCR_COV_N2019	E Gene CT	31.08993114
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	35.1
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	31.3
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.10344099
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.82175563
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.91822211
2020	11	17	PCR_COV_N2019	E Gene CT	18.22699985
2020	11	17	PCR_COV_N2019	E Gene CT	32.45070463
2020	11	17	PCR_COV_N2019	E Gene CT	34.59675459
2020	11	17	PCR_COV_N2019	E Gene CT	29.40414654
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.8512096
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.56642681
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.29033409
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.23669359
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.76546854
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.04484342
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	18.1
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	30.7
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	37.3
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	33.9
2020	11	17	PCR_FUSION_COV19_E	E Gene CT	33.6
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.37333255
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.76060282
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.00436679
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.51464575
2020	11	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.14310332
2020	11	18	PCR_COBAS_COV19	CT 2	16.61
2020	11	18	PCR_FUSION_COV19_E	E Gene CT	24
2020	11	18	PCR_FUSION_COV19_E	E Gene CT	21.3
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.17241045
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.17741482
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.98573449
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.59686684
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.04701211
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.03975316
2020	11	18	PCR_FUSION_COV19_E	E Gene CT	19.5

AB978

2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.44218244
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.64434598
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.44101129
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.32411458
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.51407805
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.82210382
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.66444965
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.45692082
2020	11	18	PCR_COV_N2019	E Gene CT	27.1429575
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.17298202
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.44696872
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.2591583
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.92858087
2020	11	18	PCR_COBAS_COV19	CT 2	34.67
2020	11	18	PCR_FUSION_COV19_E	E Gene CT	28.6
2020	11	18	PCR_FUSION_COV19_E	E Gene CT	36.8
2020	11	18	PCR_FUSION_COV19_E	E Gene CT	33.1
2020	11	18	PCR_FUSION_COV19_E	E Gene CT	35.1
2020	11	18	PCR_FUSION_COV19_E	E Gene CT	25.2
2020	11	18	PCR_FUSION_COV19_E	E Gene CT	36.8
2020	11	18	PCR_FUSION_COV19_E	E Gene CT	31.9
2020	11	18	PCR_FUSION_COV19_E	E Gene CT	26.8
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.3163748
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.6173536
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.52897885
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.4070758
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.22202725
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.18415351
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	10.96846535
2020	11	18	PCR_FUSION_COV19_E	E Gene CT	34.1
2020	11	18	PCR_FUSION_COV19_E	E Gene CT	24.3
2020	11	18	PCR_FUSION_COV19_E	E Gene CT	22.9
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.42719685
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.78094554
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.80458839
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.14900184
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.30508825
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.01982644
2020	11	18	PCR_FUSION_COV19_E	E Gene CT	19.8
2020	11	18	PCR_FUSION_COV19_E	E Gene CT	21.3
2020	11	18	PCR_FUSION_COV19_E	E Gene CT	22
2020	11	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.0413303
2020	11	19	PCR_COBAS_COV19	CT 2	37.71
2020	11	19	PCR_COBAS_COV19	CT 2	22.1
2020	11	19	PCR_COBAS_COV19	CT 2	21.57
2020	11	19	PCR_COBAS_COV19	CT 2	22.99
2020	11	19	PCR_COBAS_COV19	CT 2	19.95

AB979

2020	11	19	PCR_COBAS_COV19	CT 2	18.12
2020	11	19	PCR_COBAS_COV19	CT 2	20.34
2020	11	19	PCR_COBAS_COV19	CT 2	24.59
2020	11	19	PCR_COBAS_COV19	CT 2	17.61
2020	11	19	PCR_COBAS_COV19	CT 2	25.78
2020	11	19	PCR_COBAS_COV19	CT 2	20.63
2020	11	19	PCR_COBAS_COV19	CT 2	22.69
2020	11	19	PCR_COBAS_COV19	CT 2	27.13
2020	11	19	PCR_COBAS_COV19	CT 2	34.77
2020	11	19	PCR_COBAS_COV19	CT 2	36.8
2020	11	19	PCR_COBAS_COV19	CT 2	23.04
2020	11	19	PCR_COBAS_COV19	CT 2	17.92
2020	11	19	PCR_COBAS_COV19	CT 2	33.99
2020	11	19	PCR_COBAS_COV19	CT 2	35.81
2020	11	19	PCR_COBAS_COV19	CT 2	30.29
2020	11	19	PCR_COBAS_COV19	CT 2	27.85
2020	11	19	PCR_COBAS_COV19	CT 2	21.45
2020	11	19	PCR_COBAS_COV19	CT 2	28.8
2020	11	19	PCR_COBAS_COV19	CT 2	24.68
2020	11	19	PCR_COBAS_COV19	CT 2	17.5
2020	11	19	PCR_COBAS_COV19	CT 2	15.91
2020	11	19	PCR_COBAS_COV19	CT 2	16.33
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.77800801
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.33891221
2020	11	19	PCR_COBAS_COV19	CT 2	20.32
2020	11	19	PCR_COBAS_COV19	CT 2	24.73
2020	11	19	PCR_COBAS_COV19	CT 2	20.04
2020	11	19	PCR_COBAS_COV19	CT 2	34.88
2020	11	19	PCR_COBAS_COV19	CT 2	34.18
2020	11	19	PCR_COBAS_COV19	CT 2	21.95
2020	11	19	PCR_COBAS_COV19	CT 2	20.4
2020	11	19	PCR_COBAS_COV19	CT 2	20.03
2020	11	19	PCR_COBAS_COV19	CT 2	25.57
2020	11	19	PCR_COBAS_COV19	CT 2	34.08
2020	11	19	PCR_COBAS_COV19	CT 2	23.97
2020	11	19	PCR_COBAS_COV19	CT 2	16.4
2020	11	19	PCR_COBAS_COV19	CT 2	35.18
2020	11	19	PCR_COBAS_COV19	CT 2	24.63
2020	11	19	PCR_COBAS_COV19	CT 2	26.6
2020	11	19	PCR_COBAS_COV19	CT 2	29.59
2020	11	19	PCR_COBAS_COV19	CT 2	25.98
2020	11	19	PCR_COBAS_COV19	CT 2	33.32
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.24494078
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.42786846
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.15674076
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.59411614
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	21.4

AB980

2020	11	19	PCR_FUSION_COV19_E	E Gene CT	33.8
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	25
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	26.8
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	18.1
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	17.4
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	34.4
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	32.7
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	23.1
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	24.8
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	31.1
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	37.3
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	18.7
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	33.1
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	26.7
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.45637717
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.1062419
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	35.7
2020	11	19	PCR_COV_N2019	E Gene CT	34.16905938
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	37
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	33.7
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	37.7
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	26.3
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	29.9
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	17.5
2020	11	19	PCR_COV_N2019	E Gene CT	32.92953892
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	19.4
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	34.7
2020	11	19	PCR_COV_N2019	E Gene CT	33.58176697
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	36.1
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	17.6
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	19.6
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	24
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	20.1
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.80748333
2020	11	19	PCR_COV_N2019	E Gene CT	19.27962468
2020	11	19	PCR_COV_N2019	E Gene CT	16.46151253
2020	11	19	PCR_COV_N2019	E Gene CT	19.8814004
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.54687002
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.83062449
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.17246042
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.38747438
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.13526307
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	30.7
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	21.5
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	27.8
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	37.2
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	25.7

AB981

2020	11	19	PCR_FUSION_COV19_E	E Gene CT	27.2
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	23.2
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	23.7
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	26.6
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.22706
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.12300867
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.01445915
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.04646424
2020	11	19	PCR_COV_N2019	E Gene CT	28.47660091
2020	11	19	PCR_COV_N2019	E Gene CT	34.52717413
2020	11	19	PCR_COV_N2019	E Gene CT	29.32864713
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.06742169
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.08914803
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.9548041
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.75012017
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.69903707
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.20240513
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.07742168
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.60409017
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.26487544
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.89133506
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.39067013
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.43917624
2020	11	19	PCR_COV_N2019	E Gene CT	27.21556459
2020	11	19	PCR_COV_N2019	E Gene CT	18.66510688
2020	11	19	PCR_COV_N2019	E Gene CT	14.76404021
2020	11	19	PCR_COV_N2019	E Gene CT	35.33746764
2020	11	19	PCR_COV_N2019	E Gene CT	32.61711271
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.12366144
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.42615392
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.88662235
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.98370737
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.86447975
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.8111715
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.7788353
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.94977213
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.6613844
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	31.4
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	33.5
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	24.2
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	26.4
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	34.1
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	14.2
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	23.6
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.49325427
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.7578959
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.34987799

AB982

2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.02040637
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	34.1
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	21.6
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	19.7
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	34.9
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.08358796
2020	11	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.08885954
2020	11	19	PCR_FUSION_COV19_E	E Gene CT	20.2
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.49736394
2020	11	20	PCR_COBAS_COV19	CT 2	34.44
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.71381883
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.13373028
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.36803103
2020	11	20	PCR_FUSION_COV19_E	E Gene CT	27.3
2020	11	20	PCR_FUSION_COV19_E	E Gene CT	25.1
2020	11	20	PCR_FUSION_COV19_E	E Gene CT	23.5
2020	11	20	PCR_FUSION_COV19_E	E Gene CT	16.7
2020	11	20	PCR_FUSION_COV19_E	E Gene CT	28.2
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.88646046
2020	11	20	PCR_FUSION_COV19_E	E Gene CT	35.1
2020	11	20	PCR_FUSION_COV19_E	E Gene CT	19.1
2020	11	20	PCR_FUSION_COV19_E	E Gene CT	30
2020	11	20	PCR_FUSION_COV19_E	E Gene CT	29.7
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.2627383
2020	11	20	PCR_COBAS_COV19	CT 2	26.53
2020	11	20	PCR_COBAS_COV19	CT 2	26.36
2020	11	20	PCR_COBAS_COV19	CT 2	25.47
2020	11	20	PCR_COBAS_COV19	CT 2	24.48
2020	11	20	PCR_COBAS_COV19	CT 2	28.69
2020	11	20	PCR_COBAS_COV19	CT 2	14.79
2020	11	20	PCR_COBAS_COV19	CT 2	19.91
2020	11	20	PCR_COBAS_COV19	CT 2	21.91
2020	11	20	PCR_COBAS_COV19	CT 2	15.72
2020	11	20	PCR_COBAS_COV19	CT 2	27.42
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.63130498
2020	11	20	PCR_FUSION_COV19_E	E Gene CT	30.1
2020	11	20	PCR_FUSION_COV19_E	E Gene CT	36.3
2020	11	20	PCR_FUSION_COV19_E	E Gene CT	21.7
2020	11	20	PCR_FUSION_COV19_E	E Gene CT	24.5
2020	11	20	PCR_FUSION_COV19_E	E Gene CT	23.6
2020	11	20	PCR_FUSION_COV19_E	E Gene CT	28.8
2020	11	20	PCR_FUSION_COV19_E	E Gene CT	29.8
2020	11	20	PCR_FUSION_COV19_E	E Gene CT	20.2
2020	11	20	PCR_FUSION_COV19_E	E Gene CT	27.8
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.16619934
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.37267542
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.91456752

AB983

2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.6584777
2020	11	20	PCR_FUSION_COV19_E	E Gene CT	22.4
2020	11	20	PCR_FUSION_COV19_E	E Gene CT	29.4
2020	11	20	PCR_FUSION_COV19_E	E Gene CT	24.6
2020	11	20	PCR_FUSION_COV19_E	E Gene CT	19.5
2020	11	20	PCR_FUSION_COV19_E	E Gene CT	33.5
2020	11	20	PCR_FUSION_COV19_E	E Gene CT	21
2020	11	20	PCR_FUSION_COV19_E	E Gene CT	24.6
2020	11	20	PCR_FUSION_COV19_E	E Gene CT	24
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.4826954
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.65049409
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.60092223
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.53825789
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.77511457
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.57425455
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.02396253
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.37658199
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.49117241
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.58249451
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.03060589
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.32098258
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.79539549
2020	11	20	PCR_COBAS_COV19	CT 2	33.99
2020	11	20	PCR_COBAS_COV19	CT 2	21.09
2020	11	20	PCR_COBAS_COV19	CT 2	34.65
2020	11	20	PCR_COBAS_COV19	CT 2	36.77
2020	11	20	PCR_COBAS_COV19	CT 2	21.69
2020	11	20	PCR_COBAS_COV19	CT 2	23.69
2020	11	20	PCR_COBAS_COV19	CT 2	32.44
2020	11	20	PCR_COBAS_COV19	CT 2	37.4
2020	11	20	PCR_COBAS_COV19	CT 2	21.87
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.19172497
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.46537113
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.9085477
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.45998259
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.82548664
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.36949097
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.98466683
2020	11	20	PCR_FUSION_COV19_E	E Gene CT	20.9
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.72045248
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.39842845
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.55558921
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.89617786
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.17280473
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.74233511
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.21928715
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.79239822

AB984

2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.19568222
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.08181718
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.39432228
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.86090936
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.12713321
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.23722751
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.61341262
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.14020184
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.95042632
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.03561702
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.0741865
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.31160392
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.38339576
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.89076453
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.72369697
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.271219
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.53691031
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.17674982
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.22758917
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.44312526
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.83031031
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.14049122
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.49131857
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.54531826
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.96433168
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.59416456
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.65077746
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.4430276
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.99694225
2020	11	20	PCR_COBAS_COV19	CT 2	34.35
2020	11	20	PCR_COBAS_COV19	CT 2	22.08
2020	11	20	PCR_COBAS_COV19	CT 2	20.31
2020	11	20	PCR_COBAS_COV19	CT 2	22.02
2020	11	20	PCR_COBAS_COV19	CT 2	21.27
2020	11	20	PCR_COBAS_COV19	CT 2	24.02
2020	11	20	PCR_COBAS_COV19	CT 2	14.76
2020	11	20	PCR_COBAS_COV19	CT 2	18.26
2020	11	20	PCR_COBAS_COV19	CT 2	24.68
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.38828674
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.97073077
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.55671181
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.98605537
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.47943377
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.60954587
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.03299888
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.58798374
2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.06439131

AB985

2020	11	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.2070785
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.24891283
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.24987361
2020	11	21	PCR_COBAS_COV19	CT 2	26.58
2020	11	21	PCR_COBAS_COV19	CT 2	26.46
2020	11	21	PCR_COBAS_COV19	CT 2	34.57
2020	11	21	PCR_COBAS_COV19	CT 2	29.39
2020	11	21	PCR_COBAS_COV19	CT 2	36.66
2020	11	21	PCR_COBAS_COV19	CT 2	28.31
2020	11	21	PCR_COBAS_COV19	CT 2	34.81
2020	11	21	PCR_COBAS_COV19	CT 2	33.78
2020	11	21	PCR_COBAS_COV19	CT 2	20.82
2020	11	21	PCR_COBAS_COV19	CT 2	34.02
2020	11	21	PCR_COBAS_COV19	CT 2	23.72
2020	11	21	PCR_COBAS_COV19	CT 2	32.3
2020	11	21	PCR_COBAS_COV19	CT 2	33.38
2020	11	21	PCR_COBAS_COV19	CT 2	20.89
2020	11	21	PCR_COBAS_COV19	CT 2	32.45
2020	11	21	PCR_COBAS_COV19	CT 2	22.62
2020	11	21	PCR_COBAS_COV19	CT 2	16.27
2020	11	21	PCR_COBAS_COV19	CT 2	34.6
2020	11	21	PCR_COBAS_COV19	CT 2	36.98
2020	11	21	PCR_COBAS_COV19	CT 2	34.95
2020	11	21	PCR_COBAS_COV19	CT 2	33.71
2020	11	21	PCR_COBAS_COV19	CT 2	31.94
2020	11	21	PCR_COBAS_COV19	CT 2	15.24
2020	11	21	PCR_COBAS_COV19	CT 2	34.63
2020	11	21	PCR_COBAS_COV19	CT 2	34.05
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.76429923
2020	11	21	PCR_COBAS_COV19	CT 2	21.17
2020	11	21	PCR_COBAS_COV19	CT 2	15.99
2020	11	21	PCR_COBAS_COV19	CT 2	21.03
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.95708917
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.43547908
2020	11	21	PCR_COBAS_COV19	CT 2	37.99
2020	11	21	PCR_COBAS_COV19	CT 2	17.61
2020	11	21	PCR_COBAS_COV19	CT 2	17.69
2020	11	21	PCR_COBAS_COV19	CT 2	19.37
2020	11	21	PCR_COBAS_COV19	CT 2	32.53
2020	11	21	PCR_COBAS_COV19	CT 2	21.61
2020	11	21	PCR_COBAS_COV19	CT 2	20.7
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.5018556
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.6150366
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.3273833
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.35714605
2020	11	21	PCR_COBAS_COV19	CT 2	16.97
2020	11	21	PCR_COBAS_COV19	CT 2	23.14

AB986

2020	11	21	PCR_COBAS_COV19	CT 2	23
2020	11	21	PCR_COBAS_COV19	CT 2	22.08
2020	11	21	PCR_COBAS_COV19	CT 2	27.69
2020	11	21	PCR_COBAS_COV19	CT 2	30.36
2020	11	21	PCR_COBAS_COV19	CT 2	17.29
2020	11	21	PCR_COBAS_COV19	CT 2	18.95
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.3333289
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	24.9
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	26.4
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	36.7
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	24.1
2020	11	21	PCR_COBAS_COV19	CT 2	35.84
2020	11	21	PCR_COBAS_COV19	CT 2	37.04
2020	11	21	PCR_COBAS_COV19	CT 2	33.67
2020	11	21	PCR_COBAS_COV19	CT 2	25.69
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.2854873
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.32243483
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.42431184
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.10456482
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.65137525
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.37213404
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.04840244
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.83053634
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.01807973
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.92929432
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.19699231
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.89406808
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.91836694
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.24250152
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.1917932
2020	11	21	PCR_COBAS_COV19	CT 2	21.36
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.32536187
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.72185133
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.24584706
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.18777248
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.78069093
2020	11	21	PCR_COBAS_COV19	CT 2	19.68
2020	11	21	PCR_COBAS_COV19	CT 2	21.27
2020	11	21	PCR_COBAS_COV19	CT 2	34.62
2020	11	21	PCR_COBAS_COV19	CT 2	20.39
2020	11	21	PCR_COBAS_COV19	CT 2	40.44
2020	11	21	PCR_COBAS_COV19	CT 2	18.41
2020	11	21	PCR_COBAS_COV19	CT 2	19.61
2020	11	21	PCR_COBAS_COV19	CT 2	19
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	30.8
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	25.5
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	28

AB987

2020	11	21	PCR_COBAS_COV19	CT 2	34.01
2020	11	21	PCR_COBAS_COV19	CT 2	31.86
2020	11	21	PCR_COBAS_COV19	CT 2	21.57
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.26928499
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.03849767
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.59808814
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.77183259
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.08570557
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.40245477
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.28448676
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.48934592
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.04138314
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.32385526
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	18.1
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	20.9
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	19.7
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	24.4
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	21.5
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	19.2
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	21.1
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	22.4
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	19.8
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	31
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	23.4
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	31.8
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	28.1
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.52681174
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.43707388
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.2670588
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.22527865
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.13455956
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.97665329
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	29.2
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	23.5
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.35375364
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	35.8
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	17.1
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	32
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	36.8
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	22.7
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.19299378
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.60905963
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.66735848
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.37207578
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.1817946
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.23215115
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.87137885

AB988

2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.20627454
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.56451603
2020	11	21	PCR_COBAS_COV19	CT 2	23.2
2020	11	21	PCR_COBAS_COV19	CT 2	33.53
2020	11	21	PCR_COBAS_COV19	CT 2	17.69
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	35.6
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	37.9
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	34.4
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	24.7
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.8449335
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.1548443
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.66271183
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.36398859
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.27714365
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.37098673
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	37.4
2020	11	21	PCR_COBAS_COV19	CT 2	14.78
2020	11	21	PCR_COBAS_COV19	CT 2	18.76
2020	11	21	PCR_COBAS_COV19	CT 2	26.88
2020	11	21	PCR_COBAS_COV19	CT 2	31.96
2020	11	21	PCR_COBAS_COV19	CT 2	23.39
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	34.6
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	29.5
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	37.2
2020	11	21	PCR_COBAS_COV19	CT 2	19.87
2020	11	21	PCR_COBAS_COV19	CT 2	23.77
2020	11	21	PCR_COBAS_COV19	CT 2	16.31
2020	11	21	PCR_COBAS_COV19	CT 2	23.69
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.95639289
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.80485837
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	25
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.66093905
2020	11	21	PCR_COBAS_COV19	CT 2	24.31
2020	11	21	PCR_COBAS_COV19	CT 2	16.96
2020	11	21	PCR_COBAS_COV19	CT 2	23.58
2020	11	21	PCR_COBAS_COV19	CT 2	18.77
2020	11	21	PCR_COBAS_COV19	CT 2	28.63
2020	11	21	PCR_COBAS_COV19	CT 2	27.5
2020	11	21	PCR_FUSION_COV19_E	E Gene CT	17.2
2020	11	21	PCR_COBAS_COV19	CT 2	32.43
2020	11	21	PCR_COBAS_COV19	CT 2	37.98
2020	11	21	PCR_COBAS_COV19	CT 2	16.81
2020	11	21	PCR_COBAS_COV19	CT 2	27.97
2020	11	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.33398195
2020	11	22	PCR_COBAS_COV19	CT 2	17.95
2020	11	22	PCR_COBAS_COV19	CT 2	26.74
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.92004598

AB989

2020	11	22	PCR_FUSION_COV19_E	E Gene CT	36.1
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.01662699
2020	11	22	PCR_COBAS_COV19	CT 2	33.53
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	31.2
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	22
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	34.9
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.14865444
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.54437413
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	18.1
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	18.3
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	28.9
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	18.6
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	27.3
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	23
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	27.8
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	18.3
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	33.5
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	32.1
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	22.8
2020	11	22	PCR_COBAS_COV19	CT 2	22.5
2020	11	22	PCR_COBAS_COV19	CT 2	17.48
2020	11	22	PCR_COBAS_COV19	CT 2	21.19
2020	11	22	PCR_COBAS_COV19	CT 2	16.46
2020	11	22	PCR_COBAS_COV19	CT 2	15.55
2020	11	22	PCR_COBAS_COV19	CT 2	16.04
2020	11	22	PCR_COBAS_COV19	CT 2	18.4
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	37.2
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	27.8
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	30.4
2020	11	22	PCR_COBAS_COV19	CT 2	37.78
2020	11	22	PCR_COBAS_COV19	CT 2	23.9
2020	11	22	PCR_COBAS_COV19	CT 2	18.22
2020	11	22	PCR_COBAS_COV19	CT 2	17.66
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.22083165
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.87727289
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.50585067
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.19250221
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.35890819
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.7257324
2020	11	22	PCR_COBAS_COV19	CT 2	19.95
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.1228216
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.09806021
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.26657287
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.54861455
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.942123
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.63424355
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.67740025

AB990

2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.06893015
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.0556396
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	19.6
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.82883636
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.50293661
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.10100649
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.05135791
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.27496415
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.80828566
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.93817954
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.12409276
2020	11	22	PCR_COBAS_COV19	CT 2	33.89
2020	11	22	PCR_COBAS_COV19	CT 2	25.26
2020	11	22	PCR_COBAS_COV19	CT 2	15.76
2020	11	22	PCR_COBAS_COV19	CT 2	19.29
2020	11	22	PCR_COBAS_COV19	CT 2	20.14
2020	11	22	PCR_COBAS_COV19	CT 2	28.81
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	27.3
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	31.1
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	20.3
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	26.4
2020	11	22	PCR_COBAS_COV19	CT 2	36.2
2020	11	22	PCR_COBAS_COV19	CT 2	18.56
2020	11	22	PCR_COBAS_COV19	CT 2	17.95
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.84728315
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.00266503
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.74246811
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.38923402
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.88524583
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.00353676
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.03144562
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.44556275
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.72559124
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.4820603
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.73035259
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.47216754
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.93824568
2020	11	22	PCR_COBAS_COV19	CT 2	18.09
2020	11	22	PCR_COBAS_COV19	CT 2	35.44
2020	11	22	PCR_COBAS_COV19	CT 2	35.68
2020	11	22	PCR_COBAS_COV19	CT 2	33.34
2020	11	22	PCR_COBAS_COV19	CT 2	27.6
2020	11	22	PCR_COBAS_COV19	CT 2	26.91
2020	11	22	PCR_COBAS_COV19	CT 2	28.35
2020	11	22	PCR_COBAS_COV19	CT 2	20.38
2020	11	22	PCR_COBAS_COV19	CT 2	14.78
2020	11	22	PCR_COBAS_COV19	CT 2	25.33

AB991

2020	11	22	PCR_COBAS_COV19	CT 2	32.76
2020	11	22	PCR_COBAS_COV19	CT 2	19.24
2020	11	22	PCR_COBAS_COV19	CT 2	33.51
2020	11	22	PCR_COBAS_COV19	CT 2	17.88
2020	11	22	PCR_COBAS_COV19	CT 2	20.86
2020	11	22	PCR_COBAS_COV19	CT 2	22.61
2020	11	22	PCR_COBAS_COV19	CT 2	22.94
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	22.3
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	18.2
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	30.9
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	23.1
2020	11	22	PCR_COBAS_COV19	CT 2	38.61
2020	11	22	PCR_COBAS_COV19	CT 2	26.28
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.25182695
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.23866671
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.01415546
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.4248647
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.0259121
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	22.1
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.2860802
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.5853669
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	33.9
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	18.5
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	16.4
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	25.6
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	18.1
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	28.2
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	33.6
2020	11	22	PCR_COBAS_COV19	CT 2	17.77
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.62004058
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.04977789
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.85962704
2020	11	22	PCR_FUSION_COV19_E	E Gene CT	19.9
2020	11	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.07931319
2020	11	22	PCR_COBAS_COV19	CT 2	33.04
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.40634126
2020	11	23	PCR_FUSION_COV19_E	E Gene CT	22
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.43131782
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.32502787
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.98686739
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.28164934
2020	11	23	PCR_FUSION_COV19_E	E Gene CT	30.7
2020	11	23	PCR_FUSION_COV19_E	E Gene CT	21.2
2020	11	23	PCR_FUSION_COV19_E	E Gene CT	31.1
2020	11	23	PCR_FUSION_COV19_E	E Gene CT	21.2
2020	11	23	PCR_FUSION_COV19_E	E Gene CT	24.3
2020	11	23	PCR_FUSION_COV19_E	E Gene CT	16.1

2020	11	23	PCR_FUSION_COV19_E	E Gene CT	31.1
2020	11	23	PCR_FUSION_COV19_E	E Gene CT	31.9
2020	11	23	PCR_FUSION_COV19_E	E Gene CT	28.2
2020	11	23	PCR_FUSION_COV19_E	E Gene CT	23.6
2020	11	23	PCR_FUSION_COV19_E	E Gene CT	35
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.60725856
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.38079505
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.85361187
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.13560335
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.85791917
2020	11	23	PCR_COBAS_COV19	CT 2	30.19
2020	11	23	PCR_COBAS_COV19	CT 2	14.72
2020	11	23	PCR_COBAS_COV19	CT 2	32.11
2020	11	23	PCR_COBAS_COV19	CT 2	21.24
2020	11	23	PCR_COBAS_COV19	CT 2	24.27
2020	11	23	PCR_COBAS_COV19	CT 2	19.38
2020	11	23	PCR_COBAS_COV19	CT 2	18.13
2020	11	23	PCR_COBAS_COV19	CT 2	33.83
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.71346544
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.02935592
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.59368721
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.94770145
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.61188772
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.75661625
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.89066667
2020	11	23	PCR_COBAS_COV19	CT 2	36.13
2020	11	23	PCR_COBAS_COV19	CT 2	18.4
2020	11	23	PCR_COBAS_COV19	CT 2	15.72
2020	11	23	PCR_COBAS_COV19	CT 2	29.57
2020	11	23	PCR_COBAS_COV19	CT 2	33.56
2020	11	23	PCR_COBAS_COV19	CT 2	16.23
2020	11	23	PCR_COBAS_COV19	CT 2	21.64
2020	11	23	PCR_FUSION_COV19_E	E Gene CT	29.9
2020	11	23	PCR_FUSION_COV19_E	E Gene CT	30.5
2020	11	23	PCR_FUSION_COV19_E	E Gene CT	30.3
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.44770206
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.52972972
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.69202316
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.55426558
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.03057705
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.10111476
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.47612261
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.10779949
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.88465384
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.5391972
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.04982617
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.25770387

AB993

2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.68814084
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.43330277
2020	11	23	PCR_COBAS_COV19	CT 2	19.38
2020	11	23	PCR_COBAS_COV19	CT 2	36.5
2020	11	23	PCR_COBAS_COV19	CT 2	26.24
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.18539714
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.50539102
2020	11	23	PCR_COBAS_COV19	CT 2	26.74
2020	11	23	PCR_COBAS_COV19	CT 2	24.87
2020	11	23	PCR_COBAS_COV19	CT 2	30.92
2020	11	23	PCR_COBAS_COV19	CT 2	14.92
2020	11	23	PCR_COBAS_COV19	CT 2	37.82
2020	11	23	PCR_COBAS_COV19	CT 2	15.97
2020	11	23	PCR_COBAS_COV19	CT 2	17.4
2020	11	23	PCR_COBAS_COV19	CT 2	23.63
2020	11	23	PCR_COBAS_COV19	CT 2	22.41
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.85341837
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.80362225
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.21552983
2020	11	23	PCR_COBAS_COV19	CT 2	19.23
2020	11	23	PCR_COBAS_COV19	CT 2	17.53
2020	11	23	PCR_COBAS_COV19	CT 2	37.64
2020	11	23	PCR_COBAS_COV19	CT 2	15.95
2020	11	23	PCR_COBAS_COV19	CT 2	29.19
2020	11	23	PCR_COBAS_COV19	CT 2	17.07
2020	11	23	PCR_COBAS_COV19	CT 2	26.3
2020	11	23	PCR_COBAS_COV19	CT 2	18.13
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.14371403
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.11017139
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.79107002
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.13916367
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.75458016
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.44834808
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.92123639
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.50366541
2020	11	23	PCR_COBAS_COV19	CT 2	23.5
2020	11	23	PCR_COBAS_COV19	CT 2	37.44
2020	11	23	PCR_COBAS_COV19	CT 2	18.49
2020	11	23	PCR_COBAS_COV19	CT 2	22.55
2020	11	23	PCR_COBAS_COV19	CT 2	15.36
2020	11	23	PCR_FUSION_COV19_E	E Gene CT	16.5
2020	11	23	PCR_FUSION_COV19_E	E Gene CT	29.8
2020	11	23	PCR_FUSION_COV19_E	E Gene CT	18.9
2020	11	23	PCR_FUSION_COV19_E	E Gene CT	22.9
2020	11	23	PCR_COBAS_COV19	CT 2	27.34
2020	11	23	PCR_COBAS_COV19	CT 2	16.42
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.90558667

2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.42024521
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.54072117
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.90044878
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.68735513
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.16783901
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.18413897
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.65134568
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.16125821
2020	11	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.31355016
2020	11	23	PCR_COBAS_COV19	CT 2	20.67
2020	11	24	PCR_COBAS_COV19	CT 2	36.31
2020	11	24	PCR_COBAS_COV19	CT 2	31.14
2020	11	24	PCR_COBAS_COV19	CT 2	35.7
2020	11	24	PCR_COBAS_COV19	CT 2	18.92
2020	11	24	PCR_COBAS_COV19	CT 2	23.98
2020	11	24	PCR_COBAS_COV19	CT 2	30.74
2020	11	24	PCR_COBAS_COV19	CT 2	18.78
2020	11	24	PCR_COBAS_COV19	CT 2	19.26
2020	11	24	PCR_COBAS_COV19	CT 2	21.35
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.78322318
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.60085971
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.33655243
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.32903197
2020	11	24	PCR_FUSION_COV19_E	E Gene CT	31.9
2020	11	24	PCR_FUSION_COV19_E	E Gene CT	20.8
2020	11	24	PCR_FUSION_COV19_E	E Gene CT	29.6
2020	11	24	PCR_FUSION_COV19_E	E Gene CT	25.2
2020	11	24	PCR_FUSION_COV19_E	E Gene CT	28.3
2020	11	24	PCR_FUSION_COV19_E	E Gene CT	27.7
2020	11	24	PCR_FUSION_COV19_E	E Gene CT	32.2
2020	11	24	PCR_FUSION_COV19_E	E Gene CT	24
2020	11	24	PCR_COBAS_COV19	CT 2	32.54
2020	11	24	PCR_COBAS_COV19	CT 2	15.91
2020	11	24	PCR_COBAS_COV19	CT 2	19.7
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.45747812
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.92826413
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.06302604
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.21121234
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.45081401
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.48053467
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.03684992
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.14098088
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.05484425
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.3488734
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.07112052
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.33448987
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.72122092

AB995

2020	11	24	PCR_FUSION_COV19_E	E Gene CT	19
2020	11	24	PCR_FUSION_COV19_E	E Gene CT	19.2
2020	11	24	PCR_FUSION_COV19_E	E Gene CT	25.9
2020	11	24	PCR_FUSION_COV19_E	E Gene CT	20.3
2020	11	24	PCR_FUSION_COV19_E	E Gene CT	18.2
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.16639956
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.86411913
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.61968892
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.36118707
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.67289234
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.88799257
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.16628356
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.53761838
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.14801909
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.03873097
2020	11	24	PCR_FUSION_COV19_E	E Gene CT	24.8
2020	11	24	PCR_FUSION_COV19_E	E Gene CT	17
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.15736854
2020	11	24	PCR_FUSION_COV19_E	E Gene CT	21.6
2020	11	24	PCR_FUSION_COV19_E	E Gene CT	16.4
2020	11	24	PCR_FUSION_COV19_E	E Gene CT	38
2020	11	24	PCR_FUSION_COV19_E	E Gene CT	24.3
2020	11	24	PCR_FUSION_COV19_E	E Gene CT	19
2020	11	24	PCR_FUSION_COV19_E	E Gene CT	33.1
2020	11	24	PCR_FUSION_COV19_E	E Gene CT	33.3
2020	11	24	PCR_COBAS_COV19	CT 2	28.32
2020	11	24	PCR_COBAS_COV19	CT 2	15.17
2020	11	24	PCR_COBAS_COV19	CT 2	21.8
2020	11	24	PCR_COBAS_COV19	CT 2	15.7
2020	11	24	PCR_COBAS_COV19	CT 2	30.76
2020	11	24	PCR_COBAS_COV19	CT 2	17.03
2020	11	24	PCR_COBAS_COV19	CT 2	32.51
2020	11	24	PCR_COBAS_COV19	CT 2	17.66
2020	11	24	PCR_COBAS_COV19	CT 2	33.26
2020	11	24	PCR_COBAS_COV19	CT 2	28.13
2020	11	24	PCR_COBAS_COV19	CT 2	31.08
2020	11	24	PCR_COBAS_COV19	CT 2	33.33
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.0809815
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.85794475
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.03583128
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	9.019908043
2020	11	24	PCR_COBAS_COV19	CT 2	17.84
2020	11	24	PCR_COBAS_COV19	CT 2	31.59
2020	11	24	PCR_COBAS_COV19	CT 2	18.69
2020	11	24	PCR_COBAS_COV19	CT 2	22.02
2020	11	24	PCR_COBAS_COV19	CT 2	30.07
2020	11	24	PCR_COBAS_COV19	CT 2	19.73

AB996

2020	11	24	PCR_COBAS_COV19	CT 2	21.32
2020	11	24	PCR_COBAS_COV19	CT 2	26.89
2020	11	24	PCR_COBAS_COV19	CT 2	23.11
2020	11	24	PCR_COBAS_COV19	CT 2	16.79
2020	11	24	PCR_COBAS_COV19	CT 2	25.66
2020	11	24	PCR_COBAS_COV19	CT 2	19.51
2020	11	24	PCR_COBAS_COV19	CT 2	20.28
2020	11	24	PCR_COBAS_COV19	CT 2	26.88
2020	11	24	PCR_COBAS_COV19	CT 2	36.24
2020	11	24	PCR_COBAS_COV19	CT 2	32.01
2020	11	24	PCR_COBAS_COV19	CT 2	35.69
2020	11	24	PCR_COBAS_COV19	CT 2	19.06
2020	11	24	PCR_COBAS_COV19	CT 2	34.04
2020	11	24	PCR_COBAS_COV19	CT 2	26.7
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.41240104
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.48570586
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.27916764
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.38455839
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.28160866
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.82823358
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.16814593
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.93707465
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.90127606
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.34114694
2020	11	24	PCR_FUSION_COV19_E	E Gene CT	36.7
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.53630352
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.74155392
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.95950122
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.99436403
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.90962598
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.73420905
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.70202773
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.87165729
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.02051827
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.50099333
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.62908783
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.8439855
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.80096514
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.97214228
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.55195093
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.47322571
2020	11	24	PCR_COBAS_COV19	CT 2	25.65
2020	11	24	PCR_COBAS_COV19	CT 2	31.21
2020	11	24	PCR_COBAS_COV19	CT 2	25.72
2020	11	24	PCR_COBAS_COV19	CT 2	18.51
2020	11	24	PCR_COBAS_COV19	CT 2	17.09
2020	11	24	PCR_COBAS_COV19	CT 2	27.49

2020	11	24	PCR_COBAS_COV19	CT 2	31.83
2020	11	24	PCR_COBAS_COV19	CT 2	20.06
2020	11	24	PCR_COBAS_COV19	CT 2	24.19
2020	11	24	PCR_COBAS_COV19	CT 2	30.43
2020	11	24	PCR_COBAS_COV19	CT 2	18.19
2020	11	24	PCR_COBAS_COV19	CT 2	29.18
2020	11	24	PCR_COBAS_COV19	CT 2	16.34
2020	11	24	PCR_COBAS_COV19	CT 2	19.73
2020	11	24	PCR_FUSION_COV19_E	E Gene CT	29.5
2020	11	24	PCR_COBAS_COV19	CT 2	20.5
2020	11	24	PCR_COBAS_COV19	CT 2	34.37
2020	11	24	PCR_COBAS_COV19	CT 2	30.47
2020	11	24	PCR_COBAS_COV19	CT 2	30.18
2020	11	24	PCR_COBAS_COV19	CT 2	20.2
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.70019902
2020	11	24	PCR_FUSION_COV19_E	E Gene CT	27.6
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.76044987
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.59610789
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.08463276
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.66486225
2020	11	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.73445802
2020	11	25	PCR_COBAS_COV19	CT 2	27.83
2020	11	25	PCR_COBAS_COV19	CT 2	17.28
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	33.5
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.41714911
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	26.3
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.24492473
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	22.1
2020	11	25	PCR_COBAS_COV19	CT 2	33.13
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	34
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	20.5
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	18.3
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	22.1
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	28.7
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.07292292
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	22.6
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	17.3
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	29
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	21.4
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	20.2
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.04425817
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.10925778
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.17661285
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.95905554
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	31.4
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.49403404
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	24.4

AB998

2020	11	25	PCR_FUSION_COV19_E	E Gene CT	24.7
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	19.8
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	21
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.53428603
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.54568588
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	17
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	21.4
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	18.1
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.45005568
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.06926261
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.11184483
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.41996373
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	22.3
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	20.5
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	19.9
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.98983005
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.20085581
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.9020552
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.46235116
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.0103658
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.09404227
2020	11	25	PCR_COBAS_COV19	CT 2	25.65
2020	11	25	PCR_COBAS_COV19	CT 2	30.58
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.9749825
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.74826381
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.63801361
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.15211625
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.4437086
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.88827188
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.50303195
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.68539184
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.29191173
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.45971846
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.87971156
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.36986261
2020	11	25	PCR_COBAS_COV19	CT 2	33.79
2020	11	25	PCR_COBAS_COV19	CT 2	35.07
2020	11	25	PCR_COBAS_COV19	CT 2	35.23
2020	11	25	PCR_COBAS_COV19	CT 2	25.66
2020	11	25	PCR_COBAS_COV19	CT 2	20.81
2020	11	25	PCR_COBAS_COV19	CT 2	34.07
2020	11	25	PCR_COBAS_COV19	CT 2	24.28
2020	11	25	PCR_COBAS_COV19	CT 2	36.65
2020	11	25	PCR_COBAS_COV19	CT 2	19.59
2020	11	25	PCR_COBAS_COV19	CT 2	19.87
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.99799956
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.30335681

2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.46896133
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.74318978
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.38277503
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.75024533
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.47359418
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.02371408
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.07493231
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.2149876
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.0969343
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.3391381
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.28736565
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.16254323
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	9.940762003
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.39633551
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	21.8
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	18
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	22.8
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	20.1
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	20.6
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	30.6
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.47527777
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.3547885
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.16365103
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.21935799
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.09180418
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.02609768
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.46318318
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.50420668
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	23.4
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	19.1
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	20.3
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	15.9
2020	11	25	PCR_COBAS_COV19	CT 2	17.02
2020	11	25	PCR_COBAS_COV19	CT 2	35.61
2020	11	25	PCR_COBAS_COV19	CT 2	33.09
2020	11	25	PCR_COBAS_COV19	CT 2	36.62
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.06152157
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.16686749
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.79893137
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	18.5
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	34.1
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	32
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	20.3
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	18.8
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	19.4
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	34.7
2020	11	25	PCR_FUSION_COV19_E	E Gene CT	23.5

AB1000

2020	11	25	PCR_COBAS_COV19	CT 2	22.1
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.41291628
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.59370546
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.18053172
2020	11	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.54505105
2020	11	25	PCR_COBAS_COV19	CT 2	32.6
2020	11	26	PCR_FUSION_COV19_E	E Gene CT	22.1
2020	11	26	PCR_COBAS_COV19	CT 2	27.6
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.47462036
2020	11	26	PCR_FUSION_COV19_E	E Gene CT	19.7
2020	11	26	PCR_FUSION_COV19_E	E Gene CT	34.7
2020	11	26	PCR_FUSION_COV19_E	E Gene CT	25
2020	11	26	PCR_FUSION_COV19_E	E Gene CT	20
2020	11	26	PCR_COBAS_COV19	CT 2	31.09
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.98039007
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.81336759
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.82563172
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.82876062
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.27464129
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.18075441
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.74275199
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.38206602
2020	11	26	PCR_FUSION_COV19_E	E Gene CT	37
2020	11	26	PCR_FUSION_COV19_E	E Gene CT	23.3
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.79850251
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.76831982
2020	11	26	PCR_FUSION_COV19_E	E Gene CT	16
2020	11	26	PCR_FUSION_COV19_E	E Gene CT	37.8
2020	11	26	PCR_FUSION_COV19_E	E Gene CT	28.6
2020	11	26	PCR_FUSION_COV19_E	E Gene CT	22
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.7485213
2020	11	26	PCR_FUSION_COV19_E	E Gene CT	18.8
2020	11	26	PCR_COBAS_COV19	CT 2	21.69
2020	11	26	PCR_COBAS_COV19	CT 2	22.79
2020	11	26	PCR_COBAS_COV19	CT 2	15.21
2020	11	26	PCR_COBAS_COV19	CT 2	16.88
2020	11	26	PCR_COBAS_COV19	CT 2	18.03
2020	11	26	PCR_COBAS_COV19	CT 2	24.55
2020	11	26	PCR_COBAS_COV19	CT 2	32.35
2020	11	26	PCR_COBAS_COV19	CT 2	16.95
2020	11	26	PCR_COBAS_COV19	CT 2	21.74
2020	11	26	PCR_COBAS_COV19	CT 2	31.39
2020	11	26	PCR_COBAS_COV19	CT 2	33.02
2020	11	26	PCR_COBAS_COV19	CT 2	18.45
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	10.08432273
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.13563581
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.07077134

2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.8506464
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.88599789
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.39815724
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.15773599
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.72428695
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.15876634
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.11747752
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.50650644
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.65534347
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.98818095
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.34812675
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.03539472
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.88437244
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.32349439
2020	11	26	PCR_COBAS_COV19	CT 2	19.62
2020	11	26	PCR_COBAS_COV19	CT 2	17.24
2020	11	26	PCR_COBAS_COV19	CT 2	29.76
2020	11	26	PCR_COBAS_COV19	CT 2	16.93
2020	11	26	PCR_COBAS_COV19	CT 2	21.36
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.35525115
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.68625065
2020	11	26	PCR_FUSION_COV19_E	E Gene CT	28.7
2020	11	26	PCR_FUSION_COV19_E	E Gene CT	29.2
2020	11	26	PCR_FUSION_COV19_E	E Gene CT	37.5
2020	11	26	PCR_FUSION_COV19_E	E Gene CT	20.1
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.99797261
2020	11	26	PCR_FUSION_COV19_E	E Gene CT	32.1
2020	11	26	PCR_FUSION_COV19_E	E Gene CT	26.5
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	10.33863879
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.86664181
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.59548719
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.36675578
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.85862823
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.0569756
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.80259345
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.07221982
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.29666984
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.94862779
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.22592453
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.17350169
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.19654235
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.73302625
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.29648829
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.1439536
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.24346398
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.05571761
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.11819139

AB1002

2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.21789951
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.00982233
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.2658192
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.77521731
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.23551337
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.12824757
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.48383334
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.02311884
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.26155985
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.931597
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.62264861
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.38877785
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.43798609
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.55805451
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.38075101
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.36648145
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.24669216
2020	11	26	PCR_FUSION_COV19_E	E Gene CT	19.1
2020	11	26	PCR_FUSION_COV19_E	E Gene CT	21.4
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.56083024
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.15180611
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.26172937
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.1693067
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.25319563
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.19160139
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.82912864
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.15182185
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.62385526
2020	11	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.33500243
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.5561462
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.86295666
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.62048916
2020	11	27	PCR_COBAS_COV19	CT 2	18.48
2020	11	27	PCR_FUSION_COV19_E	E Gene CT	23.8
2020	11	27	PCR_COBAS_COV19	CT 2	26.8
2020	11	27	PCR_COBAS_COV19	CT 2	15.28
2020	11	27	PCR_COBAS_COV19	CT 2	37.94
2020	11	27	PCR_COBAS_COV19	CT 2	17.43
2020	11	27	PCR_FUSION_COV19_E	E Gene CT	21.5
2020	11	27	PCR_FUSION_COV19_E	E Gene CT	21.2
2020	11	27	PCR_COBAS_COV19	CT 2	16.68
2020	11	27	PCR_COBAS_COV19	CT 2	18.95
2020	11	27	PCR_COBAS_COV19	CT 2	26.17
2020	11	27	PCR_COBAS_COV19	CT 2	31.63
2020	11	27	PCR_COBAS_COV19	CT 2	33.35
2020	11	27	PCR_COBAS_COV19	CT 2	19.89
2020	11	27	PCR_COBAS_COV19	CT 2	35.88

AB1003

2020	11	27	PCR_FUSION_COV19_E	E Gene CT	36.5
2020	11	27	PCR_FUSION_COV19_E	E Gene CT	32.5
2020	11	27	PCR_FUSION_COV19_E	E Gene CT	26.7
2020	11	27	PCR_COBAS_COV19	CT 2	25.69
2020	11	27	PCR_COBAS_COV19	CT 2	23.93
2020	11	27	PCR_COBAS_COV19	CT 2	21.25
2020	11	27	PCR_COBAS_COV19	CT 2	37.82
2020	11	27	PCR_COBAS_COV19	CT 2	19.94
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.579142
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.41200235
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.02429554
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.95235065
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.83042
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.6455234
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.28712825
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.46347905
2020	11	27	PCR_COBAS_COV19	CT 2	17.51
2020	11	27	PCR_COBAS_COV19	CT 2	28.42
2020	11	27	PCR_COBAS_COV19	CT 2	35.54
2020	11	27	PCR_FUSION_COV19_E	E Gene CT	20.2
2020	11	27	PCR_FUSION_COV19_E	E Gene CT	37.7
2020	11	27	PCR_FUSION_COV19_E	E Gene CT	22.6
2020	11	27	PCR_FUSION_COV19_E	E Gene CT	21.8
2020	11	27	PCR_FUSION_COV19_E	E Gene CT	18.3
2020	11	27	PCR_FUSION_COV19_E	E Gene CT	33.1
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.28172192
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.30156598
2020	11	27	PCR_COBAS_COV19	CT 2	17.8
2020	11	27	PCR_COBAS_COV19	CT 2	37.75
2020	11	27	PCR_COBAS_COV19	CT 2	33.69
2020	11	27	PCR_COBAS_COV19	CT 2	22.33
2020	11	27	PCR_COBAS_COV19	CT 2	28.13
2020	11	27	PCR_COBAS_COV19	CT 2	28.17
2020	11	27	PCR_COBAS_COV19	CT 2	36.56
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.90084194
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.83579789
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.33193369
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.98417034
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.6454657
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.20430907
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.53797337
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.61634071
2020	11	27	PCR_FUSION_COV19_E	E Gene CT	24.9
2020	11	27	PCR_FUSION_COV19_E	E Gene CT	22.3
2020	11	27	PCR_FUSION_COV19_E	E Gene CT	21.9
2020	11	27	PCR_FUSION_COV19_E	E Gene CT	24.1
2020	11	27	PCR_FUSION_COV19_E	E Gene CT	21.4

2020	11	27	PCR_FUSION_COV19_E	E Gene CT	28.5
2020	11	27	PCR_FUSION_COV19_E	E Gene CT	28.8
2020	11	27	PCR_FUSION_COV19_E	E Gene CT	25.4
2020	11	27	PCR_FUSION_COV19_E	E Gene CT	19.4
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.23591605
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.79911656
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.13859873
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.31230767
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.74182774
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.2736928
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.65800624
2020	11	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.70541641
2020	11	27	PCR_COBAS_COV19	CT 2	25.74
2020	11	27	PCR_COBAS_COV19	CT 2	19.62
2020	11	27	PCR_COBAS_COV19	CT 2	38.66
2020	11	27	PCR_COBAS_COV19	CT 2	25.6
2020	11	27	PCR_COBAS_COV19	CT 2	25.49
2020	11	27	PCR_COBAS_COV19	CT 2	30.98
2020	11	27	PCR_COBAS_COV19	CT 2	31.87
2020	11	27	PCR_COBAS_COV19	CT 2	35.67
2020	11	27	PCR_COBAS_COV19	CT 2	18.55
2020	11	27	PCR_COBAS_COV19	CT 2	34.86
2020	11	27	PCR_COBAS_COV19	CT 2	33.66
2020	11	27	PCR_COBAS_COV19	CT 2	20.51
2020	11	27	PCR_COBAS_COV19	CT 2	19.95
2020	11	27	PCR_COBAS_COV19	CT 2	29.28
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.74730757
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.30142424
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.38440034
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.22225952
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.21344677
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.60788993
2020	11	28	PCR_FUSION_COV19_E	E Gene CT	29.7
2020	11	28	PCR_FUSION_COV19_E	E Gene CT	25.4
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.31430762
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.87363715
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.98370747
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.93832327
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.63836627
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.33536073
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.07440197
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.37178926
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.82744119
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.20825453
2020	11	28	PCR_COBAS_COV19	CT 2	34.15
2020	11	28	PCR_COBAS_COV19	CT 2	24.13
2020	11	28	PCR_COBAS_COV19	CT 2	23.46

AB1005

2020	11	28	PCR_COBAS_COV19	CT 2	25.47
2020	11	28	PCR_COBAS_COV19	CT 2	27.51
2020	11	28	PCR_COBAS_COV19	CT 2	14.37
2020	11	28	PCR_COBAS_COV19	CT 2	19.72
2020	11	28	PCR_COBAS_COV19	CT 2	21.41
2020	11	28	PCR_COBAS_COV19	CT 2	15.16
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.41676408
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.30280118
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.31608563
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.69411441
2020	11	28	PCR_FUSION_COV19_E	E Gene CT	25
2020	11	28	PCR_FUSION_COV19_E	E Gene CT	18.8
2020	11	28	PCR_FUSION_COV19_E	E Gene CT	28.6
2020	11	28	PCR_FUSION_COV19_E	E Gene CT	17.4
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.31179196
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.38549951
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.41146422
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.16964338
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.46752969
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.39965022
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.26351513
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.50458132
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.95891067
2020	11	28	PCR_COBAS_COV19	CT 2	19.12
2020	11	28	PCR_COBAS_COV19	CT 2	20.39
2020	11	28	PCR_COBAS_COV19	CT 2	28.47
2020	11	28	PCR_COBAS_COV19	CT 2	33.54
2020	11	28	PCR_COBAS_COV19	CT 2	26.68
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.34219427
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.43320894
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.23350908
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.66557973
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.85877083
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.94260788
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.10484263
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.27624357
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.26413417
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.5198807
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.5233528
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.64655089
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.81050403
2020	11	28	PCR_COBAS_COV19	CT 2	26.82
2020	11	28	PCR_COBAS_COV19	CT 2	20.42
2020	11	28	PCR_COBAS_COV19	CT 2	34.3
2020	11	28	PCR_COBAS_COV19	CT 2	16.98
2020	11	28	PCR_COBAS_COV19	CT 2	23.1
2020	11	28	PCR_COBAS_COV19	CT 2	21.68

AB1006

2020	11	28	PCR_COBAS_COV19	CT 2	18.02
2020	11	28	PCR_COBAS_COV19	CT 2	21.33
2020	11	28	PCR_COBAS_COV19	CT 2	20.75
2020	11	28	PCR_COBAS_COV19	CT 2	22.3
2020	11	28	PCR_COBAS_COV19	CT 2	33.1
2020	11	28	PCR_COBAS_COV19	CT 2	28.18
2020	11	28	PCR_COBAS_COV19	CT 2	16.32
2020	11	28	PCR_COBAS_COV19	CT 2	20.85
2020	11	28	PCR_COBAS_COV19	CT 2	16.16
2020	11	28	PCR_COBAS_COV19	CT 2	23.39
2020	11	28	PCR_COBAS_COV19	CT 2	19.4
2020	11	28	PCR_FUSION_COV19_E	E Gene CT	37.6
2020	11	28	PCR_FUSION_COV19_E	E Gene CT	35.3
2020	11	28	PCR_FUSION_COV19_E	E Gene CT	34.3
2020	11	28	PCR_FUSION_COV19_E	E Gene CT	29.1
2020	11	28	PCR_FUSION_COV19_E	E Gene CT	30.7
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.74518965
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.01021499
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.10062122
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.35907633
2020	11	28	PCR_COBAS_COV19	CT 2	24.99
2020	11	28	PCR_COBAS_COV19	CT 2	20.45
2020	11	28	PCR_COBAS_COV19	CT 2	21.67
2020	11	28	PCR_COBAS_COV19	CT 2	36.51
2020	11	28	PCR_COBAS_COV19	CT 2	25.65
2020	11	28	PCR_COBAS_COV19	CT 2	22.26
2020	11	28	PCR_COBAS_COV19	CT 2	28.94
2020	11	28	PCR_COBAS_COV19	CT 2	33.71
2020	11	28	PCR_COBAS_COV19	CT 2	25.12
2020	11	28	PCR_COBAS_COV19	CT 2	16.07
2020	11	28	PCR_COBAS_COV19	CT 2	36.2
2020	11	28	PCR_COBAS_COV19	CT 2	19.4
2020	11	28	PCR_COBAS_COV19	CT 2	25.78
2020	11	28	PCR_COBAS_COV19	CT 2	28.11
2020	11	28	PCR_COBAS_COV19	CT 2	26.09
2020	11	28	PCR_COBAS_COV19	CT 2	29.73
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.47973958
2020	11	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.29582896
2020	11	28	PCR_COBAS_COV19	CT 2	19.17
2020	11	29	PCR_FUSION_COV19_E	E Gene CT	24.6
2020	11	29	PCR_FUSION_COV19_E	E Gene CT	30.1
2020	11	29	PCR_FUSION_COV19_E	E Gene CT	21.7
2020	11	29	PCR_FUSION_COV19_E	E Gene CT	36.5
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.32516051
2020	11	29	PCR_FUSION_COV19_E	E Gene CT	20.6
2020	11	29	PCR_FUSION_COV19_E	E Gene CT	18.1
2020	11	29	PCR_FUSION_COV19_E	E Gene CT	23.1

AB1007

2020	11	29	PCR_FUSION_COV19_E	E Gene CT	25.7
2020	11	29	PCR_FUSION_COV19_E	E Gene CT	25.8
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.70755082
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.95729805
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.74179757
2020	11	29	PCR_FUSION_COV19_E	E Gene CT	36.9
2020	11	29	PCR_FUSION_COV19_E	E Gene CT	27.4
2020	11	29	PCR_FUSION_COV19_E	E Gene CT	17.5
2020	11	29	PCR_FUSION_COV19_E	E Gene CT	18.6
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.40778235
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.51206533
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.35298778
2020	11	29	PCR_COBAS_COV19	CT 2	26.46
2020	11	29	PCR_COBAS_COV19	CT 2	20.48
2020	11	29	PCR_COBAS_COV19	CT 2	27.01
2020	11	29	PCR_COBAS_COV19	CT 2	34.69
2020	11	29	PCR_COBAS_COV19	CT 2	38.92
2020	11	29	PCR_COBAS_COV19	CT 2	17.47
2020	11	29	PCR_COBAS_COV19	CT 2	22.99
2020	11	29	PCR_COBAS_COV19	CT 2	28.69
2020	11	29	PCR_COBAS_COV19	CT 2	29.59
2020	11	29	PCR_COBAS_COV19	CT 2	23.93
2020	11	29	PCR_COBAS_COV19	CT 2	23.03
2020	11	29	PCR_COBAS_COV19	CT 2	20.45
2020	11	29	PCR_COBAS_COV19	CT 2	28.11
2020	11	29	PCR_COBAS_COV19	CT 2	25.22
2020	11	29	PCR_COBAS_COV19	CT 2	17.98
2020	11	29	PCR_COBAS_COV19	CT 2	22.85
2020	11	29	PCR_COBAS_COV19	CT 2	35.52
2020	11	29	PCR_COBAS_COV19	CT 2	20.72
2020	11	29	PCR_COBAS_COV19	CT 2	20.9
2020	11	29	PCR_FUSION_COV19_E	E Gene CT	37.6
2020	11	29	PCR_FUSION_COV19_E	E Gene CT	24.6
2020	11	29	PCR_FUSION_COV19_E	E Gene CT	32.6
2020	11	29	PCR_FUSION_COV19_E	E Gene CT	19.2
2020	11	29	PCR_FUSION_COV19_E	E Gene CT	27.8
2020	11	29	PCR_COBAS_COV19	CT 2	38.14
2020	11	29	PCR_COBAS_COV19	CT 2	15.42
2020	11	29	PCR_COBAS_COV19	CT 2	18.41
2020	11	29	PCR_COBAS_COV19	CT 2	34.34
2020	11	29	PCR_COBAS_COV19	CT 2	14.35
2020	11	29	PCR_COBAS_COV19	CT 2	28.89
2020	11	29	PCR_COBAS_COV19	CT 2	18.71
2020	11	29	PCR_COBAS_COV19	CT 2	22.97
2020	11	29	PCR_COBAS_COV19	CT 2	20.71
2020	11	29	PCR_COBAS_COV19	CT 2	24.88
2020	11	29	PCR_COBAS_COV19	CT 2	24.98

AB1008

2020	11	29	PCR_COBAS_COV19	CT 2	25.87
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.00701276
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.1345861
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.70786645
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.56805715
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.44378234
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.92913125
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.01278037
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.16195856
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.48605434
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.81412966
2020	11	29	PCR_FUSION_COV19_E	E Gene CT	22.3
2020	11	29	PCR_FUSION_COV19_E	E Gene CT	20.9
2020	11	29	PCR_FUSION_COV19_E	E Gene CT	26.2
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.35690657
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.17956667
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.04282008
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.62338557
2020	11	29	PCR_COBAS_COV19	CT 2	16.86
2020	11	29	PCR_COBAS_COV19	CT 2	35.29
2020	11	29	PCR_COBAS_COV19	CT 2	28.09
2020	11	29	PCR_COBAS_COV19	CT 2	27.87
2020	11	29	PCR_COBAS_COV19	CT 2	27.75
2020	11	29	PCR_COBAS_COV19	CT 2	30.73
2020	11	29	PCR_COBAS_COV19	CT 2	34.55
2020	11	29	PCR_COBAS_COV19	CT 2	19.09
2020	11	29	PCR_COBAS_COV19	CT 2	17.06
2020	11	29	PCR_COBAS_COV19	CT 2	36.89
2020	11	29	PCR_COBAS_COV19	CT 2	27.01
2020	11	29	PCR_COBAS_COV19	CT 2	16.37
2020	11	29	PCR_COBAS_COV19	CT 2	26.01
2020	11	29	PCR_COBAS_COV19	CT 2	24.01
2020	11	29	PCR_COBAS_COV19	CT 2	26.02
2020	11	29	PCR_COBAS_COV19	CT 2	20.41
2020	11	29	PCR_COBAS_COV19	CT 2	33.43
2020	11	29	PCR_COBAS_COV19	CT 2	30.44
2020	11	29	PCR_COBAS_COV19	CT 2	31.4
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.94872643
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.95845166
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.0412465
2020	11	29	PCR_FUSION_COV19_E	E Gene CT	21.4
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.08225236
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.94435309
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.64045376
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.08656991
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.61541778
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.59603379

2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.16827544
2020	11	29	PCR_FUSION_COV19_E	E Gene CT	29.6
2020	11	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.64922411
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.47349719
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.60821906
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.62777856
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.87765784
2020	11	30	PCR_COBAS_COV19	CT 2	35.48
2020	11	30	PCR_COBAS_COV19	CT 2	37.58
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.32904498
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.49276386
2020	11	30	PCR_FUSION_COV19_E	E Gene CT	24.3
2020	11	30	PCR_FUSION_COV19_E	E Gene CT	23.2
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.70255519
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.97376104
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.47082304
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.5100724
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.51170564
2020	11	30	PCR_FUSION_COV19_E	E Gene CT	34.2
2020	11	30	PCR_FUSION_COV19_E	E Gene CT	19.6
2020	11	30	PCR_FUSION_COV19_E	E Gene CT	26.3
2020	11	30	PCR_FUSION_COV19_E	E Gene CT	23
2020	11	30	PCR_FUSION_COV19_E	E Gene CT	22.5
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.79035114
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.54443212
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.85808136
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.21437412
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.499956
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.44937682
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.07467328
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.97248586
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.44745188
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.9955146
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.02235314
2020	11	30	PCR_FUSION_COV19_E	E Gene CT	23.2
2020	11	30	PCR_FUSION_COV19_E	E Gene CT	18.8
2020	11	30	PCR_FUSION_COV19_E	E Gene CT	21.1
2020	11	30	PCR_FUSION_COV19_E	E Gene CT	22.3
2020	11	30	PCR_FUSION_COV19_E	E Gene CT	37.1
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.72115367
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.19447341
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.16318422
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.96496349
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.57957283
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.94173538
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.17913382
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.75562159

AB1010

2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.30496962
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.70986048
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.51724842
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.26352067
2020	11	30	PCR_FUSION_COV19_E	E Gene CT	22.9
2020	11	30	PCR_FUSION_COV19_E	E Gene CT	34.2
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.54493294
2020	11	30	PCR_FUSION_COV19_E	E Gene CT	33
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.34047948
2020	11	30	PCR_FUSION_COV19_E	E Gene CT	18.4
2020	11	30	PCR_FUSION_COV19_E	E Gene CT	17.2
2020	11	30	PCR_FUSION_COV19_E	E Gene CT	25.8
2020	11	30	PCR_FUSION_COV19_E	E Gene CT	16.1
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.04423156
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.42844396
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.01363375
2020	11	30	PCR_COBAS_COV19	CT 2	35.68
2020	11	30	PCR_COBAS_COV19	CT 2	32.47
2020	11	30	PCR_COBAS_COV19	CT 2	35.79
2020	11	30	PCR_COBAS_COV19	CT 2	36.26
2020	11	30	PCR_COBAS_COV19	CT 2	37.58
2020	11	30	PCR_COBAS_COV19	CT 2	29.04
2020	11	30	PCR_COBAS_COV19	CT 2	27.74
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.44506206
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.1018398
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.53580875
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.20463875
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.6125188
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.7864849
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.12857748
2020	11	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.31382565
2020	11	30	PCR_COBAS_COV19	CT 2	21.53
2020	11	30	PCR_COBAS_COV19	CT 2	17.36
2020	11	30	PCR_COBAS_COV19	CT 2	34.63
2020	11	30	PCR_COBAS_COV19	CT 2	20.33
2020	11	30	PCR_COBAS_COV19	CT 2	22.62
2020	11	30	PCR_COBAS_COV19	CT 2	19.6
2020	11	30	PCR_COBAS_COV19	CT 2	34.11
2020	11	30	PCR_COBAS_COV19	CT 2	16.77
2020	11	30	PCR_COBAS_COV19	CT 2	15.61
2020	11	30	PCR_COBAS_COV19	CT 2	18.16
2020	11	30	PCR_COBAS_COV19	CT 2	20.71
2020	11	30	PCR_COBAS_COV19	CT 2	26.89
2020	11	30	PCR_COBAS_COV19	CT 2	22.9
2020	11	30	PCR_FUSION_COV19_E	E Gene CT	32.5
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	21.5
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	17.7

AB1011

2020	12	1	PCR_FUSION_COV19_E	E Gene CT	18.7
2020	12	1	PCR_COBAS_COV19	CT 2	17.17
2020	12	1	PCR_COBAS_COV19	CT 2	25.49
2020	12	1	PCR_COBAS_COV19	CT 2	32.71
2020	12	1	PCR_COBAS_COV19	CT 2	18.31
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	35.3
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	30.7
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	24
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	36.5
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	22.3
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	20.2
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	36
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	23.4
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	37.2
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	21
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	23.1
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.00478267
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.23367221
2020	12	1	PCR_COBAS_COV19	CT 2	17.1
2020	12	1	PCR_COBAS_COV19	CT 2	20.38
2020	12	1	PCR_COBAS_COV19	CT 2	14.99
2020	12	1	PCR_COBAS_COV19	CT 2	21.63
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	24.4
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	26.4
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.22637344
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.35915167
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.34403013
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.42949193
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.63843896
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.80996659
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.76480519
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.08102626
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.33421208
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.22020306
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.25778465
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.07170509
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.82135105
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.01510592
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.04599354
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.52126698
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	21.5
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	19.6
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	27
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	31.7
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	30.1
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	30.1
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	20.7

AB1012

2020	12	1	PCR_FUSION_COV19_E	E Gene CT	27.1
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	24.1
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	18.6
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	22.4
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.36031547
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.24809459
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.76299362
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.84044043
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	16.5
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	29.2
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	26.3
2020	12	1	PCR_COBAS_COV19	CT 2	37.87
2020	12	1	PCR_COBAS_COV19	CT 2	24.7
2020	12	1	PCR_COBAS_COV19	CT 2	23.08
2020	12	1	PCR_COBAS_COV19	CT 2	19.47
2020	12	1	PCR_COBAS_COV19	CT 2	22.08
2020	12	1	PCR_COBAS_COV19	CT 2	35.01
2020	12	1	PCR_COBAS_COV19	CT 2	15.92
2020	12	1	PCR_COBAS_COV19	CT 2	30.23
2020	12	1	PCR_COBAS_COV19	CT 2	26.53
2020	12	1	PCR_COBAS_COV19	CT 2	29.39
2020	12	1	PCR_COBAS_COV19	CT 2	31.88
2020	12	1	PCR_COBAS_COV19	CT 2	18.95
2020	12	1	PCR_COBAS_COV19	CT 2	18.75
2020	12	1	PCR_COBAS_COV19	CT 2	23.66
2020	12	1	PCR_COBAS_COV19	CT 2	31.23
2020	12	1	PCR_COBAS_COV19	CT 2	27.87
2020	12	1	PCR_COBAS_COV19	CT 2	23.11
2020	12	1	PCR_COBAS_COV19	CT 2	18.47
2020	12	1	PCR_COBAS_COV19	CT 2	20.33
2020	12	1	PCR_COBAS_COV19	CT 2	32.39
2020	12	1	PCR_COBAS_COV19	CT 2	34.42
2020	12	1	PCR_COBAS_COV19	CT 2	21.34
2020	12	1	PCR_COBAS_COV19	CT 2	16.8
2020	12	1	PCR_COBAS_COV19	CT 2	16.28
2020	12	1	PCR_COBAS_COV19	CT 2	26.61
2020	12	1	PCR_COBAS_COV19	CT 2	35.19
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	28
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	20.8
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	17.9
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	35
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	30.2
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	21.9
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	17
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	26.4
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.12653965
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	25.5

AB1013

2020	12	1	PCR_FUSION_COV19_E	E Gene CT	23.7
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	29.5
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	21.1
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.75646587
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.0034876
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.05050666
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.45418208
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.1717854
2020	12	1	PCR_COBAS_COV19	CT 2	20.8
2020	12	1	PCR_COBAS_COV19	CT 2	38.77
2020	12	1	PCR_COBAS_COV19	CT 2	20.62
2020	12	1	PCR_COBAS_COV19	CT 2	21.3
2020	12	1	PCR_COBAS_COV19	CT 2	24.54
2020	12	1	PCR_COBAS_COV19	CT 2	32.49
2020	12	1	PCR_COBAS_COV19	CT 2	33.26
2020	12	1	PCR_COBAS_COV19	CT 2	37.46
2020	12	1	PCR_COBAS_COV19	CT 2	33.28
2020	12	1	PCR_COBAS_COV19	CT 2	29.22
2020	12	1	PCR_COBAS_COV19	CT 2	27.96
2020	12	1	PCR_COBAS_COV19	CT 2	24.88
2020	12	1	PCR_COBAS_COV19	CT 2	36.68
2020	12	1	PCR_COBAS_COV19	CT 2	36.58
2020	12	1	PCR_COBAS_COV19	CT 2	25.46
2020	12	1	PCR_COBAS_COV19	CT 2	30.29
2020	12	1	PCR_COBAS_COV19	CT 2	22.84
2020	12	1	PCR_COBAS_COV19	CT 2	27.33
2020	12	1	PCR_COBAS_COV19	CT 2	31.14
2020	12	1	PCR_COBAS_COV19	CT 2	32.09
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.03358235
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	33
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	31.2
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	22.5
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	35
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	35.1
2020	12	1	PCR_COBAS_COV19	CT 2	30.09
2020	12	1	PCR_COBAS_COV19	CT 2	22.04
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.85668981
2020	12	1	PCR_COBAS_COV19	CT 2	35.21
2020	12	1	PCR_COBAS_COV19	CT 2	18.4
2020	12	1	PCR_COBAS_COV19	CT 2	21.14
2020	12	1	PCR_COBAS_COV19	CT 2	34.14
2020	12	1	PCR_COBAS_COV19	CT 2	19.05
2020	12	1	PCR_COBAS_COV19	CT 2	36.88
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.63325377
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.10119695
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.06288394
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.80129503

AB1014

2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.30800414
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.05704331
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.83434341
2020	12	1	PCR_FUSION_COV19_E	E Gene CT	35
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.95468328
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.25084193
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.18727435
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.12311208
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.20115155
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.01528528
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.83338949
2020	12	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.94924863
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.26276086
2020	12	2	PCR_FUSION_COV19_E	E Gene CT	29.9
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.56031504
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.25127475
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.13984625
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.45389182
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.0103534
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.90136493
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.89130977
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.68381627
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.32961794
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.57493481
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.87297914
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.77383485
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.01327119
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.54311171
2020	12	2	PCR_FUSION_COV19_E	E Gene CT	19.6
2020	12	2	PCR_FUSION_COV19_E	E Gene CT	21.1
2020	12	2	PCR_FUSION_COV19_E	E Gene CT	22.5
2020	12	2	PCR_FUSION_COV19_E	E Gene CT	17.1
2020	12	2	PCR_FUSION_COV19_E	E Gene CT	28
2020	12	2	PCR_FUSION_COV19_E	E Gene CT	21.9
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.63341818
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.11071071
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.60180347
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.54206135
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.92963796
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.37722939
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.05156857
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.41937854
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.04895278
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.20963122
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.01589734
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.55045827
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.36070043

AB1015

2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.96601507
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.39074313
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.32593734
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.25225663
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.82377259
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.83453792
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.62944806
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.70295017
2020	12	2	PCR_FUSION_COV19_E	E Gene CT	18.1
2020	12	2	PCR_FUSION_COV19_E	E Gene CT	23.5
2020	12	2	PCR_FUSION_COV19_E	E Gene CT	32
2020	12	2	PCR_FUSION_COV19_E	E Gene CT	22.9
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.34178684
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.7957534
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.42277074
2020	12	2	PCR_COBAS_COV19	CT 2	36.48
2020	12	2	PCR_COBAS_COV19	CT 2	17.07
2020	12	2	PCR_COBAS_COV19	CT 2	28.7
2020	12	2	PCR_COBAS_COV19	CT 2	26
2020	12	2	PCR_COBAS_COV19	CT 2	35.1
2020	12	2	PCR_FUSION_COV19_E	E Gene CT	29
2020	12	2	PCR_COBAS_COV19	CT 2	26.94
2020	12	2	PCR_COBAS_COV19	CT 2	25.61
2020	12	2	PCR_COBAS_COV19	CT 2	27.71
2020	12	2	PCR_COBAS_COV19	CT 2	24.08
2020	12	2	PCR_COBAS_COV19	CT 2	24.53
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.30883117
2020	12	2	PCR_FUSION_COV19_E	E Gene CT	25.9
2020	12	2	PCR_FUSION_COV19_E	E Gene CT	21.1
2020	12	2	PCR_FUSION_COV19_E	E Gene CT	17.4
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.99008846
2020	12	2	PCR_FUSION_COV19_E	E Gene CT	28.6
2020	12	2	PCR_FUSION_COV19_E	E Gene CT	27.9
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.29191177
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.41123462
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.43569811
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.76043855
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.5280343
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.11362353
2020	12	2	PCR_COBAS_COV19	CT 2	27.08
2020	12	2	PCR_COBAS_COV19	CT 2	31.49
2020	12	2	PCR_COBAS_COV19	CT 2	35.45
2020	12	2	PCR_COBAS_COV19	CT 2	20.8
2020	12	2	PCR_COBAS_COV19	CT 2	22.76
2020	12	2	PCR_FUSION_COV19_E	E Gene CT	18.8
2020	12	2	PCR_FUSION_COV19_E	E Gene CT	30.6
2020	12	2	PCR_FUSION_COV19_E	E Gene CT	30.5

AB1016

2020	12	2	PCR_FUSION_COV19_E	E Gene CT	25.6
2020	12	2	PCR_FUSION_COV19_E	E Gene CT	23.7
2020	12	2	PCR_FUSION_COV19_E	E Gene CT	17.5
2020	12	2	PCR_FUSION_COV19_E	E Gene CT	21.1
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.08808306
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.71600487
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.58872533
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.49340948
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.66584784
2020	12	2	PCR_COBAS_COV19	CT 2	23.18
2020	12	2	PCR_COBAS_COV19	CT 2	24.12
2020	12	2	PCR_COBAS_COV19	CT 2	34.4
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.2142347
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.60967627
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.81027094
2020	12	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.01618123
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.52700357
2020	12	3	PCR_COBAS_COV19	CT 2	37.44
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.56493228
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.37578729
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.07441699
2020	12	3	PCR_FUSION_COV19_E	E Gene CT	31
2020	12	3	PCR_FUSION_COV19_E	E Gene CT	15.6
2020	12	3	PCR_COBAS_COV19	CT 2	34.22
2020	12	3	PCR_COBAS_COV19	CT 2	21.47
2020	12	3	PCR_COBAS_COV19	CT 2	38.85
2020	12	3	PCR_COBAS_COV19	CT 2	36.07
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.21969847
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.45169412
2020	12	3	PCR_FUSION_COV19_E	E Gene CT	22.1
2020	12	3	PCR_FUSION_COV19_E	E Gene CT	20.5
2020	12	3	PCR_FUSION_COV19_E	E Gene CT	26.1
2020	12	3	PCR_FUSION_COV19_E	E Gene CT	29.7
2020	12	3	PCR_COBAS_COV19	CT 2	16.64
2020	12	3	PCR_COBAS_COV19	CT 2	30.48
2020	12	3	PCR_COBAS_COV19	CT 2	36.69
2020	12	3	PCR_COBAS_COV19	CT 2	38.42
2020	12	3	PCR_COBAS_COV19	CT 2	33.51
2020	12	3	PCR_COBAS_COV19	CT 2	33.44
2020	12	3	PCR_COBAS_COV19	CT 2	20.97
2020	12	3	PCR_COBAS_COV19	CT 2	20.45
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.15128205
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.5615382
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.68505399
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.39007461
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.58330045
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.07075948

2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.17141283
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.32050113
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.89302419
2020	12	3	PCR_FUSION_COV19_E	E Gene CT	23.2
2020	12	3	PCR_COBAS_COV19	CT 2	18.67
2020	12	3	PCR_COBAS_COV19	CT 2	20.48
2020	12	3	PCR_COBAS_COV19	CT 2	21.11
2020	12	3	PCR_COBAS_COV19	CT 2	35.84
2020	12	3	PCR_COBAS_COV19	CT 2	19.61
2020	12	3	PCR_COBAS_COV19	CT 2	32.24
2020	12	3	PCR_COBAS_COV19	CT 2	20.98
2020	12	3	PCR_COBAS_COV19	CT 2	14.61
2020	12	3	PCR_COBAS_COV19	CT 2	33.33
2020	12	3	PCR_COBAS_COV19	CT 2	32.09
2020	12	3	PCR_COBAS_COV19	CT 2	22.26
2020	12	3	PCR_COBAS_COV19	CT 2	19.55
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.87527054
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.14867296
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.99811568
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.0951092
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.29030495
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.40612438
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.81957853
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.24899572
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.70670628
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.21052992
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.00259245
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.66555711
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.69605487
2020	12	3	PCR_COBAS_COV19	CT 2	20.52
2020	12	3	PCR_COBAS_COV19	CT 2	28.28
2020	12	3	PCR_COBAS_COV19	CT 2	18.97
2020	12	3	PCR_COBAS_COV19	CT 2	24.41
2020	12	3	PCR_COBAS_COV19	CT 2	23.49
2020	12	3	PCR_COBAS_COV19	CT 2	26.29
2020	12	3	PCR_COBAS_COV19	CT 2	23.01
2020	12	3	PCR_COBAS_COV19	CT 2	29.58
2020	12	3	PCR_COBAS_COV19	CT 2	17.93
2020	12	3	PCR_COBAS_COV19	CT 2	17.7
2020	12	3	PCR_COBAS_COV19	CT 2	18.39
2020	12	3	PCR_FUSION_COV19_E	E Gene CT	37.9
2020	12	3	PCR_FUSION_COV19_E	E Gene CT	25.5
2020	12	3	PCR_FUSION_COV19_E	E Gene CT	27.5
2020	12	3	PCR_FUSION_COV19_E	E Gene CT	22.5
2020	12	3	PCR_FUSION_COV19_E	E Gene CT	18.9
2020	12	3	PCR_FUSION_COV19_E	E Gene CT	20
2020	12	3	PCR_FUSION_COV19_E	E Gene CT	16.8

2020	12	3	PCR_FUSION_COV19_E	E Gene CT	25.7
2020	12	3	PCR_FUSION_COV19_E	E Gene CT	21.7
2020	12	3	PCR_FUSION_COV19_E	E Gene CT	23
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.05797968
2020	12	3	PCR_COBAS_COV19	CT 2	27.17
2020	12	3	PCR_COBAS_COV19	CT 2	24.06
2020	12	3	PCR_COBAS_COV19	CT 2	31.32
2020	12	3	PCR_COBAS_COV19	CT 2	36.03
2020	12	3	PCR_COBAS_COV19	CT 2	17.44
2020	12	3	PCR_COBAS_COV19	CT 2	37.99
2020	12	3	PCR_COBAS_COV19	CT 2	27.97
2020	12	3	PCR_COBAS_COV19	CT 2	17.5
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.57666323
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.21385052
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.19820725
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.99604046
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.35059803
2020	12	3	PCR_FUSION_COV19_E	E Gene CT	25.1
2020	12	3	PCR_FUSION_COV19_E	E Gene CT	28.5
2020	12	3	PCR_FUSION_COV19_E	E Gene CT	19.6
2020	12	3	PCR_FUSION_COV19_E	E Gene CT	21.5
2020	12	3	PCR_FUSION_COV19_E	E Gene CT	37.2
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.24609723
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.97036374
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.23902927
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.88241449
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.07659005
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.97562872
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.4178918
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.81782543
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.97313651
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.41911346
2020	12	3	PCR_FUSION_COV19_E	E Gene CT	29.5
2020	12	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.55595822
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.48617248
2020	12	4	PCR_FUSION_COV19_E	E Gene CT	26
2020	12	4	PCR_FUSION_COV19_E	E Gene CT	32.1
2020	12	4	PCR_FUSION_COV19_E	E Gene CT	35.2
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.94299051
2020	12	4	PCR_COBAS_COV19	CT 2	20.2
2020	12	4	PCR_COBAS_COV19	CT 2	26.32
2020	12	4	PCR_COBAS_COV19	CT 2	34.38
2020	12	4	PCR_COBAS_COV19	CT 2	20.83
2020	12	4	PCR_COBAS_COV19	CT 2	19.82
2020	12	4	PCR_FUSION_COV19_E	E Gene CT	24.8
2020	12	4	PCR_FUSION_COV19_E	E Gene CT	37.5
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.93072581

AB1019

2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.57961666
2020	12	4	PCR_FUSION_COV19_E	E Gene CT	28.2
2020	12	4	PCR_FUSION_COV19_E	E Gene CT	25.8
2020	12	4	PCR_FUSION_COV19_E	E Gene CT	18.3
2020	12	4	PCR_FUSION_COV19_E	E Gene CT	21
2020	12	4	PCR_FUSION_COV19_E	E Gene CT	32.5
2020	12	4	PCR_FUSION_COV19_E	E Gene CT	18.9
2020	12	4	PCR_COBAS_COV19	CT 2	20.83
2020	12	4	PCR_COBAS_COV19	CT 2	22.76
2020	12	4	PCR_COBAS_COV19	CT 2	35.57
2020	12	4	PCR_COBAS_COV19	CT 2	17.85
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.18467729
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.66313904
2020	12	4	PCR_COBAS_COV19	CT 2	17.22
2020	12	4	PCR_COBAS_COV19	CT 2	35.99
2020	12	4	PCR_COBAS_COV19	CT 2	18.73
2020	12	4	PCR_FUSION_COV19_E	E Gene CT	22.7
2020	12	4	PCR_FUSION_COV19_E	E Gene CT	18.6
2020	12	4	PCR_COBAS_COV19	CT 2	18.09
2020	12	4	PCR_COBAS_COV19	CT 2	21.18
2020	12	4	PCR_COBAS_COV19	CT 2	23.84
2020	12	4	PCR_COBAS_COV19	CT 2	30.2
2020	12	4	PCR_COBAS_COV19	CT 2	27.37
2020	12	4	PCR_COBAS_COV19	CT 2	28.04
2020	12	4	PCR_COBAS_COV19	CT 2	24.59
2020	12	4	PCR_COBAS_COV19	CT 2	27.65
2020	12	4	PCR_COBAS_COV19	CT 2	24.53
2020	12	4	PCR_COBAS_COV19	CT 2	17.67
2020	12	4	PCR_COBAS_COV19	CT 2	31.36
2020	12	4	PCR_FUSION_COV19_E	E Gene CT	19
2020	12	4	PCR_FUSION_COV19_E	E Gene CT	19.6
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.16685702
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.11144437
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.57054978
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.07623431
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.01252421
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.1591207
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.299605
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.52603359
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.9157859
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.41061184
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.98597279
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.06217288
2020	12	4	PCR_COBAS_COV19	CT 2	31.04
2020	12	4	PCR_COBAS_COV19	CT 2	21.59
2020	12	4	PCR_COBAS_COV19	CT 2	14.53
2020	12	4	PCR_COBAS_COV19	CT 2	38.47

2020	12	4	PCR_COBAS_COV19	CT 2	31.27
2020	12	4	PCR_COBAS_COV19	CT 2	21.56
2020	12	4	PCR_COBAS_COV19	CT 2	17.3
2020	12	4	PCR_COBAS_COV19	CT 2	19.81
2020	12	4	PCR_COBAS_COV19	CT 2	19.73
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.60998164
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.32397937
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.92480401
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.48357311
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.37802023
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.97160124
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.16559506
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.76852393
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.63316454
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.36014622
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.67922231
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.96363462
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.58419974
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.59097678
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.1255505
2020	12	4	PCR_FUSION_COV19_E	E Gene CT	17.7
2020	12	4	PCR_FUSION_COV19_E	E Gene CT	18
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.71612616
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.46715598
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.27469921
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.52027634
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.49913522
2020	12	4	PCR_COBAS_COV19	CT 2	31.89
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.93064597
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.65401483
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.12116738
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.89925236
2020	12	4	PCR_FUSION_COV19_E	E Gene CT	20.8
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.37963318
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.74388814
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.44567796
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.70390429
2020	12	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.64596719
2020	12	4	PCR_FUSION_COV19_E	E Gene CT	29.9
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.61627864
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	18.9
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	20.7
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	28.2
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	27.6
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.92249807
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.57246482
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	24.2

AB1021

2020	12	5	PCR_FUSION_COV19_E	E Gene CT	30.5
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	28.1
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	18.8
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	26.9
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	18.1
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	22.8
2020	12	5	PCR_COBAS_COV19	CT 2	26.02
2020	12	5	PCR_COBAS_COV19	CT 2	36.05
2020	12	5	PCR_COBAS_COV19	CT 2	29.96
2020	12	5	PCR_COBAS_COV19	CT 2	30.87
2020	12	5	PCR_COBAS_COV19	CT 2	17.88
2020	12	5	PCR_COBAS_COV19	CT 2	22.62
2020	12	5	PCR_COBAS_COV19	CT 2	23.51
2020	12	5	PCR_COBAS_COV19	CT 2	25.01
2020	12	5	PCR_COBAS_COV19	CT 2	26.24
2020	12	5	PCR_COBAS_COV19	CT 2	21.9
2020	12	5	PCR_COBAS_COV19	CT 2	37.64
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	37.9
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	21.2
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	18.2
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.57045352
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.58038001
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	34.2
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	19.5
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	24
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	28.3
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	19.3
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	21.1
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	18.9
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	18.6
2020	12	5	PCR_COBAS_COV19	CT 2	29.59
2020	12	5	PCR_COBAS_COV19	CT 2	23.23
2020	12	5	PCR_COBAS_COV19	CT 2	27.45
2020	12	5	PCR_COBAS_COV19	CT 2	15
2020	12	5	PCR_COBAS_COV19	CT 2	18.69
2020	12	5	PCR_COBAS_COV19	CT 2	20.13
2020	12	5	PCR_COBAS_COV19	CT 2	28.06
2020	12	5	PCR_COBAS_COV19	CT 2	17.38
2020	12	5	PCR_COBAS_COV19	CT 2	20.4
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	18.5
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	32.2
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	25.4
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	31.6
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	20.4
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.68635201
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.95100161
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.98120985

AB1022

2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.20604519
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.95714929
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.03248698
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.62188565
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.71908367
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.97690581
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.03472903
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.16520159
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.34732061
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	21
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	35.8
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	35.6
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	29.3
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	24
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.45831282
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.78024917
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.39364512
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.64428395
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.9616888
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.37875592
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.64307908
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.38284183
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.01166575
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.79647781
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.97436442
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.51941299
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.40290934
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.6782568
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.37289688
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.94672548
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.17782329
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.75591578
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.33909484
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.53458522
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.20457214
2020	12	5	PCR_COBAS_COV19	CT 2	33.63
2020	12	5	PCR_COBAS_COV19	CT 2	24.1
2020	12	5	PCR_COBAS_COV19	CT 2	14.76
2020	12	5	PCR_COBAS_COV19	CT 2	29.18
2020	12	5	PCR_COBAS_COV19	CT 2	23.84
2020	12	5	PCR_COBAS_COV19	CT 2	31.47
2020	12	5	PCR_COBAS_COV19	CT 2	26.06
2020	12	5	PCR_COBAS_COV19	CT 2	23.27
2020	12	5	PCR_COBAS_COV19	CT 2	22.63
2020	12	5	PCR_COBAS_COV19	CT 2	29.52
2020	12	5	PCR_COBAS_COV19	CT 2	33.05
2020	12	5	PCR_COBAS_COV19	CT 2	32.5

AB1023

2020	12	5	PCR_COBAS_COV19	CT 2	19.03
2020	12	5	PCR_COBAS_COV19	CT 2	33.87
2020	12	5	PCR_COBAS_COV19	CT 2	19.1
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.45174674
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.63201062
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.34544196
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.72780338
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.37419694
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.21547332
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.12453834
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.23001195
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.64256859
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.72634765
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	34
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	20.5
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	27.9
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	27.6
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	23.6
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	33.9
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.1236315
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.36806197
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	35.2
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	22.4
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.56444789
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.15281883
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	39.43954866
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.09690616
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	29.7
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	28.2
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	30.3
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	24.5
2020	12	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.577057
2020	12	5	PCR_COBAS_COV19	CT 2	27.07
2020	12	5	PCR_COBAS_COV19	CT 2	20.72
2020	12	5	PCR_COBAS_COV19	CT 2	15.76
2020	12	5	PCR_FUSION_COV19_E	E Gene CT	20.5
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.11035155
2020	12	6	PCR_FUSION_COV19_E	E Gene CT	27.5
2020	12	6	PCR_FUSION_COV19_E	E Gene CT	23.4
2020	12	6	PCR_FUSION_COV19_E	E Gene CT	31.3
2020	12	6	PCR_FUSION_COV19_E	E Gene CT	21.7
2020	12	6	PCR_FUSION_COV19_E	E Gene CT	26.4
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.27809332
2020	12	6	PCR_FUSION_COV19_E	E Gene CT	21.1
2020	12	6	PCR_FUSION_COV19_E	E Gene CT	32.6
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.86971675
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.79798166

AB1024

2020	12	6	PCR_FUSION_COV19_E	E Gene CT	27.7
2020	12	6	PCR_FUSION_COV19_E	E Gene CT	35.8
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.37696161
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.25256279
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.49482446
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.59691803
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.03592801
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.84414542
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.01850391
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.03422454
2020	12	6	PCR_COBAS_COV19	CT 2	25.94
2020	12	6	PCR_COBAS_COV19	CT 2	16.75
2020	12	6	PCR_COBAS_COV19	CT 2	17.25
2020	12	6	PCR_COBAS_COV19	CT 2	17.49
2020	12	6	PCR_COBAS_COV19	CT 2	22.51
2020	12	6	PCR_COBAS_COV19	CT 2	24.83
2020	12	6	PCR_COBAS_COV19	CT 2	23.44
2020	12	6	PCR_COBAS_COV19	CT 2	35.8
2020	12	6	PCR_COBAS_COV19	CT 2	33.87
2020	12	6	PCR_FUSION_COV19_E	E Gene CT	23
2020	12	6	PCR_FUSION_COV19_E	E Gene CT	28
2020	12	6	PCR_FUSION_COV19_E	E Gene CT	21.7
2020	12	6	PCR_FUSION_COV19_E	E Gene CT	22.3
2020	12	6	PCR_FUSION_COV19_E	E Gene CT	19.4
2020	12	6	PCR_FUSION_COV19_E	E Gene CT	36.5
2020	12	6	PCR_FUSION_COV19_E	E Gene CT	19.4
2020	12	6	PCR_COBAS_COV19	CT 2	37.71
2020	12	6	PCR_COBAS_COV19	CT 2	35.16
2020	12	6	PCR_COBAS_COV19	CT 2	15.74
2020	12	6	PCR_COBAS_COV19	CT 2	27.66
2020	12	6	PCR_COBAS_COV19	CT 2	19.72
2020	12	6	PCR_COBAS_COV19	CT 2	33.56
2020	12	6	PCR_COBAS_COV19	CT 2	37.79
2020	12	6	PCR_COBAS_COV19	CT 2	22.53
2020	12	6	PCR_COBAS_COV19	CT 2	21.08
2020	12	6	PCR_COBAS_COV19	CT 2	18.21
2020	12	6	PCR_COBAS_COV19	CT 2	17.51
2020	12	6	PCR_COBAS_COV19	CT 2	17.93
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.89764973
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.76632707
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.86967221
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.9388069
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.12388336
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.491448
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.03947409
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.87787373
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.93711522

AB1025

2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.81236825
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.21173812
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.1163164
2020	12	6	PCR_COBAS_COV19	CT 2	19.51
2020	12	6	PCR_COBAS_COV19	CT 2	28.12
2020	12	6	PCR_COBAS_COV19	CT 2	31.24
2020	12	6	PCR_COBAS_COV19	CT 2	24.26
2020	12	6	PCR_FUSION_COV19_E	E Gene CT	26.1
2020	12	6	PCR_FUSION_COV19_E	E Gene CT	30.6
2020	12	6	PCR_FUSION_COV19_E	E Gene CT	23.9
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.22638656
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.79305256
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.4341544
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.98719629
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.97523043
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.71629555
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.95057362
2020	12	6	PCR_FUSION_COV19_E	E Gene CT	36.2
2020	12	6	PCR_FUSION_COV19_E	E Gene CT	21
2020	12	6	PCR_FUSION_COV19_E	E Gene CT	36
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.21796888
2020	12	6	PCR_FUSION_COV19_E	E Gene CT	24.4
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.20206694
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.63174792
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.69041805
2020	12	6	PCR_FUSION_COV19_E	E Gene CT	23.4
2020	12	6	PCR_FUSION_COV19_E	E Gene CT	20.8
2020	12	6	PCR_FUSION_COV19_E	E Gene CT	23.4
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.32108664
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.26003636
2020	12	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.10808791
2020	12	7	PCR_PANTH_COV19	RLU	1142
2020	12	7	PCR_PANTH_COV19	RLU	1207
2020	12	7	PCR_PANTH_COV19	RLU	1193
2020	12	7	PCR_PANTH_COV19	RLU	1198
2020	12	7	PCR_PANTH_COV19	RLU	1183
2020	12	7	PCR_PANTH_COV19	RLU	1226
2020	12	7	PCR_PANTH_COV19	RLU	1203
2020	12	7	PCR_PANTH_COV19	RLU	1147
2020	12	7	PCR_PANTH_COV19	RLU	1164
2020	12	7	PCR_PANTH_COV19	RLU	1196
2020	12	7	PCR_PANTH_COV19	RLU	1179
2020	12	7	PCR_PANTH_COV19	RLU	1176
2020	12	7	PCR_PANTH_COV19	RLU	1158
2020	12	7	PCR_PANTH_COV19	RLU	1144
2020	12	7	PCR_PANTH_COV19	RLU	1146
2020	12	7	PCR_PANTH_COV19	RLU	1150

AB1026

2020	12	7	PCR_PANTH_COV19	RLU	1214
2020	12	7	PCR_PANTH_COV19	RLU	1203
2020	12	7	PCR_PANTH_COV19	RLU	1147
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.2044908
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.25614134
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.41898351
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.29167654
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.03394182
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	35.3
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	32
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	18.8
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	22.9
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	20.8
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	24.9
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	20.6
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	17.2
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	32.5
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	19.7
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.53003592
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	22.4
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	25.4
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.03835063
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.03405964
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.8662372
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.62384
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.46190571
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.27269469
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.42613203
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.70126546
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.56645459
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	17.2
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	24.7
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.42937079
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	30.3
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	25.4
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	30
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	29.6
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.58374016
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	33.4
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	37.4
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	28.7
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	27
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	17.4
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	29.7
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	25.2
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	35.3
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	18.5

AB1027

2020	12	7	PCR_FUSION_COV19_E	E Gene CT	18.6
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	27.7
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	16.3
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	24.7
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.14665872
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.57259658
2020	12	7	PCR_COBAS_COV19	CT 2	23.53
2020	12	7	PCR_COBAS_COV19	CT 2	30.21
2020	12	7	PCR_COBAS_COV19	CT 2	27.44
2020	12	7	PCR_COBAS_COV19	CT 2	35.72
2020	12	7	PCR_COBAS_COV19	CT 2	22.87
2020	12	7	PCR_COBAS_COV19	CT 2	27.73
2020	12	7	PCR_COBAS_COV19	CT 2	30.72
2020	12	7	PCR_COBAS_COV19	CT 2	34.3
2020	12	7	PCR_COBAS_COV19	CT 2	21.52
2020	12	7	PCR_COBAS_COV19	CT 2	21.14
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.48060141
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.95291004
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.49289038
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.72649393
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.46791928
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.38393281
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.10402756
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.23337418
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.45828704
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.49483316
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.71236996
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.7186367
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	27.2
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	21
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	28.9
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	24.2
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	25.7
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.43094826
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.2322384
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.83691897
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.77403162
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.03172662
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.22656667
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.22421221
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.15339185
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.1010838
2020	12	7	PCR_COBAS_COV19	CT 2	16.72
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	21.1
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	34.4
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.52056813
2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.378993

AB1028

2020	12	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.78031318
2020	12	7	PCR_FUSION_COV19_E	E Gene CT	26.7
2020	12	8	PCR_PANTH_COV19	RLU	1183
2020	12	8	PCR_PANTH_COV19	RLU	1184
2020	12	8	PCR_PANTH_COV19	RLU	1154
2020	12	8	PCR_PANTH_COV19	RLU	1214
2020	12	8	PCR_PANTH_COV19	RLU	1209
2020	12	8	PCR_PANTH_COV19	RLU	1180
2020	12	8	PCR_PANTH_COV19	RLU	1195
2020	12	8	PCR_PANTH_COV19	RLU	1092
2020	12	8	PCR_PANTH_COV19	RLU	1164
2020	12	8	PCR_PANTH_COV19	RLU	1148
2020	12	8	PCR_PANTH_COV19	RLU	1141
2020	12	8	PCR_PANTH_COV19	RLU	1183
2020	12	8	PCR_PANTH_COV19	RLU	1202
2020	12	8	PCR_PANTH_COV19	RLU	1185
2020	12	8	PCR_PANTH_COV19	RLU	1212
2020	12	8	PCR_PANTH_COV19	RLU	1187
2020	12	8	PCR_PANTH_COV19	RLU	1156
2020	12	8	PCR_PANTH_COV19	RLU	1211
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.27339402
2020	12	8	PCR_PANTH_COV19	RLU	1183
2020	12	8	PCR_PANTH_COV19	RLU	1210
2020	12	8	PCR_PANTH_COV19	RLU	1178
2020	12	8	PCR_PANTH_COV19	RLU	1183
2020	12	8	PCR_PANTH_COV19	RLU	1184
2020	12	8	PCR_PANTH_COV19	RLU	1154
2020	12	8	PCR_PANTH_COV19	RLU	1162
2020	12	8	PCR_PANTH_COV19	RLU	1170
2020	12	8	PCR_PANTH_COV19	RLU	1140
2020	12	8	PCR_PANTH_COV19	RLU	1145
2020	12	8	PCR_PANTH_COV19	RLU	1121
2020	12	8	PCR_COBAS_COV19	CT 2	22.18
2020	12	8	PCR_COBAS_COV19	CT 2	20.29
2020	12	8	PCR_COBAS_COV19	CT 2	28.62
2020	12	8	PCR_COBAS_COV19	CT 2	19.01
2020	12	8	PCR_COBAS_COV19	CT 2	34.52
2020	12	8	PCR_COBAS_COV19	CT 2	19.64
2020	12	8	PCR_COBAS_COV19	CT 2	16.74
2020	12	8	PCR_COBAS_COV19	CT 2	35.24
2020	12	8	PCR_COBAS_COV19	CT 2	25.94
2020	12	8	PCR_COBAS_COV19	CT 2	15.67
2020	12	8	PCR_FUSION_COV19_E	E Gene CT	35.7
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.99900494
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.73479278
2020	12	8	PCR_COBAS_COV19	CT 2	20.33
2020	12	8	PCR_COBAS_COV19	CT 2	34.22

AB1029

2020	12	8	PCR_COBAS_COV19	CT 2	28.21
2020	12	8	PCR_COBAS_COV19	CT 2	31.16
2020	12	8	PCR_COBAS_COV19	CT 2	38.18
2020	12	8	PCR_COBAS_COV19	CT 2	36.42
2020	12	8	PCR_FUSION_COV19_E	E Gene CT	34.4
2020	12	8	PCR_FUSION_COV19_E	E Gene CT	31.6
2020	12	8	PCR_FUSION_COV19_E	E Gene CT	25
2020	12	8	PCR_FUSION_COV19_E	E Gene CT	24.8
2020	12	8	PCR_FUSION_COV19_E	E Gene CT	19.2
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.8471057
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.33925458
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.37263546
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.62574332
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.47137026
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.11632432
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.06625911
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.43747853
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.06489316
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.96580831
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.87112423
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.44590488
2020	12	8	PCR_COBAS_COV19	CT 2	36.1
2020	12	8	PCR_COBAS_COV19	CT 2	22.73
2020	12	8	PCR_COBAS_COV19	CT 2	21.8
2020	12	8	PCR_COBAS_COV19	CT 2	15.76
2020	12	8	PCR_COBAS_COV19	CT 2	37.5
2020	12	8	PCR_COBAS_COV19	CT 2	37.67
2020	12	8	PCR_COBAS_COV19	CT 2	20.84
2020	12	8	PCR_COBAS_COV19	CT 2	33.38
2020	12	8	PCR_COBAS_COV19	CT 2	22.93
2020	12	8	PCR_FUSION_COV19_E	E Gene CT	17.6
2020	12	8	PCR_FUSION_COV19_E	E Gene CT	28
2020	12	8	PCR_FUSION_COV19_E	E Gene CT	35.9
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.94530666
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.40720704
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.57711369
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.73657914
2020	12	8	PCR_COBAS_COV19	CT 2	18.95
2020	12	8	PCR_COBAS_COV19	CT 2	18.94
2020	12	8	PCR_COBAS_COV19	CT 2	17.45
2020	12	8	PCR_COBAS_COV19	CT 2	16.73
2020	12	8	PCR_COBAS_COV19	CT 2	16.91
2020	12	8	PCR_COBAS_COV19	CT 2	16.87
2020	12	8	PCR_COBAS_COV19	CT 2	36.38
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.72294225
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.16196368
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.86030143

AB1030

2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.4423552
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.21516664
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.65681822
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.50496707
2020	12	8	PCR_COBAS_COV19	CT 2	19.99
2020	12	8	PCR_COBAS_COV19	CT 2	28.71
2020	12	8	PCR_COBAS_COV19	CT 2	17.62
2020	12	8	PCR_COBAS_COV19	CT 2	35.94
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.68861484
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.66022408
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.99702176
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.12163949
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.60095685
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.09133759
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.18147379
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.56627849
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.23712403
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.06723127
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.09430826
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.05413598
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.47762318
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.28010996
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.01872164
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.34994162
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.21810013
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.29393467
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.89326263
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.20269176
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.18251395
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.89779454
2020	12	8	PCR_FUSION_COV19_E	E Gene CT	22.2
2020	12	8	PCR_FUSION_COV19_E	E Gene CT	25.1
2020	12	8	PCR_FUSION_COV19_E	E Gene CT	23
2020	12	8	PCR_FUSION_COV19_E	E Gene CT	17.3
2020	12	8	PCR_FUSION_COV19_E	E Gene CT	29.1
2020	12	8	PCR_FUSION_COV19_E	E Gene CT	23.2
2020	12	8	PCR_FUSION_COV19_E	E Gene CT	22.3
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.69605805
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.76241581
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.65497972
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.95158656
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.38013893
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.05679758
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.07028327
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.09693447
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.34455989
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.54525784

AB1031

2020	12	8	PCR_PANTH_COV19	RLU	1067
2020	12	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.11248598
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	18.8
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	17.2
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	24.9
2020	12	9	PCR_COBAS_COV19	CT 2	32.73
2020	12	9	PCR_COBAS_COV19	CT 2	15.77
2020	12	9	PCR_COBAS_COV19	CT 2	34.9
2020	12	9	PCR_COBAS_COV19	CT 2	28.38
2020	12	9	PCR_COBAS_COV19	CT 2	37.77
2020	12	9	PCR_COBAS_COV19	CT 2	14.94
2020	12	9	PCR_COBAS_COV19	CT 2	20.99
2020	12	9	PCR_COBAS_COV19	CT 2	24.25
2020	12	9	PCR_COBAS_COV19	CT 2	18.77
2020	12	9	PCR_COBAS_COV19	CT 2	18.61
2020	12	9	PCR_COBAS_COV19	CT 2	24.72
2020	12	9	PCR_COBAS_COV19	CT 2	20.45
2020	12	9	PCR_COBAS_COV19	CT 2	34.38
2020	12	9	PCR_COBAS_COV19	CT 2	23.89
2020	12	9	PCR_COBAS_COV19	CT 2	18.17
2020	12	9	PCR_COBAS_COV19	CT 2	26.69
2020	12	9	PCR_COBAS_COV19	CT 2	25.22
2020	12	9	PCR_COBAS_COV19	CT 2	38.9
2020	12	9	PCR_COBAS_COV19	CT 2	36.57
2020	12	9	PCR_COBAS_COV19	CT 2	34.84
2020	12	9	PCR_COBAS_COV19	CT 2	35.33
2020	12	9	PCR_COBAS_COV19	CT 2	24.6
2020	12	9	PCR_COBAS_COV19	CT 2	27.86
2020	12	9	PCR_COBAS_COV19	CT 2	29.53
2020	12	9	PCR_COBAS_COV19	CT 2	35.4
2020	12	9	PCR_COBAS_COV19	CT 2	34.79
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.41236466
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.03766469
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.35760908
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.78393836
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.69350759
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.6491111
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.8168021
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.20189897
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.15705294
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.28827219
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.31378984
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.59540705
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.23441764
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.35699553
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.20286795
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.09344767

2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.43678289
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.87971742
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.38030161
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.74323409
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.69496892
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.48948179
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.18782819
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.44510234
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.19090168
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.03266975
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.58766608
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.87106932
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.20841865
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	28.5
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	18.4
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	18
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	20.9
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	24.8
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	16.4
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	33.8
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	31.2
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	19.4
2020	12	9	PCR_PANTH_COV19	RLU	1204
2020	12	9	PCR_PANTH_COV19	RLU	1199
2020	12	9	PCR_PANTH_COV19	RLU	1140
2020	12	9	PCR_PANTH_COV19	RLU	1160
2020	12	9	PCR_PANTH_COV19	RLU	1162
2020	12	9	PCR_PANTH_COV19	RLU	1163
2020	12	9	PCR_PANTH_COV19	RLU	1154
2020	12	9	PCR_PANTH_COV19	RLU	1220
2020	12	9	PCR_PANTH_COV19	RLU	1181
2020	12	9	PCR_PANTH_COV19	RLU	1171
2020	12	9	PCR_PANTH_COV19	RLU	1171
2020	12	9	PCR_PANTH_COV19	RLU	1187
2020	12	9	PCR_PANTH_COV19	RLU	1211
2020	12	9	PCR_PANTH_COV19	RLU	1193
2020	12	9	PCR_PANTH_COV19	RLU	1169
2020	12	9	PCR_PANTH_COV19	RLU	1178
2020	12	9	PCR_PANTH_COV19	RLU	1171
2020	12	9	PCR_PANTH_COV19	RLU	1199
2020	12	9	PCR_PANTH_COV19	RLU	1174
2020	12	9	PCR_PANTH_COV19	RLU	1172
2020	12	9	PCR_PANTH_COV19	RLU	1189
2020	12	9	PCR_PANTH_COV19	RLU	1201
2020	12	9	PCR_PANTH_COV19	RLU	1161
2020	12	9	PCR_PANTH_COV19	RLU	1241
2020	12	9	PCR_PANTH_COV19	RLU	1221

AB1033

2020	12	9	PCR_PANTH_COV19	RLU	1173
2020	12	9	PCR_PANTH_COV19	RLU	1204
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.01304843
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.7613529
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.61864775
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.18281627
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.50508623
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.8345766
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.44851003
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	16.1
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	19
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	22.4
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	27
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	36.3
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	26.4
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	32.8
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	36.5
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	26
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	20.5
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	19.5
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	28.1
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	28.6
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	19
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.21618789
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.77464716
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.80344709
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.47041072
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.74883114
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.92134096
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.55411556
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.01453824
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.22384041
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.40374509
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.78440086
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.35906348
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.21645779
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.17280978
2020	12	9	PCR_PANTH_COV19	RLU	1214
2020	12	9	PCR_PANTH_COV19	RLU	1178
2020	12	9	PCR_PANTH_COV19	RLU	1224
2020	12	9	PCR_PANTH_COV19	RLU	1225
2020	12	9	PCR_PANTH_COV19	RLU	1193
2020	12	9	PCR_PANTH_COV19	RLU	1173
2020	12	9	PCR_PANTH_COV19	RLU	1190
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.06924308
2020	12	9	PCR_COBAS_COV19	CT 2	23.23
2020	12	9	PCR_COBAS_COV19	CT 2	32.86

AB1034

2020	12	9	PCR_COBAS_COV19	CT 2	27.2
2020	12	9	PCR_COBAS_COV19	CT 2	16.91
2020	12	9	PCR_COBAS_COV19	CT 2	32.51
2020	12	9	PCR_COBAS_COV19	CT 2	20.58
2020	12	9	PCR_COBAS_COV19	CT 2	18.89
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.09426777
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.44053563
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.38075044
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.81058158
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.13329248
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.09713968
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.2807249
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.52978721
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.81238608
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.09684157
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.09112743
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.21853542
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.43801832
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.20794529
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.35699387
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.98909203
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.21737127
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.15637867
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.73733758
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.49584405
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.28755697
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.14182118
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.0446745
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.65895681
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.73368344
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.06683858
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.79938823
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.37019747
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	29.8
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	24.4
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	20.1
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	20.5
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	26.5
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	21.1
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	24.7
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	25.6
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	28
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	20.8
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.05680308
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	25.4
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.02841037
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.15242756

AB1035

2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.74683949
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.10913754
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.3381769
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.92867329
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.66175642
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.40926702
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.93164014
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.61222343
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.92119852
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.65509715
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.36695549
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.69035375
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.07493164
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.20826025
2020	12	9	PCR_PANTH_COV19	RLU	1161
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.75
2020	12	9	PCR_PANTH_COV19	RLU	1148
2020	12	9	PCR_PANTH_COV19	RLU	1158
2020	12	9	PCR_PANTH_COV19	RLU	1154
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	15.3
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	25.4
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	16.9
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	35.1
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	24
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	32.9
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	19.6
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	28.4
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	28
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	21.1
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	31.6
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	18.4
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	25.1
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	20.4
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	24.5
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	33.9
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.41472098
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.2915071
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.21294876
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.96778643
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.70309571
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.46551245
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.19285713
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.94582977
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.63588309
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.32851164
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.46396008
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.90638225

2020	12	9	PCR_PANTH_COV19	RLU	1021
2020	12	9	PCR_PANTH_COV19	RLU	1177
2020	12	9	PCR_PANTH_COV19	RLU	1171
2020	12	9	PCR_PANTH_COV19	RLU	1193
2020	12	9	PCR_PANTH_COV19	RLU	1165
2020	12	9	PCR_PANTH_COV19	RLU	1241
2020	12	9	PCR_PANTH_COV19	RLU	1149
2020	12	9	PCR_PANTH_COV19	RLU	1236
2020	12	9	PCR_PANTH_COV19	RLU	1157
2020	12	9	PCR_PANTH_COV19	RLU	1193
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	37.9
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	30.1
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	19.4
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	36.2
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	19.9
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	26.9
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	19.3
2020	12	9	PCR_PANTH_COV19	RLU	1162
2020	12	9	PCR_PANTH_COV19	RLU	1171
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.29737664
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.18454616
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.70239839
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.00035655
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	27.4
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	23.4
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	29.4
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	22
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	19
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	26.1
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	22.9
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	26.5
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	24.4
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	18.1
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	37.6
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	36.1
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	28.6
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	33.2
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	22.2
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	33.3
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.73113387
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.25797644
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.48298866
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.50704424
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.78745889
2020	12	9	PCR_COBAS_COV19	CT 2	18.24
2020	12	9	PCR_COBAS_COV19	CT 2	34.7
2020	12	9	PCR_COBAS_COV19	CT 2	25.1

2020	12	9	PCR_COBAS_COV19	CT 2	28.27
2020	12	9	PCR_COBAS_COV19	CT 2	24.16
2020	12	9	PCR_COBAS_COV19	CT 2	17.21
2020	12	9	PCR_COBAS_COV19	CT 2	22.98
2020	12	9	PCR_COBAS_COV19	CT 2	26.85
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.09267051
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.21922421
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.74392372
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.44909424
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.61301487
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.65222273
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.96302681
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.06910127
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.01219921
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.34368477
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	30.3
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	34.6
2020	12	9	PCR_PANTH_COV19	RLU	1161
2020	12	9	PCR_PANTH_COV19	RLU	1219
2020	12	9	PCR_PANTH_COV19	RLU	1203
2020	12	9	PCR_PANTH_COV19	RLU	1150
2020	12	9	PCR_PANTH_COV19	RLU	1163
2020	12	9	PCR_PANTH_COV19	RLU	1195
2020	12	9	PCR_PANTH_COV19	RLU	1193
2020	12	9	PCR_PANTH_COV19	RLU	1170
2020	12	9	PCR_PANTH_COV19	RLU	1159
2020	12	9	PCR_PANTH_COV19	RLU	1171
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.15210777
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.90561663
2020	12	9	PCR_COBAS_COV19	CT 2	23.89
2020	12	9	PCR_COBAS_COV19	CT 2	28.61
2020	12	9	PCR_COBAS_COV19	CT 2	34.55
2020	12	9	PCR_COBAS_COV19	CT 2	33.23
2020	12	9	PCR_COBAS_COV19	CT 2	34.33
2020	12	9	PCR_PANTH_COV19	RLU	1143
2020	12	9	PCR_PANTH_COV19	RLU	1172
2020	12	9	PCR_PANTH_COV19	RLU	1206
2020	12	9	PCR_PANTH_COV19	RLU	1162
2020	12	9	PCR_PANTH_COV19	RLU	1155
2020	12	9	PCR_PANTH_COV19	RLU	1161
2020	12	9	PCR_PANTH_COV19	RLU	1132
2020	12	9	PCR_PANTH_COV19	RLU	1160
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	16.4
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	17.5
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	20.2
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	25.4
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	19.7

AB1038

2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.35136272
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.48820229
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.20398657
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.54621329
2020	12	9	PCR_PANTH_COV19	RLU	1130
2020	12	9	PCR_PANTH_COV19	RLU	1166
2020	12	9	PCR_PANTH_COV19	RLU	1201
2020	12	9	PCR_PANTH_COV19	RLU	1137
2020	12	9	PCR_PANTH_COV19	RLU	1166
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.8832506
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.72965175
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.24906134
2020	12	9	PCR_COBAS_COV19	CT 2	19.93
2020	12	9	PCR_COBAS_COV19	CT 2	32.67
2020	12	9	PCR_PANTH_COV19	RLU	1161
2020	12	9	PCR_PANTH_COV19	RLU	1177
2020	12	9	PCR_PANTH_COV19	RLU	1166
2020	12	9	PCR_PANTH_COV19	RLU	1156
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.94294747
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.08804694
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.58720179
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.32673738
2020	12	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.37
2020	12	9	PCR_PANTH_COV19	RLU	1155
2020	12	9	PCR_PANTH_COV19	RLU	1152
2020	12	9	PCR_PANTH_COV19	RLU	1170
2020	12	9	PCR_PANTH_COV19	RLU	1142
2020	12	9	PCR_PANTH_COV19	RLU	1154
2020	12	9	PCR_FUSION_COV19_E	E Gene CT	29.9
2020	12	9	PCR_PANTH_COV19	RLU	1145
2020	12	9	PCR_PANTH_COV19	RLU	1177
2020	12	10	PCR_COBAS_COV19	CT 2	19.35
2020	12	10	PCR_PANTH_COV19	RLU	1142
2020	12	10	PCR_COBAS_COV19	CT 2	25.27
2020	12	10	PCR_COBAS_COV19	CT 2	16.97
2020	12	10	PCR_PANTH_COV19	RLU	1150
2020	12	10	PCR_PANTH_COV19	RLU	1141
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.38683612
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.59783557
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.00040147
2020	12	10	PCR_PANTH_COV19	RLU	1194
2020	12	10	PCR_PANTH_COV19	RLU	1200
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.96807879
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.01023039
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.93561449
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.49639508
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.71870867

AB1039

2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.91904476
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.17920176
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.73416846
2020	12	10	PCR_FUSION_COV19_E	E Gene CT	21.5
2020	12	10	PCR_FUSION_COV19_E	E Gene CT	30.1
2020	12	10	PCR_FUSION_COV19_E	E Gene CT	24
2020	12	10	PCR_FUSION_COV19_E	E Gene CT	15.8
2020	12	10	PCR_FUSION_COV19_E	E Gene CT	19.4
2020	12	10	PCR_FUSION_COV19_E	E Gene CT	20.7
2020	12	10	PCR_FUSION_COV19_E	E Gene CT	34.8
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.7256138
2020	12	10	PCR_FUSION_COV19_E	E Gene CT	20.2
2020	12	10	PCR_FUSION_COV19_E	E Gene CT	27.5
2020	12	10	PCR_FUSION_COV19_E	E Gene CT	28.1
2020	12	10	PCR_FUSION_COV19_E	E Gene CT	17.3
2020	12	10	PCR_FUSION_COV19_E	E Gene CT	29.5
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.34595286
2020	12	10	PCR_FUSION_COV19_E	E Gene CT	32.4
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.54416802
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.29765211
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.62880005
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.98034641
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.90957868
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.8140478
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.90651024
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.25378847
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.33918058
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.56519037
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.75045321
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.72987477
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.24642928
2020	12	10	PCR_FUSION_COV19_E	E Gene CT	28.5
2020	12	10	PCR_FUSION_COV19_E	E Gene CT	19.9
2020	12	10	PCR_FUSION_COV19_E	E Gene CT	27.8
2020	12	10	PCR_FUSION_COV19_E	E Gene CT	31.6
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.30619234
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.29404412
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.17549871
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.64496609
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.8089597
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.70923661
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.67373886
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.32531431
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.94912659
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.07283649
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.58299769
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.0609097

AB1040

2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.60625785
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.70428486
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.40102453
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.66854763
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.70392039
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.10717251
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.65275652
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.07724886
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.56876135
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.66616467
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.05404008
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.6263228
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.58311733
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.14090013
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.01983018
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.45867838
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.37442354
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.12221951
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.14797604
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.95576386
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.01151426
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.15376915
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.03732067
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.12605975
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.8089311
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.1695037
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.79299401
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.88543051
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.43946565
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.76038595
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.89552864
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.63225309
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.20039712
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.97294536
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.15659139
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.90393173
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.23215447
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.95723904
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.37520325
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.02778645
2020	12	10	PCR_COBAS_COV19	CT 2	35.11
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.71560148
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.00681048
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.39134194
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.54933248
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.97837007
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.04374308

2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.24234929
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.29901973
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.59718744
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.84622327
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.17753354
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.40798377
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.87247879
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.8439504
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.66455926
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.13249536
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.12810791
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.44039964
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.550596
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.71825442
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.6751791
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.81455352
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.66464972
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.67408024
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.47949337
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.1759688
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.2985931
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.54287684
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.88870595
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.30232995
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.05584938
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.83731491
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.54018688
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.40129808
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.25562424
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.99540513
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.07561899
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.34062425
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.66312533
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.46183865
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.33359638
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.80124532
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.56736585
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.14683144
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.7231294
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.95541502
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.09747832
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.36187387
2020	12	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.05269806
2020	12	11	PCR_PANTH_COV19	RLU	1177
2020	12	11	PCR_PANTH_COV19	RLU	1148
2020	12	11	PCR_PANTH_COV19	RLU	1191
2020	12	11	PCR_PANTH_COV19	RLU	1171

AB1042

2020	12	11	PCR_PANTH_COV19	RLU	1166
2020	12	11	PCR_FUSION_COV19_E	E Gene CT	27.8
2020	12	11	PCR_FUSION_COV19_E	E Gene CT	27.8
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.68682361
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.85385355
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.31728694
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.25905194
2020	12	11	PCR_COBAS_COV19	CT 2	21.14
2020	12	11	PCR_COBAS_COV19	CT 2	24.31
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.75618076
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.73264184
2020	12	11	PCR_PANTH_COV19	RLU	1128
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.4148762
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.07218918
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.23821411
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.05109072
2020	12	11	PCR_COBAS_COV19	CT 2	17.92
2020	12	11	PCR_COBAS_COV19	CT 2	30.17
2020	12	11	PCR_COBAS_COV19	CT 2	17.37
2020	12	11	PCR_COBAS_COV19	CT 2	19.27
2020	12	11	PCR_PANTH_COV19	RLU	1142
2020	12	11	PCR_PANTH_COV19	RLU	1239
2020	12	11	PCR_PANTH_COV19	RLU	1157
2020	12	11	PCR_PANTH_COV19	RLU	1123
2020	12	11	PCR_PANTH_COV19	RLU	1142
2020	12	11	PCR_PANTH_COV19	RLU	1193
2020	12	11	PCR_PANTH_COV19	RLU	1170
2020	12	11	PCR_PANTH_COV19	RLU	1114
2020	12	11	PCR_PANTH_COV19	RLU	1141
2020	12	11	PCR_PANTH_COV19	RLU	1132
2020	12	11	PCR_PANTH_COV19	RLU	1161
2020	12	11	PCR_PANTH_COV19	RLU	1140
2020	12	11	PCR_PANTH_COV19	RLU	1189
2020	12	11	PCR_PANTH_COV19	RLU	1205
2020	12	11	PCR_PANTH_COV19	RLU	1145
2020	12	11	PCR_PANTH_COV19	RLU	1201
2020	12	11	PCR_PANTH_COV19	RLU	1144
2020	12	11	PCR_PANTH_COV19	RLU	1159
2020	12	11	PCR_PANTH_COV19	RLU	1176
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.12663489
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.74421529
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.77484085
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.49067327
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.46994236
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.55887446
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.19401743
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.77726025

2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.62017269
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.80463812
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.80609546
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.23887537
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.49221906
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.8441767
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.72339093
2020	12	11	PCR_PANTH_COV19	RLU	1150
2020	12	11	PCR_PANTH_COV19	RLU	1126
2020	12	11	PCR_PANTH_COV19	RLU	1131
2020	12	11	PCR_PANTH_COV19	RLU	1153
2020	12	11	PCR_PANTH_COV19	RLU	1220
2020	12	11	PCR_PANTH_COV19	RLU	1175
2020	12	11	PCR_PANTH_COV19	RLU	1161
2020	12	11	PCR_PANTH_COV19	RLU	1140
2020	12	11	PCR_PANTH_COV19	RLU	1187
2020	12	11	PCR_PANTH_COV19	RLU	1173
2020	12	11	PCR_PANTH_COV19	RLU	1142
2020	12	11	PCR_PANTH_COV19	RLU	1243
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.40977806
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.87523994
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.24584681
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.15194761
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.69083305
2020	12	11	PCR_PANTH_COV19	RLU	1124
2020	12	11	PCR_PANTH_COV19	RLU	1173
2020	12	11	PCR_PANTH_COV19	RLU	1144
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.26689093
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.73626925
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.23222238
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.44176668
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.37468052
2020	12	11	PCR_COBAS_COV19	CT 2	36.22
2020	12	11	PCR_COBAS_COV19	CT 2	19.51
2020	12	11	PCR_COBAS_COV19	CT 2	27.86
2020	12	11	PCR_COBAS_COV19	CT 2	21.36
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.91859853
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.07062252
2020	12	11	PCR_PANTH_COV19	RLU	1178
2020	12	11	PCR_PANTH_COV19	RLU	1161
2020	12	11	PCR_PANTH_COV19	RLU	1211
2020	12	11	PCR_PANTH_COV19	RLU	1141
2020	12	11	PCR_COBAS_COV19	CT 2	17.5
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.50154914
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.49987638
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.77294891
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.4166867

AB1044

2020	12	11	PCR_FUSION_COV19_E	E Gene CT	20.7
2020	12	11	PCR_PANTH_COV19	RLU	1121
2020	12	11	PCR_PANTH_COV19	RLU	1114
2020	12	11	PCR_PANTH_COV19	RLU	1105
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.41705716
2020	12	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.29086899
2020	12	12	PCR_COBAS_COV19	CT 2	26.08
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.60081172
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.1307308
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.81924307
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.79288035
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.31390157
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.82394857
2020	12	12	PCR_COBAS_COV19	CT 2	19.77
2020	12	12	PCR_COBAS_COV19	CT 2	35.66
2020	12	12	PCR_COBAS_COV19	CT 2	33.93
2020	12	12	PCR_COBAS_COV19	CT 2	23.54
2020	12	12	PCR_COBAS_COV19	CT 2	27.76
2020	12	12	PCR_COBAS_COV19	CT 2	33.34
2020	12	12	PCR_COBAS_COV19	CT 2	19.55
2020	12	12	PCR_FUSION_COV19_E	E Gene CT	22
2020	12	12	PCR_COBAS_COV19	CT 2	32.92
2020	12	12	PCR_COBAS_COV19	CT 2	34
2020	12	12	PCR_COBAS_COV19	CT 2	35.48
2020	12	12	PCR_COBAS_COV19	CT 2	31.45
2020	12	12	PCR_COBAS_COV19	CT 2	20.47
2020	12	12	PCR_COBAS_COV19	CT 2	38.08
2020	12	12	PCR_COBAS_COV19	CT 2	16.33
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.11829603
2020	12	12	PCR_COBAS_COV19	CT 2	25.72
2020	12	12	PCR_COBAS_COV19	CT 2	21.33
2020	12	12	PCR_COBAS_COV19	CT 2	30.49
2020	12	12	PCR_COBAS_COV19	CT 2	24.66
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.7703357
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.40921435
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.81533103
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.64614056
2020	12	12	PCR_PANTH_COV19	RLU	1174
2020	12	12	PCR_PANTH_COV19	RLU	1172
2020	12	12	PCR_PANTH_COV19	RLU	1164
2020	12	12	PCR_PANTH_COV19	RLU	1175
2020	12	12	PCR_FUSION_COV19_E	E Gene CT	29.1
2020	12	12	PCR_FUSION_COV19_E	E Gene CT	33.3
2020	12	12	PCR_FUSION_COV19_E	E Gene CT	22.9
2020	12	12	PCR_FUSION_COV19_E	E Gene CT	31.4
2020	12	12	PCR_FUSION_COV19_E	E Gene CT	23.2
2020	12	12	PCR_FUSION_COV19_E	E Gene CT	27.4

AB1045

2020	12	12	PCR_FUSION_COV19_E	E Gene CT	30.4
2020	12	12	PCR_FUSION_COV19_E	E Gene CT	29.5
2020	12	12	PCR_FUSION_COV19_E	E Gene CT	32
2020	12	12	PCR_FUSION_COV19_E	E Gene CT	27.7
2020	12	12	PCR_FUSION_COV19_E	E Gene CT	18.5
2020	12	12	PCR_FUSION_COV19_E	E Gene CT	18.3
2020	12	12	PCR_COBAS_COV19	CT 2	37.17
2020	12	12	PCR_COBAS_COV19	CT 2	37.14
2020	12	12	PCR_COBAS_COV19	CT 2	18.48
2020	12	12	PCR_COBAS_COV19	CT 2	29.16
2020	12	12	PCR_COBAS_COV19	CT 2	31.96
2020	12	12	PCR_COBAS_COV19	CT 2	22.09
2020	12	12	PCR_COBAS_COV19	CT 2	33.03
2020	12	12	PCR_COBAS_COV19	CT 2	21.11
2020	12	12	PCR_COBAS_COV19	CT 2	18.38
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.26966538
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.69940293
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.63549201
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.26795363
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.56680934
2020	12	12	PCR_FUSION_COV19_E	E Gene CT	22.5
2020	12	12	PCR_FUSION_COV19_E	E Gene CT	19
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.22106632
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.89432498
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.72521263
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.15608548
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.37627061
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	9.249744056
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.19709624
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.22053602
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.09158003
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.07657676
2020	12	12	PCR_COBAS_COV19	CT 2	29.78
2020	12	12	PCR_COBAS_COV19	CT 2	34.52
2020	12	12	PCR_COBAS_COV19	CT 2	25.26
2020	12	12	PCR_COBAS_COV19	CT 2	38.07
2020	12	12	PCR_COBAS_COV19	CT 2	26.59
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.48334895
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.36455499
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.42382443
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.14404035
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.00890498
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.94796486
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.48758547
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.92088428
2020	12	12	PCR_PANTH_COV19	RLU	1143
2020	12	12	PCR_PANTH_COV19	RLU	1135

AB1046

2020	12	12	PCR_PANTH_COV19	RLU	1130
2020	12	12	PCR_PANTH_COV19	RLU	1131
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.07435192
2020	12	12	PCR_PANTH_COV19	RLU	1153
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.17740232
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.39770862
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.1024982
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.18382864
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.25963793
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.34953413
2020	12	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.41339243
2020	12	12	PCR_COBAS_COV19	CT 2	34.85
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.63139799
2020	12	13	PCR_COBAS_COV19	CT 2	17.79
2020	12	13	PCR_COBAS_COV19	CT 2	26.02
2020	12	13	PCR_COBAS_COV19	CT 2	28.93
2020	12	13	PCR_COBAS_COV19	CT 2	22.45
2020	12	13	PCR_COBAS_COV19	CT 2	24.71
2020	12	13	PCR_COBAS_COV19	CT 2	16.69
2020	12	13	PCR_COBAS_COV19	CT 2	19.34
2020	12	13	PCR_COBAS_COV19	CT 2	31.46
2020	12	13	PCR_COBAS_COV19	CT 2	17.94
2020	12	13	PCR_COBAS_COV19	CT 2	20.72
2020	12	13	PCR_COBAS_COV19	CT 2	21.1
2020	12	13	PCR_COBAS_COV19	CT 2	19.39
2020	12	13	PCR_COBAS_COV19	CT 2	33.76
2020	12	13	PCR_COBAS_COV19	CT 2	19.67
2020	12	13	PCR_COBAS_COV19	CT 2	15.62
2020	12	13	PCR_COBAS_COV19	CT 2	16.49
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.30330298
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.51121239
2020	12	13	PCR_PANTH_COV19	RLU	1137
2020	12	13	PCR_COBAS_COV19	CT 2	33.76
2020	12	13	PCR_COBAS_COV19	CT 2	17.44
2020	12	13	PCR_COBAS_COV19	CT 2	21.16
2020	12	13	PCR_COBAS_COV19	CT 2	13.13
2020	12	13	PCR_COBAS_COV19	CT 2	21.74
2020	12	13	PCR_COBAS_COV19	CT 2	22.01
2020	12	13	PCR_COBAS_COV19	CT 2	25.41
2020	12	13	PCR_COBAS_COV19	CT 2	33.18
2020	12	13	PCR_COBAS_COV19	CT 2	36.06
2020	12	13	PCR_PANTH_COV19	RLU	1190
2020	12	13	PCR_PANTH_COV19	RLU	1136
2020	12	13	PCR_COBAS_COV19	CT 2	19.92
2020	12	13	PCR_COBAS_COV19	CT 2	18.4
2020	12	13	PCR_COBAS_COV19	CT 2	17.27
2020	12	13	PCR_COBAS_COV19	CT 2	28.02

AB1047

2020	12	13	PCR_COBAS_COV19	CT 2	36.75
2020	12	13	PCR_COBAS_COV19	CT 2	20.72
2020	12	13	PCR_COBAS_COV19	CT 2	16.3
2020	12	13	PCR_COBAS_COV19	CT 2	31.88
2020	12	13	PCR_PANTH_COV19	RLU	1150
2020	12	13	PCR_PANTH_COV19	RLU	1108
2020	12	13	PCR_PANTH_COV19	RLU	1127
2020	12	13	PCR_PANTH_COV19	RLU	1115
2020	12	13	PCR_PANTH_COV19	RLU	1096
2020	12	13	PCR_PANTH_COV19	RLU	1131
2020	12	13	PCR_PANTH_COV19	RLU	1103
2020	12	13	PCR_PANTH_COV19	RLU	1115
2020	12	13	PCR_PANTH_COV19	RLU	1094
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.01859388
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.35361033
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.04840267
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.58661076
2020	12	13	PCR_COBAS_COV19	CT 2	34.63
2020	12	13	PCR_COBAS_COV19	CT 2	16.81
2020	12	13	PCR_COBAS_COV19	CT 2	18.03
2020	12	13	PCR_COBAS_COV19	CT 2	27.25
2020	12	13	PCR_COBAS_COV19	CT 2	26.05
2020	12	13	PCR_COBAS_COV19	CT 2	21.22
2020	12	13	PCR_COBAS_COV19	CT 2	38.38
2020	12	13	PCR_COBAS_COV19	CT 2	30.81
2020	12	13	PCR_COBAS_COV19	CT 2	15.24
2020	12	13	PCR_COBAS_COV19	CT 2	23.64
2020	12	13	PCR_COBAS_COV19	CT 2	22.17
2020	12	13	PCR_COBAS_COV19	CT 2	19.5
2020	12	13	PCR_COBAS_COV19	CT 2	18.57
2020	12	13	PCR_COBAS_COV19	CT 2	17.03
2020	12	13	PCR_COBAS_COV19	CT 2	28.39
2020	12	13	PCR_COBAS_COV19	CT 2	29.74
2020	12	13	PCR_COBAS_COV19	CT 2	29.85
2020	12	13	PCR_COBAS_COV19	CT 2	33.2
2020	12	13	PCR_COBAS_COV19	CT 2	21.28
2020	12	13	PCR_COBAS_COV19	CT 2	16.42
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.43520552
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.24860863
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.94913929
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.29365784
2020	12	13	PCR_COBAS_COV19	CT 2	22.3
2020	12	13	PCR_COBAS_COV19	CT 2	28.04
2020	12	13	PCR_COBAS_COV19	CT 2	18.71
2020	12	13	PCR_COBAS_COV19	CT 2	23.62
2020	12	13	PCR_COBAS_COV19	CT 2	28.67
2020	12	13	PCR_COBAS_COV19	CT 2	27.6

AB1048

2020	12	13	PCR_COBAS_COV19	CT 2	19.76
2020	12	13	PCR_COBAS_COV19	CT 2	28.43
2020	12	13	PCR_COBAS_COV19	CT 2	35.01
2020	12	13	PCR_COBAS_COV19	CT 2	25
2020	12	13	PCR_COBAS_COV19	CT 2	37.38
2020	12	13	PCR_COBAS_COV19	CT 2	20.99
2020	12	13	PCR_COBAS_COV19	CT 2	24.93
2020	12	13	PCR_COBAS_COV19	CT 2	26.36
2020	12	13	PCR_COBAS_COV19	CT 2	24.45
2020	12	13	PCR_COBAS_COV19	CT 2	17.97
2020	12	13	PCR_COBAS_COV19	CT 2	28.64
2020	12	13	PCR_COBAS_COV19	CT 2	30.75
2020	12	13	PCR_COBAS_COV19	CT 2	30.71
2020	12	13	PCR_COBAS_COV19	CT 2	22.85
2020	12	13	PCR_COBAS_COV19	CT 2	19.99
2020	12	13	PCR_COBAS_COV19	CT 2	21.36
2020	12	13	PCR_COBAS_COV19	CT 2	24.09
2020	12	13	PCR_COBAS_COV19	CT 2	31.45
2020	12	13	PCR_COBAS_COV19	CT 2	29.53
2020	12	13	PCR_COBAS_COV19	CT 2	26.81
2020	12	13	PCR_COBAS_COV19	CT 2	21.68
2020	12	13	PCR_COBAS_COV19	CT 2	29.3
2020	12	13	PCR_COBAS_COV19	CT 2	22.62
2020	12	13	PCR_COBAS_COV19	CT 2	32.96
2020	12	13	PCR_COBAS_COV19	CT 2	22.93
2020	12	13	PCR_COBAS_COV19	CT 2	16.96
2020	12	13	PCR_COBAS_COV19	CT 2	23.69
2020	12	13	PCR_COBAS_COV19	CT 2	33.83
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.53190823
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.19186016
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.38729231
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.63483416
2020	12	13	PCR_FUSION_COV19_E	E Gene CT	21.7
2020	12	13	PCR_FUSION_COV19_E	E Gene CT	17.4
2020	12	13	PCR_FUSION_COV19_E	E Gene CT	25.9
2020	12	13	PCR_FUSION_COV19_E	E Gene CT	36.3
2020	12	13	PCR_FUSION_COV19_E	E Gene CT	19.4
2020	12	13	PCR_FUSION_COV19_E	E Gene CT	29.8
2020	12	13	PCR_FUSION_COV19_E	E Gene CT	28
2020	12	13	PCR_FUSION_COV19_E	E Gene CT	24
2020	12	13	PCR_FUSION_COV19_E	E Gene CT	29
2020	12	13	PCR_FUSION_COV19_E	E Gene CT	25.5
2020	12	13	PCR_FUSION_COV19_E	E Gene CT	27.3
2020	12	13	PCR_FUSION_COV19_E	E Gene CT	24.3
2020	12	13	PCR_FUSION_COV19_E	E Gene CT	19.7
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.70730347
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.38086587

AB1049

2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.72588422
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.24973811
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	9.942582133
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.45608471
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.30470469
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.77013327
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.1465025
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.88408061
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.91134724
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.77653048
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.20322905
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	9.740682991
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.88706815
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.45801988
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.75690334
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.20504025
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.52594053
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.66912912
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.07434276
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.27283591
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.91216226
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.05459408
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.43373485
2020	12	13	PCR_COBAS_COV19	CT 2	27.57
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.65251558
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.8965445
2020	12	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.20795222
2020	12	14	PCR_COBAS_COV19	CT 2	21.59
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.10940474
2020	12	14	PCR_PANTH_COV19	RLU	1172
2020	12	14	PCR_PANTH_COV19	RLU	1137
2020	12	14	PCR_COBAS_COV19	CT 2	27.08
2020	12	14	PCR_COBAS_COV19	CT 2	21.04
2020	12	14	PCR_COBAS_COV19	CT 2	26.66
2020	12	14	PCR_COBAS_COV19	CT 2	32
2020	12	14	PCR_COBAS_COV19	CT 2	30.83
2020	12	14	PCR_COBAS_COV19	CT 2	25.35
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.49098082
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.53530306
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.2983223
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.34651191
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.21913466
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.89957716
2020	12	14	PCR_FUSION_COV19_E	E Gene CT	20.7
2020	12	14	PCR_FUSION_COV19_E	E Gene CT	25
2020	12	14	PCR_FUSION_COV19_E	E Gene CT	16.3
2020	12	14	PCR_FUSION_COV19_E	E Gene CT	17.4

AB1050

2020	12	14	PCR_FUSION_COV19_E	E Gene CT	18.3
2020	12	14	PCR_PANTH_COV19	RLU	1111
2020	12	14	PCR_PANTH_COV19	RLU	1167
2020	12	14	PCR_PANTH_COV19	RLU	1145
2020	12	14	PCR_PANTH_COV19	RLU	1154
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.84272994
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.18548728
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.29161605
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.23124544
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.51939093
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.31313628
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.05897838
2020	12	14	PCR_COBAS_COV19	CT 2	26
2020	12	14	PCR_COBAS_COV19	CT 2	23.68
2020	12	14	PCR_COBAS_COV19	CT 2	17.95
2020	12	14	PCR_COBAS_COV19	CT 2	36.2
2020	12	14	PCR_COBAS_COV19	CT 2	31.92
2020	12	14	PCR_COBAS_COV19	CT 2	30.69
2020	12	14	PCR_COBAS_COV19	CT 2	21.48
2020	12	14	PCR_COBAS_COV19	CT 2	17.75
2020	12	14	PCR_COBAS_COV19	CT 2	23.03
2020	12	14	PCR_COBAS_COV19	CT 2	18.73
2020	12	14	PCR_COBAS_COV19	CT 2	32.36
2020	12	14	PCR_COBAS_COV19	CT 2	18.34
2020	12	14	PCR_COBAS_COV19	CT 2	18.57
2020	12	14	PCR_PANTH_COV19	RLU	1239
2020	12	14	PCR_PANTH_COV19	RLU	1078
2020	12	14	PCR_PANTH_COV19	RLU	1159
2020	12	14	PCR_PANTH_COV19	RLU	1151
2020	12	14	PCR_PANTH_COV19	RLU	1130
2020	12	14	PCR_PANTH_COV19	RLU	1103
2020	12	14	PCR_PANTH_COV19	RLU	1093
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.26374682
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.01157871
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.14627692
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.06170805
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.6967583
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.70085043
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.71793561
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.21137639
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.17703727
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.53149127
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.66130242
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.09911053
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.33668827
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.34600819
2020	12	14	PCR_PANTH_COV19	RLU	1136

2020	12	14	PCR_PANTH_COV19	RLU	1150
2020	12	14	PCR_PANTH_COV19	RLU	1152
2020	12	14	PCR_PANTH_COV19	RLU	1122
2020	12	14	PCR_PANTH_COV19	RLU	1151
2020	12	14	PCR_PANTH_COV19	RLU	1090
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.71754142
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.03056612
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.02541539
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.21454513
2020	12	14	PCR_COBAS_COV19	CT 2	24.98
2020	12	14	PCR_COBAS_COV19	CT 2	16.93
2020	12	14	PCR_COBAS_COV19	CT 2	21.48
2020	12	14	PCR_COBAS_COV19	CT 2	18.78
2020	12	14	PCR_COBAS_COV19	CT 2	20.1
2020	12	14	PCR_COBAS_COV19	CT 2	16
2020	12	14	PCR_COBAS_COV19	CT 2	23.28
2020	12	14	PCR_COBAS_COV19	CT 2	22.53
2020	12	14	PCR_COBAS_COV19	CT 2	18.4
2020	12	14	PCR_COBAS_COV19	CT 2	20.72
2020	12	14	PCR_COBAS_COV19	CT 2	20.43
2020	12	14	PCR_COBAS_COV19	CT 2	23.92
2020	12	14	PCR_COBAS_COV19	CT 2	19.56
2020	12	14	PCR_COBAS_COV19	CT 2	19.9
2020	12	14	PCR_COBAS_COV19	CT 2	29.01
2020	12	14	PCR_COBAS_COV19	CT 2	36.39
2020	12	14	PCR_COBAS_COV19	CT 2	33.86
2020	12	14	PCR_COBAS_COV19	CT 2	34.04
2020	12	14	PCR_FUSION_COV19_E	E Gene CT	37.9
2020	12	14	PCR_FUSION_COV19_E	E Gene CT	23.1
2020	12	14	PCR_FUSION_COV19_E	E Gene CT	20.7
2020	12	14	PCR_FUSION_COV19_E	E Gene CT	25.1
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	39.84699688
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.7948029
2020	12	14	PCR_PANTH_COV19	RLU	1118
2020	12	14	PCR_PANTH_COV19	RLU	1145
2020	12	14	PCR_PANTH_COV19	RLU	1163
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.77811254
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.13312916
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.05812066
2020	12	14	PCR_COBAS_COV19	CT 2	28.98
2020	12	14	PCR_COBAS_COV19	CT 2	22.51
2020	12	14	PCR_COBAS_COV19	CT 2	20.7
2020	12	14	PCR_COBAS_COV19	CT 2	21.46
2020	12	14	PCR_COBAS_COV19	CT 2	19.39
2020	12	14	PCR_COBAS_COV19	CT 2	28.58
2020	12	14	PCR_COBAS_COV19	CT 2	25.16
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.85793307

AB1052

2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.98302369
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.26885451
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.59917083
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.67835733
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.53373665
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.45482487
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.9073678
2020	12	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.53152293
2020	12	14	PCR_PANTH_COV19	RLU	1154
2020	12	14	PCR_PANTH_COV19	RLU	1142
2020	12	14	PCR_PANTH_COV19	RLU	1154
2020	12	14	PCR_PANTH_COV19	RLU	1167
2020	12	14	PCR_PANTH_COV19	RLU	1171
2020	12	14	PCR_PANTH_COV19	RLU	1116
2020	12	14	PCR_PANTH_COV19	RLU	1094
2020	12	14	PCR_PANTH_COV19	RLU	1099
2020	12	14	PCR_PANTH_COV19	RLU	1143
2020	12	14	PCR_PANTH_COV19	RLU	1169
2020	12	14	PCR_COBAS_COV19	CT 2	21.53
2020	12	14	PCR_COBAS_COV19	CT 2	31.22
2020	12	14	PCR_COBAS_COV19	CT 2	29.1
2020	12	14	PCR_COBAS_COV19	CT 2	22.25
2020	12	14	PCR_COBAS_COV19	CT 2	17.03
2020	12	14	PCR_COBAS_COV19	CT 2	19.51
2020	12	14	PCR_COBAS_COV19	CT 2	31.4
2020	12	14	PCR_PANTH_COV19	RLU	1161
2020	12	14	PCR_PANTH_COV19	RLU	1142
2020	12	14	PCR_PANTH_COV19	RLU	1178
2020	12	15	PCR_COBAS_COV19	CT 2	35.41
2020	12	15	PCR_COBAS_COV19	CT 2	32.51
2020	12	15	PCR_PANTH_COV19	RLU	1178
2020	12	15	PCR_PANTH_COV19	RLU	1160
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	26.6
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	35.9
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.07517788
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.77900182
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.33691455
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.53445462
2020	12	15	PCR_PANTH_COV19	RLU	1131
2020	12	15	PCR_PANTH_COV19	RLU	1123
2020	12	15	PCR_PANTH_COV19	RLU	1111
2020	12	15	PCR_COBAS_COV19	CT 2	14.93
2020	12	15	PCR_COBAS_COV19	CT 2	25.33
2020	12	15	PCR_COBAS_COV19	CT 2	28.9
2020	12	15	PCR_COBAS_COV19	CT 2	30.56
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.38215897
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.7240757

2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.48966184
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	20.1
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	34.2
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	35.6
2020	12	15	PCR_PANTH_COV19	RLU	1142
2020	12	15	PCR_PANTH_COV19	RLU	1187
2020	12	15	PCR_PANTH_COV19	RLU	1142
2020	12	15	PCR_PANTH_COV19	RLU	1116
2020	12	15	PCR_PANTH_COV19	RLU	1092
2020	12	15	PCR_PANTH_COV19	RLU	1102
2020	12	15	PCR_PANTH_COV19	RLU	1097
2020	12	15	PCR_PANTH_COV19	RLU	1089
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.00213232
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.25119239
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.11615115
2020	12	15	PCR_PANTH_COV19	RLU	1137
2020	12	15	PCR_PANTH_COV19	RLU	1150
2020	12	15	PCR_PANTH_COV19	RLU	1177
2020	12	15	PCR_PANTH_COV19	RLU	1113
2020	12	15	PCR_PANTH_COV19	RLU	1201
2020	12	15	PCR_PANTH_COV19	RLU	1109
2020	12	15	PCR_PANTH_COV19	RLU	1119
2020	12	15	PCR_PANTH_COV19	RLU	1114
2020	12	15	PCR_PANTH_COV19	RLU	1143
2020	12	15	PCR_PANTH_COV19	RLU	1099
2020	12	15	PCR_COBAS_COV19	CT 2	24.08
2020	12	15	PCR_COBAS_COV19	CT 2	29.23
2020	12	15	PCR_COBAS_COV19	CT 2	21.41
2020	12	15	PCR_COBAS_COV19	CT 2	21.63
2020	12	15	PCR_COBAS_COV19	CT 2	20.71
2020	12	15	PCR_COBAS_COV19	CT 2	32.7
2020	12	15	PCR_COBAS_COV19	CT 2	19.72
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	32.5
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	15.1
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	32.2
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	21.1
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	25.8
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.26733072
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.52213379
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.77814858
2020	12	15	PCR_COBAS_COV19	CT 2	29.76
2020	12	15	PCR_COBAS_COV19	CT 2	17.81
2020	12	15	PCR_COBAS_COV19	CT 2	15.06
2020	12	15	PCR_COBAS_COV19	CT 2	21.51
2020	12	15	PCR_COBAS_COV19	CT 2	20.19
2020	12	15	PCR_COBAS_COV19	CT 2	24.11
2020	12	15	PCR_COBAS_COV19	CT 2	17.14

2020	12	15	PCR_COBAS_COV19	CT 2	28
2020	12	15	PCR_COBAS_COV19	CT 2	17.64
2020	12	15	PCR_COBAS_COV19	CT 2	17.3
2020	12	15	PCR_COBAS_COV19	CT 2	27.02
2020	12	15	PCR_COBAS_COV19	CT 2	24.71
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.05734339
2020	12	15	PCR_COBAS_COV19	CT 2	23.59
2020	12	15	PCR_COBAS_COV19	CT 2	36.04
2020	12	15	PCR_COBAS_COV19	CT 2	14.02
2020	12	15	PCR_COBAS_COV19	CT 2	18.79
2020	12	15	PCR_COBAS_COV19	CT 2	26.11
2020	12	15	PCR_COBAS_COV19	CT 2	37.88
2020	12	15	PCR_COBAS_COV19	CT 2	18.56
2020	12	15	PCR_COBAS_COV19	CT 2	22.3
2020	12	15	PCR_COBAS_COV19	CT 2	21.77
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.56158953
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.64661888
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.60850996
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.93521868
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.66459857
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.08614823
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.39625614
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.99399993
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	33.5
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	35.2
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.0289949
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	27.3
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	29.4
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	16
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	18.8
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	35.2
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	36.2
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	36.6
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	16.2
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	30.4
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	24.2
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.83976297
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	36.3
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	26.4
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.48962322
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	29.6
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	27.5
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.71270435
2020	12	15	PCR_COBAS_COV19	CT 2	36.3
2020	12	15	PCR_COBAS_COV19	CT 2	37.89
2020	12	15	PCR_COBAS_COV19	CT 2	15.97
2020	12	15	PCR_COBAS_COV19	CT 2	31.13

AB1055

2020	12	15	PCR_COBAS_COV19	CT 2	28.93
2020	12	15	PCR_COBAS_COV19	CT 2	37.67
2020	12	15	PCR_COBAS_COV19	CT 2	19.06
2020	12	15	PCR_COBAS_COV19	CT 2	34.22
2020	12	15	PCR_COBAS_COV19	CT 2	18.79
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	36.7
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	32.2
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	25.1
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	36.2
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	31.4
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	33.6
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	15.2
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	19.1
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	32
2020	12	15	PCR_PANTH_COV19	RLU	1154
2020	12	15	PCR_PANTH_COV19	RLU	1138
2020	12	15	PCR_PANTH_COV19	RLU	1140
2020	12	15	PCR_PANTH_COV19	RLU	1181
2020	12	15	PCR_PANTH_COV19	RLU	1165
2020	12	15	PCR_PANTH_COV19	RLU	1137
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.88276991
2020	12	15	PCR_COBAS_COV19	CT 2	16.72
2020	12	15	PCR_COBAS_COV19	CT 2	31.11
2020	12	15	PCR_COBAS_COV19	CT 2	17.28
2020	12	15	PCR_COBAS_COV19	CT 2	33.25
2020	12	15	PCR_COBAS_COV19	CT 2	29.64
2020	12	15	PCR_COBAS_COV19	CT 2	33.11
2020	12	15	PCR_COBAS_COV19	CT 2	21.19
2020	12	15	PCR_COBAS_COV19	CT 2	36.76
2020	12	15	PCR_COBAS_COV19	CT 2	35.18
2020	12	15	PCR_COBAS_COV19	CT 2	21.77
2020	12	15	PCR_COBAS_COV19	CT 2	27.13
2020	12	15	PCR_COBAS_COV19	CT 2	37.9
2020	12	15	PCR_COBAS_COV19	CT 2	27.93
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.37293276
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.50034254
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.570345
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.36071174
2020	12	15	PCR_PANTH_COV19	RLU	1109
2020	12	15	PCR_PANTH_COV19	RLU	1146
2020	12	15	PCR_PANTH_COV19	RLU	1166
2020	12	15	PCR_PANTH_COV19	RLU	1133
2020	12	15	PCR_PANTH_COV19	RLU	1134
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.54283448
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.01338166
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.64376062
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.33333272

AB1056

2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.40145483
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.56255399
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.87772519
2020	12	15	PCR_PANTH_COV19	RLU	1173
2020	12	15	PCR_PANTH_COV19	RLU	1097
2020	12	15	PCR_PANTH_COV19	RLU	1185
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.09473335
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.07207459
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.25152011
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.2842088
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.42653243
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.18746808
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.69776394
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.48338153
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.08728313
2020	12	15	PCR_PANTH_COV19	RLU	1127
2020	12	15	PCR_PANTH_COV19	RLU	1115
2020	12	15	PCR_PANTH_COV19	RLU	1095
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	19.4
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	16.7
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	18.7
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	30.4
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	36.8
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	18.9
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	25.1
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	26
2020	12	15	PCR_PANTH_COV19	RLU	1139
2020	12	15	PCR_PANTH_COV19	RLU	1142
2020	12	15	PCR_PANTH_COV19	RLU	1155
2020	12	15	PCR_PANTH_COV19	RLU	1140
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	33
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	28.8
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	35.3
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	24.1
2020	12	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.99886437
2020	12	15	PCR_PANTH_COV19	RLU	1173
2020	12	15	PCR_PANTH_COV19	RLU	1145
2020	12	15	PCR_PANTH_COV19	RLU	1129
2020	12	15	PCR_PANTH_COV19	RLU	1129
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	21.2
2020	12	15	PCR_FUSION_COV19_E	E Gene CT	17.2
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.09868634
2020	12	16	PCR_PANTH_COV19	RLU	1163
2020	12	16	PCR_PANTH_COV19	RLU	1132
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.51531529
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	17.5
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	20.9

2020	12	16	PCR_FUSION_COV19_E	E Gene CT	22.8
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	17.8
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	16.8
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	24.3
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	17.7
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	23.6
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	36.6
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	27.4
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	17.2
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	16.8
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	25.7
2020	12	16	PCR_PANTH_COV19	RLU	1240
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	21.1
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	22.5
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	21.4
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	31.1
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.79703987
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.00599359
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.79516358
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.59068068
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	34.5
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	28.5
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	33.5
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.83832258
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	27.1
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	19.7
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	18.3
2020	12	16	PCR_PANTH_COV19	RLU	1125
2020	12	16	PCR_PANTH_COV19	RLU	1178
2020	12	16	PCR_PANTH_COV19	RLU	1147
2020	12	16	PCR_PANTH_COV19	RLU	1171
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.90882954
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	19
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	37.4
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	21.7
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	19.4
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	18.3
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.90315127
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.0479037
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.25856381
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.44521089
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.13530504
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.5069184
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.18858098
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.87710704
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	29.9
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.55683599

AB1059

2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.63712009
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.09237851
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.34480659
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.28994692
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.51517752
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.5692116
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.26780317
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.12927105
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.46440454
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.64088752
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.38625085
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.19525475
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.73423544
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.48466326
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.46287932
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.05679212
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	36.2
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	22.9
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	21.4
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	32.3
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	18.6
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	28
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	17.7
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	26.1
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	25.2
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	25.1
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	27.5
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	25.9
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.66187342
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.45711382
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.56981824
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.63813267
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.42373286
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.7259996
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.68243564
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.5057647
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.88820531
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.72246574
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.54729316
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.19524972
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.37786501
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.69461302
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.3824192
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.25777096
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.9792227
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.65845656
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.51081112

AB1060

2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.27122964
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.25102992
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.53590892
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.2715459
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.24726852
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.87259509
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.98049955
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.30737468
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.4252847
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.362659
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.35290551
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.03708487
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	21.7
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.15155431
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.40833509
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.95656932
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.03424008
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.01192468
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.37965162
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.8849569
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.51100585
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.34624461
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.98919912
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.42401417
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.06341746
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.47030045
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.03392366
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.08265833
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.07446753
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.68085365
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.02664859
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.01152172
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.83848303
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.26898911
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.54250948
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.33377366
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.4363377
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.78039506
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.15508829
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.88471356
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.17345885
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.69855311
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.42150523
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.46524288
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.24600454
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.76015244
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.23329654

2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.42597436
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.68318601
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.75529034
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.16677417
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.60974196
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.05154
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.89591941
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.15677707
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.67521613
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.18819316
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.57480928
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.98978158
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.89344309
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.45476262
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.44445992
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.09457874
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.14972585
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.39229949
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.57827718
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.44852769
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.0718957
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.76180898
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.04118422
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.63417034
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.27793598
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.07176133
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	36.5
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	28.4
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	17.7
2020	12	16	PCR_FUSION_COV19_E	E Gene CT	28
2020	12	16	PCR_COBAS_COV19	CT 2	38.09
2020	12	16	PCR_COBAS_COV19	CT 2	29.86
2020	12	16	PCR_COBAS_COV19	CT 2	35.44
2020	12	16	PCR_COBAS_COV19	CT 2	33.44
2020	12	16	PCR_COBAS_COV19	CT 2	20.95
2020	12	16	PCR_COBAS_COV19	CT 2	29.2
2020	12	16	PCR_COBAS_COV19	CT 2	19.03
2020	12	16	PCR_PANTH_COV19	RLU	1224
2020	12	16	PCR_PANTH_COV19	RLU	1181
2020	12	16	PCR_PANTH_COV19	RLU	1176
2020	12	16	PCR_COBAS_COV19	CT 2	26.99
2020	12	16	PCR_PANTH_COV19	RLU	1109
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.12175573
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.19941267
2020	12	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.14652602
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.182674
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.15521001

AB1062

2020	12	17	PCR_FUSION_COV19_E	E Gene CT	35.6
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	37.2
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.34244052
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	35
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	33.7
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	37.5
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	28.2
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	36.1
2020	12	17	PCR_COBAS_COV19	CT 2	20.14
2020	12	17	PCR_COBAS_COV19	CT 2	21.64
2020	12	17	PCR_COBAS_COV19	CT 2	33.65
2020	12	17	PCR_COBAS_COV19	CT 2	19.11
2020	12	17	PCR_COBAS_COV19	CT 2	25.56
2020	12	17	PCR_COBAS_COV19	CT 2	17.31
2020	12	17	PCR_COBAS_COV19	CT 2	29.43
2020	12	17	PCR_COBAS_COV19	CT 2	31.92
2020	12	17	PCR_COBAS_COV19	CT 2	25.48
2020	12	17	PCR_COBAS_COV19	CT 2	32.73
2020	12	17	PCR_COBAS_COV19	CT 2	16.9
2020	12	17	PCR_COBAS_COV19	CT 2	30.82
2020	12	17	PCR_COBAS_COV19	CT 2	15.42
2020	12	17	PCR_PANTH_COV19	RLU	1167
2020	12	17	PCR_PANTH_COV19	RLU	1140
2020	12	17	PCR_PANTH_COV19	RLU	1114
2020	12	17	PCR_PANTH_COV19	RLU	1131
2020	12	17	PCR_PANTH_COV19	RLU	1159
2020	12	17	PCR_PANTH_COV19	RLU	1106
2020	12	17	PCR_PANTH_COV19	RLU	1111
2020	12	17	PCR_PANTH_COV19	RLU	1166
2020	12	17	PCR_PANTH_COV19	RLU	1141
2020	12	17	PCR_PANTH_COV19	RLU	1141
2020	12	17	PCR_PANTH_COV19	RLU	1162
2020	12	17	PCR_COBAS_COV19	CT 2	28.28
2020	12	17	PCR_COBAS_COV19	CT 2	21.03
2020	12	17	PCR_COBAS_COV19	CT 2	25.31
2020	12	17	PCR_COBAS_COV19	CT 2	17.21
2020	12	17	PCR_COBAS_COV19	CT 2	20.76
2020	12	17	PCR_COBAS_COV19	CT 2	36.49
2020	12	17	PCR_COBAS_COV19	CT 2	38.88
2020	12	17	PCR_COBAS_COV19	CT 2	33.82
2020	12	17	PCR_COBAS_COV19	CT 2	36.84
2020	12	17	PCR_COBAS_COV19	CT 2	25.79
2020	12	17	PCR_PANTH_COV19	RLU	1152
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	15.4
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	34.4
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.80224658
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.17286493

AB1063

2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.52340853
2020	12	17	PCR_PANTH_COV19	RLU	1156
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	37.3
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	24.8
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	20.5
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	20.7
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	19.3
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.74687616
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.14444541
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.40648065
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.72435231
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.14110494
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.38409351
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	37.8
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	19.1
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.73817935
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	23.1
2020	12	17	PCR_PANTH_COV19	RLU	1177
2020	12	17	PCR_PANTH_COV19	RLU	1154
2020	12	17	PCR_PANTH_COV19	RLU	1134
2020	12	17	PCR_PANTH_COV19	RLU	1224
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.16766465
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.49476267
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.68912995
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.84459654
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.5345753
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.23993947
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	29
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.64721339
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	31.7
2020	12	17	PCR_PANTH_COV19	RLU	1157
2020	12	17	PCR_PANTH_COV19	RLU	1185
2020	12	17	PCR_PANTH_COV19	RLU	1172
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	26.1
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	22.7
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	36.1
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	34.6
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	20.2
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	16.6
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	24.4
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	22.7
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	32.7
2020	12	17	PCR_PANTH_COV19	RLU	1213
2020	12	17	PCR_PANTH_COV19	RLU	1122
2020	12	17	PCR_PANTH_COV19	RLU	1204
2020	12	17	PCR_PANTH_COV19	RLU	1066
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.40062636

AB1064

2020	12	17	PCR_PANTH_COV19	RLU	1103
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.36143778
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.59595925
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.87276012
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	16.6
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	26.1
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	21.4
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	32.1
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	35.4
2020	12	17	PCR_FUSION_COV19_E	E Gene CT	21.6
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.56393639
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.15127573
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.86524694
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.05777048
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.33186054
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.34127791
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.29573055
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.23075197
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.02423699
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.59772801
2020	12	17	PCR_PANTH_COV19	RLU	1168
2020	12	17	PCR_PANTH_COV19	RLU	1163
2020	12	17	PCR_COBAS_COV19	CT 2	16.45
2020	12	17	PCR_COBAS_COV19	CT 2	25.41
2020	12	17	PCR_COBAS_COV19	CT 2	35.65
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.00432314
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.13948031
2020	12	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.10189847
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.99368354
2020	12	18	PCR_COBAS_COV19	CT 2	30.53
2020	12	18	PCR_COBAS_COV19	CT 2	18.09
2020	12	18	PCR_COBAS_COV19	CT 2	37.29
2020	12	18	PCR_PANTH_COV19	RLU	1159
2020	12	18	PCR_PANTH_COV19	RLU	1159
2020	12	18	PCR_FUSION_COV19_E	E Gene CT	20.3
2020	12	18	PCR_PANTH_COV19	RLU	1193
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.76202487
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.5442229
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.25383967
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.79913582
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.53835652
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	10.98789612
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.05664527
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.12560993
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.22172971
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.14953028
2020	12	18	PCR_FUSION_COV19_E	E Gene CT	28

2020	12	18	PCR_FUSION_COV19_E	E Gene CT	20
2020	12	18	PCR_FUSION_COV19_E	E Gene CT	22.5
2020	12	18	PCR_COBAS_COV19	CT 2	35.45
2020	12	18	PCR_COBAS_COV19	CT 2	25.69
2020	12	18	PCR_COBAS_COV19	CT 2	19.63
2020	12	18	PCR_COBAS_COV19	CT 2	31.92
2020	12	18	PCR_COBAS_COV19	CT 2	30.63
2020	12	18	PCR_COBAS_COV19	CT 2	33.31
2020	12	18	PCR_COBAS_COV19	CT 2	31.41
2020	12	18	PCR_COBAS_COV19	CT 2	25.79
2020	12	18	PCR_COBAS_COV19	CT 2	16.44
2020	12	18	PCR_COBAS_COV19	CT 2	18.8
2020	12	18	PCR_COBAS_COV19	CT 2	34.5
2020	12	18	PCR_COBAS_COV19	CT 2	26
2020	12	18	PCR_COBAS_COV19	CT 2	21.29
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.12591645
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.34156889
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.0562289
2020	12	18	PCR_PANTH_COV19	RLU	1180
2020	12	18	PCR_PANTH_COV19	RLU	1173
2020	12	18	PCR_PANTH_COV19	RLU	1168
2020	12	18	PCR_PANTH_COV19	RLU	1178
2020	12	18	PCR_PANTH_COV19	RLU	1149
2020	12	18	PCR_PANTH_COV19	RLU	1204
2020	12	18	PCR_PANTH_COV19	RLU	1125
2020	12	18	PCR_PANTH_COV19	RLU	1127
2020	12	18	PCR_PANTH_COV19	RLU	1149
2020	12	18	PCR_PANTH_COV19	RLU	1122
2020	12	18	PCR_PANTH_COV19	RLU	1164
2020	12	18	PCR_PANTH_COV19	RLU	1110
2020	12	18	PCR_PANTH_COV19	RLU	1160
2020	12	18	PCR_PANTH_COV19	RLU	1136
2020	12	18	PCR_PANTH_COV19	RLU	1169
2020	12	18	PCR_PANTH_COV19	RLU	1169
2020	12	18	PCR_PANTH_COV19	RLU	1196
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.68959496
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.68549124
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.44553241
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.8482714
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.3424265
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.96036723
2020	12	18	PCR_PANTH_COV19	RLU	1184
2020	12	18	PCR_PANTH_COV19	RLU	1204
2020	12	18	PCR_PANTH_COV19	RLU	1181
2020	12	18	PCR_PANTH_COV19	RLU	1201
2020	12	18	PCR_PANTH_COV19	RLU	1180
2020	12	18	PCR_PANTH_COV19	RLU	1166

AB1066

2020	12	18	PCR_PANTH_COV19	RLU	1189
2020	12	18	PCR_PANTH_COV19	RLU	1186
2020	12	18	PCR_PANTH_COV19	RLU	1156
2020	12	18	PCR_PANTH_COV19	RLU	1167
2020	12	18	PCR_PANTH_COV19	RLU	1150
2020	12	18	PCR_FUSION_COV19_E	E Gene CT	36.8
2020	12	18	PCR_FUSION_COV19_E	E Gene CT	37.6
2020	12	18	PCR_FUSION_COV19_E	E Gene CT	25.3
2020	12	18	PCR_FUSION_COV19_E	E Gene CT	21.3
2020	12	18	PCR_FUSION_COV19_E	E Gene CT	36.1
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.96668354
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.429636
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.34166832
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.79091173
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.63050986
2020	12	18	PCR_PANTH_COV19	RLU	1192
2020	12	18	PCR_PANTH_COV19	RLU	1133
2020	12	18	PCR_PANTH_COV19	RLU	1146
2020	12	18	PCR_PANTH_COV19	RLU	1134
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.75443065
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.81351001
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.39993771
2020	12	18	PCR_FUSION_COV19_E	E Gene CT	24.3
2020	12	18	PCR_FUSION_COV19_E	E Gene CT	31.4
2020	12	18	PCR_FUSION_COV19_E	E Gene CT	32.2
2020	12	18	PCR_FUSION_COV19_E	E Gene CT	37
2020	12	18	PCR_FUSION_COV19_E	E Gene CT	32.6
2020	12	18	PCR_FUSION_COV19_E	E Gene CT	26.5
2020	12	18	PCR_FUSION_COV19_E	E Gene CT	37.7
2020	12	18	PCR_FUSION_COV19_E	E Gene CT	17.5
2020	12	18	PCR_COBAS_COV19	CT 2	36.72
2020	12	18	PCR_COBAS_COV19	CT 2	34.05
2020	12	18	PCR_COBAS_COV19	CT 2	19.85
2020	12	18	PCR_PANTH_COV19	RLU	1205
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.60832893
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.40788329
2020	12	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.31504028
2020	12	19	PCR_COBAS_COV19	CT 2	38.29
2020	12	19	PCR_COBAS_COV19	CT 2	18.61
2020	12	19	PCR_COBAS_COV19	CT 2	16.5
2020	12	19	PCR_COBAS_COV19	CT 2	31.87
2020	12	19	PCR_COBAS_COV19	CT 2	23.42
2020	12	19	PCR_COBAS_COV19	CT 2	34.86
2020	12	19	PCR_COBAS_COV19	CT 2	21.98
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.97585346
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.70867428
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.42868126

AB1067

2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.19242382
2020	12	19	PCR_COBAS_COV19	CT 2	27.87
2020	12	19	PCR_COBAS_COV19	CT 2	19.86
2020	12	19	PCR_COBAS_COV19	CT 2	34.87
2020	12	19	PCR_COBAS_COV19	CT 2	19.17
2020	12	19	PCR_PANTH_COV19	RLU	1207
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.592272
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.58212193
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.66117851
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.13250348
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.69115854
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.24455222
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.57286791
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.46789642
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.01082267
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.63450762
2020	12	19	PCR_PANTH_COV19	RLU	1120
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.08769583
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.66329504
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	24.8
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	23.5
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	29.2
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	37
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	34.2
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	32.7
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	37
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	20
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	30.6
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	20.7
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	22.9
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	22
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	34.3
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	35.8
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.90521331
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.39988015
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.21740893
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.01034941
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	35.3
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	32.2
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	24.5
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	25.2
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.31429174
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.53320445
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.61085797
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.18003148
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.83591404
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	33.3

AB1068

2020	12	19	PCR_FUSION_COV19_E	E Gene CT	34
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	18.6
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	21.4
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	31.7
2020	12	19	PCR_COBAS_COV19	CT 2	16.14
2020	12	19	PCR_COBAS_COV19	CT 2	18.47
2020	12	19	PCR_COBAS_COV19	CT 2	18.84
2020	12	19	PCR_COBAS_COV19	CT 2	22.72
2020	12	19	PCR_COBAS_COV19	CT 2	20.28
2020	12	19	PCR_COBAS_COV19	CT 2	33.03
2020	12	19	PCR_COBAS_COV19	CT 2	19.45
2020	12	19	PCR_COBAS_COV19	CT 2	18.07
2020	12	19	PCR_COBAS_COV19	CT 2	32.37
2020	12	19	PCR_COBAS_COV19	CT 2	33.48
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	31.8
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	37.4
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	20.7
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	31.7
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	35.8
2020	12	19	PCR_FUSION_COV19_E	E Gene CT	28.2
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.68128325
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.23779351
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.56009514
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.20390954
2020	12	19	PCR_COBAS_COV19	CT 2	20.4
2020	12	19	PCR_COBAS_COV19	CT 2	36.06
2020	12	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.41053273
2020	12	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.64939267
2020	12	20	PCR_COBAS_COV19	CT 2	30.9
2020	12	20	PCR_COBAS_COV19	CT 2	20.58
2020	12	20	PCR_COBAS_COV19	CT 2	34.27
2020	12	20	PCR_COBAS_COV19	CT 2	19.3
2020	12	20	PCR_COBAS_COV19	CT 2	19.36
2020	12	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.38684885
2020	12	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.75650277
2020	12	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.14715817
2020	12	20	PCR_PANTH_COV19	RLU	1148
2020	12	20	PCR_PANTH_COV19	RLU	1129
2020	12	20	PCR_PANTH_COV19	RLU	1163
2020	12	20	PCR_PANTH_COV19	RLU	1151
2020	12	20	PCR_PANTH_COV19	RLU	1141
2020	12	20	PCR_COBAS_COV19	CT 2	36.56
2020	12	20	PCR_COBAS_COV19	CT 2	34.03
2020	12	20	PCR_COBAS_COV19	CT 2	18.26
2020	12	20	PCR_COBAS_COV19	CT 2	32.96
2020	12	20	PCR_COBAS_COV19	CT 2	34.2
2020	12	20	PCR_COBAS_COV19	CT 2	33.3

AB1069

2020	12	20	PCR_COBAS_COV19	CT 2	17.15
2020	12	20	PCR_COBAS_COV19	CT 2	24.4
2020	12	20	PCR_COBAS_COV19	CT 2	18.92
2020	12	20	PCR_COBAS_COV19	CT 2	15.26
2020	12	20	PCR_COBAS_COV19	CT 2	24.52
2020	12	20	PCR_PANTH_COV19	RLU	1126
2020	12	20	PCR_PANTH_COV19	RLU	1172
2020	12	20	PCR_PANTH_COV19	RLU	1112
2020	12	20	PCR_PANTH_COV19	RLU	1217
2020	12	20	PCR_PANTH_COV19	RLU	1132
2020	12	20	PCR_PANTH_COV19	RLU	1145
2020	12	20	PCR_PANTH_COV19	RLU	1156
2020	12	20	PCR_PANTH_COV19	RLU	1168
2020	12	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.19004276
2020	12	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.68815781
2020	12	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.17102385
2020	12	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.00803923
2020	12	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.12805344
2020	12	20	PCR_PANTH_COV19	RLU	1169
2020	12	20	PCR_PANTH_COV19	RLU	1125
2020	12	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.65008987
2020	12	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.85396598
2020	12	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.59203592
2020	12	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.16787808
2020	12	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.82669392
2020	12	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.52068153
2020	12	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.82645859
2020	12	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.15721471
2020	12	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.05009962
2020	12	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.56599689
2020	12	20	PCR_FUSION_COV19_E	E Gene CT	16.3
2020	12	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.96457799
2020	12	20	PCR_FUSION_COV19_E	E Gene CT	33.3
2020	12	20	PCR_FUSION_COV19_E	E Gene CT	37.8
2020	12	20	PCR_FUSION_COV19_E	E Gene CT	20.7
2020	12	20	PCR_FUSION_COV19_E	E Gene CT	20.9
2020	12	20	PCR_FUSION_COV19_E	E Gene CT	20.6
2020	12	20	PCR_FUSION_COV19_E	E Gene CT	18
2020	12	20	PCR_FUSION_COV19_E	E Gene CT	32.4
2020	12	20	PCR_FUSION_COV19_E	E Gene CT	35.1
2020	12	20	PCR_FUSION_COV19_E	E Gene CT	34.3
2020	12	20	PCR_FUSION_COV19_E	E Gene CT	37.1
2020	12	20	PCR_FUSION_COV19_E	E Gene CT	25.5
2020	12	20	PCR_FUSION_COV19_E	E Gene CT	35.3
2020	12	20	PCR_FUSION_COV19_E	E Gene CT	25.6
2020	12	20	PCR_FUSION_COV19_E	E Gene CT	36.1
2020	12	20	PCR_FUSION_COV19_E	E Gene CT	26.2

AB1070

2020	12	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.09481849
2020	12	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.82501748
2020	12	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.16068878
2020	12	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.70616279
2020	12	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.0963305
2020	12	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.19283764
2020	12	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.6845632
2020	12	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.86103732
2020	12	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.88574493
2020	12	21	PCR_FUSION_COV19_E	E Gene CT	21.7
2020	12	21	PCR_COBAS_COV19	CT 2	25.64
2020	12	21	PCR_COBAS_COV19	CT 2	20.04
2020	12	21	PCR_COBAS_COV19	CT 2	20.88
2020	12	21	PCR_COBAS_COV19	CT 2	17.98
2020	12	21	PCR_COBAS_COV19	CT 2	17.76
2020	12	21	PCR_COBAS_COV19	CT 2	14.44
2020	12	21	PCR_COBAS_COV19	CT 2	33.74
2020	12	21	PCR_COBAS_COV19	CT 2	17.01
2020	12	21	PCR_COBAS_COV19	CT 2	16.53
2020	12	21	PCR_COBAS_COV19	CT 2	18.44
2020	12	21	PCR_COBAS_COV19	CT 2	22.2
2020	12	21	PCR_COBAS_COV19	CT 2	17.06
2020	12	21	PCR_COBAS_COV19	CT 2	20.52
2020	12	21	PCR_COBAS_COV19	CT 2	22.99
2020	12	21	PCR_COBAS_COV19	CT 2	18.47
2020	12	21	PCR_COBAS_COV19	CT 2	27.13
2020	12	21	PCR_COBAS_COV19	CT 2	18.58
2020	12	21	PCR_COBAS_COV19	CT 2	18.92
2020	12	21	PCR_COBAS_COV19	CT 2	17.75
2020	12	21	PCR_COBAS_COV19	CT 2	20.42
2020	12	21	PCR_COBAS_COV19	CT 2	16.67
2020	12	21	PCR_COBAS_COV19	CT 2	34.85
2020	12	21	PCR_COBAS_COV19	CT 2	19.42
2020	12	21	PCR_COBAS_COV19	CT 2	22.67
2020	12	21	PCR_COBAS_COV19	CT 2	34.22
2020	12	21	PCR_COBAS_COV19	CT 2	28.69
2020	12	21	PCR_COBAS_COV19	CT 2	19.83
2020	12	21	PCR_COBAS_COV19	CT 2	19.17
2020	12	21	PCR_COBAS_COV19	CT 2	26.81
2020	12	21	PCR_COBAS_COV19	CT 2	21.08
2020	12	21	PCR_COBAS_COV19	CT 2	26.66
2020	12	21	PCR_COBAS_COV19	CT 2	19.97
2020	12	21	PCR_COBAS_COV19	CT 2	17.47
2020	12	21	PCR_COBAS_COV19	CT 2	18.65
2020	12	21	PCR_COBAS_COV19	CT 2	36.14
2020	12	21	PCR_COBAS_COV19	CT 2	18.65
2020	12	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.36445204

AB1071

2020	12	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.90591442
2020	12	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.28517866
2020	12	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.24580361
2020	12	21	PCR_FUSION_COV19_E	E Gene CT	16.9
2020	12	21	PCR_FUSION_COV19_E	E Gene CT	37.8
2020	12	21	PCR_FUSION_COV19_E	E Gene CT	36
2020	12	21	PCR_FUSION_COV19_E	E Gene CT	30
2020	12	21	PCR_FUSION_COV19_E	E Gene CT	27.3
2020	12	21	PCR_FUSION_COV19_E	E Gene CT	18.5
2020	12	21	PCR_FUSION_COV19_E	E Gene CT	31.6
2020	12	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.36637852
2020	12	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.42762007
2020	12	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.57472537
2020	12	21	PCR_FUSION_COV19_E	E Gene CT	34.2
2020	12	21	PCR_COBAS_COV19	CT 2	34.55
2020	12	21	PCR_COBAS_COV19	CT 2	21.92
2020	12	21	PCR_COBAS_COV19	CT 2	15.34
2020	12	21	PCR_COBAS_COV19	CT 2	22.51
2020	12	21	PCR_COBAS_COV19	CT 2	16.18
2020	12	21	PCR_COBAS_COV19	CT 2	20.62
2020	12	21	PCR_COBAS_COV19	CT 2	18.65
2020	12	21	PCR_COBAS_COV19	CT 2	19.72
2020	12	21	PCR_COBAS_COV19	CT 2	18.01
2020	12	21	PCR_COBAS_COV19	CT 2	34.48
2020	12	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.55842806
2020	12	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.83697092
2020	12	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.59689757
2020	12	21	PCR_PANTH_COV19	RLU	1141
2020	12	21	PCR_PANTH_COV19	RLU	1159
2020	12	21	PCR_PANTH_COV19	RLU	1087
2020	12	21	PCR_PANTH_COV19	RLU	1138
2020	12	21	PCR_PANTH_COV19	RLU	1096
2020	12	21	PCR_PANTH_COV19	RLU	1128
2020	12	21	PCR_PANTH_COV19	RLU	1137
2020	12	21	PCR_PANTH_COV19	RLU	1104
2020	12	21	PCR_PANTH_COV19	RLU	1150
2020	12	21	PCR_FUSION_COV19_E	E Gene CT	35.5
2020	12	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.38588297
2020	12	21	PCR_PANTH_COV19	RLU	1122
2020	12	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.99308144
2020	12	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.19993366
2020	12	21	PCR_PANTH_COV19	RLU	1169
2020	12	21	PCR_PANTH_COV19	RLU	1159
2020	12	21	PCR_PANTH_COV19	RLU	1126
2020	12	21	PCR_PANTH_COV19	RLU	1231
2020	12	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.27495784
2020	12	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.06962427

AB1072

2020	12	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.09425716
2020	12	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.63933327
2020	12	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.5680177
2020	12	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.49148919
2020	12	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.23878436
2020	12	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.32926143
2020	12	21	PCR_PANTH_COV19	RLU	1154
2020	12	21	PCR_PANTH_COV19	RLU	1166
2020	12	21	PCR_PANTH_COV19	RLU	1183
2020	12	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.3671922
2020	12	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.03162263
2020	12	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.37308424
2020	12	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.05753114
2020	12	22	PCR_PANTH_COV19	RLU	1129
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.68073208
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.23329822
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.64490046
2020	12	22	PCR_COBAS_COV19	CT 2	27.62
2020	12	22	PCR_COBAS_COV19	CT 2	30.91
2020	12	22	PCR_COBAS_COV19	CT 2	17.35
2020	12	22	PCR_COBAS_COV19	CT 2	18.58
2020	12	22	PCR_COBAS_COV19	CT 2	19.89
2020	12	22	PCR_COBAS_COV19	CT 2	25.01
2020	12	22	PCR_COBAS_COV19	CT 2	30.47
2020	12	22	PCR_COBAS_COV19	CT 2	23.79
2020	12	22	PCR_COBAS_COV19	CT 2	32.5
2020	12	22	PCR_COBAS_COV19	CT 2	34.36
2020	12	22	PCR_COBAS_COV19	CT 2	18.37
2020	12	22	PCR_COBAS_COV19	CT 2	17.98
2020	12	22	PCR_COBAS_COV19	CT 2	25.25
2020	12	22	PCR_COBAS_COV19	CT 2	33.96
2020	12	22	PCR_COBAS_COV19	CT 2	16.37
2020	12	22	PCR_COBAS_COV19	CT 2	20.4
2020	12	22	PCR_COBAS_COV19	CT 2	33.98
2020	12	22	PCR_COBAS_COV19	CT 2	34.73
2020	12	22	PCR_COBAS_COV19	CT 2	23.7
2020	12	22	PCR_FUSION_COV19_E	E Gene CT	33.3
2020	12	22	PCR_FUSION_COV19_E	E Gene CT	19.5
2020	12	22	PCR_PANTH_COV19	RLU	1199
2020	12	22	PCR_PANTH_COV19	RLU	1167
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.4010257
2020	12	22	PCR_PANTH_COV19	RLU	1164
2020	12	22	PCR_PANTH_COV19	RLU	1127
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.04939636
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.228048
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.61379437
2020	12	22	PCR_FUSION_COV19_E	E Gene CT	20.7

AB1073

2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.17458136
2020	12	22	PCR_FUSION_COV19_E	E Gene CT	21.9
2020	12	22	PCR_FUSION_COV19_E	E Gene CT	22.7
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.47896622
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.32406305
2020	12	22	PCR_PANTH_COV19	RLU	1016
2020	12	22	PCR_PANTH_COV19	RLU	1185
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.11335972
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.68348417
2020	12	22	PCR_COBAS_COV19	CT 2	33.79
2020	12	22	PCR_COBAS_COV19	CT 2	32.35
2020	12	22	PCR_COBAS_COV19	CT 2	22.46
2020	12	22	PCR_COBAS_COV19	CT 2	19.95
2020	12	22	PCR_COBAS_COV19	CT 2	32.53
2020	12	22	PCR_COBAS_COV19	CT 2	34.44
2020	12	22	PCR_COBAS_COV19	CT 2	30.82
2020	12	22	PCR_COBAS_COV19	CT 2	33.34
2020	12	22	PCR_COBAS_COV19	CT 2	26.6
2020	12	22	PCR_COBAS_COV19	CT 2	22.58
2020	12	22	PCR_COBAS_COV19	CT 2	35.75
2020	12	22	PCR_COBAS_COV19	CT 2	25.52
2020	12	22	PCR_COBAS_COV19	CT 2	18.44
2020	12	22	PCR_COBAS_COV19	CT 2	38.01
2020	12	22	PCR_COBAS_COV19	CT 2	23.83
2020	12	22	PCR_COBAS_COV19	CT 2	26.68
2020	12	22	PCR_COBAS_COV19	CT 2	32.98
2020	12	22	PCR_COBAS_COV19	CT 2	32.38
2020	12	22	PCR_COBAS_COV19	CT 2	25.97
2020	12	22	PCR_COBAS_COV19	CT 2	33.99
2020	12	22	PCR_COBAS_COV19	CT 2	34.25
2020	12	22	PCR_COBAS_COV19	CT 2	23.78
2020	12	22	PCR_COBAS_COV19	CT 2	26.58
2020	12	22	PCR_COBAS_COV19	CT 2	34.98
2020	12	22	PCR_COBAS_COV19	CT 2	35.59
2020	12	22	PCR_COBAS_COV19	CT 2	22.46
2020	12	22	PCR_COBAS_COV19	CT 2	32.28
2020	12	22	PCR_COBAS_COV19	CT 2	16.37
2020	12	22	PCR_COBAS_COV19	CT 2	20.07
2020	12	22	PCR_PANTH_COV19	RLU	1160
2020	12	22	PCR_PANTH_COV19	RLU	1162
2020	12	22	PCR_PANTH_COV19	RLU	1155
2020	12	22	PCR_PANTH_COV19	RLU	1168
2020	12	22	PCR_PANTH_COV19	RLU	1143
2020	12	22	PCR_PANTH_COV19	RLU	1139
2020	12	22	PCR_PANTH_COV19	RLU	1116
2020	12	22	PCR_PANTH_COV19	RLU	1126
2020	12	22	PCR_PANTH_COV19	RLU	1159

AB1074

2020	12	22	PCR_PANTH_COV19	RLU	1155
2020	12	22	PCR_PANTH_COV19	RLU	1140
2020	12	22	PCR_PANTH_COV19	RLU	1152
2020	12	22	PCR_PANTH_COV19	RLU	1179
2020	12	22	PCR_PANTH_COV19	RLU	1118
2020	12	22	PCR_PANTH_COV19	RLU	1126
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.80572196
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.56418958
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.14338281
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.93810186
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.08253087
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.89701307
2020	12	22	PCR_FUSION_COV19_E	E Gene CT	29.1
2020	12	22	PCR_FUSION_COV19_E	E Gene CT	38
2020	12	22	PCR_FUSION_COV19_E	E Gene CT	36.1
2020	12	22	PCR_FUSION_COV19_E	E Gene CT	33.3
2020	12	22	PCR_FUSION_COV19_E	E Gene CT	20.8
2020	12	22	PCR_PANTH_COV19	RLU	1150
2020	12	22	PCR_PANTH_COV19	RLU	1173
2020	12	22	PCR_PANTH_COV19	RLU	1153
2020	12	22	PCR_PANTH_COV19	RLU	1147
2020	12	22	PCR_PANTH_COV19	RLU	1142
2020	12	22	PCR_PANTH_COV19	RLU	1076
2020	12	22	PCR_PANTH_COV19	RLU	1169
2020	12	22	PCR_PANTH_COV19	RLU	1165
2020	12	22	PCR_FUSION_COV19_E	E Gene CT	18.3
2020	12	22	PCR_FUSION_COV19_E	E Gene CT	26.5
2020	12	22	PCR_FUSION_COV19_E	E Gene CT	25.6
2020	12	22	PCR_FUSION_COV19_E	E Gene CT	19.4
2020	12	22	PCR_FUSION_COV19_E	E Gene CT	30.6
2020	12	22	PCR_FUSION_COV19_E	E Gene CT	18
2020	12	22	PCR_FUSION_COV19_E	E Gene CT	16.6
2020	12	22	PCR_FUSION_COV19_E	E Gene CT	23.1
2020	12	22	PCR_FUSION_COV19_E	E Gene CT	18.8
2020	12	22	PCR_PANTH_COV19	RLU	1199
2020	12	22	PCR_PANTH_COV19	RLU	1119
2020	12	22	PCR_PANTH_COV19	RLU	1187
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.78186247
2020	12	22	PCR_PANTH_COV19	RLU	1149
2020	12	22	PCR_PANTH_COV19	RLU	1169
2020	12	22	PCR_PANTH_COV19	RLU	1207
2020	12	22	PCR_PANTH_COV19	RLU	1179
2020	12	22	PCR_PANTH_COV19	RLU	1208
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.08155607
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.72155071
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.4330944
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.89157429

AB1075

2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.12163068
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.65656209
2020	12	22	PCR_COBAS_COV19	CT 2	24.4
2020	12	22	PCR_COBAS_COV19	CT 2	20.8
2020	12	22	PCR_COBAS_COV19	CT 2	32.95
2020	12	22	PCR_COBAS_COV19	CT 2	33.12
2020	12	22	PCR_COBAS_COV19	CT 2	31.97
2020	12	22	PCR_COBAS_COV19	CT 2	20.17
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.57012629
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.643434
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.47400891
2020	12	22	PCR_FUSION_COV19_E	E Gene CT	24
2020	12	22	PCR_FUSION_COV19_E	E Gene CT	25.1
2020	12	22	PCR_FUSION_COV19_E	E Gene CT	19.1
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.15954285
2020	12	22	PCR_FUSION_COV19_E	E Gene CT	36.8
2020	12	22	PCR_FUSION_COV19_E	E Gene CT	34.9
2020	12	22	PCR_FUSION_COV19_E	E Gene CT	17.2
2020	12	22	PCR_FUSION_COV19_E	E Gene CT	22
2020	12	22	PCR_FUSION_COV19_E	E Gene CT	18.3
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.50709275
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.23553233
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.017193
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.41529676
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.12759001
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.35165726
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.20513873
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.01727405
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.42553668
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.95116904
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.34526519
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.82383422
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.51609718
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.76463805
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.39241788
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.73320971
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.61533306
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.16875934
2020	12	22	PCR_COBAS_COV19	CT 2	20.11
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.50747294
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.95119654
2020	12	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.18512258
2020	12	22	PCR_COBAS_COV19	CT 2	36.53
2020	12	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.75
2020	12	23	PCR_COBAS_COV19	CT 2	18.75
2020	12	23	PCR_COBAS_COV19	CT 2	37.31
2020	12	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.3600319

AB1076

2020	12	23	PCR_COBAS_COV19	CT 2	31.03
2020	12	23	PCR_COBAS_COV19	CT 2	24.81
2020	12	23	PCR_COBAS_COV19	CT 2	26.1
2020	12	23	PCR_COBAS_COV19	CT 2	31.81
2020	12	23	PCR_COBAS_COV19	CT 2	26.7
2020	12	23	PCR_COBAS_COV19	CT 2	18.67
2020	12	23	PCR_COBAS_COV19	CT 2	22.08
2020	12	23	PCR_COBAS_COV19	CT 2	17.52
2020	12	23	PCR_COBAS_COV19	CT 2	20.36
2020	12	23	PCR_COBAS_COV19	CT 2	18.08
2020	12	23	PCR_COBAS_COV19	CT 2	21.46
2020	12	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.37853282
2020	12	23	PCR_FUSION_COV19_E	E Gene CT	36
2020	12	23	PCR_FUSION_COV19_E	E Gene CT	23.5
2020	12	23	PCR_FUSION_COV19_E	E Gene CT	22.5
2020	12	23	PCR_FUSION_COV19_E	E Gene CT	21.8
2020	12	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.91943522
2020	12	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.96447074
2020	12	23	PCR_PANTH_COV19	RLU	1199
2020	12	23	PCR_PANTH_COV19	RLU	1212
2020	12	23	PCR_PANTH_COV19	RLU	1197
2020	12	23	PCR_PANTH_COV19	RLU	1216
2020	12	23	PCR_PANTH_COV19	RLU	1176
2020	12	23	PCR_PANTH_COV19	RLU	1161
2020	12	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.42444242
2020	12	23	PCR_PANTH_COV19	RLU	1188
2020	12	23	PCR_PANTH_COV19	RLU	1100
2020	12	23	PCR_PANTH_COV19	RLU	1182
2020	12	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.27106478
2020	12	23	PCR_PANTH_COV19	RLU	1172
2020	12	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.63852201
2020	12	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.94742696
2020	12	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.82157507
2020	12	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.82919323
2020	12	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.27437369
2020	12	23	PCR_PANTH_COV19	RLU	1136
2020	12	23	PCR_PANTH_COV19	RLU	1180
2020	12	23	PCR_PANTH_COV19	RLU	1177
2020	12	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.66653314
2020	12	23	PCR_PANTH_COV19	RLU	1214
2020	12	23	PCR_PANTH_COV19	RLU	1148
2020	12	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.223838
2020	12	23	PCR_PANTH_COV19	RLU	1149
2020	12	23	PCR_PANTH_COV19	RLU	1093
2020	12	23	PCR_PANTH_COV19	RLU	1179
2020	12	23	PCR_PANTH_COV19	RLU	1146
2020	12	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.34536726

AB1077

2020	12	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.29487848
2020	12	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.43015808
2020	12	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.37846967
2020	12	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.52008705
2020	12	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.19731995
2020	12	23	PCR_FUSION_COV19_E	E Gene CT	32.7
2020	12	23	PCR_PANTH_COV19	RLU	1151
2020	12	23	PCR_PANTH_COV19	RLU	1152
2020	12	23	PCR_PANTH_COV19	RLU	1208
2020	12	23	PCR_PANTH_COV19	RLU	1174
2020	12	23	PCR_PANTH_COV19	RLU	1192
2020	12	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.69652061
2020	12	23	PCR_FUSION_COV19_E	E Gene CT	21.1
2020	12	23	PCR_FUSION_COV19_E	E Gene CT	19.3
2020	12	23	PCR_FUSION_COV19_E	E Gene CT	23.6
2020	12	23	PCR_FUSION_COV19_E	E Gene CT	19.2
2020	12	23	PCR_FUSION_COV19_E	E Gene CT	24.8
2020	12	23	PCR_FUSION_COV19_E	E Gene CT	34.1
2020	12	23	PCR_FUSION_COV19_E	E Gene CT	28.9
2020	12	23	PCR_FUSION_COV19_E	E Gene CT	31.4
2020	12	23	PCR_FUSION_COV19_E	E Gene CT	34.7
2020	12	23	PCR_FUSION_COV19_E	E Gene CT	35.6
2020	12	23	PCR_FUSION_COV19_E	E Gene CT	34.6
2020	12	23	PCR_PANTH_COV19	RLU	1184
2020	12	23	PCR_PANTH_COV19	RLU	1122
2020	12	23	PCR_PANTH_COV19	RLU	1158
2020	12	23	PCR_PANTH_COV19	RLU	1142
2020	12	23	PCR_PANTH_COV19	RLU	1162
2020	12	23	PCR_PANTH_COV19	RLU	1192
2020	12	23	PCR_PANTH_COV19	RLU	1171
2020	12	23	PCR_PANTH_COV19	RLU	1173
2020	12	23	PCR_PANTH_COV19	RLU	1180
2020	12	23	PCR_PANTH_COV19	RLU	1192
2020	12	23	PCR_PANTH_COV19	RLU	1177
2020	12	23	PCR_PANTH_COV19	RLU	1211
2020	12	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.00149653
2020	12	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.97692394
2020	12	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.19901575
2020	12	23	PCR_COBAS_COV19	CT 2	29.69
2020	12	23	PCR_PANTH_COV19	RLU	1161
2020	12	23	PCR_PANTH_COV19	RLU	1173
2020	12	23	PCR_PANTH_COV19	RLU	1203
2020	12	23	PCR_PANTH_COV19	RLU	1121
2020	12	23	PCR_PANTH_COV19	RLU	1159
2020	12	23	PCR_FUSION_COV19_E	E Gene CT	35.6
2020	12	23	PCR_FUSION_COV19_E	E Gene CT	28.5
2020	12	23	PCR_FUSION_COV19_E	E Gene CT	19.9

AB1078

2020	12	23	PCR_FUSION_COV19_E	E Gene CT	25.3
2020	12	23	PCR_FUSION_COV19_E	E Gene CT	35.8
2020	12	23	PCR_FUSION_COV19_E	E Gene CT	37.2
2020	12	23	PCR_COBAS_COV19	CT 2	25.49
2020	12	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.52639651
2020	12	23	PCR_FUSION_COV19_E	E Gene CT	17.2
2020	12	24	PCR_COBAS_COV19	CT 2	27.18
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.30077481
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	17.9
2020	12	24	PCR_COBAS_COV19	CT 2	19.25
2020	12	24	PCR_COBAS_COV19	CT 2	26.55
2020	12	24	PCR_COBAS_COV19	CT 2	22.05
2020	12	24	PCR_COBAS_COV19	CT 2	17.22
2020	12	24	PCR_COBAS_COV19	CT 2	23.22
2020	12	24	PCR_COBAS_COV19	CT 2	24.88
2020	12	24	PCR_COBAS_COV19	CT 2	30.73
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.40796639
2020	12	24	PCR_COBAS_COV19	CT 2	24.18
2020	12	24	PCR_COBAS_COV19	CT 2	22.88
2020	12	24	PCR_COBAS_COV19	CT 2	16.17
2020	12	24	PCR_COBAS_COV19	CT 2	23.5
2020	12	24	PCR_COBAS_COV19	CT 2	30.1
2020	12	24	PCR_COBAS_COV19	CT 2	16.63
2020	12	24	PCR_COBAS_COV19	CT 2	15.81
2020	12	24	PCR_COBAS_COV19	CT 2	20.17
2020	12	24	PCR_COBAS_COV19	CT 2	31.6
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	30.1
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	27.1
2020	12	24	PCR_PANTH_COV19	RLU	1220
2020	12	24	PCR_PANTH_COV19	RLU	1147
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.25324615
2020	12	24	PCR_PANTH_COV19	RLU	1136
2020	12	24	PCR_PANTH_COV19	RLU	1137
2020	12	24	PCR_PANTH_COV19	RLU	1137
2020	12	24	PCR_PANTH_COV19	RLU	1180
2020	12	24	PCR_PANTH_COV19	RLU	1177
2020	12	24	PCR_PANTH_COV19	RLU	1155
2020	12	24	PCR_PANTH_COV19	RLU	1141
2020	12	24	PCR_PANTH_COV19	RLU	1088
2020	12	24	PCR_PANTH_COV19	RLU	1134
2020	12	24	PCR_PANTH_COV19	RLU	1125
2020	12	24	PCR_PANTH_COV19	RLU	1102
2020	12	24	PCR_PANTH_COV19	RLU	1120
2020	12	24	PCR_PANTH_COV19	RLU	1157
2020	12	24	PCR_PANTH_COV19	RLU	1114
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.38770115
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.4252349

AB1079

2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.19820722
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.17640576
2020	12	24	PCR_PANTH_COV19	RLU	1160
2020	12	24	PCR_PANTH_COV19	RLU	1151
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.77923076
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	21.2
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	18
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	28.9
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	21.5
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	25.7
2020	12	24	PCR_PANTH_COV19	RLU	1077
2020	12	24	PCR_PANTH_COV19	RLU	1105
2020	12	24	PCR_PANTH_COV19	RLU	1187
2020	12	24	PCR_PANTH_COV19	RLU	1152
2020	12	24	PCR_PANTH_COV19	RLU	1134
2020	12	24	PCR_PANTH_COV19	RLU	1096
2020	12	24	PCR_PANTH_COV19	RLU	1120
2020	12	24	PCR_PANTH_COV19	RLU	1173
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.38249948
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.19125172
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.02566244
2020	12	24	PCR_PANTH_COV19	RLU	1091
2020	12	24	PCR_PANTH_COV19	RLU	1097
2020	12	24	PCR_PANTH_COV19	RLU	1149
2020	12	24	PCR_PANTH_COV19	RLU	1107
2020	12	24	PCR_PANTH_COV19	RLU	1093
2020	12	24	PCR_PANTH_COV19	RLU	1148
2020	12	24	PCR_PANTH_COV19	RLU	1085
2020	12	24	PCR_PANTH_COV19	RLU	1054
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	27.6
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	24.1
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	27.5
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	21.9
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	25.6
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	28.5
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	23.8
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	20.9
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	16.4
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	18.6
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	18.3
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	20.1
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.53172933
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	26.3
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	28.3
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	23.4
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	18
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	24.2

AB1080

2020	12	24	PCR_FUSION_COV19_E	E Gene CT	21.1
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	20.9
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	22.7
2020	12	24	PCR_PANTH_COV19	RLU	1118
2020	12	24	PCR_PANTH_COV19	RLU	1149
2020	12	24	PCR_PANTH_COV19	RLU	1091
2020	12	24	PCR_PANTH_COV19	RLU	1129
2020	12	24	PCR_PANTH_COV19	RLU	1129
2020	12	24	PCR_PANTH_COV19	RLU	1074
2020	12	24	PCR_PANTH_COV19	RLU	1084
2020	12	24	PCR_PANTH_COV19	RLU	1126
2020	12	24	PCR_PANTH_COV19	RLU	1125
2020	12	24	PCR_PANTH_COV19	RLU	1121
2020	12	24	PCR_PANTH_COV19	RLU	1107
2020	12	24	PCR_PANTH_COV19	RLU	1129
2020	12	24	PCR_PANTH_COV19	RLU	1137
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.89867496
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.57726192
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.19723966
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.95578616
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.1172307
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.30654194
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.25900434
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.94404271
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.57612969
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.51310841
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.29305937
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.74260951
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.21203844
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.23838952
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.52515789
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.46246616
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.84439873
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.36860749
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.34217383
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.4684329
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.19218468
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.77011073
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.48743574
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.79139123
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.05313366
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.88591464
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.45722874
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.52063128
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.03824881
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.69062484
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.40689256

AB1081

2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.94258819
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.15182217
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.15666456
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.88906053
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	20.1
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.77999588
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.12207497
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.99683518
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	34
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	36
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	37.4
2020	12	24	PCR_FUSION_COV19_E	E Gene CT	36.2
2020	12	24	PCR_COBAS_COV19	CT 2	14.42
2020	12	24	PCR_COBAS_COV19	CT 2	36.77
2020	12	24	PCR_COBAS_COV19	CT 2	19.18
2020	12	24	PCR_COBAS_COV19	CT 2	15.68
2020	12	24	PCR_COBAS_COV19	CT 2	20.38
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.12878107
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.0266167
2020	12	24	PCR_COBAS_COV19	CT 2	35.37
2020	12	24	PCR_COBAS_COV19	CT 2	21.19
2020	12	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.95803426
2020	12	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.26151214
2020	12	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.05906642
2020	12	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.0633712
2020	12	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.08726631
2020	12	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.30401612
2020	12	25	PCR_PANTH_COV19	RLU	1232
2020	12	25	PCR_PANTH_COV19	RLU	1219
2020	12	25	PCR_PANTH_COV19	RLU	1121
2020	12	25	PCR_PANTH_COV19	RLU	1134
2020	12	25	PCR_PANTH_COV19	RLU	1182
2020	12	25	PCR_PANTH_COV19	RLU	1134
2020	12	25	PCR_PANTH_COV19	RLU	1161
2020	12	25	PCR_COBAS_COV19	CT 2	18.96
2020	12	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.94333366
2020	12	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.67493005
2020	12	25	PCR_COBAS_COV19	CT 2	20.28
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	18.1
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	32.5
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	21.3
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	36.7
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	34.1
2020	12	25	PCR_COBAS_COV19	CT 2	33.86
2020	12	25	PCR_COBAS_COV19	CT 2	33.24
2020	12	25	PCR_COBAS_COV19	CT 2	17.97
2020	12	25	PCR_COBAS_COV19	CT 2	28.69

AB1082

2020	12	25	PCR_COBAS_COV19	CT 2	31.55
2020	12	25	PCR_COBAS_COV19	CT 2	33.58
2020	12	25	PCR_COBAS_COV19	CT 2	33.47
2020	12	25	PCR_COBAS_COV19	CT 2	30.16
2020	12	25	PCR_COBAS_COV19	CT 2	27.85
2020	12	25	PCR_COBAS_COV19	CT 2	16.6
2020	12	25	PCR_COBAS_COV19	CT 2	21.83
2020	12	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.59583921
2020	12	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.51901025
2020	12	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.2402424
2020	12	25	PCR_COBAS_COV19	CT 2	24.09
2020	12	25	PCR_COBAS_COV19	CT 2	24.52
2020	12	25	PCR_COBAS_COV19	CT 2	34
2020	12	25	PCR_COBAS_COV19	CT 2	29.48
2020	12	25	PCR_COBAS_COV19	CT 2	23.99
2020	12	25	PCR_COBAS_COV19	CT 2	28.45
2020	12	25	PCR_COBAS_COV19	CT 2	23
2020	12	25	PCR_COBAS_COV19	CT 2	23.22
2020	12	25	PCR_COBAS_COV19	CT 2	16.57
2020	12	25	PCR_COBAS_COV19	CT 2	34.5
2020	12	25	PCR_COBAS_COV19	CT 2	35.6
2020	12	25	PCR_COBAS_COV19	CT 2	19.62
2020	12	25	PCR_COBAS_COV19	CT 2	18
2020	12	25	PCR_COBAS_COV19	CT 2	36.04
2020	12	25	PCR_COBAS_COV19	CT 2	23.91
2020	12	25	PCR_COBAS_COV19	CT 2	37.4
2020	12	25	PCR_COBAS_COV19	CT 2	31.58
2020	12	25	PCR_COBAS_COV19	CT 2	32.92
2020	12	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.86243847
2020	12	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.59705896
2020	12	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.92847646
2020	12	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.89050235
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	27.2
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	29.5
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	34.9
2020	12	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.20327985
2020	12	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.95206415
2020	12	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.04316863
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	32.6
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	26.2
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	29.8
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	19.1
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	34
2020	12	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.69457074
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	21.5
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	36.1
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	19.1

AB1083

2020	12	25	PCR_FUSION_COV19_E	E Gene CT	32.5
2020	12	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.8870911
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	27.5
2020	12	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.01261101
2020	12	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.33291923
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	17.6
2020	12	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	39.010956
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	17.7
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	26.4
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	24
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	33.8
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	20.4
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	25.7
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	32.3
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	20.1
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	26.1
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	26.8
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	20.2
2020	12	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.35723206
2020	12	25	PCR_COBAS_COV19	CT 2	35.37
2020	12	25	PCR_COBAS_COV19	CT 2	18.45
2020	12	25	PCR_COBAS_COV19	CT 2	28.5
2020	12	25	PCR_COBAS_COV19	CT 2	33.21
2020	12	25	PCR_COBAS_COV19	CT 2	23.12
2020	12	25	PCR_COBAS_COV19	CT 2	22.85
2020	12	25	PCR_COBAS_COV19	CT 2	30.72
2020	12	25	PCR_COBAS_COV19	CT 2	35.09
2020	12	25	PCR_COBAS_COV19	CT 2	32.09
2020	12	25	PCR_COBAS_COV19	CT 2	21.78
2020	12	25	PCR_COBAS_COV19	CT 2	34.81
2020	12	25	PCR_COBAS_COV19	CT 2	33.96
2020	12	25	PCR_COBAS_COV19	CT 2	32.94
2020	12	25	PCR_COBAS_COV19	CT 2	30.87
2020	12	25	PCR_COBAS_COV19	CT 2	35.5
2020	12	25	PCR_COBAS_COV19	CT 2	32.11
2020	12	25	PCR_COBAS_COV19	CT 2	23.68
2020	12	25	PCR_COBAS_COV19	CT 2	33.1
2020	12	25	PCR_COBAS_COV19	CT 2	19.34
2020	12	25	PCR_COBAS_COV19	CT 2	37.05
2020	12	25	PCR_COBAS_COV19	CT 2	34.3
2020	12	25	PCR_COBAS_COV19	CT 2	33.57
2020	12	25	PCR_COBAS_COV19	CT 2	31.23
2020	12	25	PCR_COBAS_COV19	CT 2	34.69
2020	12	25	PCR_COBAS_COV19	CT 2	30.34
2020	12	25	PCR_COBAS_COV19	CT 2	35
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	36.6
2020	12	25	PCR_FUSION_COV19_E	E Gene CT	25.6

AB1084

2020	12	25	PCR_FUSION_COV19_E	E Gene CT	19.2
2020	12	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.36041997
2020	12	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.24102524
2020	12	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.2209523
2020	12	26	PCR_COBAS_COV19	CT 2	34.72
2020	12	26	PCR_COBAS_COV19	CT 2	17.83
2020	12	26	PCR_COBAS_COV19	CT 2	37.65
2020	12	26	PCR_FUSION_COV19_E	E Gene CT	37.1
2020	12	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.74387162
2020	12	26	PCR_FUSION_COV19_E	E Gene CT	34.4
2020	12	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.4020771
2020	12	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.92864102
2020	12	26	PCR_FUSION_COV19_E	E Gene CT	27.7
2020	12	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.85920457
2020	12	26	PCR_FUSION_COV19_E	E Gene CT	26.9
2020	12	26	PCR_FUSION_COV19_E	E Gene CT	30.9
2020	12	26	PCR_FUSION_COV19_E	E Gene CT	23.1
2020	12	26	PCR_FUSION_COV19_E	E Gene CT	36.5
2020	12	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.19535048
2020	12	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.44065809
2020	12	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.56476964
2020	12	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.25404357
2020	12	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.11400631
2020	12	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.92398203
2020	12	26	PCR_PANTH_COV19	RLU	1129
2020	12	26	PCR_PANTH_COV19	RLU	1180
2020	12	26	PCR_PANTH_COV19	RLU	1115
2020	12	26	PCR_PANTH_COV19	RLU	1134
2020	12	26	PCR_PANTH_COV19	RLU	1099
2020	12	26	PCR_PANTH_COV19	RLU	1170
2020	12	26	PCR_PANTH_COV19	RLU	1141
2020	12	26	PCR_PANTH_COV19	RLU	1110
2020	12	26	PCR_PANTH_COV19	RLU	1153
2020	12	26	PCR_PANTH_COV19	RLU	1161
2020	12	26	PCR_PANTH_COV19	RLU	1163
2020	12	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.22566724
2020	12	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.04986389
2020	12	26	PCR_PANTH_COV19	RLU	1222
2020	12	27	PCR_PANTH_COV19	RLU	1245
2020	12	27	PCR_PANTH_COV19	RLU	1185
2020	12	27	PCR_PANTH_COV19	RLU	1080
2020	12	27	PCR_PANTH_COV19	RLU	1160
2020	12	27	PCR_PANTH_COV19	RLU	1061
2020	12	27	PCR_PANTH_COV19	RLU	1139
2020	12	27	PCR_PANTH_COV19	RLU	1123
2020	12	27	PCR_PANTH_COV19	RLU	1085
2020	12	27	PCR_PANTH_COV19	RLU	1141

2020	12	27	PCR_PANTH_COV19	RLU	1144
2020	12	27	PCR_PANTH_COV19	RLU	1146
2020	12	27	PCR_PANTH_COV19	RLU	1092
2020	12	27	PCR_COBAS_COV19	CT 2	21.89
2020	12	27	PCR_COBAS_COV19	CT 2	35.52
2020	12	27	PCR_COBAS_COV19	CT 2	27.96
2020	12	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.39477818
2020	12	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.45692489
2020	12	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.7703066
2020	12	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.85681456
2020	12	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.25911067
2020	12	27	PCR_PANTH_COV19	RLU	1139
2020	12	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.44306538
2020	12	27	PCR_PANTH_COV19	RLU	1101
2020	12	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.52448197
2020	12	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.02198353
2020	12	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.97279471
2020	12	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.17232755
2020	12	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.13951628
2020	12	27	PCR_PANTH_COV19	RLU	1059
2020	12	27	PCR_PANTH_COV19	RLU	1043
2020	12	27	PCR_PANTH_COV19	RLU	1080
2020	12	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.43458287
2020	12	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.13556735
2020	12	27	PCR_COBAS_COV19	CT 2	28.5
2020	12	27	PCR_COBAS_COV19	CT 2	34.3
2020	12	27	PCR_COBAS_COV19	CT 2	25.37
2020	12	27	PCR_COBAS_COV19	CT 2	25.94
2020	12	27	PCR_COBAS_COV19	CT 2	20.26
2020	12	28	PCR_COBAS_COV19	CT 2	26.92
2020	12	28	PCR_COBAS_COV19	CT 2	30.35
2020	12	28	PCR_COBAS_COV19	CT 2	28.42
2020	12	28	PCR_COBAS_COV19	CT 2	18.86
2020	12	28	PCR_COBAS_COV19	CT 2	32.61
2020	12	28	PCR_COBAS_COV19	CT 2	30.98
2020	12	28	PCR_COBAS_COV19	CT 2	19.69
2020	12	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.46843085
2020	12	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.80217972
2020	12	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.33804503
2020	12	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.81709895
2020	12	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.82623809
2020	12	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.23249062
2020	12	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.33517019
2020	12	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.74886017
2020	12	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	39.77
2020	12	28	PCR_PANTH_COV19	RLU	1185
2020	12	28	PCR_PANTH_COV19	RLU	1168

AB1086

2020	12	28	PCR_PANTH_COV19	RLU	1134
2020	12	28	PCR_COBAS_COV19	CT 2	34.39
2020	12	28	PCR_COBAS_COV19	CT 2	36.15
2020	12	28	PCR_COBAS_COV19	CT 2	37.38
2020	12	28	PCR_COBAS_COV19	CT 2	35.38
2020	12	28	PCR_COBAS_COV19	CT 2	36.39
2020	12	28	PCR_COBAS_COV19	CT 2	29.37
2020	12	28	PCR_COBAS_COV19	CT 2	18.52
2020	12	28	PCR_COBAS_COV19	CT 2	19.51
2020	12	28	PCR_COBAS_COV19	CT 2	23.86
2020	12	28	PCR_COBAS_COV19	CT 2	19.11
2020	12	28	PCR_COBAS_COV19	CT 2	20.82
2020	12	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.51338376
2020	12	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.89483382
2020	12	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.20375862
2020	12	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.83977823
2020	12	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.98067122
2020	12	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.18928031
2020	12	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.09830573
2020	12	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.00516928
2020	12	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.31280981
2020	12	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.09823004
2020	12	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.32252877
2020	12	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.52937199
2020	12	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.99942697
2020	12	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.93736153
2020	12	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.80660134
2020	12	28	PCR_COBAS_COV19	CT 2	18.09
2020	12	28	PCR_COBAS_COV19	CT 2	30.58
2020	12	28	PCR_COBAS_COV19	CT 2	19.75
2020	12	28	PCR_COBAS_COV19	CT 2	19.69
2020	12	28	PCR_COBAS_COV19	CT 2	15.98
2020	12	28	PCR_COBAS_COV19	CT 2	20.42
2020	12	28	PCR_COBAS_COV19	CT 2	25.69
2020	12	28	PCR_COBAS_COV19	CT 2	32.24
2020	12	28	PCR_COBAS_COV19	CT 2	23.69
2020	12	28	PCR_COBAS_COV19	CT 2	21.25
2020	12	28	PCR_COBAS_COV19	CT 2	25.31
2020	12	28	PCR_COBAS_COV19	CT 2	29.31
2020	12	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.08205181
2020	12	29	PCR_COBAS_COV19	CT 2	36.26
2020	12	29	PCR_FUSION_COV19_E	E Gene CT	37.3
2020	12	29	PCR_COBAS_COV19	CT 2	27.29
2020	12	29	PCR_COBAS_COV19	CT 2	33.26
2020	12	29	PCR_COBAS_COV19	CT 2	36.39
2020	12	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.01006431
2020	12	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.14598275

AB1087

2020	12	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.75005061
2020	12	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.09360624
2020	12	29	PCR_COBAS_COV19	CT 2	27.15
2020	12	29	PCR_COBAS_COV19	CT 2	29.29
2020	12	29	PCR_COBAS_COV19	CT 2	16.4
2020	12	29	PCR_COBAS_COV19	CT 2	25.91
2020	12	29	PCR_COBAS_COV19	CT 2	16.36
2020	12	29	PCR_COBAS_COV19	CT 2	31.55
2020	12	29	PCR_COBAS_COV19	CT 2	24.06
2020	12	29	PCR_COBAS_COV19	CT 2	20.46
2020	12	29	PCR_COBAS_COV19	CT 2	16.14
2020	12	29	PCR_COBAS_COV19	CT 2	37.49
2020	12	29	PCR_COBAS_COV19	CT 2	27.36
2020	12	29	PCR_COBAS_COV19	CT 2	18.37
2020	12	29	PCR_COBAS_COV19	CT 2	22.4
2020	12	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.84622799
2020	12	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.23638002
2020	12	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.26598759
2020	12	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.79534336
2020	12	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.59616614
2020	12	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.70972271
2020	12	29	PCR_PANTH_COV19	RLU	1211
2020	12	29	PCR_PANTH_COV19	RLU	1204
2020	12	29	PCR_PANTH_COV19	RLU	1212
2020	12	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.13607645
2020	12	29	PCR_FUSION_COV19_E	E Gene CT	31.9
2020	12	29	PCR_FUSION_COV19_E	E Gene CT	32.4
2020	12	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.98155195
2020	12	29	PCR_FUSION_COV19_E	E Gene CT	33.1
2020	12	29	PCR_FUSION_COV19_E	E Gene CT	22.6
2020	12	29	PCR_PANTH_COV19	RLU	1182
2020	12	29	PCR_PANTH_COV19	RLU	1173
2020	12	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.92608812
2020	12	29	PCR_PANTH_COV19	RLU	1122
2020	12	29	PCR_PANTH_COV19	RLU	1056
2020	12	29	PCR_PANTH_COV19	RLU	1192
2020	12	29	PCR_PANTH_COV19	RLU	1155
2020	12	29	PCR_PANTH_COV19	RLU	1218
2020	12	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.96970843
2020	12	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.58356601
2020	12	29	PCR_PANTH_COV19	RLU	1162
2020	12	29	PCR_PANTH_COV19	RLU	1194
2020	12	29	PCR_PANTH_COV19	RLU	1179
2020	12	29	PCR_PANTH_COV19	RLU	1182
2020	12	29	PCR_PANTH_COV19	RLU	1191
2020	12	29	PCR_PANTH_COV19	RLU	1141
2020	12	29	PCR_PANTH_COV19	RLU	1177

AB1088

2020	12	29	PCR_PANTH_COV19	RLU	1169
2020	12	29	PCR_PANTH_COV19	RLU	1178
2020	12	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.08793421
2020	12	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.63887963
2020	12	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.91955483
2020	12	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.75225785
2020	12	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.16350315
2020	12	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.05344005
2020	12	29	PCR_PANTH_COV19	RLU	1159
2020	12	29	PCR_PANTH_COV19	RLU	1163
2020	12	29	PCR_PANTH_COV19	RLU	1181
2020	12	29	PCR_PANTH_COV19	RLU	1208
2020	12	29	PCR_PANTH_COV19	RLU	1178
2020	12	29	PCR_PANTH_COV19	RLU	1111
2020	12	29	PCR_PANTH_COV19	RLU	1215
2020	12	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.09383127
2020	12	29	PCR_FUSION_COV19_E	E Gene CT	27.9
2020	12	29	PCR_FUSION_COV19_E	E Gene CT	20
2020	12	29	PCR_FUSION_COV19_E	E Gene CT	22.2
2020	12	29	PCR_COBAS_COV19	CT 2	21.38
2020	12	29	PCR_COBAS_COV19	CT 2	15.86
2020	12	29	PCR_COBAS_COV19	CT 2	34.02
2020	12	29	PCR_COBAS_COV19	CT 2	17.04
2020	12	29	PCR_COBAS_COV19	CT 2	35.11
2020	12	29	PCR_COBAS_COV19	CT 2	35.42
2020	12	29	PCR_FUSION_COV19_E	E Gene CT	25.4
2020	12	29	PCR_FUSION_COV19_E	E Gene CT	22
2020	12	29	PCR_FUSION_COV19_E	E Gene CT	28.6
2020	12	29	PCR_FUSION_COV19_E	E Gene CT	19.6
2020	12	29	PCR_FUSION_COV19_E	E Gene CT	17.7
2020	12	29	PCR_COBAS_COV19	CT 2	31.48
2020	12	29	PCR_COBAS_COV19	CT 2	30.15
2020	12	29	PCR_COBAS_COV19	CT 2	32.86
2020	12	29	PCR_COBAS_COV19	CT 2	31.2
2020	12	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.23476409
2020	12	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.25556685
2020	12	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.33968495
2020	12	30	PCR_FUSION_COV19_E	E Gene CT	28.4
2020	12	30	PCR_FUSION_COV19_E	E Gene CT	17.4
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.54965923
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.14099736
2020	12	30	PCR_COBAS_COV19	CT 2	19.07
2020	12	30	PCR_COBAS_COV19	CT 2	29.44
2020	12	30	PCR_COBAS_COV19	CT 2	37.85
2020	12	30	PCR_COBAS_COV19	CT 2	36.38
2020	12	30	PCR_COBAS_COV19	CT 2	27.75
2020	12	30	PCR_COBAS_COV19	CT 2	17

AB1089

2020	12	30	PCR_FUSION_COV19_E	E Gene CT	25.4
2020	12	30	PCR_FUSION_COV19_E	E Gene CT	17.7
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.95368399
2020	12	30	PCR_FUSION_COV19_E	E Gene CT	30
2020	12	30	PCR_FUSION_COV19_E	E Gene CT	30
2020	12	30	PCR_FUSION_COV19_E	E Gene CT	30.3
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.80936514
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.30707995
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.09
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.16605978
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.02085069
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.09691419
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.29358644
2020	12	30	PCR_FUSION_COV19_E	E Gene CT	18.4
2020	12	30	PCR_FUSION_COV19_E	E Gene CT	22.8
2020	12	30	PCR_FUSION_COV19_E	E Gene CT	20.3
2020	12	30	PCR_FUSION_COV19_E	E Gene CT	33.8
2020	12	30	PCR_FUSION_COV19_E	E Gene CT	31.4
2020	12	30	PCR_FUSION_COV19_E	E Gene CT	32.4
2020	12	30	PCR_FUSION_COV19_E	E Gene CT	27.5
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.07644862
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.69630111
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.20975917
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.15945628
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.868395
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.73313313
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.19
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.36840911
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.74994956
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.71033213
2020	12	30	PCR_COBAS_COV19	CT 2	24.61
2020	12	30	PCR_COBAS_COV19	CT 2	18.54
2020	12	30	PCR_COBAS_COV19	CT 2	19.46
2020	12	30	PCR_COBAS_COV19	CT 2	29.94
2020	12	30	PCR_COBAS_COV19	CT 2	32.56
2020	12	30	PCR_COBAS_COV19	CT 2	35.61
2020	12	30	PCR_COBAS_COV19	CT 2	29.83
2020	12	30	PCR_COBAS_COV19	CT 2	29.4
2020	12	30	PCR_COBAS_COV19	CT 2	31.44
2020	12	30	PCR_COBAS_COV19	CT 2	24.84
2020	12	30	PCR_COBAS_COV19	CT 2	27.86
2020	12	30	PCR_COBAS_COV19	CT 2	24.3
2020	12	30	PCR_COBAS_COV19	CT 2	25.33
2020	12	30	PCR_COBAS_COV19	CT 2	24.83
2020	12	30	PCR_COBAS_COV19	CT 2	22.33
2020	12	30	PCR_COBAS_COV19	CT 2	31.11
2020	12	30	PCR_COBAS_COV19	CT 2	28.65

AB1090

2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.58797001
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.91624766
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.57827805
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.03926261
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.6465284
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.03020402
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.22271908
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.95416233
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.06619942
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.6283783
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.64861972
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.29042213
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.64589622
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.0216364
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.44801425
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.01349748
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.52650704
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.03267678
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.2330779
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.51284206
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.06563521
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.15031017
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.59732987
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.80650505
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.54958556
2020	12	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.76732229
2020	12	30	PCR_PANTH_COV19	RLU	1133
2020	12	31	PCR_COBAS_COV19	CT 2	28.89
2020	12	31	PCR_COBAS_COV19	CT 2	35.37
2020	12	31	PCR_COBAS_COV19	CT 2	35.55
2020	12	31	PCR_COBAS_COV19	CT 2	27.39
2020	12	31	PCR_COBAS_COV19	CT 2	28.16
2020	12	31	PCR_COBAS_COV19	CT 2	34.56
2020	12	31	PCR_COBAS_COV19	CT 2	33.53
2020	12	31	PCR_COBAS_COV19	CT 2	32.71
2020	12	31	PCR_COBAS_COV19	CT 2	23.7
2020	12	31	PCR_COBAS_COV19	CT 2	32.73
2020	12	31	PCR_PANTH_COV19	RLU	1130
2020	12	31	PCR_PANTH_COV19	RLU	1210
2020	12	31	PCR_PANTH_COV19	RLU	1147
2020	12	31	PCR_PANTH_COV19	RLU	1177
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.10801851
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.19103698
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.19051144
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.42424958
2020	12	31	PCR_PANTH_COV19	RLU	1208
2020	12	31	PCR_PANTH_COV19	RLU	1165

AB1091

2020	12	31	PCR_PANTH_COV19	RLU	1161
2020	12	31	PCR_PANTH_COV19	RLU	1140
2020	12	31	PCR_PANTH_COV19	RLU	1186
2020	12	31	PCR_PANTH_COV19	RLU	1194
2020	12	31	PCR_PANTH_COV19	RLU	1125
2020	12	31	PCR_PANTH_COV19	RLU	1161
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.77229383
2020	12	31	PCR_PANTH_COV19	RLU	1128
2020	12	31	PCR_PANTH_COV19	RLU	1145
2020	12	31	PCR_PANTH_COV19	RLU	1198
2020	12	31	PCR_PANTH_COV19	RLU	1158
2020	12	31	PCR_PANTH_COV19	RLU	1177
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.06694291
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.76279162
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.24341017
2020	12	31	PCR_FUSION_COV19_E	E Gene CT	37.4
2020	12	31	PCR_FUSION_COV19_E	E Gene CT	29.8
2020	12	31	PCR_FUSION_COV19_E	E Gene CT	23.4
2020	12	31	PCR_FUSION_COV19_E	E Gene CT	24
2020	12	31	PCR_FUSION_COV19_E	E Gene CT	16.6
2020	12	31	PCR_PANTH_COV19	RLU	1166
2020	12	31	PCR_PANTH_COV19	RLU	1193
2020	12	31	PCR_PANTH_COV19	RLU	1085
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.33998948
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.88690914
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.04187161
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.15021922
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.76559558
2020	12	31	PCR_FUSION_COV19_E	E Gene CT	36.3
2020	12	31	PCR_FUSION_COV19_E	E Gene CT	17.9
2020	12	31	PCR_FUSION_COV19_E	E Gene CT	34.2
2020	12	31	PCR_FUSION_COV19_E	E Gene CT	36
2020	12	31	PCR_FUSION_COV19_E	E Gene CT	29.7
2020	12	31	PCR_FUSION_COV19_E	E Gene CT	27.2
2020	12	31	PCR_FUSION_COV19_E	E Gene CT	19.8
2020	12	31	PCR_FUSION_COV19_E	E Gene CT	19.7
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.75229017
2020	12	31	PCR_FUSION_COV19_E	E Gene CT	29.5
2020	12	31	PCR_FUSION_COV19_E	E Gene CT	26.3
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.0585276
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.2111946
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.85338197
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.29045072
2020	12	31	PCR_FUSION_COV19_E	E Gene CT	35.7
2020	12	31	PCR_FUSION_COV19_E	E Gene CT	24.6
2020	12	31	PCR_FUSION_COV19_E	E Gene CT	18.5
2020	12	31	PCR_FUSION_COV19_E	E Gene CT	22.1

AB1092

2020	12	31	PCR_FUSION_COV19_E	E Gene CT	29
2020	12	31	PCR_FUSION_COV19_E	E Gene CT	27.1
2020	12	31	PCR_FUSION_COV19_E	E Gene CT	22
2020	12	31	PCR_FUSION_COV19_E	E Gene CT	21.1
2020	12	31	PCR_FUSION_COV19_E	E Gene CT	28.9
2020	12	31	PCR_FUSION_COV19_E	E Gene CT	24.8
2020	12	31	PCR_FUSION_COV19_E	E Gene CT	36.9
2020	12	31	PCR_FUSION_COV19_E	E Gene CT	16.9
2020	12	31	PCR_FUSION_COV19_E	E Gene CT	32.3
2020	12	31	PCR_COBAS_COV19	CT 2	17.56
2020	12	31	PCR_COBAS_COV19	CT 2	16.81
2020	12	31	PCR_COBAS_COV19	CT 2	16.27
2020	12	31	PCR_COBAS_COV19	CT 2	35.76
2020	12	31	PCR_COBAS_COV19	CT 2	29.48
2020	12	31	PCR_COBAS_COV19	CT 2	31.04
2020	12	31	PCR_COBAS_COV19	CT 2	35.96
2020	12	31	PCR_COBAS_COV19	CT 2	24.23
2020	12	31	PCR_COBAS_COV19	CT 2	34.97
2020	12	31	PCR_COBAS_COV19	CT 2	36.41
2020	12	31	PCR_COBAS_COV19	CT 2	31.27
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.42285471
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.0239479
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.03053465
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.50621691
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.25424403
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.24300285
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.60212331
2020	12	31	PCR_PANTH_COV19	RLU	1182
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.54799936
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.67859595
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.76085983
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.24140801
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.40561752
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.14805689
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.20433119
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.45132602
2020	12	31	PCR_COBAS_COV19	CT 2	31.31
2020	12	31	PCR_COBAS_COV19	CT 2	36.36
2020	12	31	PCR_COBAS_COV19	CT 2	18.35
2020	12	31	PCR_COBAS_COV19	CT 2	35.01
2020	12	31	PCR_COBAS_COV19	CT 2	27.29
2020	12	31	PCR_COBAS_COV19	CT 2	22.73
2020	12	31	PCR_COBAS_COV19	CT 2	19.04
2020	12	31	PCR_COBAS_COV19	CT 2	17.8
2020	12	31	PCR_COBAS_COV19	CT 2	22.82
2020	12	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.38021331
2020	12	31	PCR_COBAS_COV19	CT 2	16.3

AB1093

2020	12	31	PCR_COBAS_COV19	CT 2	35.81
2021	1	1	PCR_COBAS_COV19	CT 2	32.89
2021	1	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.74658358
2021	1	1	PCR_COBAS_COV19	CT 2	24.77
2021	1	1	PCR_COBAS_COV19	CT 2	25.07
2021	1	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.69757267
2021	1	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.53259013
2021	1	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.33872992
2021	1	1	PCR_FUSION_COV19_E	E Gene CT	28.7
2021	1	1	PCR_COBAS_COV19	CT 2	22.91
2021	1	1	PCR_COBAS_COV19	CT 2	35.11
2021	1	1	PCR_COBAS_COV19	CT 2	30.97
2021	1	1	PCR_COBAS_COV19	CT 2	25.25
2021	1	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.52148338
2021	1	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.96439366
2021	1	1	PCR_COBAS_COV19	CT 2	16.96
2021	1	1	PCR_COBAS_COV19	CT 2	22.2
2021	1	1	PCR_COBAS_COV19	CT 2	17.88
2021	1	1	PCR_COBAS_COV19	CT 2	37.78
2021	1	1	PCR_COBAS_COV19	CT 2	32.14
2021	1	1	PCR_COBAS_COV19	CT 2	33.94
2021	1	1	PCR_COBAS_COV19	CT 2	27.18
2021	1	1	PCR_COBAS_COV19	CT 2	26.48
2021	1	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.60054438
2021	1	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.99190731
2021	1	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.31793494
2021	1	1	PCR_FUSION_COV19_E	E Gene CT	23.2
2021	1	1	PCR_FUSION_COV19_E	E Gene CT	31.7
2021	1	1	PCR_FUSION_COV19_E	E Gene CT	35
2021	1	1	PCR_FUSION_COV19_E	E Gene CT	22.9
2021	1	1	PCR_FUSION_COV19_E	E Gene CT	19.3
2021	1	1	PCR_FUSION_COV19_E	E Gene CT	36.4
2021	1	1	PCR_FUSION_COV19_E	E Gene CT	18.6
2021	1	1	PCR_FUSION_COV19_E	E Gene CT	26.6
2021	1	1	PCR_FUSION_COV19_E	E Gene CT	21.4
2021	1	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.19633578
2021	1	1	PCR_FUSION_COV19_E	E Gene CT	36.3
2021	1	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.09390811
2021	1	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.89825199
2021	1	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.07732935
2021	1	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	10.84649287
2021	1	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.70357392
2021	1	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.59268752
2021	1	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.60909903
2021	1	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.02345577
2021	1	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.98087168
2021	1	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.12779993

AB1094

2021	1	1	PCR_COBAS_COV19	CT 2	26.27
2021	1	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.78544623
2021	1	2	PCR_COBAS_COV19	CT 2	17.47
2021	1	2	PCR_COBAS_COV19	CT 2	18.19
2021	1	2	PCR_COBAS_COV19	CT 2	22.34
2021	1	2	PCR_COBAS_COV19	CT 2	37.09
2021	1	2	PCR_COBAS_COV19	CT 2	20.3
2021	1	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.9803043
2021	1	2	PCR_COBAS_COV19	CT 2	18.65
2021	1	2	PCR_COBAS_COV19	CT 2	36.55
2021	1	2	PCR_COBAS_COV19	CT 2	24.63
2021	1	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.68966189
2021	1	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.48940153
2021	1	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.61536831
2021	1	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.50528436
2021	1	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.63011464
2021	1	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.08272357
2021	1	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.52803168
2021	1	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.28899872
2021	1	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.67720964
2021	1	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.22233701
2021	1	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.34597411
2021	1	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.89153964
2021	1	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.18641291
2021	1	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.19166587
2021	1	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.24666536
2021	1	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.25828409
2021	1	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.14599011
2021	1	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.43195177
2021	1	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.56440182
2021	1	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.51792373
2021	1	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.45937867
2021	1	2	PCR_FUSION_COV19_E	E Gene CT	16.1
2021	1	3	PCR_COBAS_COV19	CT 2	30.48
2021	1	3	PCR_FUSION_COV19_E	E Gene CT	18.9
2021	1	3	PCR_COBAS_COV19	CT 2	36.41
2021	1	3	PCR_COBAS_COV19	CT 2	23.76
2021	1	3	PCR_COBAS_COV19	CT 2	35.28
2021	1	3	PCR_COBAS_COV19	CT 2	26.58
2021	1	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.68462361
2021	1	3	PCR_FUSION_COV19_E	E Gene CT	20
2021	1	3	PCR_FUSION_COV19_E	E Gene CT	30.2
2021	1	3	PCR_FUSION_COV19_E	E Gene CT	21.6
2021	1	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.50706425
2021	1	3	PCR_COBAS_COV19	CT 2	35.51
2021	1	3	PCR_COBAS_COV19	CT 2	16.32
2021	1	3	PCR_COBAS_COV19	CT 2	34.83

AB1095

2021	1	3	PCR_COBAS_COV19	CT 2	26.33
2021	1	3	PCR_COBAS_COV19	CT 2	24.89
2021	1	3	PCR_COBAS_COV19	CT 2	35.79
2021	1	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.56487069
2021	1	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.7836009
2021	1	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.24947381
2021	1	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.41312067
2021	1	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.78732115
2021	1	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.52370223
2021	1	3	PCR_FUSION_COV19_E	E Gene CT	37.2
2021	1	3	PCR_FUSION_COV19_E	E Gene CT	35
2021	1	3	PCR_FUSION_COV19_E	E Gene CT	31.4
2021	1	3	PCR_FUSION_COV19_E	E Gene CT	33.4
2021	1	3	PCR_FUSION_COV19_E	E Gene CT	33.2
2021	1	3	PCR_FUSION_COV19_E	E Gene CT	21
2021	1	3	PCR_FUSION_COV19_E	E Gene CT	22.3
2021	1	3	PCR_FUSION_COV19_E	E Gene CT	31.4
2021	1	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.82331794
2021	1	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.73315746
2021	1	3	PCR_FUSION_COV19_E	E Gene CT	38
2021	1	3	PCR_COBAS_COV19	CT 2	37.3
2021	1	4	PCR_FUSION_COV19_E	E Gene CT	30.5
2021	1	4	PCR_FUSION_COV19_E	E Gene CT	26.1
2021	1	4	PCR_COBAS_COV19	CT 2	31.64
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.74112799
2021	1	4	PCR_FUSION_COV19_E	E Gene CT	25.3
2021	1	4	PCR_FUSION_COV19_E	E Gene CT	16.8
2021	1	4	PCR_FUSION_COV19_E	E Gene CT	38
2021	1	4	PCR_FUSION_COV19_E	E Gene CT	24.4
2021	1	4	PCR_FUSION_COV19_E	E Gene CT	15
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.04365182
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.33397579
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.23023477
2021	1	4	PCR_COBAS_COV19	CT 2	29.94
2021	1	4	PCR_COBAS_COV19	CT 2	30.08
2021	1	4	PCR_COBAS_COV19	CT 2	32.71
2021	1	4	PCR_COBAS_COV19	CT 2	22.44
2021	1	4	PCR_COBAS_COV19	CT 2	26.56
2021	1	4	PCR_COBAS_COV19	CT 2	23.66
2021	1	4	PCR_COBAS_COV19	CT 2	22.75
2021	1	4	PCR_COBAS_COV19	CT 2	35.8
2021	1	4	PCR_COBAS_COV19	CT 2	28.54
2021	1	4	PCR_COBAS_COV19	CT 2	32.37
2021	1	4	PCR_COBAS_COV19	CT 2	30.31
2021	1	4	PCR_COBAS_COV19	CT 2	33.64
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.90438429
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.62879804

AB1096

2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.18050804
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.40905936
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.74257309
2021	1	4	PCR_COBAS_COV19	CT 2	36.71
2021	1	4	PCR_COBAS_COV19	CT 2	30.55
2021	1	4	PCR_COBAS_COV19	CT 2	34.02
2021	1	4	PCR_COBAS_COV19	CT 2	37.99
2021	1	4	PCR_COBAS_COV19	CT 2	36.2
2021	1	4	PCR_COBAS_COV19	CT 2	23.21
2021	1	4	PCR_COBAS_COV19	CT 2	20.88
2021	1	4	PCR_COBAS_COV19	CT 2	34.76
2021	1	4	PCR_COBAS_COV19	CT 2	25
2021	1	4	PCR_COBAS_COV19	CT 2	16.43
2021	1	4	PCR_COBAS_COV19	CT 2	30.6
2021	1	4	PCR_COBAS_COV19	CT 2	17.41
2021	1	4	PCR_COBAS_COV19	CT 2	19.93
2021	1	4	PCR_COBAS_COV19	CT 2	19.09
2021	1	4	PCR_COBAS_COV19	CT 2	15.51
2021	1	4	PCR_COBAS_COV19	CT 2	28.66
2021	1	4	PCR_COBAS_COV19	CT 2	29.41
2021	1	4	PCR_COBAS_COV19	CT 2	24.38
2021	1	4	PCR_COBAS_COV19	CT 2	16.99
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.28171332
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.06175098
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.81512538
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.01760645
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.24034136
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.23929022
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.76655083
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.92573464
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.36399638
2021	1	4	PCR_FUSION_COV19_E	E Gene CT	18.9
2021	1	4	PCR_FUSION_COV19_E	E Gene CT	25.1
2021	1	4	PCR_FUSION_COV19_E	E Gene CT	35.3
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.25082406
2021	1	4	PCR_COBAS_COV19	CT 2	20.14
2021	1	4	PCR_COBAS_COV19	CT 2	17.44
2021	1	4	PCR_COBAS_COV19	CT 2	17.16
2021	1	4	PCR_COBAS_COV19	CT 2	33.19
2021	1	4	PCR_COBAS_COV19	CT 2	26.75
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.19417761
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.26625236
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.11614968
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.47995272
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.26333205
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.20713031
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.34717946

AB1097

2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.15814501
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.56675322
2021	1	4	PCR_COBAS_COV19	CT 2	16.01
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.16134407
2021	1	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.01065682
2021	1	5	PCR_COBAS_COV19	CT 2	37.1
2021	1	5	PCR_COBAS_COV19	CT 2	38.06
2021	1	5	PCR_COBAS_COV19	CT 2	36.13
2021	1	5	PCR_COBAS_COV19	CT 2	20.51
2021	1	5	PCR_COBAS_COV19	CT 2	20.27
2021	1	5	PCR_COBAS_COV19	CT 2	27.73
2021	1	5	PCR_COBAS_COV19	CT 2	18.63
2021	1	5	PCR_COBAS_COV19	CT 2	24.67
2021	1	5	PCR_COBAS_COV19	CT 2	29.33
2021	1	5	PCR_COBAS_COV19	CT 2	24.75
2021	1	5	PCR_FUSION_COV19_E	E Gene CT	17.5
2021	1	5	PCR_FUSION_COV19_E	E Gene CT	36.7
2021	1	5	PCR_FUSION_COV19_E	E Gene CT	27.1
2021	1	5	PCR_FUSION_COV19_E	E Gene CT	28.2
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.25348613
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.80444731
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.40113693
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.56220811
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.3156062
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.83473508
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.81621108
2021	1	5	PCR_COBAS_COV19	CT 2	19.22
2021	1	5	PCR_COBAS_COV19	CT 2	32.31
2021	1	5	PCR_COBAS_COV19	CT 2	26.83
2021	1	5	PCR_COBAS_COV19	CT 2	35.07
2021	1	5	PCR_COBAS_COV19	CT 2	26
2021	1	5	PCR_COBAS_COV19	CT 2	32.76
2021	1	5	PCR_COBAS_COV19	CT 2	33.28
2021	1	5	PCR_COBAS_COV19	CT 2	18.89
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.72262046
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.96551764
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.31805355
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.22493463
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.07043376
2021	1	5	PCR_FUSION_COV19_E	E Gene CT	29.6
2021	1	5	PCR_FUSION_COV19_E	E Gene CT	24.5
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.44365318
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.72113289
2021	1	5	PCR_FUSION_COV19_E	E Gene CT	25.6
2021	1	5	PCR_FUSION_COV19_E	E Gene CT	31.9
2021	1	5	PCR_FUSION_COV19_E	E Gene CT	33.2
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.02672845

AB1098

2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.1528533
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.686339
2021	1	5	PCR_FUSION_COV19_E	E Gene CT	36.6
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.42245459
2021	1	5	PCR_FUSION_COV19_E	E Gene CT	24.7
2021	1	5	PCR_FUSION_COV19_E	E Gene CT	37.1
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.71203626
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.10341566
2021	1	5	PCR_FUSION_COV19_E	E Gene CT	36.2
2021	1	5	PCR_FUSION_COV19_E	E Gene CT	23
2021	1	5	PCR_FUSION_COV19_E	E Gene CT	20.9
2021	1	5	PCR_FUSION_COV19_E	E Gene CT	16.7
2021	1	5	PCR_FUSION_COV19_E	E Gene CT	31.2
2021	1	5	PCR_FUSION_COV19_E	E Gene CT	36.8
2021	1	5	PCR_FUSION_COV19_E	E Gene CT	38
2021	1	5	PCR_FUSION_COV19_E	E Gene CT	28.7
2021	1	5	PCR_FUSION_COV19_E	E Gene CT	36.1
2021	1	5	PCR_COBAS_COV19	CT 2	19.51
2021	1	5	PCR_COBAS_COV19	CT 2	15.8
2021	1	5	PCR_COBAS_COV19	CT 2	33.19
2021	1	5	PCR_COBAS_COV19	CT 2	36.62
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.60126808
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.97201731
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.49054516
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.08531869
2021	1	5	PCR_COBAS_COV19	CT 2	21.83
2021	1	5	PCR_COBAS_COV19	CT 2	24.27
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.59983619
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.64452494
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.02959129
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.19415999
2021	1	5	PCR_COBAS_COV19	CT 2	36.92
2021	1	5	PCR_COBAS_COV19	CT 2	34.4
2021	1	5	PCR_COBAS_COV19	CT 2	35.3
2021	1	5	PCR_COBAS_COV19	CT 2	31.59
2021	1	5	PCR_COBAS_COV19	CT 2	33.4
2021	1	5	PCR_COBAS_COV19	CT 2	35.97
2021	1	5	PCR_COBAS_COV19	CT 2	33.46
2021	1	5	PCR_COBAS_COV19	CT 2	37.82
2021	1	5	PCR_COBAS_COV19	CT 2	25.03
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.01953948
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.76172755
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.49717226
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.30146972
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.69341283
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.81139116
2021	1	5	PCR_COBAS_COV19	CT 2	37.49

AB1099

2021	1	5	PCR_COBAS_COV19	CT 2	28.76
2021	1	5	PCR_COBAS_COV19	CT 2	35.27
2021	1	5	PCR_COBAS_COV19	CT 2	20.12
2021	1	5	PCR_COBAS_COV19	CT 2	21.72
2021	1	5	PCR_COBAS_COV19	CT 2	21.14
2021	1	5	PCR_COBAS_COV19	CT 2	28.37
2021	1	5	PCR_COBAS_COV19	CT 2	22.05
2021	1	5	PCR_COBAS_COV19	CT 2	35.37
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.03358122
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.99768634
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.61459372
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.15922283
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.91725078
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.64780759
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.52490945
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.46838507
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.53623189
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.00588544
2021	1	5	PCR_PANTH_COV19	RLU	1170
2021	1	5	PCR_PANTH_COV19	RLU	1197
2021	1	5	PCR_PANTH_COV19	RLU	1183
2021	1	5	PCR_PANTH_COV19	RLU	1234
2021	1	5	PCR_PANTH_COV19	RLU	1163
2021	1	5	PCR_PANTH_COV19	RLU	1205
2021	1	5	PCR_PANTH_COV19	RLU	1197
2021	1	5	PCR_PANTH_COV19	RLU	1153
2021	1	5	PCR_PANTH_COV19	RLU	1138
2021	1	5	PCR_PANTH_COV19	RLU	1180
2021	1	5	PCR_PANTH_COV19	RLU	1177
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.18524424
2021	1	5	PCR_PANTH_COV19	RLU	1178
2021	1	5	PCR_PANTH_COV19	RLU	1144
2021	1	5	PCR_PANTH_COV19	RLU	1182
2021	1	5	PCR_PANTH_COV19	RLU	1151
2021	1	5	PCR_PANTH_COV19	RLU	1151
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.12100466
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.73019674
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.12729194
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.89067013
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.29800724
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.18699493
2021	1	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.06646735
2021	1	5	PCR_COBAS_COV19	CT 2	34
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.10711035
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.18671717
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.03786221
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.50030727

AB1100

2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.59460176
2021	1	6	PCR_PANTH_COV19	RLU	1176
2021	1	6	PCR_PANTH_COV19	RLU	1175
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.41953831
2021	1	6	PCR_PANTH_COV19	RLU	1165
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.26131612
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.30984926
2021	1	6	PCR_PANTH_COV19	RLU	1183
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.14966247
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.35694566
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.16296859
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.04887877
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.83573623
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.97698485
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.3068066
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.22712978
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.09615037
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.35556406
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.73215973
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.34695302
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.92710551
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.16970257
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.35576736
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.67791765
2021	1	6	PCR_PANTH_COV19	RLU	1172
2021	1	6	PCR_PANTH_COV19	RLU	1215
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.85494504
2021	1	6	PCR_PANTH_COV19	RLU	1140
2021	1	6	PCR_PANTH_COV19	RLU	1171
2021	1	6	PCR_PANTH_COV19	RLU	1150
2021	1	6	PCR_PANTH_COV19	RLU	1149
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.10128985
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.89907904
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.52114072
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.03088411
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.30399346
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.4057841
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.88612359
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.47239275
2021	1	6	PCR_FUSION_COV19_E	E Gene CT	16.9
2021	1	6	PCR_FUSION_COV19_E	E Gene CT	36.5
2021	1	6	PCR_FUSION_COV19_E	E Gene CT	37.3
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.30706001
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.45197857
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.53783254
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.58548523
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.19923058

AB1101

2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.05241633
2021	1	6	PCR_FUSION_COV19_E	E Gene CT	19.2
2021	1	6	PCR_FUSION_COV19_E	E Gene CT	36.6
2021	1	6	PCR_FUSION_COV19_E	E Gene CT	18.6
2021	1	6	PCR_FUSION_COV19_E	E Gene CT	37.3
2021	1	6	PCR_FUSION_COV19_E	E Gene CT	21.3
2021	1	6	PCR_FUSION_COV19_E	E Gene CT	32.5
2021	1	6	PCR_FUSION_COV19_E	E Gene CT	19.5
2021	1	6	PCR_FUSION_COV19_E	E Gene CT	37.4
2021	1	6	PCR_FUSION_COV19_E	E Gene CT	35.2
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.99885205
2021	1	6	PCR_FUSION_COV19_E	E Gene CT	24.9
2021	1	6	PCR_FUSION_COV19_E	E Gene CT	34.4
2021	1	6	PCR_FUSION_COV19_E	E Gene CT	36.3
2021	1	6	PCR_FUSION_COV19_E	E Gene CT	35.6
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.38224597
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.59416612
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.92215419
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.67949204
2021	1	6	PCR_COBAS_COV19	CT 2	15.93
2021	1	6	PCR_COBAS_COV19	CT 2	19
2021	1	6	PCR_COBAS_COV19	CT 2	32.3
2021	1	6	PCR_COBAS_COV19	CT 2	18.92
2021	1	6	PCR_COBAS_COV19	CT 2	30.05
2021	1	6	PCR_COBAS_COV19	CT 2	33.12
2021	1	6	PCR_COBAS_COV19	CT 2	28.32
2021	1	6	PCR_COBAS_COV19	CT 2	31.9
2021	1	6	PCR_COBAS_COV19	CT 2	27.39
2021	1	6	PCR_COBAS_COV19	CT 2	16.7
2021	1	6	PCR_COBAS_COV19	CT 2	35.91
2021	1	6	PCR_COBAS_COV19	CT 2	35.33
2021	1	6	PCR_COBAS_COV19	CT 2	32.2
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.09585797
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.07164489
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.73440247
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.5638655
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.58312258
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.19624954
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.78997545
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.13526365
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.6510753
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.84366187
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.02943246
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.86931765
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.17677223
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.33749109
2021	1	6	PCR_COBAS_COV19	CT 2	36.72

2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.11921236
2021	1	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.64767736
2021	1	7	PCR_COBAS_COV19	CT 2	29.48
2021	1	7	PCR_COBAS_COV19	CT 2	26.98
2021	1	7	PCR_COBAS_COV19	CT 2	14.45
2021	1	7	PCR_COBAS_COV19	CT 2	20.06
2021	1	7	PCR_PANTH_COV19	RLU	1245
2021	1	7	PCR_PANTH_COV19	RLU	1172
2021	1	7	PCR_PANTH_COV19	RLU	1217
2021	1	7	PCR_PANTH_COV19	RLU	1235
2021	1	7	PCR_PANTH_COV19	RLU	1150
2021	1	7	PCR_PANTH_COV19	RLU	1218
2021	1	7	PCR_PANTH_COV19	RLU	1127
2021	1	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.55493587
2021	1	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.95932682
2021	1	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.64312485
2021	1	7	PCR_PANTH_COV19	RLU	1141
2021	1	7	PCR_PANTH_COV19	RLU	1255
2021	1	7	PCR_PANTH_COV19	RLU	1222
2021	1	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.52748832
2021	1	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.6604651
2021	1	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.3761925
2021	1	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.45632313
2021	1	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.07353745
2021	1	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.36908423
2021	1	7	PCR_PANTH_COV19	RLU	1181
2021	1	7	PCR_PANTH_COV19	RLU	1103
2021	1	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.06880394
2021	1	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.7087463
2021	1	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.70653839
2021	1	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.19931595
2021	1	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.10412516
2021	1	7	PCR_PANTH_COV19	RLU	1174
2021	1	7	PCR_PANTH_COV19	RLU	1176
2021	1	7	PCR_PANTH_COV19	RLU	1187
2021	1	7	PCR_PANTH_COV19	RLU	1217
2021	1	7	PCR_PANTH_COV19	RLU	1216
2021	1	7	PCR_PANTH_COV19	RLU	1196
2021	1	7	PCR_PANTH_COV19	RLU	1228
2021	1	7	PCR_PANTH_COV19	RLU	1196
2021	1	7	PCR_PANTH_COV19	RLU	1168
2021	1	7	PCR_PANTH_COV19	RLU	1205
2021	1	7	PCR_PANTH_COV19	RLU	1165
2021	1	7	PCR_PANTH_COV19	RLU	1161
2021	1	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.2664026
2021	1	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.87606557
2021	1	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.66973469

AB1103

2021	1	7	PCR_PANTH_COV19	RLU	1162
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	22.5
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	19.3
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	18.3
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	22
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	17.7
2021	1	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.60514129
2021	1	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.39512089
2021	1	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.09831179
2021	1	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.06397505
2021	1	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.1662946
2021	1	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.48416325
2021	1	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.8448668
2021	1	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.71144054
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	32.5
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	27.4
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	29.9
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	33.3
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	30.2
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	31.3
2021	1	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.65280924
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	16
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	23
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	20.3
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	28
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	23.2
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	35.8
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	15.6
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	32.8
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	26.9
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	33.7
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	15.5
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	25.4
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	24.7
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	29.4
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	20
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	16.2
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	18.6
2021	1	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.00548244
2021	1	7	PCR_FUSION_COV19_E	E Gene CT	25.1
2021	1	7	PCR_COBAS_COV19	CT 2	29.05
2021	1	7	PCR_COBAS_COV19	CT 2	23.01
2021	1	7	PCR_COBAS_COV19	CT 2	38
2021	1	7	PCR_COBAS_COV19	CT 2	25.11
2021	1	7	PCR_COBAS_COV19	CT 2	17.37
2021	1	7	PCR_COBAS_COV19	CT 2	24.9
2021	1	7	PCR_COBAS_COV19	CT 2	17.78

AB1104

2021	1	7	PCR_COBAS_COV19	CT 2	30.02
2021	1	8	PCR_FUSION_COV19_E	E Gene CT	21.6
2021	1	8	PCR_FUSION_COV19_E	E Gene CT	16.4
2021	1	8	PCR_FUSION_COV19_E	E Gene CT	24.2
2021	1	8	PCR_FUSION_COV19_E	E Gene CT	23.7
2021	1	8	PCR_FUSION_COV19_E	E Gene CT	23.7
2021	1	8	PCR_FUSION_COV19_E	E Gene CT	24.2
2021	1	8	PCR_FUSION_COV19_E	E Gene CT	20.6
2021	1	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.39714997
2021	1	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.24721823
2021	1	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.49602998
2021	1	8	PCR_COBAS_COV19	CT 2	37.63
2021	1	8	PCR_COBAS_COV19	CT 2	34.1
2021	1	8	PCR_COBAS_COV19	CT 2	24.09
2021	1	8	PCR_COBAS_COV19	CT 2	23.8
2021	1	8	PCR_COBAS_COV19	CT 2	25.01
2021	1	8	PCR_COBAS_COV19	CT 2	33.32
2021	1	8	PCR_COBAS_COV19	CT 2	28.9
2021	1	8	PCR_COBAS_COV19	CT 2	36.54
2021	1	8	PCR_COBAS_COV19	CT 2	22.4
2021	1	8	PCR_COBAS_COV19	CT 2	36.06
2021	1	8	PCR_COBAS_COV19	CT 2	34.35
2021	1	8	PCR_COBAS_COV19	CT 2	32.9
2021	1	8	PCR_COBAS_COV19	CT 2	32.69
2021	1	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.59067466
2021	1	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.13154669
2021	1	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.13677754
2021	1	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.94373872
2021	1	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.18907788
2021	1	8	PCR_PANTH_COV19	RLU	1154
2021	1	8	PCR_PANTH_COV19	RLU	1074
2021	1	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.82328729
2021	1	8	PCR_PANTH_COV19	RLU	1145
2021	1	8	PCR_PANTH_COV19	RLU	1185
2021	1	8	PCR_PANTH_COV19	RLU	1128
2021	1	8	PCR_PANTH_COV19	RLU	1168
2021	1	8	PCR_PANTH_COV19	RLU	1181
2021	1	8	PCR_PANTH_COV19	RLU	1228
2021	1	8	PCR_PANTH_COV19	RLU	1143
2021	1	8	PCR_PANTH_COV19	RLU	1176
2021	1	8	PCR_PANTH_COV19	RLU	1212
2021	1	8	PCR_PANTH_COV19	RLU	1201
2021	1	8	PCR_PANTH_COV19	RLU	1178
2021	1	8	PCR_PANTH_COV19	RLU	1164
2021	1	8	PCR_PANTH_COV19	RLU	1164
2021	1	8	PCR_PANTH_COV19	RLU	1180
2021	1	8	PCR_PANTH_COV19	RLU	1140

2021	1	8	PCR_PANTH_COV19	RLU	1173
2021	1	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.53295679
2021	1	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.54499947
2021	1	8	PCR_PANTH_COV19	RLU	1226
2021	1	8	PCR_PANTH_COV19	RLU	1231
2021	1	8	PCR_PANTH_COV19	RLU	1196
2021	1	8	PCR_PANTH_COV19	RLU	1162
2021	1	8	PCR_PANTH_COV19	RLU	1169
2021	1	8	PCR_PANTH_COV19	RLU	1181
2021	1	8	PCR_PANTH_COV19	RLU	1164
2021	1	8	PCR_PANTH_COV19	RLU	1181
2021	1	8	PCR_PANTH_COV19	RLU	1204
2021	1	8	PCR_PANTH_COV19	RLU	1162
2021	1	8	PCR_PANTH_COV19	RLU	1173
2021	1	8	PCR_PANTH_COV19	RLU	1163
2021	1	8	PCR_PANTH_COV19	RLU	1163
2021	1	8	PCR_PANTH_COV19	RLU	1199
2021	1	8	PCR_PANTH_COV19	RLU	1171
2021	1	8	PCR_PANTH_COV19	RLU	1192
2021	1	8	PCR_PANTH_COV19	RLU	1189
2021	1	8	PCR_PANTH_COV19	RLU	1228
2021	1	8	PCR_PANTH_COV19	RLU	1187
2021	1	8	PCR_PANTH_COV19	RLU	1167
2021	1	8	PCR_PANTH_COV19	RLU	1232
2021	1	8	PCR_PANTH_COV19	RLU	1135
2021	1	8	PCR_PANTH_COV19	RLU	1197
2021	1	8	PCR_PANTH_COV19	RLU	1176
2021	1	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.42591852
2021	1	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.99695295
2021	1	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.33802277
2021	1	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.62232716
2021	1	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.36555536
2021	1	8	PCR_PANTH_COV19	RLU	1153
2021	1	8	PCR_PANTH_COV19	RLU	1165
2021	1	8	PCR_PANTH_COV19	RLU	1145
2021	1	8	PCR_PANTH_COV19	RLU	1169
2021	1	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.79758107
2021	1	8	PCR_COBAS_COV19	CT 2	16.93
2021	1	8	PCR_COBAS_COV19	CT 2	28.87
2021	1	8	PCR_COBAS_COV19	CT 2	30.2
2021	1	8	PCR_COBAS_COV19	CT 2	36.55
2021	1	8	PCR_COBAS_COV19	CT 2	34.8
2021	1	8	PCR_PANTH_COV19	RLU	1141
2021	1	8	PCR_FUSION_COV19_E	E Gene CT	37.3
2021	1	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.01547751
2021	1	8	PCR_PANTH_COV19	RLU	1123
2021	1	8	PCR_COBAS_COV19	CT 2	13.79

AB1106

2021	1	8	PCR_COBAS_COV19	CT 2	37.17
2021	1	8	PCR_COBAS_COV19	CT 2	14.89
2021	1	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.00221225
2021	1	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.1333484
2021	1	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.79414803
2021	1	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.5937242
2021	1	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.71800448
2021	1	8	PCR_PANTH_COV19	RLU	1114
2021	1	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.65899962
2021	1	9	PCR_PANTH_COV19	RLU	1162
2021	1	9	PCR_PANTH_COV19	RLU	1196
2021	1	9	PCR_PANTH_COV19	RLU	1208
2021	1	9	PCR_PANTH_COV19	RLU	1161
2021	1	9	PCR_PANTH_COV19	RLU	1203
2021	1	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.16903758
2021	1	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.29855527
2021	1	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.0594258
2021	1	9	PCR_PANTH_COV19	RLU	1190
2021	1	9	PCR_PANTH_COV19	RLU	1177
2021	1	9	PCR_PANTH_COV19	RLU	1205
2021	1	9	PCR_PANTH_COV19	RLU	1185
2021	1	9	PCR_PANTH_COV19	RLU	1170
2021	1	9	PCR_PANTH_COV19	RLU	1164
2021	1	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.82804144
2021	1	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.04306335
2021	1	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.3910237
2021	1	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.92550664
2021	1	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.25554944
2021	1	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.76218972
2021	1	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.54227236
2021	1	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.06743093
2021	1	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.72807333
2021	1	9	PCR_PANTH_COV19	RLU	1164
2021	1	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.67589773
2021	1	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.9786862
2021	1	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.2897734
2021	1	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.54459089
2021	1	9	PCR_PANTH_COV19	RLU	1187
2021	1	9	PCR_PANTH_COV19	RLU	1157
2021	1	9	PCR_PANTH_COV19	RLU	1186
2021	1	9	PCR_PANTH_COV19	RLU	1217
2021	1	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.30071571
2021	1	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.07134948
2021	1	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.39259186
2021	1	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.35603833
2021	1	9	PCR_PANTH_COV19	RLU	1220
2021	1	9	PCR_PANTH_COV19	RLU	1222

2021	1	9	PCR_PANTH_COV19	RLU	1172
2021	1	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.38130684
2021	1	9	PCR_PANTH_COV19	RLU	1189
2021	1	9	PCR_PANTH_COV19	RLU	1173
2021	1	9	PCR_PANTH_COV19	RLU	1178
2021	1	9	PCR_PANTH_COV19	RLU	1189
2021	1	9	PCR_PANTH_COV19	RLU	1142
2021	1	9	PCR_PANTH_COV19	RLU	1175
2021	1	9	PCR_PANTH_COV19	RLU	1169
2021	1	9	PCR_PANTH_COV19	RLU	1199
2021	1	9	PCR_PANTH_COV19	RLU	1164
2021	1	9	PCR_PANTH_COV19	RLU	1181
2021	1	9	PCR_PANTH_COV19	RLU	1213
2021	1	9	PCR_PANTH_COV19	RLU	1168
2021	1	9	PCR_PANTH_COV19	RLU	1174
2021	1	9	PCR_PANTH_COV19	RLU	1170
2021	1	9	PCR_COBAS_COV19	CT 2	19.59
2021	1	9	PCR_COBAS_COV19	CT 2	16.85
2021	1	9	PCR_COBAS_COV19	CT 2	28.43
2021	1	9	PCR_COBAS_COV19	CT 2	35.64
2021	1	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.22176761
2021	1	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.97502663
2021	1	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.54417907
2021	1	9	PCR_COBAS_COV19	CT 2	25.51
2021	1	9	PCR_COBAS_COV19	CT 2	27.76
2021	1	9	PCR_COBAS_COV19	CT 2	24.43
2021	1	9	PCR_COBAS_COV19	CT 2	25.38
2021	1	9	PCR_COBAS_COV19	CT 2	24.88
2021	1	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.85658603
2021	1	10	PCR_FUSION_COV19_E	E Gene CT	22.2
2021	1	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.35531059
2021	1	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.92621641
2021	1	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.10115886
2021	1	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.41587133
2021	1	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.356625
2021	1	10	PCR_COBAS_COV19	CT 2	22.6
2021	1	10	PCR_COBAS_COV19	CT 2	33.01
2021	1	10	PCR_COBAS_COV19	CT 2	35.02
2021	1	10	PCR_COBAS_COV19	CT 2	29.71
2021	1	10	PCR_COBAS_COV19	CT 2	35.41
2021	1	10	PCR_COBAS_COV19	CT 2	26.88
2021	1	10	PCR_FUSION_COV19_E	E Gene CT	20.5
2021	1	10	PCR_FUSION_COV19_E	E Gene CT	20.5
2021	1	10	PCR_FUSION_COV19_E	E Gene CT	33.3
2021	1	10	PCR_FUSION_COV19_E	E Gene CT	36.2
2021	1	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.14892556
2021	1	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.7500415

AB1108

2021	1	10	PCR_FUSION_COV19_E	E Gene CT	20.4
2021	1	10	PCR_FUSION_COV19_E	E Gene CT	33.3
2021	1	10	PCR_COBAS_COV19	CT 2	25.53
2021	1	10	PCR_COBAS_COV19	CT 2	21.37
2021	1	10	PCR_FUSION_COV19_E	E Gene CT	28.7
2021	1	10	PCR_FUSION_COV19_E	E Gene CT	18.7
2021	1	10	PCR_FUSION_COV19_E	E Gene CT	16.7
2021	1	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.38658487
2021	1	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.82226591
2021	1	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.18697938
2021	1	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.82619989
2021	1	10	PCR_FUSION_COV19_E	E Gene CT	17.1
2021	1	10	PCR_FUSION_COV19_E	E Gene CT	21.7
2021	1	10	PCR_FUSION_COV19_E	E Gene CT	24.1
2021	1	10	PCR_FUSION_COV19_E	E Gene CT	27.2
2021	1	10	PCR_FUSION_COV19_E	E Gene CT	19.1
2021	1	10	PCR_FUSION_COV19_E	E Gene CT	35.4
2021	1	10	PCR_FUSION_COV19_E	E Gene CT	29
2021	1	10	PCR_FUSION_COV19_E	E Gene CT	23.2
2021	1	10	PCR_FUSION_COV19_E	E Gene CT	17.1
2021	1	10	PCR_FUSION_COV19_E	E Gene CT	21
2021	1	10	PCR_FUSION_COV19_E	E Gene CT	22.4
2021	1	10	PCR_FUSION_COV19_E	E Gene CT	21.2
2021	1	10	PCR_FUSION_COV19_E	E Gene CT	19.6
2021	1	10	PCR_FUSION_COV19_E	E Gene CT	35.3
2021	1	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.55686416
2021	1	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.59646932
2021	1	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.08345164
2021	1	10	PCR_FUSION_COV19_E	E Gene CT	30
2021	1	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.13496937
2021	1	10	PCR_COBAS_COV19	CT 2	30.32
2021	1	10	PCR_COBAS_COV19	CT 2	25.24
2021	1	10	PCR_COBAS_COV19	CT 2	17.47
2021	1	11	PCR_PANTH_COV19	RLU	1132
2021	1	11	PCR_COBAS_COV19	CT 2	29.51
2021	1	11	PCR_COBAS_COV19	CT 2	25.42
2021	1	11	PCR_COBAS_COV19	CT 2	22.2
2021	1	11	PCR_COBAS_COV19	CT 2	25.93
2021	1	11	PCR_COBAS_COV19	CT 2	36.69
2021	1	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.38754092
2021	1	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.86484279
2021	1	11	PCR_PANTH_COV19	RLU	1172
2021	1	11	PCR_PANTH_COV19	RLU	1189
2021	1	11	PCR_COBAS_COV19	CT 2	20.89
2021	1	11	PCR_COBAS_COV19	CT 2	30.85
2021	1	11	PCR_COBAS_COV19	CT 2	14.57
2021	1	11	PCR_COBAS_COV19	CT 2	17.85

AB1109

2021	1	11	PCR_COBAS_COV19	CT 2	14.1
2021	1	11	PCR_COBAS_COV19	CT 2	30.76
2021	1	11	PCR_COBAS_COV19	CT 2	35.95
2021	1	11	PCR_COBAS_COV19	CT 2	32.1
2021	1	11	PCR_COBAS_COV19	CT 2	32.78
2021	1	11	PCR_COBAS_COV19	CT 2	32.35
2021	1	11	PCR_COBAS_COV19	CT 2	34.94
2021	1	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.06
2021	1	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.64464655
2021	1	11	PCR_PANTH_COV19	RLU	1135
2021	1	11	PCR_PANTH_COV19	RLU	1154
2021	1	11	PCR_PANTH_COV19	RLU	1144
2021	1	11	PCR_PANTH_COV19	RLU	1146
2021	1	11	PCR_PANTH_COV19	RLU	1205
2021	1	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.63823624
2021	1	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.08500672
2021	1	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.66667696
2021	1	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.04933958
2021	1	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.04748211
2021	1	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.05007955
2021	1	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.68578341
2021	1	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.18014312
2021	1	11	PCR_COBAS_COV19	CT 2	18.11
2021	1	11	PCR_COBAS_COV19	CT 2	36.34
2021	1	11	PCR_COBAS_COV19	CT 2	24.34
2021	1	11	PCR_COBAS_COV19	CT 2	25.97
2021	1	11	PCR_COBAS_COV19	CT 2	25.65
2021	1	11	PCR_COBAS_COV19	CT 2	34.83
2021	1	11	PCR_COBAS_COV19	CT 2	36.35
2021	1	11	PCR_COBAS_COV19	CT 2	22.61
2021	1	11	PCR_COBAS_COV19	CT 2	19.64
2021	1	11	PCR_COBAS_COV19	CT 2	26.47
2021	1	11	PCR_COBAS_COV19	CT 2	34.86
2021	1	11	PCR_COBAS_COV19	CT 2	34
2021	1	11	PCR_COBAS_COV19	CT 2	23.25
2021	1	11	PCR_COBAS_COV19	CT 2	20.22
2021	1	11	PCR_COBAS_COV19	CT 2	36.48
2021	1	11	PCR_COBAS_COV19	CT 2	35.6
2021	1	11	PCR_COBAS_COV19	CT 2	23.15
2021	1	11	PCR_COBAS_COV19	CT 2	31.87
2021	1	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.85139675
2021	1	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.66561878
2021	1	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.50150878
2021	1	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.10476121
2021	1	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.13004072
2021	1	11	PCR_PANTH_COV19	RLU	1155
2021	1	11	PCR_PANTH_COV19	RLU	1184

AB1110

2021	1	11	PCR_PANTH_COV19	RLU	1121
2021	1	11	PCR_PANTH_COV19	RLU	1129
2021	1	11	PCR_PANTH_COV19	RLU	1199
2021	1	11	PCR_PANTH_COV19	RLU	1182
2021	1	11	PCR_PANTH_COV19	RLU	1206
2021	1	11	PCR_PANTH_COV19	RLU	1169
2021	1	11	PCR_PANTH_COV19	RLU	1171
2021	1	11	PCR_PANTH_COV19	RLU	1199
2021	1	11	PCR_PANTH_COV19	RLU	1106
2021	1	11	PCR_PANTH_COV19	RLU	1194
2021	1	11	PCR_PANTH_COV19	RLU	1142
2021	1	11	PCR_PANTH_COV19	RLU	1177
2021	1	11	PCR_PANTH_COV19	RLU	1129
2021	1	11	PCR_PANTH_COV19	RLU	1167
2021	1	11	PCR_PANTH_COV19	RLU	1173
2021	1	11	PCR_PANTH_COV19	RLU	1147
2021	1	11	PCR_PANTH_COV19	RLU	1165
2021	1	11	PCR_PANTH_COV19	RLU	1196
2021	1	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.20142339
2021	1	11	PCR_PANTH_COV19	RLU	1177
2021	1	11	PCR_PANTH_COV19	RLU	1143
2021	1	11	PCR_PANTH_COV19	RLU	1174
2021	1	11	PCR_PANTH_COV19	RLU	1157
2021	1	11	PCR_COBAS_COV19	CT 2	34.01
2021	1	11	PCR_COBAS_COV19	CT 2	34.91
2021	1	11	PCR_COBAS_COV19	CT 2	20.64
2021	1	11	PCR_COBAS_COV19	CT 2	19.42
2021	1	11	PCR_COBAS_COV19	CT 2	33.78
2021	1	11	PCR_COBAS_COV19	CT 2	18.12
2021	1	11	PCR_COBAS_COV19	CT 2	32.55
2021	1	11	PCR_COBAS_COV19	CT 2	22.11
2021	1	11	PCR_COBAS_COV19	CT 2	18.2
2021	1	11	PCR_COBAS_COV19	CT 2	23.05
2021	1	11	PCR_COBAS_COV19	CT 2	31.2
2021	1	11	PCR_COBAS_COV19	CT 2	36.07
2021	1	11	PCR_COBAS_COV19	CT 2	31.82
2021	1	11	PCR_COBAS_COV19	CT 2	35.98
2021	1	11	PCR_PANTH_COV19	RLU	1215
2021	1	11	PCR_PANTH_COV19	RLU	1180
2021	1	11	PCR_PANTH_COV19	RLU	1154
2021	1	11	PCR_PANTH_COV19	RLU	1160
2021	1	11	PCR_PANTH_COV19	RLU	1188
2021	1	11	PCR_PANTH_COV19	RLU	1259
2021	1	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.50237608
2021	1	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.20117345
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.04504338
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.67997263

AB1111

2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.56150387
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.40947965
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.48925533
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.55298306
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.97383092
2021	1	12	PCR_PANTH_COV19	RLU	1231
2021	1	12	PCR_PANTH_COV19	RLU	1178
2021	1	12	PCR_PANTH_COV19	RLU	1205
2021	1	12	PCR_PANTH_COV19	RLU	1186
2021	1	12	PCR_PANTH_COV19	RLU	1193
2021	1	12	PCR_PANTH_COV19	RLU	1202
2021	1	12	PCR_PANTH_COV19	RLU	1237
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.55182879
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.45787648
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.05855689
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.67112803
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.17271461
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.83203283
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.17073779
2021	1	12	PCR_PANTH_COV19	RLU	1163
2021	1	12	PCR_PANTH_COV19	RLU	1140
2021	1	12	PCR_PANTH_COV19	RLU	1216
2021	1	12	PCR_PANTH_COV19	RLU	1162
2021	1	12	PCR_PANTH_COV19	RLU	1132
2021	1	12	PCR_PANTH_COV19	RLU	1136
2021	1	12	PCR_PANTH_COV19	RLU	1166
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.51342291
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.53508564
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.14783021
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.80508777
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.03338829
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.29726033
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.14355142
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.21895687
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.33671848
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.37259792
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.10891392
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.14586931
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.49649317
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.96729698
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.5830597
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.20749548
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.81354232
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.079024
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.1013906
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.90950623
2021	1	12	PCR_PANTH_COV19	RLU	1162

AB1112

2021	1	12	PCR_PANTH_COV19	RLU	1151
2021	1	12	PCR_PANTH_COV19	RLU	1191
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.56545662
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.58082451
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.45340178
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.94167778
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.13647847
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.65639672
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.40582103
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.22946129
2021	1	12	PCR_PANTH_COV19	RLU	1161
2021	1	12	PCR_PANTH_COV19	RLU	1178
2021	1	12	PCR_PANTH_COV19	RLU	1158
2021	1	12	PCR_PANTH_COV19	RLU	1191
2021	1	12	PCR_PANTH_COV19	RLU	1134
2021	1	12	PCR_PANTH_COV19	RLU	1181
2021	1	12	PCR_PANTH_COV19	RLU	1161
2021	1	12	PCR_PANTH_COV19	RLU	1160
2021	1	12	PCR_PANTH_COV19	RLU	1184
2021	1	12	PCR_PANTH_COV19	RLU	1166
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	28.4
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	23.1
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	19.1
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	36.4
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	30.6
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.92426854
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.39742179
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.70201085
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.06399053
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.71860558
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.53508337
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.53107974
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.39786337
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.20520979
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.99370452
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.3857585
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.31624279
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.82981489
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.18755129
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.39499893
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.97393113
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.13302716
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	14
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	29.5
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	33.6
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	26.7
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.62655251

AB1113

2021	1	12	PCR_FUSION_COV19_E	E Gene CT	27.2
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	18.8
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	23.7
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	21.5
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	37.1
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	24.8
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	25
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	21
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	28.3
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	29.7
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	36.5
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	31.8
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	30.8
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	22.7
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	22.5
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	29
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	24
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	20.4
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	18.8
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	26.1
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	24.2
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.88436532
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.20563928
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.0040001
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.47638758
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.49397827
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.73370547
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.0959655
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.25650136
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.72728526
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.47589596
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.78186876
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.23836673
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.21126955
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.71005485
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.4662345
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.73156416
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.90805792
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	23
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.45093062
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.63143429
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.43887228
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.40006765
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.62729086
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.00742558
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.3311933
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.21463141

2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.66487545
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.32544162
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.36007499
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.54990425
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.98608212
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.89412425
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.61738929
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	17.2
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	35
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	31.8
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	26.2
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	33
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	22.5
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	36.9
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	19.4
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	24
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	30.3
2021	1	12	PCR_FUSION_COV19_E	E Gene CT	27
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.4794117
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.38117234
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.31014766
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.60961755
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.86013094
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.15899307
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.62379179
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.46264141
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.23815472
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.12870169
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.38334261
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.91958364
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.71405472
2021	1	12	PCR_COBAS_COV19	CT 2	37.07
2021	1	12	PCR_COBAS_COV19	CT 2	27.07
2021	1	12	PCR_COBAS_COV19	CT 2	33.15
2021	1	12	PCR_COBAS_COV19	CT 2	33
2021	1	12	PCR_COBAS_COV19	CT 2	15.66
2021	1	12	PCR_COBAS_COV19	CT 2	33.32
2021	1	12	PCR_COBAS_COV19	CT 2	36.56
2021	1	12	PCR_COBAS_COV19	CT 2	28.32
2021	1	12	PCR_COBAS_COV19	CT 2	33.92
2021	1	12	PCR_COBAS_COV19	CT 2	32.25
2021	1	12	PCR_COBAS_COV19	CT 2	25.04
2021	1	12	PCR_COBAS_COV19	CT 2	25.7
2021	1	12	PCR_COBAS_COV19	CT 2	21.01
2021	1	12	PCR_COBAS_COV19	CT 2	34.46
2021	1	12	PCR_COBAS_COV19	CT 2	35.63
2021	1	12	PCR_COBAS_COV19	CT 2	14.45

AB1115

2021	1	12	PCR_COBAS_COV19	CT 2	33.98
2021	1	12	PCR_COBAS_COV19	CT 2	30.83
2021	1	12	PCR_COBAS_COV19	CT 2	19.91
2021	1	12	PCR_COBAS_COV19	CT 2	22.92
2021	1	12	PCR_PANTH_COV19	RLU	1210
2021	1	12	PCR_PANTH_COV19	RLU	1158
2021	1	12	PCR_PANTH_COV19	RLU	1182
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	0
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.9303551
2021	1	12	PCR_PANTH_COV19	RLU	1033
2021	1	12	PCR_PANTH_COV19	RLU	1199
2021	1	12	PCR_PANTH_COV19	RLU	1219
2021	1	12	PCR_PANTH_COV19	RLU	1210
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	0
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.00111029
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	0
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.76427779
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	0
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.10028375
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	0
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.65319868
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	0
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.71761027
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	0
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.01722209
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	0
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.11089473
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	0
2021	1	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.28422787
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.22638906
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	0
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.34493145
2021	1	13	PCR_PANTH_COV19	RLU	1140
2021	1	13	PCR_PANTH_COV19	RLU	1124
2021	1	13	PCR_PANTH_COV19	RLU	1229
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	0
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.57838915
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	0
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.21702133
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	0
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.89074421
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	0
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.63620456
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	0
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.98675737
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	0
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.90952574

AB1116

2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	0
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.19283467
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	0
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.55060252
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	0
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.11363091
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	0
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.8472331
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	0
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.90384881
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	0
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.42878406
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	0
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.02233731
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	0
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.35199852
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.41608448
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.74558179
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.1102392
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.12302355
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.0040148
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.36233581
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.45618082
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.04846108
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.96208841
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.91798669
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.68486731
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.8730941
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.0672976
2021	1	13	PCR_PANTH_COV19	RLU	1212
2021	1	13	PCR_PANTH_COV19	RLU	1181
2021	1	13	PCR_PANTH_COV19	RLU	1186
2021	1	13	PCR_PANTH_COV19	RLU	1183
2021	1	13	PCR_PANTH_COV19	RLU	1195
2021	1	13	PCR_PANTH_COV19	RLU	1164
2021	1	13	PCR_PANTH_COV19	RLU	1156
2021	1	13	PCR_PANTH_COV19	RLU	1165
2021	1	13	PCR_PANTH_COV19	RLU	1146
2021	1	13	PCR_PANTH_COV19	RLU	1140
2021	1	13	PCR_PANTH_COV19	RLU	1184
2021	1	13	PCR_PANTH_COV19	RLU	1179
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.38592461
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	23.2
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.29802845
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	20
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	26
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.137538

AB1117

2021	1	13	PCR_FUSION_COV19_E	E Gene CT	37.4
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	32.2
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	21.4
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	32.2
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.32002624
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.1364689
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.2227892
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	23.3
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	30.5
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	22.4
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	21.2
2021	1	13	PCR_PANTH_COV19	RLU	1166
2021	1	13	PCR_PANTH_COV19	RLU	1183
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	20
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	16.1
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.65759101
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.99017219
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.36830723
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.00509216
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.22725452
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.8464435
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.3658553
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.18732324
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.68034118
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	35.5
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	27.4
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	29
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	23.8
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	23.8
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	19.6
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	36.6
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	26
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	19.7
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	19.2
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	23.4
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	20.3
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	31.3
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	26.2
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	30.4
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	35.3
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	25.8
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	34.1
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	27.7
2021	1	13	PCR_FUSION_COV19_E	E Gene CT	36.1
2021	1	13	PCR_COBAS_COV19	CT 2	34.86
2021	1	13	PCR_COBAS_COV19	CT 2	29.98
2021	1	13	PCR_COBAS_COV19	CT 2	36.7

AB1118

2021	1	13	PCR_COBAS_COV19	CT 2	34.1
2021	1	13	PCR_COBAS_COV19	CT 2	37.95
2021	1	13	PCR_COBAS_COV19	CT 2	28.88
2021	1	13	PCR_COBAS_COV19	CT 2	32.19
2021	1	13	PCR_COBAS_COV19	CT 2	36.81
2021	1	13	PCR_COBAS_COV19	CT 2	32.13
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.51182187
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.95983197
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.79076841
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.82863685
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.82927746
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.27804639
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.67714734
2021	1	13	PCR_COBAS_COV19	CT 2	25.6
2021	1	13	PCR_COBAS_COV19	CT 2	30.6
2021	1	13	PCR_COBAS_COV19	CT 2	20.28
2021	1	13	PCR_COBAS_COV19	CT 2	37.63
2021	1	13	PCR_COBAS_COV19	CT 2	18.79
2021	1	13	PCR_COBAS_COV19	CT 2	33.05
2021	1	13	PCR_COBAS_COV19	CT 2	19.05
2021	1	13	PCR_COBAS_COV19	CT 2	33.5
2021	1	13	PCR_COBAS_COV19	CT 2	33.88
2021	1	13	PCR_COBAS_COV19	CT 2	36.87
2021	1	13	PCR_COBAS_COV19	CT 2	21.93
2021	1	13	PCR_COBAS_COV19	CT 2	19.27
2021	1	13	PCR_COBAS_COV19	CT 2	36.49
2021	1	13	PCR_COBAS_COV19	CT 2	31.17
2021	1	13	PCR_COBAS_COV19	CT 2	23.34
2021	1	13	PCR_COBAS_COV19	CT 2	32.05
2021	1	13	PCR_COBAS_COV19	CT 2	31.03
2021	1	13	PCR_PANTH_COV19	RLU	1184
2021	1	13	PCR_PANTH_COV19	RLU	1169
2021	1	13	PCR_PANTH_COV19	RLU	1188
2021	1	13	PCR_PANTH_COV19	RLU	1173
2021	1	13	PCR_PANTH_COV19	RLU	1175
2021	1	13	PCR_PANTH_COV19	RLU	1188
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.83259121
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.70819883
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.01641621
2021	1	13	PCR_PANTH_COV19	RLU	1187
2021	1	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.89977257
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.35696744
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.13185406
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.14827359
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.52801573
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.4665176
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.45781109

AB1119

2021	1	14	PCR_PANTH_COV19	RLU	1138
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.28502791
2021	1	14	PCR_PANTH_COV19	RLU	1198
2021	1	14	PCR_PANTH_COV19	RLU	1208
2021	1	14	PCR_PANTH_COV19	RLU	1129
2021	1	14	PCR_PANTH_COV19	RLU	1139
2021	1	14	PCR_PANTH_COV19	RLU	1160
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.2570805
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.02668608
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.76370835
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.53767205
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.54951349
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.33335281
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.07148032
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.29388655
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.94525393
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.69602484
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.89685679
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.87073299
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.24415183
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.00233858
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.87421555
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.25094085
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.36650577
2021	1	14	PCR_PANTH_COV19	RLU	1167
2021	1	14	PCR_FUSION_COV19_E	E Gene CT	35.8
2021	1	14	PCR_FUSION_COV19_E	E Gene CT	35.9
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.43836609
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.9469312
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.06829949
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.22555853
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.41641938
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.4080408
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.56235823
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.73602335
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.66397002
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.27722409
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.73798063
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	10.16557619
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.05663856
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.044008
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.30063471
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.89932536
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.01267398
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.54478897
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.58136741
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.5160484

2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.80598378
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.35581259
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.47605764
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.41052722
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.0168448
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.0434635
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.65956431
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.85700471
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.9425171
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.07777392
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.55068201
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.06176785
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.21775496
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.03941178
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.37420522
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.71722253
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.25052639
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.56664234
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.83309317
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.29781252
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.51584636
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.64712082
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.55519568
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.64989845
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.97480519
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.61004841
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.55634784
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.33544113
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.90357342
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.84234412
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.84219072
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.34986586
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.89885177
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.62120057
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.88788994
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.24468786
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.28989572
2021	1	14	PCR_COBAS_COV19	CT 2	21.33
2021	1	14	PCR_COBAS_COV19	CT 2	26.42
2021	1	14	PCR_COBAS_COV19	CT 2	24.44
2021	1	14	PCR_COBAS_COV19	CT 2	26.93
2021	1	14	PCR_COBAS_COV19	CT 2	17.67
2021	1	14	PCR_COBAS_COV19	CT 2	18.24
2021	1	14	PCR_COBAS_COV19	CT 2	28.09
2021	1	14	PCR_COBAS_COV19	CT 2	36.33
2021	1	14	PCR_COBAS_COV19	CT 2	27.65
2021	1	14	PCR_COBAS_COV19	CT 2	19.06

2021	1	14	PCR_COBAS_COV19	CT 2	23.64
2021	1	14	PCR_COBAS_COV19	CT 2	30.63
2021	1	14	PCR_COBAS_COV19	CT 2	36.27
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.10278373
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.72917101
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.88124423
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.91920139
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.50534837
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.9518946
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.35304033
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.93107235
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.87175233
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.14616915
2021	1	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.8792529
2021	1	15	PCR_PANTH_COV19	RLU	1171
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.94129744
2021	1	15	PCR_PANTH_COV19	RLU	1184
2021	1	15	PCR_PANTH_COV19	RLU	1183
2021	1	15	PCR_PANTH_COV19	RLU	1114
2021	1	15	PCR_PANTH_COV19	RLU	1175
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.21631106
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.13545981
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.35482833
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.93113004
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.82275803
2021	1	15	PCR_PANTH_COV19	RLU	1209
2021	1	15	PCR_PANTH_COV19	RLU	1182
2021	1	15	PCR_PANTH_COV19	RLU	1185
2021	1	15	PCR_PANTH_COV19	RLU	1121
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.5502573
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.50591394
2021	1	15	PCR_PANTH_COV19	RLU	1244
2021	1	15	PCR_PANTH_COV19	RLU	1173
2021	1	15	PCR_PANTH_COV19	RLU	1218
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.39504205
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.28225832
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.44576145
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.49406354
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.92585712
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.83533942
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.57281136
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.25949459
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.07784505
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.2547594
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.71636728
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.675839
2021	1	15	PCR_PANTH_COV19	RLU	1223

AB1122

2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.75700175
2021	1	15	PCR_PANTH_COV19	RLU	1212
2021	1	15	PCR_PANTH_COV19	RLU	1172
2021	1	15	PCR_PANTH_COV19	RLU	1187
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.61420271
2021	1	15	PCR_PANTH_COV19	RLU	1172
2021	1	15	PCR_PANTH_COV19	RLU	1178
2021	1	15	PCR_PANTH_COV19	RLU	1182
2021	1	15	PCR_PANTH_COV19	RLU	1215
2021	1	15	PCR_PANTH_COV19	RLU	1217
2021	1	15	PCR_PANTH_COV19	RLU	1175
2021	1	15	PCR_PANTH_COV19	RLU	1174
2021	1	15	PCR_PANTH_COV19	RLU	1205
2021	1	15	PCR_PANTH_COV19	RLU	1223
2021	1	15	PCR_PANTH_COV19	RLU	1164
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.13374009
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.18449648
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.55178265
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.44367742
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.11587277
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.85912679
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.7735522
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.46850784
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.6246212
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.09731332
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.38334126
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.67581839
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.73585151
2021	1	15	PCR_PANTH_COV19	RLU	1208
2021	1	15	PCR_PANTH_COV19	RLU	1168
2021	1	15	PCR_PANTH_COV19	RLU	1150
2021	1	15	PCR_PANTH_COV19	RLU	1195
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.12972571
2021	1	15	PCR_PANTH_COV19	RLU	1153
2021	1	15	PCR_PANTH_COV19	RLU	1189
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.56640205
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.55803702
2021	1	15	PCR_FUSION_COV19_E	E Gene CT	19.9
2021	1	15	PCR_FUSION_COV19_E	E Gene CT	22.6
2021	1	15	PCR_FUSION_COV19_E	E Gene CT	31.4
2021	1	15	PCR_FUSION_COV19_E	E Gene CT	26.5
2021	1	15	PCR_FUSION_COV19_E	E Gene CT	23.8
2021	1	15	PCR_FUSION_COV19_E	E Gene CT	17
2021	1	15	PCR_FUSION_COV19_E	E Gene CT	25.3
2021	1	15	PCR_FUSION_COV19_E	E Gene CT	27.1
2021	1	15	PCR_FUSION_COV19_E	E Gene CT	15.3
2021	1	15	PCR_FUSION_COV19_E	E Gene CT	19.1

AB1123

2021	1	15	PCR_FUSION_COV19_E	E Gene CT	17.1
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.22822596
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.02306409
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.98916134
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.52643091
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.83938135
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.095702
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.47506835
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.8435045
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.34306772
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.42199012
2021	1	15	PCR_COBAS_COV19	CT 2	20.13
2021	1	15	PCR_COBAS_COV19	CT 2	33.68
2021	1	15	PCR_COBAS_COV19	CT 2	26.09
2021	1	15	PCR_COBAS_COV19	CT 2	32.43
2021	1	15	PCR_COBAS_COV19	CT 2	25.4
2021	1	15	PCR_COBAS_COV19	CT 2	34.46
2021	1	15	PCR_COBAS_COV19	CT 2	24.81
2021	1	15	PCR_COBAS_COV19	CT 2	19.15
2021	1	15	PCR_COBAS_COV19	CT 2	32.21
2021	1	15	PCR_COBAS_COV19	CT 2	17.34
2021	1	15	PCR_COBAS_COV19	CT 2	26.86
2021	1	15	PCR_COBAS_COV19	CT 2	34.48
2021	1	15	PCR_COBAS_COV19	CT 2	27.77
2021	1	15	PCR_COBAS_COV19	CT 2	35.81
2021	1	15	PCR_COBAS_COV19	CT 2	36.97
2021	1	15	PCR_COBAS_COV19	CT 2	22.91
2021	1	15	PCR_COBAS_COV19	CT 2	23.45
2021	1	15	PCR_COBAS_COV19	CT 2	32.08
2021	1	15	PCR_COBAS_COV19	CT 2	23.88
2021	1	15	PCR_COBAS_COV19	CT 2	16.85
2021	1	15	PCR_COBAS_COV19	CT 2	31.95
2021	1	15	PCR_COBAS_COV19	CT 2	34.75
2021	1	15	PCR_COBAS_COV19	CT 2	27.95
2021	1	15	PCR_COBAS_COV19	CT 2	37.39
2021	1	15	PCR_COBAS_COV19	CT 2	28.18
2021	1	15	PCR_COBAS_COV19	CT 2	29.32
2021	1	15	PCR_COBAS_COV19	CT 2	16.92
2021	1	15	PCR_COBAS_COV19	CT 2	21.39
2021	1	15	PCR_COBAS_COV19	CT 2	29.9
2021	1	15	PCR_PANTH_COV19	RLU	1120
2021	1	15	PCR_PANTH_COV19	RLU	1148
2021	1	15	PCR_PANTH_COV19	RLU	1158
2021	1	15	PCR_PANTH_COV19	RLU	1209
2021	1	15	PCR_PANTH_COV19	RLU	1171
2021	1	15	PCR_PANTH_COV19	RLU	1113
2021	1	15	PCR_PANTH_COV19	RLU	1142

AB1124

2021	1	15	PCR_PANTH_COV19	RLU	1152
2021	1	15	PCR_PANTH_COV19	RLU	1138
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.69590725
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.51432571
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.4459818
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.4474238
2021	1	15	PCR_PANTH_COV19	RLU	1141
2021	1	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.93473451
2021	1	16	PCR_PANTH_COV19	RLU	1184
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.19126157
2021	1	16	PCR_PANTH_COV19	RLU	1140
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.81944612
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.41884821
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.88085271
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.38170192
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.52925661
2021	1	16	PCR_PANTH_COV19	RLU	1148
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.88230105
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.09953391
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.94871877
2021	1	16	PCR_PANTH_COV19	RLU	1016
2021	1	16	PCR_PANTH_COV19	RLU	1133
2021	1	16	PCR_PANTH_COV19	RLU	1156
2021	1	16	PCR_PANTH_COV19	RLU	1179
2021	1	16	PCR_PANTH_COV19	RLU	1152
2021	1	16	PCR_PANTH_COV19	RLU	1144
2021	1	16	PCR_PANTH_COV19	RLU	1212
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.85447235
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.55323433
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.16201675
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.51345764
2021	1	16	PCR_FUSION_COV19_E	E Gene CT	20.2
2021	1	16	PCR_FUSION_COV19_E	E Gene CT	26.1
2021	1	16	PCR_FUSION_COV19_E	E Gene CT	21.9
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.93370961
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.75632993
2021	1	16	PCR_FUSION_COV19_E	E Gene CT	33.2
2021	1	16	PCR_FUSION_COV19_E	E Gene CT	19.7
2021	1	16	PCR_FUSION_COV19_E	E Gene CT	20.7
2021	1	16	PCR_FUSION_COV19_E	E Gene CT	22.3
2021	1	16	PCR_FUSION_COV19_E	E Gene CT	21.3
2021	1	16	PCR_FUSION_COV19_E	E Gene CT	28.3
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.77684953
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.28683187
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.29498055
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.70998746
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.10111563

AB1125

2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.80796474
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.32556428
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.70170713
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.11806687
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.50003723
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.00494662
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.17109016
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.45763324
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.31102947
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.19984232
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.76837541
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.62644286
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.16386847
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.55071325
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.44968639
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.57543758
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.80263151
2021	1	16	PCR_PANTH_COV19	RLU	1159
2021	1	16	PCR_PANTH_COV19	RLU	1190
2021	1	16	PCR_PANTH_COV19	RLU	1143
2021	1	16	PCR_PANTH_COV19	RLU	1144
2021	1	16	PCR_PANTH_COV19	RLU	1174
2021	1	16	PCR_PANTH_COV19	RLU	1131
2021	1	16	PCR_COBAS_COV19	CT 2	18.19
2021	1	16	PCR_COBAS_COV19	CT 2	23.92
2021	1	16	PCR_COBAS_COV19	CT 2	32.25
2021	1	16	PCR_COBAS_COV19	CT 2	25.62
2021	1	16	PCR_COBAS_COV19	CT 2	30.89
2021	1	16	PCR_COBAS_COV19	CT 2	24.16
2021	1	16	PCR_COBAS_COV19	CT 2	28.17
2021	1	16	PCR_COBAS_COV19	CT 2	32.58
2021	1	16	PCR_COBAS_COV19	CT 2	17.89
2021	1	16	PCR_COBAS_COV19	CT 2	17.47
2021	1	16	PCR_COBAS_COV19	CT 2	26.4
2021	1	16	PCR_COBAS_COV19	CT 2	22.51
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.79153677
2021	1	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.45157135
2021	1	16	PCR_PANTH_COV19	RLU	1135
2021	1	16	PCR_PANTH_COV19	RLU	1196
2021	1	16	PCR_PANTH_COV19	RLU	1148
2021	1	16	PCR_PANTH_COV19	RLU	1125
2021	1	16	PCR_COBAS_COV19	CT 2	18.56
2021	1	16	PCR_COBAS_COV19	CT 2	26.91
2021	1	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.88776714
2021	1	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.35733671
2021	1	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.15947127
2021	1	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.88788198

AB1126

2021	1	17	PCR_COBAS_COV19	CT 2	30.85
2021	1	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.76705934
2021	1	17	PCR_PANTH_COV19	RLU	1099
2021	1	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.9375829
2021	1	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.83290465
2021	1	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.39397759
2021	1	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.42141989
2021	1	17	PCR_PANTH_COV19	RLU	1131
2021	1	17	PCR_PANTH_COV19	RLU	1122
2021	1	17	PCR_PANTH_COV19	RLU	1122
2021	1	17	PCR_PANTH_COV19	RLU	1126
2021	1	17	PCR_PANTH_COV19	RLU	1126
2021	1	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.03290898
2021	1	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.0786188
2021	1	17	PCR_FUSION_COV19_E	E Gene CT	31.2
2021	1	17	PCR_FUSION_COV19_E	E Gene CT	28.2
2021	1	17	PCR_FUSION_COV19_E	E Gene CT	23.8
2021	1	17	PCR_FUSION_COV19_E	E Gene CT	28.2
2021	1	17	PCR_FUSION_COV19_E	E Gene CT	31
2021	1	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.33866625
2021	1	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.02159311
2021	1	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.7494151
2021	1	17	PCR_COBAS_COV19	CT 2	23.58
2021	1	17	PCR_COBAS_COV19	CT 2	34.56
2021	1	17	PCR_COBAS_COV19	CT 2	33.61
2021	1	17	PCR_COBAS_COV19	CT 2	20.85
2021	1	17	PCR_COBAS_COV19	CT 2	17.29
2021	1	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.34395265
2021	1	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.04332734
2021	1	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.01859323
2021	1	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.80584519
2021	1	18	PCR_COBAS_COV19	CT 2	35.68
2021	1	18	PCR_COBAS_COV19	CT 2	31.31
2021	1	18	PCR_COBAS_COV19	CT 2	17.28
2021	1	18	PCR_COBAS_COV19	CT 2	36.24
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.72059016
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.3888964
2021	1	18	PCR_COBAS_COV19	CT 2	33.27
2021	1	18	PCR_COBAS_COV19	CT 2	16.84
2021	1	18	PCR_COBAS_COV19	CT 2	22.57
2021	1	18	PCR_COBAS_COV19	CT 2	32.34
2021	1	18	PCR_COBAS_COV19	CT 2	32.22
2021	1	18	PCR_COBAS_COV19	CT 2	22.83
2021	1	18	PCR_COBAS_COV19	CT 2	26.59
2021	1	18	PCR_COBAS_COV19	CT 2	24.65
2021	1	18	PCR_COBAS_COV19	CT 2	17.04
2021	1	18	PCR_COBAS_COV19	CT 2	32.57

AB1127

2021	1	18	PCR_COBAS_COV19	CT 2	16.78
2021	1	18	PCR_COBAS_COV19	CT 2	20.53
2021	1	18	PCR_COBAS_COV19	CT 2	19.12
2021	1	18	PCR_COBAS_COV19	CT 2	35.92
2021	1	18	PCR_COBAS_COV19	CT 2	19.06
2021	1	18	PCR_COBAS_COV19	CT 2	25.64
2021	1	18	PCR_COBAS_COV19	CT 2	21.33
2021	1	18	PCR_COBAS_COV19	CT 2	18.05
2021	1	18	PCR_COBAS_COV19	CT 2	30.49
2021	1	18	PCR_COBAS_COV19	CT 2	21.41
2021	1	18	PCR_COBAS_COV19	CT 2	29.17
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.20054816
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.72469944
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.3287375
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.88809346
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.36519391
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.19976051
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.49294875
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.80537544
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	26.5
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.15458139
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	18.7
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.05484901
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.65952948
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.96171526
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	21
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	25
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	29.8
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	22.5
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	26.9
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.84823915
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	19.6
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	34
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	21.2
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	36
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	23.2
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	27.8
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	20.8
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	29.6
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	18.5
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	30.8
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	19.8
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	19
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	25.2
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	30.1
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.42197813
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.83567523

AB1128

2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.80048033
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.03222407
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	19.2
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	22.1
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	19
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	30.9
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	31.8
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	34.7
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.59395233
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	16.6
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	19.7
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	16.3
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	30.8
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	20.8
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	25.9
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	27.9
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	35.1
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.34412743
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	19.6
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	34
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	24.7
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	28.8
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	23.5
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	37.7
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	32.6
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	35.7
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	32.3
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	31.7
2021	1	18	PCR_FUSION_COV19_E	E Gene CT	35.5
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.57420367
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.29519761
2021	1	18	PCR_COBAS_COV19	CT 2	20.34
2021	1	18	PCR_COBAS_COV19	CT 2	25.35
2021	1	18	PCR_COBAS_COV19	CT 2	24.12
2021	1	18	PCR_COBAS_COV19	CT 2	34.68
2021	1	18	PCR_COBAS_COV19	CT 2	34.47
2021	1	18	PCR_COBAS_COV19	CT 2	33.31
2021	1	18	PCR_COBAS_COV19	CT 2	31.65
2021	1	18	PCR_COBAS_COV19	CT 2	19.48
2021	1	18	PCR_COBAS_COV19	CT 2	30.58
2021	1	18	PCR_COBAS_COV19	CT 2	33.48
2021	1	18	PCR_COBAS_COV19	CT 2	35.36
2021	1	18	PCR_COBAS_COV19	CT 2	19.7
2021	1	18	PCR_COBAS_COV19	CT 2	37.72
2021	1	18	PCR_COBAS_COV19	CT 2	20.76
2021	1	18	PCR_COBAS_COV19	CT 2	16.44
2021	1	18	PCR_COBAS_COV19	CT 2	22.78

AB1129

2021	1	18	PCR_COBAS_COV19	CT 2	24.66
2021	1	18	PCR_COBAS_COV19	CT 2	28.59
2021	1	18	PCR_COBAS_COV19	CT 2	32.67
2021	1	18	PCR_COBAS_COV19	CT 2	35.64
2021	1	18	PCR_COBAS_COV19	CT 2	35.55
2021	1	18	PCR_COBAS_COV19	CT 2	24.07
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.03189439
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.15799357
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.2332982
2021	1	18	PCR_COBAS_COV19	CT 2	32.08
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.13331139
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.34518145
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.75424415
2021	1	18	PCR_COBAS_COV19	CT 2	32.8
2021	1	18	PCR_COBAS_COV19	CT 2	25.98
2021	1	18	PCR_COBAS_COV19	CT 2	15.23
2021	1	18	PCR_COBAS_COV19	CT 2	28.57
2021	1	18	PCR_COBAS_COV19	CT 2	19.87
2021	1	18	PCR_COBAS_COV19	CT 2	37.19
2021	1	18	PCR_COBAS_COV19	CT 2	31.27
2021	1	18	PCR_COBAS_COV19	CT 2	33.82
2021	1	18	PCR_PANTH_COV19	RLU	1106
2021	1	18	PCR_PANTH_COV19	RLU	1146
2021	1	18	PCR_PANTH_COV19	RLU	1128
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.90564981
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.16483042
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.85538618
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.05221959
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.52041861
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.0864764
2021	1	18	PCR_PANTH_COV19	RLU	1123
2021	1	18	PCR_PANTH_COV19	RLU	1112
2021	1	18	PCR_PANTH_COV19	RLU	1117
2021	1	18	PCR_PANTH_COV19	RLU	1161
2021	1	18	PCR_PANTH_COV19	RLU	1110
2021	1	18	PCR_PANTH_COV19	RLU	1186
2021	1	18	PCR_PANTH_COV19	RLU	1173
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.94558666
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.58028908
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.3949828
2021	1	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.35082173
2021	1	18	PCR_PANTH_COV19	RLU	1145
2021	1	19	PCR_COBAS_COV19	CT 2	34.75
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.47335495
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.63948525
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.1687719
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.16890152

AB1130

2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.72377698
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.67461374
2021	1	19	PCR_PANTH_COV19	RLU	1154
2021	1	19	PCR_PANTH_COV19	RLU	1158
2021	1	19	PCR_PANTH_COV19	RLU	1146
2021	1	19	PCR_PANTH_COV19	RLU	1150
2021	1	19	PCR_PANTH_COV19	RLU	1223
2021	1	19	PCR_PANTH_COV19	RLU	1122
2021	1	19	PCR_PANTH_COV19	RLU	1156
2021	1	19	PCR_PANTH_COV19	RLU	1144
2021	1	19	PCR_PANTH_COV19	RLU	1148
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.63723181
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.17198587
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.24858073
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.33023461
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.76627565
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.49868978
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.94091488
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.04789747
2021	1	19	PCR_PANTH_COV19	RLU	1138
2021	1	19	PCR_PANTH_COV19	RLU	1119
2021	1	19	PCR_PANTH_COV19	RLU	1169
2021	1	19	PCR_PANTH_COV19	RLU	1143
2021	1	19	PCR_PANTH_COV19	RLU	1171
2021	1	19	PCR_PANTH_COV19	RLU	1151
2021	1	19	PCR_PANTH_COV19	RLU	1132
2021	1	19	PCR_PANTH_COV19	RLU	1098
2021	1	19	PCR_PANTH_COV19	RLU	1162
2021	1	19	PCR_PANTH_COV19	RLU	1132
2021	1	19	PCR_PANTH_COV19	RLU	1170
2021	1	19	PCR_PANTH_COV19	RLU	1141
2021	1	19	PCR_PANTH_COV19	RLU	1138
2021	1	19	PCR_PANTH_COV19	RLU	1156
2021	1	19	PCR_PANTH_COV19	RLU	1164
2021	1	19	PCR_PANTH_COV19	RLU	1126
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.57849284
2021	1	19	PCR_FUSION_COV19_E	E Gene CT	28.3
2021	1	19	PCR_FUSION_COV19_E	E Gene CT	25.9
2021	1	19	PCR_FUSION_COV19_E	E Gene CT	29.8
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.46184307
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.28306904
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.28130695
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.84175517
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.42319565
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.273015
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.37048526
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.24494376

AB1131

2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.39431143
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.43071709
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.02859007
2021	1	19	PCR_PANTH_COV19	RLU	1209
2021	1	19	PCR_PANTH_COV19	RLU	1138
2021	1	19	PCR_PANTH_COV19	RLU	1180
2021	1	19	PCR_PANTH_COV19	RLU	1214
2021	1	19	PCR_PANTH_COV19	RLU	1158
2021	1	19	PCR_PANTH_COV19	RLU	1135
2021	1	19	PCR_PANTH_COV19	RLU	1137
2021	1	19	PCR_PANTH_COV19	RLU	1158
2021	1	19	PCR_PANTH_COV19	RLU	1105
2021	1	19	PCR_FUSION_COV19_E	E Gene CT	28.3
2021	1	19	PCR_FUSION_COV19_E	E Gene CT	22.1
2021	1	19	PCR_FUSION_COV19_E	E Gene CT	26.9
2021	1	19	PCR_FUSION_COV19_E	E Gene CT	30.6
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.89184942
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.95608516
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.16087457
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.37287306
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.74174011
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.34871544
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.22415254
2021	1	19	PCR_PANTH_COV19	RLU	1106
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.6159444
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.52587734
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.62255428
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.11811369
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.59562537
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.7251342
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.19399426
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.03392527
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.22812327
2021	1	19	PCR_PANTH_COV19	RLU	1161
2021	1	19	PCR_PANTH_COV19	RLU	1122
2021	1	19	PCR_PANTH_COV19	RLU	1163
2021	1	19	PCR_PANTH_COV19	RLU	1178
2021	1	19	PCR_PANTH_COV19	RLU	1127
2021	1	19	PCR_PANTH_COV19	RLU	1104
2021	1	19	PCR_PANTH_COV19	RLU	1057
2021	1	19	PCR_PANTH_COV19	RLU	1106
2021	1	19	PCR_PANTH_COV19	RLU	1176
2021	1	19	PCR_PANTH_COV19	RLU	1122
2021	1	19	PCR_PANTH_COV19	RLU	1243
2021	1	19	PCR_PANTH_COV19	RLU	1138
2021	1	19	PCR_PANTH_COV19	RLU	1150
2021	1	19	PCR_PANTH_COV19	RLU	1152

AB1132

2021	1	19	PCR_PANTH_COV19	RLU	1183
2021	1	19	PCR_PANTH_COV19	RLU	1156
2021	1	19	PCR_FUSION_COV19_E	E Gene CT	26.3
2021	1	19	PCR_FUSION_COV19_E	E Gene CT	27.1
2021	1	19	PCR_FUSION_COV19_E	E Gene CT	25.2
2021	1	19	PCR_FUSION_COV19_E	E Gene CT	17.6
2021	1	19	PCR_FUSION_COV19_E	E Gene CT	24.3
2021	1	19	PCR_FUSION_COV19_E	E Gene CT	27.2
2021	1	19	PCR_FUSION_COV19_E	E Gene CT	17.3
2021	1	19	PCR_FUSION_COV19_E	E Gene CT	22.7
2021	1	19	PCR_FUSION_COV19_E	E Gene CT	25.6
2021	1	19	PCR_FUSION_COV19_E	E Gene CT	26.2
2021	1	19	PCR_FUSION_COV19_E	E Gene CT	32.8
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.10874577
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.8580197
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.59717182
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.86345063
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.50271167
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.4128094
2021	1	19	PCR_FUSION_COV19_E	E Gene CT	28.9
2021	1	19	PCR_FUSION_COV19_E	E Gene CT	19
2021	1	19	PCR_FUSION_COV19_E	E Gene CT	24.2
2021	1	19	PCR_FUSION_COV19_E	E Gene CT	36
2021	1	19	PCR_FUSION_COV19_E	E Gene CT	21
2021	1	19	PCR_FUSION_COV19_E	E Gene CT	27.2
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.56577102
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.06822119
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.55791839
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.6003418
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.06785384
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.02575558
2021	1	19	PCR_COBAS_COV19	CT 2	26.7
2021	1	19	PCR_COBAS_COV19	CT 2	24.58
2021	1	19	PCR_COBAS_COV19	CT 2	36.63
2021	1	19	PCR_COBAS_COV19	CT 2	30.14
2021	1	19	PCR_COBAS_COV19	CT 2	35.69
2021	1	19	PCR_COBAS_COV19	CT 2	22.29
2021	1	19	PCR_COBAS_COV19	CT 2	36.04
2021	1	19	PCR_COBAS_COV19	CT 2	36.39
2021	1	19	PCR_COBAS_COV19	CT 2	20.91
2021	1	19	PCR_COBAS_COV19	CT 2	31.85
2021	1	19	PCR_COBAS_COV19	CT 2	22.73
2021	1	19	PCR_COBAS_COV19	CT 2	34.64
2021	1	19	PCR_COBAS_COV19	CT 2	35.79
2021	1	19	PCR_COBAS_COV19	CT 2	20.58
2021	1	19	PCR_COBAS_COV19	CT 2	36.79
2021	1	19	PCR_PANTH_COV19	RLU	1177

AB1133

2021	1	19	PCR_PANTH_COV19	RLU	1238
2021	1	19	PCR_PANTH_COV19	RLU	1202
2021	1	19	PCR_PANTH_COV19	RLU	1199
2021	1	19	PCR_PANTH_COV19	RLU	1156
2021	1	19	PCR_PANTH_COV19	RLU	1200
2021	1	19	PCR_PANTH_COV19	RLU	1185
2021	1	19	PCR_PANTH_COV19	RLU	1191
2021	1	19	PCR_PANTH_COV19	RLU	1186
2021	1	19	PCR_PANTH_COV19	RLU	1175
2021	1	19	PCR_PANTH_COV19	RLU	1182
2021	1	19	PCR_PANTH_COV19	RLU	1189
2021	1	19	PCR_PANTH_COV19	RLU	1198
2021	1	19	PCR_PANTH_COV19	RLU	1233
2021	1	19	PCR_PANTH_COV19	RLU	1240
2021	1	19	PCR_PANTH_COV19	RLU	1200
2021	1	19	PCR_PANTH_COV19	RLU	1197
2021	1	19	PCR_PANTH_COV19	RLU	1166
2021	1	19	PCR_PANTH_COV19	RLU	1189
2021	1	19	PCR_PANTH_COV19	RLU	1211
2021	1	19	PCR_PANTH_COV19	RLU	1182
2021	1	19	PCR_PANTH_COV19	RLU	1186
2021	1	19	PCR_PANTH_COV19	RLU	1169
2021	1	19	PCR_PANTH_COV19	RLU	1186
2021	1	19	PCR_PANTH_COV19	RLU	1176
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.53973175
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.09878476
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.57769112
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.21158701
2021	1	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.46949997
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.25755974
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.29733817
2021	1	20	PCR_PANTH_COV19	RLU	1188
2021	1	20	PCR_PANTH_COV19	RLU	1186
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.83953715
2021	1	20	PCR_PANTH_COV19	RLU	1148
2021	1	20	PCR_PANTH_COV19	RLU	1184
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.7939654
2021	1	20	PCR_PANTH_COV19	RLU	1199
2021	1	20	PCR_PANTH_COV19	RLU	1160
2021	1	20	PCR_PANTH_COV19	RLU	1198
2021	1	20	PCR_PANTH_COV19	RLU	1198
2021	1	20	PCR_PANTH_COV19	RLU	1221
2021	1	20	PCR_PANTH_COV19	RLU	1180
2021	1	20	PCR_PANTH_COV19	RLU	1137
2021	1	20	PCR_PANTH_COV19	RLU	1158
2021	1	20	PCR_PANTH_COV19	RLU	1198
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.08427599

AB1134

2021	1	20	PCR_PANTH_COV19	RLU	1178
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.96834122
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.97205543
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.98313466
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.40144982
2021	1	20	PCR_PANTH_COV19	RLU	1197
2021	1	20	PCR_PANTH_COV19	RLU	1159
2021	1	20	PCR_PANTH_COV19	RLU	1209
2021	1	20	PCR_PANTH_COV19	RLU	1173
2021	1	20	PCR_PANTH_COV19	RLU	1172
2021	1	20	PCR_PANTH_COV19	RLU	1218
2021	1	20	PCR_PANTH_COV19	RLU	1248
2021	1	20	PCR_PANTH_COV19	RLU	1167
2021	1	20	PCR_PANTH_COV19	RLU	1163
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.2466112
2021	1	20	PCR_PANTH_COV19	RLU	1185
2021	1	20	PCR_PANTH_COV19	RLU	1202
2021	1	20	PCR_FUSION_COV19_E	E Gene CT	20.7
2021	1	20	PCR_FUSION_COV19_E	E Gene CT	26.1
2021	1	20	PCR_FUSION_COV19_E	E Gene CT	21.3
2021	1	20	PCR_FUSION_COV19_E	E Gene CT	34.8
2021	1	20	PCR_FUSION_COV19_E	E Gene CT	26.6
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.21079732
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.79044352
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.83280821
2021	1	20	PCR_FUSION_COV19_E	E Gene CT	33
2021	1	20	PCR_FUSION_COV19_E	E Gene CT	28
2021	1	20	PCR_FUSION_COV19_E	E Gene CT	28.1
2021	1	20	PCR_FUSION_COV19_E	E Gene CT	26.7
2021	1	20	PCR_FUSION_COV19_E	E Gene CT	26.6
2021	1	20	PCR_FUSION_COV19_E	E Gene CT	25.2
2021	1	20	PCR_FUSION_COV19_E	E Gene CT	31.4
2021	1	20	PCR_FUSION_COV19_E	E Gene CT	29.5
2021	1	20	PCR_FUSION_COV19_E	E Gene CT	29.6
2021	1	20	PCR_FUSION_COV19_E	E Gene CT	19.2
2021	1	20	PCR_FUSION_COV19_E	E Gene CT	20.6
2021	1	20	PCR_FUSION_COV19_E	E Gene CT	17.3
2021	1	20	PCR_FUSION_COV19_E	E Gene CT	32.8
2021	1	20	PCR_FUSION_COV19_E	E Gene CT	16.4
2021	1	20	PCR_FUSION_COV19_E	E Gene CT	25.8
2021	1	20	PCR_FUSION_COV19_E	E Gene CT	20.1
2021	1	20	PCR_FUSION_COV19_E	E Gene CT	26.5
2021	1	20	PCR_FUSION_COV19_E	E Gene CT	26.3
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.91680023
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.10443018
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.16166537
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.23284441

AB1135

2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.66865625
2021	1	20	PCR_COBAS_COV19	CT 2	23
2021	1	20	PCR_COBAS_COV19	CT 2	37.68
2021	1	20	PCR_COBAS_COV19	CT 2	20.54
2021	1	20	PCR_COBAS_COV19	CT 2	33.94
2021	1	20	PCR_COBAS_COV19	CT 2	34.38
2021	1	20	PCR_COBAS_COV19	CT 2	32.14
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.71423696
2021	1	20	PCR_COBAS_COV19	CT 2	31.33
2021	1	20	PCR_COBAS_COV19	CT 2	24.39
2021	1	20	PCR_COBAS_COV19	CT 2	32.68
2021	1	20	PCR_COBAS_COV19	CT 2	21.71
2021	1	20	PCR_COBAS_COV19	CT 2	36.37
2021	1	20	PCR_COBAS_COV19	CT 2	33.71
2021	1	20	PCR_COBAS_COV19	CT 2	24.53
2021	1	20	PCR_COBAS_COV19	CT 2	33.91
2021	1	20	PCR_COBAS_COV19	CT 2	37.34
2021	1	20	PCR_COBAS_COV19	CT 2	20.07
2021	1	20	PCR_COBAS_COV19	CT 2	35.85
2021	1	20	PCR_COBAS_COV19	CT 2	30.52
2021	1	20	PCR_COBAS_COV19	CT 2	33.13
2021	1	20	PCR_COBAS_COV19	CT 2	34.46
2021	1	20	PCR_COBAS_COV19	CT 2	31.41
2021	1	20	PCR_COBAS_COV19	CT 2	33.16
2021	1	20	PCR_COBAS_COV19	CT 2	34.15
2021	1	20	PCR_COBAS_COV19	CT 2	19.28
2021	1	20	PCR_COBAS_COV19	CT 2	32.7
2021	1	20	PCR_COBAS_COV19	CT 2	31.69
2021	1	20	PCR_PANTH_COV19	RLU	1184
2021	1	20	PCR_PANTH_COV19	RLU	1197
2021	1	20	PCR_PANTH_COV19	RLU	1225
2021	1	20	PCR_PANTH_COV19	RLU	1159
2021	1	20	PCR_PANTH_COV19	RLU	1196
2021	1	20	PCR_PANTH_COV19	RLU	1234
2021	1	20	PCR_PANTH_COV19	RLU	1177
2021	1	20	PCR_PANTH_COV19	RLU	1188
2021	1	20	PCR_PANTH_COV19	RLU	1170
2021	1	20	PCR_PANTH_COV19	RLU	1168
2021	1	20	PCR_PANTH_COV19	RLU	1209
2021	1	20	PCR_PANTH_COV19	RLU	1206
2021	1	20	PCR_PANTH_COV19	RLU	1193
2021	1	20	PCR_PANTH_COV19	RLU	1184
2021	1	20	PCR_PANTH_COV19	RLU	1183
2021	1	20	PCR_PANTH_COV19	RLU	1222
2021	1	20	PCR_PANTH_COV19	RLU	1215
2021	1	20	PCR_PANTH_COV19	RLU	1174
2021	1	20	PCR_PANTH_COV19	RLU	1102

AB1136

2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.09385031
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.47721489
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.23873679
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.86294984
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.93166442
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.78650153
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.9456117
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.17031949
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.25757172
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.63115182
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.35157546
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.45365678
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.69121083
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.73068985
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.24071123
2021	1	20	PCR_FUSION_COV19_E	E Gene CT	32.4
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.37350543
2021	1	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.01790666
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.09629227
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	23.3
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	22.6
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.04293669
2021	1	21	PCR_PANTH_COV19	RLU	1265
2021	1	21	PCR_PANTH_COV19	RLU	1184
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.01994452
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.65049297
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.78842934
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	21.2
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.42594533
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	21.1
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	29.2
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.0695484
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.22735256
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	22.6
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.00163035
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.50657545
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	35
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	24.3
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	25.5
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	37.7
2021	1	21	PCR_PANTH_COV19	RLU	1202
2021	1	21	PCR_PANTH_COV19	RLU	1212
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	36.4
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	23.2
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	29.9
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	22.2
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	26.1

AB1137

2021	1	21	PCR_FUSION_COV19_E	E Gene CT	27.7
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	18.2
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	35.1
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	36.1
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	36
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.14704553
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	37.1
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.97620007
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	33
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.46150011
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.80691982
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	23.9
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	36.3
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	34.5
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	32.7
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.23001291
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	27
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.967198
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.0249597
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.17753243
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.16468593
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.34616732
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	23.6
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	33.2
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	24.2
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	32.8
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.40889472
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	23.7
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	37.5
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	20.3
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	16.9
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.57846304
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.3794668
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.19315388
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.28519637
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.08866414
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	29.7
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	19.5
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	21.7
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	19
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	16.5
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	21.3
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	17.1
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	29.3
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	35.2
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	34.7
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	37.6

AB1138

2021	1	21	PCR_FUSION_COV19_E	E Gene CT	19.9
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	24.4
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	19.2
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	36.6
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	29.5
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	23.5
2021	1	21	PCR_FUSION_COV19_E	E Gene CT	34.7
2021	1	21	PCR_COBAS_COV19	CT 2	27.89
2021	1	21	PCR_COBAS_COV19	CT 2	25.34
2021	1	21	PCR_COBAS_COV19	CT 2	22.41
2021	1	21	PCR_COBAS_COV19	CT 2	28.11
2021	1	21	PCR_COBAS_COV19	CT 2	27.14
2021	1	21	PCR_COBAS_COV19	CT 2	26.48
2021	1	21	PCR_COBAS_COV19	CT 2	20.03
2021	1	21	PCR_COBAS_COV19	CT 2	31.68
2021	1	21	PCR_COBAS_COV19	CT 2	35.32
2021	1	21	PCR_COBAS_COV19	CT 2	17.02
2021	1	21	PCR_COBAS_COV19	CT 2	23.39
2021	1	21	PCR_COBAS_COV19	CT 2	26.58
2021	1	21	PCR_COBAS_COV19	CT 2	19.59
2021	1	21	PCR_COBAS_COV19	CT 2	32.51
2021	1	21	PCR_COBAS_COV19	CT 2	15.73
2021	1	21	PCR_COBAS_COV19	CT 2	31.06
2021	1	21	PCR_COBAS_COV19	CT 2	15.61
2021	1	21	PCR_COBAS_COV19	CT 2	21.46
2021	1	21	PCR_COBAS_COV19	CT 2	23.5
2021	1	21	PCR_COBAS_COV19	CT 2	37.23
2021	1	21	PCR_COBAS_COV19	CT 2	14.79
2021	1	21	PCR_COBAS_COV19	CT 2	21.5
2021	1	21	PCR_COBAS_COV19	CT 2	18.2
2021	1	21	PCR_COBAS_COV19	CT 2	33.68
2021	1	21	PCR_COBAS_COV19	CT 2	14.46
2021	1	21	PCR_COBAS_COV19	CT 2	16.54
2021	1	21	PCR_COBAS_COV19	CT 2	31.66
2021	1	21	PCR_COBAS_COV19	CT 2	18.82
2021	1	21	PCR_COBAS_COV19	CT 2	31.18
2021	1	21	PCR_COBAS_COV19	CT 2	33.13
2021	1	21	PCR_COBAS_COV19	CT 2	27.79
2021	1	21	PCR_COBAS_COV19	CT 2	20.77
2021	1	21	PCR_COBAS_COV19	CT 2	18.97
2021	1	21	PCR_COBAS_COV19	CT 2	22.03
2021	1	21	PCR_COBAS_COV19	CT 2	34.09
2021	1	21	PCR_COBAS_COV19	CT 2	25.61
2021	1	21	PCR_COBAS_COV19	CT 2	27.14
2021	1	21	PCR_COBAS_COV19	CT 2	37.94
2021	1	21	PCR_COBAS_COV19	CT 2	36.05
2021	1	21	PCR_COBAS_COV19	CT 2	35.05

2021	1	21	PCR_COBAS_COV19	CT 2	34.38
2021	1	21	PCR_COBAS_COV19	CT 2	32.78
2021	1	21	PCR_COBAS_COV19	CT 2	37.67
2021	1	21	PCR_COBAS_COV19	CT 2	28.7
2021	1	21	PCR_COBAS_COV19	CT 2	35.42
2021	1	21	PCR_COBAS_COV19	CT 2	20.79
2021	1	21	PCR_PANTH_COV19	RLU	1153
2021	1	21	PCR_PANTH_COV19	RLU	1172
2021	1	21	PCR_PANTH_COV19	RLU	1165
2021	1	21	PCR_PANTH_COV19	RLU	1203
2021	1	21	PCR_PANTH_COV19	RLU	1157
2021	1	21	PCR_PANTH_COV19	RLU	1138
2021	1	21	PCR_PANTH_COV19	RLU	1166
2021	1	21	PCR_PANTH_COV19	RLU	1170
2021	1	21	PCR_PANTH_COV19	RLU	1145
2021	1	21	PCR_PANTH_COV19	RLU	1132
2021	1	21	PCR_PANTH_COV19	RLU	1137
2021	1	21	PCR_PANTH_COV19	RLU	1207
2021	1	21	PCR_PANTH_COV19	RLU	1159
2021	1	21	PCR_PANTH_COV19	RLU	1202
2021	1	21	PCR_PANTH_COV19	RLU	1224
2021	1	21	PCR_PANTH_COV19	RLU	1085
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.08281544
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.2371171
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.94059979
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.40555497
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.1356929
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.57149602
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.37642779
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.7867677
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.7411021
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.9561026
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.64460639
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.90685302
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.69618316
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.12471083
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.41526672
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.41666311
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.70662613
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.60310474
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.08977735
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.57036371
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.82359831
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.79209724
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.61678608
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.22768918
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.35703911

2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.03730724
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.00362086
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.22138801
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.10825445
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.33288683
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.53259092
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.30646781
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.75995349
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.26982306
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.16257142
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.84326134
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.35590908
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.51250463
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.3563881
2021	1	21	PCR_PANTH_COV19	RLU	1173
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.95728596
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.55284783
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.63772284
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.63530727
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.17539817
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.04874479
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.62816299
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.09791026
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.56722034
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.77247555
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.05131493
2021	1	21	PCR_PANTH_COV19	RLU	1157
2021	1	21	PCR_PANTH_COV19	RLU	1154
2021	1	21	PCR_PANTH_COV19	RLU	1142
2021	1	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.05934484
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.97349483
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.73410656
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.92566671
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	39.4688531
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.94968649
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.87235386
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.7858411
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.15362111
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.12293232
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.12420395
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.5526964
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.96734869
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.11102018
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.49779733
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.35794435
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.49094615
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.11462379

AB1141

2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.58850395
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.94495881
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.01518798
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.92481779
2021	1	22	PCR_PANTH_COV19	RLU	1188
2021	1	22	PCR_PANTH_COV19	RLU	1159
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.23624966
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.54954668
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.06312094
2021	1	22	PCR_PANTH_COV19	RLU	1143
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.27065792
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.19437448
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.54312903
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.09828969
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.29785851
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.88434598
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.25731868
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.78502172
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.04949158
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.40008308
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.81117864
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.89371524
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.27434983
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.17656279
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.68694824
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.48141019
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.95862161
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	34.6
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.13127897
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	26.4
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	32.8
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	28.7
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	28
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	19.1
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.17398481
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	35.1
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	18.6
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	24.1
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	25.3
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.61624159
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	25
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	23.3
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	27.6
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	22
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	17.6
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	34.1
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	24.9

AB1142

2021	1	22	PCR_FUSION_COV19_E	E Gene CT	36
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	33
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	23.3
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	24.1
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	19.5
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	21.6
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	15.1
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	26.3
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	37.2
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	31.5
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	35.7
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	19.2
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.11821843
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.38944981
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.24756217
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.15572604
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.35091986
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	34.1
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	29
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	19.5
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.33380255
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	34.5
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	20.8
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	20
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	21.6
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.7481141
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.17251741
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	26.8
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	30.4
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	16.9
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	24.8
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	24.2
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.35606745
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.18319636
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.09054893
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.72063097
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.86913877
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	24
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	16.9
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	19.4
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	15.5
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	28.6
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	33.2
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	24.1
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.87790088
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.20286216
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.69615731

AB1143

2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.79838
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.10675122
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.71687888
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.19407034
2021	1	22	PCR_COBAS_COV19	CT 2	35.94
2021	1	22	PCR_COBAS_COV19	CT 2	35.98
2021	1	22	PCR_COBAS_COV19	CT 2	37.91
2021	1	22	PCR_COBAS_COV19	CT 2	32.16
2021	1	22	PCR_COBAS_COV19	CT 2	31.93
2021	1	22	PCR_COBAS_COV19	CT 2	35.11
2021	1	22	PCR_COBAS_COV19	CT 2	28.74
2021	1	22	PCR_COBAS_COV19	CT 2	32.77
2021	1	22	PCR_COBAS_COV19	CT 2	31.39
2021	1	22	PCR_COBAS_COV19	CT 2	15.14
2021	1	22	PCR_COBAS_COV19	CT 2	25.09
2021	1	22	PCR_COBAS_COV19	CT 2	26.39
2021	1	22	PCR_COBAS_COV19	CT 2	20.29
2021	1	22	PCR_COBAS_COV19	CT 2	36.26
2021	1	22	PCR_COBAS_COV19	CT 2	20.85
2021	1	22	PCR_COBAS_COV19	CT 2	19.88
2021	1	22	PCR_COBAS_COV19	CT 2	18.38
2021	1	22	PCR_COBAS_COV19	CT 2	35.94
2021	1	22	PCR_COBAS_COV19	CT 2	28.43
2021	1	22	PCR_COBAS_COV19	CT 2	36.57
2021	1	22	PCR_COBAS_COV19	CT 2	19.92
2021	1	22	PCR_COBAS_COV19	CT 2	27.23
2021	1	22	PCR_COBAS_COV19	CT 2	29.69
2021	1	22	PCR_COBAS_COV19	CT 2	31.99
2021	1	22	PCR_COBAS_COV19	CT 2	17.29
2021	1	22	PCR_COBAS_COV19	CT 2	27.41
2021	1	22	PCR_COBAS_COV19	CT 2	20.92
2021	1	22	PCR_COBAS_COV19	CT 2	20.13
2021	1	22	PCR_COBAS_COV19	CT 2	17.76
2021	1	22	PCR_COBAS_COV19	CT 2	37.35
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	20.3
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	30.2
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	29.6
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	23.2
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	18.2
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	32.4
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	36.1
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.46161345
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.68807919
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.53589332
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.13072979
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.22386156
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.53838648

AB1144

2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.7691603
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.5316105
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.44325601
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	26
2021	1	22	PCR_FUSION_COV19_E	E Gene CT	33.9
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.42799047
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.04875339
2021	1	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.45941113
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.69575507
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.2462127
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.45628277
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.26982488
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.63123738
2021	1	23	PCR_FUSION_COV19_E	E Gene CT	36.2
2021	1	23	PCR_FUSION_COV19_E	E Gene CT	35.5
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.68902487
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.51622055
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.90062718
2021	1	23	PCR_FUSION_COV19_E	E Gene CT	24.3
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.27863992
2021	1	23	PCR_FUSION_COV19_E	E Gene CT	17.6
2021	1	23	PCR_FUSION_COV19_E	E Gene CT	37.4
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.93333878
2021	1	23	PCR_FUSION_COV19_E	E Gene CT	31.6
2021	1	23	PCR_FUSION_COV19_E	E Gene CT	21.2
2021	1	23	PCR_FUSION_COV19_E	E Gene CT	36.9
2021	1	23	PCR_FUSION_COV19_E	E Gene CT	34.6
2021	1	23	PCR_COBAS_COV19	CT 2	31.1
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.19205374
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.47957509
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.01873144
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.82168433
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.88267121
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.08482236
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.57056417
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.7589448
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.15868099
2021	1	23	PCR_FUSION_COV19_E	E Gene CT	22
2021	1	23	PCR_FUSION_COV19_E	E Gene CT	27
2021	1	23	PCR_FUSION_COV19_E	E Gene CT	26.3
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.92813704
2021	1	23	PCR_FUSION_COV19_E	E Gene CT	27.2
2021	1	23	PCR_FUSION_COV19_E	E Gene CT	25.9
2021	1	23	PCR_FUSION_COV19_E	E Gene CT	35
2021	1	23	PCR_FUSION_COV19_E	E Gene CT	37.4
2021	1	23	PCR_FUSION_COV19_E	E Gene CT	26.4
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.09519332

2021	1	23	PCR_FUSION_COV19_E	E Gene CT	36.1
2021	1	23	PCR_FUSION_COV19_E	E Gene CT	29.8
2021	1	23	PCR_FUSION_COV19_E	E Gene CT	32.1
2021	1	23	PCR_FUSION_COV19_E	E Gene CT	31
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.58628247
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.75729781
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.58950597
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.40056635
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.43588867
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.68352188
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.18058545
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.39532164
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.74278704
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.24309898
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.0694626
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.39596052
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.39198874
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.06780532
2021	1	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.68581249
2021	1	23	PCR_COBAS_COV19	CT 2	28.66
2021	1	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.26855059
2021	1	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.47569602
2021	1	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.38401417
2021	1	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.85128297
2021	1	24	PCR_FUSION_COV19_E	E Gene CT	21.4
2021	1	24	PCR_FUSION_COV19_E	E Gene CT	20.4
2021	1	24	PCR_FUSION_COV19_E	E Gene CT	29.1
2021	1	24	PCR_FUSION_COV19_E	E Gene CT	28.1
2021	1	24	PCR_FUSION_COV19_E	E Gene CT	21.9
2021	1	24	PCR_COBAS_COV19	CT 2	20.72
2021	1	24	PCR_COBAS_COV19	CT 2	18.92
2021	1	24	PCR_COBAS_COV19	CT 2	20.55
2021	1	24	PCR_COBAS_COV19	CT 2	20.15
2021	1	24	PCR_COBAS_COV19	CT 2	32.74
2021	1	24	PCR_COBAS_COV19	CT 2	19.75
2021	1	24	PCR_COBAS_COV19	CT 2	29.91
2021	1	24	PCR_COBAS_COV19	CT 2	31.58
2021	1	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.12077669
2021	1	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.57255752
2021	1	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.39402678
2021	1	24	PCR_COBAS_COV19	CT 2	30.48
2021	1	24	PCR_COBAS_COV19	CT 2	33.16
2021	1	24	PCR_COBAS_COV19	CT 2	17.96
2021	1	24	PCR_COBAS_COV19	CT 2	16.6
2021	1	24	PCR_PANTH_COV19	RLU	1120
2021	1	24	PCR_PANTH_COV19	RLU	1080
2021	1	24	PCR_COBAS_COV19	CT 2	36.53

AB1146

2021	1	24	PCR_COBAS_COV19	CT 2	33.93
2021	1	24	PCR_COBAS_COV19	CT 2	24.98
2021	1	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.96687821
2021	1	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.40575912
2021	1	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.19541127
2021	1	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.42194189
2021	1	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.75391451
2021	1	24	PCR_PANTH_COV19	RLU	1146
2021	1	24	PCR_PANTH_COV19	RLU	1157
2021	1	24	PCR_PANTH_COV19	RLU	1141
2021	1	24	PCR_PANTH_COV19	RLU	1178
2021	1	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.29126909
2021	1	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.61526441
2021	1	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.15797208
2021	1	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.931447
2021	1	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.13684651
2021	1	25	PCR_COBAS_COV19	CT 2	17.41
2021	1	25	PCR_COBAS_COV19	CT 2	23.43
2021	1	25	PCR_COBAS_COV19	CT 2	36.35
2021	1	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.03516848
2021	1	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.41294732
2021	1	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.50701226
2021	1	25	PCR_COBAS_COV19	CT 2	34.74
2021	1	25	PCR_COBAS_COV19	CT 2	18.96
2021	1	25	PCR_COBAS_COV19	CT 2	32.79
2021	1	25	PCR_COBAS_COV19	CT 2	35.93
2021	1	25	PCR_COBAS_COV19	CT 2	26.2
2021	1	25	PCR_PANTH_COV19	RLU	1187
2021	1	25	PCR_PANTH_COV19	RLU	1078
2021	1	25	PCR_PANTH_COV19	RLU	1144
2021	1	25	PCR_PANTH_COV19	RLU	1143
2021	1	25	PCR_PANTH_COV19	RLU	1152
2021	1	25	PCR_COBAS_COV19	CT 2	20.68
2021	1	25	PCR_COBAS_COV19	CT 2	36.23
2021	1	25	PCR_COBAS_COV19	CT 2	27.12
2021	1	25	PCR_COBAS_COV19	CT 2	24.36
2021	1	25	PCR_COBAS_COV19	CT 2	13.89
2021	1	25	PCR_COBAS_COV19	CT 2	30.39
2021	1	25	PCR_COBAS_COV19	CT 2	24.74
2021	1	25	PCR_COBAS_COV19	CT 2	31.87
2021	1	25	PCR_COBAS_COV19	CT 2	19.16
2021	1	25	PCR_COBAS_COV19	CT 2	23
2021	1	25	PCR_COBAS_COV19	CT 2	20.56
2021	1	25	PCR_COBAS_COV19	CT 2	16.79
2021	1	25	PCR_COBAS_COV19	CT 2	35.05
2021	1	25	PCR_COBAS_COV19	CT 2	16.37
2021	1	25	PCR_COBAS_COV19	CT 2	33.83

AB1147

2021	1	25	PCR_PANTH_COV19	RLU	1162
2021	1	25	PCR_PANTH_COV19	RLU	1147
2021	1	25	PCR_PANTH_COV19	RLU	1098
2021	1	25	PCR_PANTH_COV19	RLU	1167
2021	1	25	PCR_PANTH_COV19	RLU	1183
2021	1	25	PCR_PANTH_COV19	RLU	1136
2021	1	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.70986252
2021	1	25	PCR_PANTH_COV19	RLU	1169
2021	1	25	PCR_PANTH_COV19	RLU	1151
2021	1	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.73418312
2021	1	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.64784738
2021	1	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.66773102
2021	1	25	PCR_PANTH_COV19	RLU	1106
2021	1	25	PCR_PANTH_COV19	RLU	1173
2021	1	25	PCR_PANTH_COV19	RLU	1152
2021	1	25	PCR_PANTH_COV19	RLU	1192
2021	1	25	PCR_PANTH_COV19	RLU	1154
2021	1	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.29293914
2021	1	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.88064094
2021	1	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.38094726
2021	1	25	PCR_PANTH_COV19	RLU	1186
2021	1	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	39.71694114
2021	1	25	PCR_FUSION_COV19_E	E Gene CT	37.1
2021	1	25	PCR_FUSION_COV19_E	E Gene CT	31
2021	1	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.98760494
2021	1	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.11270113
2021	1	25	PCR_COBAS_COV19	CT 2	20.45
2021	1	25	PCR_COBAS_COV19	CT 2	23.02
2021	1	25	PCR_COBAS_COV19	CT 2	37.42
2021	1	25	PCR_COBAS_COV19	CT 2	28.4
2021	1	25	PCR_PANTH_COV19	RLU	1122
2021	1	25	PCR_PANTH_COV19	RLU	1120
2021	1	25	PCR_PANTH_COV19	RLU	1167
2021	1	25	PCR_PANTH_COV19	RLU	1110
2021	1	25	PCR_PANTH_COV19	RLU	1094
2021	1	25	PCR_PANTH_COV19	RLU	1132
2021	1	25	PCR_PANTH_COV19	RLU	1117
2021	1	25	PCR_PANTH_COV19	RLU	1147
2021	1	25	PCR_PANTH_COV19	RLU	1102
2021	1	25	PCR_PANTH_COV19	RLU	1126
2021	1	25	PCR_PANTH_COV19	RLU	1110
2021	1	25	PCR_PANTH_COV19	RLU	1152
2021	1	25	PCR_COBAS_COV19	CT 2	20.03
2021	1	25	PCR_COBAS_COV19	CT 2	28.04
2021	1	25	PCR_COBAS_COV19	CT 2	33.76
2021	1	25	PCR_COBAS_COV19	CT 2	22.83
2021	1	25	PCR_COBAS_COV19	CT 2	17.97

AB1148

2021	1	25	PCR_COBAS_COV19	CT 2	35.5
2021	1	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.24232244
2021	1	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.39897543
2021	1	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.1535011
2021	1	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.25893586
2021	1	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.79388594
2021	1	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.5964612
2021	1	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.75707527
2021	1	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.98164792
2021	1	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.15555103
2021	1	26	PCR_COBAS_COV19	CT 2	30.22
2021	1	26	PCR_COBAS_COV19	CT 2	25.83
2021	1	26	PCR_COBAS_COV19	CT 2	32.32
2021	1	26	PCR_COBAS_COV19	CT 2	34.29
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.34742705
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.21016088
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.1709453
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.43083855
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.94917774
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.26794424
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.46623993
2021	1	26	PCR_PANTH_COV19	RLU	1108
2021	1	26	PCR_PANTH_COV19	RLU	1132
2021	1	26	PCR_PANTH_COV19	RLU	1128
2021	1	26	PCR_PANTH_COV19	RLU	1077
2021	1	26	PCR_PANTH_COV19	RLU	1098
2021	1	26	PCR_PANTH_COV19	RLU	1107
2021	1	26	PCR_PANTH_COV19	RLU	1083
2021	1	26	PCR_PANTH_COV19	RLU	1146
2021	1	26	PCR_PANTH_COV19	RLU	1109
2021	1	26	PCR_PANTH_COV19	RLU	1083
2021	1	26	PCR_PANTH_COV19	RLU	1152
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.85986928
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.84789997
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.38698629
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.74061188
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.83070597
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.35225214
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.12032562
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.70371261
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.20458353
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.31756248
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.5324281
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.04400101
2021	1	26	PCR_PANTH_COV19	RLU	1090
2021	1	26	PCR_PANTH_COV19	RLU	1150
2021	1	26	PCR_PANTH_COV19	RLU	1105

AB1149

2021	1	26	PCR_PANTH_COV19	RLU	1101
2021	1	26	PCR_PANTH_COV19	RLU	1119
2021	1	26	PCR_PANTH_COV19	RLU	1080
2021	1	26	PCR_PANTH_COV19	RLU	1102
2021	1	26	PCR_PANTH_COV19	RLU	1134
2021	1	26	PCR_PANTH_COV19	RLU	1147
2021	1	26	PCR_PANTH_COV19	RLU	1138
2021	1	26	PCR_PANTH_COV19	RLU	1090
2021	1	26	PCR_PANTH_COV19	RLU	1107
2021	1	26	PCR_PANTH_COV19	RLU	1108
2021	1	26	PCR_PANTH_COV19	RLU	1134
2021	1	26	PCR_PANTH_COV19	RLU	1115
2021	1	26	PCR_PANTH_COV19	RLU	1135
2021	1	26	PCR_PANTH_COV19	RLU	1138
2021	1	26	PCR_FUSION_COV19_E	E Gene CT	33.8
2021	1	26	PCR_FUSION_COV19_E	E Gene CT	30.3
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.2335307
2021	1	26	PCR_FUSION_COV19_E	E Gene CT	32.7
2021	1	26	PCR_FUSION_COV19_E	E Gene CT	29.6
2021	1	26	PCR_FUSION_COV19_E	E Gene CT	21.4
2021	1	26	PCR_FUSION_COV19_E	E Gene CT	19.2
2021	1	26	PCR_FUSION_COV19_E	E Gene CT	35
2021	1	26	PCR_FUSION_COV19_E	E Gene CT	32.5
2021	1	26	PCR_FUSION_COV19_E	E Gene CT	19.7
2021	1	26	PCR_FUSION_COV19_E	E Gene CT	21.1
2021	1	26	PCR_FUSION_COV19_E	E Gene CT	33.6
2021	1	26	PCR_FUSION_COV19_E	E Gene CT	16
2021	1	26	PCR_FUSION_COV19_E	E Gene CT	26.6
2021	1	26	PCR_FUSION_COV19_E	E Gene CT	34.5
2021	1	26	PCR_FUSION_COV19_E	E Gene CT	23.6
2021	1	26	PCR_FUSION_COV19_E	E Gene CT	26.5
2021	1	26	PCR_FUSION_COV19_E	E Gene CT	32.5
2021	1	26	PCR_FUSION_COV19_E	E Gene CT	24.4
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	39.76181313
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.62207213
2021	1	26	PCR_FUSION_COV19_E	E Gene CT	15.3
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.35495038
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.12263674
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.93486235
2021	1	26	PCR_FUSION_COV19_E	E Gene CT	26.2
2021	1	26	PCR_FUSION_COV19_E	E Gene CT	22
2021	1	26	PCR_PANTH_COV19	RLU	1102
2021	1	26	PCR_PANTH_COV19	RLU	1128
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.75646806
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.47000105
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.02842908
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.0831237

AB1150

2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.32099034
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.98425759
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	10.05837747
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.53217122
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.96884133
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.55760472
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.0372249
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.14080708
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.07556907
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.51187488
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.57257486
2021	1	26	PCR_FUSION_COV19_E	E Gene CT	21
2021	1	26	PCR_COBAS_COV19	CT 2	18.75
2021	1	26	PCR_COBAS_COV19	CT 2	35.98
2021	1	26	PCR_COBAS_COV19	CT 2	33.6
2021	1	26	PCR_COBAS_COV19	CT 2	36.31
2021	1	26	PCR_COBAS_COV19	CT 2	35.95
2021	1	26	PCR_COBAS_COV19	CT 2	37.42
2021	1	26	PCR_COBAS_COV19	CT 2	32.4
2021	1	26	PCR_COBAS_COV19	CT 2	32.74
2021	1	26	PCR_COBAS_COV19	CT 2	22.6
2021	1	26	PCR_COBAS_COV19	CT 2	35.19
2021	1	26	PCR_COBAS_COV19	CT 2	28.54
2021	1	26	PCR_COBAS_COV19	CT 2	31
2021	1	26	PCR_COBAS_COV19	CT 2	33.61
2021	1	26	PCR_COBAS_COV19	CT 2	30.13
2021	1	26	PCR_PANTH_COV19	RLU	1079
2021	1	26	PCR_PANTH_COV19	RLU	1155
2021	1	26	PCR_PANTH_COV19	RLU	1231
2021	1	26	PCR_PANTH_COV19	RLU	1185
2021	1	26	PCR_PANTH_COV19	RLU	1024
2021	1	26	PCR_PANTH_COV19	RLU	1108
2021	1	26	PCR_PANTH_COV19	RLU	1115
2021	1	26	PCR_PANTH_COV19	RLU	1140
2021	1	26	PCR_PANTH_COV19	RLU	1084
2021	1	26	PCR_PANTH_COV19	RLU	1169
2021	1	26	PCR_PANTH_COV19	RLU	1126
2021	1	26	PCR_PANTH_COV19	RLU	1120
2021	1	26	PCR_PANTH_COV19	RLU	1146
2021	1	26	PCR_PANTH_COV19	RLU	1249
2021	1	26	PCR_PANTH_COV19	RLU	1150
2021	1	26	PCR_PANTH_COV19	RLU	1116
2021	1	26	PCR_PANTH_COV19	RLU	1153
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.71287636
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.35285168
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.40893678
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.40203278

2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.51664602
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.60088362
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.1784089
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.25114323
2021	1	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.36651356
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.27566632
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.59721462
2021	1	27	PCR_PANTH_COV19	RLU	1162
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.388817
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.58652817
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.44020333
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.60433481
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.77311208
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.30165353
2021	1	27	PCR_PANTH_COV19	RLU	1137
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.54606692
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.00939307
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.86175375
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	36.3
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	27.4
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	21
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	19.2
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	18
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	18.2
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	27
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	24.6
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.80214895
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.09656449
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	27.2
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	27
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	18.7
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	22.2
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	35.5
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.14285692
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	17.8
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.10554349
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.32330772
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	26.7
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	32.2
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.83600688
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	32.5
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	37
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	37.2
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	29.1
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.17684944
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.21381857
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.54501972

AB1152

2021	1	27	PCR_FUSION_COV19_E	E Gene CT	23.9
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	24.1
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	29.3
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.52361049
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.35801076
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.53609381
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.06220291
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.3144752
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	28.8
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	31.4
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	19.1
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	29.1
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.54169013
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	33.3
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	25.1
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	25
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	35.4
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	20.2
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	24.3
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	20.7
2021	1	27	PCR_FUSION_COV19_E	E Gene CT	21.5
2021	1	27	PCR_COBAS_COV19	CT 2	33.64
2021	1	27	PCR_COBAS_COV19	CT 2	22.86
2021	1	27	PCR_COBAS_COV19	CT 2	29.73
2021	1	27	PCR_COBAS_COV19	CT 2	22.41
2021	1	27	PCR_COBAS_COV19	CT 2	30.69
2021	1	27	PCR_COBAS_COV19	CT 2	18.64
2021	1	27	PCR_COBAS_COV19	CT 2	34.49
2021	1	27	PCR_COBAS_COV19	CT 2	25.17
2021	1	27	PCR_PANTH_COV19	RLU	1126
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.55278958
2021	1	27	PCR_PANTH_COV19	RLU	1139
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.70613785
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.22375048
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.00129339
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.5728084
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.53778475
2021	1	27	PCR_COBAS_COV19	CT 2	37.05
2021	1	27	PCR_COBAS_COV19	CT 2	29.05
2021	1	27	PCR_COBAS_COV19	CT 2	17.8
2021	1	27	PCR_COBAS_COV19	CT 2	25.06
2021	1	27	PCR_COBAS_COV19	CT 2	34.55
2021	1	27	PCR_COBAS_COV19	CT 2	20.04
2021	1	27	PCR_COBAS_COV19	CT 2	24.48
2021	1	27	PCR_COBAS_COV19	CT 2	33.31
2021	1	27	PCR_COBAS_COV19	CT 2	35.46
2021	1	27	PCR_COBAS_COV19	CT 2	35.6

AB1153

2021	1	27	PCR_COBAS_COV19	CT 2	35.75
2021	1	27	PCR_COBAS_COV19	CT 2	32.96
2021	1	27	PCR_COBAS_COV19	CT 2	33.14
2021	1	27	PCR_COBAS_COV19	CT 2	29.63
2021	1	27	PCR_COBAS_COV19	CT 2	37.65
2021	1	27	PCR_COBAS_COV19	CT 2	37.82
2021	1	27	PCR_PANTH_COV19	RLU	1118
2021	1	27	PCR_PANTH_COV19	RLU	1129
2021	1	27	PCR_PANTH_COV19	RLU	1115
2021	1	27	PCR_PANTH_COV19	RLU	1159
2021	1	27	PCR_PANTH_COV19	RLU	1151
2021	1	27	PCR_PANTH_COV19	RLU	1126
2021	1	27	PCR_PANTH_COV19	RLU	1154
2021	1	27	PCR_PANTH_COV19	RLU	1149
2021	1	27	PCR_PANTH_COV19	RLU	1148
2021	1	27	PCR_PANTH_COV19	RLU	1151
2021	1	27	PCR_PANTH_COV19	RLU	1116
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.70285662
2021	1	27	PCR_PANTH_COV19	RLU	1175
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.26928601
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.21693641
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.6871711
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.59095824
2021	1	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.08626013
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.94419856
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.86354971
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	39.35059419
2021	1	28	PCR_PANTH_COV19	RLU	1096
2021	1	28	PCR_PANTH_COV19	RLU	1161
2021	1	28	PCR_PANTH_COV19	RLU	1112
2021	1	28	PCR_PANTH_COV19	RLU	1031
2021	1	28	PCR_PANTH_COV19	RLU	1191
2021	1	28	PCR_PANTH_COV19	RLU	1194
2021	1	28	PCR_PANTH_COV19	RLU	1149
2021	1	28	PCR_PANTH_COV19	RLU	1158
2021	1	28	PCR_PANTH_COV19	RLU	1158
2021	1	28	PCR_PANTH_COV19	RLU	1170
2021	1	28	PCR_PANTH_COV19	RLU	1146
2021	1	28	PCR_PANTH_COV19	RLU	1114
2021	1	28	PCR_FUSION_COV19_E	E Gene CT	23.5
2021	1	28	PCR_FUSION_COV19_E	E Gene CT	29.7
2021	1	28	PCR_FUSION_COV19_E	E Gene CT	27.8
2021	1	28	PCR_PANTH_COV19	RLU	1121
2021	1	28	PCR_PANTH_COV19	RLU	1113
2021	1	28	PCR_PANTH_COV19	RLU	1196
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.16772836
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.56475821

AB1154

2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.98546485
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.6147204
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.98841681
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.21923072
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.77632164
2021	1	28	PCR_FUSION_COV19_E	E Gene CT	23.1
2021	1	28	PCR_FUSION_COV19_E	E Gene CT	22.5
2021	1	28	PCR_FUSION_COV19_E	E Gene CT	26.1
2021	1	28	PCR_FUSION_COV19_E	E Gene CT	33
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.29135034
2021	1	28	PCR_FUSION_COV19_E	E Gene CT	22.7
2021	1	28	PCR_FUSION_COV19_E	E Gene CT	26.4
2021	1	28	PCR_FUSION_COV19_E	E Gene CT	38
2021	1	28	PCR_FUSION_COV19_E	E Gene CT	35.9
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.02321221
2021	1	28	PCR_FUSION_COV19_E	E Gene CT	35.4
2021	1	28	PCR_FUSION_COV19_E	E Gene CT	21.5
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.26731616
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.06126248
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.52597341
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.62750194
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.3189434
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.7918781
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.11412797
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.00360264
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.33584165
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.36203978
2021	1	28	PCR_FUSION_COV19_E	E Gene CT	26.7
2021	1	28	PCR_FUSION_COV19_E	E Gene CT	33.3
2021	1	28	PCR_FUSION_COV19_E	E Gene CT	28.2
2021	1	28	PCR_FUSION_COV19_E	E Gene CT	31.2
2021	1	28	PCR_FUSION_COV19_E	E Gene CT	20.3
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.94698084
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.87219229
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.01850285
2021	1	28	PCR_FUSION_COV19_E	E Gene CT	35.9
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.45055785
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.04093459
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.05065394
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.25848086
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.39594289
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.17502477
2021	1	28	PCR_COBAS_COV19	CT 2	18.83
2021	1	28	PCR_COBAS_COV19	CT 2	28.11
2021	1	28	PCR_COBAS_COV19	CT 2	34.63
2021	1	28	PCR_COBAS_COV19	CT 2	26.51
2021	1	28	PCR_COBAS_COV19	CT 2	31.4

AB1155

2021	1	28	PCR_COBAS_COV19	CT 2	16.13
2021	1	28	PCR_COBAS_COV19	CT 2	18.65
2021	1	28	PCR_COBAS_COV19	CT 2	22.67
2021	1	28	PCR_PANTH_COV19	RLU	1193
2021	1	28	PCR_PANTH_COV19	RLU	1157
2021	1	28	PCR_PANTH_COV19	RLU	1179
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.20307734
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.2423203
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.23762431
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.04723507
2021	1	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.93746563
2021	1	29	PCR_PANTH_COV19	RLU	1131
2021	1	29	PCR_PANTH_COV19	RLU	1217
2021	1	29	PCR_PANTH_COV19	RLU	1185
2021	1	29	PCR_PANTH_COV19	RLU	1170
2021	1	29	PCR_PANTH_COV19	RLU	1226
2021	1	29	PCR_PANTH_COV19	RLU	1133
2021	1	29	PCR_PANTH_COV19	RLU	1142
2021	1	29	PCR_PANTH_COV19	RLU	1179
2021	1	29	PCR_PANTH_COV19	RLU	1188
2021	1	29	PCR_PANTH_COV19	RLU	1207
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.19812308
2021	1	29	PCR_PANTH_COV19	RLU	1144
2021	1	29	PCR_PANTH_COV19	RLU	1150
2021	1	29	PCR_PANTH_COV19	RLU	1182
2021	1	29	PCR_PANTH_COV19	RLU	1150
2021	1	29	PCR_PANTH_COV19	RLU	1202
2021	1	29	PCR_PANTH_COV19	RLU	1166
2021	1	29	PCR_PANTH_COV19	RLU	1171
2021	1	29	PCR_PANTH_COV19	RLU	1182
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.31704894
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.36173736
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.34826361
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.53793046
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.26035671
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.48873464
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.13627645
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.6370201
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.66981017
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.31419486
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.03424581
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.68303124
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.34116743
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.12156453
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.24356922
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.51345004
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.02650886

AB1156

2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.89138541
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.54831609
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.76448913
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.34662028
2021	1	29	PCR_PANTH_COV19	RLU	1174
2021	1	29	PCR_PANTH_COV19	RLU	1183
2021	1	29	PCR_PANTH_COV19	RLU	1197
2021	1	29	PCR_PANTH_COV19	RLU	1192
2021	1	29	PCR_PANTH_COV19	RLU	1150
2021	1	29	PCR_PANTH_COV19	RLU	1162
2021	1	29	PCR_PANTH_COV19	RLU	1211
2021	1	29	PCR_PANTH_COV19	RLU	1151
2021	1	29	PCR_PANTH_COV19	RLU	1171
2021	1	29	PCR_PANTH_COV19	RLU	1158
2021	1	29	PCR_PANTH_COV19	RLU	1149
2021	1	29	PCR_PANTH_COV19	RLU	1179
2021	1	29	PCR_PANTH_COV19	RLU	1171
2021	1	29	PCR_PANTH_COV19	RLU	1186
2021	1	29	PCR_PANTH_COV19	RLU	1165
2021	1	29	PCR_PANTH_COV19	RLU	1139
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.07569658
2021	1	29	PCR_PANTH_COV19	RLU	1151
2021	1	29	PCR_PANTH_COV19	RLU	1161
2021	1	29	PCR_PANTH_COV19	RLU	1133
2021	1	29	PCR_PANTH_COV19	RLU	1157
2021	1	29	PCR_PANTH_COV19	RLU	1141
2021	1	29	PCR_PANTH_COV19	RLU	1162
2021	1	29	PCR_FUSION_COV19_E	E Gene CT	36.5
2021	1	29	PCR_FUSION_COV19_E	E Gene CT	28.4
2021	1	29	PCR_FUSION_COV19_E	E Gene CT	26.6
2021	1	29	PCR_FUSION_COV19_E	E Gene CT	23.1
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.50022103
2021	1	29	PCR_FUSION_COV19_E	E Gene CT	18.5
2021	1	29	PCR_FUSION_COV19_E	E Gene CT	26
2021	1	29	PCR_FUSION_COV19_E	E Gene CT	30.3
2021	1	29	PCR_FUSION_COV19_E	E Gene CT	19.4
2021	1	29	PCR_FUSION_COV19_E	E Gene CT	26.7
2021	1	29	PCR_FUSION_COV19_E	E Gene CT	19.3
2021	1	29	PCR_FUSION_COV19_E	E Gene CT	25.3
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.40863656
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.56174674
2021	1	29	PCR_FUSION_COV19_E	E Gene CT	29.6
2021	1	29	PCR_COBAS_COV19	CT 2	34.18
2021	1	29	PCR_COBAS_COV19	CT 2	34.32
2021	1	29	PCR_COBAS_COV19	CT 2	28.7
2021	1	29	PCR_COBAS_COV19	CT 2	24.56
2021	1	29	PCR_COBAS_COV19	CT 2	35.63

AB1157

2021	1	29	PCR_COBAS_COV19	CT 2	35.72
2021	1	29	PCR_COBAS_COV19	CT 2	19.98
2021	1	29	PCR_COBAS_COV19	CT 2	25.33
2021	1	29	PCR_COBAS_COV19	CT 2	22.59
2021	1	29	PCR_COBAS_COV19	CT 2	36.69
2021	1	29	PCR_COBAS_COV19	CT 2	15.73
2021	1	29	PCR_COBAS_COV19	CT 2	34.54
2021	1	29	PCR_COBAS_COV19	CT 2	36.89
2021	1	29	PCR_COBAS_COV19	CT 2	35.76
2021	1	29	PCR_FUSION_COV19_E	E Gene CT	21.1
2021	1	29	PCR_FUSION_COV19_E	E Gene CT	36.7
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.13537522
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.87384069
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.10801206
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.82697873
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.67628888
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.77450361
2021	1	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.05351138
2021	1	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.94165267
2021	1	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.97305243
2021	1	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.28447263
2021	1	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	10.18511727
2021	1	30	PCR_FUSION_COV19_E	E Gene CT	25.6
2021	1	30	PCR_FUSION_COV19_E	E Gene CT	18.3
2021	1	30	PCR_FUSION_COV19_E	E Gene CT	26
2021	1	30	PCR_FUSION_COV19_E	E Gene CT	28.7
2021	1	30	PCR_FUSION_COV19_E	E Gene CT	26.9
2021	1	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.07448432
2021	1	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.18967159
2021	1	30	PCR_FUSION_COV19_E	E Gene CT	32.1
2021	1	30	PCR_FUSION_COV19_E	E Gene CT	32.5
2021	1	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.97747609
2021	1	30	PCR_FUSION_COV19_E	E Gene CT	28.3
2021	1	30	PCR_FUSION_COV19_E	E Gene CT	28.3
2021	1	30	PCR_FUSION_COV19_E	E Gene CT	37.2
2021	1	30	PCR_FUSION_COV19_E	E Gene CT	23.8
2021	1	30	PCR_FUSION_COV19_E	E Gene CT	24.6
2021	1	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.98959081
2021	1	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.5590669
2021	1	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.52595483
2021	1	30	PCR_FUSION_COV19_E	E Gene CT	36.8
2021	1	30	PCR_FUSION_COV19_E	E Gene CT	26.8
2021	1	30	PCR_FUSION_COV19_E	E Gene CT	25.6
2021	1	30	PCR_FUSION_COV19_E	E Gene CT	32.2
2021	1	30	PCR_FUSION_COV19_E	E Gene CT	35.3
2021	1	30	PCR_FUSION_COV19_E	E Gene CT	22.1
2021	1	30	PCR_FUSION_COV19_E	E Gene CT	35.4

AB1158

2021	1	30	PCR_FUSION_COV19_E	E Gene CT	26.1
2021	1	30	PCR_FUSION_COV19_E	E Gene CT	37.7
2021	1	30	PCR_FUSION_COV19_E	E Gene CT	34.2
2021	1	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.26934993
2021	1	30	PCR_FUSION_COV19_E	E Gene CT	30
2021	1	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.31208068
2021	1	30	PCR_FUSION_COV19_E	E Gene CT	31
2021	1	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.95572076
2021	1	30	PCR_FUSION_COV19_E	E Gene CT	18.1
2021	1	30	PCR_FUSION_COV19_E	E Gene CT	37
2021	1	30	PCR_FUSION_COV19_E	E Gene CT	19.5
2021	1	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.15260224
2021	1	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.68421232
2021	1	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.71667085
2021	1	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.77235889
2021	1	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.78520138
2021	1	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.10448742
2021	1	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.82719467
2021	1	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.35436936
2021	1	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.32552133
2021	1	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.24569044
2021	1	30	PCR_COBAS_COV19	CT 2	23.83
2021	1	30	PCR_COBAS_COV19	CT 2	36.54
2021	1	30	PCR_COBAS_COV19	CT 2	17.73
2021	1	30	PCR_COBAS_COV19	CT 2	20.55
2021	1	30	PCR_COBAS_COV19	CT 2	35.07
2021	1	30	PCR_COBAS_COV19	CT 2	32.1
2021	1	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.50171627
2021	1	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.9164635
2021	1	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.12975884
2021	1	30	PCR_COBAS_COV19	CT 2	34.37
2021	1	30	PCR_COBAS_COV19	CT 2	33.14
2021	1	30	PCR_COBAS_COV19	CT 2	33.22
2021	1	30	PCR_COBAS_COV19	CT 2	26.04
2021	1	31	PCR_COBAS_COV19	CT 2	33.25
2021	1	31	PCR_COBAS_COV19	CT 2	36.18
2021	1	31	PCR_COBAS_COV19	CT 2	19.02
2021	1	31	PCR_FUSION_COV19_E	E Gene CT	36.2
2021	1	31	PCR_FUSION_COV19_E	E Gene CT	22.7
2021	1	31	PCR_FUSION_COV19_E	E Gene CT	37.4
2021	1	31	PCR_COBAS_COV19	CT 2	32.83
2021	1	31	PCR_COBAS_COV19	CT 2	33.35
2021	1	31	PCR_COBAS_COV19	CT 2	25.9
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.88245783
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.12789908
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.04156931
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.59467785

AB1159

2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.61240332
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.21267937
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.62741512
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.04558881
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.97561642
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.90307127
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.68648275
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.85230272
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.85280715
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.48219874
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.78291536
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.03112343
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.42698106
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.53134374
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.37882069
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.38368592
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.57794939
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.87459112
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.40170838
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.0749564
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.97560734
2021	1	31	PCR_FUSION_COV19_E	E Gene CT	26.7
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.09350613
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.09747967
2021	1	31	PCR_FUSION_COV19_E	E Gene CT	35.5
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.97238187
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.00524917
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.5072559
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.02554264
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.23712177
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.38685845
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.47151074
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.64066923
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.02762315
2021	1	31	PCR_COBAS_COV19	CT 2	32
2021	1	31	PCR_COBAS_COV19	CT 2	26.78
2021	1	31	PCR_COBAS_COV19	CT 2	32.97
2021	1	31	PCR_COBAS_COV19	CT 2	28.81
2021	1	31	PCR_COBAS_COV19	CT 2	20.18
2021	1	31	PCR_COBAS_COV19	CT 2	34.53
2021	1	31	PCR_COBAS_COV19	CT 2	20.65
2021	1	31	PCR_COBAS_COV19	CT 2	22.47
2021	1	31	PCR_FUSION_COV19_E	E Gene CT	20
2021	1	31	PCR_FUSION_COV19_E	E Gene CT	16.9
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.5533308
2021	1	31	PCR_FUSION_COV19_E	E Gene CT	18.6
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.6176313

2021	1	31	PCR_FUSION_COV19_E	E Gene CT	21.9
2021	1	31	PCR_FUSION_COV19_E	E Gene CT	23.2
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.73474407
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.16113996
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.95733776
2021	1	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.23138493
2021	2	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.21540128
2021	2	1	PCR_COBAS_COV19	CT 2	24.61
2021	2	1	PCR_COBAS_COV19	CT 2	22.39
2021	2	1	PCR_COBAS_COV19	CT 2	37.58
2021	2	1	PCR_COBAS_COV19	CT 2	29.39
2021	2	1	PCR_COBAS_COV19	CT 2	25.72
2021	2	1	PCR_COBAS_COV19	CT 2	17.81
2021	2	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.09341078
2021	2	1	PCR_FUSION_COV19_E	E Gene CT	26.2
2021	2	1	PCR_FUSION_COV19_E	E Gene CT	29.1
2021	2	1	PCR_FUSION_COV19_E	E Gene CT	30.4
2021	2	1	PCR_FUSION_COV19_E	E Gene CT	30.9
2021	2	1	PCR_FUSION_COV19_E	E Gene CT	26.3
2021	2	1	PCR_FUSION_COV19_E	E Gene CT	35.9
2021	2	1	PCR_COBAS_COV19	CT 2	16.16
2021	2	1	PCR_COBAS_COV19	CT 2	35.02
2021	2	1	PCR_COBAS_COV19	CT 2	35.5
2021	2	1	PCR_COBAS_COV19	CT 2	20.16
2021	2	1	PCR_COBAS_COV19	CT 2	37.02
2021	2	1	PCR_COBAS_COV19	CT 2	34.02
2021	2	1	PCR_COBAS_COV19	CT 2	36.58
2021	2	1	PCR_COBAS_COV19	CT 2	27.05
2021	2	1	PCR_COBAS_COV19	CT 2	23.92
2021	2	1	PCR_COBAS_COV19	CT 2	34.12
2021	2	1	PCR_COBAS_COV19	CT 2	26.82
2021	2	1	PCR_COBAS_COV19	CT 2	35.23
2021	2	1	PCR_COBAS_COV19	CT 2	34.91
2021	2	1	PCR_COBAS_COV19	CT 2	17.77
2021	2	1	PCR_COBAS_COV19	CT 2	17.78
2021	2	1	PCR_COBAS_COV19	CT 2	19.19
2021	2	1	PCR_COBAS_COV19	CT 2	17.93
2021	2	1	PCR_COBAS_COV19	CT 2	35.09
2021	2	1	PCR_COBAS_COV19	CT 2	21.38
2021	2	1	PCR_COBAS_COV19	CT 2	23.35
2021	2	1	PCR_COBAS_COV19	CT 2	30.89
2021	2	1	PCR_COBAS_COV19	CT 2	17.65
2021	2	1	PCR_COBAS_COV19	CT 2	29.19
2021	2	1	PCR_COBAS_COV19	CT 2	31.7
2021	2	1	PCR_COBAS_COV19	CT 2	25.18
2021	2	1	PCR_COBAS_COV19	CT 2	24.9
2021	2	1	PCR_COBAS_COV19	CT 2	32.09

AB1161

2021	2	1	PCR_COBAS_COV19	CT 2	22.11
2021	2	1	PCR_COBAS_COV19	CT 2	28.48
2021	2	1	PCR_COBAS_COV19	CT 2	35.4
2021	2	1	PCR_COBAS_COV19	CT 2	35.82
2021	2	1	PCR_COBAS_COV19	CT 2	20.71
2021	2	1	PCR_COBAS_COV19	CT 2	23.03
2021	2	1	PCR_COBAS_COV19	CT 2	24.96
2021	2	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	39.06808705
2021	2	1	PCR_FUSION_COV19_E	E Gene CT	35.3
2021	2	1	PCR_FUSION_COV19_E	E Gene CT	22.6
2021	2	1	PCR_FUSION_COV19_E	E Gene CT	29.5
2021	2	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.11423715
2021	2	1	PCR_FUSION_COV19_E	E Gene CT	31.7
2021	2	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.30436073
2021	2	1	PCR_FUSION_COV19_E	E Gene CT	27.3
2021	2	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.05563819
2021	2	1	PCR_COBAS_COV19	CT 2	17.02
2021	2	1	PCR_COBAS_COV19	CT 2	20.27
2021	2	1	PCR_COBAS_COV19	CT 2	18
2021	2	1	PCR_COBAS_COV19	CT 2	36.25
2021	2	1	PCR_COBAS_COV19	CT 2	36.07
2021	2	1	PCR_COBAS_COV19	CT 2	35.05
2021	2	1	PCR_COBAS_COV19	CT 2	24.15
2021	2	1	PCR_COBAS_COV19	CT 2	26.79
2021	2	1	PCR_COBAS_COV19	CT 2	25.03
2021	2	1	PCR_COBAS_COV19	CT 2	35.75
2021	2	1	PCR_COBAS_COV19	CT 2	35
2021	2	1	PCR_COBAS_COV19	CT 2	26.76
2021	2	1	PCR_COBAS_COV19	CT 2	25.69
2021	2	1	PCR_COBAS_COV19	CT 2	37.71
2021	2	1	PCR_COBAS_COV19	CT 2	22.26
2021	2	1	PCR_PANTH_COV19	RLU	1130
2021	2	1	PCR_PANTH_COV19	RLU	1135
2021	2	1	PCR_PANTH_COV19	RLU	1114
2021	2	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.67014079
2021	2	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.6690568
2021	2	2	PCR_PANTH_COV19	RLU	1158
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.41752505
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.48384672
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.28390253
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.10134521
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.02501086
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.06658786
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.2451721
2021	2	2	PCR_PANTH_COV19	RLU	1158
2021	2	2	PCR_PANTH_COV19	RLU	1154
2021	2	2	PCR_PANTH_COV19	RLU	1114

AB1162

2021	2	2	PCR_PANTH_COV19	RLU	1160
2021	2	2	PCR_PANTH_COV19	RLU	1150
2021	2	2	PCR_PANTH_COV19	RLU	1153
2021	2	2	PCR_PANTH_COV19	RLU	1140
2021	2	2	PCR_PANTH_COV19	RLU	1130
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.46915213
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.36401305
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.55528732
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.2626629
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.03159328
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.67253804
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.55353008
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.07042341
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.64127669
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.01508869
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.59512115
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.73493977
2021	2	2	PCR_PANTH_COV19	RLU	1135
2021	2	2	PCR_PANTH_COV19	RLU	1140
2021	2	2	PCR_PANTH_COV19	RLU	1126
2021	2	2	PCR_PANTH_COV19	RLU	1138
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.65517226
2021	2	2	PCR_PANTH_COV19	RLU	1180
2021	2	2	PCR_PANTH_COV19	RLU	1152
2021	2	2	PCR_PANTH_COV19	RLU	1138
2021	2	2	PCR_PANTH_COV19	RLU	1159
2021	2	2	PCR_PANTH_COV19	RLU	1166
2021	2	2	PCR_PANTH_COV19	RLU	1166
2021	2	2	PCR_PANTH_COV19	RLU	1148
2021	2	2	PCR_PANTH_COV19	RLU	1180
2021	2	2	PCR_PANTH_COV19	RLU	1093
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.87945159
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.32481294
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.16600489
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.8256051
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.54554332
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.91428947
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.83051578
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.27217673
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.67403059
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.87325208
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.17501391
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.87876536
2021	2	2	PCR_FUSION_COV19_E	E Gene CT	32.2
2021	2	2	PCR_FUSION_COV19_E	E Gene CT	36.6
2021	2	2	PCR_FUSION_COV19_E	E Gene CT	20.4
2021	2	2	PCR_FUSION_COV19_E	E Gene CT	33.3

2021	2	2	PCR_FUSION_COV19_E	E Gene CT	17.9
2021	2	2	PCR_FUSION_COV19_E	E Gene CT	24.2
2021	2	2	PCR_FUSION_COV19_E	E Gene CT	19.4
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.21866147
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.69445692
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.32460771
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.90754395
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.47371199
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.00130546
2021	2	2	PCR_FUSION_COV19_E	E Gene CT	22
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.78819744
2021	2	2	PCR_FUSION_COV19_E	E Gene CT	35.9
2021	2	2	PCR_FUSION_COV19_E	E Gene CT	25.1
2021	2	2	PCR_FUSION_COV19_E	E Gene CT	24.1
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.78565978
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.19991906
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.78947203
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.90018267
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.57005928
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.45122478
2021	2	2	PCR_FUSION_COV19_E	E Gene CT	29.9
2021	2	2	PCR_FUSION_COV19_E	E Gene CT	34.1
2021	2	2	PCR_FUSION_COV19_E	E Gene CT	19.7
2021	2	2	PCR_FUSION_COV19_E	E Gene CT	16
2021	2	2	PCR_FUSION_COV19_E	E Gene CT	22.7
2021	2	2	PCR_FUSION_COV19_E	E Gene CT	19.9
2021	2	2	PCR_FUSION_COV19_E	E Gene CT	24.4
2021	2	2	PCR_FUSION_COV19_E	E Gene CT	28.6
2021	2	2	PCR_FUSION_COV19_E	E Gene CT	29.9
2021	2	2	PCR_FUSION_COV19_E	E Gene CT	30.8
2021	2	2	PCR_FUSION_COV19_E	E Gene CT	37.2
2021	2	2	PCR_FUSION_COV19_E	E Gene CT	33.4
2021	2	2	PCR_FUSION_COV19_E	E Gene CT	25.3
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.15757285
2021	2	2	PCR_FUSION_COV19_E	E Gene CT	17.8
2021	2	2	PCR_FUSION_COV19_E	E Gene CT	27.2
2021	2	2	PCR_FUSION_COV19_E	E Gene CT	28.5
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.61397813
2021	2	2	PCR_COBAS_COV19	CT 2	36.63
2021	2	2	PCR_COBAS_COV19	CT 2	38.32
2021	2	2	PCR_COBAS_COV19	CT 2	25
2021	2	2	PCR_COBAS_COV19	CT 2	35.65
2021	2	2	PCR_COBAS_COV19	CT 2	36.64
2021	2	2	PCR_COBAS_COV19	CT 2	35.41
2021	2	2	PCR_COBAS_COV19	CT 2	24.09
2021	2	2	PCR_PANTH_COV19	RLU	1282
2021	2	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.62917863

AB1164

2021	2	3	PCR_PANTH_COV19	RLU	1208
2021	2	3	PCR_PANTH_COV19	RLU	1250
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.25753951
2021	2	3	PCR_PANTH_COV19	RLU	1352
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.57707174
2021	2	3	PCR_PANTH_COV19	RLU	1292
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.54692935
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.72982815
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.41449906
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.06571777
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.07650486
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.08668037
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.21733352
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.31164435
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.88293466
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.13551916
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.98202124
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.47030443
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.2277041
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.68908717
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.32941814
2021	2	3	PCR_PANTH_COV19	RLU	1263
2021	2	3	PCR_PANTH_COV19	RLU	1261
2021	2	3	PCR_PANTH_COV19	RLU	1248
2021	2	3	PCR_PANTH_COV19	RLU	1305
2021	2	3	PCR_PANTH_COV19	RLU	1275
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.18086585
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.0720235
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.00921299
2021	2	3	PCR_PANTH_COV19	RLU	1251
2021	2	3	PCR_PANTH_COV19	RLU	1241
2021	2	3	PCR_PANTH_COV19	RLU	1242
2021	2	3	PCR_PANTH_COV19	RLU	1282
2021	2	3	PCR_PANTH_COV19	RLU	1269
2021	2	3	PCR_PANTH_COV19	RLU	1254
2021	2	3	PCR_PANTH_COV19	RLU	1272
2021	2	3	PCR_PANTH_COV19	RLU	1265
2021	2	3	PCR_FUSION_COV19_E	E Gene CT	27.1
2021	2	3	PCR_FUSION_COV19_E	E Gene CT	21.4
2021	2	3	PCR_FUSION_COV19_E	E Gene CT	29
2021	2	3	PCR_FUSION_COV19_E	E Gene CT	27
2021	2	3	PCR_FUSION_COV19_E	E Gene CT	23
2021	2	3	PCR_FUSION_COV19_E	E Gene CT	27.9
2021	2	3	PCR_FUSION_COV19_E	E Gene CT	28.5
2021	2	3	PCR_FUSION_COV19_E	E Gene CT	34.5
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.15397757
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.68942651

AB1165

2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.26002036
2021	2	3	PCR_FUSION_COV19_E	E Gene CT	21
2021	2	3	PCR_FUSION_COV19_E	E Gene CT	34.1
2021	2	3	PCR_FUSION_COV19_E	E Gene CT	28.7
2021	2	3	PCR_FUSION_COV19_E	E Gene CT	15.9
2021	2	3	PCR_FUSION_COV19_E	E Gene CT	17.4
2021	2	3	PCR_FUSION_COV19_E	E Gene CT	17.7
2021	2	3	PCR_FUSION_COV19_E	E Gene CT	31.6
2021	2	3	PCR_FUSION_COV19_E	E Gene CT	34.3
2021	2	3	PCR_FUSION_COV19_E	E Gene CT	26.8
2021	2	3	PCR_FUSION_COV19_E	E Gene CT	15
2021	2	3	PCR_FUSION_COV19_E	E Gene CT	21.3
2021	2	3	PCR_FUSION_COV19_E	E Gene CT	20.4
2021	2	3	PCR_FUSION_COV19_E	E Gene CT	16.6
2021	2	3	PCR_FUSION_COV19_E	E Gene CT	35.9
2021	2	3	PCR_FUSION_COV19_E	E Gene CT	31.7
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.76618477
2021	2	3	PCR_COBAS_COV19	CT 2	22.5
2021	2	3	PCR_COBAS_COV19	CT 2	27.65
2021	2	3	PCR_COBAS_COV19	CT 2	38.22
2021	2	3	PCR_COBAS_COV19	CT 2	33.26
2021	2	3	PCR_COBAS_COV19	CT 2	33.64
2021	2	3	PCR_COBAS_COV19	CT 2	33.91
2021	2	3	PCR_COBAS_COV19	CT 2	25.68
2021	2	3	PCR_PANTH_COV19	RLU	1131
2021	2	3	PCR_PANTH_COV19	RLU	1127
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.09499819
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.78838751
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.04318812
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.65651561
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.12579589
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.07836497
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.99290496
2021	2	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.27752021
2021	2	4	PCR_PANTH_COV19	RLU	1150
2021	2	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.50267534
2021	2	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.05399012
2021	2	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.65261316
2021	2	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.3554882
2021	2	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.29249424
2021	2	4	PCR_PANTH_COV19	RLU	1164
2021	2	4	PCR_PANTH_COV19	RLU	1125
2021	2	4	PCR_PANTH_COV19	RLU	1139
2021	2	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	10.33366098
2021	2	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.69967642
2021	2	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.16447142
2021	2	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.23583376

AB1166

2021	2	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.29188468
2021	2	4	PCR_PANTH_COV19	RLU	1016
2021	2	4	PCR_PANTH_COV19	RLU	1201
2021	2	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.19093283
2021	2	4	PCR_PANTH_COV19	RLU	1160
2021	2	4	PCR_PANTH_COV19	RLU	1117
2021	2	4	PCR_PANTH_COV19	RLU	1154
2021	2	4	PCR_PANTH_COV19	RLU	1116
2021	2	4	PCR_PANTH_COV19	RLU	1161
2021	2	4	PCR_PANTH_COV19	RLU	1133
2021	2	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.95940898
2021	2	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.26551366
2021	2	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.56261923
2021	2	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.8403816
2021	2	4	PCR_COBAS_COV19	CT 2	34.9
2021	2	4	PCR_COBAS_COV19	CT 2	33.61
2021	2	4	PCR_COBAS_COV19	CT 2	34.69
2021	2	4	PCR_COBAS_COV19	CT 2	36.12
2021	2	4	PCR_COBAS_COV19	CT 2	30.75
2021	2	4	PCR_COBAS_COV19	CT 2	33.16
2021	2	4	PCR_COBAS_COV19	CT 2	33.78
2021	2	4	PCR_COBAS_COV19	CT 2	32.2
2021	2	4	PCR_COBAS_COV19	CT 2	35.4
2021	2	4	PCR_COBAS_COV19	CT 2	35.23
2021	2	4	PCR_COBAS_COV19	CT 2	22.83
2021	2	4	PCR_COBAS_COV19	CT 2	28.77
2021	2	4	PCR_COBAS_COV19	CT 2	36.44
2021	2	4	PCR_COBAS_COV19	CT 2	31.97
2021	2	4	PCR_COBAS_COV19	CT 2	37.76
2021	2	4	PCR_FUSION_COV19_E	E Gene CT	23.1
2021	2	4	PCR_FUSION_COV19_E	E Gene CT	24
2021	2	4	PCR_PANTH_COV19	RLU	1108
2021	2	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.93416422
2021	2	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.97031063
2021	2	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.38953002
2021	2	5	PCR_PANTH_COV19	RLU	1121
2021	2	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.09494017
2021	2	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.9726549
2021	2	5	PCR_PANTH_COV19	RLU	1135
2021	2	5	PCR_PANTH_COV19	RLU	1105
2021	2	5	PCR_PANTH_COV19	RLU	1152
2021	2	5	PCR_PANTH_COV19	RLU	1194
2021	2	5	PCR_PANTH_COV19	RLU	1140
2021	2	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.33600925
2021	2	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.76711693
2021	2	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.39653079
2021	2	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.21011522

AB1167

2021	2	5	PCR_PANTH_COV19	RLU	1195
2021	2	5	PCR_PANTH_COV19	RLU	1176
2021	2	5	PCR_PANTH_COV19	RLU	1141
2021	2	5	PCR_PANTH_COV19	RLU	1163
2021	2	5	PCR_PANTH_COV19	RLU	1205
2021	2	5	PCR_PANTH_COV19	RLU	1110
2021	2	5	PCR_PANTH_COV19	RLU	1116
2021	2	5	PCR_PANTH_COV19	RLU	1143
2021	2	5	PCR_PANTH_COV19	RLU	1173
2021	2	5	PCR_PANTH_COV19	RLU	1138
2021	2	5	PCR_PANTH_COV19	RLU	1121
2021	2	5	PCR_PANTH_COV19	RLU	1149
2021	2	5	PCR_PANTH_COV19	RLU	1107
2021	2	5	PCR_PANTH_COV19	RLU	1060
2021	2	5	PCR_PANTH_COV19	RLU	1164
2021	2	5	PCR_PANTH_COV19	RLU	1148
2021	2	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.24971434
2021	2	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.82440996
2021	2	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	10.7010388
2021	2	5	PCR_COBAS_COV19	CT 2	19.82
2021	2	5	PCR_COBAS_COV19	CT 2	31.98
2021	2	5	PCR_COBAS_COV19	CT 2	31.55
2021	2	5	PCR_COBAS_COV19	CT 2	33.67
2021	2	5	PCR_COBAS_COV19	CT 2	35.85
2021	2	5	PCR_COBAS_COV19	CT 2	32.54
2021	2	5	PCR_COBAS_COV19	CT 2	27.66
2021	2	5	PCR_COBAS_COV19	CT 2	36.42
2021	2	5	PCR_COBAS_COV19	CT 2	31.44
2021	2	5	PCR_COBAS_COV19	CT 2	20.76
2021	2	5	PCR_COBAS_COV19	CT 2	25.94
2021	2	5	PCR_PANTH_COV19	RLU	1137
2021	2	5	PCR_PANTH_COV19	RLU	1112
2021	2	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.77396687
2021	2	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.58656852
2021	2	6	PCR_COV_N2019	E Gene CT	36.4
2021	2	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.76851929
2021	2	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.16585856
2021	2	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.8661361
2021	2	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.91663303
2021	2	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.50228876
2021	2	6	PCR_PANTH_COV19	RLU	1128
2021	2	6	PCR_PANTH_COV19	RLU	1108
2021	2	6	PCR_PANTH_COV19	RLU	1147
2021	2	6	PCR_PANTH_COV19	RLU	1126
2021	2	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.22074851
2021	2	6	PCR_PANTH_COV19	RLU	1160
2021	2	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.51551325

2021	2	6	PCR_PANTH_COV19	RLU	1147
2021	2	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.45392033
2021	2	6	PCR_PANTH_COV19	RLU	1123
2021	2	6	PCR_PANTH_COV19	RLU	1120
2021	2	7	PCR_PANTH_COV19	RLU	1104
2021	2	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.04803822
2021	2	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.62941104
2021	2	7	PCR_COBAS_COV19	CT 2	25.81
2021	2	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.50886982
2021	2	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.63971128
2021	2	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.53846841
2021	2	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.24156534
2021	2	7	PCR_COBAS_COV19	CT 2	33.39
2021	2	7	PCR_COBAS_COV19	CT 2	34.05
2021	2	7	PCR_COBAS_COV19	CT 2	37.31
2021	2	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.14777364
2021	2	7	PCR_PANTH_COV19	RLU	1117
2021	2	7	PCR_COBAS_COV19	CT 2	19.89
2021	2	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.09760836
2021	2	7	PCR_PANTH_COV19	RLU	1181
2021	2	7	PCR_PANTH_COV19	RLU	1135
2021	2	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.61852295
2021	2	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.53438253
2021	2	8	PCR_PANTH_COV19	RLU	1109
2021	2	8	PCR_PANTH_COV19	RLU	1094
2021	2	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.49972821
2021	2	8	PCR_PANTH_COV19	RLU	1085
2021	2	8	PCR_PANTH_COV19	RLU	1091
2021	2	8	PCR_PANTH_COV19	RLU	1094
2021	2	8	PCR_PANTH_COV19	RLU	1109
2021	2	8	PCR_PANTH_COV19	RLU	1093
2021	2	8	PCR_PANTH_COV19	RLU	1089
2021	2	8	PCR_PANTH_COV19	RLU	1112
2021	2	8	PCR_PANTH_COV19	RLU	1179
2021	2	8	PCR_PANTH_COV19	RLU	1144
2021	2	8	PCR_PANTH_COV19	RLU	1091
2021	2	8	PCR_PANTH_COV19	RLU	1076
2021	2	8	PCR_PANTH_COV19	RLU	1086
2021	2	8	PCR_PANTH_COV19	RLU	1097
2021	2	8	PCR_PANTH_COV19	RLU	1070
2021	2	8	PCR_PANTH_COV19	RLU	1084
2021	2	8	PCR_PANTH_COV19	RLU	1118
2021	2	8	PCR_PANTH_COV19	RLU	1131
2021	2	8	PCR_PANTH_COV19	RLU	1124
2021	2	8	PCR_PANTH_COV19	RLU	1080
2021	2	8	PCR_PANTH_COV19	RLU	1111
2021	2	8	PCR_PANTH_COV19	RLU	1118

2021	2	8	PCR_PANTH_COV19	RLU	1103
2021	2	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.76680543
2021	2	8	PCR_PANTH_COV19	RLU	1125
2021	2	8	PCR_PANTH_COV19	RLU	1129
2021	2	8	PCR_PANTH_COV19	RLU	1121
2021	2	8	PCR_PANTH_COV19	RLU	1121
2021	2	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.31760649
2021	2	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.10051904
2021	2	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.44605954
2021	2	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.41484125
2021	2	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.78498591
2021	2	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.33730039
2021	2	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.32638666
2021	2	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.28305901
2021	2	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.52219791
2021	2	8	PCR_COBAS_COV19	CT 2	36.88
2021	2	8	PCR_COBAS_COV19	CT 2	29.11
2021	2	8	PCR_COBAS_COV19	CT 2	28.98
2021	2	8	PCR_COBAS_COV19	CT 2	29.62
2021	2	8	PCR_PANTH_COV19	RLU	1086
2021	2	8	PCR_PANTH_COV19	RLU	1088
2021	2	8	PCR_COBAS_COV19	CT 2	16.78
2021	2	8	PCR_COBAS_COV19	CT 2	29.68
2021	2	9	PCR_PANTH_COV19	RLU	1111
2021	2	9	PCR_PANTH_COV19	RLU	1125
2021	2	9	PCR_PANTH_COV19	RLU	1122
2021	2	9	PCR_PANTH_COV19	RLU	1103
2021	2	9	PCR_PANTH_COV19	RLU	1073
2021	2	9	PCR_PANTH_COV19	RLU	1085
2021	2	9	PCR_PANTH_COV19	RLU	1139
2021	2	9	PCR_PANTH_COV19	RLU	1103
2021	2	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.72836531
2021	2	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.85942607
2021	2	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.11938538
2021	2	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.53133917
2021	2	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.94096577
2021	2	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.81918506
2021	2	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.59905737
2021	2	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.64313843
2021	2	9	PCR_PANTH_COV19	RLU	1110
2021	2	9	PCR_PANTH_COV19	RLU	1110
2021	2	9	PCR_PANTH_COV19	RLU	1125
2021	2	9	PCR_PANTH_COV19	RLU	1140
2021	2	9	PCR_PANTH_COV19	RLU	1153
2021	2	9	PCR_PANTH_COV19	RLU	1115
2021	2	9	PCR_PANTH_COV19	RLU	1136
2021	2	9	PCR_PANTH_COV19	RLU	1098

2021	2	9	PCR_PANTH_COV19	RLU	1166
2021	2	9	PCR_PANTH_COV19	RLU	1154
2021	2	9	PCR_PANTH_COV19	RLU	1053
2021	2	9	PCR_PANTH_COV19	RLU	1120
2021	2	9	PCR_PANTH_COV19	RLU	1115
2021	2	9	PCR_PANTH_COV19	RLU	1101
2021	2	9	PCR_PANTH_COV19	RLU	1150
2021	2	9	PCR_PANTH_COV19	RLU	1186
2021	2	9	PCR_PANTH_COV19	RLU	1179
2021	2	9	PCR_PANTH_COV19	RLU	1146
2021	2	9	PCR_PANTH_COV19	RLU	1187
2021	2	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.18419086
2021	2	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.50702217
2021	2	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.46853466
2021	2	9	PCR_PANTH_COV19	RLU	1165
2021	2	9	PCR_PANTH_COV19	RLU	1159
2021	2	9	PCR_PANTH_COV19	RLU	1048
2021	2	9	PCR_PANTH_COV19	RLU	1183
2021	2	9	PCR_PANTH_COV19	RLU	1137
2021	2	9	PCR_PANTH_COV19	RLU	1102
2021	2	9	PCR_PANTH_COV19	RLU	1140
2021	2	9	PCR_PANTH_COV19	RLU	1169
2021	2	9	PCR_PANTH_COV19	RLU	1152
2021	2	9	PCR_PANTH_COV19	RLU	1181
2021	2	9	PCR_PANTH_COV19	RLU	1160
2021	2	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.07359883
2021	2	9	PCR_COBAS_COV19	CT 2	35.01
2021	2	9	PCR_COBAS_COV19	CT 2	33.57
2021	2	9	PCR_COBAS_COV19	CT 2	35.43
2021	2	9	PCR_COBAS_COV19	CT 2	35.83
2021	2	9	PCR_COBAS_COV19	CT 2	18.98
2021	2	9	PCR_COBAS_COV19	CT 2	34.63
2021	2	9	PCR_COBAS_COV19	CT 2	34.31
2021	2	9	PCR_COBAS_COV19	CT 2	28.28
2021	2	9	PCR_COBAS_COV19	CT 2	34.54
2021	2	9	PCR_COBAS_COV19	CT 2	19.63
2021	2	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.49259372
2021	2	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.35782808
2021	2	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.02809938
2021	2	10	PCR_PANTH_COV19	RLU	1148
2021	2	10	PCR_PANTH_COV19	RLU	1125
2021	2	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.72530824
2021	2	10	PCR_PANTH_COV19	RLU	1186
2021	2	10	PCR_PANTH_COV19	RLU	1165
2021	2	10	PCR_PANTH_COV19	RLU	1122
2021	2	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.40346878
2021	2	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.64558019

2021	2	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.38907876
2021	2	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.05580118
2021	2	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.74891893
2021	2	10	PCR_PANTH_COV19	RLU	1201
2021	2	10	PCR_PANTH_COV19	RLU	1176
2021	2	10	PCR_PANTH_COV19	RLU	1156
2021	2	10	PCR_PANTH_COV19	RLU	1172
2021	2	10	PCR_PANTH_COV19	RLU	1138
2021	2	10	PCR_PANTH_COV19	RLU	1175
2021	2	10	PCR_PANTH_COV19	RLU	1191
2021	2	10	PCR_PANTH_COV19	RLU	1167
2021	2	10	PCR_PANTH_COV19	RLU	1114
2021	2	10	PCR_PANTH_COV19	RLU	1176
2021	2	10	PCR_PANTH_COV19	RLU	1156
2021	2	10	PCR_PANTH_COV19	RLU	1199
2021	2	10	PCR_PANTH_COV19	RLU	1196
2021	2	10	PCR_PANTH_COV19	RLU	1136
2021	2	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.60543186
2021	2	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.16429033
2021	2	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.01031699
2021	2	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.99210911
2021	2	10	PCR_COBAS_COV19	CT 2	37.66
2021	2	10	PCR_COBAS_COV19	CT 2	19.77
2021	2	10	PCR_COBAS_COV19	CT 2	15.54
2021	2	10	PCR_COBAS_COV19	CT 2	22.78
2021	2	10	PCR_COBAS_COV19	CT 2	18.13
2021	2	10	PCR_COBAS_COV19	CT 2	20.12
2021	2	10	PCR_COBAS_COV19	CT 2	35.44
2021	2	10	PCR_COBAS_COV19	CT 2	21.74
2021	2	10	PCR_COBAS_COV19	CT 2	29.02
2021	2	10	PCR_COBAS_COV19	CT 2	20.91
2021	2	10	PCR_COBAS_COV19	CT 2	23.38
2021	2	10	PCR_COBAS_COV19	CT 2	26.52
2021	2	10	PCR_COBAS_COV19	CT 2	28.89
2021	2	10	PCR_COBAS_COV19	CT 2	24.86
2021	2	10	PCR_COBAS_COV19	CT 2	35.32
2021	2	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.26233654
2021	2	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.16703669
2021	2	11	PCR_PANTH_COV19	IC Result	1081
2021	2	11	PCR_PANTH_COV19	RLU	1081
2021	2	11	PCR_PANTH_COV19	RLU	1109
2021	2	11	PCR_PANTH_COV19	RLU	1113
2021	2	11	PCR_PANTH_COV19	RLU	1074
2021	2	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.02625691
2021	2	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.14392082
2021	2	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.20484078
2021	2	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.60108978

AB1172

2021	2	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.87956867
2021	2	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.22264836
2021	2	11	PCR_PANTH_COV19	RLU	1096
2021	2	11	PCR_PANTH_COV19	RLU	1099
2021	2	11	PCR_PANTH_COV19	RLU	1109
2021	2	11	PCR_PANTH_COV19	RLU	1109
2021	2	11	PCR_PANTH_COV19	RLU	1101
2021	2	11	PCR_PANTH_COV19	RLU	1112
2021	2	11	PCR_PANTH_COV19	RLU	1118
2021	2	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.48596487
2021	2	11	PCR_PANTH_COV19	RLU	1101
2021	2	11	PCR_PANTH_COV19	RLU	1108
2021	2	11	PCR_PANTH_COV19	RLU	1125
2021	2	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.09377096
2021	2	11	PCR_PANTH_COV19	RLU	1135
2021	2	11	PCR_PANTH_COV19	RLU	1122
2021	2	11	PCR_PANTH_COV19	RLU	1122
2021	2	11	PCR_PANTH_COV19	RLU	1084
2021	2	11	PCR_PANTH_COV19	RLU	1089
2021	2	11	PCR_PANTH_COV19	RLU	1131
2021	2	11	PCR_PANTH_COV19	RLU	1183
2021	2	11	PCR_PANTH_COV19	RLU	1136
2021	2	11	PCR_PANTH_COV19	RLU	1121
2021	2	11	PCR_PANTH_COV19	RLU	1121
2021	2	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.98671599
2021	2	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.26506203
2021	2	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.23145537
2021	2	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.06554466
2021	2	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.02498198
2021	2	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.77021102
2021	2	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.23481831
2021	2	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.4895731
2021	2	11	PCR_PANTH_COV19	RLU	1120
2021	2	11	PCR_PANTH_COV19	RLU	1142
2021	2	11	PCR_PANTH_COV19	RLU	1134
2021	2	11	PCR_PANTH_COV19	RLU	1134
2021	2	11	PCR_PANTH_COV19	RLU	1099
2021	2	11	PCR_PANTH_COV19	RLU	1075
2021	2	11	PCR_PANTH_COV19	RLU	1122
2021	2	11	PCR_PANTH_COV19	RLU	1165
2021	2	11	PCR_PANTH_COV19	RLU	1114
2021	2	11	PCR_PANTH_COV19	RLU	1109
2021	2	11	PCR_PANTH_COV19	RLU	1100
2021	2	11	PCR_PANTH_COV19	RLU	1123
2021	2	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.81794346
2021	2	11	PCR_COBAS_COV19	CT 2	33.9
2021	2	11	PCR_COBAS_COV19	CT 2	34.82

2021	2	11	PCR_COBAS_COV19	CT 2	36.53
2021	2	11	PCR_COBAS_COV19	CT 2	35.26
2021	2	11	PCR_COBAS_COV19	CT 2	33.46
2021	2	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.728535
2021	2	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.12536366
2021	2	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.36783434
2021	2	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.33755273
2021	2	12	PCR_PANTH_COV19	RLU	1086
2021	2	12	PCR_PANTH_COV19	RLU	1136
2021	2	12	PCR_PANTH_COV19	RLU	1106
2021	2	12	PCR_PANTH_COV19	RLU	1127
2021	2	12	PCR_PANTH_COV19	RLU	1022
2021	2	12	PCR_PANTH_COV19	RLU	1140
2021	2	12	PCR_PANTH_COV19	RLU	1106
2021	2	12	PCR_PANTH_COV19	RLU	1134
2021	2	12	PCR_PANTH_COV19	RLU	1120
2021	2	12	PCR_PANTH_COV19	RLU	1111
2021	2	12	PCR_PANTH_COV19	RLU	1125
2021	2	12	PCR_PANTH_COV19	RLU	1165
2021	2	12	PCR_PANTH_COV19	RLU	1117
2021	2	12	PCR_PANTH_COV19	RLU	1117
2021	2	12	PCR_PANTH_COV19	RLU	1125
2021	2	12	PCR_PANTH_COV19	RLU	1136
2021	2	12	PCR_PANTH_COV19	RLU	1087
2021	2	12	PCR_PANTH_COV19	RLU	1129
2021	2	12	PCR_PANTH_COV19	RLU	1150
2021	2	12	PCR_PANTH_COV19	RLU	1132
2021	2	12	PCR_PANTH_COV19	RLU	1136
2021	2	12	PCR_PANTH_COV19	RLU	1116
2021	2	12	PCR_PANTH_COV19	RLU	1121
2021	2	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.55518745
2021	2	12	PCR_PANTH_COV19	RLU	1181
2021	2	12	PCR_PANTH_COV19	RLU	1139
2021	2	12	PCR_PANTH_COV19	RLU	1160
2021	2	12	PCR_PANTH_COV19	RLU	1169
2021	2	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.00860565
2021	2	12	PCR_PANTH_COV19	RLU	1126
2021	2	12	PCR_PANTH_COV19	RLU	1134
2021	2	12	PCR_PANTH_COV19	RLU	1145
2021	2	12	PCR_PANTH_COV19	RLU	1076
2021	2	12	PCR_PANTH_COV19	RLU	1153
2021	2	12	PCR_PANTH_COV19	RLU	1160
2021	2	12	PCR_PANTH_COV19	RLU	1089
2021	2	12	PCR_PANTH_COV19	RLU	1103
2021	2	12	PCR_PANTH_COV19	RLU	1138
2021	2	12	PCR_PANTH_COV19	RLU	1148
2021	2	12	PCR_PANTH_COV19	RLU	1124

2021	2	12	PCR_PANTH_COV19	RLU	1147
2021	2	12	PCR_PANTH_COV19	RLU	1148
2021	2	12	PCR_PANTH_COV19	RLU	1120
2021	2	12	PCR_PANTH_COV19	RLU	1114
2021	2	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.45836832
2021	2	12	PCR_PANTH_COV19	RLU	1069
2021	2	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.73335292
2021	2	12	PCR_PANTH_COV19	RLU	1115
2021	2	12	PCR_PANTH_COV19	RLU	1102
2021	2	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.40527123
2021	2	12	PCR_COBAS_COV19	CT 2	35.97
2021	2	12	PCR_COBAS_COV19	CT 2	36.05
2021	2	12	PCR_COBAS_COV19	CT 2	18.01
2021	2	12	PCR_COBAS_COV19	CT 2	36.29
2021	2	12	PCR_COBAS_COV19	CT 2	22.39
2021	2	12	PCR_PANTH_COV19	RLU	1141
2021	2	12	PCR_PANTH_COV19	RLU	1129
2021	2	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.1993576
2021	2	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.85801396
2021	2	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.82741017
2021	2	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.37413362
2021	2	13	PCR_PANTH_COV19	RLU	1111
2021	2	13	PCR_PANTH_COV19	RLU	1069
2021	2	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.96410651
2021	2	13	PCR_PANTH_COV19	RLU	1148
2021	2	13	PCR_PANTH_COV19	RLU	1199
2021	2	13	PCR_PANTH_COV19	RLU	1148
2021	2	13	PCR_PANTH_COV19	RLU	1199
2021	2	13	PCR_PANTH_COV19	RLU	1172
2021	2	13	PCR_PANTH_COV19	RLU	1118
2021	2	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.33669237
2021	2	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.16383071
2021	2	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.55320015
2021	2	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.52006606
2021	2	13	PCR_PANTH_COV19	RLU	1143
2021	2	13	PCR_PANTH_COV19	RLU	1187
2021	2	13	PCR_PANTH_COV19	RLU	1143
2021	2	13	PCR_PANTH_COV19	RLU	1173
2021	2	13	PCR_PANTH_COV19	RLU	1135
2021	2	13	PCR_PANTH_COV19	RLU	1108
2021	2	13	PCR_PANTH_COV19	RLU	1138
2021	2	13	PCR_PANTH_COV19	RLU	1168
2021	2	13	PCR_PANTH_COV19	RLU	1107
2021	2	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.18428268
2021	2	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.94873509
2021	2	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.93015797
2021	2	13	PCR_PANTH_COV19	RLU	1121

2021	2	13	PCR_PANTH_COV19	RLU	1114
2021	2	13	PCR_PANTH_COV19	RLU	1141
2021	2	13	PCR_PANTH_COV19	RLU	1197
2021	2	13	PCR_PANTH_COV19	RLU	1058
2021	2	13	PCR_PANTH_COV19	RLU	1128
2021	2	13	PCR_PANTH_COV19	RLU	1121
2021	2	13	PCR_PANTH_COV19	RLU	1104
2021	2	13	PCR_PANTH_COV19	RLU	1119
2021	2	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.31499101
2021	2	13	PCR_PANTH_COV19	RLU	1149
2021	2	13	PCR_PANTH_COV19	RLU	1125
2021	2	13	PCR_PANTH_COV19	RLU	1114
2021	2	13	PCR_PANTH_COV19	RLU	1156
2021	2	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.30751036
2021	2	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.48461573
2021	2	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.44444145
2021	2	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.55841741
2021	2	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.09447129
2021	2	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.55134241
2021	2	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.60535062
2021	2	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.32296911
2021	2	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.9456398
2021	2	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.02265208
2021	2	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.07360945
2021	2	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.50318486
2021	2	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.4842269
2021	2	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.98890986
2021	2	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.8391067
2021	2	14	PCR_PANTH_COV19	RLU	1150
2021	2	14	PCR_PANTH_COV19	RLU	1107
2021	2	14	PCR_PANTH_COV19	RLU	1165
2021	2	14	PCR_PANTH_COV19	RLU	1109
2021	2	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.62708107
2021	2	14	PCR_PANTH_COV19	RLU	1206
2021	2	14	PCR_PANTH_COV19	RLU	1173
2021	2	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.95779294
2021	2	14	PCR_PANTH_COV19	RLU	1129
2021	2	14	PCR_PANTH_COV19	RLU	1132
2021	2	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.95618545
2021	2	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.68468605
2021	2	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.48848332
2021	2	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.41919681
2021	2	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.17297658
2021	2	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.87932602
2021	2	14	PCR_PANTH_COV19	RLU	1207
2021	2	14	PCR_PANTH_COV19	RLU	1055
2021	2	14	PCR_PANTH_COV19	RLU	1180

2021	2	14	PCR_PANTH_COV19	RLU	1186
2021	2	14	PCR_PANTH_COV19	RLU	1115
2021	2	14	PCR_PANTH_COV19	RLU	1116
2021	2	14	PCR_PANTH_COV19	RLU	1151
2021	2	14	PCR_PANTH_COV19	RLU	1179
2021	2	14	PCR_PANTH_COV19	RLU	1157
2021	2	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.60669728
2021	2	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.87083255
2021	2	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.69739678
2021	2	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.35011379
2021	2	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.42550431
2021	2	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.69976573
2021	2	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.33722864
2021	2	14	PCR_PANTH_COV19	RLU	1129
2021	2	14	PCR_PANTH_COV19	RLU	1134
2021	2	14	PCR_PANTH_COV19	RLU	1114
2021	2	14	PCR_PANTH_COV19	RLU	1158
2021	2	14	PCR_PANTH_COV19	RLU	1097
2021	2	14	PCR_PANTH_COV19	RLU	1114
2021	2	14	PCR_PANTH_COV19	RLU	1166
2021	2	14	PCR_PANTH_COV19	RLU	1107
2021	2	14	PCR_PANTH_COV19	RLU	1089
2021	2	14	PCR_PANTH_COV19	RLU	1199
2021	2	14	PCR_PANTH_COV19	RLU	1176
2021	2	14	PCR_PANTH_COV19	RLU	1186
2021	2	14	PCR_PANTH_COV19	RLU	1138
2021	2	14	PCR_PANTH_COV19	RLU	1192
2021	2	14	PCR_PANTH_COV19	RLU	1190
2021	2	14	PCR_PANTH_COV19	RLU	1175
2021	2	14	PCR_PANTH_COV19	RLU	1201
2021	2	15	PCR_PANTH_COV19	RLU	1166
2021	2	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.26139053
2021	2	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.812305
2021	2	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.68588588
2021	2	15	PCR_PANTH_COV19	RLU	1126
2021	2	15	PCR_PANTH_COV19	RLU	1131
2021	2	15	PCR_PANTH_COV19	RLU	1167
2021	2	15	PCR_PANTH_COV19	RLU	1133
2021	2	15	PCR_PANTH_COV19	RLU	1142
2021	2	15	PCR_PANTH_COV19	RLU	1145
2021	2	15	PCR_PANTH_COV19	RLU	1140
2021	2	15	PCR_PANTH_COV19	RLU	1109
2021	2	15	PCR_PANTH_COV19	RLU	1154
2021	2	15	PCR_PANTH_COV19	RLU	1160
2021	2	15	PCR_PANTH_COV19	RLU	1138
2021	2	15	PCR_PANTH_COV19	RLU	1142
2021	2	15	PCR_PANTH_COV19	RLU	1123

AB1177

2021	2	15	PCR_PANTH_COV19	RLU	1161
2021	2	15	PCR_PANTH_COV19	RLU	1131
2021	2	15	PCR_PANTH_COV19	RLU	1163
2021	2	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.31123674
2021	2	15	PCR_PANTH_COV19	RLU	1203
2021	2	15	PCR_PANTH_COV19	RLU	1172
2021	2	15	PCR_PANTH_COV19	RLU	1150
2021	2	15	PCR_PANTH_COV19	RLU	1127
2021	2	15	PCR_PANTH_COV19	RLU	1176
2021	2	15	PCR_PANTH_COV19	RLU	1133
2021	2	15	PCR_PANTH_COV19	RLU	1134
2021	2	15	PCR_PANTH_COV19	RLU	1175
2021	2	15	PCR_PANTH_COV19	RLU	1195
2021	2	15	PCR_PANTH_COV19	RLU	1147
2021	2	15	PCR_COBAS_COV19	CT 2	34.06
2021	2	15	PCR_COBAS_COV19	CT 2	37.57
2021	2	15	PCR_COBAS_COV19	CT 2	21.78
2021	2	15	PCR_COBAS_COV19	CT 2	24.34
2021	2	15	PCR_COBAS_COV19	CT 2	23.76
2021	2	15	PCR_COBAS_COV19	CT 2	34.27
2021	2	15	PCR_COBAS_COV19	CT 2	22.09
2021	2	15	PCR_COBAS_COV19	CT 2	25.16
2021	2	15	PCR_COBAS_COV19	CT 2	20.11
2021	2	15	PCR_COBAS_COV19	CT 2	26.76
2021	2	15	PCR_COBAS_COV19	CT 2	35.3
2021	2	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.14170715
2021	2	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.42236144
2021	2	16	PCR_COBAS_COV19	CT 2	27.81
2021	2	16	PCR_COBAS_COV19	CT 2	24.75
2021	2	16	PCR_COBAS_COV19	CT 2	34.48
2021	2	16	PCR_COBAS_COV19	CT 2	33.4
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.79006424
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.76729789
2021	2	16	PCR_COBAS_COV19	CT 2	33.9
2021	2	16	PCR_COBAS_COV19	CT 2	16.62
2021	2	16	PCR_COBAS_COV19	CT 2	33.4
2021	2	16	PCR_COBAS_COV19	CT 2	26.97
2021	2	16	PCR_COBAS_COV19	CT 2	27.03
2021	2	16	PCR_COBAS_COV19	CT 2	21.21
2021	2	16	PCR_COBAS_COV19	CT 2	26.3
2021	2	16	PCR_COBAS_COV19	CT 2	30.49
2021	2	16	PCR_COBAS_COV19	CT 2	18.45
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.51538769
2021	2	16	PCR_PANTH_COV19	RLU	1130
2021	2	16	PCR_PANTH_COV19	RLU	1165
2021	2	16	PCR_PANTH_COV19	RLU	1184
2021	2	16	PCR_PANTH_COV19	RLU	1109

AB1178

2021	2	16	PCR_PANTH_COV19	RLU	1149
2021	2	16	PCR_PANTH_COV19	RLU	1162
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.2021742
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.19985096
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.6961428
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.41730578
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.5268273
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.10179361
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.35035394
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.5265477
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.64494639
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.38517735
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.52071567
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.22984707
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.91389811
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.38233852
2021	2	16	PCR_PANTH_COV19	RLU	1133
2021	2	16	PCR_PANTH_COV19	RLU	1096
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.20848232
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.95807217
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.78803065
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.79362961
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.84095665
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.26589233
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.59199834
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.74899927
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.87000192
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.22959646
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.51738486
2021	2	16	PCR_PANTH_COV19	RLU	1152
2021	2	16	PCR_PANTH_COV19	RLU	1109
2021	2	16	PCR_PANTH_COV19	RLU	1124
2021	2	16	PCR_PANTH_COV19	RLU	1150
2021	2	16	PCR_PANTH_COV19	RLU	1207
2021	2	16	PCR_PANTH_COV19	RLU	1159
2021	2	16	PCR_PANTH_COV19	RLU	1146
2021	2	16	PCR_PANTH_COV19	RLU	1114
2021	2	16	PCR_PANTH_COV19	RLU	1140
2021	2	16	PCR_PANTH_COV19	RLU	1123
2021	2	16	PCR_PANTH_COV19	RLU	1171
2021	2	16	PCR_PANTH_COV19	RLU	1155
2021	2	16	PCR_PANTH_COV19	RLU	1164
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.24924323
2021	2	16	PCR_PANTH_COV19	RLU	1146
2021	2	16	PCR_PANTH_COV19	RLU	1168
2021	2	16	PCR_PANTH_COV19	RLU	1162
2021	2	16	PCR_PANTH_COV19	RLU	1129

2021	2	16	PCR_PANTH_COV19	RLU	1201
2021	2	16	PCR_PANTH_COV19	RLU	1139
2021	2	16	PCR_PANTH_COV19	RLU	1196
2021	2	16	PCR_COBAS_COV19	CT 2	32.29
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.88898726
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.00005602
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.49194478
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.19272948
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.58012947
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.20585544
2021	2	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.93645167
2021	2	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.85344664
2021	2	17	PCR_COBAS_COV19	CT 2	34.37
2021	2	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.60092275
2021	2	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	39.03521746
2021	2	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.15533004
2021	2	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.18802887
2021	2	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.15897681
2021	2	17	PCR_COBAS_COV19	CT 2	27.07
2021	2	17	PCR_COBAS_COV19	CT 2	33.94
2021	2	17	PCR_COBAS_COV19	CT 2	34.32
2021	2	17	PCR_COBAS_COV19	CT 2	37.64
2021	2	17	PCR_COBAS_COV19	CT 2	24.93
2021	2	17	PCR_COBAS_COV19	CT 2	21.43
2021	2	17	PCR_COBAS_COV19	CT 2	35.41
2021	2	17	PCR_COBAS_COV19	CT 2	27.94
2021	2	17	PCR_COBAS_COV19	CT 2	32.68
2021	2	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.27095464
2021	2	17	PCR_COBAS_COV19	CT 2	30.52
2021	2	17	PCR_COBAS_COV19	CT 2	32.18
2021	2	17	PCR_COBAS_COV19	CT 2	23.72
2021	2	17	PCR_COBAS_COV19	CT 2	34.17
2021	2	17	PCR_COBAS_COV19	CT 2	22.76
2021	2	17	PCR_COBAS_COV19	CT 2	23.92
2021	2	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.06292807
2021	2	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.25834686
2021	2	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.72115094
2021	2	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.72487067
2021	2	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.70785622
2021	2	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.80850489
2021	2	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.58702125
2021	2	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.38184239
2021	2	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.95825407
2021	2	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.19721812
2021	2	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.10908188
2021	2	17	PCR_PANTH_COV19	RLU	1199
2021	2	17	PCR_PANTH_COV19	RLU	1223

AB1180

2021	2	17	PCR_PANTH_COV19	RLU	1094
2021	2	17	PCR_PANTH_COV19	RLU	1149
2021	2	17	PCR_PANTH_COV19	RLU	1140
2021	2	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.12451263
2021	2	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.91833262
2021	2	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.01548504
2021	2	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.55659437
2021	2	17	PCR_PANTH_COV19	RLU	1160
2021	2	17	PCR_PANTH_COV19	RLU	1169
2021	2	17	PCR_PANTH_COV19	RLU	1143
2021	2	17	PCR_PANTH_COV19	RLU	1158
2021	2	17	PCR_PANTH_COV19	RLU	1154
2021	2	17	PCR_PANTH_COV19	RLU	1135
2021	2	17	PCR_PANTH_COV19	RLU	1137
2021	2	17	PCR_PANTH_COV19	RLU	1138
2021	2	17	PCR_PANTH_COV19	RLU	1133
2021	2	17	PCR_PANTH_COV19	RLU	1165
2021	2	17	PCR_PANTH_COV19	RLU	1013
2021	2	17	PCR_PANTH_COV19	RLU	1191
2021	2	17	PCR_PANTH_COV19	RLU	1200
2021	2	17	PCR_PANTH_COV19	RLU	1047
2021	2	17	PCR_PANTH_COV19	RLU	1149
2021	2	17	PCR_PANTH_COV19	RLU	1149
2021	2	17	PCR_PANTH_COV19	RLU	1165
2021	2	17	PCR_PANTH_COV19	RLU	1009
2021	2	17	PCR_PANTH_COV19	RLU	1172
2021	2	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.06151609
2021	2	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.30599147
2021	2	17	PCR_PANTH_COV19	RLU	1113
2021	2	17	PCR_PANTH_COV19	RLU	1161
2021	2	17	PCR_PANTH_COV19	RLU	1122
2021	2	17	PCR_PANTH_COV19	RLU	1122
2021	2	17	PCR_PANTH_COV19	RLU	1151
2021	2	17	PCR_PANTH_COV19	RLU	1182
2021	2	17	PCR_PANTH_COV19	RLU	1158
2021	2	17	PCR_PANTH_COV19	RLU	1143
2021	2	17	PCR_PANTH_COV19	RLU	1130
2021	2	17	PCR_PANTH_COV19	RLU	1139
2021	2	17	PCR_PANTH_COV19	RLU	1136
2021	2	17	PCR_PANTH_COV19	RLU	1166
2021	2	17	PCR_PANTH_COV19	RLU	1132
2021	2	17	PCR_PANTH_COV19	RLU	1132
2021	2	17	PCR_PANTH_COV19	RLU	1152
2021	2	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.93209588
2021	2	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.19046163
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.49595217
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.39214552

AB1181

2021	2	18	PCR_COBAS_COV19	CT 2	34.07
2021	2	18	PCR_COBAS_COV19	CT 2	37.74
2021	2	18	PCR_COBAS_COV19	CT 2	33.28
2021	2	18	PCR_COBAS_COV19	CT 2	25.77
2021	2	18	PCR_PANTH_COV19	RLU	1139
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.07229357
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.12700787
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.0143048
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.7433528
2021	2	18	PCR_PANTH_COV19	RLU	1166
2021	2	18	PCR_PANTH_COV19	RLU	1207
2021	2	18	PCR_PANTH_COV19	RLU	1149
2021	2	18	PCR_PANTH_COV19	RLU	1146
2021	2	18	PCR_PANTH_COV19	RLU	1143
2021	2	18	PCR_PANTH_COV19	RLU	1175
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.15193314
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.08260545
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.70444745
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.52083463
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.18708131
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.96887308
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.17507734
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.13416925
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.64360313
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.15052316
2021	2	18	PCR_PANTH_COV19	RLU	1094
2021	2	18	PCR_PANTH_COV19	RLU	1163
2021	2	18	PCR_PANTH_COV19	RLU	1170
2021	2	18	PCR_PANTH_COV19	RLU	1119
2021	2	18	PCR_PANTH_COV19	RLU	1114
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.24712883
2021	2	18	PCR_PANTH_COV19	RLU	1046
2021	2	18	PCR_PANTH_COV19	RLU	1149
2021	2	18	PCR_PANTH_COV19	RLU	1113
2021	2	18	PCR_PANTH_COV19	RLU	1099
2021	2	18	PCR_PANTH_COV19	RLU	1129
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.27478114
2021	2	18	PCR_PANTH_COV19	RLU	1024
2021	2	18	PCR_PANTH_COV19	RLU	1112
2021	2	18	PCR_PANTH_COV19	RLU	1137
2021	2	18	PCR_PANTH_COV19	RLU	1102
2021	2	18	PCR_PANTH_COV19	RLU	1103
2021	2	18	PCR_PANTH_COV19	RLU	1178
2021	2	18	PCR_PANTH_COV19	RLU	1101
2021	2	18	PCR_PANTH_COV19	RLU	1103
2021	2	18	PCR_PANTH_COV19	RLU	1149
2021	2	18	PCR_PANTH_COV19	RLU	1087

AB1182

2021	2	18	PCR_PANTH_COV19	RLU	1057
2021	2	18	PCR_PANTH_COV19	RLU	1126
2021	2	18	PCR_PANTH_COV19	RLU	1085
2021	2	18	PCR_PANTH_COV19	RLU	1089
2021	2	18	PCR_PANTH_COV19	RLU	1057
2021	2	18	PCR_PANTH_COV19	RLU	1099
2021	2	18	PCR_PANTH_COV19	RLU	1124
2021	2	18	PCR_PANTH_COV19	RLU	1117
2021	2	18	PCR_PANTH_COV19	RLU	1116
2021	2	18	PCR_COBAS_COV19	CT 2	30.5
2021	2	18	PCR_COBAS_COV19	CT 2	34.62
2021	2	18	PCR_COBAS_COV19	CT 2	23.6
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.7515444
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.09328173
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.22411254
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.70071916
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.31884894
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.87687886
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.53841713
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.28672998
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.06430134
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.28827319
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.6894867
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.36170271
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.06772453
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.94148989
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.40540832
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.60487663
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.0635577
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.04141075
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.1631541
2021	2	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.03985094
2021	2	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.61245346
2021	2	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.31032062
2021	2	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.51216038
2021	2	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.14609435
2021	2	19	PCR_PANTH_COV19	RLU	1121
2021	2	19	PCR_PANTH_COV19	RLU	1144
2021	2	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.21228936
2021	2	19	PCR_PANTH_COV19	RLU	1105
2021	2	19	PCR_PANTH_COV19	RLU	1109
2021	2	19	PCR_PANTH_COV19	RLU	1107
2021	2	19	PCR_PANTH_COV19	RLU	1167
2021	2	19	PCR_PANTH_COV19	RLU	1118
2021	2	19	PCR_PANTH_COV19	RLU	1128
2021	2	19	PCR_PANTH_COV19	RLU	1130
2021	2	19	PCR_PANTH_COV19	RLU	1105

AB1183

2021	2	19	PCR_PANTH_COV19	RLU	1119
2021	2	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.14998424
2021	2	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.33135586
2021	2	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.57470548
2021	2	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.04777382
2021	2	19	PCR_PANTH_COV19	RLU	1145
2021	2	19	PCR_PANTH_COV19	RLU	1098
2021	2	19	PCR_PANTH_COV19	RLU	1148
2021	2	19	PCR_PANTH_COV19	RLU	1133
2021	2	19	PCR_PANTH_COV19	RLU	1176
2021	2	19	PCR_PANTH_COV19	RLU	1128
2021	2	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.42741774
2021	2	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.87789971
2021	2	20	PCR_COBAS_COV19	CT 2	23.63
2021	2	20	PCR_COBAS_COV19	CT 2	32.46
2021	2	20	PCR_COBAS_COV19	CT 2	34.93
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.48554039
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.00936555
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.67024273
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.74810736
2021	2	20	PCR_COBAS_COV19	CT 2	19.18
2021	2	20	PCR_COBAS_COV19	CT 2	36.74
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.43723297
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.81742595
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.88224978
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.71259641
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.95340737
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.65762272
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.04068777
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.13969456
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.13492672
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.45796986
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.46725718
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.52015749
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.18979196
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.3624048
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.31425599
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.17156911
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.7959444
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.09456449
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.22369756
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	10.04174044
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.34496052
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.64671051
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.71875122
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.30030234
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.56715135

AB1184

2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.97128694
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.11192223
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.34903132
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.81742847
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.41723574
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.7006129
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.45845185
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.02251364
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.13815388
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.58587252
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.35641284
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.54878303
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.21305109
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.14663341
2021	2	20	PCR_PANTH_COV19	RLU	1148
2021	2	20	PCR_PANTH_COV19	RLU	1161
2021	2	20	PCR_PANTH_COV19	RLU	1142
2021	2	20	PCR_PANTH_COV19	RLU	1126
2021	2	20	PCR_PANTH_COV19	RLU	1171
2021	2	20	PCR_PANTH_COV19	RLU	1136
2021	2	20	PCR_PANTH_COV19	RLU	1117
2021	2	20	PCR_PANTH_COV19	RLU	1108
2021	2	20	PCR_PANTH_COV19	RLU	1075
2021	2	20	PCR_PANTH_COV19	RLU	1107
2021	2	20	PCR_PANTH_COV19	RLU	1109
2021	2	20	PCR_PANTH_COV19	RLU	1094
2021	2	20	PCR_PANTH_COV19	RLU	1102
2021	2	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.65677565
2021	2	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.03400326
2021	2	21	PCR_PANTH_COV19	RLU	1115
2021	2	21	PCR_PANTH_COV19	RLU	1115
2021	2	21	PCR_PANTH_COV19	RLU	1070
2021	2	21	PCR_PANTH_COV19	RLU	1114
2021	2	21	PCR_PANTH_COV19	RLU	1147
2021	2	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.69243695
2021	2	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.36879729
2021	2	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.31270549
2021	2	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.27810775
2021	2	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.61566094
2021	2	21	PCR_PANTH_COV19	RLU	1150
2021	2	21	PCR_PANTH_COV19	RLU	1118
2021	2	21	PCR_PANTH_COV19	RLU	1148
2021	2	21	PCR_PANTH_COV19	RLU	1124
2021	2	21	PCR_PANTH_COV19	RLU	1203
2021	2	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.55558558
2021	2	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.27397345
2021	2	21	PCR_PANTH_COV19	RLU	1179

AB1185

2021	2	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.61903596
2021	2	22	PCR_COBAS_COV19	CT 2	16.27
2021	2	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.10703585
2021	2	22	PCR_COBAS_COV19	CT 2	34.11
2021	2	22	PCR_PANTH_COV19	RLU	1174
2021	2	22	PCR_PANTH_COV19	RLU	1170
2021	2	22	PCR_PANTH_COV19	RLU	1146
2021	2	22	PCR_PANTH_COV19	RLU	1131
2021	2	22	PCR_PANTH_COV19	RLU	1151
2021	2	22	PCR_PANTH_COV19	RLU	1141
2021	2	22	PCR_PANTH_COV19	RLU	1167
2021	2	22	PCR_PANTH_COV19	RLU	1167
2021	2	22	PCR_PANTH_COV19	RLU	1171
2021	2	22	PCR_PANTH_COV19	RLU	1014
2021	2	22	PCR_PANTH_COV19	RLU	1158
2021	2	22	PCR_PANTH_COV19	RLU	1199
2021	2	22	PCR_COBAS_COV19	CT 2	35.64
2021	2	22	PCR_COBAS_COV19	CT 2	18.99
2021	2	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.17682111
2021	2	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.05269104
2021	2	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.84796144
2021	2	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.52779857
2021	2	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.86422544
2021	2	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.81356379
2021	2	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.1194932
2021	2	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.17279952
2021	2	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.83175413
2021	2	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.58296288
2021	2	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.44750181
2021	2	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.62463878
2021	2	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.11274898
2021	2	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.58755237
2021	2	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.41819743
2021	2	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.71173513
2021	2	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.76159865
2021	2	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.51996854
2021	2	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.40765962
2021	2	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.01738611
2021	2	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.95057446
2021	2	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.78552704
2021	2	23	PCR_PANTH_COV19	RLU	1209
2021	2	23	PCR_PANTH_COV19	RLU	1215
2021	2	23	PCR_PANTH_COV19	RLU	1211
2021	2	23	PCR_PANTH_COV19	RLU	1273
2021	2	23	PCR_PANTH_COV19	RLU	1245
2021	2	23	PCR_PANTH_COV19	RLU	1148
2021	2	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.14099323

AB1186

2021	2	23	PCR_PANTH_COV19	RLU	1215
2021	2	23	PCR_PANTH_COV19	RLU	1229
2021	2	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.7148979
2021	2	23	PCR_PANTH_COV19	RLU	1213
2021	2	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.47917931
2021	2	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.36978799
2021	2	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.87452327
2021	2	23	PCR_PANTH_COV19	RLU	1254
2021	2	23	PCR_PANTH_COV19	RLU	1259
2021	2	23	PCR_PANTH_COV19	RLU	1235
2021	2	23	PCR_PANTH_COV19	RLU	1270
2021	2	23	PCR_PANTH_COV19	RLU	1259
2021	2	23	PCR_PANTH_COV19	RLU	1241
2021	2	23	PCR_PANTH_COV19	RLU	1267
2021	2	23	PCR_PANTH_COV19	RLU	1270
2021	2	23	PCR_PANTH_COV19	RLU	1208
2021	2	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.30849599
2021	2	23	PCR_PANTH_COV19	RLU	1242
2021	2	23	PCR_PANTH_COV19	RLU	1258
2021	2	23	PCR_PANTH_COV19	RLU	1244
2021	2	23	PCR_PANTH_COV19	RLU	1275
2021	2	23	PCR_PANTH_COV19	RLU	1253
2021	2	23	PCR_PANTH_COV19	RLU	1182
2021	2	23	PCR_PANTH_COV19	RLU	1142
2021	2	23	PCR_PANTH_COV19	RLU	1165
2021	2	23	PCR_PANTH_COV19	RLU	1109
2021	2	23	PCR_PANTH_COV19	RLU	1137
2021	2	23	PCR_PANTH_COV19	RLU	1186
2021	2	23	PCR_PANTH_COV19	RLU	1172
2021	2	24	PCR_COBAS_COV19	CT 2	27.96
2021	2	24	PCR_COBAS_COV19	CT 2	26.55
2021	2	24	PCR_COBAS_COV19	CT 2	37.21
2021	2	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.84621616
2021	2	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.12321242
2021	2	24	PCR_COBAS_COV19	CT 2	33.58
2021	2	24	PCR_COBAS_COV19	CT 2	32.29
2021	2	24	PCR_COBAS_COV19	CT 2	33.22
2021	2	24	PCR_COBAS_COV19	CT 2	34.2
2021	2	24	PCR_COBAS_COV19	CT 2	14.58
2021	2	24	PCR_COBAS_COV19	CT 2	28.74
2021	2	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.47715492
2021	2	24	PCR_COBAS_COV19	CT 2	37.84
2021	2	24	PCR_COBAS_COV19	CT 2	27.66
2021	2	24	PCR_COBAS_COV19	CT 2	31.56
2021	2	24	PCR_COBAS_COV19	CT 2	28.75
2021	2	24	PCR_COBAS_COV19	CT 2	29.46
2021	2	24	PCR_COBAS_COV19	CT 2	21.97

2021	2	24	PCR_PANTH_COV19	RLU	1170
2021	2	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.82933219
2021	2	24	PCR_PANTH_COV19	RLU	1185
2021	2	24	PCR_PANTH_COV19	RLU	1124
2021	2	24	PCR_PANTH_COV19	RLU	1155
2021	2	24	PCR_PANTH_COV19	RLU	1176
2021	2	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.6160719
2021	2	24	PCR_COBAS_COV19	CT 2	24.17
2021	2	24	PCR_COBAS_COV19	CT 2	35.68
2021	2	24	PCR_COBAS_COV19	CT 2	23.06
2021	2	24	PCR_COBAS_COV19	CT 2	21.94
2021	2	24	PCR_COBAS_COV19	CT 2	26.08
2021	2	24	PCR_PANTH_COV19	RLU	1178
2021	2	24	PCR_PANTH_COV19	RLU	1085
2021	2	24	PCR_PANTH_COV19	RLU	1152
2021	2	24	PCR_PANTH_COV19	RLU	1141
2021	2	24	PCR_PANTH_COV19	RLU	1124
2021	2	24	PCR_PANTH_COV19	RLU	1093
2021	2	24	PCR_PANTH_COV19	RLU	1120
2021	2	24	PCR_PANTH_COV19	RLU	1261
2021	2	24	PCR_PANTH_COV19	RLU	1297
2021	2	24	PCR_PANTH_COV19	RLU	1236
2021	2	24	PCR_PANTH_COV19	RLU	1254
2021	2	24	PCR_PANTH_COV19	RLU	1319
2021	2	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.46461069
2021	2	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.66049471
2021	2	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.94353329
2021	2	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.30955168
2021	2	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.51228452
2021	2	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.68315593
2021	2	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.00457003
2021	2	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.28124594
2021	2	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.37627922
2021	2	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.79138425
2021	2	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.94885684
2021	2	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.54089485
2021	2	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.48042138
2021	2	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.04925894
2021	2	25	PCR_COBAS_COV19	CT 2	36.3
2021	2	25	PCR_COBAS_COV19	CT 2	34.96
2021	2	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.39967158
2021	2	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.05819547
2021	2	25	PCR_COBAS_COV19	CT 2	34.52
2021	2	25	PCR_COBAS_COV19	CT 2	37.18
2021	2	25	PCR_COBAS_COV19	CT 2	33.96
2021	2	25	PCR_COBAS_COV19	CT 2	32.25
2021	2	25	PCR_PANTH_COV19	RLU	1306

AB1188

2021	2	25	PCR_PANTH_COV19	RLU	1238
2021	2	25	PCR_PANTH_COV19	RLU	1284
2021	2	25	PCR_PANTH_COV19	RLU	1266
2021	2	25	PCR_PANTH_COV19	RLU	1320
2021	2	25	PCR_PANTH_COV19	RLU	1267
2021	2	25	PCR_PANTH_COV19	RLU	1232
2021	2	25	PCR_PANTH_COV19	RLU	1279
2021	2	25	PCR_PANTH_COV19	RLU	1203
2021	2	25	PCR_PANTH_COV19	RLU	1249
2021	2	25	PCR_PANTH_COV19	RLU	1278
2021	2	25	PCR_PANTH_COV19	RLU	1271
2021	2	25	PCR_PANTH_COV19	RLU	1261
2021	2	25	PCR_PANTH_COV19	RLU	1244
2021	2	25	PCR_PANTH_COV19	RLU	1266
2021	2	25	PCR_PANTH_COV19	RLU	1239
2021	2	25	PCR_PANTH_COV19	RLU	1228
2021	2	25	PCR_PANTH_COV19	RLU	1219
2021	2	25	PCR_PANTH_COV19	RLU	1237
2021	2	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.20167546
2021	2	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.44291129
2021	2	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.98167351
2021	2	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.80752373
2021	2	25	PCR_COBAS_COV19	CT 2	34.98
2021	2	25	PCR_COBAS_COV19	CT 2	23.31
2021	2	25	PCR_PANTH_COV19	RLU	1290
2021	2	25	PCR_PANTH_COV19	RLU	1241
2021	2	25	PCR_PANTH_COV19	RLU	1252
2021	2	25	PCR_PANTH_COV19	RLU	1235
2021	2	25	PCR_PANTH_COV19	RLU	1264
2021	2	25	PCR_PANTH_COV19	RLU	1204
2021	2	25	PCR_PANTH_COV19	RLU	1242
2021	2	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	39.15121553
2021	2	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.01803495
2021	2	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.5035658
2021	2	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.14806907
2021	2	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.35474153
2021	2	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.82751518
2021	2	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.5397538
2021	2	26	PCR_COBAS_COV19	CT 2	16.91
2021	2	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.16882888
2021	2	26	PCR_COBAS_COV19	CT 2	29.71
2021	2	26	PCR_COBAS_COV19	CT 2	26.33
2021	2	26	PCR_COBAS_COV19	CT 2	31.74
2021	2	26	PCR_COBAS_COV19	CT 2	25.92
2021	2	26	PCR_COBAS_COV19	CT 2	18.61
2021	2	26	PCR_COBAS_COV19	CT 2	22.03
2021	2	26	PCR_COBAS_COV19	CT 2	29.77

2021	2	26	PCR_COBAS_COV19	CT 2	29.49
2021	2	26	PCR_COBAS_COV19	CT 2	35.81
2021	2	26	PCR_COBAS_COV19	CT 2	30.25
2021	2	26	PCR_COBAS_COV19	CT 2	27.07
2021	2	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.00001057
2021	2	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.2093533
2021	2	26	PCR_PANTH_COV19	RLU	1266
2021	2	26	PCR_PANTH_COV19	RLU	1198
2021	2	26	PCR_PANTH_COV19	RLU	1208
2021	2	26	PCR_PANTH_COV19	RLU	1235
2021	2	26	PCR_PANTH_COV19	RLU	1219
2021	2	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.79402749
2021	2	26	PCR_PANTH_COV19	RLU	1254
2021	2	26	PCR_PANTH_COV19	RLU	1196
2021	2	26	PCR_PANTH_COV19	RLU	1178
2021	2	26	PCR_PANTH_COV19	RLU	1256
2021	2	26	PCR_PANTH_COV19	RLU	1245
2021	2	26	PCR_PANTH_COV19	RLU	1194
2021	2	26	PCR_PANTH_COV19	RLU	1214
2021	2	26	PCR_PANTH_COV19	RLU	1248
2021	2	26	PCR_PANTH_COV19	RLU	1248
2021	2	26	PCR_PANTH_COV19	RLU	1225
2021	2	26	PCR_COBAS_COV19	CT 2	35.42
2021	2	26	PCR_COBAS_COV19	CT 2	18.19
2021	2	26	PCR_COBAS_COV19	CT 2	33.47
2021	2	26	PCR_COBAS_COV19	CT 2	19.9
2021	2	26	PCR_COBAS_COV19	CT 2	36.68
2021	2	26	PCR_COBAS_COV19	CT 2	19.88
2021	2	27	PCR_COBAS_COV19	CT 2	28.79
2021	2	27	PCR_COBAS_COV19	CT 2	33.93
2021	2	27	PCR_COBAS_COV19	CT 2	29.82
2021	2	27	PCR_COBAS_COV19	CT 2	20.89
2021	2	27	PCR_COBAS_COV19	CT 2	23.93
2021	2	27	PCR_COBAS_COV19	CT 2	26.37
2021	2	27	PCR_COBAS_COV19	CT 2	23.22
2021	2	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.26755072
2021	2	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.52374713
2021	2	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.41465707
2021	2	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.56664278
2021	2	27	PCR_PANTH_COV19	RLU	1213
2021	2	27	PCR_PANTH_COV19	RLU	1284
2021	2	27	PCR_PANTH_COV19	RLU	1236
2021	2	27	PCR_PANTH_COV19	RLU	1185
2021	2	27	PCR_PANTH_COV19	RLU	1251
2021	2	27	PCR_PANTH_COV19	RLU	1302
2021	2	27	PCR_PANTH_COV19	RLU	1232
2021	2	27	PCR_PANTH_COV19	RLU	1215

AB1190

2021	2	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.02951648
2021	2	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.53452323
2021	2	28	PCR_PANTH_COV19	RLU	1241
2021	2	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.902943
2021	2	28	PCR_PANTH_COV19	RLU	1267
2021	2	28	PCR_PANTH_COV19	RLU	1283
2021	2	28	PCR_PANTH_COV19	RLU	1266
2021	2	28	PCR_PANTH_COV19	RLU	1257
2021	2	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.28146604
2021	2	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.32340832
2021	2	28	PCR_PANTH_COV19	RLU	1280
2021	2	28	PCR_PANTH_COV19	RLU	1251
2021	2	28	PCR_PANTH_COV19	RLU	1276
2021	2	28	PCR_PANTH_COV19	RLU	1304
2021	2	28	PCR_PANTH_COV19	RLU	1255
2021	2	28	PCR_PANTH_COV19	RLU	1219
2021	2	28	PCR_PANTH_COV19	RLU	1226
2021	2	28	PCR_PANTH_COV19	RLU	1238
2021	2	28	PCR_PANTH_COV19	RLU	1242
2021	2	28	PCR_PANTH_COV19	RLU	1174
2021	2	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.76177778
2021	2	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.73816358
2021	2	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.263088
2021	2	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.08578367
2021	2	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.34426132
2021	2	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	39.55325542
2021	2	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.33289428
2021	2	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.93138505
2021	2	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.33222037
2021	2	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.57753384
2021	3	1	PCR_PANTH_COV19	RLU	1274
2021	3	1	PCR_PANTH_COV19	RLU	1270
2021	3	1	PCR_PANTH_COV19	RLU	1229
2021	3	1	PCR_PANTH_COV19	RLU	1209
2021	3	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.43887648
2021	3	1	PCR_PANTH_COV19	RLU	1208
2021	3	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.57005635
2021	3	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.34151056
2021	3	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.32041046
2021	3	1	PCR_PANTH_COV19	RLU	1245
2021	3	1	PCR_PANTH_COV19	RLU	1206
2021	3	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.25372857
2021	3	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.84369013
2021	3	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.42333286
2021	3	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.23495493
2021	3	1	PCR_PANTH_COV19	RLU	1241
2021	3	1	PCR_PANTH_COV19	RLU	1194

AB1191

2021	3	1	PCR_PANTH_COV19	RLU	1238
2021	3	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.66129116
2021	3	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.21882111
2021	3	1	PCR_COBAS_COV19	CT 2	34.53
2021	3	1	PCR_COBAS_COV19	CT 2	18.54
2021	3	1	PCR_PANTH_COV19	RLU	1244
2021	3	1	PCR_PANTH_COV19	RLU	1278
2021	3	1	PCR_PANTH_COV19	RLU	1228
2021	3	1	PCR_PANTH_COV19	RLU	1235
2021	3	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.60059597
2021	3	1	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.00393939
2021	3	2	PCR_COBAS_COV19	CT 2	29.2
2021	3	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.32684593
2021	3	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.4206441
2021	3	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.49837519
2021	3	2	PCR_PANTH_COV19	RLU	1271
2021	3	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.52701362
2021	3	2	PCR_PANTH_COV19	RLU	1259
2021	3	2	PCR_PANTH_COV19	RLU	1235
2021	3	2	PCR_PANTH_COV19	RLU	1272
2021	3	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.73624516
2021	3	2	PCR_PANTH_COV19	RLU	1229
2021	3	2	PCR_PANTH_COV19	RLU	1263
2021	3	2	PCR_PANTH_COV19	RLU	1265
2021	3	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.1160955
2021	3	2	PCR_PANTH_COV19	RLU	1190
2021	3	2	PCR_PANTH_COV19	RLU	1281
2021	3	2	PCR_PANTH_COV19	RLU	1286
2021	3	2	PCR_PANTH_COV19	RLU	1275
2021	3	2	PCR_PANTH_COV19	RLU	1274
2021	3	2	PCR_PANTH_COV19	RLU	1318
2021	3	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.61016478
2021	3	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.65340465
2021	3	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.10397457
2021	3	2	PCR_COBAS_COV19	CT 2	35.47
2021	3	2	PCR_COBAS_COV19	CT 2	36.05
2021	3	2	PCR_COBAS_COV19	CT 2	36.88
2021	3	2	PCR_COBAS_COV19	CT 2	35.45
2021	3	2	PCR_COBAS_COV19	CT 2	38.01
2021	3	2	PCR_COBAS_COV19	CT 2	36.09
2021	3	2	PCR_PANTH_COV19	RLU	1207
2021	3	2	PCR_PANTH_COV19	RLU	1255
2021	3	2	PCR_PANTH_COV19	RLU	1250
2021	3	2	PCR_PANTH_COV19	RLU	1258
2021	3	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.28363509
2021	3	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.88763094
2021	3	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.20351242

2021	3	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.74683153
2021	3	2	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.81462142
2021	3	3	PCR_COBAS_COV19	CT 2	24.93
2021	3	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.49701585
2021	3	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.93065804
2021	3	3	PCR_COBAS_COV19	CT 2	28.05
2021	3	3	PCR_COBAS_COV19	CT 2	29.56
2021	3	3	PCR_COBAS_COV19	CT 2	27.33
2021	3	3	PCR_COBAS_COV19	CT 2	24.89
2021	3	3	PCR_COBAS_COV19	CT 2	32.35
2021	3	3	PCR_COBAS_COV19	CT 2	30.4
2021	3	3	PCR_COBAS_COV19	CT 2	21.79
2021	3	3	PCR_COBAS_COV19	CT 2	28.92
2021	3	3	PCR_COBAS_COV19	CT 2	36.78
2021	3	3	PCR_COBAS_COV19	CT 2	20.69
2021	3	3	PCR_PANTH_COV19	RLU	1227
2021	3	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.19659586
2021	3	3	PCR_PANTH_COV19	RLU	1194
2021	3	3	PCR_PANTH_COV19	RLU	1187
2021	3	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.70317189
2021	3	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.46449231
2021	3	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.84698713
2021	3	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.64076048
2021	3	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.18141752
2021	3	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.0568652
2021	3	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.57104589
2021	3	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.19531185
2021	3	3	PCR_PANTH_COV19	RLU	1246
2021	3	3	PCR_PANTH_COV19	RLU	1221
2021	3	3	PCR_PANTH_COV19	RLU	1187
2021	3	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.45028231
2021	3	3	PCR_PANTH_COV19	RLU	1166
2021	3	3	PCR_COBAS_COV19	CT 2	16.38
2021	3	3	PCR_COBAS_COV19	CT 2	24.5
2021	3	3	PCR_COBAS_COV19	CT 2	19.86
2021	3	3	PCR_COBAS_COV19	CT 2	34.47
2021	3	3	PCR_COBAS_COV19	CT 2	27.65
2021	3	3	PCR_COBAS_COV19	CT 2	17.5
2021	3	3	PCR_COBAS_COV19	CT 2	14.8
2021	3	3	PCR_COBAS_COV19	CT 2	18.17
2021	3	3	PCR_COBAS_COV19	CT 2	26.65
2021	3	3	PCR_COBAS_COV19	CT 2	14.29
2021	3	3	PCR_PANTH_COV19	RLU	1231
2021	3	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	10.94287201
2021	3	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.28932468
2021	3	3	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.83180654
2021	3	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.89114354

AB1193

2021	3	4	PCR_COBAS_COV19	CT 2	38.15
2021	3	4	PCR_PANTH_COV19	RLU	1235
2021	3	4	PCR_PANTH_COV19	RLU	1258
2021	3	4	PCR_PANTH_COV19	RLU	1260
2021	3	4	PCR_PANTH_COV19	RLU	1175
2021	3	4	PCR_PANTH_COV19	RLU	1253
2021	3	4	PCR_COBAS_COV19	CT 2	17.19
2021	3	4	PCR_COBAS_COV19	CT 2	37.99
2021	3	4	PCR_COBAS_COV19	CT 2	21.2
2021	3	4	PCR_COBAS_COV19	CT 2	35.74
2021	3	4	PCR_COBAS_COV19	CT 2	34.17
2021	3	4	PCR_COBAS_COV19	CT 2	24.64
2021	3	4	PCR_COBAS_COV19	CT 2	36.28
2021	3	4	PCR_PANTH_COV19	RLU	1218
2021	3	4	PCR_PANTH_COV19	RLU	1228
2021	3	4	PCR_PANTH_COV19	RLU	1259
2021	3	4	PCR_PANTH_COV19	RLU	1199
2021	3	4	PCR_PANTH_COV19	RLU	1239
2021	3	4	PCR_PANTH_COV19	RLU	1283
2021	3	4	PCR_PANTH_COV19	RLU	1203
2021	3	4	PCR_PANTH_COV19	RLU	1242
2021	3	4	PCR_PANTH_COV19	RLU	1220
2021	3	4	PCR_PANTH_COV19	RLU	1219
2021	3	4	PCR_PANTH_COV19	RLU	1224
2021	3	4	PCR_PANTH_COV19	RLU	1262
2021	3	4	PCR_PANTH_COV19	RLU	1208
2021	3	4	PCR_PANTH_COV19	RLU	1243
2021	3	4	PCR_PANTH_COV19	RLU	1234
2021	3	4	PCR_PANTH_COV19	RLU	1234
2021	3	4	PCR_PANTH_COV19	RLU	1249
2021	3	4	PCR_PANTH_COV19	RLU	1251
2021	3	4	PCR_PANTH_COV19	RLU	1221
2021	3	4	PCR_PANTH_COV19	RLU	1257
2021	3	4	PCR_PANTH_COV19	RLU	1226
2021	3	4	PCR_PANTH_COV19	RLU	1200
2021	3	4	PCR_PANTH_COV19	RLU	1203
2021	3	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.69015009
2021	3	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.24357047
2021	3	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.21820638
2021	3	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.09365133
2021	3	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.62089284
2021	3	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.43039863
2021	3	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.08486711
2021	3	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.82118555
2021	3	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.25840608
2021	3	4	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.80632222
2021	3	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.5277871

2021	3	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.62795416
2021	3	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.86307826
2021	3	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.70010622
2021	3	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.77275935
2021	3	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.17038923
2021	3	5	PCR_COBAS_COV19	CT 2	23.85
2021	3	5	PCR_COBAS_COV19	CT 2	30.21
2021	3	5	PCR_COBAS_COV19	CT 2	29.54
2021	3	5	PCR_COBAS_COV19	CT 2	20.79
2021	3	5	PCR_COBAS_COV19	CT 2	27.08
2021	3	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.46224291
2021	3	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.21688329
2021	3	5	PCR_PANTH_COV19	RLU	1232
2021	3	5	PCR_PANTH_COV19	RLU	1252
2021	3	5	PCR_PANTH_COV19	RLU	1201
2021	3	5	PCR_PANTH_COV19	RLU	1231
2021	3	5	PCR_PANTH_COV19	RLU	1267
2021	3	5	PCR_PANTH_COV19	RLU	1302
2021	3	5	PCR_PANTH_COV19	RLU	1175
2021	3	5	PCR_PANTH_COV19	RLU	1245
2021	3	5	PCR_COBAS_COV19	CT 2	32.77
2021	3	5	PCR_COBAS_COV19	CT 2	30.37
2021	3	5	PCR_COBAS_COV19	CT 2	33.04
2021	3	5	PCR_COBAS_COV19	CT 2	17.87
2021	3	5	PCR_COBAS_COV19	CT 2	36.51
2021	3	5	PCR_COBAS_COV19	CT 2	31.34
2021	3	5	PCR_COBAS_COV19	CT 2	17.6
2021	3	5	PCR_PANTH_COV19	RLU	1185
2021	3	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.22391062
2021	3	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.10219501
2021	3	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.99123665
2021	3	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.36319577
2021	3	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.25833952
2021	3	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.07948032
2021	3	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.47405041
2021	3	5	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.6372541
2021	3	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.36084321
2021	3	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.19778561
2021	3	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.69906541
2021	3	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.65333309
2021	3	6	PCR_COBAS_COV19	CT 2	35.74
2021	3	6	PCR_COBAS_COV19	CT 2	25.95
2021	3	6	PCR_COBAS_COV19	CT 2	18.43
2021	3	6	PCR_COBAS_COV19	CT 2	26.59
2021	3	6	PCR_COBAS_COV19	CT 2	32.04
2021	3	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.4492777
2021	3	6	PCR_COBAS_COV19	CT 2	22.86

AB1195

2021	3	6	PCR_COBAS_COV19	CT 2	22.3
2021	3	6	PCR_COBAS_COV19	CT 2	27.46
2021	3	6	PCR_PANTH_COV19	RLU	1228
2021	3	6	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.22967995
2021	3	6	PCR_PANTH_COV19	RLU	1231
2021	3	6	PCR_PANTH_COV19	RLU	1222
2021	3	6	PCR_PANTH_COV19	RLU	1232
2021	3	6	PCR_PANTH_COV19	RLU	1200
2021	3	6	PCR_PANTH_COV19	RLU	1251
2021	3	7	PCR_PANTH_COV19	RLU	1249
2021	3	7	PCR_PANTH_COV19	RLU	1199
2021	3	7	PCR_PANTH_COV19	RLU	1200
2021	3	7	PCR_PANTH_COV19	RLU	1239
2021	3	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.90585049
2021	3	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.46434251
2021	3	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.94363228
2021	3	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.17194715
2021	3	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.31783859
2021	3	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.3507629
2021	3	7	PCR_PANTH_COV19	RLU	1209
2021	3	7	PCR_PANTH_COV19	RLU	1280
2021	3	7	PCR_PANTH_COV19	RLU	1195
2021	3	7	PCR_PANTH_COV19	RLU	1243
2021	3	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.50207567
2021	3	7	PCR_PANTH_COV19	RLU	1326
2021	3	7	PCR_PANTH_COV19	RLU	1198
2021	3	7	PCR_PANTH_COV19	RLU	1250
2021	3	7	PCR_PANTH_COV19	RLU	1251
2021	3	7	PCR_PANTH_COV19	RLU	1190
2021	3	7	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.73740635
2021	3	7	PCR_COBAS_COV19	CT 2	36.03
2021	3	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.41173634
2021	3	8	PCR_COBAS_COV19	CT 2	21.97
2021	3	8	PCR_COBAS_COV19	CT 2	20.76
2021	3	8	PCR_COBAS_COV19	CT 2	35.72
2021	3	8	PCR_COBAS_COV19	CT 2	19.23
2021	3	8	PCR_COBAS_COV19	CT 2	16.94
2021	3	8	PCR_COBAS_COV19	CT 2	21.33
2021	3	8	PCR_COBAS_COV19	CT 2	32.96
2021	3	8	PCR_COBAS_COV19	CT 2	28.52
2021	3	8	PCR_COBAS_COV19	CT 2	35.85
2021	3	8	PCR_COBAS_COV19	CT 2	34.67
2021	3	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.11722535
2021	3	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.00188462
2021	3	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.53519543
2021	3	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.95184718
2021	3	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.66111242

AB1196

2021	3	8	PCR_COBAS_COV19	CT 2	27.01
2021	3	8	PCR_COBAS_COV19	CT 2	25.06
2021	3	8	PCR_PANTH_COV19	RLU	1186
2021	3	8	PCR_PANTH_COV19	RLU	1315
2021	3	8	PCR_PANTH_COV19	RLU	1210
2021	3	8	PCR_PANTH_COV19	RLU	1206
2021	3	8	PCR_PANTH_COV19	RLU	1208
2021	3	8	PCR_PANTH_COV19	RLU	1219
2021	3	8	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.72497416
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.66944043
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.44134647
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.35633631
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.41104312
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.68053176
2021	3	9	PCR_COBAS_COV19	CT 2	37.5
2021	3	9	PCR_COBAS_COV19	CT 2	18.84
2021	3	9	PCR_COBAS_COV19	CT 2	19.17
2021	3	9	PCR_COBAS_COV19	CT 2	22.91
2021	3	9	PCR_COBAS_COV19	CT 2	18.16
2021	3	9	PCR_COBAS_COV19	CT 2	35.28
2021	3	9	PCR_COBAS_COV19	CT 2	33.08
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.55336822
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.80482825
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.95185231
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.19719526
2021	3	9	PCR_COBAS_COV19	CT 2	37.18
2021	3	9	PCR_COBAS_COV19	CT 2	31.21
2021	3	9	PCR_PANTH_COV19	RLU	1212
2021	3	9	PCR_PANTH_COV19	RLU	1208
2021	3	9	PCR_PANTH_COV19	RLU	1209
2021	3	9	PCR_PANTH_COV19	RLU	1200
2021	3	9	PCR_PANTH_COV19	RLU	1233
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.21441971
2021	3	9	PCR_COBAS_COV19	CT 2	32.19
2021	3	9	PCR_COBAS_COV19	CT 2	24.25
2021	3	9	PCR_COBAS_COV19	CT 2	34.14
2021	3	9	PCR_COBAS_COV19	CT 2	18.37
2021	3	9	PCR_COBAS_COV19	CT 2	21.11
2021	3	9	PCR_COBAS_COV19	CT 2	30.14
2021	3	9	PCR_COBAS_COV19	CT 2	20.39
2021	3	9	PCR_COBAS_COV19	CT 2	32.31
2021	3	9	PCR_COBAS_COV19	CT 2	29.25
2021	3	9	PCR_PANTH_COV19	RLU	1283
2021	3	9	PCR_PANTH_COV19	RLU	1230
2021	3	9	PCR_PANTH_COV19	RLU	1173
2021	3	9	PCR_PANTH_COV19	RLU	1260
2021	3	9	PCR_PANTH_COV19	RLU	1223

AB1197

2021	3	9	PCR_PANTH_COV19	RLU	1208
2021	3	9	PCR_PANTH_COV19	RLU	1194
2021	3	9	PCR_PANTH_COV19	RLU	1163
2021	3	9	PCR_PANTH_COV19	RLU	1156
2021	3	9	PCR_PANTH_COV19	RLU	1236
2021	3	9	PCR_PANTH_COV19	RLU	1215
2021	3	9	PCR_PANTH_COV19	RLU	1190
2021	3	9	PCR_PANTH_COV19	RLU	1214
2021	3	9	PCR_PANTH_COV19	RLU	1208
2021	3	9	PCR_PANTH_COV19	RLU	1264
2021	3	9	PCR_PANTH_COV19	RLU	1241
2021	3	9	PCR_PANTH_COV19	RLU	1209
2021	3	9	PCR_PANTH_COV19	RLU	1215
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.87182545
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.60701399
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.02122188
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.86721006
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.37350923
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.10738217
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.15826037
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.51287173
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.20272913
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.48245059
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.10694549
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.92683477
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.38233913
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.41405228
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.60296068
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.73308535
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.37281148
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.69414646
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.97256687
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.95083396
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.50386099
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.65856064
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.19212882
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.0122992
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.65393689
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.6895343
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.5206479
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.61284921
2021	3	9	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.14470799
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.07346524
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.98367546
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.07835251
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.03027447
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.55054539

2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.35182413
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.25932171
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.35146926
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.68331112
2021	3	10	PCR_COBAS_COV19	CT 2	37.65
2021	3	10	PCR_COBAS_COV19	CT 2	22.77
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.574815
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.16924622
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.90232441
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.94067042
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.08974262
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.7340422
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.07272131
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.66011466
2021	3	10	PCR_COBAS_COV19	CT 2	20.02
2021	3	10	PCR_COBAS_COV19	CT 2	19.3
2021	3	10	PCR_COBAS_COV19	CT 2	23.57
2021	3	10	PCR_COBAS_COV19	CT 2	19.45
2021	3	10	PCR_COBAS_COV19	CT 2	22.2
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.14066821
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.61994411
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.37292542
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.06670432
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.0643366
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.44451471
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.49880513
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.80020787
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.8351271
2021	3	10	PCR_COBAS_COV19	CT 2	17.05
2021	3	10	PCR_COBAS_COV19	CT 2	18.9
2021	3	10	PCR_COBAS_COV19	CT 2	26.79
2021	3	10	PCR_PANTH_COV19	RLU	1224
2021	3	10	PCR_PANTH_COV19	RLU	1231
2021	3	10	PCR_PANTH_COV19	RLU	1199
2021	3	10	PCR_PANTH_COV19	RLU	1224
2021	3	10	PCR_PANTH_COV19	RLU	1200
2021	3	10	PCR_PANTH_COV19	RLU	1245
2021	3	10	PCR_PANTH_COV19	RLU	1190
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.29681812
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	39.96862464
2021	3	10	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.22793307
2021	3	11	PCR_COBAS_COV19	CT 2	37.63
2021	3	11	PCR_COBAS_COV19	CT 2	24.45
2021	3	11	PCR_COBAS_COV19	CT 2	19.74
2021	3	11	PCR_COBAS_COV19	CT 2	15.41
2021	3	11	PCR_COBAS_COV19	CT 2	36.23
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.59292458

AB1199

2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.52733808
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.11836792
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.59737065
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.6534956
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.02540522
2021	3	11	PCR_PANTH_COV19	RLU	1250
2021	3	11	PCR_PANTH_COV19	RLU	1270
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.08556591
2021	3	11	PCR_PANTH_COV19	RLU	1254
2021	3	11	PCR_PANTH_COV19	RLU	1195
2021	3	11	PCR_PANTH_COV19	RLU	1239
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.10338522
2021	3	11	PCR_COBAS_COV19	CT 2	27.28
2021	3	11	PCR_COBAS_COV19	CT 2	23.16
2021	3	11	PCR_COBAS_COV19	CT 2	21.84
2021	3	11	PCR_COBAS_COV19	CT 2	34.13
2021	3	11	PCR_COBAS_COV19	CT 2	37.09
2021	3	11	PCR_COBAS_COV19	CT 2	31
2021	3	11	PCR_COBAS_COV19	CT 2	30.14
2021	3	11	PCR_COBAS_COV19	CT 2	18.61
2021	3	11	PCR_COBAS_COV19	CT 2	24.23
2021	3	11	PCR_COBAS_COV19	CT 2	18.62
2021	3	11	PCR_COBAS_COV19	CT 2	33.52
2021	3	11	PCR_COBAS_COV19	CT 2	33.21
2021	3	11	PCR_COBAS_COV19	CT 2	38.5
2021	3	11	PCR_COBAS_COV19	CT 2	28.99
2021	3	11	PCR_COBAS_COV19	CT 2	16.83
2021	3	11	PCR_PANTH_COV19	RLU	1220
2021	3	11	PCR_PANTH_COV19	RLU	1218
2021	3	11	PCR_PANTH_COV19	RLU	1227
2021	3	11	PCR_PANTH_COV19	RLU	1242
2021	3	11	PCR_PANTH_COV19	RLU	1195
2021	3	11	PCR_PANTH_COV19	RLU	1161
2021	3	11	PCR_PANTH_COV19	RLU	1211
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.36471459
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.81967836
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.49379884
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.75265961
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.67029397
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.21048266
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.88210707
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.01553379
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.07282967
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.82487737
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.19568913
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.84032775
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.9741161

AB1200

2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.30478412
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.91164284
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.16823139
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.06170412
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.15095563
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.76970553
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.33279821
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.81198093
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.3328949
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.05148401
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.23371673
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.49298705
2021	3	11	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.88818002
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.19078937
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.42489498
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.33516606
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.84830486
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.06514968
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.66648882
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.72596298
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.15713854
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.80226858
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.60131263
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.19021759
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.59726672
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.14837266
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.75087344
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.93244256
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.61114687
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.14021801
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.64468603
2021	3	12	PCR_COBAS_COV19	CT 2	32.84
2021	3	12	PCR_COBAS_COV19	CT 2	17.42
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.86110414
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.34446331
2021	3	12	PCR_PANTH_COV19	RLU	1228
2021	3	12	PCR_PANTH_COV19	RLU	1199
2021	3	12	PCR_PANTH_COV19	RLU	1178
2021	3	12	PCR_PANTH_COV19	RLU	1271
2021	3	12	PCR_COBAS_COV19	CT 2	32.6
2021	3	12	PCR_COBAS_COV19	CT 2	37.71
2021	3	12	PCR_COBAS_COV19	CT 2	34.22
2021	3	12	PCR_COBAS_COV19	CT 2	32.41
2021	3	12	PCR_COBAS_COV19	CT 2	15.14
2021	3	12	PCR_PANTH_COV19	RLU	1182
2021	3	12	PCR_PANTH_COV19	RLU	1198
2021	3	12	PCR_PANTH_COV19	RLU	1218

AB1201

2021	3	12	PCR_PANTH_COV19	RLU	1233
2021	3	12	PCR_PANTH_COV19	RLU	1193
2021	3	12	PCR_PANTH_COV19	RLU	1237
2021	3	12	PCR_PANTH_COV19	RLU	1294
2021	3	12	PCR_PANTH_COV19	RLU	1279
2021	3	12	PCR_PANTH_COV19	RLU	1225
2021	3	12	PCR_PANTH_COV19	RLU	1204
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.09990774
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.58673265
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.44213775
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.51726644
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.18074152
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.01715727
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.64156979
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.29839047
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.90928963
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.89860612
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.22692984
2021	3	12	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.0147663
2021	3	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.6529012
2021	3	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.07364346
2021	3	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.34258571
2021	3	13	PCR_COBAS_COV19	CT 2	31.25
2021	3	13	PCR_COBAS_COV19	CT 2	18.88
2021	3	13	PCR_COBAS_COV19	CT 2	29.16
2021	3	13	PCR_COBAS_COV19	CT 2	29.84
2021	3	13	PCR_COBAS_COV19	CT 2	26.2
2021	3	13	PCR_COBAS_COV19	CT 2	38.27
2021	3	13	PCR_COBAS_COV19	CT 2	35.39
2021	3	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.26776373
2021	3	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.11566836
2021	3	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.17914534
2021	3	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.30827078
2021	3	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.419917
2021	3	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.10346182
2021	3	13	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.44953895
2021	3	13	PCR_PANTH_COV19	RLU	1177
2021	3	13	PCR_PANTH_COV19	RLU	1219
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.76311416
2021	3	14	PCR_PANTH_COV19	RLU	1173
2021	3	14	PCR_PANTH_COV19	RLU	1208
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.31041618
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.08584469
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.06871478
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.2788148
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.62549567
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.50135897

AB1202

2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.6483441
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.98579568
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.16687694
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.43415013
2021	3	14	PCR_PANTH_COV19	RLU	1207
2021	3	14	PCR_PANTH_COV19	RLU	1249
2021	3	14	PCR_PANTH_COV19	RLU	1226
2021	3	14	PCR_PANTH_COV19	RLU	1200
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.15405893
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.81201551
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.93361338
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.69964241
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.68119527
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.10353119
2021	3	14	PCR_PANTH_COV19	RLU	1238
2021	3	14	PCR_PANTH_COV19	RLU	1235
2021	3	14	PCR_PANTH_COV19	RLU	1256
2021	3	14	PCR_PANTH_COV19	RLU	1243
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.55532602
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.61416519
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.19426544
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.30124478
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.84537607
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.05456468
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.62649905
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.43951394
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.78954668
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.98544054
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.24191995
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.17280038
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.20177601
2021	3	14	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.4751254
2021	3	14	PCR_COBAS_COV19	CT 2	34.34
2021	3	15	PCR_COBAS_COV19	CT 2	35.68
2021	3	15	PCR_COBAS_COV19	CT 2	37.51
2021	3	15	PCR_COBAS_COV19	CT 2	37.84
2021	3	15	PCR_COBAS_COV19	CT 2	37.76
2021	3	15	PCR_COBAS_COV19	CT 2	35.57
2021	3	15	PCR_COBAS_COV19	CT 2	34.4
2021	3	15	PCR_COBAS_COV19	CT 2	34.56
2021	3	15	PCR_COBAS_COV19	CT 2	28.12
2021	3	15	PCR_COBAS_COV19	CT 2	30.1
2021	3	15	PCR_COBAS_COV19	CT 2	29.95
2021	3	15	PCR_COBAS_COV19	CT 2	30.4
2021	3	15	PCR_COBAS_COV19	CT 2	34.47
2021	3	15	PCR_PANTH_COV19	RLU	1135
2021	3	15	PCR_PANTH_COV19	RLU	1134

2021	3	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.32717915
2021	3	15	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.51143531
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.26099753
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.03761449
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.51860728
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.55336288
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.24359442
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.12184114
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.69989326
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.06176349
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.66433835
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.41095185
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.32862519
2021	3	16	PCR_COBAS_COV19	CT 2	22.04
2021	3	16	PCR_COBAS_COV19	CT 2	16.69
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.98692937
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.5171616
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.23372609
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.98195925
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.18889017
2021	3	16	PCR_PANTH_COV19	RLU	1303
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.62990544
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.61068194
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.92665397
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.70732861
2021	3	16	PCR_PANTH_COV19	RLU	1310
2021	3	16	PCR_PANTH_COV19	RLU	1338
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.55536928
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.23961447
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.19065369
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.7121956
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.2213757
2021	3	16	PCR_COBAS_COV19	CT 2	36.78
2021	3	16	PCR_COBAS_COV19	CT 2	31.72
2021	3	16	PCR_COBAS_COV19	CT 2	30.4
2021	3	16	PCR_COBAS_COV19	CT 2	32.45
2021	3	16	PCR_COBAS_COV19	CT 2	15.99
2021	3	16	PCR_COBAS_COV19	CT 2	31.25
2021	3	16	PCR_COBAS_COV19	CT 2	31.33
2021	3	16	PCR_COBAS_COV19	CT 2	33.35
2021	3	16	PCR_COBAS_COV19	CT 2	32.18
2021	3	16	PCR_COBAS_COV19	CT 2	38.25
2021	3	16	PCR_COBAS_COV19	CT 2	27.61
2021	3	16	PCR_COBAS_COV19	CT 2	29.9
2021	3	16	PCR_COBAS_COV19	CT 2	34.55
2021	3	16	PCR_COBAS_COV19	CT 2	34.79
2021	3	16	PCR_COBAS_COV19	CT 2	33.43

AB1204

2021	3	16	PCR_COBAS_COV19	CT 2	37.04
2021	3	16	PCR_COBAS_COV19	CT 2	31.02
2021	3	16	PCR_COBAS_COV19	CT 2	30.86
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.24174038
2021	3	16	PCR_PANTH_COV19	RLU	1260
2021	3	16	PCR_PANTH_COV19	RLU	1245
2021	3	16	PCR_PANTH_COV19	RLU	1313
2021	3	16	PCR_PANTH_COV19	RLU	1295
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.31196511
2021	3	16	PCR_PANTH_COV19	RLU	1279
2021	3	16	PCR_PANTH_COV19	RLU	1309
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.37171478
2021	3	16	PCR_PANTH_COV19	RLU	1301
2021	3	16	PCR_PANTH_COV19	RLU	1269
2021	3	16	PCR_PANTH_COV19	RLU	1088
2021	3	16	PCR_PANTH_COV19	RLU	1158
2021	3	16	PCR_PANTH_COV19	RLU	1262
2021	3	16	PCR_PANTH_COV19	RLU	1280
2021	3	16	PCR_PANTH_COV19	RLU	1229
2021	3	16	PCR_PANTH_COV19	RLU	1221
2021	3	16	PCR_PANTH_COV19	RLU	1200
2021	3	16	PCR_PANTH_COV19	RLU	1250
2021	3	16	PCR_PANTH_COV19	RLU	1274
2021	3	16	PCR_PANTH_COV19	RLU	1215
2021	3	16	PCR_PANTH_COV19	RLU	1282
2021	3	16	PCR_PANTH_COV19	RLU	1237
2021	3	16	PCR_PANTH_COV19	RLU	1264
2021	3	16	PCR_PANTH_COV19	RLU	1278
2021	3	16	PCR_PANTH_COV19	RLU	1260
2021	3	16	PCR_PANTH_COV19	RLU	1187
2021	3	16	PCR_PANTH_COV19	RLU	1224
2021	3	16	PCR_PANTH_COV19	RLU	1232
2021	3	16	PCR_PANTH_COV19	RLU	1244
2021	3	16	PCR_PANTH_COV19	RLU	1275
2021	3	16	PCR_PANTH_COV19	RLU	1220
2021	3	16	PCR_PANTH_COV19	RLU	1207
2021	3	16	PCR_PANTH_COV19	RLU	1144
2021	3	16	PCR_PANTH_COV19	RLU	1219
2021	3	16	PCR_PANTH_COV19	RLU	1192
2021	3	16	PCR_PANTH_COV19	RLU	1214
2021	3	16	PCR_PANTH_COV19	RLU	1141
2021	3	16	PCR_PANTH_COV19	RLU	1207
2021	3	16	PCR_PANTH_COV19	RLU	1201
2021	3	16	PCR_PANTH_COV19	RLU	1223
2021	3	16	PCR_PANTH_COV19	RLU	1200
2021	3	16	PCR_PANTH_COV19	RLU	1160
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.01952716

AB1205

2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.73800121
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.24998341
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.53899302
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.34392795
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.23713815
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.41023102
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.08190854
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.98347716
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.01902659
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.66328878
2021	3	16	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.49130892
2021	3	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.14005142
2021	3	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.73854111
2021	3	17	PCR_COBAS_COV19	CT 2	16.62
2021	3	17	PCR_COBAS_COV19	CT 2	25.09
2021	3	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.43120066
2021	3	17	PCR_COBAS_COV19	CT 2	27.66
2021	3	17	PCR_COBAS_COV19	CT 2	18.96
2021	3	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.43353273
2021	3	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.48593477
2021	3	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.5233903
2021	3	17	PCR_PANTH_COV19	RLU	1138
2021	3	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.93542789
2021	3	17	PCR_PANTH_COV19	RLU	1071
2021	3	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.64522932
2021	3	17	PCR_COBAS_COV19	CT 2	36.69
2021	3	17	PCR_COBAS_COV19	CT 2	29.58
2021	3	17	PCR_COBAS_COV19	CT 2	34.16
2021	3	17	PCR_COBAS_COV19	CT 2	25.52
2021	3	17	PCR_COBAS_COV19	CT 2	22.2
2021	3	17	PCR_COBAS_COV19	CT 2	33.5
2021	3	17	PCR_COBAS_COV19	CT 2	35.25
2021	3	17	PCR_COBAS_COV19	CT 2	36.55
2021	3	17	PCR_COBAS_COV19	CT 2	28.51
2021	3	17	PCR_COBAS_COV19	CT 2	34.32
2021	3	17	PCR_COBAS_COV19	CT 2	30.78
2021	3	17	PCR_COBAS_COV19	CT 2	34.26
2021	3	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.8743114
2021	3	17	PCR_PANTH_COV19	RLU	1193
2021	3	17	PCR_PANTH_COV19	RLU	1226
2021	3	17	PCR_PANTH_COV19	RLU	1212
2021	3	17	PCR_PANTH_COV19	RLU	1232
2021	3	17	PCR_PANTH_COV19	RLU	1353
2021	3	17	PCR_PANTH_COV19	RLU	1358
2021	3	17	PCR_PANTH_COV19	RLU	1362
2021	3	17	PCR_PANTH_COV19	RLU	1167
2021	3	17	PCR_PANTH_COV19	RLU	1330

AB1206

2021	3	17	PCR_PANTH_COV19	RLU	1283
2021	3	17	PCR_PANTH_COV19	RLU	1390
2021	3	17	PCR_PANTH_COV19	RLU	1017
2021	3	17	PCR_PANTH_COV19	RLU	1306
2021	3	17	PCR_PANTH_COV19	RLU	1294
2021	3	17	PCR_PANTH_COV19	RLU	1184
2021	3	17	PCR_PANTH_COV19	RLU	1144
2021	3	17	PCR_PANTH_COV19	RLU	1181
2021	3	17	PCR_PANTH_COV19	RLU	1228
2021	3	17	PCR_PANTH_COV19	RLU	1171
2021	3	17	PCR_PANTH_COV19	RLU	1246
2021	3	17	PCR_PANTH_COV19	RLU	1241
2021	3	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.20335557
2021	3	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.52571722
2021	3	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.57764827
2021	3	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.82849649
2021	3	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.80705263
2021	3	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.47885578
2021	3	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.25661618
2021	3	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.97007171
2021	3	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.83548027
2021	3	17	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.85557757
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.75513304
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.24108712
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.38590938
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.03002958
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.84136582
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.7037923
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.881264
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.81512051
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.48646462
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.67983173
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.89822511
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.2659475
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.18524131
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.17714487
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.84213545
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.22227786
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.63670976
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.08154172
2021	3	18	PCR_PANTH_COV19	RLU	1192
2021	3	18	PCR_PANTH_COV19	RLU	1122
2021	3	18	PCR_PANTH_COV19	RLU	1216
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.70466784
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.49896436
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.27596809
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.24494742

AB1207

2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.90295419
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.31449922
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.0894055
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.78668754
2021	3	18	PCR_COBAS_COV19	CT 2	31.99
2021	3	18	PCR_COBAS_COV19	CT 2	32.9
2021	3	18	PCR_COBAS_COV19	CT 2	33.07
2021	3	18	PCR_COBAS_COV19	CT 2	33.45
2021	3	18	PCR_COBAS_COV19	CT 2	35.45
2021	3	18	PCR_COBAS_COV19	CT 2	24.47
2021	3	18	PCR_COBAS_COV19	CT 2	33.44
2021	3	18	PCR_COBAS_COV19	CT 2	33.61
2021	3	18	PCR_COBAS_COV19	CT 2	29.4
2021	3	18	PCR_COBAS_COV19	CT 2	33.99
2021	3	18	PCR_COBAS_COV19	CT 2	34.55
2021	3	18	PCR_COBAS_COV19	CT 2	22.27
2021	3	18	PCR_COBAS_COV19	CT 2	34.9
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.12318928
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.39607028
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.01443206
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.65036555
2021	3	18	PCR_COBAS_COV19	CT 2	33.16
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.75557292
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.48468691
2021	3	18	PCR_PANTH_COV19	RLU	1244
2021	3	18	PCR_COBAS_COV19	CT 2	31.53
2021	3	18	PCR_COBAS_COV19	CT 2	35.65
2021	3	18	PCR_COBAS_COV19	CT 2	36.21
2021	3	18	PCR_COBAS_COV19	CT 2	35.9
2021	3	18	PCR_COBAS_COV19	CT 2	35.29
2021	3	18	PCR_COBAS_COV19	CT 2	37.83
2021	3	18	PCR_COBAS_COV19	CT 2	27.98
2021	3	18	PCR_COBAS_COV19	CT 2	21.99
2021	3	18	PCR_COBAS_COV19	CT 2	18.65
2021	3	18	PCR_COBAS_COV19	CT 2	36.64
2021	3	18	PCR_PANTH_COV19	RLU	1279
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.06861154
2021	3	18	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.20812927
2021	3	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.15770959
2021	3	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.10391726
2021	3	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.85716519
2021	3	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.0455345
2021	3	19	PCR_COBAS_COV19	CT 2	29.91
2021	3	19	PCR_COBAS_COV19	CT 2	35.95
2021	3	19	PCR_COBAS_COV19	CT 2	29.83
2021	3	19	PCR_COBAS_COV19	CT 2	37.64
2021	3	19	PCR_COBAS_COV19	CT 2	36.81

AB1208

2021	3	19	PCR_COBAS_COV19	CT 2	35.26
2021	3	19	PCR_COBAS_COV19	CT 2	31.64
2021	3	19	PCR_COBAS_COV19	CT 2	36.37
2021	3	19	PCR_COBAS_COV19	CT 2	23.37
2021	3	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.5351623
2021	3	19	PCR_COBAS_COV19	CT 2	31.77
2021	3	19	PCR_COBAS_COV19	CT 2	33.49
2021	3	19	PCR_COBAS_COV19	CT 2	20.56
2021	3	19	PCR_COBAS_COV19	CT 2	17.14
2021	3	19	PCR_COBAS_COV19	CT 2	37.4
2021	3	19	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.25482506
2021	3	19	PCR_PANTH_COV19	RLU	1280
2021	3	19	PCR_PANTH_COV19	RLU	1245
2021	3	19	PCR_PANTH_COV19	RLU	1299
2021	3	19	PCR_PANTH_COV19	RLU	1318
2021	3	19	PCR_PANTH_COV19	RLU	1306
2021	3	19	PCR_PANTH_COV19	RLU	1304
2021	3	19	PCR_PANTH_COV19	RLU	1277
2021	3	19	PCR_PANTH_COV19	RLU	1249
2021	3	19	PCR_PANTH_COV19	RLU	1314
2021	3	19	PCR_PANTH_COV19	RLU	1250
2021	3	19	PCR_PANTH_COV19	RLU	1283
2021	3	19	PCR_PANTH_COV19	RLU	1092
2021	3	19	PCR_COBAS_COV19	CT 2	37.02
2021	3	19	PCR_COBAS_COV19	CT 2	31.79
2021	3	19	PCR_COBAS_COV19	CT 2	31.63
2021	3	19	PCR_COBAS_COV19	CT 2	34.3
2021	3	19	PCR_COBAS_COV19	CT 2	35.23
2021	3	19	PCR_COBAS_COV19	CT 2	37.03
2021	3	19	PCR_COBAS_COV19	CT 2	17.8
2021	3	19	PCR_COBAS_COV19	CT 2	26.82
2021	3	19	PCR_COBAS_COV19	CT 2	18.26
2021	3	19	PCR_COBAS_COV19	CT 2	33.57
2021	3	19	PCR_COBAS_COV19	CT 2	31.59
2021	3	19	PCR_COBAS_COV19	CT 2	36.74
2021	3	19	PCR_COBAS_COV19	CT 2	19.12
2021	3	19	PCR_COBAS_COV19	CT 2	22.37
2021	3	19	PCR_COBAS_COV19	CT 2	14.8
2021	3	19	PCR_COBAS_COV19	CT 2	26.51
2021	3	19	PCR_PANTH_COV19	RLU	1309
2021	3	19	PCR_PANTH_COV19	RLU	1194
2021	3	19	PCR_PANTH_COV19	RLU	1320
2021	3	19	PCR_PANTH_COV19	RLU	1331
2021	3	19	PCR_PANTH_COV19	RLU	1265
2021	3	19	PCR_PANTH_COV19	RLU	1257
2021	3	19	PCR_PANTH_COV19	RLU	1180
2021	3	19	PCR_PANTH_COV19	RLU	1209

AB1209

2021	3	19	PCR_PANTH_COV19	RLU	1234
2021	3	19	PCR_PANTH_COV19	RLU	1195
2021	3	19	PCR_PANTH_COV19	RLU	1214
2021	3	19	PCR_PANTH_COV19	RLU	1225
2021	3	19	PCR_COBAS_COV19	CT 2	29.93
2021	3	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.11704954
2021	3	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.46688697
2021	3	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.18465777
2021	3	20	PCR_COBAS_COV19	CT 2	31.95
2021	3	20	PCR_COBAS_COV19	CT 2	33.25
2021	3	20	PCR_PANTH_COV19	RLU	1289
2021	3	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.3398252
2021	3	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.11622848
2021	3	20	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.06628936
2021	3	20	PCR_PANTH_COV19	RLU	1241
2021	3	20	PCR_PANTH_COV19	RLU	1246
2021	3	20	PCR_PANTH_COV19	RLU	1188
2021	3	20	PCR_PANTH_COV19	RLU	1177
2021	3	20	PCR_PANTH_COV19	RLU	1196
2021	3	20	PCR_PANTH_COV19	RLU	1232
2021	3	21	PCR_PANTH_COV19	RLU	1255
2021	3	21	PCR_PANTH_COV19	RLU	1229
2021	3	21	PCR_PANTH_COV19	RLU	1213
2021	3	21	PCR_PANTH_COV19	RLU	1225
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.44763548
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.14765951
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.80798431
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.29792507
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.13785076
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.0494144
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.12723584
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.2489333
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.60477433
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.78
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.12583512
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.2910432
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.96496941
2021	3	21	PCR_PANTH_COV19	RLU	1199
2021	3	21	PCR_PANTH_COV19	RLU	1209
2021	3	21	PCR_PANTH_COV19	RLU	1245
2021	3	21	PCR_PANTH_COV19	RLU	1190
2021	3	21	PCR_PANTH_COV19	RLU	1212
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.01024088
2021	3	21	PCR_PANTH_COV19	RLU	1223
2021	3	21	PCR_PANTH_COV19	RLU	1196
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.43553992
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.56961916

AB1210

2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.52178652
2021	3	21	PCR_PANTH_COV19	RLU	1234
2021	3	21	PCR_PANTH_COV19	RLU	1244
2021	3	21	PCR_PANTH_COV19	RLU	1174
2021	3	21	PCR_PANTH_COV19	RLU	1204
2021	3	21	PCR_PANTH_COV19	RLU	1264
2021	3	21	PCR_PANTH_COV19	RLU	1235
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.81713011
2021	3	21	PCR_PANTH_COV19	RLU	1215
2021	3	21	PCR_PANTH_COV19	RLU	1198
2021	3	21	PCR_PANTH_COV19	RLU	1059
2021	3	21	PCR_PANTH_COV19	RLU	1208
2021	3	21	PCR_PANTH_COV19	RLU	1268
2021	3	21	PCR_PANTH_COV19	RLU	1239
2021	3	21	PCR_PANTH_COV19	RLU	1243
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.36190733
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.23801437
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.41784381
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.34915929
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.69316265
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.97128047
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.58420717
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.11878257
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.07179546
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.1324062
2021	3	21	PCR_PANTH_COV19	RLU	1255
2021	3	21	PCR_PANTH_COV19	RLU	1253
2021	3	21	PCR_PANTH_COV19	RLU	1263
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.46661382
2021	3	21	PCR_PANTH_COV19	RLU	1254
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.66
2021	3	21	PCR_PANTH_COV19	RLU	1240
2021	3	21	PCR_PANTH_COV19	RLU	1237
2021	3	21	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.70952019
2021	3	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.79117176
2021	3	22	PCR_COBAS_COV19	CT 2	36.66
2021	3	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.37775527
2021	3	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.7
2021	3	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.13
2021	3	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.04
2021	3	22	PCR_PANTH_COV19	RLU	1248
2021	3	22	PCR_PANTH_COV19	RLU	1251
2021	3	22	PCR_PANTH_COV19	RLU	1234
2021	3	22	PCR_PANTH_COV19	RLU	1211
2021	3	22	PCR_COBAS_COV19	CT 2	17.14
2021	3	22	PCR_COBAS_COV19	CT 2	33.17
2021	3	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.70698519

AB1211

2021	3	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.46966068
2021	3	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.56781592
2021	3	22	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.42529571
2021	3	22	PCR_COBAS_COV19	CT 2	20
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.32823279
2021	3	23	PCR_COBAS_COV19	CT 2	21.81
2021	3	23	PCR_COBAS_COV19	CT 2	35.29
2021	3	23	PCR_COBAS_COV19	CT 2	33.22
2021	3	23	PCR_COBAS_COV19	CT 2	31.7
2021	3	23	PCR_COBAS_COV19	CT 2	36.31
2021	3	23	PCR_COBAS_COV19	CT 2	36.62
2021	3	23	PCR_COBAS_COV19	CT 2	34.15
2021	3	23	PCR_COBAS_COV19	CT 2	31.19
2021	3	23	PCR_COBAS_COV19	CT 2	34.29
2021	3	23	PCR_COBAS_COV19	CT 2	22.9
2021	3	23	PCR_COBAS_COV19	CT 2	17.38
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.15348407
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.3556611
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.17709737
2021	3	23	PCR_COBAS_COV19	CT 2	22.25
2021	3	23	PCR_COBAS_COV19	CT 2	17
2021	3	23	PCR_COBAS_COV19	CT 2	21.69
2021	3	23	PCR_COBAS_COV19	CT 2	32.55
2021	3	23	PCR_COBAS_COV19	CT 2	31.24
2021	3	23	PCR_COBAS_COV19	CT 2	19.67
2021	3	23	PCR_COBAS_COV19	CT 2	24.01
2021	3	23	PCR_PANTH_COV19	RLU	1229
2021	3	23	PCR_PANTH_COV19	RLU	1207
2021	3	23	PCR_PANTH_COV19	RLU	1272
2021	3	23	PCR_PANTH_COV19	RLU	1342
2021	3	23	PCR_PANTH_COV19	RLU	1281
2021	3	23	PCR_PANTH_COV19	RLU	1258
2021	3	23	PCR_PANTH_COV19	RLU	1254
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.3199912
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.95816348
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.2147316
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.22460794
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.52786887
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.42410338
2021	3	23	PCR_PANTH_COV19	RLU	1204
2021	3	23	PCR_PANTH_COV19	RLU	1275
2021	3	23	PCR_PANTH_COV19	RLU	1273
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.87945187
2021	3	23	PCR_PANTH_COV19	RLU	1265
2021	3	23	PCR_PANTH_COV19	RLU	1243
2021	3	23	PCR_PANTH_COV19	RLU	1313
2021	3	23	PCR_PANTH_COV19	RLU	1264

AB1212

2021	3	23	PCR_PANTH_COV19	RLU	1224
2021	3	23	PCR_PANTH_COV19	RLU	1230
2021	3	23	PCR_PANTH_COV19	RLU	1247
2021	3	23	PCR_PANTH_COV19	RLU	1213
2021	3	23	PCR_PANTH_COV19	RLU	1257
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.60233387
2021	3	23	PCR_PANTH_COV19	RLU	1261
2021	3	23	PCR_COBAS_COV19	CT 2	35.39
2021	3	23	PCR_COBAS_COV19	CT 2	30.96
2021	3	23	PCR_PANTH_COV19	RLU	1305
2021	3	23	PCR_PANTH_COV19	RLU	1232
2021	3	23	PCR_PANTH_COV19	RLU	1226
2021	3	23	PCR_PANTH_COV19	RLU	1210
2021	3	23	PCR_PANTH_COV19	RLU	1208
2021	3	23	PCR_PANTH_COV19	RLU	1215
2021	3	23	PCR_PANTH_COV19	RLU	1216
2021	3	23	PCR_PANTH_COV19	RLU	1231
2021	3	23	PCR_PANTH_COV19	RLU	1222
2021	3	23	PCR_PANTH_COV19	RLU	1234
2021	3	23	PCR_COBAS_COV19	CT 2	22.84
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.15466234
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.21208544
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.59896228
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.12344573
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.6277624
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	25.19483
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.11994418
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	39.66019743
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.50009256
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.48591662
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.08352472
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.88564567
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.51591197
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.35235004
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.48490135
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	29.27136557
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.1568108
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	28.37299526
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.50740782
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.74166694
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.42543842
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.86388346
2021	3	23	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.17291772
2021	3	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.31093097
2021	3	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.75500694
2021	3	24	PCR_COBAS_COV19	CT 2	16.52
2021	3	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.33296116

AB1213

2021	3	24	PCR_PANTH_COV19	RLU	1225
2021	3	24	PCR_PANTH_COV19	RLU	1227
2021	3	24	PCR_PANTH_COV19	RLU	1246
2021	3	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.70571975
2021	3	24	PCR_PANTH_COV19	RLU	1241
2021	3	24	PCR_PANTH_COV19	RLU	1299
2021	3	24	PCR_PANTH_COV19	RLU	1234
2021	3	24	PCR_PANTH_COV19	RLU	1237
2021	3	24	PCR_PANTH_COV19	RLU	1242
2021	3	24	PCR_PANTH_COV19	RLU	1268
2021	3	24	PCR_PANTH_COV19	RLU	1273
2021	3	24	PCR_PANTH_COV19	RLU	1289
2021	3	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.4184615
2021	3	24	PCR_PANTH_COV19	RLU	1283
2021	3	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.87508709
2021	3	24	PCR_PANTH_COV19	RLU	1226
2021	3	24	PCR_PANTH_COV19	RLU	1278
2021	3	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.84119161
2021	3	24	PCR_PANTH_COV19	RLU	1266
2021	3	24	PCR_PANTH_COV19	RLU	1249
2021	3	24	PCR_PANTH_COV19	RLU	1235
2021	3	24	PCR_PANTH_COV19	RLU	1284
2021	3	24	PCR_PANTH_COV19	RLU	1249
2021	3	24	PCR_PANTH_COV19	RLU	1214
2021	3	24	PCR_PANTH_COV19	RLU	1224
2021	3	24	PCR_PANTH_COV19	RLU	1252
2021	3	24	PCR_PANTH_COV19	RLU	1258
2021	3	24	PCR_PANTH_COV19	RLU	1238
2021	3	24	PCR_PANTH_COV19	RLU	1218
2021	3	24	PCR_PANTH_COV19	RLU	1226
2021	3	24	PCR_PANTH_COV19	RLU	1260
2021	3	24	PCR_PANTH_COV19	RLU	1069
2021	3	24	PCR_PANTH_COV19	RLU	1228
2021	3	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.27490691
2021	3	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.76688167
2021	3	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	18.63780255
2021	3	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.66814515
2021	3	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.10907651
2021	3	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.95674697
2021	3	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.4842533
2021	3	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.60212504
2021	3	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.0492177
2021	3	24	PCR_PANTH_COV19	RLU	1220
2021	3	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.05153125
2021	3	24	PCR_COBAS_COV19	CT 2	22.83
2021	3	24	PCR_COBAS_COV19	CT 2	32.63
2021	3	24	PCR_COBAS_COV19	CT 2	27.45

2021	3	24	PCR_COBAS_COV19	CT 2	32.17
2021	3	24	PCR_COBAS_COV19	CT 2	19.4
2021	3	24	PCR_PANTH_COV19	RLU	1259
2021	3	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.1771526
2021	3	24	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.28023347
2021	3	25	PCR_COBAS_COV19	CT 2	35.68
2021	3	25	PCR_COBAS_COV19	CT 2	19.04
2021	3	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.66165001
2021	3	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.95128764
2021	3	25	PCR_PANTH_COV19	RLU	1298
2021	3	25	PCR_PANTH_COV19	RLU	1214
2021	3	25	PCR_PANTH_COV19	RLU	1216
2021	3	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.43129959
2021	3	25	PCR_PANTH_COV19	RLU	1250
2021	3	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.3736953
2021	3	25	PCR_COBAS_COV19	CT 2	33.6
2021	3	25	PCR_COBAS_COV19	CT 2	32.3
2021	3	25	PCR_COBAS_COV19	CT 2	20.76
2021	3	25	PCR_COBAS_COV19	CT 2	19.46
2021	3	25	PCR_COBAS_COV19	CT 2	34.14
2021	3	25	PCR_COBAS_COV19	CT 2	26.28
2021	3	25	PCR_COBAS_COV19	CT 2	34.52
2021	3	25	PCR_COBAS_COV19	CT 2	27.63
2021	3	25	PCR_PANTH_COV19	RLU	1224
2021	3	25	PCR_PANTH_COV19	RLU	1258
2021	3	25	PCR_PANTH_COV19	RLU	1200
2021	3	25	PCR_PANTH_COV19	RLU	1281
2021	3	25	PCR_PANTH_COV19	RLU	1238
2021	3	25	PCR_PANTH_COV19	RLU	1260
2021	3	25	PCR_PANTH_COV19	RLU	1235
2021	3	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.05306238
2021	3	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	24.91106316
2021	3	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.31575578
2021	3	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.47714551
2021	3	25	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.44164834
2021	3	25	PCR_PANTH_COV19	RLU	1261
2021	3	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.13493854
2021	3	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.1651211
2021	3	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.0850222
2021	3	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.28286723
2021	3	26	PCR_COBAS_COV19	CT 2	16.82
2021	3	26	PCR_COBAS_COV19	CT 2	26.37
2021	3	26	PCR_COBAS_COV19	CT 2	15.72
2021	3	26	PCR_COBAS_COV19	CT 2	18.95
2021	3	26	PCR_COBAS_COV19	CT 2	30.86
2021	3	26	PCR_PANTH_COV19	RLU	1298
2021	3	26	PCR_PANTH_COV19	RLU	1267

AB1215

2021	3	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.99922256
2021	3	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.27227941
2021	3	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.04772727
2021	3	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.21818175
2021	3	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.55521531
2021	3	26	PCR_COBAS_COV19	CT 2	33.47
2021	3	26	PCR_COBAS_COV19	CT 2	30.2
2021	3	26	PCR_COBAS_COV19	CT 2	17.66
2021	3	26	PCR_COBAS_COV19	CT 2	22.85
2021	3	26	PCR_COBAS_COV19	CT 2	34.6
2021	3	26	PCR_COBAS_COV19	CT 2	34.6
2021	3	26	PCR_PANTH_COV19	RLU	1280
2021	3	26	PCR_PANTH_COV19	RLU	1288
2021	3	26	PCR_PANTH_COV19	RLU	1311
2021	3	26	PCR_PANTH_COV19	RLU	1227
2021	3	26	PCR_PANTH_COV19	RLU	1246
2021	3	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.5565506
2021	3	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.12614058
2021	3	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.04124404
2021	3	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.8541908
2021	3	26	PCR_COV_FLU_RSV	SARS-CoV-2 CT	14.22985954
2021	3	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.44117932
2021	3	27	PCR_COBAS_COV19	CT 2	26.37
2021	3	27	PCR_COBAS_COV19	CT 2	34.44
2021	3	27	PCR_COBAS_COV19	CT 2	36.41
2021	3	27	PCR_COBAS_COV19	CT 2	37.44
2021	3	27	PCR_COBAS_COV19	CT 2	31.77
2021	3	27	PCR_COBAS_COV19	CT 2	26.34
2021	3	27	PCR_COBAS_COV19	CT 2	30.86
2021	3	27	PCR_COBAS_COV19	CT 2	37.36
2021	3	27	PCR_COBAS_COV19	CT 2	30.04
2021	3	27	PCR_COBAS_COV19	CT 2	35.84
2021	3	27	PCR_COBAS_COV19	CT 2	21.3
2021	3	27	PCR_COBAS_COV19	CT 2	34.98
2021	3	27	PCR_COBAS_COV19	CT 2	26.53
2021	3	27	PCR_PANTH_COV19	RLU	1236
2021	3	27	PCR_PANTH_COV19	RLU	1245
2021	3	27	PCR_PANTH_COV19	RLU	1283
2021	3	27	PCR_PANTH_COV19	RLU	1287
2021	3	27	PCR_PANTH_COV19	RLU	1282
2021	3	27	PCR_PANTH_COV19	RLU	1236
2021	3	27	PCR_PANTH_COV19	RLU	1245
2021	3	27	PCR_PANTH_COV19	RLU	1287
2021	3	27	PCR_PANTH_COV19	RLU	1273
2021	3	27	PCR_PANTH_COV19	RLU	1276
2021	3	27	PCR_PANTH_COV19	RLU	1082
2021	3	27	PCR_PANTH_COV19	RLU	1261

2021	3	27	PCR_PANTH_COV19	RLU	1276
2021	3	27	PCR_PANTH_COV19	RLU	1235
2021	3	27	PCR_PANTH_COV19	RLU	1220
2021	3	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	23.92923831
2021	3	27	PCR_COV_FLU_RSV	SARS-CoV-2 CT	27.08260139
2021	3	28	PCR_PANTH_COV19	RLU	1319
2021	3	28	PCR_PANTH_COV19	RLU	1233
2021	3	28	PCR_PANTH_COV19	RLU	1305
2021	3	28	PCR_PANTH_COV19	RLU	1229
2021	3	28	PCR_PANTH_COV19	RLU	1279
2021	3	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.14477624
2021	3	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.13640733
2021	3	28	PCR_PANTH_COV19	RLU	1269
2021	3	28	PCR_PANTH_COV19	RLU	1237
2021	3	28	PCR_PANTH_COV19	RLU	1251
2021	3	28	PCR_PANTH_COV19	RLU	1264
2021	3	28	PCR_PANTH_COV19	RLU	1237
2021	3	28	PCR_PANTH_COV19	RLU	1271
2021	3	28	PCR_PANTH_COV19	RLU	1280
2021	3	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	21.87743444
2021	3	28	PCR_COV_FLU_RSV	SARS-CoV-2 CT	30.48864787
2021	3	28	PCR_PANTH_COV19	RLU	1249
2021	3	28	PCR_PANTH_COV19	RLU	1320
2021	3	28	PCR_PANTH_COV19	RLU	1149
2021	3	28	PCR_PANTH_COV19	RLU	1298
2021	3	28	PCR_PANTH_COV19	RLU	1243
2021	3	28	PCR_PANTH_COV19	RLU	1250
2021	3	28	PCR_PANTH_COV19	RLU	1259
2021	3	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.43464945
2021	3	29	PCR_COBAS_COV19	CT 2	21.52
2021	3	29	PCR_COBAS_COV19	CT 2	15.92
2021	3	29	PCR_COBAS_COV19	CT 2	26.41
2021	3	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	15.98349469
2021	3	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	16.97933122
2021	3	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	33.98560482
2021	3	29	PCR_COBAS_COV19	CT 2	34.25
2021	3	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.36077007
2021	3	29	PCR_COBAS_COV19	CT 2	32.96
2021	3	29	PCR_COBAS_COV19	CT 2	34.93
2021	3	29	PCR_PANTH_COV19	RLU	1254
2021	3	29	PCR_PANTH_COV19	RLU	1038
2021	3	29	PCR_PANTH_COV19	RLU	1279
2021	3	29	PCR_PANTH_COV19	RLU	1275
2021	3	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.77224104
2021	3	29	PCR_COV_FLU_RSV	SARS-CoV-2 CT	31.7892234
2021	3	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	38.05336826
2021	3	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	34.9948431

AB1217

2021	3	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	36.12078812
2021	3	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	22.18727262
2021	3	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	32.9596482
2021	3	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.06508163
2021	3	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	37.67418547
2021	3	30	PCR_COBAS_COV19	CT 2	32
2021	3	30	PCR_COBAS_COV19	CT 2	36.66
2021	3	30	PCR_COBAS_COV19	CT 2	37.85
2021	3	30	PCR_COBAS_COV19	CT 2	21.88
2021	3	30	PCR_COBAS_COV19	CT 2	17.63
2021	3	30	PCR_COBAS_COV19	CT 2	32.66
2021	3	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	13.81629599
2021	3	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	12.66881694
2021	3	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	26.11682018
2021	3	30	PCR_COBAS_COV19	CT 2	20.63
2021	3	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	20.97048677
2021	3	30	PCR_PANTH_COV19	RLU	1254
2021	3	30	PCR_PANTH_COV19	RLU	1303
2021	3	30	PCR_PANTH_COV19	RLU	1277
2021	3	30	PCR_COBAS_COV19	CT 2	26.87
2021	3	30	PCR_PANTH_COV19	RLU	1218
2021	3	30	PCR_PANTH_COV19	RLU	1306
2021	3	30	PCR_PANTH_COV19	RLU	1229
2021	3	30	PCR_PANTH_COV19	RLU	1301
2021	3	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.2017123
2021	3	30	PCR_COV_FLU_RSV	SARS-CoV-2 CT	17.26631443
2021	3	30	PCR_PANTH_COV19	RLU	1288
2021	3	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	11.13984917
2021	3	31	PCR_PANTH_COV19	RLU	1235
2021	3	31	PCR_PANTH_COV19	RLU	1253
2021	3	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	19.12553765
2021	3	31	PCR_PANTH_COV19	RLU	1267
2021	3	31	PCR_PANTH_COV19	RLU	1254
2021	3	31	PCR_PANTH_COV19	RLU	1019
2021	3	31	PCR_PANTH_COV19	RLU	1211
2021	3	31	PCR_PANTH_COV19	RLU	1134
2021	3	31	PCR_PANTH_COV19	RLU	1139
2021	3	31	PCR_COV_FLU_RSV	SARS-CoV-2 CT	35.62203141
2021	3	31	PCR_PANTH_COV19	RLU	1213
2021	3	31	PCR_PANTH_COV19	RLU	1026
2021	3	31	PCR_PANTH_COV19	RLU	1198
2021	3	31	PCR_PANTH_COV19	RLU	1183
2021	3	31	PCR_PANTH_COV19	RLU	1224
2021	3	31	PCR_PANTH_COV19	RLU	1251
2021	3	31	PCR_PANTH_COV19	RLU	1234
2021	3	31	PCR_PANTH_COV19	RLU	1219
2021	3	31	PCR_PANTH_COV19	RLU	1269

AB1218

2021	3	31	PCR_PANTH_COV19	RLU	1222
2021	3	31	PCR_PANTH_COV19	RLU	1235

EXHIBIT "E"

AB1220

THIS IS EXHIBIT " E "
referred to in the Affidavit of
David Hersey
Sworn before me this 20
day of April A.D. 20 21
A Commissioner in and for the Province of Alberta
John Carpay
Barrister and Solicitor

From: "Conner, Michael (JUS)" <[redacted]
Date: Thursday, April 8, 2021 at 12:02 PM
To: Allison Pejovic [redacted]
Cc: Jay Cameron <[redacted] Jared Brown <[redacted] Denis (JUS)" [redacted] "Leonoff, Heather (JUS)" [redacted] 'Boyd, Sean (JUS)" [redacted]
Subject: RE: Gateway Bible Baptist Church et al. v. MB et al - request for further documents

Good morning,

Further to our letter dated April 6, 2021, please see the attached information on daily ICU capacity and ICU patients from April 1, 2016 to March 31, 2021.

Michael Conner
Constitutional Law Section
[redacted]

From: Allison Pejovic [redacted]
Sent: April 6, 2021 8:47 PM

To: Conner, Michael (JUS) <[redacted]>
Cc: Jay Cameron [redacted]; Jared Brown <[redacted] Guenette, Denis (JUS) [redacted]; Leonoff, Heather (JUS) [redacted]; Boyd, Sean (JUS) [redacted]>
Subject: [Caution: Suspicious Email] Re: Gateway Bible Baptist Church et al. v. MB et al - request for further documents

CAUTION: This email originated from an External Sender. Please do not click links or open attachments unless you recognize the source.
ATTENTION: ce courriel provient d'un expéditeur externe. Ne cliquez sur aucun lien et n'ouvrez pas de pièce jointe, excepté si vous connaissez l'expéditeur.

We confirm receipt of your email and letter. Thank you.

Allison Kindle Pejovic, B.A., LL.B., LL.M.
Barrister and Solicitor
Justice Centre for Constitutional Freedoms
[redacted]

www.jccf.ca

"Defending the constitutional freedoms of Canadians"

From: "Conner, Michael (JUS)" <[redacted]>
Date: Tuesday, April 6, 2021 at 4:50 PM
To: Allison Pejovic [redacted]>
Cc: Jay Cameron [redacted], Jared Brown [redacted] "Guenette, Denis (JUS)" [redacted], "Leonoff, Heather (JUS)" [redacted], "Boyd, Sean (JUS)" [redacted]
Subject: RE: Gateway Bible Baptist Church et al. v. MB et al - request for further documents

Further to your letter dated April 1, 2021 requesting further documents, please see the attached letter and enclosed spreadsheet of Ct values for positive PCR tests from March 2020 to March 2021.

We hope to be able to provide you with available information on ICU shortly.

Michael Conner
General Counsel
[redacted]

From: Allison Pejovic <a[redacted]>
Sent: April 6, 2021 3:47 PM
To: Conner, Michael (JUS) [redacted]>; Guenette, Denis (JUS) <[redacted];
Leonoff, Heather (JUS) [redacted]; Boyd, Sean (JUS) [redacted]
Cc: Jay Cameron <[redacted]; Jared Brown [redacted]>
Subject: [Caution: Suspicious Email] Gateway Bible Baptist Church et al. v. MB et al - April 6, 2021 Letter to Chief Justice Joyal

CAUTION: This email originated from an External Sender. Please do not click links or open attachments unless you recognize the source.
ATTENTION: ce courriel provient d'un expéditeur externe. Ne cliquez sur aucun lien et n'ouvrez pas de pièce jointe, excepté si vous connaissez l'expéditeur.

Please find enclosed a copy of correspondence which was filed with the court this afternoon.

Allison Kindle Pejovic, B.A., LL.B., LL.M.
Barrister and Solicitor
[redacted]

www.jccf.ca

"Defending the constitutional freedoms of Canadians"

AB1223

Source: Provincial Data Repository (DSS Datamart)

DateValue	***Total ICU Beds**	**Midnight Census** *(Number of ICU patients at midnight census)*
2016-04-01	78	69
2016-04-02	78	69
2016-04-03	78	68
2016-04-04	78	65
2016-04-05	78	71
2016-04-06	78	68
2016-04-07	78	64
2016-04-08	78	63
2016-04-09	78	66
2016-04-10	78	67
2016-04-11	78	71
2016-04-12	78	68
2016-04-13	78	65
2016-04-14	78	68
2016-04-15	78	65
2016-04-16	78	62
2016-04-17	78	63
2016-04-18	78	61
2016-04-19	78	65
2016-04-20	78	65
2016-04-21	78	61
2016-04-22	78	55
2016-04-23	78	60
2016-04-24	78	62
2016-04-25	78	60
2016-04-26	78	65
2016-04-27	78	60
2016-04-28	78	63
2016-04-29	78	62
2016-04-30	78	61
2016-05-01	78	60
2016-05-02	78	61
2016-05-03	78	64
2016-05-04	78	67
2016-05-05	78	64
2016-05-06	78	65
2016-05-07	78	65
2016-05-08	78	59
2016-05-09	78	59
2016-05-10	78	65
2016-05-11	78	62
2016-05-12	78	61
2016-05-13	78	57
2016-05-14	78	57
2016-05-15	78	59
2016-05-16	78	58
2016-05-17	78	57
2016-05-18	78	57
2016-05-19	78	56
2016-05-20	78	62
2016-05-21	78	63

2016-05-22	78	62
2016-05-23	78	61
2016-05-24	78	59
2016-05-25	78	58
2016-05-26	78	63
2016-05-27	78	68
2016-05-28	78	66
2016-05-29	78	62
2016-05-30	78	59
2016-05-31	78	61
2016-06-01	78	62
2016-06-02	78	59
2016-06-03	78	59
2016-06-04	78	58
2016-06-05	78	58
2016-06-06	78	58
2016-06-07	78	58
2016-06-08	78	58
2016-06-09	78	56
2016-06-10	78	58
2016-06-11	78	56
2016-06-12	78	51
2016-06-13	78	53
2016-06-14	78	58
2016-06-15	78	61
2016-06-16	78	57
2016-06-17	78	56
2016-06-18	78	57
2016-06-19	78	53
2016-06-20	78	57
2016-06-21	78	59
2016-06-22	78	59
2016-06-23	78	61
2016-06-24	78	62
2016-06-25	78	55
2016-06-26	78	51
2016-06-27	78	48
2016-06-28	78	54
2016-06-29	78	54
2016-06-30	78	56
2016-07-01	78	56
2016-07-02	78	55
2016-07-03	78	51
2016-07-04	78	52
2016-07-05	78	53
2016-07-06	78	58
2016-07-07	78	53
2016-07-08	78	54
2016-07-09	78	58
2016-07-10	78	52
2016-07-11	78	54
2016-07-12	78	60
2016-07-13	78	58
2016-07-14	78	59
2016-07-15	78	66
2016-07-16	78	59
2016-07-17	78	57
2016-07-18	78	55
2016-07-19	78	63
2016-07-20	78	64
2016-07-21	78	65

AB1225

2016-07-22	78	62
2016-07-23	78	62
2016-07-24	78	59
2016-07-25	78	58
2016-07-26	78	59
2016-07-27	78	58
2016-07-28	78	59
2016-07-29	78	62
2016-07-30	78	63
2016-07-31	78	56
2016-08-01	78	57
2016-08-02	78	55
2016-08-03	78	64
2016-08-04	78	58
2016-08-05	78	63
2016-08-06	78	58
2016-08-07	78	51
2016-08-08	78	55
2016-08-09	78	62
2016-08-10	78	56
2016-08-11	78	60
2016-08-12	78	57
2016-08-13	78	55
2016-08-14	78	53
2016-08-15	78	50
2016-08-16	78	56
2016-08-17	78	54
2016-08-18	78	55
2016-08-19	78	57
2016-08-20	78	54
2016-08-21	78	57
2016-08-22	78	53
2016-08-23	78	63
2016-08-24	78	61
2016-08-25	78	64
2016-08-26	78	58
2016-08-27	78	59
2016-08-28	78	60
2016-08-29	78	59
2016-08-30	78	58
2016-08-31	78	59
2016-09-01	78	60
2016-09-02	78	59
2016-09-03	78	57
2016-09-04	78	52
2016-09-05	78	55
2016-09-06	78	54
2016-09-07	78	62
2016-09-08	78	58
2016-09-09	78	60
2016-09-10	78	61
2016-09-11	78	59
2016-09-12	78	59
2016-09-13	78	62
2016-09-14	78	54
2016-09-15	78	58
2016-09-16	78	59
2016-09-17	78	65
2016-09-18	78	60
2016-09-19	78	56
2016-09-20	78	57

2016-09-21	78	54
2016-09-22	78	50
2016-09-23	78	54
2016-09-24	78	55
2016-09-25	78	57
2016-09-26	78	53
2016-09-27	78	57
2016-09-28	78	53
2016-09-29	78	61
2016-09-30	78	58
2016-10-01	78	61
2016-10-02	78	59
2016-10-03	78	60
2016-10-04	78	63
2016-10-05	78	63
2016-10-06	78	66
2016-10-07	78	66
2016-10-08	78	62
2016-10-09	78	63
2016-10-10	78	59
2016-10-11	78	62
2016-10-12	78	65
2016-10-13	78	61
2016-10-14	78	60
2016-10-15	78	60
2016-10-16	78	59
2016-10-17	78	58
2016-10-18	78	62
2016-10-19	78	64
2016-10-20	78	62
2016-10-21	78	58
2016-10-22	78	60
2016-10-23	78	60
2016-10-24	78	58
2016-10-25	78	61
2016-10-26	78	56
2016-10-27	78	55
2016-10-28	78	63
2016-10-29	78	59
2016-10-30	78	56
2016-10-31	78	55
2016-11-01	78	59
2016-11-02	78	60
2016-11-03	78	62
2016-11-04	78	61
2016-11-05	78	57
2016-11-06	78	58
2016-11-07	78	55
2016-11-08	78	55
2016-11-09	78	63
2016-11-10	78	61
2016-11-11	78	60
2016-11-12	78	59
2016-11-13	78	57
2016-11-14	78	57
2016-11-15	78	63
2016-11-16	78	56
2016-11-17	78	52
2016-11-18	78	57
2016-11-19	78	55
2016-11-20	78	51

AB1227

2016-11-21	78	55
2016-11-22	78	61
2016-11-23	78	58
2016-11-24	78	56
2016-11-25	78	65
2016-11-26	78	64
2016-11-27	78	55
2016-11-28	78	57
2016-11-29	78	61
2016-11-30	78	65
2016-12-01	78	58
2016-12-02	78	65
2016-12-03	78	61
2016-12-04	78	58
2016-12-05	78	57
2016-12-06	78	62
2016-12-07	78	60
2016-12-08	78	53
2016-12-09	78	58
2016-12-10	78	64
2016-12-11	78	60
2016-12-12	78	56
2016-12-13	78	60
2016-12-14	78	63
2016-12-15	78	61
2016-12-16	78	57
2016-12-17	78	59
2016-12-18	78	56
2016-12-19	78	57
2016-12-20	78	61
2016-12-21	78	59
2016-12-22	78	54
2016-12-23	78	57
2016-12-24	78	53
2016-12-25	78	50
2016-12-26	78	49
2016-12-27	78	53
2016-12-28	78	53
2016-12-29	78	55
2016-12-30	78	56
2016-12-31	78	56
2017-01-01	78	58
2017-01-02	78	58
2017-01-03	78	61
2017-01-04	78	63
2017-01-05	78	60
2017-01-06	78	59
2017-01-07	78	60
2017-01-08	78	61
2017-01-09	78	60
2017-01-10	78	61
2017-01-11	78	59
2017-01-12	78	54
2017-01-13	78	53
2017-01-14	78	56
2017-01-15	78	57
2017-01-16	78	55
2017-01-17	78	57
2017-01-18	78	60
2017-01-19	78	59
2017-01-20	78	60

2017-01-21	78	53
2017-01-22	78	55
2017-01-23	78	57
2017-01-24	78	58
2017-01-25	78	60
2017-01-26	78	58
2017-01-27	78	58
2017-01-28	78	53
2017-01-29	78	52
2017-01-30	78	47
2017-01-31	78	53
2017-02-01	78	59
2017-02-02	78	59
2017-02-03	78	58
2017-02-04	78	55
2017-02-05	78	58
2017-02-06	78	62
2017-02-07	78	58
2017-02-08	78	58
2017-02-09	78	56
2017-02-10	78	58
2017-02-11	78	61
2017-02-12	78	56
2017-02-13	78	56
2017-02-14	78	60
2017-02-15	78	61
2017-02-16	78	59
2017-02-17	78	61
2017-02-18	78	60
2017-02-19	78	57
2017-02-20	78	57
2017-02-21	78	61
2017-02-22	78	63
2017-02-23	78	58
2017-02-24	78	59
2017-02-25	78	59
2017-02-26	78	57
2017-02-27	78	55
2017-02-28	78	56
2017-03-01	78	59
2017-03-02	78	54
2017-03-03	78	53
2017-03-04	78	54
2017-03-05	78	57
2017-03-06	78	56
2017-03-07	78	55
2017-03-08	78	62
2017-03-09	78	59
2017-03-10	78	62
2017-03-11	78	58
2017-03-12	78	63
2017-03-13	78	59
2017-03-14	78	63
2017-03-15	78	61
2017-03-16	78	57
2017-03-17	78	60
2017-03-18	78	59
2017-03-19	78	54
2017-03-20	78	62
2017-03-21	78	59
2017-03-22	78	62

2017-03-23	78	63
2017-03-24	78	64
2017-03-25	78	65
2017-03-26	78	56
2017-03-27	78	54
2017-03-28	78	57
2017-03-29	78	59
2017-03-30	78	57
2017-03-31	78	53
2017-04-01	78	56
2017-04-02	78	58
2017-04-03	78	58
2017-04-04	78	58
2017-04-05	78	61
2017-04-06	78	55
2017-04-07	78	61
2017-04-08	78	59
2017-04-09	78	63
2017-04-10	78	67
2017-04-11	78	66
2017-04-12	78	64
2017-04-13	78	63
2017-04-14	78	62
2017-04-15	78	58
2017-04-16	78	62
2017-04-17	78	55
2017-04-18	78	52
2017-04-19	78	59
2017-04-20	78	61
2017-04-21	78	59
2017-04-22	78	64
2017-04-23	78	60
2017-04-24	78	55
2017-04-25	78	61
2017-04-26	78	59
2017-04-27	78	55
2017-04-28	78	59
2017-04-29	78	58
2017-04-30	78	56
2017-05-01	78	54
2017-05-02	78	57
2017-05-03	78	60
2017-05-04	78	63
2017-05-05	78	63
2017-05-06	78	55
2017-05-07	78	58
2017-05-08	78	54
2017-05-09	78	57
2017-05-10	78	58
2017-05-11	78	57
2017-05-12	78	58
2017-05-13	78	54
2017-05-14	78	57
2017-05-15	78	55
2017-05-16	78	59
2017-05-17	78	54
2017-05-18	78	52
2017-05-19	78	58
2017-05-20	78	58
2017-05-21	78	58
2017-05-22	78	54

AB1230

2017-05-23	78	54
2017-05-24	78	66
2017-05-25	78	60
2017-05-26	78	65
2017-05-27	78	60
2017-05-28	78	57
2017-05-29	78	55
2017-05-30	78	54
2017-05-31	78	56
2017-06-01	78	51
2017-06-02	78	54
2017-06-03	78	52
2017-06-04	78	53
2017-06-05	78	51
2017-06-06	78	53
2017-06-07	78	57
2017-06-08	78	55
2017-06-09	78	52
2017-06-10	78	54
2017-06-11	78	52
2017-06-12	78	48
2017-06-13	78	53
2017-06-14	78	58
2017-06-15	78	52
2017-06-16	78	55
2017-06-17	78	61
2017-06-18	78	55
2017-06-19	78	54
2017-06-20	78	56
2017-06-21	78	55
2017-06-22	78	55
2017-06-23	78	56
2017-06-24	78	54
2017-06-25	78	53
2017-06-26	78	57
2017-06-27	78	62
2017-06-28	78	59
2017-06-29	78	58
2017-06-30	78	54
2017-07-01	78	55
2017-07-02	78	51
2017-07-03	78	59
2017-07-04	78	55
2017-07-05	78	59
2017-07-06	78	55
2017-07-07	78	57
2017-07-08	78	55
2017-07-09	78	57
2017-07-10	78	56
2017-07-11	78	57
2017-07-12	78	59
2017-07-13	78	58
2017-07-14	78	58
2017-07-15	78	51
2017-07-16	78	53
2017-07-17	78	51
2017-07-18	78	55
2017-07-19	78	56
2017-07-20	78	56
2017-07-21	78	53
2017-07-22	78	57

AB1231

2017-07-23	78	51
2017-07-24	78	53
2017-07-25	78	52
2017-07-26	78	50
2017-07-27	78	50
2017-07-28	78	51
2017-07-29	78	50
2017-07-30	78	52
2017-07-31	78	54
2017-08-01	78	57
2017-08-02	78	56
2017-08-03	78	53
2017-08-04	78	61
2017-08-05	78	62
2017-08-06	78	53
2017-08-07	78	53
2017-08-08	78	56
2017-08-09	78	61
2017-08-10	78	58
2017-08-11	78	61
2017-08-12	78	62
2017-08-13	78	56
2017-08-14	78	55
2017-08-15	78	58
2017-08-16	78	57
2017-08-17	78	58
2017-08-18	78	58
2017-08-19	78	58
2017-08-20	78	59
2017-08-21	78	55
2017-08-22	78	59
2017-08-23	78	57
2017-08-24	78	60
2017-08-25	78	57
2017-08-26	78	53
2017-08-27	78	50
2017-08-28	78	47
2017-08-29	78	54
2017-08-30	78	54
2017-08-31	78	56
2017-09-01	78	57
2017-09-02	78	56
2017-09-03	78	49
2017-09-04	78	47
2017-09-05	78	57
2017-09-06	78	53
2017-09-07	78	54
2017-09-08	78	54
2017-09-09	78	52
2017-09-10	78	51
2017-09-11	78	56
2017-09-12	78	58
2017-09-13	78	56
2017-09-14	78	51
2017-09-15	78	56
2017-09-16	78	61
2017-09-17	78	60
2017-09-18	78	49
2017-09-19	78	52
2017-09-20	78	54
2017-09-21	78	57

2017-09-22	78	59
2017-09-23	78	50
2017-09-24	78	49
2017-09-25	78	49
2017-09-26	78	54
2017-09-27	78	58
2017-09-28	78	59
2017-09-29	78	59
2017-09-30	78	56
2017-10-01	78	49
2017-10-02	78	57
2017-10-03	79	54
2017-10-04	79	63
2017-10-05	79	59
2017-10-06	79	59
2017-10-07	79	59
2017-10-08	79	60
2017-10-09	79	57
2017-10-10	81	62
2017-10-11	81	57
2017-10-12	81	56
2017-10-13	81	59
2017-10-14	81	61
2017-10-15	81	63
2017-10-16	81	57
2017-10-17	81	63
2017-10-18	81	64
2017-10-19	81	64
2017-10-20	81	63
2017-10-21	81	59
2017-10-22	81	63
2017-10-23	81	62
2017-10-24	81	59
2017-10-25	81	63
2017-10-26	81	64
2017-10-27	81	63
2017-10-28	81	64
2017-10-29	81	61
2017-10-30	81	57
2017-10-31	81	58
2017-11-01	81	53
2017-11-02	81	60
2017-11-03	81	63
2017-11-04	81	60
2017-11-05	81	59
2017-11-06	81	53
2017-11-07	81	60
2017-11-08	81	62
2017-11-09	81	59
2017-11-10	81	62
2017-11-11	81	63
2017-11-12	81	61
2017-11-13	81	62
2017-11-14	81	65
2017-11-15	81	59
2017-11-16	81	55
2017-11-17	81	53
2017-11-18	81	56
2017-11-19	81	61
2017-11-20	81	57
2017-11-21	81	63

2017-11-22	81	58
2017-11-23	81	62
2017-11-24	81	64
2017-11-25	81	60
2017-11-26	81	62
2017-11-27	81	60
2017-11-28	81	63
2017-11-29	81	61
2017-11-30	81	63
2017-12-01	81	58
2017-12-02	81	67
2017-12-03	81	64
2017-12-04	81	63
2017-12-05	81	69
2017-12-06	81	64
2017-12-07	81	59
2017-12-08	81	66
2017-12-09	81	59
2017-12-10	81	57
2017-12-11	81	56
2017-12-12	81	63
2017-12-13	81	66
2017-12-14	81	65
2017-12-15	81	67
2017-12-16	81	65
2017-12-17	81	61
2017-12-18	81	65
2017-12-19	81	67
2017-12-20	81	71
2017-12-21	81	69
2017-12-22	81	65
2017-12-23	81	66
2017-12-24	81	65
2017-12-25	81	63
2017-12-26	81	60
2017-12-27	81	64
2017-12-28	81	58
2017-12-29	81	63
2017-12-30	81	63
2017-12-31	81	60
2018-01-01	81	59
2018-01-02	81	58
2018-01-03	81	61
2018-01-04	81	69
2018-01-05	81	61
2018-01-06	81	66
2018-01-07	81	66
2018-01-08	81	62
2018-01-09	81	65
2018-01-10	81	59
2018-01-11	81	65
2018-01-12	81	64
2018-01-13	81	61
2018-01-14	81	64
2018-01-15	81	65
2018-01-16	81	65
2018-01-17	81	63
2018-01-18	81	59
2018-01-19	81	61
2018-01-20	81	66
2018-01-21	81	60

AB1234

2018-01-22	81	55
2018-01-23	81	67
2018-01-24	81	66
2018-01-25	81	63
2018-01-26	81	64
2018-01-27	81	63
2018-01-28	81	68
2018-01-29	81	60
2018-01-30	81	62
2018-01-31	81	67
2018-02-01	81	66
2018-02-02	81	69
2018-02-03	81	63
2018-02-04	81	62
2018-02-05	81	63
2018-02-06	81	66
2018-02-07	81	66
2018-02-08	81	63
2018-02-09	81	65
2018-02-10	81	63
2018-02-11	81	65
2018-02-12	81	63
2018-02-13	81	66
2018-02-14	81	65
2018-02-15	81	65
2018-02-16	81	65
2018-02-17	81	67
2018-02-18	81	68
2018-02-19	81	65
2018-02-20	81	64
2018-02-21	81	66
2018-02-22	81	66
2018-02-23	81	63
2018-02-24	81	61
2018-02-25	81	56
2018-02-26	81	62
2018-02-27	81	68
2018-02-28	81	69
2018-03-01	81	68
2018-03-02	81	69
2018-03-03	81	62
2018-03-04	81	62
2018-03-05	81	59
2018-03-06	81	66
2018-03-07	81	69
2018-03-08	81	66
2018-03-09	81	65
2018-03-10	81	58
2018-03-11	81	58
2018-03-12	81	55
2018-03-13	81	62
2018-03-14	81	62
2018-03-15	81	66
2018-03-16	81	67
2018-03-17	81	66
2018-03-18	81	62
2018-03-19	81	58
2018-03-20	81	65
2018-03-21	81	63
2018-03-22	81	66
2018-03-23	81	67

2018-03-24	81	64
2018-03-25	81	63
2018-03-26	81	63
2018-03-27	81	73
2018-03-28	81	69
2018-03-29	81	70
2018-03-30	81	66
2018-03-31	81	68
2018-04-01	82	63
2018-04-02	82	73
2018-04-03	82	72
2018-04-04	82	73
2018-04-05	82	73
2018-04-06	82	66
2018-04-07	82	69
2018-04-08	82	66
2018-04-09	82	63
2018-04-10	82	76
2018-04-11	82	74
2018-04-12	82	74
2018-04-13	82	69
2018-04-14	82	68
2018-04-15	82	65
2018-04-16	82	61
2018-04-17	82	67
2018-04-18	82	67
2018-04-19	82	68
2018-04-20	82	66
2018-04-21	82	65
2018-04-22	82	66
2018-04-23	82	64
2018-04-24	82	70
2018-04-25	82	70
2018-04-26	82	70
2018-04-27	82	66
2018-04-28	82	65
2018-04-29	82	62
2018-04-30	82	68
2018-05-01	82	69
2018-05-02	82	72
2018-05-03	82	70
2018-05-04	82	66
2018-05-05	82	64
2018-05-06	82	60
2018-05-07	82	60
2018-05-08	82	61
2018-05-09	82	63
2018-05-10	82	60
2018-05-11	82	65
2018-05-12	82	68
2018-05-13	82	66
2018-05-14	82	64
2018-05-15	82	61
2018-05-16	82	66
2018-05-17	82	70
2018-05-18	82	69
2018-05-19	82	68
2018-05-20	82	65
2018-05-21	82	64
2018-05-22	82	61
2018-05-23	82	64

AB1236

2018-05-24	82	69
2018-05-25	82	71
2018-05-26	82	70
2018-05-27	82	62
2018-05-28	82	61
2018-05-29	82	63
2018-05-30	82	66
2018-05-31	82	61
2018-06-01	82	62
2018-06-02	82	65
2018-06-03	82	62
2018-06-04	82	59
2018-06-05	82	64
2018-06-06	82	63
2018-06-07	82	61
2018-06-08	82	58
2018-06-09	82	64
2018-06-10	82	62
2018-06-11	82	65
2018-06-12	82	66
2018-06-13	82	66
2018-06-14	82	57
2018-06-15	82	65
2018-06-16	82	65
2018-06-17	82	63
2018-06-18	82	61
2018-06-19	82	67
2018-06-20	82	67
2018-06-21	82	64
2018-06-22	82	66
2018-06-23	82	63
2018-06-24	82	64
2018-06-25	82	60
2018-06-26	82	59
2018-06-27	82	61
2018-06-28	82	62
2018-06-29	82	61
2018-06-30	82	60
2018-07-01	82	58
2018-07-02	82	59
2018-07-03	82	60
2018-07-04	82	61
2018-07-05	82	57
2018-07-06	82	57
2018-07-07	82	60
2018-07-08	82	66
2018-07-09	82	56
2018-07-10	82	62
2018-07-11	82	69
2018-07-12	82	58
2018-07-13	82	57
2018-07-14	82	63
2018-07-15	82	60
2018-07-16	82	62
2018-07-17	82	66
2018-07-18	82	64
2018-07-19	82	60
2018-07-20	82	59
2018-07-21	82	55
2018-07-22	82	54
2018-07-23	82	53

2018-07-24	82	55
2018-07-25	82	54
2018-07-26	82	61
2018-07-27	82	63
2018-07-28	82	61
2018-07-29	82	60
2018-07-30	82	53
2018-07-31	82	57
2018-08-01	82	55
2018-08-02	82	55
2018-08-03	82	58
2018-08-04	82	55
2018-08-05	82	57
2018-08-06	82	52
2018-08-07	82	59
2018-08-08	82	60
2018-08-09	82	57
2018-08-10	82	57
2018-08-11	82	57
2018-08-12	82	59
2018-08-13	82	57
2018-08-14	82	63
2018-08-15	82	59
2018-08-16	82	57
2018-08-17	82	57
2018-08-18	82	59
2018-08-19	82	57
2018-08-20	82	58
2018-08-21	82	59
2018-08-22	82	62
2018-08-23	82	55
2018-08-24	82	57
2018-08-25	82	57
2018-08-26	82	53
2018-08-27	82	56
2018-08-28	82	54
2018-08-29	82	59
2018-08-30	82	56
2018-08-31	82	60
2018-09-01	82	57
2018-09-02	82	59
2018-09-03	82	60
2018-09-04	82	60
2018-09-05	82	62
2018-09-06	82	64
2018-09-07	82	63
2018-09-08	82	58
2018-09-09	82	62
2018-09-10	82	59
2018-09-11	82	60
2018-09-12	82	64
2018-09-13	82	58
2018-09-14	82	56
2018-09-15	82	58
2018-09-16	82	57
2018-09-17	82	57
2018-09-18	82	59
2018-09-19	82	65
2018-09-20	82	58
2018-09-21	82	56
2018-09-22	82	59

AB1238

2018-09-23	82	60
2018-09-24	82	58
2018-09-25	82	61
2018-09-26	82	54
2018-09-27	82	58
2018-09-28	82	62
2018-09-29	82	66
2018-09-30	82	63
2018-10-01	82	63
2018-10-02	82	65
2018-10-03	82	65
2018-10-04	82	66
2018-10-05	82	69
2018-10-06	82	65
2018-10-07	82	66
2018-10-08	82	64
2018-10-09	82	59
2018-10-10	82	65
2018-10-11	82	66
2018-10-12	82	65
2018-10-13	82	67
2018-10-14	82	64
2018-10-15	82	65
2018-10-16	82	63
2018-10-17	82	67
2018-10-18	82	65
2018-10-19	82	71
2018-10-20	82	69
2018-10-21	82	65
2018-10-22	82	65
2018-10-23	82	59
2018-10-24	82	60
2018-10-25	82	62
2018-10-26	82	66
2018-10-27	82	64
2018-10-28	82	59
2018-10-29	82	60
2018-10-30	82	62
2018-10-31	82	62
2018-11-01	82	60
2018-11-02	82	62
2018-11-03	82	62
2018-11-04	82	59
2018-11-05	82	57
2018-11-06	82	59
2018-11-07	82	57
2018-11-08	82	57
2018-11-09	82	59
2018-11-10	82	65
2018-11-11	82	63
2018-11-12	82	63
2018-11-13	82	62
2018-11-14	82	65
2018-11-15	82	59
2018-11-16	82	60
2018-11-17	82	59
2018-11-18	82	54
2018-11-19	82	54
2018-11-20	82	60
2018-11-21	82	61
2018-11-22	82	62

2018-11-23	82	67
2018-11-24	82	68
2018-11-25	82	61
2018-11-26	82	64
2018-11-27	82	66
2018-11-28	82	62
2018-11-29	82	63
2018-11-30	82	62
2018-12-01	82	59
2018-12-02	82	64
2018-12-03	82	59
2018-12-04	82	61
2018-12-05	82	67
2018-12-06	82	67
2018-12-07	82	65
2018-12-08	82	61
2018-12-09	82	63
2018-12-10	82	64
2018-12-11	82	59
2018-12-12	82	61
2018-12-13	82	64
2018-12-14	82	64
2018-12-15	82	70
2018-12-16	82	65
2018-12-17	82	63
2018-12-18	82	65
2018-12-19	82	65
2018-12-20	82	65
2018-12-21	82	66
2018-12-22	82	63
2018-12-23	82	64
2018-12-24	82	65
2018-12-25	82	62
2018-12-26	82	63
2018-12-27	82	67
2018-12-28	82	64
2018-12-29	82	64
2018-12-30	82	64
2018-12-31	82	65
2019-01-01	82	64
2019-01-02	82	63
2019-01-03	82	64
2019-01-04	82	63
2019-01-05	82	64
2019-01-06	82	64
2019-01-07	82	64
2019-01-08	82	68
2019-01-09	82	69
2019-01-10	82	71
2019-01-11	82	68
2019-01-12	82	69
2019-01-13	82	65
2019-01-14	82	64
2019-01-15	82	62
2019-01-16	82	72
2019-01-17	82	65
2019-01-18	82	66
2019-01-19	82	66
2019-01-20	82	63
2019-01-21	82	64
2019-01-22	82	65

2019-01-23	82	59
2019-01-24	82	62
2019-01-25	82	65
2019-01-26	82	67
2019-01-27	82	61
2019-01-28	82	60
2019-01-29	82	65
2019-01-30	82	67
2019-01-31	82	61
2019-02-01	82	65
2019-02-02	82	64
2019-02-03	82	64
2019-02-04	82	63
2019-02-05	82	65
2019-02-06	82	64
2019-02-07	82	58
2019-02-08	82	58
2019-02-09	82	59
2019-02-10	82	58
2019-02-11	82	54
2019-02-12	82	70
2019-02-13	82	69
2019-02-14	82	66
2019-02-15	82	67
2019-02-16	82	66
2019-02-17	82	66
2019-02-18	82	62
2019-02-19	82	66
2019-02-20	82	64
2019-02-21	82	65
2019-02-22	82	62
2019-02-23	82	57
2019-02-24	82	59
2019-02-25	82	64
2019-02-26	82	63
2019-02-27	82	60
2019-02-28	82	64
2019-03-01	82	66
2019-03-02	82	60
2019-03-03	82	59
2019-03-04	82	61
2019-03-05	82	61
2019-03-06	82	65
2019-03-07	82	59
2019-03-08	82	67
2019-03-09	82	71
2019-03-10	82	67
2019-03-11	82	67
2019-03-12	82	70
2019-03-13	82	68
2019-03-14	82	72
2019-03-15	82	66
2019-03-16	82	69
2019-03-17	82	62
2019-03-18	82	62
2019-03-19	82	65
2019-03-20	82	67
2019-03-21	82	63
2019-03-22	82	64
2019-03-23	82	61
2019-03-24	82	65

AB1241

2019-03-25	82	63
2019-03-26	82	67
2019-03-27	82	72
2019-03-28	82	71
2019-03-29	82	73
2019-03-30	82	75
2019-03-31	82	68
2019-04-01	82	60
2019-04-02	82	68
2019-04-03	82	70
2019-04-04	82	73
2019-04-05	82	67
2019-04-06	82	64
2019-04-07	82	68
2019-04-08	82	66
2019-04-09	82	68
2019-04-10	82	68
2019-04-11	82	68
2019-04-12	82	67
2019-04-13	82	75
2019-04-14	82	70
2019-04-15	82	64
2019-04-16	82	71
2019-04-17	82	72
2019-04-18	82	71
2019-04-19	82	70
2019-04-20	82	68
2019-04-21	82	62
2019-04-22	82	62
2019-04-23	82	64
2019-04-24	82	67
2019-04-25	82	71
2019-04-26	82	66
2019-04-27	82	67
2019-04-28	82	62
2019-04-29	82	62
2019-04-30	82	67
2019-05-01	82	70
2019-05-02	82	68
2019-05-03	82	67
2019-05-04	82	70
2019-05-05	82	69
2019-05-06	82	65
2019-05-07	82	68
2019-05-08	82	71
2019-05-09	82	72
2019-05-10	82	72
2019-05-11	82	68
2019-05-12	82	65
2019-05-13	82	64
2019-05-14	82	66
2019-05-15	82	67
2019-05-16	82	61
2019-05-17	82	68
2019-05-18	82	63
2019-05-19	82	61
2019-05-20	82	58
2019-05-21	82	61
2019-05-22	82	65
2019-05-23	82	64
2019-05-24	82	68

2019-05-25	82	66
2019-05-26	82	64
2019-05-27	82	61
2019-05-28	82	66
2019-05-29	82	65
2019-05-30	82	67
2019-05-31	82	70
2019-06-01	82	70
2019-06-02	82	69
2019-06-03	82	67
2019-06-04	82	70
2019-06-05	82	66
2019-06-06	82	68
2019-06-07	82	68
2019-06-08	82	75
2019-06-09	82	70
2019-06-10	82	68
2019-06-11	82	69
2019-06-12	82	77
2019-06-13	82	66
2019-06-14	82	65
2019-06-15	82	66
2019-06-16	82	59
2019-06-17	82	61
2019-06-18	82	68
2019-06-19	82	65
2019-06-20	82	62
2019-06-21	82	64
2019-06-22	82	61
2019-06-23	82	60
2019-06-24	82	58
2019-06-25	83	67
2019-06-26	85	67
2019-06-27	85	68
2019-06-28	85	59
2019-06-29	85	60
2019-06-30	85	59
2019-07-01	85	60
2019-07-02	85	64
2019-07-03	85	62
2019-07-04	85	64
2019-07-05	85	58
2019-07-06	85	61
2019-07-07	85	59
2019-07-08	85	61
2019-07-09	85	67
2019-07-10	85	66
2019-07-11	85	67
2019-07-12	85	66
2019-07-13	85	68
2019-07-14	85	65
2019-07-15	85	61
2019-07-16	85	62
2019-07-17	85	63
2019-07-18	85	66
2019-07-19	85	67
2019-07-20	85	64
2019-07-21	85	62
2019-07-22	85	58
2019-07-23	85	63
2019-07-24	85	63

AB1243

2019-07-25	85	66
2019-07-26	85	60
2019-07-27	85	64
2019-07-28	85	61
2019-07-29	85	60
2019-07-30	85	59
2019-07-31	85	65
2019-08-01	85	66
2019-08-02	85	65
2019-08-03	85	65
2019-08-04	85	64
2019-08-05	85	63
2019-08-06	85	62
2019-08-07	85	66
2019-08-08	85	64
2019-08-09	85	63
2019-08-10	85	65
2019-08-11	85	62
2019-08-12	85	58
2019-08-13	85	64
2019-08-14	85	65
2019-08-15	85	59
2019-08-16	85	67
2019-08-17	85	66
2019-08-18	85	64
2019-08-19	85	60
2019-08-20	85	60
2019-08-21	85	65
2019-08-22	85	61
2019-08-23	85	60
2019-08-24	85	64
2019-08-25	85	65
2019-08-26	85	61
2019-08-27	85	60
2019-08-28	85	61
2019-08-29	85	64
2019-08-30	85	55
2019-08-31	85	59
2019-09-01	85	61
2019-09-02	85	62
2019-09-03	85	62
2019-09-04	85	64
2019-09-05	85	66
2019-09-06	85	64
2019-09-07	85	65
2019-09-08	85	67
2019-09-09	85	65
2019-09-10	85	68
2019-09-11	85	70
2019-09-12	85	63
2019-09-13	85	62
2019-09-14	85	61
2019-09-15	85	61
2019-09-16	85	60
2019-09-17	85	64
2019-09-18	85	65
2019-09-19	85	66
2019-09-20	86	70
2019-09-21	86	71
2019-09-22	86	67
2019-09-23	86	64

AB1244

2019-09-24	86	70
2019-09-25	86	66
2019-09-26	86	64
2019-09-27	86	64
2019-09-28	86	64
2019-09-29	86	67
2019-09-30	86	66
2019-10-01	86	66
2019-10-02	86	61
2019-10-03	86	65
2019-10-04	86	65
2019-10-05	86	73
2019-10-06	86	69
2019-10-07	86	68
2019-10-08	86	70
2019-10-09	86	77
2019-10-10	86	73
2019-10-11	86	67
2019-10-12	86	74
2019-10-13	86	71
2019-10-14	86	70
2019-10-15	86	72
2019-10-16	86	71
2019-10-17	86	70
2019-10-18	86	71
2019-10-19	86	74
2019-10-20	86	73
2019-10-21	86	72
2019-10-22	86	72
2019-10-23	86	71
2019-10-24	86	72
2019-10-25	86	67
2019-10-26	86	68
2019-10-27	86	69
2019-10-28	86	70
2019-10-29	86	69
2019-10-30	86	70
2019-10-31	86	73
2019-11-01	86	71
2019-11-02	86	70
2019-11-03	86	71
2019-11-04	86	63
2019-11-05	86	70
2019-11-06	86	66
2019-11-07	86	61
2019-11-08	86	61
2019-11-09	86	61
2019-11-10	86	62
2019-11-11	86	60
2019-11-12	86	62
2019-11-13	86	68
2019-11-14	86	68
2019-11-15	86	67
2019-11-16	86	67
2019-11-17	86	67
2019-11-18	86	67
2019-11-19	86	66
2019-11-20	86	64
2019-11-21	86	64
2019-11-22	86	66
2019-11-23	86	66

AB1245

2019-11-24	86	62
2019-11-25	86	61
2019-11-26	86	62
2019-11-27	86	62
2019-11-28	86	62
2019-11-29	86	66
2019-11-30	86	66
2019-12-01	86	60
2019-12-02	86	63
2019-12-03	86	65
2019-12-04	86	67
2019-12-05	86	67
2019-12-06	86	70
2019-12-07	86	71
2019-12-08	86	73
2019-12-09	86	67
2019-12-10	86	72
2019-12-11	86	74
2019-12-12	86	71
2019-12-13	86	67
2019-12-14	86	68
2019-12-15	86	62
2019-12-16	86	57
2019-12-17	86	67
2019-12-18	86	66
2019-12-19	86	63
2019-12-20	86	66
2019-12-21	86	64
2019-12-22	86	67
2019-12-23	86	64
2019-12-24	86	63
2019-12-25	86	58
2019-12-26	86	58
2019-12-27	86	55
2019-12-28	86	60
2019-12-29	86	63
2019-12-30	86	59
2019-12-31	86	63
2020-01-01	86	68
2020-01-02	86	67
2020-01-03	86	73
2020-01-04	86	73
2020-01-05	86	72
2020-01-06	86	71
2020-01-07	86	74
2020-01-08	86	77
2020-01-09	86	76
2020-01-10	86	72
2020-01-11	86	74
2020-01-12	86	65
2020-01-13	86	75
2020-01-14	86	77
2020-01-15	86	73
2020-01-16	86	73
2020-01-17	86	74
2020-01-18	86	72
2020-01-19	86	69
2020-01-20	86	66
2020-01-21	86	72
2020-01-22	86	75
2020-01-23	86	73

AB1246

2020-01-24	86	77
2020-01-25	86	72
2020-01-26	86	69
2020-01-27	86	68
2020-01-28	86	74
2020-01-29	86	72
2020-01-30	86	73
2020-01-31	86	73
2020-02-01	86	72
2020-02-02	86	72
2020-02-03	86	74
2020-02-04	86	78
2020-02-05	86	73
2020-02-06	86	73
2020-02-07	86	75
2020-02-08	86	76
2020-02-09	86	68
2020-02-10	86	71
2020-02-11	86	71
2020-02-12	86	71
2020-02-13	86	72
2020-02-14	86	71
2020-02-15	86	66
2020-02-16	86	62
2020-02-17	86	58
2020-02-18	86	59
2020-02-19	86	64
2020-02-20	86	63
2020-02-21	86	66
2020-02-22	86	72
2020-02-23	86	71
2020-02-24	86	74
2020-02-25	86	69
2020-02-26	86	68
2020-02-27	86	64
2020-02-28	86	69
2020-02-29	86	68
2020-03-01	86	65
2020-03-02	86	62
2020-03-03	86	63
2020-03-04	86	63
2020-03-05	86	69
2020-03-06	86	69
2020-03-07	86	67
2020-03-08	86	66
2020-03-09	86	64
2020-03-10	86	63
2020-03-11	86	65
2020-03-12	86	64
2020-03-13	86	63
2020-03-14	86	63
2020-03-15	86	62
2020-03-16	86	59
2020-03-17	86	62
2020-03-18	86	61
2020-03-19	86	64
2020-03-20	86	61
2020-03-21	86	54
2020-03-22	86	49
2020-03-23	86	50
2020-03-24	86	56

AB1247

2020-03-25	86	52
2020-03-26	86	54
2020-03-27	86	55
2020-03-28	86	58
2020-03-29	86	59
2020-03-30	86	55
2020-03-31	86	53
2020-04-01	86	57
2020-04-02	86	56
2020-04-03	86	52
2020-04-04	86	47
2020-04-05	86	51
2020-04-06	86	51
2020-04-07	86	54
2020-04-08	86	51
2020-04-09	86	47
2020-04-10	86	49
2020-04-11	86	46
2020-04-12	86	51
2020-04-13	86	54
2020-04-14	86	63
2020-04-15	86	57
2020-04-16	86	55
2020-04-17	86	53
2020-04-18	86	55
2020-04-19	86	57
2020-04-20	86	52
2020-04-21	86	55
2020-04-22	86	54
2020-04-23	86	57
2020-04-24	86	59
2020-04-25	86	57
2020-04-26	86	57
2020-04-27	86	59
2020-04-28	86	59
2020-04-29	86	57
2020-04-30	86	65
2020-05-01	86	54
2020-05-02	86	58
2020-05-03	86	55
2020-05-04	86	56
2020-05-05	86	56
2020-05-06	86	50
2020-05-07	86	55
2020-05-08	86	54
2020-05-09	86	55
2020-05-10	86	53
2020-05-11	86	62
2020-05-12	86	60
2020-05-13	86	63
2020-05-14	86	63
2020-05-15	86	61
2020-05-16	86	59
2020-05-17	86	54
2020-05-18	86	54
2020-05-19	86	50
2020-05-20	86	59
2020-05-21	86	60
2020-05-22	86	61
2020-05-23	86	59
2020-05-24	86	59

2020-05-25	86	56
2020-05-26	86	61
2020-05-27	86	58
2020-05-28	86	58
2020-05-29	86	60
2020-05-30	86	60
2020-05-31	86	56
2020-06-01	86	57
2020-06-02	86	62
2020-06-03	86	62
2020-06-04	86	61
2020-06-05	86	58
2020-06-06	86	63
2020-06-07	86	62
2020-06-08	86	64
2020-06-09	86	65
2020-06-10	86	66
2020-06-11	86	67
2020-06-12	86	66
2020-06-13	86	67
2020-06-14	86	65
2020-06-15	86	60
2020-06-16	86	63
2020-06-17	86	67
2020-06-18	86	65
2020-06-19	86	59
2020-06-20	86	62
2020-06-21	86	62
2020-06-22	86	66
2020-06-23	86	59
2020-06-24	86	66
2020-06-25	86	62
2020-06-26	86	63
2020-06-27	86	63
2020-06-28	86	60
2020-06-29	86	60
2020-06-30	86	62
2020-07-01	86	65
2020-07-02	86	61
2020-07-03	86	63
2020-07-04	86	66
2020-07-05	86	63
2020-07-06	86	63
2020-07-07	86	71
2020-07-08	86	70
2020-07-09	86	62
2020-07-10	86	64
2020-07-11	86	63
2020-07-12	86	64
2020-07-13	86	63
2020-07-14	86	62
2020-07-15	86	61
2020-07-16	86	61
2020-07-17	86	61
2020-07-18	86	61
2020-07-19	86	60
2020-07-20	86	64
2020-07-21	86	66
2020-07-22	86	64
2020-07-23	86	58
2020-07-24	86	63

AB1249

2020-07-25	86	61
2020-07-26	86	61
2020-07-27	86	65
2020-07-28	86	60
2020-07-29	86	63
2020-07-30	86	63
2020-07-31	86	62
2020-08-01	86	65
2020-08-02	86	66
2020-08-03	86	66
2020-08-04	86	64
2020-08-05	86	70
2020-08-06	86	69
2020-08-07	86	67
2020-08-08	86	68
2020-08-09	86	68
2020-08-10	86	67
2020-08-11	86	65
2020-08-12	86	69
2020-08-13	86	72
2020-08-14	86	72
2020-08-15	86	69
2020-08-16	86	67
2020-08-17	86	62
2020-08-18	86	67
2020-08-19	86	65
2020-08-20	86	61
2020-08-21	86	66
2020-08-22	86	65
2020-08-23	86	68
2020-08-24	86	71
2020-08-25	86	67
2020-08-26	86	70
2020-08-27	86	71
2020-08-28	86	68
2020-08-29	86	70
2020-08-30	86	68
2020-08-31	86	69
2020-09-01	86	67
2020-09-02	86	67
2020-09-03	86	64
2020-09-04	86	66
2020-09-05	86	64
2020-09-06	86	62
2020-09-07	86	57
2020-09-08	86	59
2020-09-09	86	63
2020-09-10	86	61
2020-09-11	86	71
2020-09-12	86	67
2020-09-13	86	67
2020-09-14	86	69
2020-09-15	86	71
2020-09-16	86	70
2020-09-17	86	68
2020-09-18	86	72
2020-09-19	86	73
2020-09-20	86	64
2020-09-21	86	63
2020-09-22	86	72
2020-09-23	86	69

2020-09-24	86	70
2020-09-25	86	69
2020-09-26	86	70
2020-09-27	86	67
2020-09-28	86	69
2020-09-29	86	72
2020-09-30	86	69
2020-10-01	86	69
2020-10-02	86	71
2020-10-03	86	68
2020-10-04	86	70
2020-10-05	86	65
2020-10-06	86	70
2020-10-07	86	73
2020-10-08	86	75
2020-10-09	86	76
2020-10-10	86	74
2020-10-11	86	73
2020-10-12	86	72
2020-10-13	86	71
2020-10-14	86	73
2020-10-15	86	72
2020-10-16	86	73
2020-10-17	86	76
2020-10-18	86	75
2020-10-19	86	72
2020-10-20	86	67
2020-10-21	86	73
2020-10-22	86	73
2020-10-23	86	71
2020-10-24	86	75
2020-10-25	86	71
2020-10-26	86	68
2020-10-27	86	70
2020-10-28	86	71
2020-10-29	86	69
2020-10-30	86	72
2020-10-31	86	70
2020-11-01	86	72
2020-11-02	86	72
2020-11-03	86	72
2020-11-04	86	79
2020-11-05	86	83
2020-11-06	86	87
2020-11-07	86	86
2020-11-08	86	89
2020-11-09	86	92
2020-11-10	86	92
2020-11-11	86	90
2020-11-12	86	89
2020-11-13	86	94
2020-11-14	86	94
2020-11-15	86	102
2020-11-16	86	98
2020-11-17	86	101
2020-11-18	86	101
2020-11-19	86	100
2020-11-20	86	100
2020-11-21	86	96
2020-11-22	86	103
2020-11-23	86	106

2020-11-24	86	112
2020-11-25	86	120
2020-11-26	86	111
2020-11-27	86	111
2020-11-28	86	108
2020-11-29	86	108
2020-11-30	86	107
2020-12-01	86	109
2020-12-02	86	108
2020-12-03	86	116
2020-12-04	86	119
2020-12-05	86	119
2020-12-06	86	119
2020-12-07	86	117
2020-12-08	86	120
2020-12-09	86	120
2020-12-10	86	123
2020-12-11	86	123
2020-12-12	86	118
2020-12-13	86	118
2020-12-14	86	118
2020-12-15	86	128
2020-12-16	86	122
2020-12-17	86	115
2020-12-18	86	116
2020-12-19	86	123
2020-12-20	86	117
2020-12-21	86	125
2020-12-22	86	116
2020-12-23	86	116
2020-12-24	86	117
2020-12-25	86	108
2020-12-26	86	101
2020-12-27	86	110
2020-12-28	86	110
2020-12-29	86	111
2020-12-30	86	108
2020-12-31	86	112
2021-01-01	86	110
2021-01-02	86	112
2021-01-03	86	110
2021-01-04	86	113
2021-01-05	86	109
2021-01-06	86	103
2021-01-07	86	102
2021-01-08	86	102
2021-01-09	86	106
2021-01-10	86	109
2021-01-11	86	106
2021-01-12	86	109
2021-01-13	86	113
2021-01-14	86	117
2021-01-15	86	110
2021-01-16	86	113
2021-01-17	86	112
2021-01-18	86	111
2021-01-19	86	114
2021-01-20	86	109
2021-01-21	86	107
2021-01-22	86	103
2021-01-23	86	106

AB1252

2021-01-24	86	110
2021-01-25	86	101
2021-01-26	86	103
2021-01-27	86	105
2021-01-28	86	105
2021-01-29	86	109
2021-01-30	86	104
2021-01-31	86	102
2021-02-01	86	103
2021-02-02	86	106
2021-02-03	86	108
2021-02-04	86	103
2021-02-05	86	106
2021-02-06	86	103
2021-02-07	86	100
2021-02-08	86	91
2021-02-09	86	99
2021-02-10	86	100
2021-02-11	86	95
2021-02-12	86	95
2021-02-13	86	95
2021-02-14	86	93
2021-02-15	86	94
2021-02-16	86	95
2021-02-17	86	100
2021-02-18	86	100
2021-02-19	86	98
2021-02-20	86	104
2021-02-21	86	102
2021-02-22	86	101
2021-02-23	86	105
2021-02-24	86	90
2021-02-25	86	90
2021-02-26	86	96
2021-02-27	86	95
2021-02-28	86	93
2021-03-01	86	93
2021-03-02	86	94
2021-03-03	86	99
2021-03-04	86	99
2021-03-05	86	99
2021-03-06	86	102
2021-03-07	86	100
2021-03-08	86	94
2021-03-09	86	101
2021-03-10	86	96
2021-03-11	86	103
2021-03-12	86	99
2021-03-13	86	100
2021-03-14	86	103
2021-03-15	86	101
2021-03-16	86	103
2021-03-17	86	101
2021-03-18	86	95
2021-03-19	86	94
2021-03-20	86	99
2021-03-21	86	97
2021-03-22	86	95
2021-03-23	86	95
2021-03-24	86	95
2021-03-25	86	100

AB1253

2021-03-26	86	101
2021-03-27	86	94
2021-03-28	86	90
2021-03-29	86	96
2021-03-30	86	104
2021-03-31	86	99

**Total ICU Beds include Brandon and Winnipeg ICUs at Grace, Health Sciences Centre and St Boniface and Cardiac ICU at St Boniface.*

AB1254

EXHIBIT "F"

AB1255

THIS IS EXHI...... "
referred to in the Affidavit of
David Hersey
Sworn before me this 20
day of April *A.D. 20* 21

A Commissioner in and for the Province of Alberta
John Carpay
Barrister and Solicitor

Justice Centre
for Constitutional Freedoms

April 13, 2021

Via-email

Department of Justice
[redacted]

Attention: Heather Leonoff/Michael Conner/Denis Guenette/Sean Boyd

Dear Madam/Sir:

RE: Gateway Bible Baptist Church et al. v. Manitoba and Dr. Roussin – File No. CI 20-01-29284

We write in response to your email and letter dated April 6, 2021, and your email dated April 9, 2021. Thank you for providing that information.

Upon further examining the data you provided, we note the following apparent discrepancies and gaps in the data you have provided:

1. We had requested that you provide us with documents that showed the Ct values for all positive cases from March 2020-March 2021. You provided us with an excel spreadsheet which identified 15,466 positive PCR tests. We were able to determine that 2,306 of those results were from the Panther instrument that did not rely on Ct values.

   Dr. Bullard in his expert report at lines193-195 revealed that in December 2020, the lab analyzed 5,825 positive PCR results and categorized them by Ct value.

   A review of the data you provided from December 2020 reveals that there were 3,200 positive tests with a Ct value.

[redacted]

There were 610 results from December 2020 from the Panther instrument with no Ct value.

The total number of tests from December 2020 according to the data you provided is 3,810.
There appears to be a discrepancy of approximately 2,000 tests (5,825-3,810=2,015) or more depending on whether the 5,825 number provided by Dr. Bullard included results from the Panther instrument or not.

2. Dr. Loeppky's affidavit identifies 26,785 "lab confirmed" Covid-19 cases in Manitoba (Exhibit B, p.7). Since Covid-19 tests are diagnosed in the lab by PCR tests, there should be 26,785 positive tests. No time frame is given, however, her affidavit was sworn on March 4, 2021, and your spreadsheet was emailed to us on March 30, 2021.

   Your email to us identified 15,466 positive PCR test results (from March 2020-March 30, 2021). Dr. Loeppky's information indicates there may actually be 26,785 positive PCR test results (unknown start date-March 4, 2021). There seems to be a discrepancy of approximately 11,319 positive PCR tests for Covid-19. It would seem that based on Dr. Loeppky's affidavit that the number of positive test results provided to us on March 30, 2021 is less than the number of test results provided a month earlier on March 4, 2021, by 11,319.

3. The spreadsheet in regards to ICU beds in Manitoba only includes the number of ICU beds for certain hospitals (i.e. Brandon, Grace, HSC, St. Boniface). Do the other Manitoba hospitals not have any available ICU beds? If so, why was that data not included in the total? Does the number of ICU beds in the "Midnight Census" category include ICU beds from all Manitoba hospitals, or just ICUs in Brandon, Grace, HSC, and St. Boniface?

   The number of ICU beds you have listed in Manitoba for all of 2020 is 86. However, at a news conference on November 10, 2020, Ms. Lanette Siragusa explained that,

   "The surge prompted the province to add four more ICU beds to the Grace Hospital on Monday, bringing Manitoba's total number of intensive care beds to 89. Siragusa said currently 81 of those beds were being used which included the 30 COVID-19 patients…She said since the end of October, the province has added 12 ICU beds to the system and are planning to add more."

   A link to this statement is here:

https://winnipeg.ctvnews.ca/more-intensive-care-beds-added-as-strained-health-system-nears-capacity-siragusa-1.5182868

[redacted]

> Ms. Siragusa's statement contradicts the data the data that you have provided, as she indicates that the number of available ICU beds in Manitoba has not remained constant, but was increased in November 2020. Your spreadsheet data indicates the number has remained constant for the whole year. Further, Siragusa says that on November 10, 2020 there were 81 ICU beds in use. Your spreadsheet says that on November 9, and 10, 2020, there were 92 ICU beds in use. That is a discrepancy of 11 patients.
>
> Your Application brief filed yesterday also states that Manitoba's pre-Covid ICU capacity was 72 patients (p. 10, para. x). However, the spreadsheet data shows that the ICU capacity was 86 until September 2019 when it went down to 85, and hadn't been as low as 72 beds at all from 2016-2021.
>
> Further, Mr. Wab Kinew reported in January 2020, and it was on the local news, that the number of ICU beds in Manitoba was reduced to 55. That number does not correspond to the data you provided which is that there were 86 available ICU beds for all of 2020. You can see the link to that information here: https://www.mbndp.ca/pallister_cuts_18_icu_beds_across_winnipeg

There seem to be clear inconsistencies and contradictions in the data you have provided.

As you can appreciate, it is very important for the court and the public to have the correct information in order to decide the *Charter* issues at the upcoming hearing. An accurate factual foundation should be established.

The total number of PCR tests conducted in Manitoba and their results by Ct value are critical pieces of information in this hearing, and we want to be sure we are working with accurate data.

Could you kindly explain the apparent discrepancy in the number of tests (approximately 2,000 tests) which seem to be omitted from the December 2020 data in the spreadsheet, and also the discrepancy of 11,319 tests as between the Loeppky affidavit and the spreadsheet.

We re-iterate our request for anonymized lab reports (source data and documents) which correspond to the spreadsheet data that you provided, plus the additional 11,319 lab reports which appear to have not been included in your original spreadsheet. It would seem the source data and documents are necessary to resolve the discrepancies

[redacted]

in the data. Given that the Respondents were able to compile the spreadsheets, I expect the source documents remain readily available for production.

Could you further explain the apparent discrepancies in the ICU data? We want to ensure that the court properly understands the situation of the hospitals in Manitoba with accurate data.

We look forward to receiving the foregoing.

Best regards,

A.K. Pejovic

Allison Kindle Pejovic
Barrister and Solicitor
Justice Centre for Constitutional Freedoms

cc: Jay Cameron, Litigation Manager, Justice Centre for Constitutional Freedoms, [redacted]

Jared Brown, Lead Counsel, Brown Litigation, [redacted]

Heather Leonoff, Legal Services Branch, Constitutional Law Section, Manitoba Justice, [redacted]

Denis Guenette, Legal Services Branch, Civil Legal Services, Manitoba Justice, [redacted]

Michael Conner, Legal Services Branch, Constitutional Law Section, Manitoba Justice, [redacted]

Sean Boyd, Legal Services Branch, Civil Legal Services, Manitoba Justice, [redacted]

[redacted]

EXHIBIT "G"

AB1260

THIS IS EXHIBIT " G "
referred to in the Affidavit of
David Hersey
Sworn before me this 20
day of April *A.D. 20* 21

A Commissioner in and for the Province of Alberta
John Carpay
Barrister and Solicitor

From: "Leonoff, Heather (JUS)" [redacted]
Date: Wednesday, April 14, 2021 at 2:48 PM
To: Allison Pejovic <[redacted]>, "Guenette, Denis (JUS)" [redacted], "Boyd, Sean (JUS)" <[redacted]>, "Conner, Michael (JUS)" [redacted]
Cc: Jared Brown <[redacted]>, Jay Cameron <[redacted]
Subject: RE: Gateway Bible Baptist Church et al. v. MB et al. - Letter from the Applicants to the Respondents April 13, 2021

Hi Allison,

Thank you for your letter.

Please find attached a link to the FPT COVID-19 plan. Previously you requested copies of the Manitoba plan. We did not appreciate that there was also an FPT plan so we enclose that now for completeness.

fpt-response-plan-english.pdf (canada.ca)

In terms of the new materials that you request in your letter of April 13th, we decline to provide any additional information at this time.

Heather

From: Allison Pejovic <[redacted]>
Sent: April-13-21 4:49 PM
To: Leonoff, Heather (JUS) <[redacted]>; Guenette, Denis (JUS) <[redacted]>; Boyd, Sean (JUS) [redacted]>; Conner, Michael (JUS) [redacted]
Cc: Jared Brown [redacted]; Jay Cameron [redacted]
Subject: [Caution: Suspicious Email] Gateway Bible Baptist Church et al. v. MB et al. - Letter from the Applicants to the Respondents April 13, 2021

CAUTION: This email originated from an External Sender. Please do not click links or open attachments unless you recognize the source.
ATTENTION: ce courriel provient d'un expéditeur externe. Ne cliquez sur aucun lien et n'ouvrez pas de pièce jointe, excepté si vous connaissez l'expéditeur.

Good afternoon, please see the attached correspondence from the Applicants.

Best regards,

Allison Kindle Pejovic, B.A., LL.B., LL.M.
[redacted] freedoms of Canadians"

AB1262

FEDERAL/PROVINCIAL/ TERRITORIAL PUBLIC HEALTH RESPONSE PLAN FOR ONGOING MANAGEMENT OF COVID-19

2nd Edition

April 16, 2021

Public Health Agency of Canada
Agence de la santé publique du Canada

Canada

AB1263

Table of Contents

Executive Summary

This document is the second edition of the Federal/Provincial/Territorial (F/P/T) plan which was developed in collaboration with federal, provincial and territorial public health officials (via the F/P/T Special Advisory Committee on COVID-19, see Appendix 1), First Nations, Inuit and Metis partners, and health system partners, for these and other stakeholders. It is an evergreen document that is intended to provide a common forward planning approach for ongoing management of COVID-19 in Canada. The plan acknowledges jurisdictional roles and responsibilities, identifies when pan-Canadian approaches are anticipated and when provincial/territorial flexibility and customization are expected. First Nations, Inuit and Metis communities may choose to adapt approaches to the specific needs and contexts of their communities.

Key elements of the plan include:

- a goal statement,
- public health response objectives,
- planning assumptions,
- a reasonable worst-case scenario, and
- summaries of current and planned response activities for each main component of the public health response (i.e., Surveillance, Laboratory Response Activities, Public Health Measures, Infection Prevention and Control and Clinical Care Guidance, Vaccination, International Border and Travel Health Measures, Health Care System Infrastructure, Risk Communications and Outreach, and Research).

There is also content specifically addressing planning with Indigenous Communities, planning for high-risk settings and populations, and the role of modelling in the response. Much like other technical guidance, this document may require updating as our scientific knowledge of the SARS-CoV-2 pathogen increases, the epidemiological picture evolves in Canada and globally, pandemic control measures change, and new medical countermeasures become available (e.g., additional vaccines, effective treatment).

The pandemic response goal, to minimize serious illness and overall deaths while minimizing societal disruption as a result of the COVID-19 pandemic, is unchanged in this edition. While the COVID-19 response has been unprecedented with the swift implementation and public adoption of public health measures (PHM), appropriate ongoing use of these measures in the context of variants of concern (VOCs), increasing vaccination coverage, and public fatigue with the pandemic and in particular with restrictive community-based PHM will be challenging. PHM have disproportionally impacted some groups within Canada, including seniors, essential workers, racialized populations, people living with disabilities, and women. "Pandemic fatigue" is now ubiquitous and while everyone in Canada has borne the burden of these measures to protect those most at risk of severe COVID-19 disease, now more than ever there is a need to tailor the response to minimize burden and negative impacts while maximizing the benefit of protective measures like COVID-19 vaccines.

PHM have been successful in reducing the number of cases of COVID-19 and associated serious illness and deaths in Canada, however, the restrictive nature of many of these measures have had some negative health, well-being and societal consequences. Many of these consequences have disproportionately affected specific segments of the Canadian population. The goal statement and objectives continue to reflect the need to respond in a way that achieves a better balance between minimizing the impact on morbidity and mortality with the impact on societal disruption in order to support a long-term, sustainable response.

To facilitate a common approach and appropriate level of preparedness across Canada, the plan includes a list of planning assumptions, a "reasonable worst-case scenario", and a list of capabilities and requirements needed to mitigate this scenario. The scenario is not the most likely scenario, rather, it provides a realistic common scenario to guide consideration of key capabilities, capacity issues, and identification of resource needs that will help focus planning activities in light of new challenges like VOCs and pandemic fatigue. It is provided as a "stress-test", not a prediction, and is intended to stimulate thinking concerning our current response efforts and resources, capacity thresholds and resiliency. The reasonable worst-case scenario includes an epidemic curve with a large, prolonged third peak in near term driven by a combination of factors including the spread and dominance of highly transmissible VOCs, pre-mature easing of restrictive community-based PHM, and lower levels of public adherence to recommended PHM. This is followed by ongoing surges or resurgences for the rest of 2021, with surges in incidence creating a demand for resources that exceeds system capacity. It also assumes that vaccine conferred immunity is not long lasting and therefore there will be some level of ongoing transmission for the foreseeable future.

What needs to be done to mitigate this scenario, and for the ongoing management of COVID-19 in general, include the ability to:

- detect signals indicating a significant surge in cases may occur;
- prevent a large prolonged peak and surges, especially those that exceed capacity to respond;
- reduce surges in cases, hospitalizations, and deaths;
- increase health care and public health capacity;
- monitor demand for health care resources; and,
- foster ongoing public vigilance and adherence to measures and recommendations.

When and how to mitigate this scenario is described in terms of the timing and adjusted use of restrictive community-based PHM. Adjustments to restrictive PHM must be considered in the context of threat associated with VOCs and the effect of increasing vaccine coverage, while taking into account the social, economic, and situational factors that may impede the ability to comply with public health measures, particularly for marginalized population groups.

This plan, in conjunction with other foundational federal/provincial/territorial response plans, provides public health leaders with a coordinated approach to: address common issues, and to support the provincial/territorial responses to COVID-19 in the Canadian population. It includes information regarding the current focus of the public health response and anticipated needs for the short, mid and long term ongoing management of COVID-19, which will facilitate awareness and coordination both within and beyond the public health sector.

1. Purpose

The purpose of the *Federal/Provincial/Territorial Public Health Response Plan for Ongoing Management of COVID-19*, is to provide federal, provincial and territorial public health officials, First Nations, Inuit and Metis partners, health system partners and other stakeholders with a common forward planning approach for ongoing management of COVID-19 in Canada. This plan promotes a long-term approach. The first edition covered immediate planning imperatives for the fall/winter 2020 period. Plans must continue to be re-visited and updated until implemented measures and population immunity, is sufficient to decrease COVID-19 activity in Canada to a low, manageable, and tolerable level. As an evergreen document this second edition has been updated as our scientific knowledge of the SARS-CoV-2 pathogen has increased, the epidemiological picture has further evolved in Canada and globally, understanding of the disproportionate impact the pandemic has had on marginalized population groups has grown, control strategies have shifted, and new medical countermeasures have become available (i.e., vaccines and therapeutics).

Building on the ongoing public health response, this document identifies federal/provincial/territorial (F/P/T) public health preparations that are needed and already underway for the short, mid and long-term management of COVID-19 in Canada. It provides overarching guidance that is informed by existing intergovernmental pandemic preparedness, public health emergency planning and data, information and resource sharing agreements, arrangements and protocols (see *Appendix 1*) and draws extensively on the Canadian Pandemic Influenza Preparedness guidance (CPIP). The CPIP stipulates that while it is a guidance document for pandemic influenza, much of its guidance is also applicable to other public health emergencies, which has been the case for the COVID-19 response. It is assumed that an ongoing (but appropriately scaled) F/P/T coordinated response structure and activities as outlined in the F/P/T Public Health Response Plan for Biological Events (F/P/T PHRPBE), will be needed for the foreseeable future.

To facilitate a common approach and appropriate level of preparedness across Canada, this edition of the plan includes an updated "reasonable worst-case scenario." While this scenario is not necessarily the most likely scenario, it provides a baseline to guide consideration of key capabilities, capacity issues, and identification of resource needs that will help focus planning, response and recovery activities. As with other F/P/T plans, this document outlines overarching goals and objectives, acknowledges jurisdictional roles and responsibilities, identifies when national approaches are anticipated and when provincial/territorial (P/T) flexibility and customization are expected. This document has been developed to facilitate planning for an ongoing COVID-19 response that is not only flexible and adaptive but also sustainable.

2. Context

COVID-19 continues to represent an unprecedented threat to the health, social and economic well-being of Canadians, Canadian society and the global community. On January 30, 2020 the Director General of the World Health Organization (WHO) determined that COVID-19 constituted a Public Health Emergency of International Concern (PHEIC) and declared it a pandemic on March 11, 2020, due to extensive international spread. More than a year into responding to this unprecedented event, the Canadian response has been strengthened by the availability of vaccines but further challenged by the emergence of VOCs and pandemic fatigue. There is a need for ongoing adjustments and tailoring of the response as knowledge regarding both the impact of vaccines and VOCs increases. Furthermore, there is an ongoing need to take into consideration the changing attitudes and behaviours of a fatigued, and often frustrated or confused population, and the impact this has on the success of the response. Mitigating the impact of COVID-19 in Canada requires a comprehensive, integrated and cross-sectoral "whole-of-society", "whole-of-government" strategy that focuses on what is within the span of control of our country while trying to reduce the risk and impact of what is not. The context of our planning, therefore, is primarily Canadian-centric but recognizes that the global situation has a significant effect on our response activities.

Mobilizing Canada's health sector response to COVID-19 remains a critical part of that overall effort. This plan and its more detailed components that are described herein, draws heavily on the experience acquired and the work completed during the response to the introduction and subsequent waves of COVID-19 in Canada, in addition to past experience and lessons learned from the implementation of previous mass immunization campaigns. While Canada's F/P/T public health officials have conducted pandemic planning for years, plans must be customized and supplemented as the pandemic unfolds, as each pandemic is different. On the vaccine front alone, the simultaneous use of multiple vaccines using different and novel vaccine technologies while significant ongoing community transmission is occurring and threats of new VOCs with immune escape characteristics start to manifest, is unprecedented. Further unique challenges include: vaccine supply issues, prioritization of vaccine recipients by product, potential for product specific hesitancy, and the need to ensure vaccination occurs in a manner that is consistent with recommended public health measures. Through the Variants of Concern Strategy, integrated teams from a variety of backgrounds including public health laboratories, academia, and research hospitals are leveraging their shared knowledge in areas such as diagnostic testing, epidemiological analysis, and clinical expertise to proactively search for and rapidly characterize VOCs. This will ensure that public health management and control measures can be efficiently and effectively put in place to reduce transmission for VOCs. Despite the incredible effort and pace of COVID-19 response in Canada to date, we are still operating from a place of significant uncertainty and need to continue learning and adapting as we move ahead with planning activities.

While the pandemic has affected Canadians in diverse ways, Canadians have not experienced these impacts equally. Evidence indicates that social determinants of health, including low-income status, adverse physical environments, precarious housing, and race/ethnicity, among others, correlate with increased risk of COVID-19 infection[1] and unequal access to health care and other services. These social determinants put people at risk for a range of chronic conditions[2], such as obesity, heart disease, diabetes, and lung disease, which may contribute to increased morbidity and mortality from COVID-19. Similar to other countries[3], in Canada the rate of deaths due to COVID-19 is higher in males than in females but overall numbers of deaths are highest in females likely due to the higher proportion of females in the oldest, high-risk age groups[4].

These same determinants of health also contribute to other disproportionate impacts of COVID-19 restrictions on health and well-being, including impacts on mental health, family violence and problematic substance use and related overdoses. Job losses have been higher for women, with recent recoveries in the workforce disproportionally benefitting men.[5] Partly as a result of the economic downturn triggered by the pandemic, visible minorities have been particularly affected, with a larger share reporting having difficulties meeting their financial obligations or essential needs compared to White workers.[6] Visible minorities and new comers to Canada are also more likely to work in multiple jobs, in positions (e.g., personal support workers, grocery store clerks) in the food and accommodation sector and public-facing positions where there may be a higher likelihood of exposure to COVID. They also may live in multi-generation homes, which can lead to circular disease transmission patterns from work settings to the home and back to work, thus perpetuating the disproportionate impact on people in these groups. Similarly, Indigenous Peoples, persons living with disabilities, and LGBTQ2IA+ communities, among others, have been disproportionally affected by the pandemic.[7]

Furthermore, some populations have been particularly impacted by the measures implemented to control the pandemic; for example, the unprecedented extent and duration of school closures which may have long-term effects on child development, health and education[8 9]. As efforts shift towards the next phase of the response, it is imperative that the needs of diverse groups within Canada continue to be considered in order to mitigate adverse consequences and reduce both known and reasonably anticipated inequities.

3. COVID-19 Response Goal, Objectives and Response to Date

3.1 Goal

Canada's goal for responding to COVID-19 is based on that established for pandemic influenza in the *Canadian Pandemic Influenza Preparedness: Planning Guidance for the Health Sector* document (last updated August 2018). The goal is:

- To minimize serious illness and overall deaths while minimizing societal disruption as a result of the COVID-19 pandemic.

This goal has guided F/P/T public health response actions. Measures and strategies implemented with this goal in mind have helped reduce the incidence of COVID-19 in Canada and associated serious illness and deaths. Reducing the health impact of COVID-19 while minimizing societal disruption has been extremely challenging especially as "pandemic fatigue" has increased and led to related challenges with respect to public adherence to recommended measures, which have placed an unequal burden across populations in Canada. Recognizing that some groups of Canadians face disproportionate barriers in adhering to these measures is an important first step towards establishing strategies to address them.

With the availability of vaccines and rollout of population-based vaccine programs that prioritize reducing the health impact in the most vulnerable groups first, significant progress is being made on the first part of the goal statement with respect to COVID-19 associated serious illness and overall deaths. However, a high level of adherence to the recommended public health measures (PHMs) remains essential, especially given the emergence of VOCs, which by definition[10] may be associated with increased transmission, increased virulence or change in clinical disease presentation and/or decreased effectiveness of some public health and social measures or available diagnostics, vaccines or therapeutics, depending on the variant.

The pandemic circumstances, not only in Canada but globally, led to the extraordinary implementation of broad, restrictive community-based PHM (e.g., school closure, restrictions on gatherings, workplace/ business restrictions), and the need to offer an unparalleled level of societal support measures (e.g., income support, housing support, and expansion of social services such as mental health and food assistance). Restrictive community-based PHM do reduce the risk of transmission, even transmission of VOCs, however they come at a cost with respect to societal disruption and subsequently the level of benefit is influenced by public adherence and risk tolerance. Going forward these measures will be continually adapted to fit the local context and COVID-19 activity in alignment with the response goal and objectives, taking into consideration the diverse needs of population groups based on situations of vulnerability, ethnicity/culture, ability status, and other socioeconomic and demographic factors. This requires adapting these measures to reduce barriers faced by populations in situations of vulnerability, while also taking into account local conditions.

When the original CPIP pandemic goal was developed it was thought that the main cause of societal disruption would be the absence of essential workers (including health care providers) from the workplace due to illness, need to care for ill family members, workplace outbreak control measures and/or refusals to work. The closure of international borders, businesses, schools and restrictions on social gatherings was always understood as a source of societal disruption in a severe pandemic. The COVID-19 response has been unprecedented with the swift implementation and public adoption of PHM. The restrictive measures that have averted widespread essential service disruption due to illness have, however, had significant broader direct and indirect impacts on health and wellbeing, particularly for seniors, essential workers, racialized populations, people living with disabilities, and women. At a population level physical, mental health and well-being have, in many situations, been negatively impacted by recommendations that affect non-essential services and organizations, for example, those involving sports, recreation and performance arts. These impacts together with the need for ongoing or repetitive use of restrictive measures have subsequently affected adherence levels which are critical to the collective effectiveness of PHM.

3.2 Objectives

As the focus of planning has shifted to a long-term sustainable response, striking an optimal balance between minimizing both health impacts and societal disruption remains a significant challenge. The following public health objectives aim to achieve this balance.

Objectives

To mitigate both health and societal impacts of the pandemic by:

- Taking public health action to reduce the incidence, morbidity and mortality of COVID-19 to a locally manageable level (including operationalizing the vaccine strategy);
- Ensuring access to health care services (both COVID-19 and non-COVID-19 related services), supplies and treatment options;
- Protecting high-risk populations and communities, including Indigenous communities on and off reserve;
- Reducing negative physical and mental health consequences of COVID-19 response actions;
- Taking a risk and evidence based approach to the use of restrictive public health measures;
- Facilitating and supporting high levels of adherence to all recommended measures;
- Countering misinformation and disinformation;
- Leveraging Canada's research, surveillance, national collaborating centres, public health agencies, health care and laboratory systems;
- Working with other sectors to strengthen the social and economic services and policies that protect health and prevent disease (e.g., adequate housing, employment and income supports); and
- Working collaboratively with the international community.

3.3 Response to date

F/P/T response actions to date have been comprehensive and have contributed significantly toward achieving these national public health objectives. These actions include but are not limited to:

- supporting evidence-informed decision-making by rapidly and continually collecting, analyzing and sharing surveillance and other scientific information to inform and target interventions;
- case identification, confirmation, and isolation for the period of communicability;
- contact tracing, identification, communication and quarantine of contacts for the duration of the incubation period;
- development of a comprehensive strategy for the prioritized use and monitoring of vaccines, vaccine effectiveness, and vaccine safety;
- allocating, distributing, and administering available vaccines as safely, efficiently, and equitably as possible;
- rapid outbreak identification and containment activities;
- mobilizing multi-sectorial emergency response teams;
- preventing the importation of COVID-19 through border and travel restrictions and requirements;
- providing guidance to multiple stakeholders and sectors including: public health partners, health care delivery stakeholders, and non-health sectors/settings, that facilitates an evidence-informed, risk-based approach;
- reducing the spread of infection through frequent communication to the public to promote the importance of individual, family, community and organizational mitigation strategies and PHM;
- promoting modifications to day-to-day activities to reduce transmission of COVID-19 in community settings as much as possible;
- use of COVID-19 response frameworks based on level of COVID-19 activity locally and associated levels of PHM and restrictions;
- supporting adherence to recommended measures through effective communication of: rationales, expected duration of measures, and feedback on impact/progress/success;
- protecting those most at risk of serious illness through the provision of resources, guidance and public messaging;
- promoting access to health services through alternative mediums, e.g., telehealth, virtual care visits;
- protecting those most at risk of serious illness in congregate settings and health-care facilities through targeted communications, guidance and response actions;
- establishing a protective stance through community-level screening, guidance and quarantine measures for Northern/remote/isolated communities, and Indigenous populations;
- supporting community-level health and social interventions aimed at supporting and protecting populations at high risk and mitigating negative impacts of public health interventions;
- promoting community resiliency;
- facilitating rapid access to health care supplies, personal protective equipment, healthcare equipment and resources, including medical evacuation from remote, isolated and under-serviced communities;
- supporting the continuity of health care and other essential services;
- providing additional mental health resources and social services; and
- adjusting PHM to facilitate a gradual, cautious return to community functioning in the context of ongoing COVID-19 activity.

Maintaining the trust and confidence of Canadians through timely and transparent communication of evidence-informed public health decisions; communicating appropriate and timely advice (including changes to this advice) to decision-makers, health professionals and the public; taking into consideration the diverse needs of population groups based on vulnerability, ethnicity/culture, ability status, and other socioeconomic and demographic factors; and supporting a coordinated response by working collaboratively with all orders of government, Indigenous partners and stakeholders, continue to be essential in this ongoing response. We need to prepare the public for the reality of living with COVID for the foreseeable future and the changes that will come in terms of the role of vaccination and PHM in sustaining an appropriate level of population protection against COVID-19.

In order to achieve the response goal and objectives it is essential that the effectiveness of COVID-19 control measures be assessed against any negative effects of implementation of these measures (including the re-allocation of other public health program resources); with the objective of reducing COVID-19 incidence and associated serious illness to a locally manageable level. Any reliance on State of Emergency status to achieve the necessary support for ongoing response should be considered and accounted for prior to discontinuing this declared State in order to ensure response goals and objectives will be met. This is key to a sustainable long-term response.

Public health officials are prepared to respond to the variety of challenges that the management of COVID-19 will involve as the pandemic continues to unfold. Advice, recommended measures and interventions have been made based on these shared pandemic goals and objectives. As our collective knowledge increases, these objectives will be revisited and updated as needed.

4. Forward Planning: Assumptions and Epidemiological Drivers

4.1 Planning Assumptions and Areas of Uncertainty

This plan aims to support consistent but flexible public health planning at all levels of government in order to prepare for short, mid and long-term COVID-19 response activities. Plans should reflect a combination of nationally agreed upon approaches with regionally and locally adaptable actions and be aligned with the pandemic response goals and objectives, taking into account the needs of diverse groups within Canada on the basis of health status, age, gender, ethnicity/culture, ability status, and other socio-economic and demographic factors.

Table 1 identifies general planning assumptions that aim to provide a common basis for planning in the Canadian context for the next several months to years. The areas of uncertainty, listed in the table, help identify current unknowns. Given these areas of evolving evidence and knowledge, plans need to include flexible elements or placeholders that can be updated as the pandemic progresses and knowledge and experience increase. Both planning assumptions and areas of uncertainty require validation and/or updating and may be triggers for re-visiting and modifying plans.

AB1272

Table 1: Summary of planning assumptions and areas of uncertainty

General planning assumptions

- SARS-CoV-2 spreads from an infected person to others through respiratory droplets and aerosols when an infected person coughs, sneezes, sings, shouts, or talks.
- The droplets vary in size, from large droplets that fall to the ground rapidly (within seconds or minutes) near the infected person, to smaller droplets, sometimes called aerosols, which linger in the surrounding air space under some circumstances. There is no evidence showing long distance droplet transmission.
- Infectious droplets or aerosols may come into direct contact with the mucous membranes of another person's nose, mouth or eyes, or they may be inhaled into their nose, mouth, airways and lungs. Direct contact with mucous membranes, or inhalation of, infectious droplets and aerosols is accounting for the majority of transmissions.
- The virus may also spread when a person touches another person (i.e., a handshake) or a surface or an object (fomite) that has the virus on it, and then touches their mouth, nose or eyes with unwashed hands.
- Compared to influenza, COVID-19 has higher transmissibility (i.e., it has a higher basic reproductive number or R_0) is more transmissible prior to symptom onset, and has a higher infection fatality rate.
- Transmission by asymptomatic and pre-symptomatic cases is occurring.
- Public health measures and personal protective measures reduce the risk of exposure to SARS-CoV-2, however, optimal effectiveness is dependent on comprehensive application of, and public adherence to these measures.
- Variants of concern have the potential to impact transmissibility, severity, laboratory tests, and/or effectiveness of vaccines and therapeutics, depending on the mutations present in the genome of the variant.
- A significant level of population immunity, together with PHM and other measures will be required to reduce COVID-19 to a low, manageable and tolerable level.
- Vaccine conferred immunity duration may not be long-lasting or not be able to prevent all transmission. It may reduce transmission to relatively low levels but not result in elimination of COVID-19.
- The immune response to natural infection may not be long-lasting or sufficient to prevent re-infection with all variants.
- Safe and efficacious vaccines will continue to be rolled out in a targeted manner until the whole population has access to vaccine.

- The vaccination strategy will evolve based on new evidence, availability of new vaccines and related supply, and the epidemiological situation in Canada.

- There will be a national approach to prioritization/targeting of any limited resource which will be based on an ethics framework. Policy development around prioritizing limited resources will also be informed by other logistical, epidemiological and societal considerations, for example the Declaration of the Rights of Indigenous Peoples.

- The national epidemic curve will be a compilation of the epidemic activity in each province and territory, which will be influenced by the locally implemented public health response measures and public adherence with these measures.

- The risk of imported cases sparking localized outbreaks is ongoing.

- International borders will be open over time with corresponding increases in non-essential travel (during the period covered by this plan).

- Response measures implemented in one jurisdiction could have an impact on neighbouring jurisdictions, even if they themselves do not implement that measure.

- The level of response across Canada will vary based on local epidemiology (e.g., could be surging in multiple jurisdictions at same time, different times or lulls could coincide) and available health system resources.

- Our health care system and public health system capacity has limits that could be breached during peaks of COVID-19 activity. Public health workforce fatigue and burnout may also affect response capacity and timeliness.

- The impact of concurrent circulation of influenza and other respiratory viruses on health care (including long-term and other community care) and public health system capacity will be lower than usual seasonal increases while there is a high level of adherence to COVID-19 public health and infection prevention and control measures and recommendations.

- The occurrence of multisystem inflammatory syndrome in children (MIS-C) correlates with COVID-19 rates in children and youth (under 18 years of age), and could increase hospitalization rates in these age groups.

- Public health programs (e.g., seasonal influenza vaccination programs) that mitigate surges in the demand for hospital resources are part of the overall long-term strategy for the ongoing management for COVID-19.

- Public health capacity to respond to other priorities (e.g., the overdose crisis and higher rates of problematic substance use) needs to be maintained. Capacity to catch-up on interrupted program delivery may also be required.

Areas of uncertainty

- The degree to which new variants will require adjustments to the pandemic response in order to achieve current goals and objectives.
- How best to prevent takeover of VOCs and/or reduce their impact until coverage with an effective vaccine is higher.
- To what degree different vaccines and different vaccine series will prevent transmission.
- How potential global vaccine supply disruption may affect progress with vaccine roll-out.
- How easily the virus spreads through contact with surfaces or objects.
- Duration of immunity, what constitutes immunity, and whether infection with other coronaviruses provides cross-protection.
- Duration of vaccine conferred immunity and whether there will be a need for booster doses and/or seasonal vaccine programs akin to influenza.
- The number of people who need to be immune to COVID-19 to achieve sufficient population immunity (i.e., sufficient to reduce and maintain low, manageable and tolerable levels of COVID-19 in Canada).
- How effective different vaccines will be in response to new VOCs.
- How adverse events following immunizations (AEFI) will affect vaccine confidence.
- How much impact vaccine hesitancy/confidence and vaccine preference will have on vaccine coverage and timelines to achieving sufficient population immunity.
- Whether COVID-19 will eventually have a seasonal pattern similar to other respiratory infections.
- Whether lack of adherence to restrictive community based PHM will impact effectiveness of these measures to the point where their utility is compromised.
- How potential variations in risk tolerance over time and in different geographic areas will impact response actions.
- How variations in public adherence to PHMs will evolve over time.
- Sequelae and long-term health impacts of COVID-19 infection.
- Whether in the long-term significant rates of co-infection with SARS-CoV-2 and a seasonal influenza virus or other respiratory pathogen will occur and whether co-infection will significantly impact morbidity or mortality cases and subsequently demand on the health care system and resources.
- Robustness of international COVID-19 data and testing.

4.2 Modelling and Epidemiological Drivers

Modelling and capacity assessments may facilitate planning by exploring how possible ranges of parameters relevant to these issues affect the extent and impact of the pandemic in Canada. All modelling outputs are influenced by the underlying assumptions. Forecasting models are best suited to inform what may occur in the coming 2-3 months; therefore the role of modelling in long-term planning is focused on providing additional information to decision makers regarding the potential impact of control measures as opposed to providing possible incidence rates.

Mathematical modelling supports planning our response to epidemics and outbreaks, and the COVID-19 pandemic has demonstrated the important role and need for the full range of modelling tools required to support decision-making during a complex public heath crisis. This role and the types of models currently in use are described in Appendix 2: Modelling Support for Forward Planning.

It is important to recognize that the national epidemic curve will be a combination of the epidemic curve patterns from each province and territory, which in turn will be dependent on the effect of the escalation and suppression drivers in each jurisdiction. Where daily incidence is very low it is important to look at incidence over time (e.g., 2-4 weeks at a time) in order to assess the overall response and recent trends. *Figure 1* identifies epidemiological drivers that will influence the number and timing of new cases and therefore illustrates how these drivers of incidence impact the shape of the epidemic curve we experience in Canada.

Figure 1: Epidemiological Drivers: Incidence



*Vaccines that reduce transmission by preventing infection will have the largest impact on the suppression of incidence. Those that reduce symptomatic illness and/or viral load will also have a suppressive effect assuming asymptomatic cases are adequately isolated during their infectious period. Longer term suppression will be influenced by duration of vaccine-induced immunity.

Figure 1 –Text Description: This figure is an illustrative graph and therefore does not include data or numbers on the axes. The vertical axis represents increasing new cases per day and the horizontal axis reflects the passage of time. There is an orange line on the graph representing an epidemic curve with a two peaks or waves followed by a gradual decline over time. There are 4 teal coloured arrows and text boxes which link the orange line to a concept described in a text box. The first double-ended arrow located under the first large and wide peak in the orange line, depicts the duration of a peak in incidence. The corresponding text box below it identifies factors that impact duration of a peak in four bullet points. There is a vertical double-ended arrow located above the first peak that corresponds to a text box that identifies, in seven bullets, factors that affect the height of a peak in incidence. An arrow pointing to the second peak in the orange line links to a text box indicating three conditions that may lead to a subsequent peak in incidence. Finally the fourth double-ended arrow runs parallel to the orange line which is sloping down and to the right indicating decreasing incidence over time. The corresponding text box includes three bullets indicating factors that affect the steepness or rapidity of the decline in incidence over time. There is a footnote at the bottom of the graphic that indicates how vaccines may affect incidence.

AB1276

An epidemic curve pattern is one part of a planning scenario as it reflects the potential changes in the number of new cases occurring over a period of time. To ensure optimal planning it is important to consider not only the number of cases but variables that may shift the health and societal impacts of those new cases and subsequently possible surges that exceed current health care and public health capacity thresholds. *Figure 2* describes epidemiological drivers of health impact in terms of variables that may increase or decrease the occurrence of severe illness and deaths due to COVID-19. These variables include but are not limited to: changes in severity of illness experienced by the majority of cases due to increased virulence, changes in high-risk groups (i.e., both the demographic characteristics of who is getting severely ill and identification of new risk factors for severe illness), the impact of variants of concern, availability of effective therapeutics and hospital care, and vaccine coverage. The manifestation of these variables will also influence public risk perception and therefore, in a somewhat circular manner, epidemiological drivers like adherence to recommended PHM.

Figure 2: Epidemiologic Drivers: COVID-19 Related Health Impact



Figure 2- Text Description: This graphic visually conveys how epidemiological drivers influence the health impact of COVID-19 in the population. The escalation drivers (that would lead to more severe health impacts as depicted by an upward red arrow that includes the text "Increasing severe illness and deaths" on the left side of a blue text box) are listed in the left column inside the text box as: increased virulence, variants with immune escape characteristics, outbreaks in high-risk groups/settings, new/changes in high-risk groups – increasing number in this category, limited hospital/care capacity and all drivers that increase COVID-19 transmission.

The suppression drivers (that would lead to less severe health impacts as depicted by a downward green arrow that includes the text "Decreasing severe illness and deaths" on the right side of the blue text box) are listed in the right column inside the text box as: decreased virulence, dominance of strains without immune escape characteristics, increase in effective therapeutic options, high vaccine coverage with efficacious vaccine – especially in high-risk groups, adequate hospital/care capacity, and all drivers that decrease transmission.

5. Planning and the Reasonable Worst-Case Scenario

Response activities currently assume a significant level of immunity in the population, conferred by vaccination and recovery from natural infection, being achieved by the fall of 2021. This is dependent on achieving a high level of vaccination in the population with vaccines that are effective against the dominant strains and that confer immunity for a prolonged period of time. This level of population immunity will be considered significant when it is sufficient to decrease and sustain COVID-19 activity in Canada at a low, manageable, and tolerable level.

Given current uncertainties, it is also prudent to plan for delayed achievement of significant population immunity (into 2022) and the potential need for booster doses or seasonal vaccination in sustaining vaccine conferred immunity and/or protecting the those at high-risk of severe disease. In light of uncertainty regarding the duration of immunity (both from vaccination and natural infection), the propensity for respiratory viruses to spread during winter seasons, the impact of variants and travel related importations, it is possible that going forward COVID-19 will settle into a seasonal pattern similar to influenza. Regardless, living with COVID-19 will likely involve some level of PHM not only during the period of pandemic activity but on an ongoing basis.

Relaxation or lifting of restrictive community-based public health measures in the absence of a comprehensive and timely case detection, contact tracing and isolation/quarantine capability can lead to a resurgence in cases; especially if highly transmissible variants become the dominant strain in the period prior to achieving sufficient population immunity. This is what we are now seeing in some parts of the country. The size and duration of resurgence (depicted as peaks in the epidemic curve) and steepness of decline following a peak in incidence are impacted by multiple epidemiological drivers (previously described). Resurgences may be considered more tolerable as vaccine coverage increases amongst those most at risk for severe illness and death given the positive impact of lifting restrictions on minimizing societal disruption. This presumes, however, that the vaccine is effective against the circulating strain, there is no shift in virulence or high-risk groups and no significant long-term sequelae of infection. Ongoing planning needs to achieve a balance so that the pandemic response goal of minimizing all serious illness and deaths while also minimizing societal disruption is reached as soon as possible.

To facilitate ongoing planning in the context of a high degree of uncertainty, particularly around VOCs and vaccination impact, the "reasonable worst-case scenario" has been updated from the first edition of this plan. This scenario is not a prediction, but rather a common set of characteristics that will support robust forward planning (see text box).

Figure 3: Epidemic curve for reasonable worst-case scenario



Figure 3 – Text Description: This figure is a graph that has an X-axis (horizontal) with 3 points in time: January 2020, January 2021 and January 2022 and a Y-axis (vertical) that does not have a scale but represents the number of new cases of COVID-19; together these frame a general epidemic curve. The epidemic curve pattern for the reasonable worst case scenario is depicted with a line that starts out green and switches to dark blue at the point on the timeline when this Plan is being published (i.e., April 2021) – it undulates horizontally across the graph.
The green portion of the line depicts the first two waves of COVID-19 cases in Canada and the start of a third resurgence. Specifically, starting with zero cases at the start of January 2020 followed by a relatively steady increase in new cases over time, peaking in April 2020, then followed by a more gradual decrease to July 2020, the line stays relatively flat then heads upwards to form a second peak in January 2021 that is 4 to 5 times higher that the initial wave. This peak is followed by a relatively sharp decline followed by a sharp upturn in March – April 2021 depicting a resurgence and start of a possible third wave.
The line then continues into the future as a dark blue line depicting the reasonable worst case scenario which includes a third wave with a prolonged peak that is 2-3 times higher that the second wave in the early spring of 2021. This is followed by ongoing resurgences/peaks of decreasing amplitude but several exceeding health care delivery, laboratory and public health capacity thresholds and a relatively high level of ongoing transmission into 2022. A relatively high seasonal peak in winter 2021-22 occurs concurrently with severe influenza/other respiratory pathogens season
Also included in this graphic is the concept of "Capacity Threshold" which conveys the idea of an upper response capacity limit that could be breached by a high number of cases occurring over a short period of time. This is depicted with a horizontal red line.

AB1279

Reasonable worst-case scenario characteristics

- A large third wave starting with a early spring peak of prolonged duration followed by ongoing peaks of decreasing amplitude but several exceeding health care delivery, laboratory and public health capacity thresholds and a relatively high level of ongoing transmission into 2022.
- Early spring peak is 2-3 times higher than the incidence experienced at the peak of the second wave.
- Relatively high seasonal peak in winter 2021-22 occurs concurrently with severe influenza/other respiratory pathogens season.
- Similar timing of peaks across the country (each jurisdiction experiences peaks at same time).
- VOCs with high transmissibility, increased severity and immune escape properties become the dominant strain(s).
- VOCs with immune escape properties reduce vaccine effectiveness.
- There is reluctance to take the licensed vaccines (or specific vaccines) or vaccine supply is insufficient or delayed, reducing vaccine coverage and delaying achievement of sufficient population immunity.
- Available vaccines do not significantly reduce transmission and do not confer long-term immunity.
- Available treatment/therapeutics are less effective against dominant variant.
- Weak/non-sustained post-infection immunity (recovered cases become susceptible again).
- Demand for health care resources (hospitalizations, ICU beds, ventilators, personal protective equipment (PPE), Long-term care spaces, etc.) exceeds system capacity (during early third wave peaks).
- Shortage of health care providers (e.g., due to illness, burnout, work refusal, international competition).
- Demands on both laboratory and public health resources exceed capacity (during all early third wave peaks).
- Low level of compliance with public health measures.
- Permeation of mis/disinformation in Canadian society and/or loss of public trust/confidence.

Nationally the incidence was approximately 31/100,000 population or 11,849 new cases reported during the peak week in the initial wave and 149/100,000 population or 56 638 new cases reported in the peak week of the second wave. A third wave driven by the dominance of highly transmissible variants could be substantially larger than the last given that control would require enhanced, timely public health test, trace and isolate capacity at a time when much of those same resources are needed for vaccination programs. There continues to be a high degree of variation in epidemiology and response between PTs with the most populous PTs having the greatest impact on the national epidemic curve. The previous reasonable worst-case scenario included planning for a fall or winter peak, which has now occurred, however it did not specifically factor in the role of vaccine and VOCs.

The updated reasonable worst-case scenario can be used to identify any new or outstanding preparedness and response needs or issues that would require, or benefit from, a coordinated F/P/T effort should Canada be faced with this scenario. It is provided as a "stress-test" not a prediction and is intended to stimulate thinking concerning our current response efforts, capacity thresholds and resiliency.

More specifically, the scenario presents a set of potential risks, each requiring mitigation strategies based on an assessment of capacity requirements and our collective capability to manage the risks.

AB1280

Figure 4 identifies high-level capabilities that need to be in place for this scenario and *Table 2* identifies associated requirements that should be considered at all levels of government.

Figure 4: Capabilities for management of the reasonable worst-case scenario



Figure 4 – Text Description: This figure is the same as Figure 3 but includes text boxes that identify capabilities needed for the management of the reasonable worst case scenario. Several of the text boxes have arrows that point to locations on the curve pattern where it is particularly important that the capacity be in place, however the intention is that these capacities are needed on an ongoing basis throughout the response. Also included in this graphic is the concept of "Capacity Threshold" which conveys the idea of an upper response capacity limit that could be breached by a high number of cases occurring over a short period of time. This is depicted with a horizontal red line.

In this epidemic curve for the reasonable worst case scenario, the peak of the third wave and other peaks/resurgences that follow all cross over the capacity threshold line - depicting the situation where the surge in cases results in increased response capacity demands that exceed the capacity threshold. There are two red shaded text boxes that highlight the need to increase response capacity and to monitor demand. There are five text boxes that point to the epidemic curve. The first includes the text "Detect signals" and points to the epidemic curve, right before a surge in the number of new cases (depicted by an upswing and peak in curve) corresponding with a large early Spring 2021 third wave and resurgences that follow it through to the fall of 2021. The next text box includes the text "Prevent large prolonged peak" and points to the epidemic curve right where the large third wave peak is depicted. Where a subsequent peak (smaller in amplitude to the early Spring 2021 wave) occurs there are arrow from a text box that reads "Prevent surges/resurgences" and where these peaks cross the capacity threshold line, a text box indicates the need for capacities aimed at reducing demands causes by the peak in cases with the text "Reduce below threshold" included in the box. Finally in the "valleys" following peaks in the epidemic curve portion of the reasonable worst case scenario epidemic curve, there is a text box indicating the ongoing need to "Foster ongoing vigilance/adherence" particularly when new case numbers seem to be low or decreasing.

AB1281

Table 2: Reasonable worst-case scenario risk management requirements

Capability	Risk Management Requirements
DETECT –signals indicating a significant surge in cases may occur	➢ timely surveillance data (local, P/T, national and international) ➢ analysis of international data for the same or similar strain ➢ laboratory resources to rapidly distinguish between COVID-19 strains (including VOCs) and other respiratory viruses and to identify mutations associated with immune escape and/or increased transmissibility ➢ rapid analysis/investigation to assess risk of large peak based on international, national, P/T and precise/granular local level data (to assess risk of change in dominant strain, risk of importation into and within Canada, and risk of exceeding local health care and public health response capacity) ➢ screening activities including targeted use of point of care screening tests ➢ health system-wide early warning for increased demand on resources and response activities ➢ communication/education/sensitization regarding what constitutes a signal and how to ensure appropriate timely notification of potential signal ➢ ongoing vigilance/commitment to COVID-19 response
PREVENT –large prolonged peak and surges, especially those that exceed capacity to respond	➢ continued use of restrictive community-based measures until key locally-adapted indicators for relaxation of measures have been achieved ➢ public health resources to ensure ongoing response measures are adequate to control spread by highly transmissible variants and prevent new cases (e.g., use of highly conservative assumptions for defining exposure, household quarantine approach) ➢ capacity for rapid detection (through screening and testing) and isolation of cases, and rapid identification and quarantine of high exposure risk contacts ➢ public cooperation with surveillance and case and contact management activities and tools (i.e., to facilitate timely identification and isolation/quarantine, optimize use of alerting apps) ➢ use of suitable isolation and quarantine sites and high adherence to recommended measures in place in these locations ➢ gradual, controlled "re-opening" of settings and gradual resumption of activities (with modifications) that are known to be associated with increased transmission risk ➢ high adherence to ongoing modifications/controls put in place especially as restrictive PHM are lifted ➢ modified restrictions for essential workers ➢ screening strategies that aim to prevent and/or rapidly detect introduction of the virus into a susceptible high-risk population or setting ➢ consistent, clear localized indicators for implementation or re-implementation of restrictive PHM ➢ rapid deployment of targeted outbreak control/containment resources (including implementation of local "lockdowns", deployment of outbreak response teams) ➢ high compliance with personal protective measures ➢ proactive international border control measures (i.e., including quarantine, testing requirements, travel restrictions)

AB1282

	➢ increased messaging and public education regarding personal protective measures, effectiveness of vaccines and requirement for PHM following vaccination ➢ evidence-based results from vaccine hesitancy efforts and work with diverse populations to support vaccine trust, interest in getting informed, and in being vaccinated ➢ increased health care system capacity (especially in high-risk settings such as long-term care) and consideration of how to deliver needed health care (e.g., at alternate sites, using retired workers or students or alternate care providers)
REDUCE –surges in incidence and hospitalizations	➢ rapid implementation and maximizing efficiency of vaccine administration programs ➢ use of vaccine strategies that prioritize immunization of high-risk individuals, groups and settings ➢ adequate public health resources to ensure ongoing response measures to control current spread and prevent new cases, hospitalizations and deaths ➢ focus on rapid detection and isolation of cases, and rapid identification and quarantine of contacts ➢ rapid detection of outbreaks in high-risk settings and deployment of outbreak control/containment resources ➢ consideration of how to re-implement restrictive community PHM and which PHM to re-implement based on clear local-level triggers ➢ increased use of/compliance with, personal protective measures ➢ ongoing international border control measures with possible re-introduction of restrictions
INCREASE—health care and public health capacity	➢ laboratory surge capacity to: ensure rapid diagnosis and case notification, identify new VOCs, and lab-epi linkage to characterize and learn from current variants ➢ sufficient resources to facilitate optimal delivery of the vaccine program (including clinic staff; immunizers; security; schedulers; local, accessible and appropriate facilities; clear communication on who, when and how; tracking programs/registries etc.) ➢ availability of public health resources for surges in case and contact management requirements in the community (including isolation of cases and quarantine of contacts at home/alternative designated sites), development of new guidance products and provision of expert advice based on evolving scientific literature ➢ resources (i.e., human and equipment/supplies), planning and training for outbreak control activities in high-risk settings, including clear emergency back-up contact points ➢ surge capacity to ensure availability/access to health care resources including equipment (e.g., ventilators, PPE) during peaks ➢ availability of sufficient health care providers to meet surge in demand ➢ ability to access and distribute effective therapeutics ➢ ongoing monitoring of scientific literature, networks and expert advice to inform best practices for treatment and identification of effective therapeutics that reduce hospitalization requirements and/or duration of hospitalization

AB1283

	➢ recovery policies and measures (e.g., discharge for recovery at home or alternate site) to avert potential backlogs in the hospital system
MONITOR—demand for health care resources	➢ surveillance for early indicators that other illnesses that may cause a surge in demand for health care resources (e.g., seasonal influenza, other respiratory pathogens) ➢ strategic clearing of "backlog" – i.e., re-scheduling of delayed treatments, procedures and surgeries, in a way that demand is met without exceeding capacity thresholds ➢ linkages between health care delivery and public health to ensure timely establishment of alternative/over-flow care sites ➢ enhanced monitoring of global supply chains that could trigger drug shortages and identified alternatives and strategies to prioritize and conserve supply (e.g., critical supply reserve etc.)
FOSTER –ongoing public vigilance and adherence to measures and recommendations	➢ ongoing public trust in public health authorities ➢ clear, effective, culturally safe and appropriately tailored communication and education products to support continued public adherence to personal protective measures, community-based public health measures and to support vaccine confidence and uptake ➢ transparency and clarity regarding rationales for recommendations ➢ ability to provide feedback on impact, progress and success of measures ➢ public knowledge, attitudes and behavior research to inform sustainable effective behavioral changes and to combat pandemic fatigue and vaccine hesitancy ➢ monitoring of risk tolerance and public opinion in order to maximize adherence while adjusting measures to locally tolerable/sustainable levels ➢ support for enabling policy changes (e.g., paid sick leave) that facilitate adherence to public health measures and compensate affected sectors ➢ addressing of equity issues – especially those that affect access to needed resources (e.g., availability of suitable isolation and quarantine settings), ensuring public messaging is providing in multiple languages and formats etc., and ensuring these resources are shared with various partners such as Indigenous partners. ➢ consideration of incentives for adherence or adoption of new practices ➢ empowerment focused initiatives ➢ involvement of community to ensure community needs and potential barriers to adherence are considered in public health measures ➢ transparent, clear, and equitable application of reasonable enforcement activities (if necessary)

Table 1 outlines the capabilities needed to mitigate the risk of the reasonable worst-case scenario – the "what" is needed. Typically guidance and other products address the "when and how" to optimally use these capabilities. At this time, while vaccine coverage is increasing, one of the keys to preventing a large prolonged wave and ongoing surges/resurgences is the timing and adjusted use of restrictive PHM.

AB1284

Adjustments to restrictive PHM must be considered in the context of risk associated with VOCs, the effect of increasing vaccine coverage, and other factors. Specifically,

- The spread of VOCs is facilitated by less restrictive public health measures and/or insufficient application and adherence to PHM.
- More transmissible strains are more difficult to control – VOCs can be controlled by public health measures but they must be optimized. In the U.K. where VOC B1.1.7 is now the dominant strain, an increase in the stringency of public health measures resulted in declining incidence[11,12].
- As restrictive PHM are eased, VOCs will spread much faster in the community than earlier strains, necessitating stronger test, trace and isolate/quarantine capacity.
- If isolation, quarantine and other PHMs cannot control spread, closures may need to be maintained until vaccine rollout is more complete.
- High priority groups for vaccine delivery were selected to minimize serious illness and death from COVID-19.
- Current high priority groups for vaccine receipt are not the populations that are driving community transmission (i.e., younger age groups).
- When enough people in the population are immune to infection so that the virus cannot continue to spread and the disease begins to die out on its own.
- It is not yet known if the vaccines against COVID-19 can prevent disease transmission and contribute to developing sufficient population immunity, or if they simply protect against illness.
- Efforts are underway by vaccine manufacturers, governments and others to better understand the effectiveness of COVID-19 vaccines on variants.

Due to the critical role PHM play during this time period prior to achieving sufficient population immunity, *Figure 5* provides a summary of considerations for the "when and how" to ease restrictive PHM.

Figure 5 Easing of restrictive PHM

Indicators of readiness for easing restrictive PHM

- COVID-19 transmission is controlled to manageable level
- Sufficient public health capacity is in place to test, trace, isolate and quarantine a high proportion of cases and contacts
- Sufficient health care capacity exists including substantial clinical care capacity to respond to surges
- Risk reduction measures are in place for high-risk populations and settings

Timing of use of restrictive PHM

- NO EASING – if transmission is uncontrolled, VOCs becoming increasingly prevalent, insufficient health care capacity to respond to surges, limited public health capacity to test, trace and isolate
- CONSIDER –if transmission controlled, sufficient testing and contact tracing capacity, low incidence permits for testing and tracing to cope with outbreaks/surges, high vaccine coverage in higher risk populations and settings
- INSTATE/RE-INSTATE – modelling suggests resurgence, case incidence overall is increasing (and R_t rising), adherence to PHM is declining, evidence of community spread of VOCs

How to proceed with easing

- Cautious, gradual phased approach, easing up on restrictions in the least risky venues first, with at least 3 weeks between phases to allow detection of resurgence
- With clear communication of rational, objectives and possibility of re-instatement
- Targeted to address societal disruption concerns at local level
- In an equitable manner that supports adherence

Figure 5 – Text Description: This figure shows the sequencing of considerations for easing of restrictive public health measures. The content is divided into three sets of text boxes. Subtitles are in an orange text box and the corresponding text is next to it in a teal coloured box. The three subtitled sections are connected by arrows that point to the next section of text which is located below the previous section and offset to the right to suggest a progressive sequence of considerations.
The first section is subtitled "Indicators of readiness for easing restrictive public health measures (PHM)". There are four bulleted points in this section that read: COVID-19 transmission is controlled to manageable level; Sufficient public health capacity is in place to test, trace, isolate and quarantine a high proportion of cases and contacts; Sufficient health care capacity exists including substantial clinical care capacity to respond to surges; and Risk reduction measures are in place for high-risk populations and settings.
The second section is subtitled "Timing of use of restrictive PHM". There are three bulleted points in this section that read: NO EASING – if transmission is uncontrolled, VOCs becoming increasingly prevalent, insufficient health care capacity to respond to surges, limited public health capacity to test, trace and isolate; CONSIDER –if transmission controlled, sufficient testing and contact tracing capacity, low incidence permits for testing and tracing to cope with outbreaks/surges, high vaccine coverage in higher risk populations and settings; and INSTATE/RE-INSTATE – modelling suggests resurgence, case incidence overall is increasing (and Rt rising), adherence to PHM is declining, evidence of community spread of VOCs.
The third section is subtitled "How to proceed with easing". There are four bulleted points in this section that read: Cautious, gradual phased approach, easing up on restrictions in the least risky venues first, with at least 3 weeks between phases to allow detection of resurgence; With clear communication of rational, objectives and possibility of re-instatement; Targeted to address societal disruption concerns at local level; and In an equitable manner that supports adherence.

6. COVID-19 F/P/T Response Components

Forward planning will also be informed by ongoing reflection regarding what has worked well, what we have learned and what can be adjusted based on evidence and experience. Using the response components identified in the CPIP, with a focus on those requiring F/P/T public health leadership and consultation, this section provides details on F/P/T activities planned or already underway that will assist and expedite complementary planning in each federal government department, province and territory. The components covered in this section are:

- **6.1 Surveillance**
- **6.2 Laboratory Response Activities**
- **6.3 Public Health Measures**
- **6.4 Infection Prevention and Control and Clinical Care Guidance**
- **6.5 Vaccination**
- **6.6 International Border and Travel Health Measures**
- **6.7 Health Care System Infrastructure**
- **6.8 Risk Communications and Outreach**
- **6.9 Research**

6.1 Surveillance

The purpose of surveillance and risk assessment activities is to provide decision makers with the timely epidemiological and risk information they need to inform action. Similar to national influenza surveillance (FluWatch), COVID-19 surveillance is a pan-Canadian initiative that integrates numerous data streams including existing surveillance systems with novel, non-traditional data sources.

Current Status/Focus

Currently, the following data sources are facilitating monitoring across the spectrum of disease (i.e., from mild cases in the community based on sentinel surveillance to severe illness based on hospitalization data).

- Case-level data reported by PTs: Revised national dataset including more information on cases, risk factor data, improved occupational data, and the addition of race/ethnicity data is a key priority.
- Aggregate laboratory result data: Provincial public health laboratories and PHAC's National Microbiology Lab report numbers of people tested for SARS-CoV-2, as well as confirmed VOC cases.
- Aggregate sampling: Wastewater surveillance is underway and showing some promise as a surveillance and alert component.
- Data on travellers and border testing: Is used to identify positive cases at the border and prevent travel associated transmission in Canada
- Apps: User data from Canada COVID-19 and other symptom tracking applications.
- Mobility data: Partnership with BlueDot Inc., and other sources that may become available, to monitor indicators of population movement as a proxy measure for compliance with PHM, and the levels of inter-P/T movement.
- Special surveys: Impact of COVID- 19 on specific populations (e.g., health care worker).
- Sentinel Surveillance Networks:
    - Hospital networks - Several hospital-based data streams measure the impact of COVID-19 in Canadian hospitals and collect detailed case information on most severe cases.
    - Canadian Pediatric Surveillance Program - occurrence of Multi Inflammatory System in Children (MIS-C).
    - Community-based systems/ networks - Assess the level of transmission in the community and the epidemiologic characteristics of outpatient cases.
- Syndromic surveillance data: PHAC monitors individuals in Canada reporting influenza-like illness via its participating sentinel practitioners in FluWatch.
- Publicly available data: supplementary data source to add situational awareness on COVID-19 transmission in jurisdictions.
- The federal, provincial and territorial public health partners are leveraging existing mechanisms and operating procedures to collaborate on multijurisdictional and complex COVID-19 outbreak investigations. This allows sharing of capacity and resources toward the common goal of better understanding COVID-19 in our communities.
- The process to conduct joint epidemiological and laboratory investigations for variants of interest (VOIs) in Canada is currently being developed, and will be based on the current process for investigating foodborne disease.

Preparations/Forward Planning

Forward planning will support continued improvement of national surveillance and monitoring to support decision making as the pandemic evolves. The focus will be on: monitoring vaccine performance and changes in the epidemiology of COVID-19, including the impact on priority populations and reductions in severe outcome;, flexible surveillance and monitoring that can adapt to new evidence, including the evolution of the virus over time and the emergence of VOCs; interpretation of surveillance data in the context of local epidemiologic trends and, the information required to inform the appropriate easing of PHM driven by epidemiological trends. Multiple data streams are being configured in order to pick up signals and changes in epidemiology. These preparations and ongoing activities based on the anticipated short, mid or long-term timeframe are identified below.

Short term:

- Updating data dictionary, case report form and surveillance guidance as necessary.
- Monitor vaccine performance, including coverage, safety and effectiveness, waning immunity and vaccine escape.
- Implement the national Variants of Concern Strategy and Network.
- Support ramp-up of genomic capacity and screening for positive cases and linkage to associated epidemiologic data to monitor on-going viral evolution including VOCs.
- Identify signals that may require public health response.
- Further examination and use of wastewater testing as an early detection mechanism.
- Support rapid epidemiologic investigations to characterise the transmission and impacts of new variants and impact of vaccination in the context of outbreaks.
- Provide federal surge capacity support.
- Conduct surveillance to identify broader consequences of COVID-19 and associated control measures on health of Canadians.
- Enhance data and analytics by improved modelling and data access capacity.
- Share timely information effectively with partners and publicly with Canadians.

Medium to Long term:

- Support rapid epidemiologic investigations to identify areas of on-going transmission.
- Monitor vaccine performance, including coverage, safety and effectiveness, including issues such as waning immunity and vaccine escape.
- Conduct targeted surveillance on broader consequences to inform public health action.
- Enhance data integration to evaluate evolving epidemiology in the context of increased vaccination and immunity to support recovery.
- Continue to build and maintain data and analytics capacity and knowledge transfer networks to support on-going development and sharing of intelligence.

Planning Variables or Signals

It is possible that a new syndrome or rare event would require the development of a new, or adjustments to, the surveillance strategy as has occurred for Multisystem Inflammatory Syndrome in Children (MIS-C).

New settings or populations affected by outbreaks could emerge in outbreak surveillance (or via outbreak intelligence gathering) which could precipitate new data needs, additional surveillance activities or new variables to be collected to inform actions. For example, outbreaks among temporary foreign workers have highlighted the need to be prepared to rapidly implement specific surveillance and coordination mechanisms, as well as drawn attention to how social determinants of health (e.g., crowded housing, precarious work, access to medical services) can impact transmission and control of COVID-19.

6.2 Laboratory Response Activities

Laboratory-based surveillance is an integral part of monitoring respiratory virus activity. Since the start of the COVID-19 outbreak, Canada's National Microbiology Laboratory (NML) has been providing leadership in regard to testing for COVID-19 and surge capacity for provincial and territorial public health laboratories. The NML has also contributed to domestic and international efforts to better understand COVID-19 virus characteristics that can inform the development of medical countermeasures.

Canada's public health laboratories, working through the long-standing Canadian Public Health Laboratory Network (CPHLN), have been successful in optimizing molecular testing to reduce reagent consumption by reducing the number of PCR target genes (when appropriate), pooling of samples, multiplexing, evaluating the optimal types of samples, swabs and transport media. Through this effort, testing capacity has been increased to 227,000 tests/day as of February 2021. CPHLN has worked closely and successfully with northern, remote, and Indigenous communities to enable those communities to have greater access to laboratory diagnostic tools (e.g., diagnostic platforms, reagents, training, and supply chain management). Through close work with the NML, the territories have been able to set up COVID-19 testing within each territory.

Current Status/Focus

The evolution of several different virus variants with altered characteristics, such as increased transmissibility and potential immune escape, poses a new challenge to Canadians. Canada's public health laboratories, working through the CPHLN, are meeting this new challenge while continuing to address other key COVID-19 and non-COVID-19 pressures through the following activities:

- **development and validation of diagnostic VOC screening assays;**
- **continued support for implementation of whole genome sequencing of priority samples;**
- **undertaking work to standardize naming and confirming VOCs, defining what may constitute a SARS-CoV-2 variant of concern as well as acquiring variants quickly to support Canadian diagnostic initiatives and research, including vaccine efficacy in the face of evolving variants;**
- **continued work to evaluate serological testing kits as well as developing in-house serological tools such as ELISA, neutralization assays and point of care tests (serological work is in support of the broader Canadian Immunology Task Force), incorporating the ability to distinguish natural infection from vaccine-derived antibodies;**
- **continued work geared toward the augmentation of Transport of Dangerous Goods (TDG) sample shipping requirements) to meet pandemic and non-pandemic sample transport challenges in those and all Canadian communities;**
- **collaboration with other partners, such as CIHR and academic, to undertake studies that help us understand pathogen characteristics, including the differences brought on by virus variants; and,**
- **continued readiness to tackle multiple respiratory virus outbreaks as needed, recognizing that the PHM in place have largely suppressed influenza and RSV activity but a resurgence might be observed with the relaxation of PHM.**

Preparations/Forward Planning

At this time, federal and provincial public health laboratories and facilities in the territories perform on average 97,000 tests per day and have the capacity to perform as many as 227,000 test per day if required.

The NML together with the CPHLN, is undertaking the following activities in order to continue to prepare for potential surges/resurgences based on the reasonable worst-case scenario but also as part of the laboratory preparedness long-term vision.

Short term:

- Continuing strong communication among Canada's public health partners through CPHLN to ensure laboratory response strategies are aligned and appropriate.
- Continuing a strong collaborative approach toward developing and validating diagnostic testing.
- Provide support for point of care testing.
- Work together to develop a robust collaborative research agenda into SARS-CoV-2 variants of concern, their detection and public health impacts as vaccines are administered.

Mid term:

- Continue optimizing various testing platforms and their uses to determine whether individuals have been previously infected, especially for healthcare and other service providers such as police, fire fighters, employees in long-term care facilities, etc.
- Continue streamlining molecular and serological testing as well as variant screens and whole genome sequencing, including stewardship of reagents so they are conserved as testing demands increase.
- Continue developing, validating, and enabling greater access to faster diagnostic tools such as Point of Care tests (prioritizing northern, remote, isolated and Indigenous communities).
- Continue working with manufacturers to enhance the sourcing of critical laboratory supplies that meet appropriate standards to ensure continuity of operations.
- Continue working with PTs and other stakeholders to inform the use of testing in specialized settings (such as borders).

Planning Variables or Signals

Epidemiological data from February 2021 demonstrated reassuring declines in case counts in most Canadian jurisdictions, but with the combination of relaxation of public health measures and expansion of VOCs, data from April 2021 clearly shows initiation of a third wave largely driven by surges of VOC cases in the most populated provinces ahead of widespread vaccination. The timelines, strategy, and prioritization of the above activities, therefore, must now be expedited.

6.3 Public Health Measures

PHM are the range of non-pharmaceutical interventions implemented by public health authorities at the F/P/T and local level to reduce the risk of infectious disease transmission. PHM range from those applied at individual-level to community-based measures including for settings (e.g., schools, workplaces, healthcare settings). Individual-level measures include personal preventive practices such as wearing masks, physical distancing, practising hand hygiene, self-monitoring for symptoms to those measures aimed at detecting and isolating cases as well as tracing and quarantine of contacts. Community-based measures range from public education campaigns and advice on enhanced cleaning and disinfection for public spaces to restrictive measures to reduce interactions and prevent transmission in population groups, settings and the community at large. "Restrictive" community-based measures aim to reduce contacts by limiting movement, activities, or access to resources and public spaces (e.g., school closure, restrictions on gatherings, workplaces/businesses restrictions).

PHM have been shown to be effective in controlling transmission even where VOCs with increased transmission are dominant[9,10]; however, many of these measures have important consequences beyond the scope of COVID-19 management. These consequences require careful consideration and prioritization in relation to other determinants of health, such as impacts on childhood development, access to health services, mental health, domestic and intra-family violence, social isolation and exclusion, and at-risk communities. PHM effectiveness depends on the level of adherence by the public, which is influenced by pandemic fatigue and factors such as living, working, community conditions, and financial and social circumstances.

Since the start of the COVID-19 pandemic the F/P/T public health response has involved working closely with multilateral partners, other government departments, First Nations, Inuit and Métis partners to develop, update and disseminate appropriate public health guidance for a range of target audiences on how to detect, report, prevent and manage COVID-19 infection. One example of this is the formation of the Public Health Working Group on Remote, Isolated and Northern Indigenous Communities that adapts public health measures guidance to the unique needs, context and considerations of these communities in the response.

Current Status/Focus

The focus of current F/P/T PHM activities includes:

- developing and updating national guidance as new information becomes available and/or response needs change;
- increasing testing and contact tracing capacity to ensure chains of transmission are disrupted;
- rapidly detecting and isolating all cases, and tracing and quarantine of all high-risk contacts in a culturally sensitive way;
- promoting adherence to personal preventive practices by empowering individuals to play an active role in reducing transmission;
- monitoring the evolving domestic and international situation, and evaluation of PHMs to inform updated advice and adjustments to PHM accordingly (e.g., non-medical mask use, ventilation, risk associated with different settings and activities, emergence of VOCs, vaccine roll-out);
- careful easing restrictive PHM by PTs based on assessed readiness, while monitoring for signals of concern (e.g., increases in unlinked cases, transmission of VOCs); maintaining readiness to rapidly reinstate restrictive measures if surges/resurgence occurs; and protecting populations at higher risk of severe disease and outcomes;
- promoting risk based approaches to using PHM based on the setting (e.g., workplaces, gatherings, outdoor recreational spaces, child and youth settings) and consideration of the broad impacts of PHM on pandemic fatigue, health and wellbeing of diverse population groups; and,
- supporting and informing workplaces/businesses by working with the Canadian Centre for Occupational Health and Safety, to provide for safe and healthy workplaces.

Preparations/Forward Planning

In terms of F/P/T preparations, the focus is on building, adjusting and updating existing PHM guidance and resource products as needed, based on new knowledge, expert scientific opinion, experiences to date, and risk assessments.

AB1291

It is important that these ongoing activities continue to be as timely and responsive as possible and take into consideration the specific needs of high-risk populations including social, economic and demographic factors. Community-based PHM are most effective when implemented as early as possible and as a set of measures using a "layered approach" in response to epidemiological signals of concern. Therefore, preparations include ongoing readiness to reinstate restrictive community-based PHM when required, while easing them when possible to avoid negative impacts on health, wellbeing and society. Communication activities that continue to build public trust and confidence will be critical to facilitating public understanding and adherence to recommended PHM. As vaccine coverage increases in key settings and once indicators of readiness to ease measures are met (Figure 5), public health authorities will adjust public health advice, measures and restrictions accordingly. These adjustments may include changes in advice for key settings where mitigation measures and layers of protection are in place (e.g., long term care homes) and where there is high vaccination coverage. Living with COVID-19 will likely involve some level of PHM and personal preventive practices not only during the period of epidemic activity but for a longer period of time, for example, mask wearing in crowded places, hand, respiratory and environmental hygiene, and avoiding enclosed poorly ventilated spaces.

These preparations and ongoing activities based on the anticipated short, mid and long-term timeframe are identified below.

Short term:

- Ongoing updates to existing or development of new evidence-based national guidance as evidence evolves.
- Monitoring the emerging evidence and modelling the effectiveness of PHM and adjusting as appropriate.
- Monitoring the situation related to new VOCs and advising on changes to recommended PHM if warranted.
- Monitoring public adherence to PHM and adjusting messaging and enforcement as required.
- Updating public and health professional communication, guidance and education products and assessing their effectiveness (e.g., through public opinion and behavioural research).
- Developing and maintaining sufficient public health capacity to isolate cases, trace and quarantine contacts in place, including through the use of digital tools.
- Ongoing provision of comprehensive public health advice to workplaces/businesses.
- Monitoring the impact of vaccine roll-out (e.g., effectiveness to prevent asymptomatic infection, vaccine coverage rates) and updating advice on public health measures for individuals, settings and communities accordingly.

Mid term:

- Ongoing situational monitoring and international collaboration on COVID-19, including VOCs, and broader impacts of PHM and recommendations, updating advice and adjusting PHM accordingly.
- Ongoing monitoring of public adherence with PHM, and adjusting messaging and enforcement as required.
- Provide recommendations/advice on the need to reinstate restrictive PHM when a resurgence in COVID-19 is identified at P/T and national levels.
- Monitoring the impact of vaccine roll-out and adjusting advice on public health measures accordingly.

- Supporting, as necessary, Logistics Advisory Committee (LAC) re-evaluation of F/P/T plans for acquiring, stockpiling and distributing supplies (e.g., hand sanitizer, gloves, masks, disinfectant supplies) in consideration of PHM.

Long term:

- Collaborating on pandemic recovery, and adjusting PHMs as required.
- Evaluating the PHM component of the COVID-19 pandemic response and incorporating lessons learned into planning for future pandemics.
- Establishing strategy to update existing or write new F/P/T pandemic plans to address robust PHM and minimizing societal disruption, as outlined in Canada's pandemic goal.
- Providing public education to entrench PHMs as a core practices that will become the new baseline practices based on effectiveness of measures from evidence reviews.
- Working with other sectors to strengthen the social services to protect health and mitigate risk.

Planning Variables or Signals

Preparations and forward planning will consider adaptations to current activities, recommendations and guidance, e.g., if there are significant changes in disease activity, high-risk groups or public adherence to recommended PHM, and the impact these may have in various population groups.

6.4 Infection Prevention and Control and Clinical Care Guidance

While impacting the F/P/T public health response, the provision of infection prevention and control (IPC) and clinical care guidance and expert advice has predominantly been aimed at informing practising health care professionals, including infection prevention and control professionals. Therefore engagement with stakeholders outside of the public health sector, in particular front line health care and infection prevention and control professionals , is a key part of supporting preparedness.

Current Status/Focus

The current focus of response activities pertaining to IPC and Clinical Care include:

- ensuring that previously published COVID-19 Infection Prevention and Control documents continue to provide up-to-date relevant and evidence-informed guidance;
- updating (based on new information) the interim guidance for the clinical management of patients with moderate to severe COVID-19 and care of residents in long-term care during the COVID pandemic;
- providing clinical guidance on the changing presentation, complications, risk factors and outcomes of COVID-19;
- completing any outstanding guidance products;
- planning for joint PHAC/Association of Medical Microbiology and Infectious Disease Canada (AMMI) webinars addressing ongoing key clinical issues that will occur once a month starting July 2020, potentially through to June, 2021; and
- providing key clinical journal articles review and summation to F/P/T public health tables.

Preparations/Forward Planning

All Clinical Care Guidance and Infection Prevention and Control documents are being reviewed on an ongoing basis to ensure they reflect the most up to date information on clinical care and IPC. This includes key clinical findings in the literature, responding to new and/or changing science.

AB1293

Planning Variables or Signals

If additional clinical or infection prevention and control information emerges, (e.g., a change in mode of transmission, dominance of VOCs with immune escape characteristics, or additional risk groups), there may be a need to revise or develop additional IPC or Clinical care guidance documents. Similarly, the identification and availability of new effective treatments would require updating of Clinical care guidance.

6.5 Vaccination

In line with the overarching objective of Canada's COVID-19 response of minimizing serious illness and overall deaths while minimizing societal disruption, the goal of Canada's COVID-19 immunization response is:

- To enable as many Canadians as possible to be immunized as quickly as possible against COVID-19, while ensuring that high risk populations are prioritized.

This goal guides collaborative work across jurisdictions to allocate, distribute and administer vaccines as efficiently, equitably and effectively as possible; provide safe and effective vaccines as quickly as possible for all who want them; and monitor the safety, coverage and effectiveness of COVID-19 vaccines.

In December 2020, Canada received its first shipments of vaccines and proceeded to administer more than one million doses in the first two months of the national vaccination campaign. The Government of Canada anticipates having sufficient supply of authorized COVID-19 vaccines to offer a full series of vaccine to all eligible persons in Canada, by September 2021. To facilitate this, the Government of Canada signed advance purchase agreements to secure access to seven vaccine candidates, including Moderna, Pfizer-BioNTech, AstraZeneca, and Janssen vaccines, when these products were in development. P/T governments, together with federal stakeholders, have developed plans for the efficient, effective and equitable allocation of COVID-19 vaccines across Canada as well as priority setting for key populations for early vaccination based on risk of severe outcomes and risk of COVID-19 exposure. This work is informed by guidance from Canada's National Advisory Committee on Immunization (NACI), an external advisory body that provides independent advice on the use of authorized vaccines in Canada. NACI has developed guidance on the optimal use of COVID-19 vaccines, including guidance on the prioritization of key populations for COVID-19 vaccination, that is being used to optimize public health benefits from COVID-19 vaccination during the pandemic, as well as guidance on COVID-19 vaccine research priorities.

Current Status/Focus

With the Health Canada authorization granted to a total of four COVID-19 vaccines as of March 5 2021, implementation of plans as documented in the Comprehensive Distribution Plan, guided by the Vaccine Annex of the CPIP is proceeding. For example, enhanced tracking systems for adverse events following immunization (AEFI), the Vaccine Injury Support Program (VISP), vaccine effectiveness (VE) assessment and uptake/coverage; allocation, storage and handling; vaccine delivery strategies, are all being utilized as part of the vaccine strategy for COVID-19 vaccination in Canada. Federal/provincial/territorial governments, First Nations, Inuit and Metis leadership and public health authorities are collaborating[13] to ensure that vaccination programs and clinics are designed and implemented in a manner to respond to out-sized demand for vaccination in a global environment of constrained supply.

An Immunization National Operations Centre (NOC) for COVID-19 has been established as the federal logistical coordination entity and focal point for managing vaccine delivery and collaboration with provinces and territories for distribution. Supported by a multi-disciplinary team of experts, including the Canadian Armed Forces, the NOC has been designed to support partners involved in Canada's immunization roll out and lead the tracking of vaccine delivery and distribution, and reports to the President of PHAC through the Vaccine Roll-out Task Force.

As vaccines have thus far been sourced from manufacturers that do not have an existing Canadian presence, require importation from overseas locations, and/or require onward distribution from a central point in Canada, PHAC has contracted Logistics Service Providers (LSPs) who are supporting importation, storage and distribution for several candidates. The LSPs are working to complement provincial and territorial supply chains, and align with the activities that PTs have undertaken to strengthen supply chains within their jurisdiction.

In addition, the Government of Canada has strengthened vaccine cold chain supply systems through the provision of equipment and training to manage ultra low and frozen vaccine products safely and securely, and proactively procured essential supplies (e.g., needles, syringes, epinephrine, etc.) on behalf of the PTs via the National Emergency Strategic Stockpile to mitigate against potential supply shortages. Federal procurement activities also complement those being undertaken at the PT level, ensuring that all jurisdictions have contingencies in both supply chain capacity and ancillary supplies.

The federal government is also continuing to work with provinces, territories, and other partners to provide the necessary training and educational tools on COVID-19 vaccines so that vaccinators have the information they require.

Recognizing that all partners must work collaboratively to address vaccine hesitancy, cross-jurisdictional cooperation is underway to better understand public opinion and behavioural science. This enhanced understanding informs the development of educational tools and communication strategies to further educate and build trust in COVID-19 vaccines. In particular, the Federal Government is leveraging the Immunization Partnership Fund to support the efforts of key stakeholders to increase vaccine acceptance and uptake among Canadians and reduce vaccine preventable disease including COVID-19.

In addition, to support planning and response activities, the Vaccine Annex of the CPIP has been adapted to guide the implementation of the Equitable Allocation Strategy, as well as the operational work of the National Operations Centre, leveraging existing mechanisms where possible to support ordering, shipment and delivery of vaccines, logging and follow up on complaints, and reporting on inventory and wastage. Finally, VaccineConnect, a digital vaccine management platform has been designed to facilitate end to end vaccine tracking, monitoring of adverse events, data sharing and management of vaccination programs.

Preparations/Forward Planning

Guidance and tracking systems will continue to be updated as vaccine supply changes. The NESS continues to procure additional supplies as needed to support F/P/T vaccine administration.

The Government of Canada COVID-19 Vaccine Task Force is focusing on strategic investments in vaccine research, development, and domestic bio-manufacturing to facilitate domestic vaccine supply. In addition, a COVID-19 Vaccine Clinical Trial Discussion Forum is convening academic, government, and industry partners to discuss vaccine clinical trial challenges and optimal designs.

Timelines for activities that support *Canada's COVID-19 Immunization Plan* are:

Short term*:*

- Updating F/P/T public health recommendations and P/T vaccine strategies, informed by NACI guidance, as additional vaccines are authorized and as evidence on these vaccines and COVID-19 evolves.
- Work on vaccine confidence including a mass public education campaign and coordinated outreach efforts targeted to all Canadians as vaccine becomes more widely available.
- Continuing to provide ancillary supplies to PTs for vaccine administration.
- Continued collaboration with manufacturers to obtain sufficient supportive guidance and training to build provinces, territories, First Nations, Inuit and Metis partners and federal department capacity and capability to manage anticipated supply and distribution of vaccines.
- Comprehensive engagement with provinces, territories, First Nations, Inuit and Metis partners and federal departments to ensure readiness to receive, store, handle, and administer COVID-19 vaccines, including those already authorized and those anticipated in the near future.
- Ongoing F/P/T dialogues for sharing challenges and lessons learned, including strategies to better leverage the private sector (e.g., pharmacies) to bolster vaccine roll-out capacity.
- Creation and maintenance of a "control tower" for the management of logistics and distribution, Vaccine Roll Out National Operations Centre, enabling clear and coordinated engagement with provinces, territories, Indigenous partners, and federal departments.
- Build additional functionality of VaccineConnect, the digital vaccine management system to support jurisdiction vaccine program management and national reporting.
- Continued logistical planning for supply chain, including for transport /storage /use of vaccines in northern, remote, isolated settings and Indigenous communities, in collaboration with provinces, territories, Indigenous stakeholders and federal departments.

Mid term:

- Ongoing work on vaccine confidence including a mass public education campaign and outreach efforts targeted to everyone in Canada as vaccine becomes more widely available.
- Data analysis to inform the need for: vaccine modifications (e.g., substitutions) to ensure protection against emerging VOCs, booster doses, and/or seasonal vaccination programs.

Longer term:

- Strategic planning for ongoing COVID-19 vaccine supply, including domestic bio-manufacturing capacity, allocation and distribution models as needed.
- Ongoing consideration of vaccine strategies and vaccine-related research priorities to address changing epidemiological context and emerging evidence (e.g., evidence on the duration of vaccine protection and use of COVID-19 vaccines as post-exposure prophylaxis).
- Enhancements/preparations for AEFI analysis.
- Ongoing surveillance and research on duration of protection offered by COVID-19 vaccine.
- Integration of VaccineConnect to support pan-Canadian vaccination initiatives beyond COVID-19.
- Adaption of the contents of the CPIP Vaccine Annex for the COVID-19 context as necessary.
- Continued assessment and monitoring of vaccine quality, safety and effectiveness as per established processes[14].

Reducing hospitalizations due to seasonal influenza and invasive pneumococcal disease through increased vaccine coverage can preserve both public health (e.g., diagnostic/testing, outbreak response) resources and health care (i.e., outpatient visits and inpatient stays) capacity . For these reasons it has been identified as an ongoing forward planning element.

Influenza vaccines and routine programs

F/P/T public health responders and professional groups are concerned about interruptions to routine immunization programs due to COVID-19 PHM and physical distancing, and are monitoring trends. To this end, PHAC issued guidance on the importance of immunization program continuity in particular to mitigate the risk of measles and other vaccine-preventable disease outbreaks once international travel resumes.

In anticipation of ongoing COVID-19 activity during the roll-out of seasonal influenza vaccination programs, PHAC also prepared guidance on the delivery of influenza vaccine in the presence of COVID-19. The guidance focuses on alternative delivery models, clinic set up, changes to immunization practices and processes, infection prevention and control, and PPE at influenza vaccine clinics. The impact of ongoing COVID-19 activity on seasonal influenza activity is unknown and will be monitored closely.

Planning Variables or Signals

It is important that, as new COVID-19 vaccines are rolled out, their characteristics (e.g., efficacy, safety, dosing schedule), effectiveness in different populations (e.g., elderly), and the supply situation continue to be monitored and communicated to F/P/T and First Nations, Inuit and Metis partners. COVID-19 vaccines are already displaying varying levels of effectiveness and their ability to prevent asymptomatic transmission or respond to variants remains unknown. The evolving evidence on vaccine effectiveness will be important to the ongoing management of COVID-19. Continued planning should include consideration of variations in vaccine effectiveness and response to AEFI reports or signals. This requires continued AEFI surveillance, health promotion and education and risk communication expertise.

6.6 International Border and Travel Health Measures

Since the onset of the pandemic, the Public Health Agency of Canada (PHAC) has significantly shifted and expanded its border and travel health programs to focus primarily on mitigating the risk of COVID-19 importation and together with other response measures, protecting the capacity of provinces and territories to offer health services to Canadians. Prior to this pandemic, it was not envisioned that extensive international border closures would be implemented as a pandemic response measure. Successful implementation of border and travel health measures has required extensive ongoing multilateral engagement and cooperation with government and non-government stakeholders (e.g., the air travel industry).

Current Status/Focus

Several new and enhanced border and travel health measures critical to the COVID-19 response have been developed and implemented including:

AB1297

- an increased capacity for PHAC to undertake health-related risk assessments and provide travel advice and other measures to minimize the risk of Canadians' exposure to the disease, including on conveyances (air, marine, land);
- linkages between federal and P/T guidance and oversight for the management of international and domestic travellers;
- leveraging the provisions of the *Quarantine Act* and introducing more than 45 Emergency Orders;
- limiting entry of foreign nationals and imposition of new testing, enhanced quarantine and isolation requirements for incoming travellers to Canada;
- strengthening the compliance and enforcement regime through the establishment of a on-site compliance verification program to boost the capacity to follow up with travellers at their place of quarantine/isolation to verify their compliance, as well as new fines under the Contraventions Act;
- electronic case management tools to operationalize delivery of border measures, including exemptions, compliance and enforcement, etc.;
- increasing the public health presence at the border (i.e., public health officers being assigned to 36 high volume points of entry) as well as enhanced PHAC capacity to conduct virtual health assessments for COVID-19 via access to a 24/7 Central Notification System;
- the establishment of and increase in temporary federal quarantine facilities across the country and their continued management to support enforcement of public health Orders;
- ongoing cooperation and work with provincial and/or local law enforcement-related partners to support compliance verification and enforcement activities, including ticketing travellers not complying with the federal quarantine and/or testing requirements;
- enhanced partnerships with provincial and territorial health authorities and other key players to support data-sharing, compliance, enforcement of quarantine and awareness on COVID-19 (e.g., through the ArriveCAN app), and border testing pilots; and
- new and updated messaging and communication tools for the travelling public.

Preparations/Forward Planning

Moving forward as part of planning for a potential resurgence of the disease and introduction of VOCs, PHAC will continue to maintain a high level of readiness to respond to COVID-19 through a combination of border and travel measures that are calibrated to:

- evolution of the global COVID-19 situation, most notably with the aim of preventing and tracking importation of VOCs
- evolution of the domestic COVID-19 situation and provincial and territorial considerations;
- progression of COVID-19 vaccine coverage both domestically and internationally and ongoing scientific evidence on vaccine effectiveness;
- updated modelling and risk analysis of other countries and international experiences to ensure lessons learnt;
- operational capacity pre-, at- and post-border to handle anticipated incoming and outbound travel volumes along with additional measures as applied;
- evaluations of border restrictions or easing in coordination and alignment with F/P/T requirements (while factoring in whole of health system capacity);
- considerations of the public health/health system capacity to manage potential increase in imported cases (testing, contact tracing and reporting, provincial and territorial health care capacities); and,
- volumes that different classes/sectors or arrival modes bring to Canada.

AB1298

Based on these considerations, PHAC will continue to adjust its border and travel health tools including:

- implementing enhanced border requirements, such as testing and quarantine;
- adjust the needs of online tools (such as ArriveCAN) to accommodate increased requirements, including testing, and evolving usage requirements by F/P/T partners;
- examination and adjustment of border exemptions during periods of reduced or increased infection and importation;
- updated case management reporting related to variant screening among F/T/P to meet evolving needs; and
- examination and application of amendment considerations to the OICs under the *Quarantine Act*.

Planning Variables or Signals

As international and domestic contexts shift, border and travel measures may be adapted accordingly. There are a variety of possible approaches that could be explored:

- **Global restrictions:** Increase/decrease global restrictions for all destinations, control through health-related measures. Possible exclusion of high-risk countries based on country risk assessments.
- **Country-specific restrictions:** Remove global advisory/prohibition of entry, but maintain/impose restrictions for individual states or regions by exception, based on risk of importation.
- **Sectoral/class restrictions:** Decrease exemptions to travel measures based on a sectoral analysis.
- **Reciprocal:** Leave global advisory/prohibition of entry, remove or ease restrictions based on reciprocal arrangements with individual states (or regions e.g., Caribbean) and assessment of respective COVID situations.
- **Modal:** Increase/ease measures for travellers entering by air, sea or land, based on risk and operational factors.
- **Testing and/or vaccination certification:** ease or impose measures according to travellers' proof of test results and/or vaccination, in a wary that is justified by available scientific evidence and is sensitive to legal and ethical issues, including around equity and accessibility.

6.7 Health Care System Infrastructure

A peak in pandemic activity greater than the first COVID-19 wave in any jurisdiction can have a substantial impact on health care service capacity and the ability of health care organizations to keep those providing or receiving health care services safe.

Canadian businesses have stepped up to offer their solutions and expertise, or pivoted their manufacturing facilities, and Canada is now successfully producing Made-in-Canada PPE, medical equipment and supplies to address the urgent needs of frontline workers, and the safety of Canadians at large. In addition, Innovation, Science and Economic Development Canada, Health Canada, PHAC and PSPC Canada are working closely together to quickly to increase Canadian PPE manufacturing capacity to address domestic needs.

With respect to therapeutics, the Interim Order Respecting the Prevention and Alleviation of Shortages of Drugs in Relation to COVID-19, made by the Minister of Health on October 16, 2020 introduces new tools for the Minister to address drug shortages, or the risk of drug shortages, that may be caused or exacerbated, directly or indirectly, by COVID-19.

Current Status/Focus

The F/P/T public health response in terms of health care system infrastructure has involved linking with those partners responsible for monitoring, anticipating and planning for surges in health care system capacity in order to increase mutual knowledge and situational awareness, and support response activities regarding the delivery of health care to COVID-19 cases in Canada. To support this work:

- PTs have taken steps to support hospital surge capacity and ensure timely access to critical equipment and supplies;
- the Government of Canada is working with provinces and territories: to help ensure health care systems are ready for future waves of the virus, to support vulnerable Canadians – including those in long-term care, home care, acute care and palliative care – who are at risk of more severe cases of COVID-19, and to support people experiencing challenges related to mental health, substance use, or homelessness;
- PTs are working to develop, expand and launch virtual care and mental health tools, including through the use of new federal funding to support P/T services;
- through the federal Safe Long-Term Care Fund, governments will work together to protect people living and working in long-term care, including carrying out infection prevention and control readiness assessments, making improvements to ventilation and hiring and training additional staff or topping up wages to support workforce stability;
- the federal government is supporting infection prevention and control measures in long-term care, including funding for the Canadian Foundation for Healthcare Improvement to expand its LTC+ initiative and funding to engage with third parties to help identify resources to conduct readiness assessments in long-term care facilities and support training on infection prevention and control;
- the Canadian Red Cross and other non-governmental organizations are being supported by the federal government to build and maintain a humanitarian workforce to provide surge capacity in response to COVID-19 outbreaks and other large-scale emergencies;
- modelling has been used to project anticipated demands;
- sharing of hospital-based data (on rates of admission, current capacity and equipment/supplies/resources usage) has been included in surveillance products; and
- the LAC was convened in February 2020 to provide an F/P/T forum for collaboration including identification of F/P/T PPE, equipment and supply needs, informing procurement and facilitating allocation.

Preparations/Forward Planning

In terms of forward planning, the Government of Canada will continue to:

- consult with PTs and use modelling to assess the overall pan-Canadian supply and demand landscape for PPE, essential supplies, and life-saving medical equipment to support P/T health care systems and take action as necessary;
- collaborate and work with PTs to better understand the PPE needs across the Pan Canadian landscape;
- explore opportunities to consider sustainable domestic production capacity for critical PPE and other essential supplies;
- monitor for potential COVID-related drug shortages and work with PTs and stakeholders to proactively develop and implement strategies to manage these risks;
- through the Indigenous Services Canada (ISC) PPE Stockpile and PHAC's National Emergency Strategic Stockpile (NESS), provide PPE to First Nations, Inuit and Métis communities to support the

AB1300

health of workers and reduce likelihood of spread to FN, Inuit and Metis during the delivery of health care services;

- consult regularly with P/Ts to identify need for federal COVID-19 surge capacity supports to jurisdictions, including health human resources and mobile hospital units;
- facilitate sharing of best practices on alternate care facilities, triage and management of delivery of non-COVID-19 health care services review the latest available scientific evidence to inform guidance for health settings and develop tailored approaches for communities with specific health care needs, such as remote, northern and isolated communities as well as Indigenous peoples in urban settings;
- work with P/Ts to support safe resumption of in-person primary care and mental health services (where this were suspended/delayed or shifted to virtual care platforms);
- work with provinces and territories to set new national standards for long-term care so that seniors get the best support possible, and will also take more action to help people stay in their homes longer; and
- work with provinces and territories to make sure all Canadians get high-quality care, including ensuring all Canadians have access to a family doctor or primary care team, expanding capacity to deliver virtual care, and increasing access to mental health services.

Provincial and territorial governments, along with health care facilities, many of which are already working close to full capacity, continue to do further planning for how they have in some regions (and could in the future) accommodate potentially large influxes of patients, including establishing triage protocols for the allocation of scarce resources such as ICU beds and ventilators. In remote, northern and isolated communities it is also critical to plan for further potential supply-chain and medical evacuation interruptions due to weather.

Forward planning must consider the broad health care system impacts and changes that occurred during the initial wave of COVID-19 in Canada; for example, the unanticipated reduction in emergency room visits for serious conditions, the shift of primary care to virtual care, the unintended but severe health and safety consequences of removing family caregivers from long-term care facilities, increased incidence of opioid overdose, delayed/decreases in routine immunization, and the backlog of elective procedures. The implications of these impacts and changes include the need to plan for: more supportive care for seniors, "catch-up" of delayed medical tests, treatments and procedures and the need to plan for future waves in a way that doesn't impede the health care system more than is necessary. In addition, understanding gaps that appeared, and lessons to be learned from how they were addressed, in the intersection between PHM, health care services and other social determinants of health will be important to consider in a holistic way for future planning. For example, how to make sure individuals experiencing homelessness receive adequate supports to be able to follow PHM (e.g., isolation and quarantine protocols).

Planning Variables or Signals

In the event health care institutions start to see an increase in the number or change in the characteristics (e.g., demographics, underlying medical conditions) of patients being treated for COVID-19, the Government of Canada will continue to work with PTs to monitor capacity and facilitate timely access to PPE, ventilators, intensive care unit (ICU) beds, and other critical supplies. The federal government continues to be ready to respond to PT requests for assistance and surge support, (e.g., health human resource support, facilitation of mobile health services capacity, safe voluntary isolation sites).

6.8 Risk Communications and Outreach

Communication of information and advice in a public health emergency is a critical public health intervention that helps to protect public health, save lives, and minimize the overall social and economic impacts. To ensure this, information must be accessible for those with low literacy and also presented in an accessible format to guarantee that Canadians living with disabilities are able to have equal access. Using a risk communications approach, the Public Health Agency of Canada, together with other government departments and P/Ts counterparts and Indigenous partners, have worked hard to provide health care providers, Canadians and key stakeholders with the timely, trusted, accessible, evidence-informed and complete information they require to protect themselves, their families, their communities and businesses.

Current Status/Focus

The focus remains on communicating clear, concise and concrete messages that will cut through the current fatigue, confusion and fragile compliance, in order to: ensure Canadians have the information they need to protect themselves and others from the virus and the variants of concern; ensure Canadians can make informed decisions about the activities that they will participate in outside the home and how they can participate in a way that protects them, their families and communities; and ensure Canadians can make informed decisions about COVID-19 vaccination.

Key activities to date include:

- briefings by Chief Medical Officers of Health and local Medical Officers of Health in the PTs and nationally by the Chief Public Health Officer and Deputy Chief Public Health Officer –including modelling and epi updates;
- regular engagement and information sharing on COVID-19 to support response efforts by public health at federal, provincial and territorial levels with a diverse range of sectors, including health, civic society, business and labour, populations most affected by COVID-19, as well as critical infrastructure;
- targeted communications on enhanced border measures;
- specific communications and outreach efforts to encourage COVID-19 vaccine confidence and uptake, including outreach to populations disproportionately affected by COVID-19 (e.g., racialized communities, Indigenous Peoples, newcomer communities, seniors groups, families and persons living with disabilities);
- use of all communications and partnership levers (advertising, web, social media, regular media briefings, community radio, national mail outs, partnerships, community outreach, program funding etc.) to reach stakeholders, health system, Indigenous and community leaders (including the Canadian public) across a diversity of sectors (e.g., healthcare providers, faith-based leaders, agri-food-agriculture sector, retail/businesses, critical infrastructure sectors);
- engagement with diverse sectors to inform development of timely public health guidance for various settings such as workplaces, schools/childcare, post-secondary education, and other community settings;
- the implementation of a four-phased COVID-19 Risk Communications Strategy with different foci (e.g., containment and delay, tools and empowerment, mitigation and working together to prevent the spread of COVID-19, perseverance and ongoing vigilance in context of disease reduction and re-opening of society); and
- F/P/T and Indigenous partner collaboration to share best practices and lessons learned and coordination to ensure messaging is aligned and consistent (via Public Health Network Communications Working Group and the Special Advisory Committee (SAC)).

AB1302

Challenges and Considerations:

Messages in the earliest phase of the pandemic were clear – stay home; wash your hands. Now the environment is much more complex.

- There are different epidemics across the country so different public health measures are in place across jurisdictions. Messages and their delivery must be clear to avoid any confusion.
- Communication and information on COVID-19 is overwhelming and it is hard to distinguish misinformation or disinformation, from credible health information and sources.
- Canadians have gone through two distinct waves of peak transmission across the country and there is a real balance that needs to continue to be communicated with the use of a layered-approach of public health measures, even as vaccination coverage increases. This must take into consideration the impact of pandemic fatigue.
- The risk perception (and compliance) of Canadians will vary based on their individual experiences and their unique reality.
- Canadians will need to be encouraged to not abandon personal protective measures during vaccine roll-out or as the spring approaches.
- There is still much uncertainty that impacts how precise and definitive we can be in our messaging, especially with the new VOCs. As science evolves and we learn more, advice to Canadians may change.
- Canadians are being encouraged to participate in the economy as it re-opens in this period of recovery. We need to help people make an informed and conscious decision each time they leave their home to help them protect themselves and others.
- Canadians need to assess their activity, their risk tolerance, their risk to others and the importance of their own behaviour in reducing risk. Our communications efforts must arm them with the information to do so easily and accurately.
- Canadians must have access to credible information related to COVID-19 vaccines, vaccine safety and the vaccine rollout in Canada. Our communications efforts must address misinformation and provide everyone in Canada with evidence-based information to help them make the decision to vaccinate.
- Canadians expect timely and responsive communication using newer social media platforms (e.g., WhatsApp, TikTok, Instagram) and from leaders and influencers that are meaningful and trustworthy within their communities and social media circles.

Preparations/Forward Planning

It is now important to shift messaging as we transition Canadians into participating in the national vaccine administration campaign. The deployment of vaccines needs to be balanced with the message that certain PHM must remain in place in order to keep the level of transmission at a locally manageable rate. All levels of government need to communicate that Canadians should be prepared for a walk back or tightening of PHM if necessary to avoid surges/resurgences.

Forward planning for communications includes taking several approaches concurrently.

i. *Provide clear, consistent, concise and concrete messages and advice with relatable examples and tools that are easily accessible for Canadians.*
    - Apply behavioural science to test a variety of public health messages and tools.
    - Guidance to help the public minimize risk while venturing out into public spaces.
        - checklists for when you leave the house

  - decision making tools
- Information on vaccine safety and development to support vaccine confidence.
  - toolkit and training for healthcare providers to help them answer patient questions
  - evidence-based vaccine resources for the public

ii. *Use personal stories to motivate behaviour.*
- Showcase community members/organizations/spokespersons who are "doing it right."
- Leverage more storytelling to motivate behavior (continue youth testimonials, etc.).
- Sharing of images and personal stories of vaccination.
- Consider role of incentives to motivate behaviours (including adherence to PHM).

iii. *Communicate with empathy and honesty*
- The efforts of Canadians through the first phase have very likely saved thousands of lives; need to acknowledge that, and encourage everyone to keep doing that.

These approaches will be supported by F/P/T strategies, content and implementation plans that include:
- sufficient public opinion research (POR) and behavioural insights (re. behaviours, vaccine, public health measures, back to school) to identify all Canadians' priorities, values and concerns, and capture regional variations;
- public education campaigns (COVID-19 vaccines, PHMs and mental health);
- "Not the time to travel" campaigns; and,
- testing and contact tracing related communication activities.

This will be achieved through strategic outreach and engagement by the Chief Public Health Officer (CPHO), Deputy Chief Public Health Officer (DCPHO), Chief Medical Officers of Health and other P/T and local spokespersons, public education campaigns, media relations, and issues management, social media, and website updates. Significant outreach and engagement with a range of health and non-health stakeholders has been an essential part of the national response to COVID-19. This outreach and engagement has evolved throughout the pandemic from a focus on proactively sharing the latest public health developments and resources to identifying stakeholder information needs and perspectives, to collaborating on guidance development and joint communication initiatives. A range of stakeholders have been engaged through regular COVID-19 briefings, teleconferences and webinars including the following: CPHO Health Professionals Forum (national health professional organizations), national allied health organizations, local public health medical officers of health, critical infrastructure stakeholders, agriculture and agri-food stakeholders, business groups, travel associations, airlines, and childcare and education stakeholders. A range of community-level leaders have also been engaged including faith-based organizations, organizations representing racialized communities, and engagement with national and community level First Nations, Inuit and Metis organizations.

It has been and continues to be especially important to engage community leaders from: Indigenous communities, racialized communities/communities of color, groups representing newcomers to Canada, and faith-based organizations to help deliver critical information[15].

Planning Variables or Signals

Surges in cases requiring change in or implementation of restrictive community-based PHM along with any changes in science (e.g., new information about COVID-19 or COVID-19 vaccines that requires a shift in Canada's public health response or guidance to specific populations), changes to border measures, indicators of vaccine hesitancy and vaccine availability, will all necessitate updating of the current F/P/T communication strategy and products.

6.9 Research

The Government of Canada quickly mobilized Canada's research and scientific communities in response to the spread of the novel coronavirus (COVID-19). Early in the pandemic, research areas focused on medical countermeasures (vaccines, therapeutics, and diagnostics), clinical management research, predictive modelling, as well as social and policy research. Since then, the research focus has expanded to areas such as mental health and substance use during the pandemic, safety in long-term care homes, Indigenous communities' experiences with COVID-19, and variants of concern. Community engagement is important to ensure culturally appropriate research approaches.

Current Status/Focus

- The Government of Canada established mechanisms for mobilizing rapid research responses for this type of emergency, which have been activated to accelerate development of medical countermeasures, to support priority research on the transmission and severity of COVID-19, and to understand the potential benefits and potential limitations of medical, social and policy countermeasures.
- Health Canada established and continues to apply a number of temporary innovative and flexible measures to help prioritize and expedite the regulatory review of COVID-19 health products without compromising Canada's high standards for safety, efficacy and quality (these measures have been put in place to facilitate safe and timely access to products Canadians and health care workers need).
- A wide array of Clinical Trials activities for therapeutics and vaccines are underway under the Canadian Treatments for COVID-19 (CATCO) trial.
- Several federal programs available aimed at mobilizing industry, innovation and research continue to respond to COVID-19.
- Networks such as CanCOVID, COVID-END and National Collaborating Centres, have been launched to facilitate research effort and leverage transdisciplinary knowledge synthesis, translation and expertise among Canada's scientific, policy, and health communities.
- Capacity at federal research facilities is being leveraged, and federal granting agencies are strategically aligned to support Canadian research capacity.
- Knowledge on indoor air quality is being mobilized with federal, provincial, territorial and private sector partners.
- The Canadian private sector (R&D, manufacturing) is engaged in contributing to research and development solutions.
- The Government of Canada is also supporting various strategies to bring significant findings arising from these research efforts to decision-makers in a useful and timely way.

Preparations/Forward Planning

In an earlier version of this Plan, a number of needs had been identified in order to prepare against surges/resurgences based on the reasonable worst-case scenario. In addition to the activities described above, work has begun in earnest in several crucial areas.

i. *Strengthening our capacity to deliver on **relevant COVID-19 modelling work.***
   - The COVID-19 pandemic has demonstrated the important role and need for greater and ongoing capacity to implement the full range of modelling tools required to support decision-making during a complex public heath crisis. Models help to predict where and when COVID-19 infections may emerge or re-emerge, emergence of new variants of concern, and they can be used to explore the best combinations of approaches to control disease progression and protect the health of Canadians, including vaccination. . Expert groups continue their ongoing work on modelling the reproductive number (R_t) over the course of the pandemic, and are working on modelling several scenarios for de-escalation strategies, including border reopening and lifting travel restrictions.

ii. *Examining and addressing the need to **pursue research and surveillance studies** aiming at better understanding mechanisms of infections, transmission and immunity against the SARS-CoV-2 virus.*
   - F/P/T governments are currently focusing on the investigation and tracking of the genetic diversity of SARS-CoV-2, across Canada to better respond to its spread, particularly new variants of concern. However, research is needed to examine the full potential of these variants in their transmissibility, virulence and vaccine efficacy, and to monitor their emergence and presence over time. The Government of Canada launched the COVID-19 Immunity Task Force, which engages universities, hospitals and public health officials to use blood test (serologic) methods to track and study the immune status of various Canadian populations, and will be used to support vaccine surveillance, safety and efficacy. The need for research and research coordination with partners to understand transmission dynamics and impact of non-medical measures (e.g., ventilation, portable air cleaners, etc.) is beginning to take shape through early aerosol transmission studies in high-risk settings, such as hospitals, prisons, and long-term care homes. Discussions and work continues with domestic and international partners to develop COVID-19 animal models and medical countermeasures.

iii. *Strengthen our capacity to perform **rigorous and rapid evidence review.***
   - More experts within and outside of government are being leveraged to generate evidence reviews and answer specific questions to provide the most up-to-date scientific evidence for optimal decision-making.

iv. *Exploring the epidemiological value of new, innovative methods to track community spread, such as **testing SARS-CoV-2 from sewage water.***
   - Testing wastewater is providing early warning ability at the community level (municipality, special settings such as Long-Term Care Facilities, prisons, hospitals and remote communities). With its F/P/T partners, the federal wastewater testing group has begun creating a system throughout Canada for surveillance of public health outcomes such as COVID-19.

v. *Strengthen laboratory capacity in the area of genomic innovation and bio-informatics.*
   - The Government of Canada has begun to secure investments in this area.

vi. *Mobilizing knowledge from the **social sciences.***
   - There continues to be a need to invest in and mobilize knowledge relating to social sciences such as sociology, anthropology and psychology. Specifically behavioural science and ethnic research can guide future policy and regulatory actions.

Short to Mid term:
In the short to mid term, the approach to these preparations continues to be to:

- work collaboratively with National partners, F/P/T, stakeholders groups, Indigenous partners (including National Indigenous Organizations; Indigenous researchers and scholars; the National Collaborating Centres for Public Health), and the Federal Science Community to support the work of key task groups mandated to support Canada's COVID-19 response (Immunity Task Force, the Vaccine Task Force, the Therapeutic Task Group) and Indigenous-led culturally grounded research (with appropriate community engagement and cultural safety in approaches);
- work collaboratively with federal science based departments and agencies with specific targeted engagement with the CIHR and the Chief Science Advisor of Canada; and
- continue engagement with the COVID-19 Governance Structure (via the Technical Advisory Committee (TAC), LAC and SAC). Activities include sharing research, data and local experience that will inform further planning in alignment with our stated public health pandemic goal and objectives (e.g., quantifying the negative and positive consequences of the PHM that were uses in the initial response to be better able to address the inequities that have arisen).

Planning Variables or Signals

Similar to the other COVID-19 response components above, there are several factors that could potentially impact preparations for the ongoing COVID-19 response, including: a significant shift in genomic pattern of SARS-CoV2 (leading to examination of possible shift in virulence or infectivity), significant increases in the mortality ratio, data from vaccine and therapeutic clinical trials, data on immunological protection of Canadians, new/rigorous knowledge on the impact of COVID-19 specific high-risk groups, and new/rigorous knowledge of the importance of a non-respiratory mode of transmission.

7. Planning with Indigenous Communities

First Nations, Inuit and Metis communities have been supported as they worked to update and activate their community pandemic plans. Over 30 Indigenous organizations have been engaged and are collaborating together to support public health response through the Public Health Working Group on Remote, Isolated and Indigenous Communities as part of the SAC governance structure. Indigenous Services Canada (ISC) together with National Indigenous Organizations (NIOs), have been leading work with PHAC, Statistics Canada and the First Nations Information Governance Centre to address data gaps regarding the impacts of COVID-19 on Indigenous Peoples.

As a result of community supported response efforts, infection rates on-reserve and in the North remained lower than the rate in the overall Canadian population during the first wave of COVID-19. However, transmission has been greater in Indigenous communities during the second wave. It is important to note that gaps for First Nations, Métis and, Inuit living in urban and related locations are the product of historical, political, societal, and economic factors that have influenced Indigenous health. These inequalities persist in part due to systemic racism experienced in the healthcare system and increased connections to culturally safe services are required to support these populations. ISC and PHAC are working with Indigenous partners, provinces and territories, the Vaccine National Operations Centre, LAC of the COVID-19 Governance Structure, and other federal departments to ensure all Indigenous peoples, regardless of where they live, have access to support throughout the pandemic response, including prioritization for vaccines. ISC has established the COVID-19 Vaccine Planning

Working Group and the COVID-19 Vaccination Task Group for First Nations, Inuit, and Métis living in Urban and Related Homelands to support linkages between provinces and territories, other federal departments and Indigenous partners for vaccine co-planning discussions. A summary of the response activities that have been supported to date in addition to the strategy/approach, actions and deliverables for these preparations for the short, mid and long term (i.e., being before September, September to December, and 2021 and beyond, respectively) are included in *Appendix 3: COVID-19 Response Planning with Indigenous Communities*.

8. Planning for High-risk settings and populations

A specific setting may be considered as "high-risk" due to:

- the potential for higher rates of severe disease or death amongst those in the setting compared to that of the general population (because of clustering of people with underlying medical conditions, clustering of those in high-risk age group or both); and/or
- potential for high rates of transmission (because of unavoidable crowding indoors with limited ability to use or inconsistent use of protective measures, introduction of a VOC, or high-risk activities or conditions).

It can be challenging to significantly mitigate these risks; therefore planning activities need to look at the specific circumstances of each setting and what enhanced measures can be put in place to prevent and manage COVID-19 outbreaks in these highly variable contexts. This should include measures to prevent introduction of the virus into these settings, (e.g., through screening of employees and visitors, restriction of visitation, efforts to prevent work at more than one high-risk location, implementation of a quarantine period for people entering the setting). Epidemiologic investigations of outbreaks in these settings are key to improving our understanding of transmission dynamics and setting-specific risks. It is particularly important to investigate outbreaks that are caused by different VOCs and to examine the potential role of vaccines in shortening outbreaks.

To date, high-risk settings that would benefit from special planning considerations have included:

- Long-Term Care facilities;
- worksites necessitating close proximity to others (e.g., meat processing) or with communal housing (e.g., temporary foreign workers living on work farms, remote/fly-in work camps like northern mines);
- remote populations without ready access to advanced health services (e.g., fly-in only access communities), and with potentially elevated rates of underlying medical conditions or other pre-existing disparities (e.g., overcrowded housing);
- homeless shelters and other congregate living settings such as group homes; and,
- correctional facilities.

While guidance has been developed and measures have been put in place aimed at preventing further outbreaks in these settings, planning for the reasonable worst-case scenario necessitates that we undertake activities in the short term to shore up capacity to undertake prevention and outbreak response measures, as well as, continuously monitoring these measures and adjusting as necessary. For example:

- If there were to be a high level of activity caused by a VOC in the surrounding geographic areas would the response plans for these settings be applicable and sufficient?
- Given the vaccine strategy initially largely prioritizes those at greatest risk for severe disease and death but not specifically those in settings with potentially higher rates of transmission, under what circumstances would vaccine be considered for people in these other high-risk settings?
- What are the existing gaps in guidance, measures or resources, and how can these be addressed?
- Are prevention measures that were previously implemented sustainable and realistic for ongoing surges and/or the reasonable worst-case scenario?
- What impact could these measures have on high-risk populations?
- Have risk communication strategies been effective in these settings and populations?

This collaborative work to plan and support high-risk settings and populations will continue at all levels of government and across multiple sectors and stakeholders from public health, health care, education, agriculture/agri-food, immigration, economic development, corrections, social services/housing, science/research and labour.

As work continues, it is important to take into consideration the impact that these measures may have on the various sociodemographic groups most likely to be affected. Considerations for low-income workers, seniors, migrant workers, persons living in overcrowded housing, persons experiencing homelessness, and prisoners, among others, will need to remain a cornerstone of all response plans.

9. Assessment and Evaluation

Assessing and evaluating pandemic response efforts during periods of relatively lower response tempo will help identify areas of improvement and prioritize future planning efforts. It is also vital, on an ongoing basis, to determine whether response activities have been effective and implemented efficiently to achieve the intended results and whether areas of uncertainty (see Section 4.1) can or have been addressed. The F/P/T COVID-19 response governance structure (see Appendix 1), which includes the SAC, TAC and LAC, provides multiple fora for these discussions and opportunities for sharing of experience, lessons learned and identified best practices. More structured processes for assessment and evaluation, including in-action and after-action reviews should be considered at all levels of government and diverse sectors to inform forward planning and future pandemic preparations. Findings from formal audits undertaken by F/P/T governments will also be taken into consideration in future planning processes.

The broad direct and indirect consequences of the COVID-19 response in terms of other physical and mental health outcomes as well as societal and economic impacts must continue to be acknowledged and assessed so that reduction of negative impacts can be accounted for in comprehensive forward planning efforts.

This should involve consideration of the impact response measures may have on individuals' physical, social, mental and emotional health and wellbeing, including how this may affect the adoption of control measures. The broader impact of restrictive community-based PHM in terms of health, wellbeing, child development and welfare needs to be monitored and plans implemented to prevent other immediate health harms and to prevent increasing health inequities for higher risk populations. These include but are not limited to other direct impacts to health including; risks of delaying health procedures or reduced access to screening and preventive services, domestic violence, child welfare/neglect, reducing access to harm reduction services or safe drug supply and mental health services. It should also involve addressing indirect COVID-19 associated health and wellbeing risks such as congregate housing, low employment standards, lack of access to educational supports for high need students, and risk of visitor restriction policies (e.g., family caregivers in long-term care homes).

Resources and guidance to support mental health has been developed, however the need for other resources as population "pandemic fatigue" sets in needs to be considered. Furthermore, addressing social determinants of health (such as housing and employment conditions) that increase the risks associated with COVID-19, could also help reduce the health and societal impacts of future pandemics.

Appendix 1: Canada's Public Health Emergency Response System and Inventory of Resources, Guidelines and Agreements to inform COVID-19 Preparedness and Response

Canada's public health emergency response "system" comprises a series of complementary, mutually reinforcing plans, arrangements, protocols and networks that incorporate lessons-learned from previous outbreaks like SARS, 2009 H1N1 pandemic and Ebola which are regularly updated to reflect the latest evidence and scientific advance. Taken together, they span the local, provincial, territorial, pan-Canadian, North American and international levels and provide a strong and proven framework for Canada's response to COVID-19.

As public health in Canada is an area of shared jurisdiction, federal, provincial and territorial health officials and experts are working together through the *SAC on COVID-19* and its various expert committees and working groups to facilitate a coordinated and effective response to the COVID-19 pandemic in accordance with the *F/P/T Public Health Response Plan for Biological Events.* The Plan, which includes a summary of F/P/T roles and responsibilities in a public health emergency, can be found at https://www.canada.ca/en/public-health/services/emergency-preparedness/public-health-response-plan-biological-events.html

The SAC draws on the long-standing pan-Canadian Public Health Network (PHN) F/P/T governance structure. Established in 2005, the PHN reflects lessons-learned from the Severe Acute Respiratory Syndrome (SARS) outbreak, which highlighted the imperative for a proactive and collaborative approach to public health emergency planning and response in Canada. PHN has since proven its value and effectiveness as a vehicle for collaborative public health leadership during the 2009 H1N1 pandemic, Middle Eastern Respiratory Syndrome (MERS-CoV) and Zika outbreaks, as well as in non-communicable disease crises such as the ongoing contaminated street-drug overdose and overdose death epidemic.

SAC comprises members of the PHN Council and the Council of Chief Medical Officers of Health (CCMOH). Four expert groups comprising senior F/P/T officials and public health experts from across the country report to and support SAC:

- Technical Advisory Committee (TAC): monitors COVID-19 epidemiology, shares information and advises on technical issues through the development of recommendations, guidelines and protocols and leads on surveillance and outbreak investigation, laboratory, medical countermeasures (MCM), public health measures, risk assessment, technical expert engagement, research & evaluation, borders, infection prevention and control, and occupational health, etc.
- Logistics Advisory Committee (LAC): supports logistics (e.g., supplies, joint procurement, scarce resources), shares information and advises on logistical issues through the development of recommendations, guidelines and protocols, and leads on deployable resources and mutual aid, procurement, health care delivery engagement etc.
- Public Health Network Communications Group: supports consistent and coordinated public communications and messages on COVID-19 across jurisdictions and leads on strategic communications product development, information dissemination, emergency risk communications support and coordination, communications surveillance, etc.

AB1311

- **Public Health Working Group on Remote and Isolated Communities supports Indigenous public health response in remote and isolated Indigenous communities through development of guidance, resources and communications.**

Figure 6: COVID-19 Governance Structure



*Does not depict standing general and emergency management FPT governance

Figure 6 – Text Description

This graphic depicts two main hierarchical governance structures and linkages level at the federal level that includes several relevant Federal/Provincial/Territorial (F/P/T) committees. Please note that provinces and territories have the primary responsibility for public health and health care services in Canada's federalist structures. Each province and territory will also have its own response structure and advisory committees that are not represented here. The structure on the left side of the graphic on the teal background shows the Federal/Provincial/Territorial Governance structure that has been activated for the COVID-19 response as per the Federal/Provincial/Territorial (F/P/T) Public Health Response Plan for Biological Events. There is an asterisk linked to text to remind the viewer that this does not depict standing general and emergency management F/P/T governance. At the top of this structure is the Conference of FPT Ministers of Health (HMM) which operates at the Ministerial level. Directly below the HMM is the Conference of Deputy Ministers of Health (CDMH) which operates at the Deputy Minister level. Directly below the CDMH is the Special Advisory Committee (SAC) which is considered to operate at the Chief Medical Officer of Health and Assistant Deputy Minister Level. Below the SAC are its 4 committees/groups and their related sub-groups which provide technical and operational response support from a F/P/T public health response perspective These 4 committees/groups are the Technical Advisory Committee (TAC), the Public Health Network (PHN) Communications Group, the Logistic Advisory Committee (LAC) and the Public Health Working Group on Remote and Isolated Communities. This entire FPT governance structure has a health system management perspective/focus, as is indicated in a yellow bar spanning the bottom of this side of the graphic.

On the right side of the graphic on a grey background is the Federal Governance structure which has more of an incident/operations management and whole of (federal) government focus. At the top of this structure is the Cabinet which like the HMM on the left (FPT side) operates at the Ministerial Level. Reporting up to Cabinet is during this response are the Deputy Ministers Committees on COVID-19, which operates at the Deputy Minister

Level and are directly supported by an Associate Deputy Ministers Committee (that oversees federal event management and the COVID-19 whole of government policy and coordination) and the COVID-19 Secretariat. These two groups along with the Government of Canada Operations Centre (GOC), operate at the Assistant Deputy Minister Level. The Federal Health Portfolio Operations Centre (HPOC), which is linked to the GOC, provides support to the SAC, TAC and LAC in addition to the federal response. The HPOC formally links to the SAC via the SAC secretariat which functions as is a key linkage point between these two governance structures. At the working level the HPOC Incident Management Structure (IMS) includes groups that develop F/P/T response products and support the TAC, LAC PHN Communications Group and SAC.

The Government of Canada has also established a Cabinet Committee on the federal response to COVID-19 that meets regularly to ensure whole-of-government leadership, coordination, and preparedness for a response to the health and economic impacts of the virus. Additionally, existing and new expert groups (e.g., Surveillance Expert Working Group, Canadian Pandemic Influenza Preparedness-Task Group, Canadian Immunization Committee and its working groups, CPIP-TG) and networks (e.g., CanCoGen) have been contributing to the response through engagement with the governance structure.

The Canadian COVID Genomics Network (CanCOGeN) is a Genome Canada-led consortium of Canadian federal, provincial and regional public health authorities and their healthcare partners, academia, industry, hospitals, research institutes and large-scale sequencing centres. The mission of CanCOGeN is to establish a coordinated pan-Canadian, cross-agency network for large-scale SARS-CoV-2 and human host sequencing to track viral origin, spread and evolution, characterize the role of human genetics in COVID-19 disease and to inform time-sensitive critical decision making relevant to health authorities across Canada during the pandemic.

FPT Collaborative Agreements: Mutual Aid, Information Sharing and Emergency Supplies

***Federal/Provincial/Territorial Public Health Response Plan for Biological Events*: is a federal, provincial, and territorial (F/P/T) guidance document that provides an overarching governance framework to ensure a coordinated intergovernmental health sector response to public health events that are biological in nature and of a severity, scope or significance to require a high level, coordinated F/P/T response.**

***Canadian Pandemic Influenza Preparedness: Planning Guidance for the Health Sector (CPIP):* is an F/P/T guidance document that outlines how jurisdictions will work together to ensure a coordinated and consistent health-sector approach to pandemic preparedness and response. While CPIP is specific to pandemic influenza, much of its guidance is also applicable to other public health emergencies. CPIP consists of a main body, which outlines overarching principles, concepts, and shared objectives, as well as a series of technical annexes that provide operational advice and technical guidance, along with tools and checklists on specific elements of pandemic planning. CPIP is regularly updated to reflect new evidence and best practices.**

Operational Framework for Mutual Aid Surge Requests for Health Care Professionals*: is a guidance document that provides for a consistent and timely pan-Canadian approach to inter-jurisdictional health care professional mutual aid during health emergencies. The framework identifies roles and responsibilities and provides standard processes to guide jurisdictions making requests for, and offers of, mutual aid and the mobilization/demobilization of health care professionals. It also informs a complementary *Memorandum of Understanding (MOU) on the Provision of Mutual Aid in Relation to Health Resources During an Emergency Affecting the Health of the Public.

Multilateral Information Sharing Agreement (MLISA): is a legal agreement that establishes standards on sharing, usage, disclosure and protection of public health information for infectious diseases and public health emergencies of international concern. The MLISA sets out what public health information is to be shared and how it will be used. It allows for trends and/or urgent public health events to be identified more rapidly and to reduce duplication of information requests. MLISA also informs *an FPT MOU on the Sharing of Information during a Public Health Emergency*. The Memorandum of Understanding (MOU) provides a framework for the sharing of information between and among its signatories during public health emergencies.

National Emergency Strategic Stockpile (NESS): located within PHAC, contains supplies that provinces and territories can request from PHAC in emergencies, such as infectious disease outbreaks, natural disasters and other public health events, when their own resources are not enough. These include a variety of items such as medical equipment and supplies, pharmaceuticals and social service supplies, such as beds and blankets.

Public Health Ethics Framework: A Guide for Use in Response to the COVID-19 Pandemic in Canada: is a framework is intended for use by policy makers and public health professionals making public health decisions in the context of COVID-19. Section 1 articulates ethical principles and values for public health authorities to consider, and Section 2 sets out a framework to help clarify issues, analyse and weigh relevant considerations, and assess options, in order to support decision making in real situations.

Federal Emergency Response Plans

The Federal Emergency Response Plan (FERP): is the Government of Canada's all-hazards response plan. The FERP outlines the processes and mechanisms required to facilitate a whole-of-government response to an emergency. The FERP is designed to harmonize federal emergency response efforts with the efforts of PT governments, non-governmental organizations (NGO) and the private sector.

The Federal Policy on Emergency Management (FPEM): promotes an integrated and resilient whole-of-government approach to emergency management planning, which includes better prevention/mitigation of, preparedness for, response to, and recovery from emergencies. It provides direction to federal institutions on mandate-specific all-hazards risk identification and management within a federal institutions area of responsibility.

International Response Plans and Protocols

North American Plan for Animal and Pandemic Influenza (NAPAPI): outlines how Canada, the United States and Mexico intend to strengthen their emergency response capacities, as well as trilateral and cross-sectoral collaborations and capabilities, in order to assist each other and ensure a faster and more coordinated response to outbreaks of animal influenza or an influenza pandemic. The NAPAPI complements national emergency management plans in each of the three countries.

Global Health Security Initiative (GHSI): is an informal, international partnership among like-minded countries and organizations to exchange information and coordinate practices within the health sector to strengthen public health preparedness and response globally, including pandemic influenza.

International Health Regulations (IHR): represent an international agreement between all World Health Organization (WHO) Member States to build capacity to detect, prevent, assess, notify and response to public health events. Canada has a legal obligation to meet the core public health capacities set out by the IHR.

World Health Organization (WHO) Strategic Response Plan: outlines the public health measures that the international community stands ready to provide to support all countries to prepare for and respond to COVID-19. Documentation (including the Strategic Response Plan) from the WHO takes what has been learned about the SARS-CoV-2 virus and translates that knowledge into strategic action that can guide the efforts of all national and international partners when developing context-specific national and regional operational plans. This plan, like other WHO documentation, is being updated throughout the response.

AB1315

Appendix 2: Modelling Support for Forward Planning

Modelling recreates the essential components of pathogen transmission cycles from our understanding of the biology of the pathogens and their interactions with their hosts. Models help to predict where and when infectious diseases may emerge or re-emerge, and they can be used to explore the best methods or combinations of methods to control disease outbreaks or epidemics and protect the health of Canadians. Models can take into account new events during the course of the pandemic such as vaccination or emergence of new variants of concern.

For response to COVID-19, there are three broad types of model being used:

1. **Deterministic compartment models.** These are Susceptible-Exposed-Infectious-Recovered (SEIR) type dynamic models in which the population is divided into "susceptible", "exposed", "infectious" and "recovered" classes. After encountering infection, individuals in a population move from one state to the next. This basic structure includes elements to model SARS-CoV-2 and impacts of public health measures, with more realism. These elements include compartments for isolated cases and quarantined "exposed" contacts from which onward transmission to susceptible people is limited or absent, compartments for asymptomatic cases that may or may not be detected by surveillance, as well as flows to "isolation" and "quarantine" compartments that allow variation according to different levels of public health effort. These models are used to inform broad policies at a national level, including i) estimating numbers of cases, hospitalisations and deaths; ii) estimating the effects of non-pharmaceutical interventions (NPIs), (physical distancing, case detection and isolation, and contact tracing and quarantine), iii) design of vaccination programs; iv) the design of programs to enhance "herd immunity" via use of antivirals/therapies in combination of vaccination; and estimating the effect of the emergence of new variants of concern on the disease transmission.

2. **Agent-based models.** These are also SEIR models, and they can also be used to inform development of national strategies. However, because they can simulate disease transmission with some detail in and amongst homes, work places leisure spaces etc., they are particularly useful for decision-making at an individual community level regarding needs for NPIs, and strategies for relaxing restrictive closures.

3. **Branching models**. These are a more recent addition to the types of models used for COVID-19. They simply assess what factors cause single chains of transmission to expand or become extinct. They are being used to assess the needs for controlling transmission in work places and institutions.

The PHAC has developed models that can be shared, and are constantly undertaking modelling to support decisions. The PHAC External COVID-19 Modelling Expert Group was formed in February 2020, and currently comprises 33 members from 21 universities across Canada, as well as 43 members from other Federal departments/organisations provincial/territorial public health organisations. The group comprises the majority of infectious disease modelling group leads in Canadian universities, and is capable of supporting modelling needs for decision-making.

AB1316

Appendix 3: COVID-19 Response Planning with Indigenous Communities

Indigenous Services Canada (ISC), the Public Health Agency of Canada (PHAC) and the F/P/T response partners have been involved in various activities to support the COVID-19 response in First Nations, Inuit and Métis communities and organizations, including the work of SAC's FPTI Public Health Working Group on Remote and Isolated Communities. These supportive activities are summarized below.

- **Preparedness:** Resources to support pandemic planning updates/activation; access to medical supplies and PPE; training; and, guidelines.
- **Health Human Resources:** Resources to support surge capacity for health human resources, including nursing, medical and paramedical supports; as well as, charter services to get health human resources into communities with reduction to commercial airline service.
- **Infrastructure:** Resources to procure temporary shelter solutions and to support communities in efforts to re-tool existing spaces to offer safe assessment and overflow space; and, additional surge supports for food, water and other supply chain components; coordination of chartered flights to ensure availability of critical infrastructure supplies and professionals.
- **Infection prevention and control (IPC):** Ongoing sharing of information (i.e., guidance on public health measures and promoting personal health measures for individuals and health providers), training and increasing capacity to support community response, including public service announcements in Indigenous languages. Provision of training of community workers and health providers on IPC. Ongoing funding for communities and service providers to increase their capacity for infection prevention and control, including First Nations-run schools, boarding homes, family violence shelters and friendship centres.
- **Testing:** Resources to develop capacity to conduct COVID-19 testing including the provision of testing swabs and point-of-care testing devices and cartridges.
- **Governance:** Continue to work with First Nations, Inuit, and Métis partners, the Public Health Agency of Canada (PHAC), Health Canada, Public Safety's Government Operations Centre, and other departments, as well as their provincial and territorial counterparts for a coordinated and consistent Canadian approach to COVID-19 to protect the health and safety of all First Nations, Inuit and Métis peoples, regardless of where they live.
- **Communications:** Continue to develop and broadly disseminate communication messaging through Department's COVID-19 Single Window to networks with Public Service Announcements in multiple Indigenous languages. Using digital media to further reach stakeholders with communications such as public health measures and maintaining an online, publicly available repository of COVID-19 resources relevant for Indigenous peoples in multiple languages and formats. Multilateral calls with partners at the national and regional levels continue.
- **Surveillance:** Adaptation of the Department's flu surveillance tool to track COVID-19 across First Nations communities; and development of a tracking tool to inform dashboards on key indicators of COVID-19. COVID-19 case data is updated regularly on the ISC COVID-19 webpage. ISC continues to fund and facilitate partnerships with Indigenous-led, distinctions-based data initiatives. PHAC is working with provinces and territories to support collection of COVID-19 case and vaccination information, including race/ethnicity and Indigeneity to support understanding of the impacts of COVID-19 and inform response planning and actions.
- **Vaccine response planning:** Collaborating with federal departments, provinces and territories, and First Nations, Inuit and Metis partners to ensure that health facilities in Indigenous communities have the necessary immunization supplies, PPE, and health human resources to deliver the vaccine

when available. Facilitating two COVID-19 Vaccine Planning working groups with representation from federal, provincial and territorial, and First Nations, Inuit and Metis partners to co-develop approaches to support the access to COVID-19 vaccines for Indigenous communities and populations, including Indigenous Peoples living in urban settings.

Based on knowledge and feedback learned to date, ongoing collaboration and funding is needed to support First Nations, Inuit, and Métis communities and organizations to respond any future surges/resurgences. Continued access to timely testing supplies, P/T labs for processing, and results, including point of care testing for northern, remote and isolated communities and capacity to detect VOCs.

Access to care to treat more severe symptoms of COVID-19 in remote and isolated communities also requires that ongoing arrangements, or new ones, are in place to ensure an adequate number of beds in hospitals south of 60, to support the treatment of Indigenous peoples living in northern, remote and/or isolated communities without this type of service. In communities where there are long-term care facilities, or Elders residences, it is important to have access to adequate resources to support their planning in keeping Elders safe and healthy, including funding for basic infection prevention control measures (i.e., PPE, high dose flu vaccine, cleaning supplies, etc.), as well as, engineered public health measures.

Learning from H1N1, we know that long standing public health gaps and health disparities between First Nations Inuit and Metis, and non-Indigenous Canadians increase the likelihood and potential severity of a COVID-19 outbreak in Indigenous communities, and we have seen this throughout the second wave of the disease. These disparities are often exacerbated in remote or fly-in communities, where access to necessary supplies and health care services is limited as compared to non-Indigenous communities. We also know that during H1N1, data for First Nations/Inuit/Métis populations was not captured in a consistent way, or a way that supported communities in their preparedness and response efforts. A distinctions-based approach has been adopted by the Federal Government to ensure that the unique rights, interests and circumstances of the First Nations, Inuit, and Métis peoples are acknowledged, affirmed, and implemented. In this context, it takes into account the cultural and socio-economic particularities of each of the Indigenous Nations involved. Distinctions-based, Indigenous-led analysis of COVID-19 data is necessary to advancing culturally appropriate and science-based approaches, for First Nations, Inuit and Métis Nation communities.

Surveillance activities are critical to informing public health responses to a pandemic. They support the early detection and description of potential health threats present in Canada, including on-reserve First Nations communities. In order to be able to make informed decisions, decision makers and leaders throughout the system need reliable public health data. Existing data quality and gaps for First Nations, Inuit and Métis populations living both on and off reserve are critical to effectively responding to future waves of COVID-19 amongst this population, protecting their health and safety by getting them the access to care required.

The strategy/approach, actions and deliverables for these preparations for the short, mid and long-term are presented below.

Short term: In the short term, ongoing work to continue to ensure First Nations, Inuit, and Métis communities and organizations have access to necessary supplies (e.g., PPE, vaccines and related administration supplies), human resources, and funding to support the COVID-19 response and planning for future waves. Vaccine planning is a priority in the short term and is being conducted through collaborative efforts in working groups to facilitate culturally safe and equitable access to the COVID-19 vaccine for all Indigenous Peoples, regardless of where they live. Communications regarding the vaccine are being developed and distributed in multiple Indigenous languages, in partnership with Indigenous leaders and organizations, to build vaccine confidence. ISC and PHAC continue to work with partners to advocate for the prioritization of Indigenous Peoples for access to the COVID-19 vaccine. There is a need for continued work on COVID-19 surveillance and tracking of the COVID-19 vaccine administration, which is underway in collaboration with federal departments, provinces and territories, and Indigenous partners. Resources to support Indigenous-led data collection/governance/infrastructure to support data optimization for the longer term in Canada are essential. Resources to bolster community-led public health supports, culturally appropriate communication and information, and work are required, as well as training and capacity building to support these functions.

Medium term: As COVID-19 vaccine rollout continues and the supply of the vaccine increases, the tracking and reporting of vaccine uptake and effectiveness will be critical. ISC will also continue to work to increase vaccine confidence, building on lessons learned from the early vaccine rollout. Continued work is required to support access to patient care, as well as the work of community based workers and nurses in northern, remote and/or isolated communities, and increased funding for telemedicine and virtual health care providers is necessary. This will avoid a backlog of medical or specialist appointments after COVID-19, and support access to timely care supporting better health outcomes. Ongoing monitoring of forest fires and flood for possible evacuations and planning in light of COVID-19 will be maintained over the summer and fall months.

Longer term: In the fall, planning for the influenza vaccine clinics will need to be informed by current, local epidemiology of COVID-19, with respect to existing public health measures. As community spread of COVID-19 decreases and vaccine coverage increases, ISC and F/P/T public health leaders will support First Nations, Inuit, and Métis communities in re-opening economies and guidance for adjusting and eventual lifting of individual and community-based public health measures following assessment of readiness indicators. Continued work to monitor vaccine uptake and effectiveness. ISC will work with partners to facilitate after action reviews that will inform emergency management funding and planning for future pandemics.

High level signals that would necessitate a change in timelines or strategy/approach and sub-sequent actions and deliverables, include:

- community spread of VOCs;
- ongoing and prolonged active cases – either slow, or in a community outbreak scenario;
- signals and risks of community spread, where communities may be at a higher risk due to geographic location;
- access to health care to treat more severe symptoms;
- strain on system for medivacs should there be a greater need in PTs;
- shifts in hospitalization rate, ICU admission rate, case fatality rate;
- reproductive rate;
- outbreaks in long-term care facilities or Elder lodges; and,
- shift in age/sex distribution of cases.

AB1319

References

[1] Abrams, E.M. and Szefler, S.J., 2020. COVID-19 and the impact of social determinants of health. *The Lancet. Respiratory Medicine*.

[2] Cockerham, W.C., Hamby, B.W., Oates, G.R. The Social Determinants of Chronic Disease. American Journal of Preventative Medicine. Volume 52, Issue 1, Supplement 1, January 2017, Pages S5-S12. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5328595/

[3] Supplement to: Dehingia N, Raj A. Sex differences in COVID-19 case fatality: do we know enough? Lancet Glob Health 2020; published online Nov 5. http://dx.doi.org/10.1016/S2214-109X(20)30464-2. Available at https://www.thelancet.com/cms/10.1016/S2214-109X(20)30464-2/attachment/13cc9566-cd27-4d95-b590-b65637439d12/mmc1.pdf

[4] Coronavirus disease 2019 (COVID-19): Epidemiology update. Available at https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html

[5] Statistics Canada, Labour Force Survey, May 2020. Available at https://www150.statcan.gc.ca/n1/daily-quotidien/200605/dq200605a-eng.htm

[6] Statistics Canada, Economic impact of COVID-19 among visible minority groups. Available at https://www150.statcan.gc.ca/n1/pub/45-28-0001/2020001/article/00042-eng.htm?HPA=1

[7] Canadian Human Rights Commission. Statement - Inequality amplified by COVID-19 crisis. Available at https://www.chrc-ccdp.gc.ca/eng/content/statement-inequality-amplified-covid-19-crisis

[8] Public Health Ontario, Rapid Review: Negative Impacts of Community-Based Public Health Measures During a Pandemic (e.g., COVID-19) on Children and Families. Available at https://www.publichealthontario.ca/-/media/documents/ncov/cong/2020/06/covid-19-negative-impacts-public-health-pandemic-families.pdf?la=en

[9] United Nations Educational, Scientific and Cultural Organization, Adverse consequences of school closures Available at https://en.unesco.org/covid19/educationresponse/consequences

[10] World Health Organization, COVID-19 Weekly Epidemiological Update, 25 February 2021, Special edition: Proposed working definitions of SARS-CoV-2 Variants of Interest and Variants of Concern. Available at https://www.who.int/docs/default-source/coronaviruse/situation-reports/20210225_weekly_epi_update_voc-special-edition.pdf?sfvrsn=1eacfa47_7&download=true

[11] Public Health agency of Canada. (February 19 2021). Update on COVID-19 in Canada: Epidemiology and modelling. Available from: https://www.canada.ca/content/dam/phac-aspc/documents/services/diseases-maladies/coronavirus-disease-covid-19/epidemiological-economic-research-data/update-covid-19-canada-epidemiology-modelling-20210219-en.pdf

[12] Riley et al., (Feb 23 2021). REACT-1 round 9 interim report: downward trend of SARS-CoV-2 in England in February 2021 but still at high prevalence [pre-print]. medRxiv. Available from: https://www.medrxiv.org/content/10.1101/2021.02.18.21251973v1

[13] Canada's COVID-19 Immunization Plan: Saving Lives and Livelihoods. Available at: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/canadas-reponse/canadas-covid-19-immunization-plan.html

[14] Reporting Adverse Events Following Immunization (AEFI) in Canada: User guide to completion and submission of the AEFI reports. Available at: https://www.canada.ca/en/public-health/services/immunization/reporting-adverse-events-following-immunization/user-guide-completion-submission-aefi-reports.html

[15] Krishnan, L., Ogunwole, S. M., & Cooper, L. A. (2020). Historical Insights on Coronavirus Disease 2019 (COVID-19), the 1918 Influenza Pandemic, and Racial Disparities: Illuminating a Path Forward. Annals of Internal Medicine. https:// doi:10.7326/M20-2223